1	A	_	_	DT	O	-1	none	_	_
2	newly	_	_	RB	O	-1	none	_	_
3	established	_	_	VBN	O	-1	none	_	_
4	megakaryoblastic	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	erythroid	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	line	_	_	NN	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	differentiates	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	red	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	presence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	erythropoietin	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	produces	_	_	VBZ	O	-1	none	_	_
21	platelet	_	_	NN	O	-1	none	_	_
22	like	_	_	IN	O	-1	none	_	_
23	particles	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	August	_	_	NNP	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	1992	_	_	CD	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	established	_	_	VBD	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	leukemic	_	_	JJ	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	line	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	NS-Meg	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	patient	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	megakaryoblastic	_	_	JJ	O	-1	none	_	_
20	transformation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	Philadelphia	_	_	NNP	O	-1	none	_	_
23	chromosome	_	_	NN	O	-1	none	_	_
24	positive	_	_	JJ	O	-1	none	_	_
25	chronic	_	_	JJ	O	-1	none	_	_
26	myeloid	_	_	JJ	O	-1	none	_	_
27	leukemia	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NS-Meg	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	positive	_	_	JJ	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	alpha-naphthyl	_	_	JJ	O	-1	none	_	_
8	acetate	_	_	NN	O	-1	none	_	_
9	esterase	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	periodic	_	_	JJ	O	-1	none	_	_
12	acid-Schiff	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	PAS	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	staining	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	surface	_	_	NN	O	-1	none	_	_
20	CD4	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	CD7	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	CD13	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	CD34	_	_	NN	Protein	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	CD41a	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	glycophorin	_	_	NN	Protein	32	multitoken	_	_
32	A	_	_	NN	Protein	0	root	_	_
33	antigens	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Ultrastructurally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	had	_	_	VBD	O	-1	none	_	_
6	alpha-granules	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	demarcation	_	_	NN	O	-1	none	_	_
9	membranes	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	platelet	_	_	NN	O	-1	none	_	_
13	peroxidase	_	_	NN	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NS-Meg	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	spontaneously	_	_	RB	O	-1	none	_	_
5	produced	_	_	VBD	O	-1	none	_	_
6	platelet	_	_	NN	O	-1	none	_	_
7	like	_	_	IN	O	-1	none	_	_
8	particles	_	_	NNS	O	-1	none	_	_
9	which	_	_	WDT	O	-1	none	_	_
10	contained	_	_	VBD	O	-1	none	_	_
11	alpha-granules	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	mitochondria	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	dense	_	_	JJ	O	-1	none	_	_
16	bodies	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	strongly	_	_	RB	O	-1	none	_	_
19	suggesting	_	_	VBG	O	-1	none	_	_
20	platelet	_	_	NN	O	-1	none	_	_
21	production	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Erythropoietin	_	_	NN	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	Epo	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	granulocyte	_	_	NN	Protein	11	multitoken	_	_
7	and	_	_	CC	Protein	11	multitoken	_	_
8	macrophage	_	_	NN	Protein	11	multitoken	_	_
9	colony	_	_	NN	Protein	11	multitoken	_	_
10	stimulating	_	_	NN	Protein	11	multitoken	_	_
11	factor	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	GM-CSF	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	interleukin	_	_	NN	Protein	18	multitoken	_	_
18	3	_	_	CD	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	IL-3	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	promoted	_	_	VBD	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	growth	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	NS-Meg	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Phorbol-12-myristate-13-acetate	_	_	NNP	O	-1	none	_	_
2	increased	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	both	_	_	CC	O	-1	none	_	_
7	CD41a	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	CD61	_	_	NN	Protein	-1	none	_	_
10	antigens	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Ten-day	_	_	JJ	O	-1	none	_	_
2	exposure	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	Epo	_	_	NN	Protein	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	mature	_	_	JJ	O	-1	none	_	_
7	erythroblasts	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	red	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	benzidine	_	_	NN	O	-1	none	_	_
3	positive	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	positive	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	hemoglobin	_	_	NN	O	-1	none	_	_
9	F	_	_	NN	O	-1	none	_	_
10	staining	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Untreated	_	_	JJ	O	-1	none	_	_
2	NS-Meg	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	expressed	_	_	VBD	O	-1	none	_	_
5	mRNA	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	Epo	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	EpoR	_	_	NN	Protein	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	GATA-1	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	alpha	_	_	NN	O	-1	none	_	_
20	1	_	_	CD	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	alpha	_	_	NN	O	-1	none	_	_
23	2	_	_	CD	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	gamma	_	_	NN	O	-1	none	_	_
26	globin	_	_	NN	O	-1	none	_	_
27	genes	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	NS-Meg	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	undergo	_	_	VBP	O	-1	none	_	_
8	terminal	_	_	JJ	O	-1	none	_	_
9	differentiation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	megakaryocytic	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	lineages	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	line	_	_	NN	O	-1	none	_	_
4	should	_	_	MD	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	very	_	_	RB	O	-1	none	_	_
8	useful	_	_	JJ	O	-1	none	_	_
9	tool	_	_	NN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	investigation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	megakaryocytic	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	erythroid	_	_	JJ	O	-1	none	_	_
18	maturation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	FK506	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	ciclosporin	_	_	NN	O	-1	none	_	_
4	:	_	_	:	O	-1	none	_	_
5	molecular	_	_	JJ	O	-1	none	_	_
6	probes	_	_	NNS	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	studying	_	_	VBG	O	-1	none	_	_
9	intracellular	_	_	JJ	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transduction	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	immunosuppressants	_	_	NNS	O	-1	none	_	_
3	ciclosporin	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	FK506	_	_	NN	O	-1	none	_	_
6	block	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	Ca	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	2+	_	_	CD	O	-1	none	_	_
11	)-dependent	_	_	JJ	O	-1	none	_	_
12	signal-transduction	_	_	NN	O	-1	none	_	_
13	pathway	_	_	NN	O	-1	none	_	_
14	emanating	_	_	VBG	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	T-cell	_	_	NN	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	thereby	_	_	RB	O	-1	none	_	_
21	inhibiting	_	_	VBG	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	helper	_	_	NN	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	drugs	_	_	NNS	O	-1	none	_	_
4	as	_	_	IN	O	-1	none	_	_
5	probes	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	chemists	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	biologists	_	_	NNS	O	-1	none	_	_
10	have	_	_	VBP	O	-1	none	_	_
11	uncovered	_	_	VBN	O	-1	none	_	_
12	several	_	_	JJ	O	-1	none	_	_
13	intracellular	_	_	JJ	O	-1	none	_	_
14	signalling	_	_	NN	O	-1	none	_	_
15	molecules	_	_	NNS	O	-1	none	_	_
16	bridging	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	generation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	second-messenger	_	_	NN	O	-1	none	_	_
21	Ca2+	_	_	NN	O	-1	none	_	_
22	ions	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	transcriptional	_	_	JJ	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	IL-2	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	among	_	_	IN	O	-1	none	_	_
31	which	_	_	WDT	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	calmodulin	_	_	NN	Protein	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	calcineurin	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	nuclear	_	_	JJ	O	-1	none	_	_
39	factor	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	activated	_	_	VBN	O	-1	none	_	_
42	T	_	_	NN	O	-1	none	_	_
43	cells	_	_	NNS	O	-1	none	_	_
44	(	_	_	-LRB-	O	-1	none	_	_
45	NF-AT	_	_	NN	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	Hence	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Ca2+	_	_	NN	O	-1	none	_	_
4	binds	_	_	VBZ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	calmodulin	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	leading	_	_	VBG	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	calmodulin	_	_	NN	Protein	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	calcineurin	_	_	NN	O	-1	none	_	_
16	;	_	_	:	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	activated	_	_	JJ	O	-1	none	_	_
19	calcineurin	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	turn	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	may	_	_	MD	O	-1	none	_	_
25	dephosphorylate	_	_	VB	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	cytoplasmic	_	_	JJ	O	-1	none	_	_
28	subunit	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	NF-AT	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	resulting	_	_	VBG	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	its	_	_	PRP$	O	-1	none	_	_
35	translocation	_	_	NN	O	-1	none	_	_
36	from	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	cytoplasm	_	_	NN	O	-1	none	_	_
39	into	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	nucleus	_	_	NN	O	-1	none	_	_
42	to	_	_	TO	O	-1	none	_	_
43	form	_	_	VB	O	-1	none	_	_
44	a	_	_	DT	O	-1	none	_	_
45	competent	_	_	JJ	O	-1	none	_	_
46	transcriptional	_	_	JJ	O	-1	none	_	_
47	activator	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	described	_	_	VBN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	Jun	_	_	NN	O	-1	none	_	_
5	Liu	_	_	NNP	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	drugs	_	_	NNS	O	-1	none	_	_
9	manifest	_	_	VBP	O	-1	none	_	_
10	their	_	_	PRP$	O	-1	none	_	_
11	effects	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	unprecedented	_	_	JJ	O	-1	none	_	_
15	fashion	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	They	_	_	PRP	O	-1	none	_	_
2	do	_	_	VBP	O	-1	none	_	_
3	not	_	_	RB	O	-1	none	_	_
4	directly	_	_	RB	O	-1	none	_	_
5	intercept	_	_	VB	O	-1	none	_	_
6	intracellular	_	_	JJ	O	-1	none	_	_
7	signalling	_	_	NN	O	-1	none	_	_
8	molecules	_	_	NNS	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Instead	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	they	_	_	PRP	O	-1	none	_	_
4	form	_	_	VBP	O	-1	none	_	_
5	tight	_	_	JJ	O	-1	none	_	_
6	complexes	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	two	_	_	CD	O	-1	none	_	_
9	different	_	_	JJ	O	-1	none	_	_
10	classes	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	abundant	_	_	JJ	O	-1	none	_	_
13	cytosolic	_	_	JJ	O	-1	none	_	_
14	receptors	_	_	NNS	O	-1	none	_	_
15	called	_	_	VBN	O	-1	none	_	_
16	immunophilins	_	_	NNS	O	-1	none	_	_
17	upon	_	_	IN	O	-1	none	_	_
18	entering	_	_	VBG	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	consequently	_	_	RB	O	-1	none	_	_
24	inhibit	_	_	VBP	O	-1	none	_	_
25	their	_	_	PRP$	O	-1	none	_	_
26	peptidyl	_	_	JJ	O	-1	none	_	_
27	prolyl	_	_	JJ	O	-1	none	_	_
28	cis-trans	_	_	JJ	O	-1	none	_	_
29	isomerase	_	_	NN	O	-1	none	_	_
30	activities	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	two	_	_	CD	O	-1	none	_	_
3	structurally	_	_	RB	O	-1	none	_	_
4	distinct	_	_	JJ	O	-1	none	_	_
5	immunophilin-drug	_	_	JJ	O	-1	none	_	_
6	complexes	_	_	NNS	O	-1	none	_	_
7	bind	_	_	VBP	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	inhibit	_	_	VBP	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	phosphatase	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	calcineurin	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Vitamin	_	_	NN	Protein	3	multitoken	_	_
2	D	_	_	NN	Protein	3	multitoken	_	_
3	receptor	_	_	NN	Protein	0	root	_	_
4	3	_	_	CD	O	-1	none	_	_
5	'-untranslated	_	_	JJ	O	-1	none	_	_
6	region	_	_	NN	O	-1	none	_	_
7	polymorphisms	_	_	NNS	O	-1	none	_	_
8	:	_	_	:	O	-1	none	_	_
9	lack	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	effect	_	_	NN	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	stability	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Allelic	_	_	JJ	O	-1	none	_	_
2	variation	_	_	NN	O	-1	none	_	_
3	at	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	3	_	_	CD	O	-1	none	_	_
6	'-end	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	vitamin	_	_	NN	Protein	11	multitoken	_	_
10	D	_	_	NN	Protein	11	multitoken	_	_
11	receptor	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	VDR	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	has	_	_	VBZ	O	-1	none	_	_
17	been	_	_	VBN	O	-1	none	_	_
18	associated	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	3-5-fold	_	_	RB	O	-1	none	_	_
22	increased	_	_	VBN	O	-1	none	_	_
23	risk	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	developing	_	_	VBG	O	-1	none	_	_
26	prostate	_	_	NN	O	-1	none	_	_
27	cancer	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	differences	_	_	NNS	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	bone	_	_	NN	O	-1	none	_	_
33	mineralization	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	genetic	_	_	JJ	O	-1	none	_	_
3	diversity	_	_	NN	O	-1	none	_	_
4	does	_	_	VBZ	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	alter	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	VDR	_	_	NN	Protein	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	structurally	_	_	RB	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	instead	_	_	RB	O	-1	none	_	_
14	may	_	_	MD	O	-1	none	_	_
15	be	_	_	VB	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	marker	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	s	_	_	VBZ	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	other	_	_	JJ	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	nearby	_	_	JJ	O	-1	none	_	_
25	polymorphisms	_	_	NNS	O	-1	none	_	_
26	that	_	_	WDT	O	-1	none	_	_
27	influence	_	_	VBP	O	-1	none	_	_
28	message	_	_	NN	O	-1	none	_	_
29	stability	_	_	NN	O	-1	none	_	_
30	or	_	_	CC	O	-1	none	_	_
31	translation	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	work	_	_	NN	O	-1	none	_	_
3	reported	_	_	VBN	O	-1	none	_	_
4	here	_	_	RB	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	instigated	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	identify	_	_	VB	O	-1	none	_	_
9	additional	_	_	JJ	O	-1	none	_	_
10	VDR	_	_	NN	Protein	-1	none	_	_
11	3	_	_	CD	O	-1	none	_	_
12	'-UTR	_	_	NN	O	-1	none	_	_
13	polymorphisms	_	_	NNS	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	have	_	_	VB	O	-1	none	_	_
17	functional	_	_	JJ	O	-1	none	_	_
18	significance	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	then	_	_	RB	O	-1	none	_	_
22	test	_	_	VB	O	-1	none	_	_
23	whether	_	_	IN	O	-1	none	_	_
24	these	_	_	DT	O	-1	none	_	_
25	genetic	_	_	JJ	O	-1	none	_	_
26	variants	_	_	NNS	O	-1	none	_	_
27	alter	_	_	VBP	O	-1	none	_	_
28	message	_	_	NN	O	-1	none	_	_
29	stability	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Initially	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	four	_	_	CD	O	-1	none	_	_
4	novel	_	_	JJ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	frequently	_	_	RB	O	-1	none	_	_
7	occurring	_	_	VBG	O	-1	none	_	_
8	sequence	_	_	NN	O	-1	none	_	_
9	variants	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	identified	_	_	VBN	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	associated	_	_	VBD	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	two	_	_	CD	O	-1	none	_	_
16	common	_	_	JJ	O	-1	none	_	_
17	haplotypes	_	_	NNS	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	described	_	_	VBN	O	-1	none	_	_
21	previously	_	_	RB	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	common	_	_	JJ	O	-1	none	_	_
3	sequence	_	_	NN	O	-1	none	_	_
4	variants	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	found	_	_	VBN	O	-1	none	_	_
8	within	_	_	IN	O	-1	none	_	_
9	three	_	_	CD	O	-1	none	_	_
10	message	_	_	NN	O	-1	none	_	_
11	destabilizing	_	_	JJ	O	-1	none	_	_
12	elements	_	_	NNS	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	mapped	_	_	VBD	O	-1	none	_	_
16	within	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	3	_	_	CD	O	-1	none	_	_
19	'-UTR	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	vitamin	_	_	NN	Protein	24	multitoken	_	_
23	D	_	_	NN	Protein	24	multitoken	_	_
24	receptor	_	_	NN	Protein	0	root	_	_
25	mRNA	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	VDR	_	_	NN	Protein	-1	none	_	_
6	3	_	_	CD	O	-1	none	_	_
7	'-UTR	_	_	NN	O	-1	none	_	_
8	haplotypes	_	_	NNS	O	-1	none	_	_
9	conferred	_	_	VBD	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	identical	_	_	JJ	O	-1	none	_	_
12	half-life	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	heterologous	_	_	JJ	O	-1	none	_	_
16	beta-globin	_	_	NN	O	-1	none	_	_
17	reporter	_	_	NN	O	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	in	_	_	FW	O	-1	none	_	_
23	vitro	_	_	FW	O	-1	none	_	_
24	assay	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	therefore	_	_	RB	O	-1	none	_	_
3	conclude	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	common	_	_	JJ	O	-1	none	_	_
6	polymorphisms	_	_	NNS	O	-1	none	_	_
7	within	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	VDR	_	_	NN	Protein	-1	none	_	_
10	3	_	_	CD	O	-1	none	_	_
11	'-UTR	_	_	NN	O	-1	none	_	_
12	do	_	_	VBP	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	influence	_	_	VB	O	-1	none	_	_
15	message	_	_	NN	O	-1	none	_	_
16	stability	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	BCL-6	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	pathogenesis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	B-cell	_	_	NN	O	-1	none	_	_
8	lymphoma	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	presented	_	_	VBD	O	-1	none	_	_
4	identify	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	first	_	_	JJ	O	-1	none	_	_
7	genetic	_	_	JJ	O	-1	none	_	_
8	lesion	_	_	NN	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	DLCL	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	most	_	_	RBS	O	-1	none	_	_
15	clinically	_	_	RB	O	-1	none	_	_
16	relevant	_	_	JJ	O	-1	none	_	_
17	form	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	NHL	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	no	_	_	DT	O	-1	none	_	_
3	proof	_	_	NN	O	-1	none	_	_
4	yet	_	_	RB	O	-1	none	_	_
5	exists	_	_	VBZ	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	these	_	_	DT	O	-1	none	_	_
11	lesions	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	DLCL	_	_	NN	O	-1	none	_	_
14	pathogenesis	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	feature	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	BCL-6	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	product	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	its	_	_	PRP$	O	-1	none	_	_
25	specific	_	_	JJ	O	-1	none	_	_
26	pattern	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	clustering	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	lesions	_	_	NNS	O	-1	none	_	_
38	disrupting	_	_	VBG	O	-1	none	_	_
39	its	_	_	PRP$	O	-1	none	_	_
40	regulatory	_	_	JJ	O	-1	none	_	_
41	domain	_	_	NN	O	-1	none	_	_
42	strongly	_	_	RB	O	-1	none	_	_
43	suggest	_	_	VBP	O	-1	none	_	_
44	that	_	_	IN	O	-1	none	_	_
45	deregulation	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	BCL-6	_	_	NN	Protein	-1	none	_	_
48	expression	_	_	NN	O	-1	none	_	_
49	may	_	_	MD	O	-1	none	_	_
50	contribute	_	_	VB	O	-1	none	_	_
51	to	_	_	TO	O	-1	none	_	_
52	DLCL	_	_	NN	O	-1	none	_	_
53	development	_	_	NN	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	more	_	_	RBR	O	-1	none	_	_
3	precise	_	_	JJ	O	-1	none	_	_
4	definition	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	BCL-6	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	normal	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	neoplastic	_	_	JJ	O	-1	none	_	_
14	B-cell	_	_	NN	O	-1	none	_	_
15	development	_	_	NN	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	goal	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	ongoing	_	_	JJ	O	-1	none	_	_
21	study	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	transgenic	_	_	JJ	O	-1	none	_	_
24	mice	_	_	NNS	O	-1	none	_	_
25	engineered	_	_	VBN	O	-1	none	_	_
26	either	_	_	CC	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	express	_	_	VB	O	-1	none	_	_
29	BCL-6	_	_	NN	Protein	-1	none	_	_
30	under	_	_	IN	O	-1	none	_	_
31	heterologous	_	_	JJ	O	-1	none	_	_
32	promoters	_	_	NNS	O	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	lacking	_	_	VBG	O	-1	none	_	_
35	BCL-6	_	_	NN	Protein	-1	none	_	_
36	function	_	_	NN	O	-1	none	_	_
37	due	_	_	JJ	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	targeted	_	_	VBN	O	-1	none	_	_
40	deletions	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	contributing	_	_	VBG	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	understanding	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	DLCL	_	_	NN	O	-1	none	_	_
10	pathogenesis	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	identification	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	BCL-6	_	_	NN	Protein	-1	none	_	_
16	lesions	_	_	NNS	O	-1	none	_	_
17	may	_	_	MD	O	-1	none	_	_
18	have	_	_	VB	O	-1	none	_	_
19	relevant	_	_	JJ	O	-1	none	_	_
20	clinical	_	_	JJ	O	-1	none	_	_
21	implications	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	DLCL	_	_	NN	O	-1	none	_	_
2	represent	_	_	VBP	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	heterogeneous	_	_	JJ	O	-1	none	_	_
5	group	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	neoplasms	_	_	NNS	O	-1	none	_	_
8	which	_	_	WDT	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	treated	_	_	VBN	O	-1	none	_	_
11	homogeneously	_	_	RB	O	-1	none	_	_
12	despite	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	fact	_	_	NN	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	only	_	_	RB	O	-1	none	_	_
17	50	_	_	CD	O	-1	none	_	_
18	%	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	patients	_	_	NNS	O	-1	none	_	_
21	experience	_	_	VBP	O	-1	none	_	_
22	long-term	_	_	JJ	O	-1	none	_	_
23	disease-free	_	_	JJ	O	-1	none	_	_
24	survival	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	Schneider	_	_	NNP	O	-1	none	_	_
27	et	_	_	FW	O	-1	none	_	_
28	al.	_	_	FW	O	-1	none	_	_
29	1990	_	_	CD	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	fact	_	_	NN	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	BCL-6	_	_	NN	Protein	-1	none	_	_
5	rearrangements	_	_	NNS	O	-1	none	_	_
6	identify	_	_	VBP	O	-1	none	_	_
7	biologically	_	_	RB	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	clinically	_	_	RB	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	subsets	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	DLCL	_	_	NN	O	-1	none	_	_
14	suggests	_	_	VBZ	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	these	_	_	DT	O	-1	none	_	_
17	lesions	_	_	NNS	O	-1	none	_	_
18	may	_	_	MD	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	useful	_	_	JJ	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	markers	_	_	NNS	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	selection	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	differential	_	_	JJ	O	-1	none	_	_
27	therapeutic	_	_	JJ	O	-1	none	_	_
28	strategies	_	_	NNS	O	-1	none	_	_
29	based	_	_	VBN	O	-1	none	_	_
30	on	_	_	IN	O	-1	none	_	_
31	different	_	_	JJ	O	-1	none	_	_
32	risk	_	_	NN	O	-1	none	_	_
33	groups	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	BCL-6	_	_	NN	Protein	-1	none	_	_
5	rearrangements	_	_	NNS	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	used	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	identify	_	_	VB	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	monitor	_	_	VB	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	malignant	_	_	JJ	O	-1	none	_	_
15	clone	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	sensitive	_	_	JJ	O	-1	none	_	_
18	PCR	_	_	NN	O	-1	none	_	_
19	based	_	_	VBN	O	-1	none	_	_
20	techniques	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	clinical	_	_	JJ	O	-1	none	_	_
3	remission	_	_	NN	O	-1	none	_	_
4	has	_	_	VBZ	O	-1	none	_	_
5	been	_	_	VBN	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	significant	_	_	JJ	O	-1	none	_	_
10	fraction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	DLCL	_	_	NN	O	-1	none	_	_
13	cases	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	these	_	_	DT	O	-1	none	_	_
16	markers	_	_	NNS	O	-1	none	_	_
17	may	_	_	MD	O	-1	none	_	_
18	serve	_	_	VB	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	critical	_	_	JJ	O	-1	none	_	_
21	tools	_	_	NNS	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	sensitive	_	_	JJ	O	-1	none	_	_
24	monitoring	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	minimal	_	_	JJ	O	-1	none	_	_
27	residual	_	_	JJ	O	-1	none	_	_
28	disease	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	early	_	_	JJ	O	-1	none	_	_
31	diagnosis	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	relapse	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	Gribben	_	_	NNP	O	-1	none	_	_
36	et	_	_	FW	O	-1	none	_	_
37	al.	_	_	FW	O	-1	none	_	_
38	1993	_	_	CD	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	role	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	PML	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	normal	_	_	JJ	O	-1	none	_	_
9	adult	_	_	JJ	O	-1	none	_	_
10	hematopoiesis	_	_	NN	O	-1	none	_	_
11	:	_	_	:	O	-1	none	_	_
12	functional	_	_	JJ	O	-1	none	_	_
13	interaction	_	_	NN	O	-1	none	_	_
14	between	_	_	IN	O	-1	none	_	_
15	PML	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	Rb	_	_	NN	Protein	-1	none	_	_
18	proteins	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	erythropoiesis	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	PML	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	investigated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	purified	_	_	VBN	O	-1	none	_	_
11	early	_	_	JJ	O	-1	none	_	_
12	hematopoietic	_	_	JJ	O	-1	none	_	_
13	progenitor	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	HPCs	_	_	NNS	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	induced	_	_	VBD	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	unilineage	_	_	JJ	O	-1	none	_	_
21	erythroid	_	_	JJ	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	granulocytic	_	_	JJ	O	-1	none	_	_
24	differentiation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	PML	_	_	NN	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	while	_	_	IN	O	-1	none	_	_
7	barely	_	_	RB	O	-1	none	_	_
8	detectable	_	_	JJ	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	quiescent	_	_	JJ	O	-1	none	_	_
11	HPCs	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	consistently	_	_	RB	O	-1	none	_	_
15	induced	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	growth	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	stimulation	_	_	NN	O	-1	none	_	_
20	through	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	erythroid	_	_	JJ	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	granulocytic	_	_	JJ	O	-1	none	_	_
25	lineage	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Thereafter	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	PML	_	_	NN	Protein	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	downmodulated	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	late	_	_	JJ	O	-1	none	_	_
8	granulocytic	_	_	JJ	O	-1	none	_	_
9	maturation	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	whereas	_	_	IN	O	-1	none	_	_
12	it	_	_	PRP	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	sustainably	_	_	RB	O	-1	none	_	_
15	expressed	_	_	VBN	O	-1	none	_	_
16	through	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	erythroid	_	_	JJ	O	-1	none	_	_
19	pathway	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	functional	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	PML	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	inhibited	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	addition	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	antisense	_	_	JJ	O	-1	none	_	_
13	oligomers	_	_	NNS	O	-1	none	_	_
14	targeting	_	_	VBG	O	-1	none	_	_
15	PML	_	_	NN	Protein	-1	none	_	_
16	mRNA	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	alpha-PML	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	early	_	_	JJ	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	day	_	_	NN	O	-1	none	_	_
7	0	_	_	CD	O	-1	none	_	_
8	HPCs	_	_	NNS	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	alpha-PML	_	_	NN	O	-1	none	_	_
12	reduced	_	_	VBD	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	number	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	erythroid	_	_	JJ	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	granulocytic	_	_	JJ	O	-1	none	_	_
20	colonies	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	whereas	_	_	IN	O	-1	none	_	_
23	late	_	_	JJ	O	-1	none	_	_
24	treatment	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	day	_	_	NN	O	-1	none	_	_
27	5	_	_	CD	O	-1	none	_	_
28	culture	_	_	NN	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	reduced	_	_	VBD	O	-1	none	_	_
31	erythroid	_	_	JJ	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	but	_	_	CC	O	-1	none	_	_
34	not	_	_	RB	O	-1	none	_	_
35	granulocytic	_	_	JJ	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	clonogenesis	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	PML	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	required	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	early	_	_	JJ	O	-1	none	_	_
10	hematopoiesis	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	erythroid	_	_	JJ	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	granulocytic	_	_	JJ	O	-1	none	_	_
17	maturation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	pattern	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	PML	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	normal	_	_	JJ	O	-1	none	_	_
8	hematopoiesis	_	_	NN	O	-1	none	_	_
9	mimics	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	retinoblastoma	_	_	NN	O	-1	none	_	_
13	pRb	_	_	NN	Protein	14	multitoken	_	_
14	105	_	_	CD	Protein	0	root	_	_
15	.	_	_	.	O	-1	none	_	_

1	Combined	_	_	JJ	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	HPCs	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	alpha-PML	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	alpha-Rb	_	_	NN	O	-1	none	_	_
9	oligomers	_	_	NNS	O	-1	none	_	_
10	inhibited	_	_	VBD	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	PML	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	Rb	_	_	NN	Protein	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	completely	_	_	RB	O	-1	none	_	_
19	blocked	_	_	VBD	O	-1	none	_	_
20	erythroid	_	_	JJ	O	-1	none	_	_
21	colony	_	_	NN	O	-1	none	_	_
22	development	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	PML	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	pRb	_	_	NN	Protein	6	multitoken	_	_
6	105	_	_	CD	Protein	0	root	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	co-immunoprecipitated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	cellular	_	_	JJ	O	-1	none	_	_
11	lysates	_	_	NNS	O	-1	none	_	_
12	derived	_	_	VBN	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	precursors	_	_	NNS	O	-1	none	_	_
16	indicating	_	_	VBG	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	functional	_	_	JJ	O	-1	none	_	_
20	interaction	_	_	NN	O	-1	none	_	_
21	may	_	_	MD	O	-1	none	_	_
22	have	_	_	VB	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	biochemical	_	_	JJ	O	-1	none	_	_
25	basis	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	key	_	_	JJ	O	-1	none	_	_
6	functional	_	_	JJ	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	PML	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	early	_	_	JJ	O	-1	none	_	_
12	hematopoiesis	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	late	_	_	JJ	O	-1	none	_	_
15	erythropoiesis	_	_	NN	O	-1	none	_	_
16	:	_	_	:	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	latter	_	_	JJ	O	-1	none	_	_
19	phenomenon	_	_	NN	O	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	be	_	_	VB	O	-1	none	_	_
22	related	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	molecular	_	_	JJ	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	functional	_	_	JJ	O	-1	none	_	_
28	interaction	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	PML	_	_	NN	Protein	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	pRb	_	_	NN	Protein	33	multitoken	_	_
33	105	_	_	CD	Protein	0	root	_	_
34	.	_	_	.	O	-1	none	_	_

1	Aiolos	_	_	NN	Protein	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	controls	_	_	VBZ	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	death	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	regulating	_	_	VBG	O	-1	none	_	_
12	Bcl-2	_	_	NN	Protein	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	its	_	_	PRP$	O	-1	none	_	_
16	cellular	_	_	JJ	O	-1	none	_	_
17	localization	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Ras-Aiolos	_	_	NN	Protein	-1	none	_	_
3	interaction	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	confirmed	_	_	VBN	O	-1	none	_	_
6	in	_	_	FW	O	-1	none	_	_
7	vitro	_	_	FW	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	in	_	_	FW	O	-1	none	_	_
10	vivo	_	_	FW	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	co-immunoprecipitation	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Indirect	_	_	JJ	O	-1	none	_	_
2	immunofluorescence	_	_	NN	O	-1	none	_	_
3	shows	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	controls	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	cellular	_	_	JJ	O	-1	none	_	_
9	distribution	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Aiolos	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	induces	_	_	VBZ	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	required	_	_	VBN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	dissociation	_	_	NN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	Ras	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	identified	_	_	VBD	O	-1	none	_	_
4	functional	_	_	JJ	O	-1	none	_	_
5	Aiolos	_	_	NN	Protein	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	sites	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	Bcl-2	_	_	NN	Protein	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	able	_	_	JJ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	activate	_	_	VB	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	luciferase	_	_	NN	Protein	-1	none	_	_
20	reporter	_	_	NN	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Mutation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Aiolos	_	_	NN	Protein	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	sites	_	_	NNS	O	-1	none	_	_
6	within	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	Bcl-2	_	_	NN	Protein	-1	none	_	_
9	promoter	_	_	NN	O	-1	none	_	_
10	inhibits	_	_	VBZ	O	-1	none	_	_
11	transactivation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	reporter	_	_	NN	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	luciferase	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	suggesting	_	_	VBG	O	-1	none	_	_
19	direct	_	_	JJ	O	-1	none	_	_
20	control	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	Bcl-2	_	_	NN	Protein	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	Aiolos	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	model	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	regulation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	Bcl-2	_	_	NN	Protein	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	via	_	_	IN	O	-1	none	_	_
12	Aiolos	_	_	NN	Protein	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	induces	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	STAT1	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	STAT5	_	_	NN	Protein	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	T-cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-1	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	Tax	_	_	NN	Protein	-1	none	_	_
11	transforms	_	_	VBZ	O	-1	none	_	_
12	normal	_	_	JJ	O	-1	none	_	_
13	T-cells	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	presence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	interleukin	_	_	NN	Protein	22	multitoken	_	_
19	(	_	_	-LRB-	Protein	22	multitoken	_	_
20	IL	_	_	NN	Protein	22	multitoken	_	_
21	)	_	_	-RRB-	Protein	22	multitoken	_	_
22	-2	_	_	CD	Protein	0	root	_	_
23	in	_	_	FW	O	-1	none	_	_
24	vitro	_	_	FW	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	STAT	_	_	NN	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	family	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	play	_	_	VBP	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	pivotal	_	_	JJ	O	-1	none	_	_
12	role	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	cytokine	_	_	NN	O	-1	none	_	_
15	induced	_	_	VBD	O	-1	none	_	_
16	functions	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	various	_	_	JJ	O	-1	none	_	_
20	type	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	involvement	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	STATs	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	transformation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	T-cells	_	_	NNS	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	HTLV-1	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	HTLV-1-transformed	_	_	NNP	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	expressed	_	_	VBD	O	-1	none	_	_
5	higher	_	_	JJR	O	-1	none	_	_
6	amounts	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	STAT1	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	STAT3	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	STAT5	_	_	NN	Protein	-1	none	_	_
13	RNA	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	than	_	_	IN	O	-1	none	_	_
17	virus	_	_	NN	O	-1	none	_	_
18	negative	_	_	JJ	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STAT1	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	STAT5	_	_	NN	Protein	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	T-cell	_	_	NN	O	-1	none	_	_
11	line	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	Tax	_	_	NN	Protein	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	IL-2	_	_	NNP	Protein	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	STAT3	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	STAT5	_	_	NN	Protein	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	HTLV-1-transformed	_	_	JJ	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	line	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	then	_	_	RB	O	-1	none	_	_
18	stimulated	_	_	VBD	O	-1	none	_	_
19	its	_	_	PRP$	O	-1	none	_	_
20	proliferation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	did	_	_	VBD	O	-1	none	_	_
6	neither	_	_	CC	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	line	_	_	NN	O	-1	none	_	_
11	lacking	_	_	VBG	O	-1	none	_	_
12	STAT3	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	STAT5	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STAT1	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	STAT3	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	STAT5	_	_	NN	Protein	-1	none	_	_
9	mRNAs	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	T-cell	_	_	NN	O	-1	none	_	_
16	mitogen	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	normal	_	_	JJ	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	peripheral	_	_	JJ	O	-1	none	_	_
21	blood	_	_	NN	O	-1	none	_	_
22	mononuclear	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Lymphocyte	_	_	NN	O	-1	none	_	_
2	glucocorticoid	_	_	NN	Protein	3	multitoken	_	_
3	receptor	_	_	NN	Protein	0	root	_	_
4	:	_	_	:	O	-1	none	_	_
5	predictor	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	sertraline	_	_	NN	O	-1	none	_	_
8	response	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	adolescent	_	_	JJ	O	-1	none	_	_
11	major	_	_	JJ	O	-1	none	_	_
12	depressive	_	_	JJ	O	-1	none	_	_
13	disorder	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	MDD	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Major	_	_	JJ	O	-1	none	_	_
2	depressive	_	_	JJ	O	-1	none	_	_
3	disorder	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	MDD	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	adolescents	_	_	NNS	O	-1	none	_	_
9	demonstrates	_	_	VBZ	O	-1	none	_	_
10	resistance	_	_	NN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	tricyclic	_	_	JJ	O	-1	none	_	_
13	antidepressants	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	absence	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	hypercortisolemia	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	efficacy	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	serotonin	_	_	NN	O	-1	none	_	_
5	reuptake	_	_	NN	O	-1	none	_	_
6	inhibitors	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	SRIs	_	_	NNS	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	uncertain	_	_	JJ	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	predictors	_	_	NNS	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	unavailable	_	_	JJ	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Abnormal	_	_	JJ	O	-1	none	_	_
2	fast	_	_	JJ	O	-1	none	_	_
3	feedback	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	negative	_	_	JJ	O	-1	none	_	_
6	feedback	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
10	axis	_	_	NN	O	-1	none	_	_
11	implicates	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	dampened	_	_	JJ	O	-1	none	_	_
14	limbic-hippocampal	_	_	JJ	O	-1	none	_	_
15	glucocorticoid	_	_	NN	Protein	18	multitoken	_	_
16	type	_	_	NN	Protein	18	multitoken	_	_
17	II	_	_	CD	Protein	18	multitoken	_	_
18	receptor	_	_	NN	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	GCII	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	hypothesized	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	lymphocyte	_	_	NN	O	-1	none	_	_
5	GCII	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	altered	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	adolescent	_	_	JJ	O	-1	none	_	_
10	MDD	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	could	_	_	MD	O	-1	none	_	_
13	serve	_	_	VB	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	marker	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	SRIs	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	an	_	_	DT	O	-1	none	_	_
3	open-label	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	adolescents	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	n	_	_	NN	O	-1	none	_	_
9	=	_	_	JJ	O	-1	none	_	_
10	20	_	_	CD	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	meeting	_	_	NN	O	-1	none	_	_
13	DSM-III-R	_	_	NN	O	-1	none	_	_
14	criteria	_	_	NNS	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	MDD	_	_	NN	O	-1	none	_	_
17	showed	_	_	VBD	O	-1	none	_	_
18	baseline	_	_	NN	O	-1	none	_	_
19	lymphocyte	_	_	NN	O	-1	none	_	_
20	GCII	_	_	NN	Protein	-1	none	_	_
21	sites	_	_	NNS	O	-1	none	_	_
22	per	_	_	IN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	sites	_	_	NNS	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	values	_	_	NNS	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	793	_	_	CD	O	-1	none	_	_
32	+/-	_	_	CC	O	-1	none	_	_
33	106	_	_	CD	O	-1	none	_	_
34	versus	_	_	CC	O	-1	none	_	_
35	2,563	_	_	CD	O	-1	none	_	_
36	+/-	_	_	CC	O	-1	none	_	_
37	499	_	_	CD	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	+/-	_	_	CC	O	-1	none	_	_
40	SEM	_	_	NN	O	-1	none	_	_
41	)	_	_	-RRB-	O	-1	none	_	_
42	for	_	_	IN	O	-1	none	_	_
43	matched	_	_	VBN	O	-1	none	_	_
44	controls	_	_	NNS	O	-1	none	_	_
45	(	_	_	-LRB-	O	-1	none	_	_
46	n	_	_	NN	O	-1	none	_	_
47	=	_	_	JJ	O	-1	none	_	_
48	18	_	_	CD	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	(	_	_	-LRB-	O	-1	none	_	_
51	t	_	_	NN	O	-1	none	_	_
52	=	_	_	JJ	O	-1	none	_	_
53	3.5	_	_	CD	O	-1	none	_	_
54	;	_	_	:	O	-1	none	_	_
55	df	_	_	NN	O	-1	none	_	_
56	=	_	_	JJ	O	-1	none	_	_
57	36	_	_	CD	O	-1	none	_	_
58	;	_	_	:	O	-1	none	_	_
59	p	_	_	NN	O	-1	none	_	_
60	<	_	_	JJR	O	-1	none	_	_
61	.001	_	_	CD	O	-1	none	_	_
62	)	_	_	-RRB-	O	-1	none	_	_
63	.	_	_	.	O	-1	none	_	_

1	GCII	_	_	NN	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	bimodally	_	_	RB	O	-1	none	_	_
4	distributed	_	_	VBN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	SRI	_	_	NN	O	-1	none	_	_
8	responders	_	_	NNS	O	-1	none	_	_
9	differing	_	_	VBG	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	nonresponders	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	t	_	_	NN	O	-1	none	_	_
14	=	_	_	JJ	O	-1	none	_	_
15	3.9	_	_	CD	O	-1	none	_	_
16	;	_	_	:	O	-1	none	_	_
17	df	_	_	NN	O	-1	none	_	_
18	=	_	_	JJ	O	-1	none	_	_
19	14	_	_	CD	O	-1	none	_	_
20	;	_	_	:	O	-1	none	_	_
21	p	_	_	NN	O	-1	none	_	_
22	<	_	_	JJR	O	-1	none	_	_
23	.001	_	_	CD	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	GCII	_	_	NN	Protein	-1	none	_	_
2	accurately	_	_	RB	O	-1	none	_	_
3	classified	_	_	VBD	O	-1	none	_	_
4	90	_	_	CD	O	-1	none	_	_
5	percent	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	sertraline	_	_	NN	O	-1	none	_	_
8	responders	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	80	_	_	CD	O	-1	none	_	_
11	percent	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	nonresponders	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Only	_	_	RB	O	-1	none	_	_
2	SRI	_	_	NN	O	-1	none	_	_
3	responders	_	_	NNS	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	GCII	_	_	NN	Protein	-1	none	_	_
6	sites	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	upregulated	_	_	VBN	O	-1	none	_	_
10	after	_	_	IN	O	-1	none	_	_
11	6	_	_	CD	O	-1	none	_	_
12	weeks	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	treatment	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	t	_	_	NN	O	-1	none	_	_
17	=	_	_	JJ	O	-1	none	_	_
18	2.1	_	_	CD	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	df	_	_	NN	O	-1	none	_	_
21	=	_	_	JJ	O	-1	none	_	_
22	10	_	_	CD	O	-1	none	_	_
23	;	_	_	:	O	-1	none	_	_
24	p	_	_	NN	O	-1	none	_	_
25	<	_	_	JJR	O	-1	none	_	_
26	.05	_	_	CD	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	p65	_	_	NN	Protein	-1	none	_	_
3	subunit	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	NF-kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	regulates	_	_	VBZ	O	-1	none	_	_
8	I	_	_	NN	O	-1	none	_	_
9	kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	two	_	_	CD	O	-1	none	_	_
13	distinct	_	_	JJ	O	-1	none	_	_
14	mechanisms	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Transcription	_	_	NN	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	p50	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	p65	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	generally	_	_	RB	O	-1	none	_	_
12	localized	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cytoplasm	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	inhibitor	_	_	NN	O	-1	none	_	_
19	I	_	_	NN	O	-1	none	_	_
20	kappa	_	_	NN	O	-1	none	_	_
21	B.	_	_	NNP	O	-1	none	_	_
22	Overproduced	_	_	JJ	O	-1	none	_	_
23	I	_	_	NN	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	free	_	_	JJ	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	NF-kappa	_	_	NN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	is	_	_	VBZ	O	-1	none	_	_
33	rapidly	_	_	RB	O	-1	none	_	_
34	degraded	_	_	VBN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	p65	_	_	NN	Protein	-1	none	_	_
4	increases	_	_	VBZ	O	-1	none	_	_
5	endogenous	_	_	JJ	O	-1	none	_	_
6	I	_	_	NN	O	-1	none	_	_
7	kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	carcinoma	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	lymphoid	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	two	_	_	CD	O	-1	none	_	_
18	mechanisms	_	_	NNS	O	-1	none	_	_
19	:	_	_	:	O	-1	none	_	_
20	protein	_	_	NN	O	-1	none	_	_
21	stabilization	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	increased	_	_	VBD	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	I	_	_	NN	O	-1	none	_	_
27	kappa	_	_	NN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	mRNA	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	p65	_	_	NN	Protein	5	multitoken	_	_
5	delta	_	_	NN	Protein	0	root	_	_
6	,	_	_	,	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	naturally	_	_	RB	O	-1	none	_	_
9	occurring	_	_	VBG	O	-1	none	_	_
10	splice	_	_	NN	O	-1	none	_	_
11	variant	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	fails	_	_	VBZ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	markedly	_	_	RB	O	-1	none	_	_
16	augment	_	_	VB	O	-1	none	_	_
17	I	_	_	NN	O	-1	none	_	_
18	kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	protein	_	_	NN	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	overexpressed	_	_	JJ	O	-1	none	_	_
3	p65	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	coexpressed	_	_	JJ	O	-1	none	_	_
6	p50	_	_	NN	Protein	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	cytoplasmic	_	_	JJ	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	whereas	_	_	IN	O	-1	none	_	_
11	p65	_	_	NN	Protein	12	multitoken	_	_
12	delta	_	_	NN	Protein	0	root	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	partly	_	_	RB	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	indicating	_	_	VBG	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	I	_	_	NN	O	-1	none	_	_
21	kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	induced	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	can	_	_	MD	O	-1	none	_	_
27	maintain	_	_	VB	O	-1	none	_	_
28	NF-kappa	_	_	NN	O	-1	none	_	_
29	B	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	cytoplasm	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	p65	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	I	_	_	NN	O	-1	none	_	_
6	kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	linked	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	autoregulatory	_	_	JJ	O	-1	none	_	_
13	loop	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	ensuring	_	_	VBG	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	held	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	cytoplasm	_	_	NN	O	-1	none	_	_
24	until	_	_	IN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	are	_	_	VBP	O	-1	none	_	_
27	specifically	_	_	RB	O	-1	none	_	_
28	induced	_	_	VBN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	translocate	_	_	VB	O	-1	none	_	_
31	it	_	_	PRP	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	nucleus	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Interleukin	_	_	NN	O	-1	none	_	_
2	12	_	_	CD	O	-1	none	_	_
3	induces	_	_	VBZ	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylation	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	STAT4	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Interleukin	_	_	NN	O	-1	none	_	_
2	12	_	_	CD	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	IL-12	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	important	_	_	JJ	O	-1	none	_	_
9	immunoregulatory	_	_	JJ	O	-1	none	_	_
10	cytokine	_	_	NN	O	-1	none	_	_
11	whose	_	_	WP$	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	member	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	hematopoietin	_	_	NN	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	superfamily	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	stimulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	natural	_	_	JJ	O	-1	none	_	_
12	killer	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	IL-12	_	_	NN	O	-1	none	_	_
16	induces	_	_	VBZ	O	-1	none	_	_
17	tyrosine	_	_	NN	O	-1	none	_	_
18	phosphorylation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	Janus	_	_	NN	O	-1	none	_	_
22	family	_	_	NN	O	-1	none	_	_
23	tyrosine	_	_	NN	O	-1	none	_	_
24	kinase	_	_	NN	O	-1	none	_	_
25	JAK2	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Tyk2	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	implicating	_	_	VBG	O	-1	none	_	_
30	these	_	_	DT	O	-1	none	_	_
31	kinases	_	_	NNS	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	immediate	_	_	JJ	O	-1	none	_	_
35	biochemical	_	_	JJ	O	-1	none	_	_
36	response	_	_	NN	O	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	IL-12	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factors	_	_	NNS	O	-1	none	_	_
5	known	_	_	VBN	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	STATs	_	_	NNS	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	signal	_	_	NN	O	-1	none	_	_
10	transducers	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	activators	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	have	_	_	VBP	O	-1	none	_	_
17	been	_	_	VBN	O	-1	none	_	_
18	shown	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	tyrosine	_	_	NN	O	-1	none	_	_
22	phosphorylated	_	_	JJ	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	activated	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	response	_	_	NN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	number	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	cytokines	_	_	NNS	O	-1	none	_	_
32	that	_	_	WDT	O	-1	none	_	_
33	bind	_	_	VBP	O	-1	none	_	_
34	hematopoietin	_	_	NN	O	-1	none	_	_
35	receptors	_	_	NNS	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	activate	_	_	VBP	O	-1	none	_	_
38	JAK	_	_	NN	O	-1	none	_	_
39	kinases	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	report	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	demonstrate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	IL-12	_	_	NN	O	-1	none	_	_
8	induces	_	_	VBZ	O	-1	none	_	_
9	tyrosine	_	_	NN	O	-1	none	_	_
10	phosphorylation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	recently	_	_	RB	O	-1	none	_	_
14	identified	_	_	VBN	O	-1	none	_	_
15	STAT	_	_	NN	O	-1	none	_	_
16	family	_	_	NN	O	-1	none	_	_
17	member	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	STAT4	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	show	_	_	VBP	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	STAT4	_	_	NN	Protein	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	regulated	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	T-cell	_	_	NN	O	-1	none	_	_
30	activation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	IL-12	_	_	NN	O	-1	none	_	_
7	stimulates	_	_	VBZ	O	-1	none	_	_
8	formation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	complex	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	recognizes	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	sequence	_	_	NN	O	-1	none	_	_
19	previously	_	_	RB	O	-1	none	_	_
20	shown	_	_	VBN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	bind	_	_	VB	O	-1	none	_	_
23	STAT	_	_	NN	O	-1	none	_	_
24	proteins	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	that	_	_	IN	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	complex	_	_	NN	O	-1	none	_	_
29	contains	_	_	VBZ	O	-1	none	_	_
30	STAT4	_	_	NN	Protein	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	recent	_	_	JJ	O	-1	none	_	_
7	demonstration	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	JAK	_	_	NN	O	-1	none	_	_
10	phosphorylation	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	IL-12	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	identify	_	_	VBP	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	rapid	_	_	JJ	O	-1	none	_	_
17	signal-transduction	_	_	NN	O	-1	none	_	_
18	pathway	_	_	NN	O	-1	none	_	_
19	likely	_	_	JJ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	mediate	_	_	VB	O	-1	none	_	_
22	IL-12-induced	_	_	JJ	O	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	expression	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Comparison	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	retinoic	_	_	JJ	O	-1	none	_	_
4	acid	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	phorbol	_	_	NN	O	-1	none	_	_
7	myristate	_	_	NN	O	-1	none	_	_
8	acetate	_	_	NN	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	inducers	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	monocytic	_	_	JJ	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	myeloid	_	_	JJ	O	-1	none	_	_
4	leukemia	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	lines	_	_	NNS	O	-1	none	_	_
7	growing	_	_	VBG	O	-1	none	_	_
8	in	_	_	FW	O	-1	none	_	_
9	vitro	_	_	FW	O	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	be	_	_	VB	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	differentiate	_	_	VB	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	more	_	_	RBR	O	-1	none	_	_
17	mature	_	_	JJ	O	-1	none	_	_
18	monocyte	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	macrophage	_	_	NN	O	-1	none	_	_
21	like	_	_	IN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	treatment	_	_	NN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	protein	_	_	NN	O	-1	none	_	_
27	kinase	_	_	NN	O	-1	none	_	_
28	C	_	_	NN	O	-1	none	_	_
29	activating	_	_	VBG	O	-1	none	_	_
30	phorbol	_	_	NN	O	-1	none	_	_
31	esters	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	such	_	_	JJ	O	-1	none	_	_
34	as	_	_	IN	O	-1	none	_	_
35	PMA	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	PMA	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	THP-1	_	_	NN	O	-1	none	_	_
10	myeloid	_	_	JJ	O	-1	none	_	_
11	leukemia	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	line	_	_	NN	O	-1	none	_	_
14	acquire	_	_	NN	O	-1	none	_	_
15	macrophage	_	_	NN	O	-1	none	_	_
16	like	_	_	IN	O	-1	none	_	_
17	characteristics	_	_	NNS	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	treatment	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	all-trans	_	_	JJ	O	-1	none	_	_
22	retinoic	_	_	JJ	O	-1	none	_	_
23	acid	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	RA	_	_	NN	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	analyze	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	signal	_	_	NN	O	-1	none	_	_
5	transduction	_	_	NN	O	-1	none	_	_
6	mechanisms	_	_	NNS	O	-1	none	_	_
7	induced	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	RA	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	first	_	_	RB	O	-1	none	_	_
13	compared	_	_	VBD	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	effects	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	PMA	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	RA	_	_	NN	O	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	genes	_	_	NNS	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	are	_	_	VBP	O	-1	none	_	_
27	known	_	_	VBN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	be	_	_	VB	O	-1	none	_	_
30	regulated	_	_	VBN	O	-1	none	_	_
31	during	_	_	IN	O	-1	none	_	_
32	monocytic	_	_	JJ	O	-1	none	_	_
33	differentiation	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Both	_	_	CC	O	-1	none	_	_
2	RA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	PMA	_	_	NN	O	-1	none	_	_
5	effectively	_	_	RB	O	-1	none	_	_
6	down-regulated	_	_	VBD	O	-1	none	_	_
7	c-myc	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	while	_	_	IN	O	-1	none	_	_
11	c-myb	_	_	NN	Protein	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	decreased	_	_	VBD	O	-1	none	_	_
14	only	_	_	RB	O	-1	none	_	_
15	after	_	_	IN	O	-1	none	_	_
16	PMA	_	_	NN	O	-1	none	_	_
17	treatment	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	beta	_	_	NN	O	-1	none	_	_
5	2-integrin	_	_	JJ	O	-1	none	_	_
6	genes	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	CD11a	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CD11b	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	clearly	_	_	RB	O	-1	none	_	_
14	increased	_	_	VBN	O	-1	none	_	_
15	after	_	_	IN	O	-1	none	_	_
16	both	_	_	DT	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	these	_	_	DT	O	-1	none	_	_
19	treatments	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Their	_	_	PRP$	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	on	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	src	_	_	NN	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	tyrosine	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	different	_	_	JJ	O	-1	none	_	_
12	:	_	_	:	O	-1	none	_	_
13	hck	_	_	NN	Protein	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	similarly	_	_	RB	O	-1	none	_	_
17	induced	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	these	_	_	DT	O	-1	none	_	_
20	agents	_	_	NNS	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	lyn	_	_	NN	Protein	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	stronger	_	_	JJR	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	more	_	_	RBR	O	-1	none	_	_
28	rapid	_	_	JJ	O	-1	none	_	_
29	after	_	_	IN	O	-1	none	_	_
30	RA	_	_	NN	O	-1	none	_	_
31	treatment	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	RA	_	_	NN	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	enhanced	_	_	VBD	O	-1	none	_	_
4	lyn	_	_	NN	Protein	-1	none	_	_
5	mRNA	_	_	NN	O	-1	none	_	_
6	production	_	_	NN	O	-1	none	_	_
7	rapidly	_	_	RB	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	HL-60	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	indicating	_	_	VBG	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	lyn	_	_	NN	Protein	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	common	_	_	JJ	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	monocytic	_	_	JJ	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	granulocytic	_	_	JJ	O	-1	none	_	_
25	maturation	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	myeloid	_	_	JJ	O	-1	none	_	_
28	leukemia	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	examine	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	AP-1	_	_	NN	O	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	involved	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	RA	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	monocytic	_	_	JJ	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	THP-1	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	transiently	_	_	RB	O	-1	none	_	_
20	transfected	_	_	VBN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	chloramphenicol	_	_	NN	Protein	25	multitoken	_	_
24	acetyl	_	_	NN	Protein	25	multitoken	_	_
25	transferase	_	_	NN	Protein	0	root	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	CAT	_	_	NN	Protein	-1	none	_	_
28	)-reporter	_	_	JJ	O	-1	none	_	_
29	gene	_	_	NN	O	-1	none	_	_
30	containing	_	_	VBG	O	-1	none	_	_
31	5	_	_	CD	O	-1	none	_	_
32	copies	_	_	NNS	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	AP-1	_	_	NN	O	-1	none	_	_
36	binding	_	_	NN	O	-1	none	_	_
37	sites	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	PMA	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	RA	_	_	NN	O	-1	none	_	_
7	did	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	induce	_	_	VB	O	-1	none	_	_
10	any	_	_	DT	O	-1	none	_	_
11	CAT	_	_	NN	Protein	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	these	_	_	DT	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	thus	_	_	RB	O	-1	none	_	_
18	suggesting	_	_	VBG	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	RA	_	_	NN	O	-1	none	_	_
22	induced	_	_	VBD	O	-1	none	_	_
23	changes	_	_	NNS	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	those	_	_	DT	O	-1	none	_	_
29	genes	_	_	NNS	O	-1	none	_	_
30	described	_	_	VBN	O	-1	none	_	_
31	above	_	_	IN	O	-1	none	_	_
32	were	_	_	VBD	O	-1	none	_	_
33	not	_	_	RB	O	-1	none	_	_
34	dependent	_	_	JJ	O	-1	none	_	_
35	on	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	AP-1	_	_	NN	O	-1	none	_	_
38	enhancer	_	_	NN	O	-1	none	_	_
39	activity	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Single	_	_	JJ	O	-1	none	_	_
2	point	_	_	NN	O	-1	none	_	_
3	estimation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	glucocorticoid	_	_	NN	Protein	6	multitoken	_	_
6	receptors	_	_	NNS	Protein	0	root	_	_
7	in	_	_	IN	O	-1	none	_	_
8	lymphocytes	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	normal	_	_	JJ	O	-1	none	_	_
11	subjects	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	children	_	_	NNS	O	-1	none	_	_
15	under	_	_	IN	O	-1	none	_	_
16	long	_	_	JJ	O	-1	none	_	_
17	term	_	_	NN	O	-1	none	_	_
18	glucocorticoid	_	_	NN	O	-1	none	_	_
19	treatment	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	single	_	_	JJ	O	-1	none	_	_
3	point	_	_	NN	O	-1	none	_	_
4	assay	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	glucocorticoid	_	_	NN	Protein	7	multitoken	_	_
7	receptors	_	_	NNS	Protein	0	root	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	GR	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	based	_	_	VBN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	measurement	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	dexamethasone	_	_	NN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	been	_	_	VBN	O	-1	none	_	_
24	developed	_	_	VBN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	compared	_	_	VBN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	common	_	_	JJ	O	-1	none	_	_
30	multi-point	_	_	JJ	O	-1	none	_	_
31	Scatchard	_	_	NN	O	-1	none	_	_
32	analysis	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	assay	_	_	NN	O	-1	none	_	_
3	conditions	_	_	NNS	O	-1	none	_	_
4	concentration	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	ligand	_	_	NN	O	-1	none	_	_
8	20	_	_	CD	O	-1	none	_	_
9	nmol/l	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	incubation	_	_	NN	O	-1	none	_	_
12	time	_	_	NN	O	-1	none	_	_
13	2	_	_	CD	O	-1	none	_	_
14	h	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	count	_	_	NN	O	-1	none	_	_
19	2-6	_	_	CD	O	-1	none	_	_
20	mil	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	cells	_	_	NNS	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	tube	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	assay	_	_	NN	O	-1	none	_	_
7	volume	_	_	NN	O	-1	none	_	_
8	0.25	_	_	CD	O	-1	none	_	_
9	ml	_	_	NN	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	found	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	optimal	_	_	JJ	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	attempt	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	undertaken	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	use	_	_	VB	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	harvester	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	separation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	unbound	_	_	JJ	O	-1	none	_	_
18	ligand	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Though	_	_	IN	O	-1	none	_	_
2	specifically	_	_	RB	O	-1	none	_	_
3	bound	_	_	VBN	O	-1	none	_	_
4	dexamethasone	_	_	NN	O	-1	none	_	_
5	measured	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	whole-cell	_	_	JJ	O	-1	none	_	_
8	assay	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	using	_	_	VBG	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	harvester	_	_	NN	O	-1	none	_	_
14	correlated	_	_	VBD	O	-1	none	_	_
15	well	_	_	RB	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	almost	_	_	RB	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	one	_	_	CD	O	-1	none	_	_
20	order	_	_	NN	O	-1	none	_	_
21	lower	_	_	JJR	O	-1	none	_	_
22	values	_	_	NNS	O	-1	none	_	_
23	obtained	_	_	VBN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	latter	_	_	JJ	O	-1	none	_	_
27	method	_	_	NN	O	-1	none	_	_
28	render	_	_	VBP	O	-1	none	_	_
29	it	_	_	PRP	O	-1	none	_	_
30	non	_	_	JJ	O	-1	none	_	_
31	applicable	_	_	JJ	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	receptor	_	_	NN	O	-1	none	_	_
34	quantitation	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	9	_	_	CD	O	-1	none	_	_
5	healthy	_	_	JJ	O	-1	none	_	_
6	volunteers	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	average	_	_	JJ	O	-1	none	_	_
9	GR	_	_	NN	Protein	-1	none	_	_
10	concentration	_	_	NN	O	-1	none	_	_
11	7131	_	_	CD	O	-1	none	_	_
12	+/-	_	_	CC	O	-1	none	_	_
13	1256	_	_	CD	O	-1	none	_	_
14	sites	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	correlated	_	_	VBD	O	-1	none	_	_
19	excellently	_	_	RB	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	those	_	_	DT	O	-1	none	_	_
22	obtained	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	Scatchard	_	_	NN	O	-1	none	_	_
26	analysis	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	single	_	_	JJ	O	-1	none	_	_
3	point	_	_	NN	O	-1	none	_	_
4	assay	_	_	NN	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	applied	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	determination	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	GH	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	10	_	_	CD	O	-1	none	_	_
15	children	_	_	NNS	O	-1	none	_	_
16	treated	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	large	_	_	JJ	O	-1	none	_	_
19	doses	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	prednisone	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	average	_	_	JJ	O	-1	none	_	_
3	values	_	_	NNS	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	healthy	_	_	JJ	O	-1	none	_	_
6	volunteers	_	_	NNS	O	-1	none	_	_
7	did	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	differ	_	_	VB	O	-1	none	_	_
10	significantly	_	_	RB	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	those	_	_	DT	O	-1	none	_	_
13	found	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	these	_	_	DT	O	-1	none	_	_
16	children	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	though	_	_	RB	O	-1	none	_	_
19	much	_	_	RB	O	-1	none	_	_
20	broader	_	_	JJR	O	-1	none	_	_
21	range	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	found	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	patients	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	SCL	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	related	_	_	JJ	O	-1	none	_	_
4	hemopoietic	_	_	JJ	O	-1	none	_	_
5	helix-loop-helix	_	_	JJ	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	helix-loop-helix	_	_	JJ	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	HLH	_	_	JJ	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factors	_	_	NNS	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	include	_	_	VBP	O	-1	none	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	critical	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	differentiation	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	development	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	species	_	_	NNS	O	-1	none	_	_
23	ranging	_	_	VBG	O	-1	none	_	_
24	from	_	_	IN	O	-1	none	_	_
25	plants	_	_	NNS	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	mammals	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Five	_	_	CD	O	-1	none	_	_
2	members	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	family	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	MYC	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	SCL	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	TAL-2	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	LYL-1	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	E2A	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	implicated	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	oncogenic	_	_	JJ	O	-1	none	_	_
21	events	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	human	_	_	NN	O	-1	none	_	_
24	lymphoid	_	_	JJ	O	-1	none	_	_
25	tumors	_	_	NNS	O	-1	none	_	_
26	because	_	_	IN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	their	_	_	PRP$	O	-1	none	_	_
29	consistent	_	_	JJ	O	-1	none	_	_
30	involvement	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	chromosomal	_	_	JJ	O	-1	none	_	_
33	translocations	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	activated	_	_	VBN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	leukemias	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	SCL	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	LYL-1	_	_	NN	Protein	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	low	_	_	JJ	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	undetectable	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	normal	_	_	JJ	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	populations	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	SCL	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	expressed	_	_	VBN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	erythroid	_	_	JJ	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	megakaryocyte	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	mast	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	populations	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	same	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	lineages	_	_	NNS	O	-1	none	_	_
17	as	_	_	IN	O	-1	none	_	_
18	GATA-1	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	zinc-finger	_	_	JJ	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	SCL	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	GATA-1	_	_	NN	Protein	-1	none	_	_
8	undergo	_	_	VBP	O	-1	none	_	_
9	coordinate	_	_	JJ	O	-1	none	_	_
10	modulation	_	_	NN	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	chemically	_	_	RB	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	mouse	_	_	NN	O	-1	none	_	_
18	erythroleukemia	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	down-modulated	_	_	VBN	O	-1	none	_	_
23	during	_	_	IN	O	-1	none	_	_
24	myeloid	_	_	JJ	O	-1	none	_	_
25	differentiation	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	human	_	_	NN	O	-1	none	_	_
28	K562	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	thus	_	_	RB	O	-1	none	_	_
32	implying	_	_	VBG	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	role	_	_	NN	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	SCL	_	_	NN	Protein	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	erythroid	_	_	JJ	O	-1	none	_	_
39	differentiation	_	_	NN	O	-1	none	_	_
40	events	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	contrast	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	GATA-1	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	SCL	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	developing	_	_	VBG	O	-1	none	_	_
14	brain	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	function	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	SCL	_	_	NN	Protein	-1	none	_	_
7	suggest	_	_	VBP	O	-1	none	_	_
8	it	_	_	PRP	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	important	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	proliferation	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	self-renewal	_	_	JJ	O	-1	none	_	_
16	events	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	erythroid	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Impaired	_	_	JJ	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	DQ2	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	DQ8	_	_	NN	Protein	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	HSV	_	_	NN	O	-1	none	_	_
10	VP16	_	_	NN	O	-1	none	_	_
11	peptide	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	DQA1	_	_	NN	O	-1	none	_	_
15	*	_	_	SYM	O	-1	none	_	_
16	0501/DQB1	_	_	NN	O	-1	none	_	_
17	*	_	_	SYM	O	-1	none	_	_
18	0302	_	_	CD	O	-1	none	_	_
19	trans	_	_	JJ	O	-1	none	_	_
20	class	_	_	NN	O	-1	none	_	_
21	II	_	_	CD	O	-1	none	_	_
22	heterodimer	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	DQalpha	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	DQbeta	_	_	NN	Protein	-1	none	_	_
4	trans	_	_	JJ	O	-1	none	_	_
5	heterodimeric	_	_	JJ	O	-1	none	_	_
6	HLA-DQ	_	_	NN	O	-1	none	_	_
7	molecules	_	_	NNS	O	-1	none	_	_
8	form	_	_	VBP	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	individuals	_	_	NNS	O	-1	none	_	_
11	heterozygous	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	DQ2	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	DQ8	_	_	NN	O	-1	none	_	_
17	specificities	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Unique	_	_	JJ	O	-1	none	_	_
2	functions	_	_	NNS	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	disease	_	_	NN	O	-1	none	_	_
5	associations	_	_	NNS	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	postulated	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	such	_	_	JJ	O	-1	none	_	_
11	trans-dimers	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	may	_	_	MD	O	-1	none	_	_
15	be	_	_	VB	O	-1	none	_	_
16	different	_	_	JJ	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	cis	_	_	JJ	O	-1	none	_	_
19	encoded	_	_	VBN	O	-1	none	_	_
20	DQ	_	_	NN	O	-1	none	_	_
21	molecules	_	_	NNS	O	-1	none	_	_
22	encoded	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	corresponding	_	_	JJ	O	-1	none	_	_
26	haplotypes	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	analyzed	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	ability	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	trans-dimer	_	_	NN	O	-1	none	_	_
8	encoded	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	HLA-DQA1	_	_	NN	O	-1	none	_	_
11	*	_	_	SYM	O	-1	none	_	_
12	0501/DQB1	_	_	NN	O	-1	none	_	_
13	*	_	_	SYM	O	-1	none	_	_
14	0302	_	_	CD	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	bind	_	_	VB	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	peptide	_	_	NN	O	-1	none	_	_
19	antigen	_	_	NN	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	interacts	_	_	VBZ	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	DQ	_	_	NN	O	-1	none	_	_
24	molecules	_	_	NNS	O	-1	none	_	_
25	encoded	_	_	VBN	O	-1	none	_	_
26	by	_	_	IN	O	-1	none	_	_
27	both	_	_	CC	O	-1	none	_	_
28	parental	_	_	JJ	O	-1	none	_	_
29	haplotypes	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Markedly	_	_	RB	O	-1	none	_	_
2	impaired	_	_	JJ	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	consistent	_	_	JJ	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	both	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	use	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	different	_	_	JJ	O	-1	none	_	_
14	anchor	_	_	NN	O	-1	none	_	_
15	residues	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	changes	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	levels	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	DQ	_	_	NN	O	-1	none	_	_
23	cis-dimer	_	_	JJ	O	-1	none	_	_
24	availability	_	_	NN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	peptide	_	_	NN	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	interactions	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	rhombotin	_	_	NN	O	-1	none	_	_
3	family	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	cysteine	_	_	NN	O	-1	none	_	_
6	rich	_	_	JJ	O	-1	none	_	_
7	LIM-domain	_	_	JJ	O	-1	none	_	_
8	oncogenes	_	_	NNS	O	-1	none	_	_
9	:	_	_	:	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	members	_	_	NNS	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	involved	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	T-cell	_	_	NN	O	-1	none	_	_
16	translocations	_	_	NNS	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	chromosomes	_	_	NNS	O	-1	none	_	_
20	11p15	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	11p13	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	chromosomal	_	_	JJ	O	-1	none	_	_
3	translocation	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	T-cell	_	_	NN	O	-1	none	_	_
7	leukemia	_	_	NN	O	-1	none	_	_
8	involving	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	short	_	_	JJ	O	-1	none	_	_
11	arm	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	chromosome	_	_	NN	O	-1	none	_	_
15	11	_	_	CD	O	-1	none	_	_
16	at	_	_	IN	O	-1	none	_	_
17	band	_	_	NN	O	-1	none	_	_
18	11p15	_	_	NN	O	-1	none	_	_
19	disrupts	_	_	VBZ	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	rhombotin	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	encodes	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	duplicated	_	_	JJ	O	-1	none	_	_
8	cysteine	_	_	NN	O	-1	none	_	_
9	rich	_	_	JJ	O	-1	none	_	_
10	regions	_	_	NNS	O	-1	none	_	_
11	called	_	_	VBN	O	-1	none	_	_
12	LIM	_	_	NN	O	-1	none	_	_
13	domains	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	show	_	_	VBP	O	-1	none	_	_
17	homology	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	zinc	_	_	NN	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	proteins	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	iron-sulfur	_	_	JJ	O	-1	none	_	_
25	centers	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	ferredoxins	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	homologues	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	rhombotin	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	have	_	_	VBP	O	-1	none	_	_
8	now	_	_	RB	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	isolated	_	_	VBN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	designated	_	_	VBN	O	-1	none	_	_
6	Rhom-2	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	located	_	_	JJ	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	chromosome	_	_	NN	O	-1	none	_	_
13	11	_	_	CD	O	-1	none	_	_
14	at	_	_	IN	O	-1	none	_	_
15	band	_	_	NN	O	-1	none	_	_
16	11p13	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	where	_	_	WRB	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	cluster	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	T-cell	_	_	NN	O	-1	none	_	_
23	leukemia	_	_	NN	O	-1	none	_	_
24	specific	_	_	JJ	O	-1	none	_	_
25	translocations	_	_	NNS	O	-1	none	_	_
26	occur	_	_	VBP	O	-1	none	_	_
27	;	_	_	:	O	-1	none	_	_
28	all	_	_	DT	O	-1	none	_	_
29	translocation	_	_	NN	O	-1	none	_	_
30	breakpoints	_	_	NNS	O	-1	none	_	_
31	at	_	_	IN	O	-1	none	_	_
32	11p13	_	_	NN	O	-1	none	_	_
33	are	_	_	VBP	O	-1	none	_	_
34	upstream	_	_	JJ	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	Rhom-2	_	_	NN	Protein	-1	none	_	_
38	gene	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	mouse	_	_	NN	O	-1	none	_	_
4	Rhom-2	_	_	NN	Protein	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	highly	_	_	RB	O	-1	none	_	_
7	conserved	_	_	VBN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	like	_	_	IN	O	-1	none	_	_
11	rhombotin	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	encode	_	_	VBP	O	-1	none	_	_
14	two	_	_	CD	O	-1	none	_	_
15	tandem	_	_	JJ	O	-1	none	_	_
16	cysteine	_	_	NN	O	-1	none	_	_
17	rich	_	_	JJ	O	-1	none	_	_
18	LIM	_	_	NN	O	-1	none	_	_
19	domains	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Rhom-2	_	_	NNP	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	expressed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	early	_	_	JJ	O	-1	none	_	_
7	mouse	_	_	NN	O	-1	none	_	_
8	development	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	central	_	_	JJ	O	-1	none	_	_
11	nervous	_	_	JJ	O	-1	none	_	_
12	system	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	lung	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	kidney	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	liver	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	spleen	_	_	NN	O	-1	none	_	_
22	but	_	_	CC	O	-1	none	_	_
23	only	_	_	RB	O	-1	none	_	_
24	very	_	_	RB	O	-1	none	_	_
25	low	_	_	JJ	O	-1	none	_	_
26	levels	_	_	NNS	O	-1	none	_	_
27	occur	_	_	VBP	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	thymus	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	other	_	_	JJ	O	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	designated	_	_	VBN	O	-1	none	_	_
6	Rhom-3	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	chromosome	_	_	NN	O	-1	none	_	_
12	11	_	_	CD	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	also	_	_	RB	O	-1	none	_	_
15	retains	_	_	VBZ	O	-1	none	_	_
16	homology	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	LIM	_	_	NN	O	-1	none	_	_
20	domain	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	rhombotin	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	Rhom-2	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	such	_	_	JJ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	common	_	_	JJ	O	-1	none	_	_
9	site	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	chromosomal	_	_	JJ	O	-1	none	_	_
12	damage	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T-cell	_	_	NN	O	-1	none	_	_
15	tumors	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	consistency	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	translocations	_	_	NNS	O	-1	none	_	_
21	near	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	rhombotin	_	_	NN	Protein	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	further	_	_	RB	O	-1	none	_	_
27	examined	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	second	_	_	JJ	O	-1	none	_	_
3	translocation	_	_	NN	O	-1	none	_	_
4	adjacent	_	_	JJ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	rhombotin	_	_	NN	Protein	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	found	_	_	VBN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	same	_	_	JJ	O	-1	none	_	_
13	position	_	_	NN	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	previous	_	_	JJ	O	-1	none	_	_
18	example	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	chromosome	_	_	NN	O	-1	none	_	_
4	bands	_	_	NNS	O	-1	none	_	_
5	11p15	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	rhombotin	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	11p13	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	Rhom-2	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	consistent	_	_	JJ	O	-1	none	_	_
16	sites	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	chromosome	_	_	NN	O	-1	none	_	_
19	translocation	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T-cell	_	_	NN	O	-1	none	_	_
22	leukemia	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	11p15	_	_	NN	O	-1	none	_	_
27	target	_	_	NN	O	-1	none	_	_
28	more	_	_	RBR	O	-1	none	_	_
29	rarely	_	_	RB	O	-1	none	_	_
30	involved	_	_	VBN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	define	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	rhombotin	_	_	NN	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	family	_	_	NN	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	T-cell	_	_	NN	O	-1	none	_	_
13	oncogenes	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	duplicated	_	_	JJ	O	-1	none	_	_
16	cysteine	_	_	NN	O	-1	none	_	_
17	rich	_	_	JJ	O	-1	none	_	_
18	LIM	_	_	NN	O	-1	none	_	_
19	domains	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	NF-ATp	_	_	NN	Protein	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	hallmark	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	unstimulated	_	_	JJ	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	B-CLL	_	_	NN	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	B	_	_	NN	O	-1	none	_	_
2	lymphocytes	_	_	NNS	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	peripheral	_	_	JJ	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	chronic	_	_	JJ	O	-1	none	_	_
11	lymphocytic	_	_	JJ	O	-1	none	_	_
12	leukaemia	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	CLL	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	analysed	_	_	VBN	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	presence	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	DNA	_	_	NN	O	-1	none	_	_
24	binding	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	panel	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	factors	_	_	NNS	O	-1	none	_	_
31	which	_	_	WDT	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	involved	_	_	VBN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	gene	_	_	NN	O	-1	none	_	_
37	control	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	lymphoid	_	_	JJ	O	-1	none	_	_
40	cells	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	following	_	_	JJ	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factors	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	studied	_	_	VBN	O	-1	none	_	_
7	:	_	_	:	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	Octamer	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	Oct-1	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Oct-2	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	members	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	AP-1	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	family	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	NF-AT	_	_	NN	O	-1	none	_	_
23	factors	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	particular	_	_	JJ	O	-1	none	_	_
27	NF-ATp	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	members	_	_	NNS	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	Rel	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	NF-kB	_	_	NN	O	-1	none	_	_
36	family	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	constitutive	_	_	JJ	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	translocation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-ATp	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	member	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	growing	_	_	VBG	O	-1	none	_	_
16	family	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	NF-AT	_	_	NN	O	-1	none	_	_
19	factors	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	hallmark	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	nonstimulated	_	_	JJ	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	CLL	_	_	NN	O	-1	none	_	_
30	patients	_	_	NNS	O	-1	none	_	_
31	that	_	_	WDT	O	-1	none	_	_
32	distinguishes	_	_	VBZ	O	-1	none	_	_
33	B-CLL	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	from	_	_	IN	O	-1	none	_	_
36	'	_	_	''	O	-1	none	_	_
37	normal	_	_	JJ	O	-1	none	_	_
38	'	_	_	''	O	-1	none	_	_
39	B	_	_	NN	O	-1	none	_	_
40	lymphocytes	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	nuclear	_	_	JJ	O	-1	none	_	_
3	appearance	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	NF-kB2	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	p52	_	_	NN	Protein	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	further	_	_	JJ	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	DNA	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	such	_	_	JJ	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	JunD	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	c-Fos	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	FosB	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	detected	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	several	_	_	JJ	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	whereas	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	localisation	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	DNA	_	_	NN	O	-1	none	_	_
28	binding	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	other	_	_	JJ	O	-1	none	_	_
31	factors	_	_	NNS	O	-1	none	_	_
32	such	_	_	JJ	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	c-Jun	_	_	NN	Protein	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	RelA	_	_	NN	Protein	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	p65	_	_	NN	Protein	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	c-Rel	_	_	NN	Protein	-1	none	_	_
41	was	_	_	VBD	O	-1	none	_	_
42	unaltered	_	_	JJ	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	remarkable	_	_	JJ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	B-CLL	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	appearance	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	DNA	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	dramatically	_	_	RB	O	-1	none	_	_
20	affected	_	_	VBN	O	-1	none	_	_
21	whereas	_	_	IN	O	-1	none	_	_
22	other	_	_	JJ	O	-1	none	_	_
23	members	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	same	_	_	JJ	O	-1	none	_	_
27	factor	_	_	NN	O	-1	none	_	_
28	family	_	_	NN	O	-1	none	_	_
29	remained	_	_	VBD	O	-1	none	_	_
30	unaltered	_	_	JJ	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	these	_	_	DT	O	-1	none	_	_
33	leukemic	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	remains	_	_	VBZ	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	be	_	_	VB	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	molecular	_	_	JJ	O	-1	none	_	_
8	events	_	_	NNS	O	-1	none	_	_
9	lead	_	_	VBP	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	'	_	_	''	O	-1	none	_	_
14	pre-activation	_	_	NN	O	-1	none	_	_
15	'	_	_	''	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	i.e.	_	_	FW	O	-1	none	_	_
18	constitutive	_	_	JJ	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	translocation	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	DNA	_	_	NN	O	-1	none	_	_
23	binding	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	these	_	_	DT	O	-1	none	_	_
27	members	_	_	NNS	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	NF-AT	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	NF-kB	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	AP-1	_	_	NN	O	-1	none	_	_
34	factor	_	_	NN	O	-1	none	_	_
35	families	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Th1	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	Th2	_	_	NN	O	-1	none	_	_
6	type	_	_	NN	O	-1	none	_	_
7	cytokines	_	_	NNS	O	-1	none	_	_
8	responding	_	_	VBG	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	HBsAg	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	HBxAg	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	chronic	_	_	JJ	O	-1	none	_	_
15	hepatitis	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cytokine	_	_	NN	O	-1	none	_	_
3	pattern	_	_	NN	O	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	viral	_	_	JJ	O	-1	none	_	_
6	antigen	_	_	NN	O	-1	none	_	_
7	recognition	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	believed	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	exert	_	_	VB	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	profound	_	_	JJ	O	-1	none	_	_
14	influence	_	_	NN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	resolution	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	viral	_	_	JJ	O	-1	none	_	_
20	infections	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	viral	_	_	JJ	O	-1	none	_	_
23	clearance	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	initiated	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	investigate	_	_	VB	O	-1	none	_	_
7	whether	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cytokine	_	_	NN	O	-1	none	_	_
10	imbalance	_	_	NN	O	-1	none	_	_
11	oriented	_	_	VBN	O	-1	none	_	_
12	toward	_	_	IN	O	-1	none	_	_
13	Th2	_	_	NN	O	-1	none	_	_
14	type	_	_	NN	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	plays	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	role	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	chronic	_	_	JJ	O	-1	none	_	_
21	hepatitis	_	_	NN	O	-1	none	_	_
22	B.	_	_	NNP	O	-1	none	_	_
23	Cytokine	_	_	NN	O	-1	none	_	_
24	profiles	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	peripheral	_	_	JJ	O	-1	none	_	_
27	blood	_	_	NN	O	-1	none	_	_
28	mononuclear	_	_	JJ	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	associated	_	_	VBN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	chronic	_	_	JJ	O	-1	none	_	_
33	hepatitis	_	_	NN	O	-1	none	_	_
34	B	_	_	NN	O	-1	none	_	_
35	were	_	_	VBD	O	-1	none	_	_
36	analysed	_	_	VBN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	RT-PCR	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	HBsAg	_	_	NN	Protein	-1	none	_	_
3	stimulation	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	IFN-gamma	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	IL-4	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	IL-10	_	_	NN	Protein	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	detected	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	41	_	_	CD	O	-1	none	_	_
19	%	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	8	_	_	CD	O	-1	none	_	_
22	%	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	41	_	_	CD	O	-1	none	_	_
25	%	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	50	_	_	CD	O	-1	none	_	_
29	%	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	patients	_	_	NNS	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	respectively	_	_	RB	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Among	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	cytokines	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IFN-gamma	_	_	NN	Protein	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	associated	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	high	_	_	JJ	O	-1	none	_	_
13	levels	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	serum	_	_	NN	O	-1	none	_	_
16	AST	_	_	NNP	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	ALT	_	_	NNP	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	could	_	_	MD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	prove	_	_	VB	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	Th2	_	_	NN	O	-1	none	_	_
9	type	_	_	NN	O	-1	none	_	_
10	cytokines	_	_	NNS	O	-1	none	_	_
11	had	_	_	VBD	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	protective	_	_	JJ	O	-1	none	_	_
14	effect	_	_	NN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	hepatocytes	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	HBxAg	_	_	NN	Protein	-1	none	_	_
3	stimulation	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	there	_	_	EX	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	no	_	_	DT	O	-1	none	_	_
8	recognizable	_	_	JJ	O	-1	none	_	_
9	association	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cytokine	_	_	NN	O	-1	none	_	_
12	patterns	_	_	NNS	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	AST	_	_	NNP	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	ALT	_	_	NNP	O	-1	none	_	_
17	levels	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	interleukin-10	_	_	NN	Protein	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	peripheral	_	_	JJ	O	-1	none	_	_
7	blood	_	_	NN	O	-1	none	_	_
8	mononuclear	_	_	JJ	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	responses	_	_	NNS	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	Cryptococcus	_	_	NN	O	-1	none	_	_
13	neoformans	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	Candida	_	_	NN	O	-1	none	_	_
16	albicans	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	lipopolysaccharide	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Deactivation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	mononuclear	_	_	JJ	O	-1	none	_	_
4	phagocytes	_	_	NNS	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	critical	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	limit	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	inflammatory	_	_	JJ	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	can	_	_	MD	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	detrimental	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	face	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	progressive	_	_	JJ	O	-1	none	_	_
21	infection	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	compared	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	deactivating	_	_	VBG	O	-1	none	_	_
8	cytokine	_	_	NN	O	-1	none	_	_
9	interleukin	_	_	NN	Protein	10	multitoken	_	_
10	10	_	_	CD	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	IL-10	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	peripheral	_	_	JJ	O	-1	none	_	_
17	blood	_	_	NN	O	-1	none	_	_
18	mononuclear	_	_	JJ	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	PBMC	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	responses	_	_	NNS	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	lipopolysaccharide	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	LPS	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	Cryptococcus	_	_	NN	O	-1	none	_	_
31	neoformans	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	Candida	_	_	NN	O	-1	none	_	_
35	albicans	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	effected	_	_	VBD	O	-1	none	_	_
3	dose	_	_	NN	O	-1	none	_	_
4	dependent	_	_	JJ	O	-1	none	_	_
5	inhibition	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	tumor	_	_	NN	Protein	10	multitoken	_	_
8	necrosis	_	_	NN	Protein	10	multitoken	_	_
9	factor	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	TNF-alpha	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	release	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	PBMC	_	_	NN	O	-1	none	_	_
17	stimulated	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	LPS	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	C.	_	_	FW	O	-1	none	_	_
22	neoformans	_	_	FW	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	significant	_	_	JJ	O	-1	none	_	_
26	inhibition	_	_	NN	O	-1	none	_	_
27	seen	_	_	VBN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	0.1	_	_	CD	O	-1	none	_	_
30	U/ml	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	greater	_	_	JJR	O	-1	none	_	_
33	than	_	_	IN	O	-1	none	_	_
34	90	_	_	CD	O	-1	none	_	_
35	%	_	_	NN	O	-1	none	_	_
36	inhibition	_	_	NN	O	-1	none	_	_
37	noted	_	_	VBD	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	10	_	_	CD	O	-1	none	_	_
40	U/ml	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	even	_	_	RB	O	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	doses	_	_	NNS	O	-1	none	_	_
7	as	_	_	RB	O	-1	none	_	_
8	high	_	_	JJ	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	100	_	_	CD	O	-1	none	_	_
11	U/ml	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	IL-10	_	_	NN	Protein	-1	none	_	_
14	inhibited	_	_	VBD	O	-1	none	_	_
15	TNF-alpha	_	_	NN	Protein	-1	none	_	_
16	release	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	C.	_	_	NN	O	-1	none	_	_
21	albicans	_	_	NNS	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	only	_	_	RB	O	-1	none	_	_
24	50	_	_	CD	O	-1	none	_	_
25	%	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	profoundly	_	_	RB	O	-1	none	_	_
3	inhibited	_	_	VBD	O	-1	none	_	_
4	release	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IL-1beta	_	_	NN	Protein	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	PBMC	_	_	NN	O	-1	none	_	_
9	stimulated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	all	_	_	DT	O	-1	none	_	_
12	three	_	_	CD	O	-1	none	_	_
13	stimuli	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	TNF-alpha	_	_	NN	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	release	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	inhibited	_	_	VBN	O	-1	none	_	_
7	even	_	_	RB	O	-1	none	_	_
8	if	_	_	IN	O	-1	none	_	_
9	IL-10	_	_	NN	Protein	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	added	_	_	VBN	O	-1	none	_	_
12	up	_	_	RP	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	8	_	_	CD	O	-1	none	_	_
15	h	_	_	NN	O	-1	none	_	_
16	after	_	_	IN	O	-1	none	_	_
17	cryptococcal	_	_	JJ	O	-1	none	_	_
18	stimulation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	inhibition	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IL-1	_	_	NN	Protein	7	multitoken	_	_
7	beta	_	_	NN	Protein	0	root	_	_
8	mRNA	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	lesser	_	_	JJR	O	-1	none	_	_
12	magnitude	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	occurred	_	_	VBD	O	-1	none	_	_
15	only	_	_	RB	O	-1	none	_	_
16	when	_	_	WRB	O	-1	none	_	_
17	IL-10	_	_	NN	Protein	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	added	_	_	VBN	O	-1	none	_	_
20	within	_	_	IN	O	-1	none	_	_
21	2	_	_	CD	O	-1	none	_	_
22	h	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	cryptococcal	_	_	JJ	O	-1	none	_	_
25	stimulation	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	inhibited	_	_	VBD	O	-1	none	_	_
3	translocation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	NF-kappaB	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	response	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	LPS	_	_	NN	O	-1	none	_	_
10	but	_	_	CC	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	fungal	_	_	JJ	O	-1	none	_	_
14	stimuli	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	All	_	_	DT	O	-1	none	_	_
2	three	_	_	CD	O	-1	none	_	_
3	stimuli	_	_	NNS	O	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	IL-10	_	_	NN	Protein	-1	none	_	_
6	production	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	PBMC	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	although	_	_	IN	O	-1	none	_	_
11	over	_	_	IN	O	-1	none	_	_
12	10-fold	_	_	RB	O	-1	none	_	_
13	less	_	_	JJR	O	-1	none	_	_
14	IL-10	_	_	NN	Protein	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	released	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	C.	_	_	FW	O	-1	none	_	_
21	neoformans	_	_	FW	O	-1	none	_	_
22	compared	_	_	VBN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	LPS	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	C.	_	_	NN	O	-1	none	_	_
27	albicans	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	while	_	_	IN	O	-1	none	_	_
4	IL-10	_	_	NN	Protein	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	deactivating	_	_	VBG	O	-1	none	_	_
7	effects	_	_	NNS	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	PBMC	_	_	NN	O	-1	none	_	_
10	responses	_	_	NNS	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	all	_	_	DT	O	-1	none	_	_
13	three	_	_	CD	O	-1	none	_	_
14	stimuli	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	disparate	_	_	JJ	O	-1	none	_	_
17	stimulus-	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	response	_	_	NN	O	-1	none	_	_
20	specific	_	_	JJ	O	-1	none	_	_
21	patterns	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	deactivation	_	_	NN	O	-1	none	_	_
24	are	_	_	VBP	O	-1	none	_	_
25	seen	_	_	VBN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	by	_	_	IN	O	-1	none	_	_
3	IL-10	_	_	NN	Protein	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	proinflammatory	_	_	JJ	O	-1	none	_	_
6	cytokine	_	_	NN	O	-1	none	_	_
7	release	_	_	NN	O	-1	none	_	_
8	appears	_	_	VBZ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	occur	_	_	VB	O	-1	none	_	_
11	at	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	level	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	gene	_	_	NN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	TNF-alpha	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	both	_	_	DT	O	-1	none	_	_
21	transcriptionally	_	_	RB	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	posttranscriptionally	_	_	RB	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	IL-1beta	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	status	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	IL-2R-associated	_	_	JJ	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	Jak	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	STAT	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	pathway	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	HTLV-I	_	_	NN	O	-1	none	_	_
17	infected	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	examined	_	_	VBD	O	-1	none	_	_
22	tyrosine	_	_	NN	O	-1	none	_	_
23	phosphorylation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	Jak3	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	STAT3	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	STAT5	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	several	_	_	JJ	O	-1	none	_	_
33	HTLV-I	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	+	_	_	CC	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	T-cell	_	_	NN	O	-1	none	_	_
38	lines	_	_	NNS	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	uncultured	_	_	JJ	O	-1	none	_	_
42	leukemic	_	_	JJ	O	-1	none	_	_
43	T	_	_	NN	O	-1	none	_	_
44	cells	_	_	NNS	O	-1	none	_	_
45	isolated	_	_	VBN	O	-1	none	_	_
46	from	_	_	IN	O	-1	none	_	_
47	patients	_	_	NNS	O	-1	none	_	_
48	with	_	_	IN	O	-1	none	_	_
49	adult	_	_	JJ	O	-1	none	_	_
50	T-cell	_	_	NN	O	-1	none	_	_
51	lymphoma	_	_	NN	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	leukemia	_	_	NN	O	-1	none	_	_
54	(	_	_	-LRB-	O	-1	none	_	_
55	ATLL	_	_	NN	O	-1	none	_	_
56	)	_	_	-RRB-	O	-1	none	_	_
57	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Similarly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	there	_	_	EX	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	no	_	_	DT	O	-1	none	_	_
6	detectable	_	_	JJ	O	-1	none	_	_
7	basal	_	_	JJ	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Jak3	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	STAT5	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	leukemic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	ATLL	_	_	NN	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	0/8	_	_	CD	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	0/3	_	_	CD	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	respectively	_	_	RB	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	SHP-1	_	_	NN	Protein	6	multitoken	_	_
6	phosphatase	_	_	NN	Protein	0	root	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	negative	_	_	JJ	O	-1	none	_	_
11	regulator	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	cytokine	_	_	NN	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	lost	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	most	_	_	JJS	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	independent	_	_	JJ	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	lines	_	_	NNS	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	3/4	_	_	CD	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	but	_	_	CC	O	-1	none	_	_
29	not	_	_	RB	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	leukemic	_	_	JJ	O	-1	none	_	_
33	ATLL	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	0/3	_	_	CD	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	HTLV-I	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	+	_	_	CC	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	T-cell	_	_	NN	O	-1	none	_	_
9	lines	_	_	NNS	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	313	_	_	CD	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	control	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	HTLV-I	_	_	NN	O	-1	none	_	_
19	(-)	_	_	JJ	O	-1	none	_	_
20	T-cell	_	_	NN	O	-1	none	_	_
21	lines	_	_	NNS	O	-1	none	_	_
22	were	_	_	VBD	O	-1	none	_	_
23	resistant	_	_	JJ	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	rapamycin	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	its	_	_	PRP$	O	-1	none	_	_
28	novel	_	_	JJ	O	-1	none	_	_
29	analog	_	_	NN	O	-1	none	_	_
30	RAD	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	internal	_	_	JJ	O	-1	none	_	_
3	methionine	_	_	NN	O	-1	none	_	_
4	codons	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	T-cell	_	_	NN	O	-1	none	_	_
8	leukemia	_	_	NN	O	-1	none	_	_
9	virus	_	_	NN	O	-1	none	_	_
10	type	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	rex	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	required	_	_	VBN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	p24rex	_	_	NN	Protein	-1	none	_	_
19	production	_	_	NN	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	virus	_	_	NN	O	-1	none	_	_
22	replication	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	transformation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	types	_	_	NNS	O	-1	none	_	_
6	I	_	_	PRP	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	HTLV-II	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	have	_	_	VBP	O	-1	none	_	_
16	two	_	_	CD	O	-1	none	_	_
17	nonstructural	_	_	JJ	O	-1	none	_	_
18	trans-acting	_	_	JJ	O	-1	none	_	_
19	regulatory	_	_	JJ	O	-1	none	_	_
20	genes	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	tax	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	rex	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	located	_	_	JJ	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	3	_	_	CD	O	-1	none	_	_
30	'	_	_	''	O	-1	none	_	_
31	region	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	viral	_	_	JJ	O	-1	none	_	_
35	genome	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	tax	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	product	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	HTLV-I	_	_	NN	O	-1	none	_	_
7	p40tax	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	HTLV-II	_	_	NN	O	-1	none	_	_
10	p37tax	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	transcriptional	_	_	JJ	O	-1	none	_	_
15	activator	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	viral	_	_	JJ	O	-1	none	_	_
19	long	_	_	JJ	O	-1	none	_	_
20	terminal	_	_	JJ	O	-1	none	_	_
21	repeat	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	rex	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	encodes	_	_	VBZ	O	-1	none	_	_
5	two	_	_	CD	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	products	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	p27rex	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p21rex	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	p26rex	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	p24rex	_	_	NN	Protein	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	HTLV-I	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	HTLV-II	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	respectively	_	_	RB	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Rex	_	_	NN	Protein	-1	none	_	_
2	acts	_	_	VBZ	O	-1	none	_	_
3	posttranscriptionally	_	_	RB	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	facilitate	_	_	VB	O	-1	none	_	_
6	accumulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	full-length	_	_	JJ	O	-1	none	_	_
9	gag	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	pol	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	singly	_	_	RB	O	-1	none	_	_
14	spliced	_	_	VBN	O	-1	none	_	_
15	env	_	_	NN	Protein	-1	none	_	_
16	mRNA	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	cytoplasm	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	HTLV	_	_	NN	O	-1	none	_	_
22	infected	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	first	_	_	JJ	O	-1	none	_	_
7	ATG	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	rex	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	critical	_	_	JJ	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	Rex	_	_	NN	Protein	-1	none	_	_
16	production	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	function	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	importance	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	internal	_	_	JJ	O	-1	none	_	_
6	ATGs	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	Rex	_	_	NN	Protein	-1	none	_	_
9	function	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	known	_	_	VBN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	FW	O	-1	none	_	_
4	vitro	_	_	FW	O	-1	none	_	_
5	mutagenesis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	rex	_	_	NN	Protein	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	has	_	_	VBZ	O	-1	none	_	_
12	provided	_	_	VBN	O	-1	none	_	_
13	indirect	_	_	JJ	O	-1	none	_	_
14	evidence	_	_	NN	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	suggests	_	_	VBZ	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	p21rex	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	analogy	_	_	NN	O	-1	none	_	_
23	HTLV-II	_	_	NN	O	-1	none	_	_
24	p24rex	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	results	_	_	VBZ	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	initiation	_	_	NN	O	-1	none	_	_
29	at	_	_	IN	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	internal	_	_	JJ	O	-1	none	_	_
32	AUG	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	tax	_	_	NN	Protein	37	multitoken	_	_
36	and	_	_	CC	Protein	37	multitoken	_	_
37	rex	_	_	NN	Protein	0	root	_	_
38	mRNA	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	infectious	_	_	JJ	O	-1	none	_	_
5	molecular	_	_	JJ	O	-1	none	_	_
6	clone	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	HTLV-II	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	we	_	_	PRP	O	-1	none	_	_
11	investigated	_	_	VBD	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	importance	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	internal	_	_	JJ	O	-1	none	_	_
17	ATGs	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	rex	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	Rex	_	_	NN	Protein	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	production	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	function	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	p24rex	_	_	NN	Protein	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	HTLV-II	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	initiated	_	_	VBN	O	-1	none	_	_
11	at	_	_	IN	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	internal	_	_	JJ	O	-1	none	_	_
14	AUG	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	internal	_	_	JJ	O	-1	none	_	_
19	methionine	_	_	NN	O	-1	none	_	_
20	codons	_	_	NNS	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	crucial	_	_	JJ	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	function	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	rex	_	_	NN	Protein	-1	none	_	_
30	gene	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	ultimately	_	_	RB	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	transforming	_	_	VBG	O	-1	none	_	_
37	properties	_	_	NNS	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	virus	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Ras	_	_	NN	O	-1	none	_	_
2	oncogene	_	_	NN	O	-1	none	_	_
3	transformation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	lymphoblasts	_	_	NNS	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	lymphocyte	_	_	NN	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	block	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	differentiation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	p21ras	_	_	NN	Protein	-1	none	_	_
3	small	_	_	JJ	O	-1	none	_	_
4	GTP	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	participate	_	_	VBP	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	signal	_	_	NN	O	-1	none	_	_
10	transduction	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	surface	_	_	NN	O	-1	none	_	_
14	receptors	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	affect	_	_	VB	O	-1	none	_	_
17	neoplastic	_	_	JJ	O	-1	none	_	_
18	transformation	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	development	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	many	_	_	JJ	O	-1	none	_	_
23	different	_	_	JJ	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	types	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	examined	_	_	VBD	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	relationship	_	_	NN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	ras	_	_	NN	O	-1	none	_	_
12	transformation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	constitutive	_	_	JJ	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	T24	_	_	NN	O	-1	none	_	_
10	Ha-ras	_	_	NN	O	-1	none	_	_
11	oncogene	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	EBV	_	_	NN	O	-1	none	_	_
14	immortalized	_	_	VBN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	lymphoblasts	_	_	NNS	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	associated	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	induction	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	interleukin	_	_	NN	Protein	27	multitoken	_	_
25	2	_	_	CD	Protein	27	multitoken	_	_
26	receptor	_	_	NN	Protein	27	multitoken	_	_
27	alpha	_	_	NN	Protein	0	root	_	_
28	subunit	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	an	_	_	DT	O	-1	none	_	_
32	impaired	_	_	JJ	O	-1	none	_	_
33	immunoglobulin	_	_	NN	O	-1	none	_	_
34	gene	_	_	NN	O	-1	none	_	_
35	expression	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	altered	_	_	JJ	O	-1	none	_	_
38	adhesion	_	_	NN	O	-1	none	_	_
39	properties	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	increased	_	_	VBD	O	-1	none	_	_
42	survival	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	serum-free	_	_	JJ	O	-1	none	_	_
45	medium	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	7	multitoken	_	_
6	receptor	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	subunit	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	hallmark	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	lymphocyte	_	_	NN	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	we	_	_	PRP	O	-1	none	_	_
17	suggest	_	_	VBP	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	p21ras	_	_	NN	Protein	-1	none	_	_
20	naturally	_	_	RB	O	-1	none	_	_
21	triggers	_	_	VBZ	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ras	_	_	NN	O	-1	none	_	_
3	transformed	_	_	VBN	O	-1	none	_	_
4	lymphocytes	_	_	NNS	O	-1	none	_	_
5	displayed	_	_	VBD	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	fully	_	_	RB	O	-1	none	_	_
8	functional	_	_	JJ	O	-1	none	_	_
9	IL-2r	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	assessed	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	c-fos	_	_	NN	Protein	-1	none	_	_
15	induction	_	_	NN	O	-1	none	_	_
16	following	_	_	VBG	O	-1	none	_	_
17	treatment	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	IL-2	_	_	NN	Protein	-1	none	_	_
20	;	_	_	:	O	-1	none	_	_
21	nevertheless	_	_	RB	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	they	_	_	PRP	O	-1	none	_	_
24	were	_	_	VBD	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	growth	_	_	NN	O	-1	none	_	_
27	stimulated	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	this	_	_	DT	O	-1	none	_	_
30	lymphokine	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	decreased	_	_	JJ	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	immunoglobulin	_	_	NN	O	-1	none	_	_
6	genes	_	_	NNS	O	-1	none	_	_
7	indicates	_	_	VBZ	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	ras	_	_	NN	O	-1	none	_	_
11	oncogene	_	_	NN	O	-1	none	_	_
12	blocks	_	_	VBZ	O	-1	none	_	_
13	terminal	_	_	JJ	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	plasma	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	possibly	_	_	RB	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	inhibiting	_	_	VBG	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	lymphocyte	_	_	NN	O	-1	none	_	_
26	specific	_	_	JJ	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factors	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Somewhat	_	_	RB	O	-1	none	_	_
2	unexpectedly	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	constitutive	_	_	JJ	O	-1	none	_	_
6	p21ras	_	_	NN	Protein	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	did	_	_	VBD	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	cause	_	_	VB	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	increased	_	_	JJ	O	-1	none	_	_
13	DNA	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	PEA1	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	AP1	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	PEA3	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	Oct-2	_	_	NN	Protein	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	NF-kB	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Differential	_	_	JJ	O	-1	none	_	_
2	nuclear	_	_	JJ	O	-1	none	_	_
3	localization	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	p50	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	p52	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	RelB	_	_	NN	Protein	-1	none	_	_
11	proteins	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	accessory	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	immune	_	_	JJ	O	-1	none	_	_
19	response	_	_	NN	O	-1	none	_	_
20	in	_	_	FW	O	-1	none	_	_
21	situ	_	_	FW	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Rel	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	p50	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	p52	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	p65	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	c-Rel	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	RelB	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	constitute	_	_	VBP	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	family	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	factors	_	_	NNS	O	-1	none	_	_
25	involved	_	_	VBN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	positive	_	_	JJ	O	-1	none	_	_
29	regulation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	variety	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	genes	_	_	NNS	O	-1	none	_	_
35	during	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	immune	_	_	JJ	O	-1	none	_	_
38	response	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	has	_	_	VBZ	O	-1	none	_	_
5	been	_	_	VBN	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	RelB	_	_	NN	Protein	-1	none	_	_
9	knockout	_	_	NN	O	-1	none	_	_
10	mice	_	_	NNS	O	-1	none	_	_
11	have	_	_	VBP	O	-1	none	_	_
12	no	_	_	DT	O	-1	none	_	_
13	dendritic	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	DC	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p50	_	_	NN	Protein	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	described	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	follicular	_	_	JJ	O	-1	none	_	_
10	dendritic	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	FDC	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	constitutive	_	_	JJ	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	has	_	_	VBZ	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	reported	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	mature	_	_	JJ	O	-1	none	_	_
11	macrophages	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	led	_	_	VBD	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	hypothesis	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	some	_	_	DT	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	Rel	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	key	_	_	JJ	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	factors	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	functions	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	accessory	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	immune	_	_	JJ	O	-1	none	_	_
27	response	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	investigated	_	_	VBD	O	-1	none	_	_
5	in	_	_	FW	O	-1	none	_	_
6	situ	_	_	FW	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	localization	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Rel	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	accessory	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	immune	_	_	JJ	O	-1	none	_	_
22	system	_	_	NN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	immunohistochemistry	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	double	_	_	JJ	O	-1	none	_	_
27	labeling	_	_	NN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	immunofluorescence	_	_	NN	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	five	_	_	CD	O	-1	none	_	_
32	normal	_	_	JJ	O	-1	none	_	_
33	human	_	_	NN	O	-1	none	_	_
34	tonsils	_	_	NNS	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	five	_	_	CD	O	-1	none	_	_
37	lymph	_	_	NN	O	-1	none	_	_
38	nodes	_	_	NNS	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	follicular	_	_	JJ	O	-1	none	_	_
41	hyperplasia	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	p65	_	_	NN	Protein	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	c-Rel	_	_	NN	Protein	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	found	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	all	_	_	DT	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	types	_	_	NNS	O	-1	none	_	_
12	including	_	_	VBG	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Cells	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	p50	_	_	NN	Protein	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	negative	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	CD38	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	CD20	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	CD2	_	_	NN	Protein	-1	none	_	_
14	markers	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	different	_	_	JJ	O	-1	none	_	_
3	patterns	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	p50	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	p52	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	RelB	_	_	NN	Protein	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	localization	_	_	NN	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	provide	_	_	VB	O	-1	none	_	_
15	insight	_	_	NN	O	-1	none	_	_
16	into	_	_	IN	O	-1	none	_	_
17	their	_	_	PRP$	O	-1	none	_	_
18	different	_	_	JJ	O	-1	none	_	_
19	roles	_	_	NNS	O	-1	none	_	_
20	during	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	immune	_	_	JJ	O	-1	none	_	_
23	response	_	_	NN	O	-1	none	_	_
24	in	_	_	FW	O	-1	none	_	_
25	vivo	_	_	FW	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Multicolor	_	_	JJ	O	-1	none	_	_
2	flow	_	_	NN	O	-1	none	_	_
3	cytometric	_	_	JJ	O	-1	none	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	confirmed	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	coexpression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	myeloid	_	_	JJ	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	CD33	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	CD13	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	CD15	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	NK	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	associated	_	_	VBN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	CD56	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	antigens	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	each	_	_	DT	O	-1	none	_	_
27	case	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	whereas	_	_	IN	O	-1	none	_	_
30	reverse	_	_	JJ	O	-1	none	_	_
31	transcription	_	_	NN	O	-1	none	_	_
32	polymerase	_	_	NN	O	-1	none	_	_
33	chain	_	_	NN	O	-1	none	_	_
34	reaction	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	RT-PCR	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	assays	_	_	NNS	O	-1	none	_	_
39	confirmed	_	_	VBD	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	identity	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	CD56	_	_	NN	Protein	-1	none	_	_
44	(	_	_	-LRB-	O	-1	none	_	_
45	neural	_	_	JJ	O	-1	none	_	_
46	cell	_	_	NN	O	-1	none	_	_
47	adhesion	_	_	NN	O	-1	none	_	_
48	molecule	_	_	NN	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	in	_	_	IN	O	-1	none	_	_
51	leukemic	_	_	JJ	O	-1	none	_	_
52	blasts	_	_	NNS	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	two	_	_	CD	O	-1	none	_	_
3	cases	_	_	NNS	O	-1	none	_	_
4	expressed	_	_	VBD	O	-1	none	_	_
5	CD4	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	no	_	_	DT	O	-1	none	_	_
8	case	_	_	NN	O	-1	none	_	_
9	expressed	_	_	VBD	O	-1	none	_	_
10	CD2	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	CD3	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	CD8	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	no	_	_	DT	O	-1	none	_	_
18	case	_	_	NN	O	-1	none	_	_
19	showed	_	_	VBD	O	-1	none	_	_
20	clonal	_	_	JJ	O	-1	none	_	_
21	rearrangement	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	genes	_	_	NNS	O	-1	none	_	_
24	encoding	_	_	VBG	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	T-cell	_	_	NN	O	-1	none	_	_
27	receptor	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	TCR	_	_	NN	Protein	30	multitoken	_	_
30	beta	_	_	NN	Protein	0	root	_	_
31	,	_	_	,	O	-1	none	_	_
32	gamma	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	delta	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Leukemic	_	_	JJ	O	-1	none	_	_
2	blasts	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	majority	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	cases	_	_	NNS	O	-1	none	_	_
8	shared	_	_	VBN	O	-1	none	_	_
9	unique	_	_	JJ	O	-1	none	_	_
10	morphologic	_	_	JJ	O	-1	none	_	_
11	features	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	deeply	_	_	RB	O	-1	none	_	_
14	invaginated	_	_	JJ	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	membranes	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	scant	_	_	JJ	O	-1	none	_	_
19	cytoplasm	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	fine	_	_	JJ	O	-1	none	_	_
22	azurophilic	_	_	JJ	O	-1	none	_	_
23	granularity	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	finely	_	_	RB	O	-1	none	_	_
27	granular	_	_	JJ	O	-1	none	_	_
28	Sudan	_	_	NNP	O	-1	none	_	_
29	black	_	_	JJ	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	myeloperoxidase	_	_	NN	Protein	-1	none	_	_
33	cytochemical	_	_	JJ	O	-1	none	_	_
34	reactivity	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	that	_	_	WDT	O	-1	none	_	_
37	were	_	_	VBD	O	-1	none	_	_
38	remarkably	_	_	RB	O	-1	none	_	_
39	similar	_	_	JJ	O	-1	none	_	_
40	to	_	_	TO	O	-1	none	_	_
41	those	_	_	DT	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	acute	_	_	JJ	O	-1	none	_	_
44	promyelocytic	_	_	JJ	O	-1	none	_	_
45	leukemia	_	_	NN	O	-1	none	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	APL	_	_	NN	O	-1	none	_	_
48	)	_	_	-RRB-	O	-1	none	_	_
49	;	_	_	:	O	-1	none	_	_
50	particularly	_	_	RB	O	-1	none	_	_
51	the	_	_	DT	O	-1	none	_	_
52	microgranular	_	_	JJ	O	-1	none	_	_
53	variant	_	_	JJ	O	-1	none	_	_
54	(	_	_	-LRB-	O	-1	none	_	_
55	FAB	_	_	NN	O	-1	none	_	_
56	AML-M3v	_	_	NN	O	-1	none	_	_
57	)	_	_	-RRB-	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	all	_	_	DT	O	-1	none	_	_
4	20	_	_	CD	O	-1	none	_	_
5	cases	_	_	NNS	O	-1	none	_	_
6	lacked	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	t	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	15	_	_	CD	O	-1	none	_	_
11	;	_	_	:	O	-1	none	_	_
12	17	_	_	CD	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	17	_	_	CD	O	-1	none	_	_
16	cases	_	_	NNS	O	-1	none	_	_
17	tested	_	_	VBN	O	-1	none	_	_
18	lacked	_	_	VBD	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	promyelocytic	_	_	JJ	Protein	25	multitoken	_	_
21	and	_	_	CC	Protein	25	multitoken	_	_
22	retinoic	_	_	JJ	Protein	25	multitoken	_	_
23	acid	_	_	NN	Protein	25	multitoken	_	_
24	receptor	_	_	NN	Protein	25	multitoken	_	_
25	alpha	_	_	NN	Protein	0	root	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	RAR	_	_	NN	Protein	28	multitoken	_	_
28	alpha	_	_	NN	Protein	0	root	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	fusion	_	_	NN	O	-1	none	_	_
31	transcript	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	RT-PCR	_	_	NN	O	-1	none	_	_
34	assays	_	_	NNS	O	-1	none	_	_
35	;	_	_	:	O	-1	none	_	_
36	12	_	_	CD	O	-1	none	_	_
37	cases	_	_	NNS	O	-1	none	_	_
38	had	_	_	VBD	O	-1	none	_	_
39	46	_	_	CD	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	XX	_	_	NN	O	-1	none	_	_
42	or	_	_	CC	O	-1	none	_	_
43	46	_	_	CD	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	XY	_	_	NN	O	-1	none	_	_
46	karyotypes	_	_	NNS	O	-1	none	_	_
47	,	_	_	,	O	-1	none	_	_
48	whereas	_	_	IN	O	-1	none	_	_
49	2	_	_	CD	O	-1	none	_	_
50	cases	_	_	NNS	O	-1	none	_	_
51	had	_	_	VBD	O	-1	none	_	_
52	abnormalities	_	_	NNS	O	-1	none	_	_
53	of	_	_	IN	O	-1	none	_	_
54	chromosome	_	_	NN	O	-1	none	_	_
55	17q	_	_	NN	O	-1	none	_	_
56	:	_	_	:	O	-1	none	_	_
57	1	_	_	CD	O	-1	none	_	_
58	with	_	_	IN	O	-1	none	_	_
59	del	_	_	DT	O	-1	none	_	_
60	(	_	_	-LRB-	O	-1	none	_	_
61	17	_	_	CD	O	-1	none	_	_
62	)	_	_	-RRB-	O	-1	none	_	_
63	(	_	_	-LRB-	O	-1	none	_	_
64	q25	_	_	CD	O	-1	none	_	_
65	)	_	_	-RRB-	O	-1	none	_	_
66	and	_	_	CC	O	-1	none	_	_
67	the	_	_	DT	O	-1	none	_	_
68	other	_	_	JJ	O	-1	none	_	_
69	with	_	_	IN	O	-1	none	_	_
70	t	_	_	NN	O	-1	none	_	_
71	(	_	_	-LRB-	O	-1	none	_	_
72	11	_	_	CD	O	-1	none	_	_
73	;	_	_	:	O	-1	none	_	_
74	17	_	_	CD	O	-1	none	_	_
75	)	_	_	-RRB-	O	-1	none	_	_
76	(	_	_	-LRB-	O	-1	none	_	_
77	q23	_	_	NN	O	-1	none	_	_
78	;	_	_	:	O	-1	none	_	_
79	q21	_	_	NN	O	-1	none	_	_
80	)	_	_	-RRB-	O	-1	none	_	_
81	and	_	_	CC	O	-1	none	_	_
82	the	_	_	DT	O	-1	none	_	_
83	promyelocytic	_	_	JJ	Protein	86	multitoken	_	_
84	leukemia	_	_	NN	Protein	86	multitoken	_	_
85	zinc	_	_	NN	Protein	86	multitoken	_	_
86	finger	_	_	NN	Protein	0	root	_	_
87	and	_	_	CC	O	-1	none	_	_
88	RAR	_	_	NN	Protein	89	multitoken	_	_
89	alpha	_	_	NN	Protein	0	root	_	_
90	fusion	_	_	NN	O	-1	none	_	_
91	transcript	_	_	NN	O	-1	none	_	_
92	.	_	_	.	O	-1	none	_	_

1	All	_	_	DT	O	-1	none	_	_
2	cases	_	_	NNS	O	-1	none	_	_
3	tested	_	_	VBN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	6/20	_	_	CD	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	including	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	case	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	t	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	11	_	_	CD	O	-1	none	_	_
15	;	_	_	:	O	-1	none	_	_
16	17	_	_	CD	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	failed	_	_	VBD	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	differentiate	_	_	VB	O	-1	none	_	_
22	in	_	_	FW	O	-1	none	_	_
23	vitro	_	_	FW	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	response	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	all-trans	_	_	JJ	O	-1	none	_	_
28	retinoic	_	_	JJ	O	-1	none	_	_
29	acid	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	ATRA	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	suggesting	_	_	VBG	O	-1	none	_	_
35	that	_	_	IN	O	-1	none	_	_
36	these	_	_	DT	O	-1	none	_	_
37	cases	_	_	NNS	O	-1	none	_	_
38	may	_	_	MD	O	-1	none	_	_
39	account	_	_	VB	O	-1	none	_	_
40	for	_	_	IN	O	-1	none	_	_
41	some	_	_	DT	O	-1	none	_	_
42	APLs	_	_	NNS	O	-1	none	_	_
43	that	_	_	WDT	O	-1	none	_	_
44	have	_	_	VBP	O	-1	none	_	_
45	not	_	_	RB	O	-1	none	_	_
46	shown	_	_	VBN	O	-1	none	_	_
47	a	_	_	DT	O	-1	none	_	_
48	clinical	_	_	JJ	O	-1	none	_	_
49	response	_	_	NN	O	-1	none	_	_
50	to	_	_	TO	O	-1	none	_	_
51	ATRA	_	_	NN	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	form	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	acute	_	_	JJ	O	-1	none	_	_
9	leukemia	_	_	NN	O	-1	none	_	_
10	may	_	_	MD	O	-1	none	_	_
11	arise	_	_	VB	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	transformation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	precursor	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	common	_	_	JJ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	both	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	myeloid	_	_	JJ	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	NK	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	lineages	_	_	NNS	O	-1	none	_	_
27	;	_	_	:	O	-1	none	_	_
28	thus	_	_	RB	O	-1	none	_	_
29	we	_	_	PRP	O	-1	none	_	_
30	propose	_	_	VBP	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	designation	_	_	NN	O	-1	none	_	_
33	myeloid/NK	_	_	JJ	O	-1	none	_	_
34	acute	_	_	JJ	O	-1	none	_	_
35	leukemia	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Recognition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	new	_	_	JJ	O	-1	none	_	_
5	leukemic	_	_	JJ	O	-1	none	_	_
6	entity	_	_	NN	O	-1	none	_	_
7	will	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	important	_	_	JJ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	distinguishing	_	_	VBG	O	-1	none	_	_
12	these	_	_	DT	O	-1	none	_	_
13	ATRA-nonresponsive	_	_	JJ	O	-1	none	_	_
14	cases	_	_	NNS	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	ATRA	_	_	NN	O	-1	none	_	_
17	responsive	_	_	JJ	O	-1	none	_	_
18	true	_	_	JJ	O	-1	none	_	_
19	APL	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Extracellular	_	_	JJ	Protein	5	multitoken	_	_
2	signal	_	_	NN	Protein	5	multitoken	_	_
3	regulated	_	_	VBN	Protein	5	multitoken	_	_
4	protein	_	_	NN	Protein	5	multitoken	_	_
5	kinase	_	_	NN	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	ERK	_	_	NN	Protein	-1	none	_	_
8	)-dependent	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	ERK	_	_	NN	Protein	-1	none	_	_
11	independent	_	_	JJ	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	target	_	_	VBP	O	-1	none	_	_
14	STAT3	_	_	NN	Protein	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	serine	_	_	NN	O	-1	none	_	_
17	727	_	_	CD	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	neutrophils	_	_	NNS	O	-1	none	_	_
21	stimulated	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	chemotactic	_	_	JJ	O	-1	none	_	_
24	factors	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	cytokines	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	STAT3	_	_	NN	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	signal	_	_	NN	Protein	9	multitoken	_	_
4	transducer	_	_	NN	Protein	9	multitoken	_	_
5	and	_	_	CC	Protein	9	multitoken	_	_
6	activator	_	_	NN	Protein	9	multitoken	_	_
7	of	_	_	IN	Protein	9	multitoken	_	_
8	transcription	_	_	NN	Protein	9	multitoken	_	_
9	3	_	_	CD	Protein	0	root	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	latent	_	_	JJ	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	factor	_	_	NN	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	tyrosine	_	_	NN	O	-1	none	_	_
21	phosphorylation	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	Tyr	_	_	NN	O	-1	none	_	_
24	705	_	_	CD	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	stimulated	_	_	VBN	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	cytokines	_	_	NNS	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	growth	_	_	NN	O	-1	none	_	_
33	factors	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Recent	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	one	_	_	CD	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	more	_	_	JJR	O	-1	none	_	_
8	cytoplasmic	_	_	JJ	O	-1	none	_	_
9	serine	_	_	NN	O	-1	none	_	_
10	kinases	_	_	NNS	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	phosphorylate	_	_	VB	O	-1	none	_	_
13	STAT3	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	necessary	_	_	JJ	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	maximal	_	_	JJ	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	site	_	_	NN	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	antibody	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	STAT3	_	_	NN	Protein	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	phosphorylated	_	_	VBN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	Ser	_	_	NN	O	-1	none	_	_
17	727	_	_	CD	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	neutrophils	_	_	NNS	O	-1	none	_	_
21	stimulated	_	_	VBN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	chemotactic	_	_	JJ	O	-1	none	_	_
24	factors	_	_	NNS	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	N-formyl-methionyl-leucyl-phenylalanine	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	complement	_	_	NN	O	-1	none	_	_
29	C5a	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	cytokines	_	_	NNS	O	-1	none	_	_
33	[	_	_	VBP	O	-1	none	_	_
34	granulocyte	_	_	NN	Protein	39	multitoken	_	_
35	and	_	_	CC	Protein	39	multitoken	_	_
36	macrophage	_	_	NN	Protein	39	multitoken	_	_
37	colony	_	_	NN	Protein	39	multitoken	_	_
38	stimulating	_	_	NN	Protein	39	multitoken	_	_
39	factor	_	_	NN	Protein	0	root	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	GM-CSF	_	_	NN	Protein	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	granulocyte	_	_	NN	Protein	47	multitoken	_	_
45	colony	_	_	NN	Protein	47	multitoken	_	_
46	stimulating	_	_	NN	Protein	47	multitoken	_	_
47	factor	_	_	NN	Protein	0	root	_	_
48	(	_	_	-LRB-	O	-1	none	_	_
49	G-CSF	_	_	NN	Protein	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	]	_	_	NN	O	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	or	_	_	CC	O	-1	none	_	_
54	a	_	_	DT	O	-1	none	_	_
55	protein	_	_	NN	O	-1	none	_	_
56	kinase	_	_	NN	O	-1	none	_	_
57	C	_	_	NN	O	-1	none	_	_
58	activator	_	_	NN	O	-1	none	_	_
59	(	_	_	-LRB-	O	-1	none	_	_
60	PMA	_	_	NN	O	-1	none	_	_
61	)	_	_	-RRB-	O	-1	none	_	_
62	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	2-Amino-3	_	_	NN	O	-1	none	_	_
3	'-methoxyphenyl	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	oxanaphthalen-4-one	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	PD	_	_	NN	O	-1	none	_	_
8	98059	_	_	CD	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	inhibitor	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	extracellular	_	_	JJ	Protein	18	multitoken	_	_
15	signal	_	_	NN	Protein	18	multitoken	_	_
16	regulated	_	_	VBN	Protein	18	multitoken	_	_
17	protein	_	_	NN	Protein	18	multitoken	_	_
18	kinase	_	_	NN	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	ERK	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	blocked	_	_	VBD	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	serine	_	_	NN	O	-1	none	_	_
27	phosphorylation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	STAT3	_	_	NN	Protein	-1	none	_	_
30	induced	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	chemotactic	_	_	JJ	O	-1	none	_	_
33	factors	_	_	NNS	O	-1	none	_	_
34	or	_	_	CC	O	-1	none	_	_
35	PMA	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	drug	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	less	_	_	RBR	O	-1	none	_	_
5	effective	_	_	JJ	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	cytokines	_	_	NNS	O	-1	none	_	_
8	:	_	_	:	O	-1	none	_	_
9	it	_	_	PRP	O	-1	none	_	_
10	virtually	_	_	RB	O	-1	none	_	_
11	abolished	_	_	VBD	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	response	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	GM-CSF	_	_	NN	Protein	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	occurred	_	_	VBD	O	-1	none	_	_
18	5	_	_	CD	O	-1	none	_	_
19	min	_	_	NN	O	-1	none	_	_
20	after	_	_	IN	O	-1	none	_	_
21	stimulation	_	_	NN	O	-1	none	_	_
22	but	_	_	CC	O	-1	none	_	_
23	only	_	_	RB	O	-1	none	_	_
24	partly	_	_	RB	O	-1	none	_	_
25	decreased	_	_	VBD	O	-1	none	_	_
26	those	_	_	DT	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	15-30	_	_	CD	O	-1	none	_	_
29	min	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	did	_	_	VBD	O	-1	none	_	_
32	not	_	_	RB	O	-1	none	_	_
33	appreciably	_	_	RB	O	-1	none	_	_
34	alter	_	_	VB	O	-1	none	_	_
35	responses	_	_	NNS	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	G-CSF	_	_	NN	Protein	-1	none	_	_
38	regardless	_	_	RB	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	incubation	_	_	NN	O	-1	none	_	_
41	time	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	1-(	_	_	CD	O	-1	none	_	_
2	5-Isoquinolinylsulphonyl	_	_	NN	O	-1	none	_	_
3	)-2-methylpiperazine	_	_	NN	O	-1	none	_	_
4	dihydrochloride	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	H7	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	inhibitor	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	putative	_	_	JJ	O	-1	none	_	_
14	STAT3	_	_	NN	Protein	-1	none	_	_
15	serine	_	_	NN	O	-1	none	_	_
16	kinase	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	4-(	_	_	CD	O	-1	none	_	_
20	4-fluorophenyl	_	_	NN	O	-1	none	_	_
21	)-2-(	_	_	CD	O	-1	none	_	_
22	4-methylsulphinylphenyl	_	_	NN	O	-1	none	_	_
23	)-5-(	_	_	CD	O	-1	none	_	_
24	4-pyridyl	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	1H-imidazole	_	_	NN	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	SB	_	_	NN	O	-1	none	_	_
29	203580	_	_	CD	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	an	_	_	DT	O	-1	none	_	_
33	inhibitor	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	p38	_	_	NN	O	-1	none	_	_
36	mitogen	_	_	NN	O	-1	none	_	_
37	activated	_	_	VBN	O	-1	none	_	_
38	protein	_	_	NN	O	-1	none	_	_
39	(	_	_	-LRB-	O	-1	none	_	_
40	MAP	_	_	NN	O	-1	none	_	_
41	)	_	_	-RRB-	O	-1	none	_	_
42	kinase	_	_	NN	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	did	_	_	VBD	O	-1	none	_	_
45	not	_	_	RB	O	-1	none	_	_
46	dampen	_	_	VB	O	-1	none	_	_
47	any	_	_	DT	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	these	_	_	DT	O	-1	none	_	_
50	serine	_	_	NN	O	-1	none	_	_
51	phosphorylation	_	_	NN	O	-1	none	_	_
52	responses	_	_	NNS	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	neutrophils	_	_	NNS	O	-1	none	_	_
5	use	_	_	VBP	O	-1	none	_	_
6	both	_	_	CC	O	-1	none	_	_
7	ERK	_	_	NN	Protein	-1	none	_	_
8	dependent	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	ERK	_	_	NN	Protein	-1	none	_	_
11	independent	_	_	JJ	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	phosphorylate	_	_	VB	O	-1	none	_	_
15	Ser	_	_	NN	O	-1	none	_	_
16	727	_	_	CD	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	STAT3	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	former	_	_	JJ	O	-1	none	_	_
3	pathway	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	recruited	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	all	_	_	DT	O	-1	none	_	_
8	ERK	_	_	NN	Protein	-1	none	_	_
9	activating	_	_	VBG	O	-1	none	_	_
10	stimuli	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	whereas	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	latter	_	_	JJ	O	-1	none	_	_
15	pathway	_	_	NN	O	-1	none	_	_
16	uses	_	_	VBZ	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	undefined	_	_	JJ	O	-1	none	_	_
19	serine	_	_	NN	O	-1	none	_	_
20	kinase	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	recruited	_	_	VBN	O	-1	none	_	_
24	selectively	_	_	RB	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	cytokines	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	E1A	_	_	NN	Protein	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	induces	_	_	VBZ	O	-1	none	_	_
5	susceptibility	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	killing	_	_	VBG	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	NK	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	following	_	_	VBG	O	-1	none	_	_
12	immortalization	_	_	NN	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	adenovirus	_	_	NN	O	-1	none	_	_
16	infection	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Adenovirus	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	Ad	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	infection	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	E1A	_	_	NN	Protein	-1	none	_	_
8	transfection	_	_	NN	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	used	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	model	_	_	VB	O	-1	none	_	_
13	changes	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	susceptibility	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	NK	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	killing	_	_	NN	O	-1	none	_	_
20	caused	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	transient	_	_	JJ	O	-1	none	_	_
23	vs	_	_	CC	O	-1	none	_	_
24	stable	_	_	JJ	O	-1	none	_	_
25	E1A	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Only	_	_	RB	O	-1	none	_	_
2	stably	_	_	RB	O	-1	none	_	_
3	transfected	_	_	VBN	O	-1	none	_	_
4	target	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	exhibited	_	_	VBD	O	-1	none	_	_
7	cytolytic	_	_	JJ	O	-1	none	_	_
8	susceptibility	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	despite	_	_	IN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	equivalent	_	_	JJ	O	-1	none	_	_
14	levels	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	E1A	_	_	NN	Protein	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	Ad	_	_	NN	O	-1	none	_	_
20	infected	_	_	JJ	O	-1	none	_	_
21	targets	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inability	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	E1A	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	products	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	induce	_	_	VB	O	-1	none	_	_
9	cytolytic	_	_	JJ	O	-1	none	_	_
10	susceptibility	_	_	NN	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	infection	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	explained	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	inhibitory	_	_	JJ	O	-1	none	_	_
19	effect	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	viral	_	_	JJ	O	-1	none	_	_
22	infection	_	_	NN	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	otherwise	_	_	RB	O	-1	none	_	_
25	susceptible	_	_	JJ	O	-1	none	_	_
26	target	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	or	_	_	CC	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	viral	_	_	JJ	O	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	effects	_	_	NNS	O	-1	none	_	_
33	on	_	_	IN	O	-1	none	_	_
34	class	_	_	NN	O	-1	none	_	_
35	I	_	_	CD	O	-1	none	_	_
36	MHC	_	_	NN	O	-1	none	_	_
37	antigen	_	_	NN	O	-1	none	_	_
38	expression	_	_	NN	O	-1	none	_	_
39	on	_	_	IN	O	-1	none	_	_
40	target	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	differential	_	_	JJ	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	E1A	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	cytolytic	_	_	JJ	O	-1	none	_	_
10	phenotypes	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	infected	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	stably	_	_	RB	O	-1	none	_	_
15	transfected	_	_	VBN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	suggests	_	_	VBZ	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	NK	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	provide	_	_	VBP	O	-1	none	_	_
24	an	_	_	DT	O	-1	none	_	_
25	effective	_	_	JJ	O	-1	none	_	_
26	immunologic	_	_	JJ	O	-1	none	_	_
27	barrier	_	_	NN	O	-1	none	_	_
28	against	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	in	_	_	FW	O	-1	none	_	_
31	vivo	_	_	FW	O	-1	none	_	_
32	survival	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	neoplastic	_	_	JJ	O	-1	none	_	_
35	progression	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	E1A	_	_	NN	Protein	-1	none	_	_
38	immortalized	_	_	VBN	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	that	_	_	WDT	O	-1	none	_	_
41	may	_	_	MD	O	-1	none	_	_
42	emerge	_	_	VB	O	-1	none	_	_
43	from	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	reservoir	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	persistently	_	_	RB	O	-1	none	_	_
48	infected	_	_	JJ	O	-1	none	_	_
49	cells	_	_	NNS	O	-1	none	_	_
50	in	_	_	IN	O	-1	none	_	_
51	the	_	_	DT	O	-1	none	_	_
52	human	_	_	NN	O	-1	none	_	_
53	host	_	_	NN	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	Diminished	_	_	VBN	O	-1	none	_	_
2	responses	_	_	NNS	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	IL-13	_	_	NN	Protein	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	monocytes	_	_	NNS	O	-1	none	_	_
8	differentiated	_	_	VBN	O	-1	none	_	_
9	in	_	_	FW	O	-1	none	_	_
10	vitro	_	_	FW	O	-1	none	_	_
11	:	_	_	:	O	-1	none	_	_
12	role	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-13Ralpha1	_	_	NN	Protein	16	multitoken	_	_
16	chain	_	_	NN	Protein	0	root	_	_
17	and	_	_	CC	O	-1	none	_	_
18	STAT6	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	primary	_	_	JJ	O	-1	none	_	_
3	IL-13	_	_	NN	Protein	-1	none	_	_
4	receptor	_	_	NN	O	-1	none	_	_
5	complex	_	_	NN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	monocytes	_	_	NNS	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	believed	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	heterodimer	_	_	NN	O	-1	none	_	_
15	comprised	_	_	VBN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	IL-4R	_	_	NN	Protein	20	multitoken	_	_
19	alpha	_	_	NN	Protein	20	multitoken	_	_
20	chain	_	_	NN	Protein	0	root	_	_
21	and	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	IL-2R	_	_	NN	Protein	25	multitoken	_	_
24	gamma	_	_	NN	Protein	25	multitoken	_	_
25	chain	_	_	NN	Protein	0	root	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	gamma	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	c	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	)-like	_	_	JJ	O	-1	none	_	_
32	molecule	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	IL-13R	_	_	NN	Protein	35	multitoken	_	_
35	alpha1	_	_	NN	Protein	0	root	_	_
36	.	_	_	.	O	-1	none	_	_

1	mRNA	_	_	NN	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	IL-13R	_	_	NN	Protein	5	multitoken	_	_
5	alpha1	_	_	NN	Protein	0	root	_	_
6	,	_	_	,	O	-1	none	_	_
7	but	_	_	CC	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	IL-4R	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	,	_	_	,	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	markedly	_	_	RB	O	-1	none	_	_
14	decreased	_	_	VBN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	in	_	_	FW	O	-1	none	_	_
17	vitro	_	_	FW	O	-1	none	_	_
18	monocyte	_	_	NN	O	-1	none	_	_
19	derived	_	_	VBN	O	-1	none	_	_
20	macrophages	_	_	NNS	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	MDMac	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	increasing	_	_	VBG	O	-1	none	_	_
28	time	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	monocytes	_	_	NNS	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	culture	_	_	NN	O	-1	none	_	_
33	correlated	_	_	VBD	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	loss	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	IL-13	_	_	NN	Protein	-1	none	_	_
39	regulation	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	lipopolysaccharide	_	_	NN	O	-1	none	_	_
42	induced	_	_	VBD	O	-1	none	_	_
43	TNF-alpha	_	_	NN	Protein	-1	none	_	_
44	production	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	lines	_	_	NNS	O	-1	none	_	_
5	Daudi	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	THP-1	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	differentially	_	_	RB	O	-1	none	_	_
10	express	_	_	VBP	O	-1	none	_	_
11	gamma	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	c	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	IL-13R	_	_	NN	Protein	17	multitoken	_	_
17	alpha1	_	_	NN	Protein	0	root	_	_
18	showed	_	_	VBD	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	IL-13	_	_	NN	Protein	-1	none	_	_
21	can	_	_	MD	O	-1	none	_	_
22	activate	_	_	VB	O	-1	none	_	_
23	STAT6	_	_	NN	Protein	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	IL-13R	_	_	NN	Protein	26	multitoken	_	_
26	alpha1	_	_	NN	Protein	0	root	_	_
27	positive	_	_	JJ	O	-1	none	_	_
28	THP-1	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	but	_	_	CC	O	-1	none	_	_
31	not	_	_	RB	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	gamma	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	c	_	_	NN	O	-1	none	_	_
36	)-positive	_	_	JJ	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	IL-13R	_	_	NN	Protein	39	multitoken	_	_
39	alpha1	_	_	NN	Protein	0	root	_	_
40	negative	_	_	JJ	O	-1	none	_	_
41	Daudi	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	absence	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	functional	_	_	JJ	O	-1	none	_	_
6	IL-13R	_	_	NN	Protein	7	multitoken	_	_
7	alpha1	_	_	NN	Protein	0	root	_	_
8	and	_	_	CC	O	-1	none	_	_
9	gamma	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	c	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	IL-13	_	_	NN	Protein	-1	none	_	_
15	must	_	_	MD	O	-1	none	_	_
16	signal	_	_	VB	O	-1	none	_	_
17	through	_	_	IN	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	alternative	_	_	JJ	O	-1	none	_	_
20	receptor	_	_	NN	O	-1	none	_	_
21	complex	_	_	NN	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	MDMac	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Experiments	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	blocking	_	_	VBG	O	-1	none	_	_
5	antibody	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	IL-4R	_	_	NN	Protein	8	multitoken	_	_
8	alpha	_	_	NN	Protein	0	root	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	this	_	_	DT	O	-1	none	_	_
12	chain	_	_	NN	O	-1	none	_	_
13	remains	_	_	VBZ	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	essential	_	_	JJ	O	-1	none	_	_
16	component	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-13	_	_	NN	Protein	-1	none	_	_
20	receptor	_	_	NN	O	-1	none	_	_
21	complex	_	_	NN	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	MDMac	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	c-Myc	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	E1A	_	_	NN	Protein	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	cellular	_	_	JJ	O	-1	none	_	_
6	sensitivity	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	activated	_	_	VBN	O	-1	none	_	_
9	NK	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	involves	_	_	VBZ	O	-1	none	_	_
12	cytotoxic	_	_	JJ	O	-1	none	_	_
13	granules	_	_	NNS	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	death	_	_	NN	O	-1	none	_	_
16	effectors	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	contact	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	natural	_	_	JJ	O	-1	none	_	_
5	killer	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	NK	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	foreign	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	certain	_	_	JJ	O	-1	none	_	_
16	virus	_	_	NN	O	-1	none	_	_
17	infected	_	_	JJ	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	tumor	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	triggers	_	_	VBZ	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	cytolytic	_	_	JJ	O	-1	none	_	_
24	machinery	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	NK	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	triggering	_	_	NN	O	-1	none	_	_
3	leads	_	_	VBZ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	exocytosis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	cytotoxic	_	_	JJ	O	-1	none	_	_
9	NK	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	granules	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	oncoproteins	_	_	NNS	O	-1	none	_	_
3	c-Myc	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	E1A	_	_	NN	Protein	-1	none	_	_
6	render	_	_	VBP	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	vulnerable	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	NK	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	mediated	_	_	JJ	O	-1	none	_	_
13	cytolysis	_	_	NN	O	-1	none	_	_
14	yet	_	_	RB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	mechanisms	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	sensitization	_	_	NN	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	not	_	_	RB	O	-1	none	_	_
21	well	_	_	RB	O	-1	none	_	_
22	understood	_	_	VBN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	model	_	_	NN	O	-1	none	_	_
4	where	_	_	WRB	O	-1	none	_	_
5	foreign	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	rat	_	_	NN	O	-1	none	_	_
9	fibroblasts	_	_	NNS	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	cocultured	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	IL-2	_	_	NN	Protein	-1	none	_	_
16	activated	_	_	VBD	O	-1	none	_	_
17	NK	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	observed	_	_	VBD	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	NK	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	were	_	_	VBD	O	-1	none	_	_
26	capable	_	_	JJ	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	efficiently	_	_	RB	O	-1	none	_	_
29	killing	_	_	VBG	O	-1	none	_	_
30	their	_	_	PRP$	O	-1	none	_	_
31	targets	_	_	NNS	O	-1	none	_	_
32	only	_	_	RB	O	-1	none	_	_
33	if	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	overexpressed	_	_	VBD	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	oncogene	_	_	NN	O	-1	none	_	_
39	c-Myc	_	_	NN	Protein	-1	none	_	_
40	or	_	_	CC	O	-1	none	_	_
41	E1A	_	_	NN	Protein	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Both	_	_	CC	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	parental	_	_	JJ	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	oncogene	_	_	NN	O	-1	none	_	_
7	expressing	_	_	VBG	O	-1	none	_	_
8	fibroblasts	_	_	NNS	O	-1	none	_	_
9	similarly	_	_	RB	O	-1	none	_	_
10	triggered	_	_	VBD	O	-1	none	_	_
11	phosphoinositide	_	_	JJ	O	-1	none	_	_
12	hydrolysis	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	bound	_	_	JJ	O	-1	none	_	_
16	NK	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	demonstrating	_	_	VBG	O	-1	none	_	_
20	that	_	_	IN	O	-1	none	_	_
21	NK	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	were	_	_	VBD	O	-1	none	_	_
24	cytolytically	_	_	RB	O	-1	none	_	_
25	activated	_	_	VBN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	contact	_	_	NN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	both	_	_	CC	O	-1	none	_	_
30	resistant	_	_	JJ	O	-1	none	_	_
31	parental	_	_	JJ	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	oncogene	_	_	NN	O	-1	none	_	_
34	expressing	_	_	NN	O	-1	none	_	_
35	sensitive	_	_	JJ	O	-1	none	_	_
36	target	_	_	NN	O	-1	none	_	_
37	fibroblasts	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	death	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	independent	_	_	JJ	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	wild-type	_	_	JJ	O	-1	none	_	_
8	p53	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	inhibited	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	anti-apoptotic	_	_	JJ	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	EIB19K	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	provided	_	_	VBD	O	-1	none	_	_
4	evidence	_	_	NN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	c-Myc	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	E1A	_	_	NN	Protein	-1	none	_	_
9	activated	_	_	VBD	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	NK	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	induced	_	_	JJ	O	-1	none	_	_
14	cytolysis	_	_	NN	O	-1	none	_	_
15	at	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	post-triggering	_	_	JJ	O	-1	none	_	_
18	stage	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	NK	_	_	NN	O	-1	none	_	_
21	cell-target	_	_	JJ	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	interaction	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	consistence	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	c-Myc	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	E1A	_	_	NN	Protein	-1	none	_	_
8	overexpressing	_	_	NN	O	-1	none	_	_
9	fibroblasts	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	more	_	_	RBR	O	-1	none	_	_
12	sensitive	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cytolytic	_	_	JJ	O	-1	none	_	_
16	effects	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	isolated	_	_	VBN	O	-1	none	_	_
19	NK	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	derived	_	_	VBN	O	-1	none	_	_
22	granules	_	_	NNS	O	-1	none	_	_
23	than	_	_	IN	O	-1	none	_	_
24	parental	_	_	JJ	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	oncogenes	_	_	NNS	O	-1	none	_	_
6	activate	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	cytotoxicity	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	NK	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	granules	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	can	_	_	MD	O	-1	none	_	_
4	have	_	_	VB	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	directing	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cytolytic	_	_	JJ	O	-1	none	_	_
11	action	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NK	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	towards	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	virus	_	_	NN	O	-1	none	_	_
18	infected	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	cancer	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	HIV-1	_	_	NN	O	-1	none	_	_
5	enhancer	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	LEF-1	_	_	NN	Protein	-1	none	_	_
9	HMG	_	_	NN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	nucleosome	_	_	JJ	O	-1	none	_	_
13	assembled	_	_	VBN	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	in	_	_	FW	O	-1	none	_	_
16	vitro	_	_	FW	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Lymphoid	_	_	JJ	Protein	5	multitoken	_	_
2	enhancer	_	_	NN	Protein	5	multitoken	_	_
3	binding	_	_	NN	Protein	5	multitoken	_	_
4	factor	_	_	NN	Protein	5	multitoken	_	_
5	1	_	_	CD	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	LEF-1	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	regulatory	_	_	JJ	O	-1	none	_	_
12	high	_	_	JJ	O	-1	none	_	_
13	mobility	_	_	NN	O	-1	none	_	_
14	group	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	HMG	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	activates	_	_	VBZ	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	T	_	_	NN	Protein	25	multitoken	_	_
23	cell	_	_	NN	Protein	25	multitoken	_	_
24	receptor	_	_	NN	Protein	25	multitoken	_	_
25	alpha	_	_	NN	Protein	0	root	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	TCR	_	_	NN	Protein	28	multitoken	_	_
28	alpha	_	_	NN	Protein	0	root	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	enhancer	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	context	_	_	NN	O	-1	none	_	_
34	restricted	_	_	JJ	O	-1	none	_	_
35	manner	_	_	NN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	T	_	_	NN	O	-1	none	_	_
38	cells	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	paper	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	demonstrate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	distal	_	_	JJ	O	-1	none	_	_
9	region	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	immunodeficiency	_	_	NN	O	-1	none	_	_
14	virus-1	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	HIV-1	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	enhancer	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	contains	_	_	VBZ	O	-1	none	_	_
22	DNA	_	_	NN	O	-1	none	_	_
23	binding	_	_	NN	O	-1	none	_	_
24	sites	_	_	NNS	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	LEF-1	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	Ets-1	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	also	_	_	RB	O	-1	none	_	_
31	provides	_	_	VBZ	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	functional	_	_	JJ	O	-1	none	_	_
34	context	_	_	NN	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	activation	_	_	NN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	LEF-1	_	_	NN	Protein	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Second	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	recombinant	_	_	JJ	O	-1	none	_	_
4	LEF-1	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	activate	_	_	VB	O	-1	none	_	_
9	HIV-1	_	_	NN	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	chromatin	_	_	NN	O	-1	none	_	_
13	assembled	_	_	VBD	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	in	_	_	FW	O	-1	none	_	_
16	vitro	_	_	FW	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	nucleosome-assembly	_	_	JJ	O	-1	none	_	_
5	system	_	_	NN	O	-1	none	_	_
6	derived	_	_	VBN	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	Drosophila	_	_	FW	O	-1	none	_	_
9	embryos	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	we	_	_	PRP	O	-1	none	_	_
12	find	_	_	VBP	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	packaging	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	into	_	_	IN	O	-1	none	_	_
19	chromatin	_	_	NN	O	-1	none	_	_
20	in	_	_	FW	O	-1	none	_	_
21	vitro	_	_	FW	O	-1	none	_	_
22	strongly	_	_	RB	O	-1	none	_	_
23	represses	_	_	VBZ	O	-1	none	_	_
24	HIV-1	_	_	NN	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	that	_	_	IN	O	-1	none	_	_
28	repression	_	_	NN	O	-1	none	_	_
29	can	_	_	MD	O	-1	none	_	_
30	be	_	_	VB	O	-1	none	_	_
31	counteracted	_	_	VBN	O	-1	none	_	_
32	efficiently	_	_	RB	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	preincubation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	DNA	_	_	NN	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	LEF-1	_	_	NN	Protein	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	or	_	_	CC	O	-1	none	_	_
42	LEF-1	_	_	NN	Protein	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	Ets-1	_	_	NN	Protein	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	supplemented	_	_	VBN	O	-1	none	_	_
47	with	_	_	IN	O	-1	none	_	_
48	fractions	_	_	NNS	O	-1	none	_	_
49	containing	_	_	VBG	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	promoter	_	_	NN	O	-1	none	_	_
52	binding	_	_	NN	O	-1	none	_	_
53	protein	_	_	NN	O	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	Sp1	_	_	NN	Protein	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	Addition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	TFE-3	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	which	_	_	WDT	O	-1	none	_	_
6	binds	_	_	VBZ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	E-box	_	_	NN	O	-1	none	_	_
10	motif	_	_	NN	O	-1	none	_	_
11	upstream	_	_	RB	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	LEF-1	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	Ets-1	_	_	NN	Protein	-1	none	_	_
17	sites	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	further	_	_	RB	O	-1	none	_	_
20	augments	_	_	VBZ	O	-1	none	_	_
21	transcription	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	system	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Individually	_	_	RB	O	-1	none	_	_
2	or	_	_	CC	O	-1	none	_	_
3	collectively	_	_	RB	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	none	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	three	_	_	CD	O	-1	none	_	_
9	enhancer	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	proteins	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	LEF-1	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	Ets-1	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	TFE-3	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	could	_	_	MD	O	-1	none	_	_
21	activate	_	_	VB	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	absence	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	Sp1	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	truncation	_	_	NN	O	-1	none	_	_
3	mutant	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	LEF-1	_	_	NN	Protein	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	HMG-88	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	contains	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	HMG	_	_	NN	O	-1	none	_	_
14	box	_	_	NN	O	-1	none	_	_
15	but	_	_	CC	O	-1	none	_	_
16	lacks	_	_	VBZ	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	trans-activation	_	_	NN	O	-1	none	_	_
19	domain	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	did	_	_	VBD	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	activate	_	_	VB	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	from	_	_	IN	O	-1	none	_	_
26	nucleosomal	_	_	JJ	O	-1	none	_	_
27	DNA	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	indicating	_	_	VBG	O	-1	none	_	_
30	that	_	_	IN	O	-1	none	_	_
31	bending	_	_	VBG	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	DNA	_	_	NN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	HMG	_	_	NN	O	-1	none	_	_
37	domain	_	_	NN	O	-1	none	_	_
38	is	_	_	VBZ	O	-1	none	_	_
39	not	_	_	RB	O	-1	none	_	_
40	sufficient	_	_	JJ	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	activate	_	_	VB	O	-1	none	_	_
43	transcription	_	_	NN	O	-1	none	_	_
44	in	_	_	FW	O	-1	none	_	_
45	vitro	_	_	FW	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	LEF-1	_	_	NN	Protein	-1	none	_	_
8	in	_	_	FW	O	-1	none	_	_
9	vitro	_	_	FW	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	chromatin	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	process	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	requires	_	_	VBZ	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	functional	_	_	JJ	O	-1	none	_	_
19	trans-activation	_	_	NN	O	-1	none	_	_
20	domain	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	addition	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	HMG	_	_	NN	O	-1	none	_	_
26	domain	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Oxidative	_	_	JJ	O	-1	none	_	_
2	stress	_	_	NN	O	-1	none	_	_
3	triggers	_	_	VBZ	O	-1	none	_	_
4	STAT3	_	_	NN	Protein	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	translocation	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Oxidizing	_	_	JJ	O	-1	none	_	_
2	agents	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	powerful	_	_	JJ	O	-1	none	_	_
5	activators	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	responsible	_	_	JJ	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcriptional	_	_	JJ	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cytokine	_	_	NN	O	-1	none	_	_
15	encoding	_	_	NN	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	involved	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	tissue	_	_	NN	O	-1	none	_	_
20	injury	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	evidence	_	_	NN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	STAT3	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	whose	_	_	WP$	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	modulated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	H2O2	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	lymphocytes	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	which	_	_	WDT	O	-1	none	_	_
25	endogenous	_	_	JJ	O	-1	none	_	_
26	catalase	_	_	NN	O	-1	none	_	_
27	had	_	_	VBD	O	-1	none	_	_
28	previously	_	_	RB	O	-1	none	_	_
29	been	_	_	VBN	O	-1	none	_	_
30	inhibited	_	_	VBN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	H2O2	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	translocation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	STAT3	_	_	NN	Protein	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	form	_	_	VB	O	-1	none	_	_
9	sequence	_	_	NN	O	-1	none	_	_
10	specific	_	_	JJ	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	bound	_	_	VBD	O	-1	none	_	_
13	complexes	_	_	NNS	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	evidenced	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	immunoblotting	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	fractions	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	electrophoretic	_	_	JJ	O	-1	none	_	_
23	mobility	_	_	NN	O	-1	none	_	_
24	shift	_	_	NN	O	-1	none	_	_
25	assays	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	vanadate	_	_	NN	O	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	found	_	_	VBN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	strongly	_	_	RB	O	-1	none	_	_
33	synergize	_	_	VB	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	H2O2	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	anti-STAT3	_	_	JJ	Protein	-1	none	_	_
4	antibodies	_	_	NNS	O	-1	none	_	_
5	specifically	_	_	RB	O	-1	none	_	_
6	precipitated	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	92	_	_	CD	O	-1	none	_	_
11	kDa	_	_	NN	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	becomes	_	_	VBZ	O	-1	none	_	_
14	phosphorylated	_	_	VBN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	tyrosine	_	_	NN	O	-1	none	_	_
17	upon	_	_	IN	O	-1	none	_	_
18	lymphocyte	_	_	NN	O	-1	none	_	_
19	treatment	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	H2O2	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Phenylarsine	_	_	NN	O	-1	none	_	_
2	oxide	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	phosphatase	_	_	NN	O	-1	none	_	_
7	inhibitor	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	genistein	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	tyrosine	_	_	NN	O	-1	none	_	_
14	kinase	_	_	NN	O	-1	none	_	_
15	inhibitor	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	cooperated	_	_	VBD	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	cancelled	_	_	VBD	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	respectively	_	_	RB	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	H2O2	_	_	NN	O	-1	none	_	_
25	promoted	_	_	VBD	O	-1	none	_	_
26	STAT3	_	_	NN	Protein	-1	none	_	_
27	nuclear	_	_	JJ	O	-1	none	_	_
28	translocation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Evidence	_	_	NN	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	presented	_	_	VBN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	using	_	_	VBG	O	-1	none	_	_
7	Fe2	_	_	NN	O	-1	none	_	_
8	+/Cu2+	_	_	JJ	O	-1	none	_	_
9	ions	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	that.OH	_	_	NN	O	-1	none	_	_
12	generated	_	_	VBN	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	H2O2	_	_	NN	O	-1	none	_	_
15	through	_	_	IN	O	-1	none	_	_
16	Fenton	_	_	NN	O	-1	none	_	_
17	reactions	_	_	NNS	O	-1	none	_	_
18	could	_	_	MD	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	candidate	_	_	NN	O	-1	none	_	_
22	oxygen	_	_	NN	O	-1	none	_	_
23	reactive	_	_	JJ	O	-1	none	_	_
24	species	_	_	NNS	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	directly	_	_	RB	O	-1	none	_	_
27	activate	_	_	VB	O	-1	none	_	_
28	STAT3	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Present	_	_	JJ	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	H2O2	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	vanadate	_	_	NN	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	likely	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	inhibit	_	_	VB	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	intracellular	_	_	JJ	O	-1	none	_	_
16	tyrosine	_	_	NN	O	-1	none	_	_
17	phosphatase	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	s	_	_	NNS	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	leading	_	_	VBG	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	enhanced	_	_	VBN	O	-1	none	_	_
25	STAT3	_	_	NN	Protein	-1	none	_	_
26	tyrosine	_	_	NN	O	-1	none	_	_
27	phosphorylation	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	hence	_	_	RB	O	-1	none	_	_
30	its	_	_	PRP$	O	-1	none	_	_
31	translocation	_	_	NN	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	nucleus	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	STAT3	_	_	NN	Protein	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	modulated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	oxidizing	_	_	VBG	O	-1	none	_	_
16	agents	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	provide	_	_	VB	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	framework	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	understand	_	_	VB	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	effects	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	oxidative	_	_	JJ	O	-1	none	_	_
27	stress	_	_	NN	O	-1	none	_	_
28	on	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	JAK-STAT	_	_	NN	O	-1	none	_	_
31	signaling	_	_	NN	O	-1	none	_	_
32	pathway	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Differential	_	_	JJ	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	IL-4	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	IL-10	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	monocytic	_	_	JJ	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	lines	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	IL-4	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	IL-10	_	_	NN	Protein	-1	none	_	_
4	inhibit	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cytokine	_	_	NN	O	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	macrophages	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	mechanism	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	inhibitory	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	transcriptional	_	_	JJ	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	post-transcriptional	_	_	JJ	O	-1	none	_	_
14	regulation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-6	_	_	NN	Protein	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	IL-4	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	IL-10	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	we	_	_	PRP	O	-1	none	_	_
25	studied	_	_	VBD	O	-1	none	_	_
26	IL-6	_	_	NN	Protein	-1	none	_	_
27	production	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	level	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	IL-6	_	_	NN	Protein	-1	none	_	_
33	mRNA	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	IL-6	_	_	NN	Protein	-1	none	_	_
36	promoter	_	_	NN	O	-1	none	_	_
37	activity	_	_	NN	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	transcriptional	_	_	JJ	O	-1	none	_	_
40	activity	_	_	NN	O	-1	none	_	_
41	of	_	_	IN	O	-1	none	_	_
42	NF-kappaB	_	_	NN	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	NF-IL-6	_	_	NN	Protein	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	IL-6	_	_	NN	Protein	-1	none	_	_
48	mRNA	_	_	NN	O	-1	none	_	_
49	stability	_	_	NN	O	-1	none	_	_
50	in	_	_	IN	O	-1	none	_	_
51	human	_	_	NN	O	-1	none	_	_
52	monocytic	_	_	JJ	O	-1	none	_	_
53	cell	_	_	NN	O	-1	none	_	_
54	lines	_	_	NNS	O	-1	none	_	_
55	,	_	_	,	O	-1	none	_	_
56	THP-1	_	_	NN	O	-1	none	_	_
57	and	_	_	CC	O	-1	none	_	_
58	U937	_	_	NN	O	-1	none	_	_
59	,	_	_	,	O	-1	none	_	_
60	stimulated	_	_	VBN	O	-1	none	_	_
61	by	_	_	IN	O	-1	none	_	_
62	PMA	_	_	NN	O	-1	none	_	_
63	and	_	_	CC	O	-1	none	_	_
64	LPS	_	_	NN	O	-1	none	_	_
65	in	_	_	IN	O	-1	none	_	_
66	the	_	_	DT	O	-1	none	_	_
67	absence	_	_	NN	O	-1	none	_	_
68	or	_	_	CC	O	-1	none	_	_
69	the	_	_	DT	O	-1	none	_	_
70	presence	_	_	NN	O	-1	none	_	_
71	of	_	_	IN	O	-1	none	_	_
72	IL-4	_	_	NN	Protein	-1	none	_	_
73	or	_	_	CC	O	-1	none	_	_
74	IL-10	_	_	NN	Protein	-1	none	_	_
75	.	_	_	.	O	-1	none	_	_

1	Both	_	_	CC	O	-1	none	_	_
2	IL-4	_	_	NN	Protein	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	IL-10	_	_	NN	Protein	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	seen	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	inhibit	_	_	VB	O	-1	none	_	_
9	IL-6	_	_	NN	Protein	-1	none	_	_
10	production	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	IL-6	_	_	NN	Protein	-1	none	_	_
16	mRNA	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	both	_	_	CC	O	-1	none	_	_
19	monocytic	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	lines	_	_	NNS	O	-1	none	_	_
22	studied	_	_	VBN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	chloramphenicol	_	_	NN	Protein	3	multitoken	_	_
3	acetyltransferase	_	_	NN	Protein	0	root	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	utilizing	_	_	VBG	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	transient	_	_	JJ	O	-1	none	_	_
9	transfection	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	chloramphenicol	_	_	NN	Protein	13	multitoken	_	_
13	acetyltransferase	_	_	NN	Protein	0	root	_	_
14	reporter	_	_	NN	O	-1	none	_	_
15	plasmid	_	_	NN	O	-1	none	_	_
16	containing	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	IL-6	_	_	NN	Protein	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	IL-4	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	but	_	_	CC	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	IL-10	_	_	NN	Protein	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	suppressed	_	_	VBD	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	transcriptional	_	_	JJ	O	-1	none	_	_
31	activity	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	IL-6	_	_	NN	Protein	-1	none	_	_
35	gene	_	_	NN	O	-1	none	_	_
36	promoter	_	_	NN	O	-1	none	_	_
37	stimulated	_	_	VBN	O	-1	none	_	_
38	by	_	_	IN	O	-1	none	_	_
39	PMA	_	_	NN	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	LPS	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Electrophoretic	_	_	JJ	O	-1	none	_	_
2	mobility	_	_	NN	O	-1	none	_	_
3	shift	_	_	NN	O	-1	none	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	showed	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	IL-4	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	IL-10	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	inhibited	_	_	VBD	O	-1	none	_	_
14	nuclear	_	_	JJ	O	-1	none	_	_
15	NF-kappaB	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	IL-4	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	IL-10	_	_	NN	Protein	-1	none	_	_
23	did	_	_	VBD	O	-1	none	_	_
24	not	_	_	RB	O	-1	none	_	_
25	affect	_	_	VB	O	-1	none	_	_
26	NF-IL-6	_	_	NN	Protein	-1	none	_	_
27	activity	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	hand	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	IL-10	_	_	NN	Protein	-1	none	_	_
7	enhanced	_	_	VBD	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	degradation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	IL-6	_	_	NN	Protein	-1	none	_	_
12	mRNA	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	mRNA	_	_	NN	O	-1	none	_	_
16	stability	_	_	NN	O	-1	none	_	_
17	assay	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-4	_	_	NN	Protein	-1	none	_	_
6	may	_	_	MD	O	-1	none	_	_
7	inhibit	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	IL-6	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	affecting	_	_	VBG	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	while	_	_	IN	O	-1	none	_	_
21	IL-10	_	_	NN	Protein	-1	none	_	_
22	may	_	_	MD	O	-1	none	_	_
23	inhibit	_	_	VB	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	IL-6	_	_	NN	Protein	-1	none	_	_
26	mRNA	_	_	NN	O	-1	none	_	_
27	levels	_	_	NNS	O	-1	none	_	_
28	post-transcriptionally	_	_	RB	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	without	_	_	IN	O	-1	none	_	_
31	suppressing	_	_	VBG	O	-1	none	_	_
32	promoter	_	_	NN	O	-1	none	_	_
33	activity	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	conclude	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	IL-4	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	inhibit	_	_	VBP	O	-1	none	_	_
10	IL-6	_	_	NN	Protein	-1	none	_	_
11	production	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	different	_	_	JJ	O	-1	none	_	_
14	mechanisms	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	monocytic	_	_	JJ	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	lines	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Temperature	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	down-regulation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	glucocorticoid	_	_	NN	Protein	7	multitoken	_	_
7	receptor	_	_	NN	Protein	0	root	_	_
8	in	_	_	IN	O	-1	none	_	_
9	peripheral	_	_	JJ	O	-1	none	_	_
10	blood	_	_	NN	O	-1	none	_	_
11	mononuclear	_	_	JJ	O	-1	none	_	_
12	leucocyte	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	sepsis	_	_	NN	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	septic	_	_	JJ	O	-1	none	_	_
19	shock	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	OBJECTIVE	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
7	axis	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	vital	_	_	JJ	O	-1	none	_	_
11	importance	_	_	NN	O	-1	none	_	_
12	during	_	_	IN	O	-1	none	_	_
13	critical	_	_	JJ	O	-1	none	_	_
14	illness	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	studied	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	adaptive	_	_	JJ	O	-1	none	_	_
6	mechanisms	_	_	NNS	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	occur	_	_	VBP	O	-1	none	_	_
9	at	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	level	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	glucocorticoid	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	in	_	_	IN	O	-1	none	_	_
17	glucocorticoid	_	_	NN	O	-1	none	_	_
18	target	_	_	NN	O	-1	none	_	_
19	tissues	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	sepsis	_	_	NN	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	septic	_	_	JJ	O	-1	none	_	_
26	shock	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	DESIGN	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	hypercortisolaemia	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	hyperthermia	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	cellular	_	_	JJ	O	-1	none	_	_
11	composition	_	_	NN	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	number	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	glucocorticoid	_	_	NN	Protein	16	multitoken	_	_
16	receptors	_	_	NNS	Protein	0	root	_	_
17	per	_	_	IN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	their	_	_	PRP$	O	-1	none	_	_
21	affinity	_	_	NN	O	-1	none	_	_
22	were	_	_	VBD	O	-1	none	_	_
23	evaluated	_	_	VBN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	both	_	_	CC	O	-1	none	_	_
26	in	_	_	FW	O	-1	none	_	_
27	vitro	_	_	FW	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	in	_	_	FW	O	-1	none	_	_
30	vivo	_	_	FW	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	peripheral	_	_	JJ	O	-1	none	_	_
34	blood	_	_	NN	O	-1	none	_	_
35	mononuclear	_	_	JJ	O	-1	none	_	_
36	leucocytes	_	_	NNS	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	control	_	_	JJ	O	-1	none	_	_
39	subjects	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	patients	_	_	NNS	O	-1	none	_	_
43	with	_	_	IN	O	-1	none	_	_
44	sepsis	_	_	NN	O	-1	none	_	_
45	or	_	_	CC	O	-1	none	_	_
46	septic	_	_	JJ	O	-1	none	_	_
47	shock	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	SUBJECTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Fifteen	_	_	CD	O	-1	none	_	_
4	patients	_	_	NNS	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	age	_	_	NN	O	-1	none	_	_
7	25-79	_	_	CD	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	sepsis	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	septic	_	_	JJ	O	-1	none	_	_
13	shock	_	_	NN	O	-1	none	_	_
14	who	_	_	WP	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	admitted	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	intensive	_	_	JJ	O	-1	none	_	_
20	care	_	_	NN	O	-1	none	_	_
21	unit	_	_	NN	O	-1	none	_	_
22	were	_	_	VBD	O	-1	none	_	_
23	studied	_	_	VBN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	control	_	_	NN	O	-1	none	_	_
3	group	_	_	NN	O	-1	none	_	_
4	consisted	_	_	VBD	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	24	_	_	CD	O	-1	none	_	_
7	healthy	_	_	JJ	O	-1	none	_	_
8	laboratory	_	_	NN	O	-1	none	_	_
9	employees	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	MEASUREMENTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	capacity	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	affinity	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	glucocorticoid	_	_	NN	Protein	11	multitoken	_	_
11	receptors	_	_	NNS	Protein	0	root	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	measured	_	_	VBN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	compared	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	clinical	_	_	JJ	O	-1	none	_	_
18	data	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	plasma	_	_	NN	O	-1	none	_	_
22	cortisol	_	_	NN	O	-1	none	_	_
23	concentrations	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Hypercortisolaemia	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	in	_	_	FW	O	-1	none	_	_
6	vitro	_	_	FW	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	resulted	_	_	VBD	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	decreased	_	_	JJ	O	-1	none	_	_
12	affinity	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	decreased	_	_	JJ	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	capacity	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	glucocorticoid	_	_	NN	Protein	21	multitoken	_	_
21	receptor	_	_	NN	Protein	0	root	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vitro	_	_	FW	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	hyperthermia	_	_	NN	O	-1	none	_	_
5	as	_	_	RB	O	-1	none	_	_
6	well	_	_	RB	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	variations	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cellular	_	_	JJ	O	-1	none	_	_
12	composition	_	_	NN	O	-1	none	_	_
13	did	_	_	VBD	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	influence	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	glucocorticoid	_	_	NN	Protein	18	multitoken	_	_
18	receptor	_	_	NN	Protein	0	root	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vivo	_	_	FW	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	there	_	_	EX	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	no	_	_	DT	O	-1	none	_	_
7	change	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	number	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	receptors	_	_	NNS	O	-1	none	_	_
13	per	_	_	IN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	patients	_	_	NNS	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	sepsis	_	_	NN	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	septic	_	_	JJ	O	-1	none	_	_
21	shock	_	_	NN	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	compared	_	_	VBN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	healthy	_	_	JJ	O	-1	none	_	_
26	controls	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	decreased	_	_	JJ	O	-1	none	_	_
5	affinity	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	glucocorticoid	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	observed	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	weak	_	_	JJ	O	-1	none	_	_
5	but	_	_	CC	O	-1	none	_	_
6	significant	_	_	JJ	O	-1	none	_	_
7	negative	_	_	JJ	O	-1	none	_	_
8	correlation	_	_	NN	O	-1	none	_	_
9	between	_	_	IN	O	-1	none	_	_
10	body	_	_	NN	O	-1	none	_	_
11	temperature	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	number	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	glucocorticoid	_	_	NN	Protein	17	multitoken	_	_
17	receptors	_	_	NNS	Protein	0	root	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	patient	_	_	NN	O	-1	none	_	_
21	group	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	no	_	_	DT	O	-1	none	_	_
4	relation	_	_	NN	O	-1	none	_	_
5	between	_	_	IN	O	-1	none	_	_
6	circulating	_	_	VBG	O	-1	none	_	_
7	cortisol	_	_	NN	O	-1	none	_	_
8	concentrations	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	glucocorticoid	_	_	NN	Protein	11	multitoken	_	_
11	receptor	_	_	NN	Protein	0	root	_	_
12	affinity	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	number	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	There	_	_	EX	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	no	_	_	DT	O	-1	none	_	_
6	obvious	_	_	JJ	O	-1	none	_	_
7	regulation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	number	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	glucocorticoid	_	_	NN	Protein	13	multitoken	_	_
13	receptors	_	_	NNS	Protein	0	root	_	_
14	by	_	_	IN	O	-1	none	_	_
15	plasma	_	_	NN	O	-1	none	_	_
16	cortisol	_	_	NN	O	-1	none	_	_
17	concentrations	_	_	NNS	O	-1	none	_	_
18	in	_	_	FW	O	-1	none	_	_
19	vivo	_	_	FW	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	decreased	_	_	JJ	O	-1	none	_	_
3	affinity	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	glucocorticoid	_	_	NN	Protein	7	multitoken	_	_
7	receptor	_	_	NN	Protein	0	root	_	_
8	together	_	_	RB	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	negative	_	_	JJ	O	-1	none	_	_
12	correlation	_	_	NN	O	-1	none	_	_
13	between	_	_	IN	O	-1	none	_	_
14	hyperthermia	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	number	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	glucocorticoid	_	_	NN	Protein	20	multitoken	_	_
20	receptors	_	_	NNS	Protein	0	root	_	_
21	in	_	_	IN	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	sepsis	_	_	NN	O	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	septic	_	_	JJ	O	-1	none	_	_
27	shock	_	_	NN	O	-1	none	_	_
28	suggest	_	_	VBP	O	-1	none	_	_
29	that	_	_	IN	O	-1	none	_	_
30	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
31	axis	_	_	NN	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	during	_	_	IN	O	-1	none	_	_
34	critical	_	_	JJ	O	-1	none	_	_
35	illness	_	_	NN	O	-1	none	_	_
36	is	_	_	VBZ	O	-1	none	_	_
37	accompanied	_	_	VBN	O	-1	none	_	_
38	by	_	_	IN	O	-1	none	_	_
39	peripheral	_	_	JJ	O	-1	none	_	_
40	adaptation	_	_	NN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	glucocorticoid	_	_	NN	Protein	43	multitoken	_	_
43	receptor	_	_	NN	Protein	0	root	_	_
44	number	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	affinity	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	Mutual	_	_	JJ	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	activator	_	_	NN	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	its	_	_	PRP$	O	-1	none	_	_
11	inhibitor	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	I	_	_	NN	Protein	15	multitoken	_	_
14	kappa	_	_	NN	Protein	15	multitoken	_	_
15	B-alpha	_	_	NN	Protein	0	root	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NK-kappa	_	_	NN	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	complex	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	sequestered	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cytoplasm	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	inhibitory	_	_	JJ	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	I	_	_	NN	Protein	18	multitoken	_	_
17	kappa	_	_	NN	Protein	18	multitoken	_	_
18	B-alpha	_	_	NN	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	MAD-3	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Various	_	_	JJ	O	-1	none	_	_
2	cellular	_	_	JJ	O	-1	none	_	_
3	stimuli	_	_	NNS	O	-1	none	_	_
4	relieve	_	_	VBP	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	inhibition	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	mechanisms	_	_	NNS	O	-1	none	_	_
9	largely	_	_	RB	O	-1	none	_	_
10	unknown	_	_	JJ	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	leading	_	_	VBG	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	NF-kappa	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	nuclear	_	_	JJ	O	-1	none	_	_
17	localization	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	transactivation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	its	_	_	PRP$	O	-1	none	_	_
22	target	_	_	NN	O	-1	none	_	_
23	genes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	demonstrated	_	_	VBN	O	-1	none	_	_
4	here	_	_	RB	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	lymphocytes	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	monocytes	_	_	NNS	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	different	_	_	JJ	O	-1	none	_	_
13	stimuli	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	including	_	_	VBG	O	-1	none	_	_
16	tumor	_	_	NN	Protein	19	multitoken	_	_
17	necrosis	_	_	NN	Protein	19	multitoken	_	_
18	factor	_	_	NN	Protein	19	multitoken	_	_
19	alpha	_	_	NN	Protein	0	root	_	_
20	and	_	_	CC	O	-1	none	_	_
21	phorbol	_	_	NN	O	-1	none	_	_
22	12-myristate	_	_	NN	O	-1	none	_	_
23	13-acetate	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	cause	_	_	VB	O	-1	none	_	_
26	rapid	_	_	JJ	O	-1	none	_	_
27	degradation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	I	_	_	NN	Protein	31	multitoken	_	_
30	kappa	_	_	NN	Protein	31	multitoken	_	_
31	B-alpha	_	_	NN	Protein	0	root	_	_
32	,	_	_	,	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	concomitant	_	_	JJ	O	-1	none	_	_
35	activation	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	NF-kappa	_	_	NN	O	-1	none	_	_
38	B	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	followed	_	_	VBN	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	a	_	_	DT	O	-1	none	_	_
43	dramatic	_	_	JJ	O	-1	none	_	_
44	increase	_	_	NN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	I	_	_	NN	Protein	48	multitoken	_	_
47	kappa	_	_	NN	Protein	48	multitoken	_	_
48	B-alpha	_	_	NN	Protein	0	root	_	_
49	mRNA	_	_	NN	O	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	protein	_	_	NN	O	-1	none	_	_
52	synthesis	_	_	NN	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	reveal	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	I	_	_	NN	Protein	8	multitoken	_	_
7	kappa	_	_	NN	Protein	8	multitoken	_	_
8	B-alpha	_	_	NN	Protein	0	root	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	encoded	_	_	JJ	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	potently	_	_	RB	O	-1	none	_	_
16	induced	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	NF-kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	homodimers	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	p65	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	c-Rel	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	model	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	I	_	_	NN	Protein	12	multitoken	_	_
11	kappa	_	_	NN	Protein	12	multitoken	_	_
12	B-alpha	_	_	NN	Protein	0	root	_	_
13	mutually	_	_	RB	O	-1	none	_	_
14	regulate	_	_	VBP	O	-1	none	_	_
15	each	_	_	DT	O	-1	none	_	_
16	other	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	cycle	_	_	NN	O	-1	none	_	_
20	:	_	_	:	O	-1	none	_	_
21	saturating	_	_	JJ	O	-1	none	_	_
22	amounts	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	inhibitory	_	_	JJ	O	-1	none	_	_
26	I	_	_	NN	Protein	28	multitoken	_	_
27	kappa	_	_	NN	Protein	28	multitoken	_	_
28	B-alpha	_	_	NN	Protein	0	root	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	are	_	_	VBP	O	-1	none	_	_
31	destroyed	_	_	VBN	O	-1	none	_	_
32	upon	_	_	IN	O	-1	none	_	_
33	stimulation	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	allowing	_	_	VBG	O	-1	none	_	_
36	rapid	_	_	JJ	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	NF-kappa	_	_	NN	O	-1	none	_	_
40	B.	_	_	NNP	O	-1	none	_	_
41	Subsequently	_	_	NNP	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	I	_	_	NN	Protein	45	multitoken	_	_
44	kappa	_	_	NN	Protein	45	multitoken	_	_
45	B-alpha	_	_	NN	Protein	0	root	_	_
46	mRNA	_	_	NN	O	-1	none	_	_
47	and	_	_	CC	O	-1	none	_	_
48	protein	_	_	NN	O	-1	none	_	_
49	levels	_	_	NNS	O	-1	none	_	_
50	are	_	_	VBP	O	-1	none	_	_
51	quickly	_	_	RB	O	-1	none	_	_
52	induced	_	_	VBN	O	-1	none	_	_
53	by	_	_	IN	O	-1	none	_	_
54	the	_	_	DT	O	-1	none	_	_
55	activated	_	_	JJ	O	-1	none	_	_
56	NF-kappa	_	_	NN	O	-1	none	_	_
57	B	_	_	NN	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	resurgence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	I	_	_	NN	Protein	6	multitoken	_	_
5	kappa	_	_	NN	Protein	6	multitoken	_	_
6	B-alpha	_	_	NN	Protein	0	root	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	acts	_	_	VBZ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	restore	_	_	VB	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	equilibrium	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	again	_	_	RB	O	-1	none	_	_
19	inhibited	_	_	VBN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Evidence	_	_	NN	O	-1	none	_	_
2	for	_	_	IN	O	-1	none	_	_
3	normal	_	_	JJ	O	-1	none	_	_
4	vitamin	_	_	NN	Protein	6	multitoken	_	_
5	D	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	messenger	_	_	NN	O	-1	none	_	_
8	ribonucleic	_	_	JJ	O	-1	none	_	_
9	acid	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	genotype	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	absorptive	_	_	JJ	O	-1	none	_	_
14	hypercalciuria	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Absorptive	_	_	JJ	O	-1	none	_	_
2	hypercalciuria	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	stone	_	_	NN	O	-1	none	_	_
6	forming	_	_	VBG	O	-1	none	_	_
7	condition	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	characterized	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	gut	_	_	NN	O	-1	none	_	_
13	hyperabsorption	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	calcium	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	hypercalciuria	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	reduced	_	_	VBD	O	-1	none	_	_
21	bone	_	_	NN	O	-1	none	_	_
22	density	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Inasmuch	_	_	RB	O	-1	none	_	_
2	as	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	features	_	_	NNS	O	-1	none	_	_
5	implicate	_	_	VBP	O	-1	none	_	_
6	enhanced	_	_	VBN	O	-1	none	_	_
7	calcitriol	_	_	NN	O	-1	none	_	_
8	action	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	gut	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	bone	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	analyzed	_	_	VBD	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	vitamin	_	_	NN	Protein	19	multitoken	_	_
18	D	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	VDR	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	ascertain	_	_	VB	O	-1	none	_	_
26	whether	_	_	IN	O	-1	none	_	_
27	an	_	_	DT	O	-1	none	_	_
28	abnormality	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	this	_	_	DT	O	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	marks	_	_	VBZ	O	-1	none	_	_
33	patients	_	_	NNS	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	intestinal	_	_	JJ	O	-1	none	_	_
36	hyperabsorption	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	calcium	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	compared	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	frequency	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	restriction	_	_	NN	O	-1	none	_	_
9	fragment	_	_	NN	O	-1	none	_	_
10	length	_	_	NN	O	-1	none	_	_
11	polymorphism	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	Bsm	_	_	NN	O	-1	none	_	_
14	I	_	_	PRP	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	associated	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	different	_	_	JJ	O	-1	none	_	_
19	alleles	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	VDR	_	_	NN	Protein	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	group	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	33	_	_	CD	O	-1	none	_	_
29	well	_	_	RB	O	-1	none	_	_
30	characterized	_	_	VBN	O	-1	none	_	_
31	absorptive	_	_	JJ	O	-1	none	_	_
32	hypercalciuric	_	_	NN	O	-1	none	_	_
33	patients	_	_	NNS	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	a	_	_	DT	O	-1	none	_	_
36	group	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	36	_	_	CD	O	-1	none	_	_
39	normal	_	_	JJ	O	-1	none	_	_
40	race-	_	_	NN	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	age	_	_	NN	O	-1	none	_	_
43	matched	_	_	VBD	O	-1	none	_	_
44	control	_	_	JJ	O	-1	none	_	_
45	subjects	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	no	_	_	DT	O	-1	none	_	_
4	difference	_	_	NN	O	-1	none	_	_
5	between	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	distribution	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	VDR	_	_	NN	Protein	-1	none	_	_
11	alleles	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	patient	_	_	NN	O	-1	none	_	_
15	population	_	_	NN	O	-1	none	_	_
16	when	_	_	WRB	O	-1	none	_	_
17	compared	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	normal	_	_	JJ	O	-1	none	_	_
21	population	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	coding	_	_	VBG	O	-1	none	_	_
3	region	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	VDR	_	_	NN	Protein	-1	none	_	_
6	messenger	_	_	NN	O	-1	none	_	_
7	RNA	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	normal	_	_	JJ	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	determined	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	sequence	_	_	NN	O	-1	none	_	_
18	analysis	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	chemical	_	_	NN	O	-1	none	_	_
21	mismatch	_	_	NN	O	-1	none	_	_
22	cleavage	_	_	NN	O	-1	none	_	_
23	analysis	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	copy	_	_	NN	O	-1	none	_	_
26	DNA	_	_	NN	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	11	_	_	CD	O	-1	none	_	_
29	index	_	_	NN	O	-1	none	_	_
30	absorptive	_	_	JJ	O	-1	none	_	_
31	hypercalciuric	_	_	NN	O	-1	none	_	_
32	patients	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	basis	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	results	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	propose	_	_	VBP	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	enhanced	_	_	VBN	O	-1	none	_	_
13	intestinal	_	_	JJ	O	-1	none	_	_
14	calcium	_	_	NN	O	-1	none	_	_
15	absorption	_	_	NN	O	-1	none	_	_
16	invariably	_	_	RB	O	-1	none	_	_
17	seen	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	absorptive	_	_	JJ	O	-1	none	_	_
20	hypercalciuria	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	attendant	_	_	JJ	O	-1	none	_	_
23	symptoms	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	this	_	_	DT	O	-1	none	_	_
26	disorder	_	_	NN	O	-1	none	_	_
27	are	_	_	VBP	O	-1	none	_	_
28	not	_	_	RB	O	-1	none	_	_
29	attributable	_	_	JJ	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	mutations	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	VDR	_	_	NN	Protein	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	are	_	_	VBP	O	-1	none	_	_
37	not	_	_	RB	O	-1	none	_	_
38	linked	_	_	VBN	O	-1	none	_	_
39	to	_	_	TO	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	common	_	_	JJ	O	-1	none	_	_
42	VDR	_	_	NN	Protein	-1	none	_	_
43	genotype	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	HIV-1	_	_	NN	O	-1	none	_	_
5	tat	_	_	NN	Protein	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	Jurkat	_	_	NN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	using	_	_	VBG	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	BK	_	_	NN	O	-1	none	_	_
15	virus	_	_	NN	O	-1	none	_	_
16	vector	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	production	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	characterization	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Jurkat	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	lines	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	constitutively	_	_	RB	O	-1	none	_	_
11	express	_	_	VBP	O	-1	none	_	_
12	functional	_	_	JJ	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	immune	_	_	JJ	O	-1	none	_	_
15	deficiency	_	_	NN	O	-1	none	_	_
16	virus	_	_	NN	O	-1	none	_	_
17	type	_	_	NN	O	-1	none	_	_
18	1	_	_	CD	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	HIV-1	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	tat	_	_	NN	Protein	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	using	_	_	VBG	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	BK	_	_	NN	O	-1	none	_	_
28	virus	_	_	NN	O	-1	none	_	_
29	plasmid	_	_	NN	O	-1	none	_	_
30	expression	_	_	NN	O	-1	none	_	_
31	vector	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	HIV-1	_	_	NN	O	-1	none	_	_
34	tat	_	_	NN	Protein	-1	none	_	_
35	cDNA	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	is	_	_	VBZ	O	-1	none	_	_
38	described	_	_	VBN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	increased	_	_	JJ	O	-1	none	_	_
3	growth	_	_	NN	O	-1	none	_	_
4	rate	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	Jurkat-tat	_	_	NN	Protein	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	lines	_	_	NNS	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	compared	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	control	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	lines	_	_	NNS	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	observed	_	_	VBN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Bcl-6	_	_	NNP	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	reactive	_	_	JJ	O	-1	none	_	_
5	follicular	_	_	JJ	O	-1	none	_	_
6	hyperplasia	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	follicular	_	_	JJ	O	-1	none	_	_
9	lymphoma	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	angioimmunoblastic	_	_	JJ	O	-1	none	_	_
13	T-cell	_	_	NN	O	-1	none	_	_
14	lymphoma	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	hyperplastic	_	_	JJ	O	-1	none	_	_
17	germinal	_	_	JJ	O	-1	none	_	_
18	centers	_	_	NNS	O	-1	none	_	_
19	:	_	_	:	O	-1	none	_	_
20	heterogeneity	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	intrafollicular	_	_	JJ	O	-1	none	_	_
23	T-cells	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	their	_	_	PRP$	O	-1	none	_	_
26	altered	_	_	JJ	O	-1	none	_	_
27	distribution	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	pathogenesis	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	angioimmunoblastic	_	_	JJ	O	-1	none	_	_
33	T-cell	_	_	NN	O	-1	none	_	_
34	lymphoma	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	Bcl-6	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	product	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	phosphoprotein	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	expressed	_	_	VBN	O	-1	none	_	_
14	independently	_	_	RB	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	Bcl-6	_	_	NN	Protein	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	rearrangement	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	reported	_	_	VBD	O	-1	none	_	_
5	cases	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	angioimmunoblastic	_	_	JJ	O	-1	none	_	_
8	T-cell	_	_	NN	O	-1	none	_	_
9	lymphoma	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	AITL	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	hyperplastic	_	_	JJ	O	-1	none	_	_
15	GCs	_	_	NNS	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	AITL/GC	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	observed	_	_	VBD	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	borders	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	enlarged	_	_	JJ	O	-1	none	_	_
26	GCs	_	_	NNS	O	-1	none	_	_
27	were	_	_	VBD	O	-1	none	_	_
28	ill	_	_	RB	O	-1	none	_	_
29	defined	_	_	VBN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	features	_	_	NNS	O	-1	none	_	_
33	suggestive	_	_	JJ	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	an	_	_	DT	O	-1	none	_	_
36	outward	_	_	JJ	O	-1	none	_	_
37	migration	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	GC	_	_	NN	O	-1	none	_	_
40	cells	_	_	NNS	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	surrounding	_	_	VBG	O	-1	none	_	_
43	interfollicular	_	_	JJ	O	-1	none	_	_
44	zones	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	prompted	_	_	VBD	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	follicular	_	_	JJ	O	-1	none	_	_
7	borders	_	_	NNS	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	Bcl-6	_	_	NN	Protein	-1	none	_	_
10	staining	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	reactive	_	_	JJ	O	-1	none	_	_
13	follicular	_	_	JJ	O	-1	none	_	_
14	hyperplasias	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	follicular	_	_	JJ	O	-1	none	_	_
17	lymphomas	_	_	NNS	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	compare	_	_	VB	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	AITL/GC	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	MATERIALS	_	_	NNS	O	-1	none	_	_
2	AND	_	_	CC	O	-1	none	_	_
3	METHODS	_	_	NNS	O	-1	none	_	_
4	:	_	_	:	O	-1	none	_	_
5	Formalin	_	_	NNP	O	-1	none	_	_
6	fixed	_	_	VBN	O	-1	none	_	_
7	paraffin	_	_	NN	O	-1	none	_	_
8	sections	_	_	NNS	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	used	_	_	VBN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	immunostaining	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	Bcl-6	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Six	_	_	CD	O	-1	none	_	_
2	cases	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	AITL/GC	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	12	_	_	CD	O	-1	none	_	_
7	nonspecific	_	_	JJ	O	-1	none	_	_
8	reactive	_	_	JJ	O	-1	none	_	_
9	follicular	_	_	JJ	O	-1	none	_	_
10	hyperplasia	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	FH	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	7	_	_	CD	O	-1	none	_	_
16	HIV	_	_	NN	O	-1	none	_	_
17	adenopathy	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	10	_	_	CD	O	-1	none	_	_
20	follicular	_	_	JJ	O	-1	none	_	_
21	lymphoma	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	FL	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	8	_	_	CD	O	-1	none	_	_
28	typical	_	_	JJ	O	-1	none	_	_
29	AITL	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	ie	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	AITL	_	_	NN	O	-1	none	_	_
34	without	_	_	IN	O	-1	none	_	_
35	GC	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	were	_	_	VBD	O	-1	none	_	_
38	studied	_	_	VBN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Double	_	_	JJ	O	-1	none	_	_
2	staining	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	Bcl-6	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	CD20	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	Bcl-6	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CD3	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Bcl-6	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	CD57	_	_	NN	Protein	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	performed	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	selected	_	_	VBN	O	-1	none	_	_
20	cases	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	An	_	_	DT	O	-1	none	_	_
2	occasional	_	_	JJ	O	-1	none	_	_
3	GC	_	_	NN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	ill	_	_	JJ	O	-1	none	_	_
7	defined	_	_	VBN	O	-1	none	_	_
8	border	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	invariably	_	_	RB	O	-1	none	_	_
11	surrounded	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	broad	_	_	JJ	O	-1	none	_	_
15	mantle	_	_	NN	O	-1	none	_	_
16	zone	_	_	NN	O	-1	none	_	_
17	;	_	_	:	O	-1	none	_	_
18	those	_	_	DT	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	indistinct	_	_	JJ	O	-1	none	_	_
21	mantle	_	_	NN	O	-1	none	_	_
22	zones	_	_	NNS	O	-1	none	_	_
23	had	_	_	VBD	O	-1	none	_	_
24	well	_	_	RB	O	-1	none	_	_
25	defined	_	_	VBN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	regular	_	_	JJ	O	-1	none	_	_
28	borders	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	CD3+	_	_	JJ	O	-1	none	_	_
4	intrafollicular	_	_	JJ	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	depleted	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	AITL/GC	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	whereas	_	_	IN	O	-1	none	_	_
13	they	_	_	PRP	O	-1	none	_	_
14	were	_	_	VBD	O	-1	none	_	_
15	abundant	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	FH	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	typical	_	_	JJ	O	-1	none	_	_
3	AITL	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	some	_	_	DT	O	-1	none	_	_
6	neoplastic	_	_	JJ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	positive	_	_	JJ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	Bcl-6	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	showing	_	_	VBG	O	-1	none	_	_
14	variable	_	_	JJ	O	-1	none	_	_
15	degrees	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	staining	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	1	_	_	CD	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	GCs	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	AITL/GC	_	_	NN	O	-1	none	_	_
9	differed	_	_	VBD	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	those	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	other	_	_	JJ	O	-1	none	_	_
14	reactive	_	_	JJ	O	-1	none	_	_
15	follicular	_	_	JJ	O	-1	none	_	_
16	hyperplasias	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	follicular	_	_	JJ	O	-1	none	_	_
19	lymphomas	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	staining	_	_	NN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	Bcl-6	_	_	NN	Protein	-1	none	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	useful	_	_	JJ	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	discern	_	_	VB	O	-1	none	_	_
29	them	_	_	PRP	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	2	_	_	CD	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	Intrafollicular	_	_	JJ	O	-1	none	_	_
5	CD3+	_	_	JJ	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	many	_	_	JJ	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	also	_	_	RB	O	-1	none	_	_
14	positive	_	_	JJ	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	Bcl-6	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	markedly	_	_	RB	O	-1	none	_	_
20	depleted	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	AITL/GC	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	increased	_	_	VBN	O	-1	none	_	_
26	interfollicular	_	_	JJ	O	-1	none	_	_
27	Bcl-6	_	_	NN	Protein	-1	none	_	_
28	+/CD3+	_	_	JJ	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	suggesting	_	_	VBG	O	-1	none	_	_
32	an	_	_	DT	O	-1	none	_	_
33	outward	_	_	JJ	O	-1	none	_	_
34	migration	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	intrafollicular	_	_	JJ	O	-1	none	_	_
37	T	_	_	NN	O	-1	none	_	_
38	cells	_	_	NNS	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	this	_	_	DT	O	-1	none	_	_
41	condition	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	3	_	_	CD	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	Interfollicular	_	_	JJ	O	-1	none	_	_
5	Bcl-6	_	_	NN	Protein	-1	none	_	_
6	+/CD3+	_	_	JJ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	AITL/GC	_	_	NN	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	too	_	_	RB	O	-1	none	_	_
12	numerous	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	accounted	_	_	VBN	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	migration	_	_	NN	O	-1	none	_	_
19	alone	_	_	RB	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	suggesting	_	_	VBG	O	-1	none	_	_
22	local	_	_	JJ	O	-1	none	_	_
23	proliferation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	5	_	_	CD	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	Some	_	_	DT	O	-1	none	_	_
5	neoplastic	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	AITL	_	_	NN	O	-1	none	_	_
9	stained	_	_	VBD	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	Bcl-6	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	suggesting	_	_	VBG	O	-1	none	_	_
14	up-regulation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	Bcl-6	_	_	NN	Protein	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	this	_	_	DT	O	-1	none	_	_
20	tumor	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Interleukin-2	_	_	NNP	Protein	-1	none	_	_
2	induces	_	_	VBZ	O	-1	none	_	_
3	tyrosine	_	_	NN	O	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	translocation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	stat3	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	early	_	_	JJ	O	-1	none	_	_
3	biochemical	_	_	JJ	O	-1	none	_	_
4	event	_	_	NN	O	-1	none	_	_
5	associated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	through	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	interleukin-2	_	_	NN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	IL-2R	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	tyrosine	_	_	NN	O	-1	none	_	_
19	phosphorylation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	several	_	_	JJ	O	-1	none	_	_
22	intracellular	_	_	JJ	O	-1	none	_	_
23	substrates	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	exact	_	_	JJ	O	-1	none	_	_
3	mechanism	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	which	_	_	WDT	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	regulates	_	_	VBZ	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	different	_	_	JJ	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	presently	_	_	RB	O	-1	none	_	_
14	unknown	_	_	JJ	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	report	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	stimulation	_	_	NN	O	-1	none	_	_
7	through	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	IL-2R	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	tyrosine	_	_	NN	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	subsequent	_	_	JJ	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	translocation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	stat3	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	newly	_	_	RB	O	-1	none	_	_
22	identified	_	_	VBN	O	-1	none	_	_
23	member	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	signal	_	_	NN	O	-1	none	_	_
27	transducers	_	_	NNS	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	activators	_	_	NNS	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	transcription	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	STAT	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	family	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	proteins	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	stat1	_	_	NN	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	tyrosine	_	_	NN	O	-1	none	_	_
9	phosphorylated	_	_	JJ	O	-1	none	_	_
10	after	_	_	IN	O	-1	none	_	_
11	IL-2	_	_	NN	Protein	-1	none	_	_
12	ligation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	whereas	_	_	IN	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	phosphorylated	_	_	JJ	O	-1	none	_	_
17	stat1	_	_	NN	O	-1	none	_	_
18	proteins	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	91	_	_	CD	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	84	_	_	CD	O	-1	none	_	_
23	kDa	_	_	NN	O	-1	none	_	_
24	proteins	_	_	NNS	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	were	_	_	VBD	O	-1	none	_	_
27	translocated	_	_	VBN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	nucleus	_	_	NN	O	-1	none	_	_
31	following	_	_	VBG	O	-1	none	_	_
32	interferon-gamma	_	_	NN	Protein	-1	none	_	_
33	treatment	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	HeLa	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Apart	_	_	RB	O	-1	none	_	_
2	from	_	_	IN	O	-1	none	_	_
3	stat3	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	another	_	_	DT	O	-1	none	_	_
6	cytoplasmic	_	_	JJ	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	tyrosine	_	_	NN	O	-1	none	_	_
10	phosphorylated	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	subsequently	_	_	RB	O	-1	none	_	_
13	translocated	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	nucleus	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	had	_	_	VBD	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	apparent	_	_	JJ	O	-1	none	_	_
6	molecular	_	_	JJ	O	-1	none	_	_
7	mass	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	84	_	_	CD	O	-1	none	_	_
10	kDa	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	recognized	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	stat3	_	_	NN	Protein	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	stat1	_	_	NN	O	-1	none	_	_
19	mAb	_	_	NN	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	antisera	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	IL-2	_	_	NN	Protein	-1	none	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	translocation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	84	_	_	CD	O	-1	none	_	_
9	kDa	_	_	NN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	stat3	_	_	NN	Protein	-1	none	_	_
13	followed	_	_	VBD	O	-1	none	_	_
14	identical	_	_	JJ	O	-1	none	_	_
15	kinetics	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	p84	_	_	NN	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	candidate	_	_	NN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	new	_	_	JJ	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	yet	_	_	RB	O	-1	none	_	_
26	undefined	_	_	JJ	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	member	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	STAT	_	_	NN	O	-1	none	_	_
32	family	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	report	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	induces	_	_	VBZ	O	-1	none	_	_
9	tyrosine	_	_	NN	O	-1	none	_	_
10	phosphorylation	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	subsequent	_	_	JJ	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	translocation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	stat3	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	as	_	_	RB	O	-1	none	_	_
20	yet	_	_	RB	O	-1	none	_	_
21	undefined	_	_	JJ	O	-1	none	_	_
22	84-kDa	_	_	JJ	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	antigen	_	_	NN	O	-1	none	_	_
26	specific	_	_	JJ	O	-1	none	_	_
27	human	_	_	NN	O	-1	none	_	_
28	T	_	_	NN	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	lines	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Chronic	_	_	JJ	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	immunodeficiency	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	infection	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	myeloid	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	disrupts	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	autoregulatory	_	_	JJ	O	-1	none	_	_
14	control	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Rel	_	_	NN	O	-1	none	_	_
20	pathway	_	_	NN	O	-1	none	_	_
21	via	_	_	IN	O	-1	none	_	_
22	enhanced	_	_	VBN	O	-1	none	_	_
23	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
24	degradation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Productive	_	_	JJ	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	immunodeficiency	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HIV-1	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	infection	_	_	NN	O	-1	none	_	_
11	causes	_	_	VBZ	O	-1	none	_	_
12	sustained	_	_	JJ	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	chronically	_	_	RB	O	-1	none	_	_
19	infected	_	_	JJ	O	-1	none	_	_
20	monocytic	_	_	JJ	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	direct	_	_	JJ	O	-1	none	_	_
3	temporal	_	_	JJ	O	-1	none	_	_
4	correlation	_	_	NN	O	-1	none	_	_
5	exists	_	_	VBZ	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	HIV	_	_	NN	O	-1	none	_	_
8	infection	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	appearance	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	myelomonoblastic	_	_	JJ	O	-1	none	_	_
19	PLB-985	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	examine	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	basis	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	constitutive	_	_	JJ	O	-1	none	_	_
8	NF-kappaB	_	_	NN	O	-1	none	_	_
9	DNA	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	HIV1	_	_	NN	O	-1	none	_	_
14	-infected	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	we	_	_	PRP	O	-1	none	_	_
18	analyzed	_	_	VBD	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	phosphorylation	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	turnover	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
25	protein	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	double	_	_	JJ	Protein	36	multitoken	_	_
32	stranded	_	_	JJ	Protein	36	multitoken	_	_
33	RNA	_	_	NN	Protein	36	multitoken	_	_
34	dependent	_	_	JJ	Protein	36	multitoken	_	_
35	protein	_	_	NN	Protein	36	multitoken	_	_
36	kinase	_	_	NN	Protein	0	root	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	PKR	_	_	NN	Protein	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	intracellular	_	_	JJ	O	-1	none	_	_
43	levels	_	_	NNS	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	NF-kappaB	_	_	NN	O	-1	none	_	_
46	subunits	_	_	NNS	O	-1	none	_	_
47	in	_	_	IN	O	-1	none	_	_
48	the	_	_	DT	O	-1	none	_	_
49	PLB-985	_	_	NN	O	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	U937	_	_	NN	O	-1	none	_	_
52	myeloid	_	_	JJ	O	-1	none	_	_
53	cell	_	_	NN	O	-1	none	_	_
54	models	_	_	NNS	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	HIV-1	_	_	NNP	O	-1	none	_	_
2	infection	_	_	NN	O	-1	none	_	_
3	resulted	_	_	VBD	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	constitutive	_	_	JJ	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	low-level	_	_	JJ	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	type	_	_	NN	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	interferon	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	IFN	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	at	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	mRNA	_	_	NN	O	-1	none	_	_
19	level	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	PKR	_	_	NN	Protein	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	detected	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	HIV-1-infected	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	result	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	low-level	_	_	JJ	O	-1	none	_	_
15	IFN	_	_	NN	O	-1	none	_	_
16	production	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	since	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	addition	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	anti-IFN-alpha	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	beta	_	_	NN	O	-1	none	_	_
25	antibody	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	decreased	_	_	VBD	O	-1	none	_	_
30	PKR	_	_	NN	Protein	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	analysis	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
7	turnover	_	_	NN	O	-1	none	_	_
8	demonstrated	_	_	VBD	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	increased	_	_	JJ	O	-1	none	_	_
11	degradation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	HIV-1-infected	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	may	_	_	MD	O	-1	none	_	_
19	account	_	_	VB	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	constitutive	_	_	JJ	O	-1	none	_	_
23	DNA	_	_	NN	O	-1	none	_	_
24	binding	_	_	NN	O	-1	none	_	_
25	activity	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	dramatic	_	_	JJ	O	-1	none	_	_
3	increase	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	intracellular	_	_	JJ	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	subunits	_	_	NNS	O	-1	none	_	_
11	c-Rel	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	NF-kappaB2	_	_	NN	Protein	14	multitoken	_	_
14	p100	_	_	NN	Protein	0	root	_	_
15	and	_	_	CC	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	moderate	_	_	JJ	O	-1	none	_	_
18	increase	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	NF-kappaB2	_	_	NN	Protein	21	multitoken	_	_
21	p52	_	_	NN	Protein	0	root	_	_
22	and	_	_	CC	O	-1	none	_	_
23	RelA	_	_	NN	Protein	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	were	_	_	VBD	O	-1	none	_	_
28	detected	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	HIV-1-infected	_	_	JJ	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	whereas	_	_	IN	O	-1	none	_	_
34	NF-kappaB1	_	_	NN	Protein	35	multitoken	_	_
35	p105	_	_	NN	Protein	0	root	_	_
36	and	_	_	CC	O	-1	none	_	_
37	p50	_	_	NN	Protein	-1	none	_	_
38	levels	_	_	NNS	O	-1	none	_	_
39	were	_	_	VBD	O	-1	none	_	_
40	not	_	_	RB	O	-1	none	_	_
41	altered	_	_	JJ	O	-1	none	_	_
42	relative	_	_	JJ	O	-1	none	_	_
43	to	_	_	TO	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	levels	_	_	NNS	O	-1	none	_	_
46	in	_	_	IN	O	-1	none	_	_
47	uninfected	_	_	JJ	O	-1	none	_	_
48	cells	_	_	NNS	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	suggest	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	HIV-1	_	_	NN	O	-1	none	_	_
5	infection	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	myeloid	_	_	JJ	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	induces	_	_	VBZ	O	-1	none	_	_
10	IFN	_	_	NN	O	-1	none	_	_
11	production	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	PKR	_	_	NN	Protein	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	turn	_	_	NN	O	-1	none	_	_
19	contribute	_	_	VBP	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	enhanced	_	_	VBN	O	-1	none	_	_
22	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
23	phosphorylation	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	subsequent	_	_	JJ	O	-1	none	_	_
26	degradation	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	translocation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NF-kappaB	_	_	NN	O	-1	none	_	_
5	subunits	_	_	NNS	O	-1	none	_	_
6	may	_	_	MD	O	-1	none	_	_
7	ultimately	_	_	RB	O	-1	none	_	_
8	increase	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	intracellular	_	_	JJ	O	-1	none	_	_
11	pool	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	autoregulatory	_	_	JJ	O	-1	none	_	_
19	mechanism	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Enhanced	_	_	VBN	O	-1	none	_	_
2	turnover	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IkappaBalpha	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	accumulation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-kappaB	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Rel	_	_	NN	O	-1	none	_	_
12	proteins	_	_	NNS	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	contribute	_	_	VB	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	chronically	_	_	RB	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	state	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	HIV-1-infected	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Grf40	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	A	_	_	DT	O	-1	none	_	_
4	novel	_	_	JJ	O	-1	none	_	_
5	Grb2	_	_	NN	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	member	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	involved	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	signaling	_	_	NN	O	-1	none	_	_
15	through	_	_	IN	O	-1	none	_	_
16	interaction	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	SLP-76	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	LAT	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	molecularly	_	_	RB	O	-1	none	_	_
3	cloned	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	new	_	_	JJ	O	-1	none	_	_
6	Grb2	_	_	NN	O	-1	none	_	_
7	family	_	_	NN	O	-1	none	_	_
8	member	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	named	_	_	VBN	O	-1	none	_	_
11	Grf40	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	containing	_	_	VBG	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	common	_	_	JJ	O	-1	none	_	_
16	SH3-SH2-SH3	_	_	NN	O	-1	none	_	_
17	motif	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Grf40	_	_	NN	Protein	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	predominant	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	hematopoietic	_	_	JJ	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	particularly	_	_	RB	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Grf40	_	_	NN	Protein	-1	none	_	_
2	binds	_	_	VBZ	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	SH2	_	_	NN	Protein	12	multitoken	_	_
6	domain	_	_	NN	Protein	12	multitoken	_	_
7	containing	_	_	VBG	Protein	12	multitoken	_	_
8	leukocyte	_	_	NN	Protein	12	multitoken	_	_
9	protein	_	_	NN	Protein	12	multitoken	_	_
10	of	_	_	IN	Protein	12	multitoken	_	_
11	76	_	_	CD	Protein	12	multitoken	_	_
12	kD	_	_	NN	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	SLP-76	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	via	_	_	IN	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	SH3	_	_	NN	O	-1	none	_	_
19	domain	_	_	NN	O	-1	none	_	_
20	more	_	_	RBR	O	-1	none	_	_
21	tightly	_	_	RB	O	-1	none	_	_
22	than	_	_	IN	O	-1	none	_	_
23	Grb2	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Incidentally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Grf40	_	_	NN	Protein	-1	none	_	_
4	binds	_	_	VBZ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	linker	_	_	NN	Protein	11	multitoken	_	_
7	for	_	_	IN	Protein	11	multitoken	_	_
8	activation	_	_	NN	Protein	11	multitoken	_	_
9	of	_	_	IN	Protein	11	multitoken	_	_
10	T	_	_	NN	Protein	11	multitoken	_	_
11	cells	_	_	NNS	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	LAT	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	possibly	_	_	RB	O	-1	none	_	_
16	via	_	_	IN	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	SH2	_	_	NN	O	-1	none	_	_
19	domain	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	SH2	_	_	NN	O	-1	none	_	_
5	deleted	_	_	VBN	O	-1	none	_	_
6	Grf40	_	_	NN	Protein	-1	none	_	_
7	mutant	_	_	NN	O	-1	none	_	_
8	led	_	_	VBD	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	marked	_	_	JJ	O	-1	none	_	_
12	inhibition	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	these	_	_	DT	O	-1	none	_	_
15	regulatory	_	_	JJ	O	-1	none	_	_
16	activities	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	effect	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	apparently	_	_	RB	O	-1	none	_	_
24	stronger	_	_	JJR	O	-1	none	_	_
25	than	_	_	IN	O	-1	none	_	_
26	that	_	_	DT	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	SH2	_	_	NN	O	-1	none	_	_
30	deleted	_	_	VBN	O	-1	none	_	_
31	Grb2	_	_	NN	Protein	-1	none	_	_
32	mutant	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Grf40	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	adaptor	_	_	NN	O	-1	none	_	_
9	molecule	_	_	NN	O	-1	none	_	_
10	involved	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	signaling	_	_	NN	O	-1	none	_	_
15	through	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	more	_	_	RBR	O	-1	none	_	_
18	efficient	_	_	JJ	O	-1	none	_	_
19	interaction	_	_	NN	O	-1	none	_	_
20	than	_	_	IN	O	-1	none	_	_
21	Grb2	_	_	NN	Protein	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	SLP-76	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	LAT	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	nucleoside	_	_	NN	Protein	6	multitoken	_	_
5	diphosphate	_	_	NN	Protein	6	multitoken	_	_
6	kinase	_	_	NN	Protein	0	root	_	_
7	in	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	skin	_	_	NN	O	-1	none	_	_
10	cancers	_	_	NNS	O	-1	none	_	_
11	:	_	_	:	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	immunohistochemical	_	_	JJ	O	-1	none	_	_
14	study	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	nucleoside	_	_	NN	Protein	8	multitoken	_	_
4	diphosphate	_	_	NN	Protein	8	multitoken	_	_
5	(	_	_	-LRB-	Protein	8	multitoken	_	_
6	NDP	_	_	NN	Protein	8	multitoken	_	_
7	)	_	_	-RRB-	Protein	8	multitoken	_	_
8	kinase	_	_	NN	Protein	0	root	_	_
9	,	_	_	,	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	homologous	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	nm23	_	_	NN	Protein	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	product	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	variety	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	species	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	has	_	_	VBZ	O	-1	none	_	_
25	been	_	_	VBN	O	-1	none	_	_
26	found	_	_	VBN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	be	_	_	VB	O	-1	none	_	_
29	inversely	_	_	RB	O	-1	none	_	_
30	associated	_	_	VBN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	metastatic	_	_	JJ	O	-1	none	_	_
33	potential	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	relationship	_	_	NN	O	-1	none	_	_
5	remains	_	_	VBZ	O	-1	none	_	_
6	controversial	_	_	JJ	O	-1	none	_	_
7	according	_	_	VBG	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	tumor	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	types	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	experimental	_	_	JJ	O	-1	none	_	_
15	system	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	conflicting	_	_	JJ	O	-1	none	_	_
19	results	_	_	NNS	O	-1	none	_	_
20	from	_	_	IN	O	-1	none	_	_
21	different	_	_	JJ	O	-1	none	_	_
22	research	_	_	NN	O	-1	none	_	_
23	groups	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	determine	_	_	VB	O	-1	none	_	_
5	whether	_	_	IN	O	-1	none	_	_
6	NDP	_	_	NN	Protein	7	multitoken	_	_
7	kinase	_	_	NN	Protein	0	root	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	serves	_	_	VBZ	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	marker	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	metastatic	_	_	JJ	O	-1	none	_	_
15	potential	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	skin	_	_	NN	O	-1	none	_	_
19	cancer	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	we	_	_	PRP	O	-1	none	_	_
22	assessed	_	_	VBD	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	levels	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	NDP	_	_	NN	Protein	27	multitoken	_	_
27	kinase	_	_	NN	Protein	0	root	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	9	_	_	CD	O	-1	none	_	_
31	keratoacanthomas	_	_	NNS	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	KAs	_	_	NNS	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	26	_	_	CD	O	-1	none	_	_
37	squamous	_	_	JJ	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	carcinomas	_	_	NNS	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	SCCs	_	_	NNS	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	25	_	_	CD	O	-1	none	_	_
46	basal	_	_	JJ	O	-1	none	_	_
47	cell	_	_	NN	O	-1	none	_	_
48	carcinomas	_	_	NNS	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	BCCs	_	_	NNS	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	using	_	_	VBG	O	-1	none	_	_
53	immunohistochemistry	_	_	NN	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NDP	_	_	NN	Protein	5	multitoken	_	_
5	kinase	_	_	NN	Protein	0	root	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	intense	_	_	JJ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	KA	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	SCC	_	_	NN	O	-1	none	_	_
12	compared	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	BCC	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	difference	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	NDP	_	_	NN	Protein	7	multitoken	_	_
7	kinase	_	_	NN	Protein	0	root	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	between	_	_	IN	O	-1	none	_	_
10	KA	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	SCC	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	statistically	_	_	RB	O	-1	none	_	_
16	significant	_	_	JJ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	And	_	_	CC	O	-1	none	_	_
2	there	_	_	EX	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	no	_	_	DT	O	-1	none	_	_
5	statistically	_	_	RB	O	-1	none	_	_
6	significant	_	_	JJ	O	-1	none	_	_
7	difference	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	NDP	_	_	NN	Protein	10	multitoken	_	_
10	kinase	_	_	NN	Protein	0	root	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	between	_	_	IN	O	-1	none	_	_
13	SCC	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	metastasis	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	SCC	_	_	NN	O	-1	none	_	_
18	without	_	_	IN	O	-1	none	_	_
19	metastasis	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	contradict	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	hypothesis	_	_	NN	O	-1	none	_	_
6	concerning	_	_	VBG	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	possible	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	nm23	_	_	NN	Protein	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	metastatic	_	_	JJ	O	-1	none	_	_
16	suppressor	_	_	NN	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	skin	_	_	NN	O	-1	none	_	_
21	cancer	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	overexpression	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	various	_	_	JJ	O	-1	none	_	_
7	tumor	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	types	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	its	_	_	PRP$	O	-1	none	_	_
12	biological	_	_	JJ	O	-1	none	_	_
13	significance	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	cutaneous	_	_	JJ	O	-1	none	_	_
16	carcinogenesis	_	_	NN	O	-1	none	_	_
17	remain	_	_	VBP	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	determined	_	_	VBN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	MDS1	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	EVI1	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	located	_	_	JJ	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	chromosome	_	_	NN	O	-1	none	_	_
8	3	_	_	CD	O	-1	none	_	_
9	band	_	_	NN	O	-1	none	_	_
10	q26	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	encodes	_	_	VBZ	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	zinc-finger	_	_	JJ	O	-1	none	_	_
15	DNA	_	_	NN	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	activator	_	_	NN	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	detected	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	normal	_	_	JJ	O	-1	none	_	_
23	hematopoietic	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	expressed	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	several	_	_	JJ	O	-1	none	_	_
29	normal	_	_	JJ	O	-1	none	_	_
30	tissues	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	MDS1	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	EVI1	_	_	NN	Protein	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	inappropriately	_	_	RB	O	-1	none	_	_
6	activated	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	myeloid	_	_	JJ	O	-1	none	_	_
9	leukemias	_	_	NNS	O	-1	none	_	_
10	following	_	_	VBG	O	-1	none	_	_
11	chromosomal	_	_	JJ	O	-1	none	_	_
12	rearrangements	_	_	NNS	O	-1	none	_	_
13	involving	_	_	VBG	O	-1	none	_	_
14	band	_	_	NN	O	-1	none	_	_
15	3q26	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	This	_	_	DT	O	-1	none	_	_
2	fusion	_	_	NN	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	contains	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	domain	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	AML1	_	_	NN	Protein	-1	none	_	_
14	fused	_	_	VBN	O	-1	none	_	_
15	in-frame	_	_	RB	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	entire	_	_	JJ	O	-1	none	_	_
19	MDS1	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	EVI1	_	_	NN	Protein	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	exclusion	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	its	_	_	PRP$	O	-1	none	_	_
27	first	_	_	JJ	O	-1	none	_	_
28	12	_	_	CD	O	-1	none	_	_
29	amino	_	_	NN	O	-1	none	_	_
30	acids	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	They	_	_	PRP	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	growth	_	_	NN	O	-1	none	_	_
4	inhibited	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	TGF-beta1	_	_	NN	Protein	-1	none	_	_
7	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	similar	_	_	JJ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	that	_	_	DT	O	-1	none	_	_
7	previously	_	_	RB	O	-1	none	_	_
8	described	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	others	_	_	NNS	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	32Dcl3	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	express	_	_	VBP	O	-1	none	_	_
16	transgenic	_	_	JJ	O	-1	none	_	_
17	Evil	_	_	NNP	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	correlated	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	response	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	G-CSF	_	_	NN	Protein	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	TGF-beta1	_	_	NN	Protein	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	ability	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	normal	_	_	JJ	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	fusion	_	_	NN	O	-1	none	_	_
23	proteins	_	_	NNS	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	activate	_	_	VB	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	repress	_	_	VB	O	-1	none	_	_
28	promoters	_	_	NNS	O	-1	none	_	_
29	which	_	_	WDT	O	-1	none	_	_
30	they	_	_	PRP	O	-1	none	_	_
31	can	_	_	MD	O	-1	none	_	_
32	directly	_	_	RB	O	-1	none	_	_
33	regulate	_	_	VB	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	binding	_	_	VBG	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	promoter	_	_	NN	O	-1	none	_	_
39	site	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	mutations	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	MDS1	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	EVI1	_	_	NN	Protein	-1	none	_	_
9	either	_	_	CC	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	truncation	_	_	NN	O	-1	none	_	_
13	resulting	_	_	VBG	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	repressor	_	_	NN	O	-1	none	_	_
18	EVI1	_	_	NN	Protein	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	fusion	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	AML1	_	_	NN	Protein	-1	none	_	_
25	lead	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	an	_	_	DT	O	-1	none	_	_
28	altered	_	_	JJ	O	-1	none	_	_
29	cellular	_	_	JJ	O	-1	none	_	_
30	response	_	_	NN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	growth	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	differentiation	_	_	NN	O	-1	none	_	_
35	factors	_	_	NNS	O	-1	none	_	_
36	that	_	_	WDT	O	-1	none	_	_
37	could	_	_	MD	O	-1	none	_	_
38	result	_	_	VB	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	leukemic	_	_	JJ	O	-1	none	_	_
41	transformation	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	different	_	_	JJ	O	-1	none	_	_
3	response	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	myeloid	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	ectopically	_	_	RB	O	-1	none	_	_
8	expressing	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	normal	_	_	JJ	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	fusion	_	_	NN	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	G-CSF	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	TGF-beta1	_	_	NN	Protein	-1	none	_	_
19	could	_	_	MD	O	-1	none	_	_
20	depend	_	_	VB	O	-1	none	_	_
21	on	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	different	_	_	JJ	O	-1	none	_	_
24	transactivation	_	_	NN	O	-1	none	_	_
25	properties	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	these	_	_	DT	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	resulting	_	_	VBG	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	divergent	_	_	JJ	O	-1	none	_	_
32	expression	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	downstream	_	_	JJ	O	-1	none	_	_
35	genes	_	_	NNS	O	-1	none	_	_
36	regulated	_	_	VBN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	two	_	_	CD	O	-1	none	_	_
40	proteins	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	BMRF1	_	_	NN	Protein	-1	none	_	_
8	promoter	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	early	_	_	JJ	O	-1	none	_	_
11	antigen	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	EA-D	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	regulated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	EBV	_	_	NN	O	-1	none	_	_
20	transactivators	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	BRLF1	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	BZLF1	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	specific	_	_	JJ	O	-1	none	_	_
30	manner	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	early	_	_	JJ	O	-1	none	_	_
5	antigen	_	_	NN	O	-1	none	_	_
6	diffuse	_	_	JJ	O	-1	none	_	_
7	component	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	EA-D	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	essential	_	_	JJ	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	Epstein-Barr	_	_	JJ	O	-1	none	_	_
15	virus	_	_	NN	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	polymerase	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	its	_	_	PRP$	O	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	suppressed	_	_	VBN	O	-1	none	_	_
25	during	_	_	IN	O	-1	none	_	_
26	latent	_	_	JJ	O	-1	none	_	_
27	infection	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	regulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	BMRF1	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	early	_	_	JJ	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	studying	_	_	VBG	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	responsiveness	_	_	NN	O	-1	none	_	_
19	in	_	_	FW	O	-1	none	_	_
20	vitro	_	_	FW	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	two	_	_	CD	O	-1	none	_	_
23	immediate-early	_	_	JJ	O	-1	none	_	_
24	viral	_	_	JJ	O	-1	none	_	_
25	transactivators	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	BZLF1	_	_	NN	Protein	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	Z	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	BRLF1	_	_	NN	Protein	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	R	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	focusing	_	_	VBG	O	-1	none	_	_
38	on	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	differences	_	_	NNS	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	response	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	lymphoid	_	_	JJ	O	-1	none	_	_
45	cells	_	_	NNS	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	epithelial	_	_	JJ	O	-1	none	_	_
48	cells	_	_	NNS	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	lymphoid	_	_	JJ	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	Z	_	_	NN	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	R	_	_	NN	O	-1	none	_	_
8	alone	_	_	RB	O	-1	none	_	_
9	produced	_	_	VBD	O	-1	none	_	_
10	only	_	_	RB	O	-1	none	_	_
11	small	_	_	JJ	O	-1	none	_	_
12	increases	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	EA-D	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	whereas	_	_	IN	O	-1	none	_	_
19	both	_	_	DT	O	-1	none	_	_
20	transactivators	_	_	NNS	O	-1	none	_	_
21	together	_	_	RB	O	-1	none	_	_
22	produced	_	_	VBD	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	large	_	_	JJ	O	-1	none	_	_
25	stimulatory	_	_	JJ	O	-1	none	_	_
26	effect	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	epithelial	_	_	JJ	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	Z	_	_	NN	O	-1	none	_	_
7	transactivator	_	_	NN	O	-1	none	_	_
8	alone	_	_	RB	O	-1	none	_	_
9	produced	_	_	VBD	O	-1	none	_	_
10	maximal	_	_	JJ	O	-1	none	_	_
11	stimulation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	EA-D	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	;	_	_	:	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	effect	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	R	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	Z	_	_	NN	O	-1	none	_	_
23	together	_	_	RB	O	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	no	_	_	DT	O	-1	none	_	_
26	greater	_	_	JJR	O	-1	none	_	_
27	than	_	_	IN	O	-1	none	_	_
28	that	_	_	DT	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	Z	_	_	NN	O	-1	none	_	_
31	alone	_	_	RB	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Deletional	_	_	JJ	O	-1	none	_	_
2	analysis	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	site	_	_	NN	O	-1	none	_	_
5	directed	_	_	JJ	O	-1	none	_	_
6	mutagenesis	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	EA-D	_	_	NN	Protein	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	demonstrated	_	_	VBD	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	epithelial	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	potential	_	_	JJ	O	-1	none	_	_
18	AP-1	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	plays	_	_	VBZ	O	-1	none	_	_
22	an	_	_	DT	O	-1	none	_	_
23	essential	_	_	JJ	O	-1	none	_	_
24	role	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	Z	_	_	NN	O	-1	none	_	_
27	responsiveness	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	although	_	_	IN	O	-1	none	_	_
30	sequences	_	_	NNS	O	-1	none	_	_
31	further	_	_	RB	O	-1	none	_	_
32	upstream	_	_	RB	O	-1	none	_	_
33	are	_	_	VBP	O	-1	none	_	_
34	also	_	_	RB	O	-1	none	_	_
35	important	_	_	JJ	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	lymphoid	_	_	JJ	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	only	_	_	RB	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	upstream	_	_	JJ	O	-1	none	_	_
8	sequences	_	_	NNS	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	required	_	_	VBN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	transactivation	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	Z/R	_	_	NN	O	-1	none	_	_
16	combination	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	AP-1	_	_	NN	O	-1	none	_	_
21	site	_	_	NN	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	dispensable	_	_	JJ	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	EA-D	_	_	NN	Protein	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	BMRF1	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	promoter	_	_	NN	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	Z	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	R	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	type	_	_	NN	O	-1	none	_	_
18	specific	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	appears	_	_	VBZ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	involve	_	_	VB	O	-1	none	_	_
23	different	_	_	JJ	O	-1	none	_	_
24	mechanisms	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	each	_	_	DT	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	type	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Erythropoietin	_	_	NN	Protein	-1	none	_	_
2	stimulates	_	_	VBZ	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	TAL1	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	SCL	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	phosphorylation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	its	_	_	PRP$	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	products	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	TAL1	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	SCL	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	originally	_	_	RB	O	-1	none	_	_
12	identified	_	_	VBN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	its	_	_	PRP$	O	-1	none	_	_
15	involvement	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	recurrent	_	_	JJ	O	-1	none	_	_
19	chromosomal	_	_	JJ	O	-1	none	_	_
20	translocation	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	most	_	_	RBS	O	-1	none	_	_
25	frequent	_	_	JJ	O	-1	none	_	_
26	molecular	_	_	JJ	O	-1	none	_	_
27	lesion	_	_	NN	O	-1	none	_	_
28	recognized	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	T-cell	_	_	NN	O	-1	none	_	_
31	acute	_	_	JJ	O	-1	none	_	_
32	lymphoblastic	_	_	JJ	O	-1	none	_	_
33	leukemia	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	products	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	contain	_	_	VBP	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	basic-helix-loop-helix	_	_	JJ	O	-1	none	_	_
10	motif	_	_	NN	O	-1	none	_	_
11	characteristic	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	large	_	_	JJ	O	-1	none	_	_
15	family	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factors	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	bind	_	_	VBP	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	canonical	_	_	JJ	O	-1	none	_	_
24	DNA	_	_	NN	O	-1	none	_	_
25	sequence	_	_	NN	O	-1	none	_	_
26	CANNTG	_	_	NN	O	-1	none	_	_
27	as	_	_	IN	O	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	heterodimers	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	TAL1	_	_	NN	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	erythroid	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	in	_	_	FW	O	-1	none	_	_
7	vivo	_	_	FW	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	chemical	_	_	NN	O	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	erythroleukemia	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	lines	_	_	NNS	O	-1	none	_	_
15	in	_	_	FW	O	-1	none	_	_
16	vivo	_	_	FW	O	-1	none	_	_
17	suggested	_	_	VBD	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	might	_	_	MD	O	-1	none	_	_
21	regulate	_	_	VB	O	-1	none	_	_
22	aspects	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	erythroid	_	_	JJ	O	-1	none	_	_
25	differentiation	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	terminal	_	_	JJ	O	-1	none	_	_
4	events	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	erythropoiesis	_	_	NN	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	controlled	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	glycoprotein	_	_	NN	O	-1	none	_	_
12	hormone	_	_	NN	O	-1	none	_	_
13	erythropoietin	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	Epo	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	we	_	_	PRP	O	-1	none	_	_
19	investigated	_	_	VBD	O	-1	none	_	_
20	whether	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	TAL1	_	_	NN	Protein	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	its	_	_	PRP$	O	-1	none	_	_
31	protein	_	_	NN	O	-1	none	_	_
32	products	_	_	NNS	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	affected	_	_	VBN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	Epo	_	_	NN	Protein	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	splenic	_	_	JJ	O	-1	none	_	_
39	erythroblasts	_	_	NNS	O	-1	none	_	_
40	from	_	_	IN	O	-1	none	_	_
41	mice	_	_	NNS	O	-1	none	_	_
42	infected	_	_	VBN	O	-1	none	_	_
43	with	_	_	IN	O	-1	none	_	_
44	an	_	_	DT	O	-1	none	_	_
45	anemia	_	_	NN	O	-1	none	_	_
46	inducing	_	_	VBG	O	-1	none	_	_
47	strain	_	_	NN	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	Friend	_	_	NN	O	-1	none	_	_
50	virus	_	_	NN	O	-1	none	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	FVA	_	_	NN	O	-1	none	_	_
53	cells	_	_	NNS	O	-1	none	_	_
54	)	_	_	-RRB-	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	Epo	_	_	NN	Protein	-1	none	_	_
2	elicited	_	_	VBD	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	rapid	_	_	JJ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	dose	_	_	NN	O	-1	none	_	_
7	related	_	_	JJ	O	-1	none	_	_
8	increase	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	TAL1	_	_	NN	Protein	-1	none	_	_
11	mRNA	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	increasing	_	_	VBG	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	stabilizing	_	_	VBG	O	-1	none	_	_
20	one	_	_	CD	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	its	_	_	PRP$	O	-1	none	_	_
23	mRNAs	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	Epo	_	_	NN	Protein	-1	none	_	_
3	inducible	_	_	JJ	O	-1	none	_	_
4	TAL1	_	_	NN	Protein	-1	none	_	_
5	DNA	_	_	NN	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	identified	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	FVA	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	extracts	_	_	NNS	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	subsequently	_	_	RB	O	-1	none	_	_
17	decayed	_	_	VBN	O	-1	none	_	_
18	despite	_	_	IN	O	-1	none	_	_
19	accumulating	_	_	VBG	O	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	protein	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	DNA	_	_	NN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	associated	_	_	VBN	O	-1	none	_	_
8	temporally	_	_	RB	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	Epo	_	_	NN	Protein	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	nuclear	_	_	JJ	O	-1	none	_	_
15	TAL1	_	_	NN	Protein	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Epo	_	_	NN	Protein	-1	none	_	_
6	acts	_	_	VBZ	O	-1	none	_	_
7	at	_	_	IN	O	-1	none	_	_
8	both	_	_	CC	O	-1	none	_	_
9	transcriptional	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	posttranscriptional	_	_	JJ	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	TAL1	_	_	NN	Protein	-1	none	_	_
16	locus	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	Friend	_	_	NN	O	-1	none	_	_
19	virus	_	_	NN	O	-1	none	_	_
20	induced	_	_	VBD	O	-1	none	_	_
21	erythroblasts	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	establish	_	_	VB	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	link	_	_	NN	O	-1	none	_	_
26	between	_	_	IN	O	-1	none	_	_
27	Epo	_	_	NN	Protein	-1	none	_	_
28	signaling	_	_	NN	O	-1	none	_	_
29	mechanisms	_	_	NNS	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	member	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	family	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	factors	_	_	NNS	O	-1	none	_	_
39	involved	_	_	VBN	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	differentiation	_	_	NN	O	-1	none	_	_
43	of	_	_	IN	O	-1	none	_	_
44	diverse	_	_	JJ	O	-1	none	_	_
45	cell	_	_	NN	O	-1	none	_	_
46	lineages	_	_	NNS	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	Anti-immunoglobulin	_	_	NN	O	-1	none	_	_
2	M	_	_	NN	O	-1	none	_	_
3	activates	_	_	VBZ	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	calcium/calmodulin	_	_	NN	Protein	9	multitoken	_	_
6	dependent	_	_	JJ	Protein	9	multitoken	_	_
7	protein	_	_	NN	Protein	9	multitoken	_	_
8	kinase	_	_	NN	Protein	9	multitoken	_	_
9	II	_	_	CD	Protein	0	root	_	_
10	in	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	lymphocytes	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	others	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	previously	_	_	RB	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	Ets-1	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	phosphorylated	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	calcium	_	_	NN	O	-1	none	_	_
19	dependent	_	_	JJ	O	-1	none	_	_
20	manner	_	_	NN	O	-1	none	_	_
21	after	_	_	IN	O	-1	none	_	_
22	ligation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	immunoglobulin	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	Ig	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	M	_	_	NN	O	-1	none	_	_
29	on	_	_	IN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	lymphocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	phosphorylation	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	independent	_	_	JJ	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	C	_	_	NN	O	-1	none	_	_
10	activity	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	we	_	_	PRP	O	-1	none	_	_
13	tested	_	_	VBD	O	-1	none	_	_
14	whether	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	calcium/calmodulin	_	_	NN	O	-1	none	_	_
17	dependent	_	_	JJ	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	kinase	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	CaM	_	_	NN	O	-1	none	_	_
22	kinase	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	might	_	_	MD	O	-1	none	_	_
25	phosphorylate	_	_	VB	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	Ets-1	_	_	NN	Protein	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	after	_	_	IN	O	-1	none	_	_
30	elevation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	intracellular	_	_	JJ	O	-1	none	_	_
33	free	_	_	JJ	O	-1	none	_	_
34	calcium	_	_	NN	O	-1	none	_	_
35	concentrations	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	dephosphorylated	_	_	JJ	O	-1	none	_	_
3	form	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	Ets-1	_	_	NN	Protein	-1	none	_	_
6	has	_	_	VBZ	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	shown	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	bind	_	_	VB	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	chromatin	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	suggesting	_	_	VBG	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	operative	_	_	JJ	O	-1	none	_	_
18	kinase	_	_	NN	O	-1	none	_	_
19	should	_	_	MD	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	detectable	_	_	JJ	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	nucleus	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	prepared	_	_	VBD	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	extracts	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	lines	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	increased	_	_	VBN	O	-1	none	_	_
14	intracellular	_	_	JJ	O	-1	none	_	_
15	free	_	_	JJ	O	-1	none	_	_
16	calcium	_	_	NN	O	-1	none	_	_
17	levels	_	_	NNS	O	-1	none	_	_
18	correlated	_	_	VBD	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	increased	_	_	VBN	O	-1	none	_	_
21	phosphorylation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	Ets-1	_	_	NN	Protein	-1	none	_	_
25	protein	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Activity	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	CaM	_	_	NN	O	-1	none	_	_
5	kinases	_	_	NNS	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	determined	_	_	VBN	O	-1	none	_	_
8	using	_	_	VBG	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	synthetic	_	_	JJ	O	-1	none	_	_
11	peptide	_	_	NN	O	-1	none	_	_
12	substrate	_	_	NN	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	absence	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	presence	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	inhibitor	_	_	NN	O	-1	none	_	_
22	specific	_	_	JJ	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	CaM	_	_	NN	O	-1	none	_	_
26	kinase	_	_	NN	O	-1	none	_	_
27	family	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	KN-62	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Stimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	anti-IgM	_	_	JJ	O	-1	none	_	_
6	led	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	increased	_	_	VBN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	kinase	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	could	_	_	MD	O	-1	none	_	_
16	phosphorylate	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	peptide	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	this	_	_	DT	O	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	reduced	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	10	_	_	CD	O	-1	none	_	_
27	microM	_	_	NN	O	-1	none	_	_
28	KN-62	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Kinase	_	_	NN	O	-1	none	_	_
2	activity	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	reduced	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	lysates	_	_	NNS	O	-1	none	_	_
7	preadsorbed	_	_	VBN	O	-1	none	_	_
8	using	_	_	VBG	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	antibody	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	CaM	_	_	NN	Protein	15	multitoken	_	_
14	kinase	_	_	NN	Protein	15	multitoken	_	_
15	II	_	_	CD	Protein	0	root	_	_
16	.	_	_	.	O	-1	none	_	_

1	Two-dimensional	_	_	JJ	O	-1	none	_	_
2	phosphopeptide	_	_	NN	O	-1	none	_	_
3	maps	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	Ets-1	_	_	NN	Protein	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	incubated	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	ionomycin	_	_	NN	O	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	anti-IgM	_	_	NN	O	-1	none	_	_
15	contained	_	_	VBD	O	-1	none	_	_
16	two	_	_	CD	O	-1	none	_	_
17	unique	_	_	JJ	O	-1	none	_	_
18	phosphopeptides	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	were	_	_	VBD	O	-1	none	_	_
21	absent	_	_	JJ	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	untreated	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Incubation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	isolated	_	_	VBN	O	-1	none	_	_
4	Ets-1	_	_	NN	Protein	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	purified	_	_	VBN	O	-1	none	_	_
8	CaM	_	_	NN	Protein	10	multitoken	_	_
9	kinase	_	_	NN	Protein	10	multitoken	_	_
10	II	_	_	CD	Protein	0	root	_	_
11	produced	_	_	VBD	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	peptides	_	_	NNS	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	migrated	_	_	VBD	O	-1	none	_	_
17	identically	_	_	RB	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	those	_	_	DT	O	-1	none	_	_
20	found	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	incubated	_	_	VBN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	either	_	_	CC	O	-1	none	_	_
26	anti-IgM	_	_	NN	O	-1	none	_	_
27	or	_	_	CC	O	-1	none	_	_
28	ionomycin	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	model	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	signal	_	_	NN	O	-1	none	_	_
8	transduction	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	antigen	_	_	NN	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	increased	_	_	VBN	O	-1	none	_	_
19	intracellular	_	_	JJ	O	-1	none	_	_
20	free	_	_	JJ	O	-1	none	_	_
21	calcium	_	_	NN	O	-1	none	_	_
22	can	_	_	MD	O	-1	none	_	_
23	rapidly	_	_	RB	O	-1	none	_	_
24	activate	_	_	VB	O	-1	none	_	_
25	nuclear	_	_	JJ	O	-1	none	_	_
26	CaM	_	_	NN	Protein	28	multitoken	_	_
27	kinase	_	_	NN	Protein	28	multitoken	_	_
28	II	_	_	CD	Protein	0	root	_	_
29	,	_	_	,	O	-1	none	_	_
30	potentially	_	_	RB	O	-1	none	_	_
31	resulting	_	_	VBG	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	phosphorylation	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	regulation	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	DNA	_	_	NN	O	-1	none	_	_
38	binding	_	_	NN	O	-1	none	_	_
39	proteins	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	epithelial	_	_	JJ	O	-1	none	_	_
6	signal	_	_	NN	O	-1	none	_	_
7	transducer	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	activator	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	STAT	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	pathway	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	asthma	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Cytokine	_	_	NN	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	on	_	_	IN	O	-1	none	_	_
4	immunity	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	inflammation	_	_	NN	O	-1	none	_	_
7	often	_	_	RB	O	-1	none	_	_
8	depend	_	_	VBP	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factors	_	_	NNS	O	-1	none	_	_
13	termed	_	_	VBN	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	transducers	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	activators	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	STATs	_	_	NNS	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	so	_	_	RB	O	-1	none	_	_
25	STAT	_	_	NN	O	-1	none	_	_
26	signaling	_	_	NN	O	-1	none	_	_
27	pathways	_	_	NNS	O	-1	none	_	_
28	are	_	_	VBP	O	-1	none	_	_
29	candidates	_	_	NNS	O	-1	none	_	_
30	for	_	_	IN	O	-1	none	_	_
31	influencing	_	_	VBG	O	-1	none	_	_
32	inflammatory	_	_	JJ	O	-1	none	_	_
33	disease	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	reasoned	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	selective	_	_	JJ	O	-1	none	_	_
5	IFN	_	_	NN	O	-1	none	_	_
6	responsiveness	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	first	_	_	JJ	O	-1	none	_	_
10	STAT	_	_	NN	O	-1	none	_	_
11	family	_	_	NN	O	-1	none	_	_
12	member	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	Stat1	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	Stat1	_	_	NN	Protein	-1	none	_	_
18	dependent	_	_	JJ	O	-1	none	_	_
19	immune	_	_	JJ	O	-1	none	_	_
20	response	_	_	NN	O	-1	none	_	_
21	genes	_	_	NNS	O	-1	none	_	_
22	such	_	_	JJ	O	-1	none	_	_
23	as	_	_	IN	O	-1	none	_	_
24	intercellular	_	_	JJ	Protein	26	multitoken	_	_
25	adhesion	_	_	NN	Protein	26	multitoken	_	_
26	molecule-1	_	_	NN	Protein	0	root	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	ICAM-1	_	_	NN	Protein	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	IFN	_	_	NN	Protein	33	multitoken	_	_
32	regulatory	_	_	JJ	Protein	33	multitoken	_	_
33	factor-1	_	_	NN	Protein	0	root	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	IRF-1	_	_	NN	Protein	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	Stat1	_	_	NN	Protein	-1	none	_	_
40	itself	_	_	PRP	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	airway	_	_	NN	O	-1	none	_	_
43	epithelial	_	_	JJ	O	-1	none	_	_
44	cells	_	_	NNS	O	-1	none	_	_
45	provides	_	_	VBZ	O	-1	none	_	_
46	a	_	_	DT	O	-1	none	_	_
47	basis	_	_	NN	O	-1	none	_	_
48	for	_	_	IN	O	-1	none	_	_
49	detecting	_	_	VBG	O	-1	none	_	_
50	cytokine	_	_	NN	O	-1	none	_	_
51	signaling	_	_	NN	O	-1	none	_	_
52	abnormalities	_	_	NNS	O	-1	none	_	_
53	in	_	_	IN	O	-1	none	_	_
54	inflammatory	_	_	JJ	O	-1	none	_	_
55	airway	_	_	NN	O	-1	none	_	_
56	disease	_	_	NN	O	-1	none	_	_
57	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	basis	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	localization	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	we	_	_	PRP	O	-1	none	_	_
11	found	_	_	VBD	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	epithelial	_	_	JJ	O	-1	none	_	_
14	Stat1	_	_	NN	Protein	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	other	_	_	JJ	O	-1	none	_	_
19	control	_	_	NN	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factors	_	_	NNS	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	invariably	_	_	RB	O	-1	none	_	_
25	activated	_	_	VBN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	asthmatic	_	_	JJ	O	-1	none	_	_
28	compared	_	_	VBN	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	normal	_	_	JJ	O	-1	none	_	_
31	control	_	_	NN	O	-1	none	_	_
32	or	_	_	CC	O	-1	none	_	_
33	chronic	_	_	JJ	O	-1	none	_	_
34	bronchitis	_	_	NN	O	-1	none	_	_
35	subjects	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	epithelial	_	_	JJ	O	-1	none	_	_
4	levels	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	activated	_	_	VBN	O	-1	none	_	_
7	Stat1	_	_	NN	Protein	-1	none	_	_
8	correlated	_	_	VBD	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	levels	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	epithelial	_	_	JJ	O	-1	none	_	_
15	ICAM-1	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	IRF-1	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	Stat1	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	turn	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	ICAM-1	_	_	NN	Protein	-1	none	_	_
27	levels	_	_	NNS	O	-1	none	_	_
28	correlated	_	_	VBD	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	T-cell	_	_	NN	O	-1	none	_	_
31	accumulation	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	tissue	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	therefore	_	_	RB	O	-1	none	_	_
4	provide	_	_	VBP	O	-1	none	_	_
5	initial	_	_	JJ	O	-1	none	_	_
6	evidence	_	_	NN	O	-1	none	_	_
7	linking	_	_	VBG	O	-1	none	_	_
8	abnormal	_	_	JJ	O	-1	none	_	_
9	behavior	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	STAT	_	_	NN	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	cytokine	_	_	NN	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	development	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	inflammatory	_	_	JJ	O	-1	none	_	_
22	disease	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	that	_	_	DT	O	-1	none	_	_
3	context	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	results	_	_	NNS	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	change	_	_	VBP	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	current	_	_	JJ	O	-1	none	_	_
11	scheme	_	_	NN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	asthma	_	_	NN	O	-1	none	_	_
14	pathogenesis	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	one	_	_	CD	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	must	_	_	MD	O	-1	none	_	_
19	include	_	_	VB	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	localized	_	_	JJ	O	-1	none	_	_
22	gain	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	transcriptional	_	_	JJ	O	-1	none	_	_
25	signal	_	_	NN	O	-1	none	_	_
26	ordinarily	_	_	RB	O	-1	none	_	_
27	used	_	_	VBN	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	helper	_	_	NN	O	-1	none	_	_
32	1-type	_	_	JJ	O	-1	none	_	_
33	cytokine	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	IFN-gamma	_	_	NN	Protein	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	combination	_	_	NN	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	allergy	_	_	NN	O	-1	none	_	_
41	driven	_	_	VBN	O	-1	none	_	_
42	overproduction	_	_	NN	O	-1	none	_	_
43	of	_	_	IN	O	-1	none	_	_
44	T	_	_	NN	O	-1	none	_	_
45	helper	_	_	NN	O	-1	none	_	_
46	2-type	_	_	JJ	O	-1	none	_	_
47	cytokines	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	its	_	_	PRP$	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	site	_	_	NN	O	-1	none	_	_
13	leads	_	_	VBZ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	transcriptional	_	_	JJ	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	macrophage	_	_	NN	Protein	20	multitoken	_	_
20	CSF	_	_	NN	Protein	0	root	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	M-CSF	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	Mo	_	_	NN	O	-1	none	_	_
27	resulting	_	_	VBG	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	accumulation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	M-CSF	_	_	NN	Protein	-1	none	_	_
32	mRNA	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	subsequent	_	_	JJ	O	-1	none	_	_
35	release	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	bioactive	_	_	JJ	O	-1	none	_	_
38	M-CSF	_	_	NN	Protein	-1	none	_	_
39	protein	_	_	NN	O	-1	none	_	_
40	as	_	_	IN	O	-1	none	_	_
41	demonstrated	_	_	VBN	O	-1	none	_	_
42	by	_	_	IN	O	-1	none	_	_
43	ELISA	_	_	NN	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	inhibition	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	IL-2	_	_	NN	Protein	-1	none	_	_
48	induced	_	_	VBD	O	-1	none	_	_
49	release	_	_	NN	O	-1	none	_	_
50	of	_	_	IN	O	-1	none	_	_
51	an	_	_	DT	O	-1	none	_	_
52	activity	_	_	NN	O	-1	none	_	_
53	stimulating	_	_	VBG	O	-1	none	_	_
54	growth	_	_	NN	O	-1	none	_	_
55	of	_	_	IN	O	-1	none	_	_
56	monocyte-type	_	_	JJ	O	-1	none	_	_
57	colonies	_	_	NNS	O	-1	none	_	_
58	by	_	_	IN	O	-1	none	_	_
59	a	_	_	DT	O	-1	none	_	_
60	neutralizing	_	_	VBG	O	-1	none	_	_
61	anti-M-CSF	_	_	JJ	Protein	-1	none	_	_
62	antibody	_	_	NN	O	-1	none	_	_
63	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	M-CSF	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	preceded	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	enhanced	_	_	VBN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	its	_	_	PRP$	O	-1	none	_	_
23	recognition	_	_	NN	O	-1	none	_	_
24	sequence	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	5	_	_	CD	O	-1	none	_	_
28	'	_	_	''	O	-1	none	_	_
29	regulatory	_	_	JJ	O	-1	none	_	_
30	enhancer	_	_	NN	O	-1	none	_	_
31	region	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	M-CSF	_	_	NN	Protein	-1	none	_	_
35	gene	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	findings	_	_	NNS	O	-1	none	_	_
6	indicate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	induces	_	_	VBZ	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	M-CSF	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	blood	_	_	NN	O	-1	none	_	_
17	derived	_	_	VBN	O	-1	none	_	_
18	Mo	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	provide	_	_	VBP	O	-1	none	_	_
21	evidence	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	involvement	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	NF-kappa	_	_	NN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	transcriptional	_	_	JJ	O	-1	none	_	_
29	regulation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	this	_	_	DT	O	-1	none	_	_
32	gene	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Retinoid	_	_	NN	O	-1	none	_	_
2	X	_	_	NN	O	-1	none	_	_
3	receptor	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	RXR	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	agonist	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	dominant	_	_	JJ	O	-1	none	_	_
12	negative	_	_	JJ	O	-1	none	_	_
13	RXR-retinoic	_	_	JJ	Protein	16	multitoken	_	_
14	acid	_	_	NN	Protein	16	multitoken	_	_
15	receptor	_	_	NN	Protein	16	multitoken	_	_
16	alpha403	_	_	NN	Protein	0	root	_	_
17	heterodimers	_	_	NNS	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	developmentally	_	_	RB	O	-1	none	_	_
20	regulated	_	_	VBN	O	-1	none	_	_
21	during	_	_	IN	O	-1	none	_	_
22	myeloid	_	_	JJ	O	-1	none	_	_
23	differentiation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	multiple	_	_	JJ	O	-1	none	_	_
3	biologic	_	_	JJ	O	-1	none	_	_
4	activities	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	retinoic	_	_	JJ	O	-1	none	_	_
7	acid	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	RA	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	mediated	_	_	VBN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	RAR	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	retinoid	_	_	NN	O	-1	none	_	_
17	X	_	_	NN	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	RXR	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	nuclear	_	_	JJ	O	-1	none	_	_
23	receptors	_	_	NNS	O	-1	none	_	_
24	that	_	_	WDT	O	-1	none	_	_
25	interact	_	_	VBP	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	specific	_	_	JJ	O	-1	none	_	_
28	DNA	_	_	NN	O	-1	none	_	_
29	target	_	_	NN	O	-1	none	_	_
30	sequences	_	_	NNS	O	-1	none	_	_
31	as	_	_	IN	O	-1	none	_	_
32	heterodimers	_	_	NNS	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	RXR-RAR	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	or	_	_	CC	O	-1	none	_	_
37	homodimers	_	_	NNS	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	RXR-RXR	_	_	NN	O	-1	none	_	_
40	)	_	_	-RRB-	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	RA	_	_	NN	O	-1	none	_	_
2	receptor	_	_	NN	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	appears	_	_	VBZ	O	-1	none	_	_
5	critical	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	regulating	_	_	VBG	O	-1	none	_	_
8	important	_	_	JJ	O	-1	none	_	_
9	aspects	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	hematopoiesis	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	since	_	_	IN	O	-1	none	_	_
14	transducing	_	_	VBG	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	COOH-terminally	_	_	RB	O	-1	none	_	_
17	truncated	_	_	VBN	O	-1	none	_	_
18	RARalpha	_	_	NN	Protein	-1	none	_	_
19	exhibiting	_	_	VBG	O	-1	none	_	_
20	dominant	_	_	JJ	O	-1	none	_	_
21	negative	_	_	JJ	O	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	RARalpha403	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	into	_	_	IN	O	-1	none	_	_
27	normal	_	_	JJ	O	-1	none	_	_
28	mouse	_	_	NN	O	-1	none	_	_
29	bone	_	_	NN	O	-1	none	_	_
30	marrow	_	_	NN	O	-1	none	_	_
31	generates	_	_	VBZ	O	-1	none	_	_
32	hematopoietic	_	_	JJ	O	-1	none	_	_
33	growth	_	_	NN	O	-1	none	_	_
34	factor	_	_	NN	O	-1	none	_	_
35	dependent	_	_	JJ	O	-1	none	_	_
36	cell	_	_	NN	O	-1	none	_	_
37	lines	_	_	NNS	O	-1	none	_	_
38	frozen	_	_	VBN	O	-1	none	_	_
39	at	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	multipotent	_	_	JJ	O	-1	none	_	_
42	progenitor	_	_	NN	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	EML	_	_	NN	O	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	or	_	_	CC	O	-1	none	_	_
47	committed	_	_	VBN	O	-1	none	_	_
48	promyelocyte	_	_	JJ	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	MPRO	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	stages	_	_	NNS	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Nevertheless	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	relatively	_	_	RB	O	-1	none	_	_
4	high	_	_	JJ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	pharmacological	_	_	JJ	O	-1	none	_	_
7	concentrations	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	RA	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	10	_	_	CD	O	-1	none	_	_
14	&	_	_	CC	O	-1	none	_	_
15	mgr	_	_	NN	O	-1	none	_	_
16	;	_	_	:	O	-1	none	_	_
17	M	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	overcome	_	_	VBP	O	-1	none	_	_
20	these	_	_	DT	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	blocks	_	_	VBZ	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	induce	_	_	VB	O	-1	none	_	_
25	terminal	_	_	JJ	O	-1	none	_	_
26	granulocytic	_	_	JJ	O	-1	none	_	_
27	differentiation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	MPRO	_	_	NN	O	-1	none	_	_
31	promyelocytes	_	_	NNS	O	-1	none	_	_
32	while	_	_	IN	O	-1	none	_	_
33	potentiating	_	_	VBG	O	-1	none	_	_
34	interleukin-3	_	_	NN	Protein	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	IL-3	_	_	NN	Protein	-1	none	_	_
37	)-induced	_	_	JJ	O	-1	none	_	_
38	commitment	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	EML	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	to	_	_	TO	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	granulocyte	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	monocyte	_	_	NN	O	-1	none	_	_
47	lineage	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	utilized	_	_	VBD	O	-1	none	_	_
8	RXR-	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	RAR	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	agonists	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	antagonists	_	_	NNS	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	determine	_	_	VB	O	-1	none	_	_
17	how	_	_	WRB	O	-1	none	_	_
18	RA	_	_	NN	O	-1	none	_	_
19	overcomes	_	_	VBZ	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	dominant	_	_	JJ	O	-1	none	_	_
22	negative	_	_	JJ	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	truncated	_	_	JJ	O	-1	none	_	_
27	RARalpha	_	_	NN	Protein	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	these	_	_	DT	O	-1	none	_	_
30	different	_	_	JJ	O	-1	none	_	_
31	myeloid	_	_	JJ	O	-1	none	_	_
32	developmental	_	_	JJ	O	-1	none	_	_
33	stages	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Unexpectedly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	observed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	RXR	_	_	NN	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	rather	_	_	RB	O	-1	none	_	_
11	than	_	_	IN	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	RAR	_	_	NN	O	-1	none	_	_
14	specific	_	_	JJ	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	agonist	_	_	NN	O	-1	none	_	_
17	induces	_	_	VBZ	O	-1	none	_	_
18	terminal	_	_	JJ	O	-1	none	_	_
19	granulocytic	_	_	JJ	O	-1	none	_	_
20	differentiation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	MPRO	_	_	NN	O	-1	none	_	_
23	promyelocytes	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	differentiation	_	_	NN	O	-1	none	_	_
28	is	_	_	VBZ	O	-1	none	_	_
29	associated	_	_	VBN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	activation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	DNA	_	_	NN	O	-1	none	_	_
34	response	_	_	NN	O	-1	none	_	_
35	elements	_	_	NNS	O	-1	none	_	_
36	corresponding	_	_	VBG	O	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	RAR-RXR	_	_	NN	O	-1	none	_	_
39	heterodimers	_	_	NNS	O	-1	none	_	_
40	rather	_	_	RB	O	-1	none	_	_
41	than	_	_	IN	O	-1	none	_	_
42	RXR-RXR	_	_	NN	O	-1	none	_	_
43	homodimers	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	RXR	_	_	NN	O	-1	none	_	_
3	agonist	_	_	NN	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	blocked	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	RAR	_	_	NN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	antagonists	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	suggesting	_	_	VBG	O	-1	none	_	_
13	extensive	_	_	JJ	O	-1	none	_	_
14	cross-talk	_	_	NN	O	-1	none	_	_
15	between	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	partners	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	RXR	_	_	NN	O	-1	none	_	_
21	-RARalpha403	_	_	NN	Protein	-1	none	_	_
22	heterodimer	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	RA-	_	_	NN	O	-1	none	_	_
2	triggered	_	_	VBD	O	-1	none	_	_
3	GALdbd-RARalpha	_	_	NN	Protein	-1	none	_	_
4	hybrid	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	indicates	_	_	VBZ	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	multipotent	_	_	JJ	O	-1	none	_	_
13	EML	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	harbor	_	_	VBP	O	-1	none	_	_
16	substantial	_	_	JJ	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	hormone	_	_	NN	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	coactivator	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	histone	_	_	NN	O	-1	none	_	_
5	deacetylase	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	HDAC	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	inhibitor	_	_	NN	O	-1	none	_	_
10	trichostatin	_	_	NN	O	-1	none	_	_
11	A	_	_	NN	O	-1	none	_	_
12	readily	_	_	RB	O	-1	none	_	_
13	activates	_	_	VBZ	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	RXR-RAR	_	_	NN	O	-1	none	_	_
16	reporter	_	_	NN	O	-1	none	_	_
17	construct	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	multipotent	_	_	JJ	O	-1	none	_	_
21	EML	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	but	_	_	CC	O	-1	none	_	_
24	not	_	_	RB	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	committed	_	_	JJ	O	-1	none	_	_
28	MPRO	_	_	NN	O	-1	none	_	_
29	promyelocytes	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	indicating	_	_	VBG	O	-1	none	_	_
32	that	_	_	IN	O	-1	none	_	_
33	differences	_	_	NNS	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	HDAC	_	_	NN	O	-1	none	_	_
36	containing	_	_	VBG	O	-1	none	_	_
37	repressor	_	_	NN	O	-1	none	_	_
38	complexes	_	_	NNS	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	these	_	_	DT	O	-1	none	_	_
41	two	_	_	CD	O	-1	none	_	_
42	closely	_	_	RB	O	-1	none	_	_
43	related	_	_	JJ	O	-1	none	_	_
44	but	_	_	CC	O	-1	none	_	_
45	distinct	_	_	JJ	O	-1	none	_	_
46	hematopoietic	_	_	JJ	O	-1	none	_	_
47	lineages	_	_	NNS	O	-1	none	_	_
48	might	_	_	MD	O	-1	none	_	_
49	account	_	_	VB	O	-1	none	_	_
50	for	_	_	IN	O	-1	none	_	_
51	the	_	_	DT	O	-1	none	_	_
52	differential	_	_	JJ	O	-1	none	_	_
53	activation	_	_	NN	O	-1	none	_	_
54	of	_	_	IN	O	-1	none	_	_
55	the	_	_	DT	O	-1	none	_	_
56	RXR-RARalpha403	_	_	NN	Protein	-1	none	_	_
57	heterodimers	_	_	NNS	O	-1	none	_	_
58	that	_	_	IN	O	-1	none	_	_
59	we	_	_	PRP	O	-1	none	_	_
60	observed	_	_	VBD	O	-1	none	_	_
61	at	_	_	IN	O	-1	none	_	_
62	these	_	_	DT	O	-1	none	_	_
63	different	_	_	JJ	O	-1	none	_	_
64	stages	_	_	NNS	O	-1	none	_	_
65	of	_	_	IN	O	-1	none	_	_
66	myeloid	_	_	JJ	O	-1	none	_	_
67	development	_	_	NN	O	-1	none	_	_
68	.	_	_	.	O	-1	none	_	_

1	Identification	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	purification	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	Stat	_	_	NN	O	-1	none	_	_
7	proteins	_	_	NNS	O	-1	none	_	_
8	activated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	interleukin-2	_	_	NN	Protein	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	key	_	_	JJ	O	-1	none	_	_
3	cytokine	_	_	NN	O	-1	none	_	_
4	induced	_	_	VBN	O	-1	none	_	_
5	during	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	immune	_	_	JJ	O	-1	none	_	_
8	response	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Following	_	_	VBG	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	encoding	_	_	VBG	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	various	_	_	JJ	O	-1	none	_	_
13	chains	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	its	_	_	PRP$	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	transcriptionally	_	_	RB	O	-1	none	_	_
19	induced	_	_	VBN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	turn	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	secreted	_	_	VBN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	serves	_	_	VBZ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	stimulate	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	proliferation	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	differentiation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	recent	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	implicated	_	_	VBN	O	-1	none	_	_
6	Jak	_	_	NN	O	-1	none	_	_
7	kinases	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	pathway	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	IL-2	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Following	_	_	VBG	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	lead	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	set	_	_	VBD	O	-1	none	_	_
7	out	_	_	RP	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	identify	_	_	VB	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	factors	_	_	NNS	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Similar	_	_	JJ	O	-1	none	_	_
2	activities	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	transformed	_	_	JJ	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	lymphocyte	_	_	NN	O	-1	none	_	_
11	line	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	termed	_	_	VBN	O	-1	none	_	_
14	YT	_	_	NNP	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	hypothesize	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	designated	_	_	VBN	O	-1	none	_	_
10	hStat5	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	helps	_	_	VBZ	O	-1	none	_	_
13	govern	_	_	VB	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	biological	_	_	JJ	O	-1	none	_	_
16	effects	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	IL-2	_	_	NN	Protein	-1	none	_	_
19	during	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	immune	_	_	JJ	O	-1	none	_	_
22	response	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	shown	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	interaction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	interleukin	_	_	NN	Protein	12	multitoken	_	_
9	(	_	_	-LRB-	Protein	12	multitoken	_	_
10	IL	_	_	NN	Protein	12	multitoken	_	_
11	)	_	_	-RRB-	Protein	12	multitoken	_	_
12	-5	_	_	CD	Protein	0	root	_	_
13	with	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	receptor	_	_	NN	O	-1	none	_	_
16	activates	_	_	VBZ	O	-1	none	_	_
17	Lyn	_	_	NN	Protein	19	multitoken	_	_
18	tyrosine	_	_	NN	Protein	19	multitoken	_	_
19	kinase	_	_	NN	Protein	0	root	_	_
20	within	_	_	IN	O	-1	none	_	_
21	1	_	_	CD	O	-1	none	_	_
22	min	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	Jak2	_	_	NN	Protein	26	multitoken	_	_
25	tyrosine	_	_	NN	Protein	26	multitoken	_	_
26	kinase	_	_	NN	Protein	0	root	_	_
27	within	_	_	IN	O	-1	none	_	_
28	1-3	_	_	CD	O	-1	none	_	_
29	min	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	IL-5	_	_	NNP	Protein	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	stimulates	_	_	VBZ	O	-1	none	_	_
4	GTP	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	p21ras	_	_	NN	Protein	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	subsequently	_	_	RB	O	-1	none	_	_
5	propagated	_	_	VBN	O	-1	none	_	_
6	through	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Raf-1	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	MEK	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	MAP	_	_	NN	O	-1	none	_	_
16	kinases	_	_	NNS	O	-1	none	_	_
17	as	_	_	IN	O	-1	none	_	_
18	shown	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	their	_	_	PRP$	O	-1	none	_	_
21	increased	_	_	VBN	O	-1	none	_	_
22	autophosphorylation	_	_	NN	O	-1	none	_	_
23	in	_	_	FW	O	-1	none	_	_
24	vitro	_	_	FW	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	phosphorylation	_	_	NN	O	-1	none	_	_
27	in	_	_	FW	O	-1	none	_	_
28	situ	_	_	FW	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Jak2	_	_	NN	Protein	2	multitoken	_	_
2	kinase	_	_	NN	Protein	0	root	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	phosphorylate	_	_	VB	O	-1	none	_	_
8	STAT	_	_	NN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STAT	_	_	NN	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	factors	_	_	NNS	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	studied	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	electrophoretic	_	_	JJ	O	-1	none	_	_
11	mobility	_	_	NN	O	-1	none	_	_
12	shift	_	_	NN	O	-1	none	_	_
13	assay	_	_	NN	O	-1	none	_	_
14	using	_	_	VBG	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	gamma	_	_	NN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	site	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	GAS	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	probe	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	found	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	IL-5	_	_	NN	Protein	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	GAS	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	eosinophils	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	one	_	_	CD	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	STAT1	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	IL-5	_	_	NN	Protein	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	signals	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	propagated	_	_	VBN	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	two	_	_	CD	O	-1	none	_	_
11	distinct	_	_	JJ	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	:	_	_	:	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	1	_	_	CD	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	Lyn	_	_	NN	Protein	-1	none	_	_
18	--	_	_	:	O	-1	none	_	_
19	>	_	_	JJR	O	-1	none	_	_
20	Ras	_	_	NN	O	-1	none	_	_
21	--	_	_	:	O	-1	none	_	_
22	>	_	_	JJR	O	-1	none	_	_
23	Raf-1	_	_	NN	Protein	-1	none	_	_
24	--	_	_	:	O	-1	none	_	_
25	>	_	_	JJR	O	-1	none	_	_
26	MEK	_	_	NN	O	-1	none	_	_
27	--	_	_	:	O	-1	none	_	_
28	>	_	_	JJR	O	-1	none	_	_
29	MAP	_	_	NN	O	-1	none	_	_
30	kinase	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	2	_	_	CD	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	Jak2	_	_	NN	Protein	-1	none	_	_
36	--	_	_	:	O	-1	none	_	_
37	>	_	_	JJR	O	-1	none	_	_
38	STAT1	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Flutamide	_	_	NN	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	hirsutism	_	_	NN	O	-1	none	_	_
7	:	_	_	:	O	-1	none	_	_
8	long-term	_	_	JJ	O	-1	none	_	_
9	clinical	_	_	JJ	O	-1	none	_	_
10	effects	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	endocrine	_	_	JJ	O	-1	none	_	_
13	changes	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	androgen	_	_	NN	Protein	17	multitoken	_	_
17	receptor	_	_	NN	Protein	0	root	_	_
18	behavior	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	OBJECTIVE	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	To	_	_	TO	O	-1	none	_	_
4	investigate	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	long-term	_	_	JJ	O	-1	none	_	_
7	effects	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	treatment	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	low	_	_	JJ	O	-1	none	_	_
12	doses	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	flutamide	_	_	NN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	clinical	_	_	JJ	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	hormonal	_	_	JJ	O	-1	none	_	_
19	parameters	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	as	_	_	RB	O	-1	none	_	_
22	well	_	_	RB	O	-1	none	_	_
23	as	_	_	IN	O	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	androgen	_	_	NN	Protein	27	multitoken	_	_
27	receptor	_	_	NN	Protein	0	root	_	_
28	status	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	hirsute	_	_	JJ	O	-1	none	_	_
32	women	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	DESIGN	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Eighteen	_	_	CD	O	-1	none	_	_
4	hirsute	_	_	JJ	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	regular	_	_	JJ	O	-1	none	_	_
8	menses	_	_	NNS	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	studied	_	_	VBN	O	-1	none	_	_
11	basally	_	_	RB	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	during	_	_	IN	O	-1	none	_	_
14	treatment	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	125	_	_	CD	O	-1	none	_	_
17	mg	_	_	NN	O	-1	none	_	_
18	flutamide	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	three	_	_	CD	O	-1	none	_	_
21	times	_	_	NNS	O	-1	none	_	_
22	per	_	_	IN	O	-1	none	_	_
23	day	_	_	NN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	12	_	_	CD	O	-1	none	_	_
26	months	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Barrier	_	_	NN	O	-1	none	_	_
2	or	_	_	CC	O	-1	none	_	_
3	intrauterine	_	_	JJ	O	-1	none	_	_
4	contraception	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	used	_	_	VBN	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	study	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	sexually	_	_	RB	O	-1	none	_	_
12	active	_	_	JJ	O	-1	none	_	_
13	women	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Safety	_	_	NNP	O	-1	none	_	_
2	parameters	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	assessed	_	_	VBN	O	-1	none	_	_
5	throughout	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	study	_	_	NN	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	Hirsutism	_	_	NN	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	graded	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	modified	_	_	VBN	O	-1	none	_	_
7	Ferriman-Gallwey	_	_	JJ	O	-1	none	_	_
8	score	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	hormonal	_	_	JJ	O	-1	none	_	_
12	parameters	_	_	NNS	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	evaluated	_	_	VBN	O	-1	none	_	_
15	basally	_	_	RB	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	4-month	_	_	JJ	O	-1	none	_	_
19	intervals	_	_	NNS	O	-1	none	_	_
20	during	_	_	IN	O	-1	none	_	_
21	treatment	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Gonadotropin	_	_	NN	O	-1	none	_	_
2	releasing	_	_	VBG	O	-1	none	_	_
3	hormone	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	ACTH	_	_	NN	O	-1	none	_	_
6	stimulation	_	_	NN	O	-1	none	_	_
7	tests	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	performed	_	_	VBN	O	-1	none	_	_
10	before	_	_	IN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	after	_	_	IN	O	-1	none	_	_
13	3	_	_	CD	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	4	_	_	CD	O	-1	none	_	_
16	months	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	therapy	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	concentration	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	androgen	_	_	NN	Protein	8	multitoken	_	_
8	receptors	_	_	NNS	Protein	0	root	_	_
9	in	_	_	IN	O	-1	none	_	_
10	mononuclear	_	_	JJ	O	-1	none	_	_
11	leukocytes	_	_	NNS	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	measured	_	_	VBN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	follicular	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	luteal	_	_	JJ	O	-1	none	_	_
21	phases	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	menstrual	_	_	JJ	O	-1	none	_	_
25	cycle	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	basally	_	_	RB	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	after	_	_	RB	O	-1	none	_	_
30	4	_	_	CD	O	-1	none	_	_
31	months	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	flutamide	_	_	NN	O	-1	none	_	_
34	treatment	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Flutamide	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	well	_	_	RB	O	-1	none	_	_
6	tolerated	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	all	_	_	DT	O	-1	none	_	_
9	women	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	noticeable	_	_	JJ	O	-1	none	_	_
14	exception	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	one	_	_	CD	O	-1	none	_	_
17	patient	_	_	NN	O	-1	none	_	_
18	who	_	_	WP	O	-1	none	_	_
19	presented	_	_	VBD	O	-1	none	_	_
20	increased	_	_	VBN	O	-1	none	_	_
21	serum	_	_	NN	O	-1	none	_	_
22	transaminase	_	_	NN	O	-1	none	_	_
23	after	_	_	IN	O	-1	none	_	_
24	8	_	_	CD	O	-1	none	_	_
25	months	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	therapy	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Hirsutism	_	_	NN	O	-1	none	_	_
2	markedly	_	_	RB	O	-1	none	_	_
3	improved	_	_	VBD	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	all	_	_	DT	O	-1	none	_	_
6	women	_	_	NNS	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	treatment	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	Ferriman-Gallwey	_	_	JJ	O	-1	none	_	_
12	score	_	_	NN	O	-1	none	_	_
13	after	_	_	IN	O	-1	none	_	_
14	1	_	_	CD	O	-1	none	_	_
15	year	_	_	NN	O	-1	none	_	_
16	:	_	_	:	O	-1	none	_	_
17	4.1	_	_	CD	O	-1	none	_	_
18	+/-	_	_	CC	O	-1	none	_	_
19	0.5	_	_	CD	O	-1	none	_	_
20	versus	_	_	CC	O	-1	none	_	_
21	14.1	_	_	CD	O	-1	none	_	_
22	+/-	_	_	CC	O	-1	none	_	_
23	0.9	_	_	CD	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	reduction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	serum	_	_	NN	O	-1	none	_	_
5	androgens	_	_	NNS	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	found	_	_	VBN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	whereas	_	_	IN	O	-1	none	_	_
10	no	_	_	DT	O	-1	none	_	_
11	change	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	observed	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	either	_	_	CC	O	-1	none	_	_
16	basal	_	_	JJ	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	GnRH	_	_	NN	O	-1	none	_	_
19	stimulated	_	_	VBD	O	-1	none	_	_
20	gonadotropins	_	_	NNS	O	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	cortisol	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	17	_	_	CD	O	-1	none	_	_
27	alpha-hydroxyprogesterone	_	_	NN	O	-1	none	_	_
28	response	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	ACTH	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Cycles	_	_	NNS	O	-1	none	_	_
2	remained	_	_	VBD	O	-1	none	_	_
3	ovulatory	_	_	JJ	O	-1	none	_	_
4	.	_	_	.	O	-1	none	_	_

1	Before	_	_	IN	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	number	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	androgen	_	_	NN	Protein	8	multitoken	_	_
8	receptors	_	_	NNS	Protein	0	root	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	higher	_	_	JJR	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	luteal	_	_	NN	O	-1	none	_	_
14	than	_	_	IN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	follicular	_	_	JJ	O	-1	none	_	_
18	phase	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	rhythmic	_	_	JJ	O	-1	none	_	_
3	differentiation	_	_	NN	O	-1	none	_	_
4	disappeared	_	_	VBD	O	-1	none	_	_
5	after	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	patients	_	_	NNS	O	-1	none	_	_
8	had	_	_	VBD	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	given	_	_	VBN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	antiandrogen	_	_	JJ	O	-1	none	_	_
13	drug	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Flutamide	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	effective	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	treatment	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	hirsutism	_	_	NN	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	requires	_	_	VBZ	O	-1	none	_	_
13	constant	_	_	JJ	O	-1	none	_	_
14	surveillance	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	liver	_	_	NN	O	-1	none	_	_
17	function	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Androgen	_	_	NN	Protein	2	multitoken	_	_
2	receptor	_	_	NN	Protein	0	root	_	_
3	blockade	_	_	NN	O	-1	none	_	_
4	might	_	_	MD	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	potentiated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	reduction	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	serum	_	_	NN	O	-1	none	_	_
12	androgens	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Flutamide	_	_	NN	O	-1	none	_	_
2	affects	_	_	VBZ	O	-1	none	_	_
3	androgen	_	_	NN	Protein	4	multitoken	_	_
4	receptor	_	_	NN	Protein	0	root	_	_
5	behavior	_	_	NN	O	-1	none	_	_
6	during	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	menstrual	_	_	JJ	O	-1	none	_	_
9	cycle	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	meaning	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	finding	_	_	NN	O	-1	none	_	_
6	remains	_	_	VBZ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	elucidated	_	_	VBN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	tal-1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	GATA	_	_	NN	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	proteins	_	_	NNS	O	-1	none	_	_
8	during	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	hematopoiesis	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Tal-1	_	_	NNP	Protein	-1	none	_	_
2	rearrangements	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	associated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	nearly	_	_	RB	O	-1	none	_	_
7	30	_	_	CD	O	-1	none	_	_
8	%	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	acute	_	_	JJ	O	-1	none	_	_
13	lymphoblastic	_	_	JJ	O	-1	none	_	_
14	leukemia	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Tal-1	_	_	NNP	Protein	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	encodes	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	putative	_	_	JJ	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	basic	_	_	JJ	O	-1	none	_	_
11	helix-loop-helix	_	_	JJ	O	-1	none	_	_
12	domain	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	known	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	predominantly	_	_	RB	O	-1	none	_	_
19	expressed	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	hematopoietic	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	pattern	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	tal-1	_	_	NN	Protein	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	purified	_	_	VBN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	hematopoietic	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	in	_	_	FW	O	-1	none	_	_
15	situ	_	_	FW	O	-1	none	_	_
16	hybridization	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	reverse	_	_	JJ	O	-1	none	_	_
19	transcriptase	_	_	NN	O	-1	none	_	_
20	polymerase	_	_	NN	O	-1	none	_	_
21	chain	_	_	NN	O	-1	none	_	_
22	reaction	_	_	NN	O	-1	none	_	_
23	analysis	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	methods	_	_	NNS	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	tal-1	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	expressed	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	megakaryocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	erythroblasts	_	_	NNS	O	-1	none	_	_
14	as	_	_	RB	O	-1	none	_	_
15	well	_	_	RB	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	basophilic	_	_	JJ	O	-1	none	_	_
19	granulocytes	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	indicate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	tal-1	_	_	NN	Protein	-1	none	_	_
10	1A	_	_	NN	O	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	contains	_	_	VBZ	O	-1	none	_	_
15	two	_	_	CD	O	-1	none	_	_
16	consensus	_	_	NN	O	-1	none	_	_
17	GATA	_	_	NN	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	sites	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	active	_	_	JJ	O	-1	none	_	_
23	mainly	_	_	RB	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	lineages	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	GATA-1	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	known	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	transactivate	_	_	VB	O	-1	none	_	_
9	several	_	_	JJ	O	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	megakaryocytic	_	_	JJ	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	mastocytic	_	_	JJ	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	basophilic	_	_	JJ	O	-1	none	_	_
22	lineages	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	we	_	_	PRP	O	-1	none	_	_
25	studied	_	_	VBD	O	-1	none	_	_
26	GATA-1	_	_	NN	Protein	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	these	_	_	DT	O	-1	none	_	_
30	purified	_	_	VBN	O	-1	none	_	_
31	hematopoietic	_	_	JJ	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	found	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	GATA-1	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	tal-1	_	_	NN	Protein	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	coexpressed	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	three	_	_	CD	O	-1	none	_	_
13	lineages	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Remarkably	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	both	_	_	DT	O	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	downmodulated	_	_	VBN	O	-1	none	_	_
10	during	_	_	IN	O	-1	none	_	_
11	erythroid	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	megakaryocytic	_	_	JJ	O	-1	none	_	_
14	terminal	_	_	JJ	O	-1	none	_	_
15	maturation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	GATA-2	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	strongly	_	_	RB	O	-1	none	_	_
7	expressed	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	both	_	_	CC	O	-1	none	_	_
10	most	_	_	RBS	O	-1	none	_	_
11	primitive	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	committed	_	_	JJ	O	-1	none	_	_
14	progenitors	_	_	NNS	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	whereas	_	_	IN	O	-1	none	_	_
18	GATA-3	_	_	NN	Protein	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	mostly	_	_	RB	O	-1	none	_	_
21	detected	_	_	VBN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	most	_	_	JJS	O	-1	none	_	_
24	primitive	_	_	JJ	O	-1	none	_	_
25	ones	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Altogether	_	_	RB	O	-1	none	_	_
2	our	_	_	PRP$	O	-1	none	_	_
3	results	_	_	NNS	O	-1	none	_	_
4	strongly	_	_	RB	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	GATA-1	_	_	NN	Protein	-1	none	_	_
8	modulates	_	_	VBZ	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	tal-1	_	_	NN	Protein	-1	none	_	_
13	during	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	erythroid	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	megakaryocytic	_	_	JJ	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	basosophilic	_	_	JJ	O	-1	none	_	_
24	lineages	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	RanBP1	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	release	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	CRM1	_	_	NN	Protein	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	pore	_	_	NN	O	-1	none	_	_
14	complex	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	terminal	_	_	JJ	O	-1	none	_	_
18	step	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	export	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	recently	_	_	RB	O	-1	none	_	_
3	developed	_	_	VBD	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	assay	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	export	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	shuttling	_	_	NN	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	NFAT	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	activated	_	_	VBN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	can	_	_	MD	O	-1	none	_	_
25	be	_	_	VB	O	-1	none	_	_
26	reconstituted	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	permeabilized	_	_	JJ	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	GTPase	_	_	NN	O	-1	none	_	_
33	Ran	_	_	NN	Protein	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	nuclear	_	_	JJ	O	-1	none	_	_
37	export	_	_	NN	O	-1	none	_	_
38	receptor	_	_	NN	O	-1	none	_	_
39	CRM1	_	_	NN	Protein	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	now	_	_	RB	O	-1	none	_	_
4	used	_	_	VBN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	assay	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	identify	_	_	VB	O	-1	none	_	_
9	another	_	_	DT	O	-1	none	_	_
10	export	_	_	NN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	preincubation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	permeabilized	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	Ran	_	_	NN	Protein	-1	none	_	_
9	mutant	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	hydrolyze	_	_	VB	O	-1	none	_	_
14	GTP	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	RanQ69L	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	cytosol	_	_	NN	O	-1	none	_	_
20	supports	_	_	VBZ	O	-1	none	_	_
21	NFAT	_	_	NN	O	-1	none	_	_
22	export	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	but	_	_	CC	O	-1	none	_	_
25	CRM1	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Ran	_	_	NN	Protein	-1	none	_	_
28	alone	_	_	RB	O	-1	none	_	_
29	do	_	_	VBP	O	-1	none	_	_
30	not	_	_	RB	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	RanQ69L	_	_	NN	O	-1	none	_	_
3	preincubation	_	_	NN	O	-1	none	_	_
4	leads	_	_	VBZ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	accumulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	CRM1	_	_	NN	Protein	-1	none	_	_
9	at	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cytoplasmic	_	_	JJ	O	-1	none	_	_
12	periphery	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	pore	_	_	NN	O	-1	none	_	_
17	complex	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	NPC	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	association	_	_	NN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	p62	_	_	NN	Protein	-1	none	_	_
26	complex	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	Can	_	_	MD	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	Nup214	_	_	NN	Protein	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	RanGTP	_	_	NN	O	-1	none	_	_
2	dependent	_	_	JJ	O	-1	none	_	_
3	association	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	CRM1	_	_	NN	Protein	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	nucleoporins	_	_	NNS	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	reconstituted	_	_	VBN	O	-1	none	_	_
11	in	_	_	FW	O	-1	none	_	_
12	vitro	_	_	FW	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	biochemical	_	_	JJ	O	-1	none	_	_
3	fractionation	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	reconstitution	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	showed	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	RanBP1	_	_	NN	Protein	-1	none	_	_
11	restores	_	_	VBZ	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	export	_	_	NN	O	-1	none	_	_
14	after	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	RanQ69L	_	_	NN	O	-1	none	_	_
17	preincubation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	stimulates	_	_	VBZ	O	-1	none	_	_
4	nuclear	_	_	JJ	O	-1	none	_	_
5	export	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	have	_	_	VBP	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	preincubated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	RanQ69L	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	RanBP1	_	_	NN	Protein	-1	none	_	_
2	as	_	_	RB	O	-1	none	_	_
3	well	_	_	RB	O	-1	none	_	_
4	as	_	_	IN	O	-1	none	_	_
5	Ran	_	_	NN	Protein	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	domains	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cytoplasmic	_	_	JJ	O	-1	none	_	_
11	nucleoporin	_	_	NN	O	-1	none	_	_
12	RanBP2	_	_	NN	Protein	-1	none	_	_
13	promote	_	_	VBP	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	release	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	CRM1	_	_	NN	Protein	-1	none	_	_
18	from	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	NPC	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	indicate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	RanGTP	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	important	_	_	JJ	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	targeting	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	export	_	_	NN	O	-1	none	_	_
16	complexes	_	_	NNS	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	cytoplasmic	_	_	JJ	O	-1	none	_	_
20	side	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	NPC	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	RanBP1	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	probably	_	_	RB	O	-1	none	_	_
29	RanBP2	_	_	NN	Protein	-1	none	_	_
30	are	_	_	VBP	O	-1	none	_	_
31	involved	_	_	VBN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	dissociation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	nuclear	_	_	JJ	O	-1	none	_	_
37	export	_	_	NN	O	-1	none	_	_
38	complexes	_	_	NNS	O	-1	none	_	_
39	from	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	NPC	_	_	NN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	a	_	_	DT	O	-1	none	_	_
44	terminal	_	_	JJ	O	-1	none	_	_
45	step	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	transport	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Microtubules	_	_	NNS	O	-1	none	_	_
2	mediate	_	_	VBP	O	-1	none	_	_
3	cellular	_	_	JJ	O	-1	none	_	_
4	25-hydroxyvitamin	_	_	NN	O	-1	none	_	_
5	D3	_	_	NN	O	-1	none	_	_
6	trafficking	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	genomic	_	_	JJ	O	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	1,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
13	D3	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	normal	_	_	JJ	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	monocytes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	genomic	_	_	JJ	O	-1	none	_	_
3	actions	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	1,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
6	D3	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	1,25	_	_	CD	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	OH	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	2D3	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	mediated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	intracellular	_	_	JJ	O	-1	none	_	_
19	vitamin	_	_	NN	Protein	21	multitoken	_	_
20	D	_	_	NN	Protein	21	multitoken	_	_
21	receptor	_	_	NN	Protein	0	root	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	VDR	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	immunocytochemistry	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	disruption	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	microtubular	_	_	JJ	O	-1	none	_	_
9	assembly	_	_	NN	O	-1	none	_	_
10	prevents	_	_	VBZ	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	access	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	sterol	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	VDR	_	_	NN	Protein	-1	none	_	_
18	complex	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	microtubules	_	_	NNS	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	response	_	_	NN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	1,25	_	_	CD	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	OH	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	2D3	_	_	NN	O	-1	none	_	_
33	has	_	_	VBZ	O	-1	none	_	_
34	not	_	_	RB	O	-1	none	_	_
35	been	_	_	VBN	O	-1	none	_	_
36	studied	_	_	VBN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	viable	_	_	JJ	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	examined	_	_	VBN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	interaction	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	normal	_	_	JJ	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	monocytes	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Monocytes	_	_	NNS	O	-1	none	_	_
2	convert	_	_	VBP	O	-1	none	_	_
3	25	_	_	CD	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	OH	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	D3	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	1,25	_	_	CD	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	OH	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	2D3	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	24	_	_	CD	O	-1	none	_	_
17	hydroxylated	_	_	VBN	O	-1	none	_	_
18	metabolites	_	_	NNS	O	-1	none	_	_
19	more	_	_	RBR	O	-1	none	_	_
20	polar	_	_	JJ	O	-1	none	_	_
21	than	_	_	IN	O	-1	none	_	_
22	1,25	_	_	CD	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	OH	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	2D3	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Microtubule	_	_	JJ	O	-1	none	_	_
2	disruption	_	_	NN	O	-1	none	_	_
3	totally	_	_	RB	O	-1	none	_	_
4	abolished	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	ability	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	exogenous	_	_	JJ	O	-1	none	_	_
9	1,25	_	_	CD	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	OH	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	2D3	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	suppress	_	_	VB	O	-1	none	_	_
16	its	_	_	PRP$	O	-1	none	_	_
17	own	_	_	JJ	O	-1	none	_	_
18	synthesis	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	induce	_	_	VB	O	-1	none	_	_
22	24-hydroxylase	_	_	NN	O	-1	none	_	_
23	mRNA	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	activity	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	without	_	_	IN	O	-1	none	_	_
28	affecting	_	_	VBG	O	-1	none	_	_
29	either	_	_	CC	O	-1	none	_	_
30	total	_	_	JJ	O	-1	none	_	_
31	1,25	_	_	CD	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	OH	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	2D3	_	_	NN	O	-1	none	_	_
36	uptake	_	_	NN	O	-1	none	_	_
37	or	_	_	CC	O	-1	none	_	_
38	maximal	_	_	JJ	O	-1	none	_	_
39	1,25	_	_	CD	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	OH	_	_	NN	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	2D3-VDR	_	_	NN	Protein	-1	none	_	_
44	binding	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	intact	_	_	JJ	O	-1	none	_	_
4	microtubules	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	essential	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	1,25	_	_	CD	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	OH	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	2D3	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	modulation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	microtubule	_	_	JJ	O	-1	none	_	_
4	disruption	_	_	NN	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	decreased	_	_	VBD	O	-1	none	_	_
7	monocyte	_	_	NN	O	-1	none	_	_
8	1,25	_	_	CD	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	OH	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	2D3	_	_	NN	O	-1	none	_	_
13	synthesis	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	decreasing	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	Vmax	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	monocyte	_	_	NN	O	-1	none	_	_
22	mitochondrial	_	_	JJ	O	-1	none	_	_
23	1	_	_	CD	O	-1	none	_	_
24	alpha-hydroxylase	_	_	NN	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	through	_	_	IN	O	-1	none	_	_
27	an	_	_	DT	O	-1	none	_	_
28	increase	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	Km	_	_	NN	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	25	_	_	CD	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	OH	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	2D3	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	examined	_	_	VBD	O	-1	none	_	_
3	25	_	_	CD	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	OH	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	D3	_	_	NN	O	-1	none	_	_
8	transport	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Microtubule	_	_	JJ	O	-1	none	_	_
2	disruption	_	_	NN	O	-1	none	_	_
3	did	_	_	VBD	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	affect	_	_	VB	O	-1	none	_	_
6	total	_	_	JJ	O	-1	none	_	_
7	cellular	_	_	JJ	O	-1	none	_	_
8	25	_	_	CD	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	OH	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	D3	_	_	NN	O	-1	none	_	_
13	uptake	_	_	NN	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	reduced	_	_	VBD	O	-1	none	_	_
16	its	_	_	PRP$	O	-1	none	_	_
17	intracellular	_	_	JJ	O	-1	none	_	_
18	trafficking	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	mitochondria	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	microtubules	_	_	NNS	O	-1	none	_	_
4	participate	_	_	VBP	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	intracellular	_	_	JJ	O	-1	none	_	_
7	25	_	_	CD	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	OH	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	D3	_	_	NN	O	-1	none	_	_
12	transport	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	their	_	_	PRP$	O	-1	none	_	_
16	integrity	_	_	NN	O	-1	none	_	_
17	determines	_	_	VBZ	O	-1	none	_	_
18	normal	_	_	JJ	O	-1	none	_	_
19	1,25	_	_	CD	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	OH	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	2D3	_	_	NN	O	-1	none	_	_
24	synthesis	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	vascular	_	_	JJ	Protein	6	multitoken	_	_
4	cell	_	_	NN	Protein	6	multitoken	_	_
5	adhesion	_	_	NN	Protein	6	multitoken	_	_
6	molecule-1	_	_	NN	Protein	0	root	_	_
7	by	_	_	IN	O	-1	none	_	_
8	low-density	_	_	JJ	O	-1	none	_	_
9	lipoprotein	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Low-density	_	_	JJ	O	-1	none	_	_
2	lipoprotein	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	LDL	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	well	_	_	RB	O	-1	none	_	_
9	established	_	_	JJ	O	-1	none	_	_
10	risk	_	_	NN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	atherosclerosis	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	endothelial	_	_	JJ	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	incubated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	lipoprotein	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	pathophysiologic	_	_	JJ	O	-1	none	_	_
11	amounts	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	activated	_	_	VBN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Among	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	documented	_	_	VBN	O	-1	none	_	_
4	cellular	_	_	JJ	O	-1	none	_	_
5	responses	_	_	NNS	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	LDL	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	increased	_	_	VBN	O	-1	none	_	_
10	recruitment	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	believed	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	play	_	_	VB	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	major	_	_	JJ	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	promoting	_	_	VBG	O	-1	none	_	_
24	intimal	_	_	JJ	O	-1	none	_	_
25	plaque	_	_	NN	O	-1	none	_	_
26	formation	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	presented	_	_	VBN	O	-1	none	_	_
4	here	_	_	RB	O	-1	none	_	_
5	link	_	_	VBP	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	atheogenic	_	_	JJ	O	-1	none	_	_
8	lipoprotein	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	LDL	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	adhesion	_	_	NN	O	-1	none	_	_
18	molecule	_	_	NN	O	-1	none	_	_
19	important	_	_	JJ	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	atherogenesis	_	_	NN	O	-1	none	_	_
22	Human	_	_	NN	O	-1	none	_	_
23	LDL	_	_	NN	O	-1	none	_	_
24	induces	_	_	VBZ	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	vascular	_	_	JJ	Protein	29	multitoken	_	_
27	cell	_	_	NN	Protein	29	multitoken	_	_
28	adhesion	_	_	NN	Protein	29	multitoken	_	_
29	molecule-1	_	_	NN	Protein	0	root	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	VCAM-1	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	transcriptionally	_	_	RB	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	an	_	_	DT	O	-1	none	_	_
36	increase	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	mRNA	_	_	NN	O	-1	none	_	_
39	levels	_	_	NNS	O	-1	none	_	_
40	through	_	_	IN	O	-1	none	_	_
41	activation	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	VCAM	_	_	NN	O	-1	none	_	_
45	promoter	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	blocked	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	anti-VCAM	_	_	JJ	O	-1	none	_	_
7	antibodies	_	_	NNS	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	2-day	_	_	JJ	O	-1	none	_	_
4	incubation	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	LDL	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	believed	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	key	_	_	JJ	O	-1	none	_	_
21	oxidative-stress	_	_	NN	O	-1	none	_	_
22	sensor	_	_	NN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	VCAM	_	_	NN	O	-1	none	_	_
25	regulation	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	remains	_	_	VBZ	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	basal	_	_	JJ	O	-1	none	_	_
30	level	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activities	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	AP-1	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	GATA	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	other	_	_	JJ	O	-1	none	_	_
15	hand	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	increased	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	LDL	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	component	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	LDL	_	_	NN	O	-1	none	_	_
7	enhanced	_	_	VBD	O	-1	none	_	_
8	endothelial	_	_	JJ	O	-1	none	_	_
9	recruitment	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	monocytes	_	_	NNS	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	attributed	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	VCAM-1	_	_	NN	Protein	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	appears	_	_	VBZ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	be	_	_	VB	O	-1	none	_	_
22	mediated	_	_	VBN	O	-1	none	_	_
23	through	_	_	IN	O	-1	none	_	_
24	AP-1	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	GATA	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	identify	_	_	VBP	O	-1	none	_	_
4	LDL	_	_	NN	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	VCAM-inducer	_	_	NN	O	-1	none	_	_
8	possibly	_	_	RB	O	-1	none	_	_
9	distinct	_	_	JJ	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	cytokines	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	endotoxin	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	1,25-Dihydroxyvitamin	_	_	NN	Protein	3	multitoken	_	_
2	D3	_	_	NN	Protein	3	multitoken	_	_
3	receptor	_	_	NN	Protein	0	root	_	_
4	RNA	_	_	NN	O	-1	none	_	_
5	:	_	_	:	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	hematopoietic	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	1,25-Dihydroxyvitamin	_	_	NN	O	-1	none	_	_
2	D3	_	_	NN	O	-1	none	_	_
3	[	_	_	CD	O	-1	none	_	_
4	1,25	_	_	CD	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	OH	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	2D3	_	_	NN	O	-1	none	_	_
9	]	_	_	NN	O	-1	none	_	_
10	induces	_	_	VBZ	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	inhibits	_	_	VBZ	O	-1	none	_	_
14	proliferation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	myeloid	_	_	JJ	O	-1	none	_	_
17	leukemic	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	from	_	_	IN	O	-1	none	_	_
20	various	_	_	JJ	O	-1	none	_	_
21	lines	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	patients	_	_	NNS	O	-1	none	_	_
24	;	_	_	:	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	effects	_	_	NNS	O	-1	none	_	_
27	are	_	_	VBP	O	-1	none	_	_
28	probably	_	_	RB	O	-1	none	_	_
29	mediated	_	_	VBN	O	-1	none	_	_
30	through	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	1,25	_	_	CD	Protein	37	multitoken	_	_
33	(	_	_	-LRB-	Protein	37	multitoken	_	_
34	OH	_	_	NN	Protein	37	multitoken	_	_
35	)	_	_	-RRB-	Protein	37	multitoken	_	_
36	2D3	_	_	NN	Protein	37	multitoken	_	_
37	receptor	_	_	NN	Protein	0	root	_	_
38	.	_	_	.	O	-1	none	_	_

1	Little	_	_	JJ	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	known	_	_	VBN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	1,25	_	_	CD	Protein	12	multitoken	_	_
8	(	_	_	-LRB-	Protein	12	multitoken	_	_
9	OH	_	_	NN	Protein	12	multitoken	_	_
10	)	_	_	-RRB-	Protein	12	multitoken	_	_
11	2D3	_	_	NN	Protein	12	multitoken	_	_
12	receptor	_	_	NN	Protein	0	root	_	_
13	RNA	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	hematopoietic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	examined	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	modulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	1,25	_	_	CD	Protein	15	multitoken	_	_
11	(	_	_	-LRB-	Protein	15	multitoken	_	_
12	OH	_	_	NN	Protein	15	multitoken	_	_
13	)	_	_	-RRB-	Protein	15	multitoken	_	_
14	2D3	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	RNA	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	various	_	_	JJ	O	-1	none	_	_
19	proliferating	_	_	VBG	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	nonproliferating	_	_	JJ	O	-1	none	_	_
22	hematopoietic	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	1,25	_	_	CD	Protein	9	multitoken	_	_
5	(	_	_	-LRB-	Protein	9	multitoken	_	_
6	OH	_	_	NN	Protein	9	multitoken	_	_
7	)	_	_	-RRB-	Protein	9	multitoken	_	_
8	2D3	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	RNA	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	detected	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	various	_	_	JJ	O	-1	none	_	_
15	kinds	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	hematopoietic	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	including	_	_	VBG	O	-1	none	_	_
21	macrophages	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	lymphocytes	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	as	_	_	RB	O	-1	none	_	_
28	well	_	_	RB	O	-1	none	_	_
29	as	_	_	IN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	lines	_	_	NNS	O	-1	none	_	_
33	KG-1	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	myeloblasts	_	_	NNS	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	HL-60	_	_	NN	O	-1	none	_	_
39	(	_	_	-LRB-	O	-1	none	_	_
40	promyelocytes	_	_	NNS	O	-1	none	_	_
41	)	_	_	-RRB-	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	ML-3	_	_	NN	O	-1	none	_	_
44	(	_	_	-LRB-	O	-1	none	_	_
45	myelomonoblasts	_	_	NNS	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	,	_	_	,	O	-1	none	_	_
48	U937	_	_	NN	O	-1	none	_	_
49	,	_	_	,	O	-1	none	_	_
50	THP-1	_	_	NN	O	-1	none	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	monoblasts	_	_	NNS	O	-1	none	_	_
53	)	_	_	-RRB-	O	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	K562	_	_	NN	O	-1	none	_	_
56	(	_	_	-LRB-	O	-1	none	_	_
57	erythroblasts	_	_	NNS	O	-1	none	_	_
58	)	_	_	-RRB-	O	-1	none	_	_
59	,	_	_	,	O	-1	none	_	_
60	and	_	_	CC	O	-1	none	_	_
61	S-LB1	_	_	NN	O	-1	none	_	_
62	(	_	_	-LRB-	O	-1	none	_	_
63	HTLV-1-transfected	_	_	JJ	O	-1	none	_	_
64	T	_	_	NN	O	-1	none	_	_
65	lymphocytes	_	_	NNS	O	-1	none	_	_
66	)	_	_	-RRB-	O	-1	none	_	_
67	.	_	_	.	O	-1	none	_	_

1	Receptor	_	_	NN	O	-1	none	_	_
2	transcripts	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	4.6	_	_	CD	O	-1	none	_	_
5	kilobases	_	_	NNS	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	kb	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	no	_	_	DT	O	-1	none	_	_
12	variant	_	_	JJ	O	-1	none	_	_
13	sizes	_	_	NNS	O	-1	none	_	_
14	were	_	_	VBD	O	-1	none	_	_
15	observed	_	_	VBN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	All	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	examined	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	group	_	_	NN	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	expressed	_	_	VBD	O	-1	none	_	_
10	1,25	_	_	CD	Protein	15	multitoken	_	_
11	(	_	_	-LRB-	Protein	15	multitoken	_	_
12	OH	_	_	NN	Protein	15	multitoken	_	_
13	)	_	_	-RRB-	Protein	15	multitoken	_	_
14	2D3	_	_	NN	Protein	15	multitoken	_	_
15	receptors	_	_	NNS	Protein	0	root	_	_
16	.	_	_	.	O	-1	none	_	_

1	Most	_	_	JJS	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	lymphocyte	_	_	NN	O	-1	none	_	_
4	lines	_	_	NNS	O	-1	none	_	_
5	expressed	_	_	VBD	O	-1	none	_	_
6	negligible	_	_	JJ	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	1,25	_	_	CD	Protein	14	multitoken	_	_
10	(	_	_	-LRB-	Protein	14	multitoken	_	_
11	OH	_	_	NN	Protein	14	multitoken	_	_
12	)	_	_	-RRB-	Protein	14	multitoken	_	_
13	2D3	_	_	NN	Protein	14	multitoken	_	_
14	receptor	_	_	NN	Protein	0	root	_	_
15	RNA	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	;	_	_	:	O	-1	none	_	_
19	however	_	_	RB	O	-1	none	_	_
20	;	_	_	:	O	-1	none	_	_
21	analysis	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	lymphoid	_	_	JJ	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	myeloid	_	_	JJ	O	-1	none	_	_
27	somatic	_	_	JJ	O	-1	none	_	_
28	hybrid	_	_	NN	O	-1	none	_	_
29	suggested	_	_	VBD	O	-1	none	_	_
30	that	_	_	IN	O	-1	none	_	_
31	suppression	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	expression	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	1,25	_	_	CD	Protein	40	multitoken	_	_
36	(	_	_	-LRB-	Protein	40	multitoken	_	_
37	OH	_	_	NN	Protein	40	multitoken	_	_
38	)	_	_	-RRB-	Protein	40	multitoken	_	_
39	2D3	_	_	NN	Protein	40	multitoken	_	_
40	receptor	_	_	NN	Protein	0	root	_	_
41	RNA	_	_	NN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	B	_	_	NN	O	-1	none	_	_
44	lymphocytes	_	_	NNS	O	-1	none	_	_
45	may	_	_	MD	O	-1	none	_	_
46	be	_	_	VB	O	-1	none	_	_
47	a	_	_	DT	O	-1	none	_	_
48	dominant	_	_	JJ	O	-1	none	_	_
49	characteristic	_	_	JJ	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	HL-60	_	_	NNP	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	cultured	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	10	_	_	CD	O	-1	none	_	_
7	(-7)	_	_	CD	O	-1	none	_	_
8	mol/L	_	_	NN	O	-1	none	_	_
9	1,25	_	_	CD	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	OH	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	2D3	_	_	NN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	24	_	_	CD	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	72	_	_	CD	O	-1	none	_	_
18	hours	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	1,25	_	_	CD	Protein	30	multitoken	_	_
26	(	_	_	-LRB-	Protein	30	multitoken	_	_
27	OH	_	_	NN	Protein	30	multitoken	_	_
28	)	_	_	-RRB-	Protein	30	multitoken	_	_
29	2D3	_	_	NN	Protein	30	multitoken	_	_
30	receptor	_	_	NN	Protein	0	root	_	_
31	and	_	_	CC	O	-1	none	_	_
32	its	_	_	PRP$	O	-1	none	_	_
33	RNA	_	_	NN	O	-1	none	_	_
34	were	_	_	VBD	O	-1	none	_	_
35	examined	_	_	VBN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Levels	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	RNA	_	_	NN	O	-1	none	_	_
4	coding	_	_	VBG	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	modulated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	exposure	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	high	_	_	JJ	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	ligand	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Levels	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	occupied	_	_	JJ	O	-1	none	_	_
4	1,25	_	_	CD	Protein	9	multitoken	_	_
5	(	_	_	-LRB-	Protein	9	multitoken	_	_
6	OH	_	_	NN	Protein	9	multitoken	_	_
7	)	_	_	-RRB-	Protein	9	multitoken	_	_
8	2D3	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	increased	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	these	_	_	DT	O	-1	none	_	_
14	HL-60	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	;	_	_	:	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	total	_	_	JJ	O	-1	none	_	_
20	number	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	1,25	_	_	CD	Protein	27	multitoken	_	_
23	(	_	_	-LRB-	Protein	27	multitoken	_	_
24	OH	_	_	NN	Protein	27	multitoken	_	_
25	)	_	_	-RRB-	Protein	27	multitoken	_	_
26	2D3	_	_	NN	Protein	27	multitoken	_	_
27	receptors	_	_	NNS	Protein	0	root	_	_
28	decreased	_	_	VBD	O	-1	none	_	_
29	about	_	_	IN	O	-1	none	_	_
30	50	_	_	CD	O	-1	none	_	_
31	%	_	_	NN	O	-1	none	_	_
32	at	_	_	IN	O	-1	none	_	_
33	24	_	_	CD	O	-1	none	_	_
34	hours	_	_	NNS	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	returned	_	_	VBD	O	-1	none	_	_
37	toward	_	_	IN	O	-1	none	_	_
38	normal	_	_	JJ	O	-1	none	_	_
39	at	_	_	IN	O	-1	none	_	_
40	72	_	_	CD	O	-1	none	_	_
41	hours	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Steady-state	_	_	JJ	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	1,25	_	_	CD	Protein	9	multitoken	_	_
5	(	_	_	-LRB-	Protein	9	multitoken	_	_
6	OH	_	_	NN	Protein	9	multitoken	_	_
7	)	_	_	-RRB-	Protein	9	multitoken	_	_
8	2D3	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	RNA	_	_	NN	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	affected	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	terminal	_	_	JJ	O	-1	none	_	_
16	differentiation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	HL-60	_	_	NN	O	-1	none	_	_
19	toward	_	_	IN	O	-1	none	_	_
20	either	_	_	CC	O	-1	none	_	_
21	granulocytes	_	_	NNS	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	macrophages	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Nondividing	_	_	JJ	O	-1	none	_	_
2	macrophages	_	_	NNS	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	normal	_	_	JJ	O	-1	none	_	_
5	individuals	_	_	NNS	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	expressed	_	_	VBD	O	-1	none	_	_
8	1,25	_	_	CD	Protein	13	multitoken	_	_
9	(	_	_	-LRB-	Protein	13	multitoken	_	_
10	OH	_	_	NN	Protein	13	multitoken	_	_
11	)	_	_	-RRB-	Protein	13	multitoken	_	_
12	2D3	_	_	NN	Protein	13	multitoken	_	_
13	receptor	_	_	NN	Protein	0	root	_	_
14	RNA	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	nondividing	_	_	JJ	O	-1	none	_	_
5	peripheral	_	_	JJ	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	individuals	_	_	NNS	O	-1	none	_	_
11	did	_	_	VBD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	express	_	_	VB	O	-1	none	_	_
14	1,25	_	_	CD	Protein	19	multitoken	_	_
15	(	_	_	-LRB-	Protein	19	multitoken	_	_
16	OH	_	_	NN	Protein	19	multitoken	_	_
17	)	_	_	-RRB-	Protein	19	multitoken	_	_
18	2D3	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	RNA	_	_	NN	O	-1	none	_	_
21	;	_	_	:	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	stimulation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	proliferation	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	these	_	_	DT	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	accumulation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	1,25	_	_	CD	Protein	37	multitoken	_	_
33	(	_	_	-LRB-	Protein	37	multitoken	_	_
34	OH	_	_	NN	Protein	37	multitoken	_	_
35	)	_	_	-RRB-	Protein	37	multitoken	_	_
36	2D3	_	_	NN	Protein	37	multitoken	_	_
37	receptor	_	_	NN	Protein	0	root	_	_
38	RNA	_	_	NN	O	-1	none	_	_
39	increased	_	_	VBD	O	-1	none	_	_
40	markedly	_	_	RB	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Half-life	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	t1/2	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	1,25	_	_	CD	Protein	11	multitoken	_	_
7	(	_	_	-LRB-	Protein	11	multitoken	_	_
8	OH	_	_	NN	Protein	11	multitoken	_	_
9	)	_	_	-RRB-	Protein	11	multitoken	_	_
10	2D3	_	_	NN	Protein	11	multitoken	_	_
11	receptor	_	_	NN	Protein	0	root	_	_
12	RNA	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	short	_	_	JJ	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	1	_	_	CD	O	-1	none	_	_
20	hour	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	determined	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	measuring	_	_	VBG	O	-1	none	_	_
26	decay	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	message	_	_	NN	O	-1	none	_	_
30	after	_	_	IN	O	-1	none	_	_
31	addition	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	actinomycin	_	_	NN	O	-1	none	_	_
34	D.	_	_	NNP	O	-1	none	_	_
35	Consistent	_	_	JJ	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	this	_	_	DT	O	-1	none	_	_
38	short	_	_	JJ	O	-1	none	_	_
39	t1/2	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	accumulation	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	1,25	_	_	CD	Protein	48	multitoken	_	_
44	(	_	_	-LRB-	Protein	48	multitoken	_	_
45	OH	_	_	NN	Protein	48	multitoken	_	_
46	)	_	_	-RRB-	Protein	48	multitoken	_	_
47	2D3	_	_	NN	Protein	48	multitoken	_	_
48	receptor	_	_	NN	Protein	0	root	_	_
49	RNA	_	_	NN	O	-1	none	_	_
50	increased	_	_	VBN	O	-1	none	_	_
51	in	_	_	IN	O	-1	none	_	_
52	cells	_	_	NNS	O	-1	none	_	_
53	as	_	_	IN	O	-1	none	_	_
54	their	_	_	PRP$	O	-1	none	_	_
55	protein	_	_	NN	O	-1	none	_	_
56	synthesis	_	_	NN	O	-1	none	_	_
57	was	_	_	VBD	O	-1	none	_	_
58	inhibited	_	_	VBN	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	Further	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	required	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	understand	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	physiologic	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	1,25	_	_	CD	Protein	16	multitoken	_	_
12	(	_	_	-LRB-	Protein	16	multitoken	_	_
13	OH	_	_	NN	Protein	16	multitoken	_	_
14	)	_	_	-RRB-	Protein	16	multitoken	_	_
15	2D3	_	_	NN	Protein	16	multitoken	_	_
16	receptors	_	_	NNS	Protein	0	root	_	_
17	in	_	_	IN	O	-1	none	_	_
18	myeloid	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	proliferating	_	_	VBG	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	lymphocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Progesterone	_	_	NN	O	-1	none	_	_
2	suppression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	pregnancy	_	_	NN	O	-1	none	_	_
5	lymphocytes	_	_	NNS	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	mediated	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	glucocorticoid	_	_	NN	O	-1	none	_	_
11	effect	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	investigated	_	_	VBD	O	-1	none	_	_
4	whether	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	suppressive	_	_	JJ	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	progesterone	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	pregnancy	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	mediated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	progesterone	_	_	NN	O	-1	none	_	_
18	receptors	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	competitive	_	_	JJ	O	-1	none	_	_
6	progesterone	_	_	NN	O	-1	none	_	_
7	antagonist	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	RU486	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	glucocorticoid	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	blocker	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	RU43044	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	were	_	_	VBD	O	-1	none	_	_
21	tested	_	_	VBN	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	release	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	blocking	_	_	VBG	O	-1	none	_	_
28	factor	_	_	NN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	progesterone	_	_	NN	O	-1	none	_	_
31	treated	_	_	JJ	O	-1	none	_	_
32	pregnancy	_	_	NN	O	-1	none	_	_
33	lymphocytes	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	RU	_	_	NN	O	-1	none	_	_
2	486	_	_	CD	O	-1	none	_	_
3	tested	_	_	VBN	O	-1	none	_	_
4	at	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	equal	_	_	JJ	O	-1	none	_	_
7	concentration	_	_	NN	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	progesterone	_	_	NN	O	-1	none	_	_
10	significantly	_	_	RB	O	-1	none	_	_
11	inhibited	_	_	VBD	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	production	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	blocking	_	_	VBG	O	-1	none	_	_
17	factor	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	while	_	_	IN	O	-1	none	_	_
20	RU	_	_	NN	O	-1	none	_	_
21	43044	_	_	CD	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	without	_	_	IN	O	-1	none	_	_
24	effect	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	pregnancy	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	lymphocyte	_	_	NN	O	-1	none	_	_
9	progesterone	_	_	NN	O	-1	none	_	_
10	acts	_	_	VBZ	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	progesterone	_	_	NN	O	-1	none	_	_
14	receptors	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	glucocorticoid	_	_	NN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	sites	_	_	NNS	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	not	_	_	RB	O	-1	none	_	_
21	involved	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	mutation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	glucocorticoid	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	in	_	_	IN	O	-1	none	_	_
8	primary	_	_	JJ	O	-1	none	_	_
9	cortisol	_	_	NN	O	-1	none	_	_
10	resistance	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	precise	_	_	JJ	O	-1	none	_	_
3	molecular	_	_	JJ	O	-1	none	_	_
4	abnormalities	_	_	NNS	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	cause	_	_	VBP	O	-1	none	_	_
7	primary	_	_	JJ	O	-1	none	_	_
8	cortisol	_	_	NN	O	-1	none	_	_
9	resistance	_	_	NN	O	-1	none	_	_
10	have	_	_	VBP	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	been	_	_	VBN	O	-1	none	_	_
13	completely	_	_	RB	O	-1	none	_	_
14	described	_	_	VBN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	subject	_	_	JJ	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	primary	_	_	JJ	O	-1	none	_	_
6	cortisol	_	_	NN	O	-1	none	_	_
7	resistance	_	_	NN	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	have	_	_	VBP	O	-1	none	_	_
10	observed	_	_	VBN	O	-1	none	_	_
11	glucocorticoid	_	_	NN	Protein	12	multitoken	_	_
12	receptors	_	_	NNS	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	hGR	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	decreased	_	_	JJ	O	-1	none	_	_
19	affinity	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	dexamethasone	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	hypothesize	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	mutation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	hGR	_	_	NN	Protein	-1	none	_	_
9	glucocorticoid	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	domain	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	cause	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cortisol	_	_	NN	O	-1	none	_	_
17	resistance	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Total	_	_	JJ	O	-1	none	_	_
2	RNA	_	_	NN	O	-1	none	_	_
3	isolated	_	_	VBN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	index	_	_	NN	O	-1	none	_	_
7	subject	_	_	NN	O	-1	none	_	_
8	's	_	_	POS	O	-1	none	_	_
9	mononuclear	_	_	JJ	O	-1	none	_	_
10	leukocytes	_	_	NNS	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	used	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	produce	_	_	VB	O	-1	none	_	_
15	first	_	_	JJ	O	-1	none	_	_
16	strand	_	_	NN	O	-1	none	_	_
17	hGR	_	_	NN	Protein	-1	none	_	_
18	cDNAs	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	entire	_	_	JJ	O	-1	none	_	_
23	hGR	_	_	NN	Protein	-1	none	_	_
24	cDNA	_	_	NN	O	-1	none	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	amplified	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	segments	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	sequenced	_	_	VBN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	nucleotide	_	_	NN	O	-1	none	_	_
3	2,317	_	_	CD	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	identified	_	_	VBD	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	homozygous	_	_	JJ	O	-1	none	_	_
8	A	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	G	_	_	NN	O	-1	none	_	_
11	point	_	_	NN	O	-1	none	_	_
12	mutation	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	predicts	_	_	VBZ	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	isoleucine	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	ATT	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	valine	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	GTT	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	substitution	_	_	NN	O	-1	none	_	_
26	at	_	_	IN	O	-1	none	_	_
27	amino	_	_	NN	O	-1	none	_	_
28	acid	_	_	NN	O	-1	none	_	_
29	729	_	_	CD	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	isoleucine	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	valine	_	_	NN	O	-1	none	_	_
5	substitution	_	_	NN	O	-1	none	_	_
6	at	_	_	IN	O	-1	none	_	_
7	amino	_	_	NN	O	-1	none	_	_
8	acid	_	_	NN	O	-1	none	_	_
9	729	_	_	CD	O	-1	none	_	_
10	impairs	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	function	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	hGR	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	likely	_	_	JJ	O	-1	none	_	_
20	cause	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	primary	_	_	JJ	O	-1	none	_	_
23	cortisol	_	_	NN	O	-1	none	_	_
24	resistance	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	subject	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Tyrosine	_	_	NN	O	-1	none	_	_
2	kinase	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	cAMP	_	_	NN	O	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	activities	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	CD40	_	_	NN	Protein	-1	none	_	_
11	activated	_	_	VBN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vitro	_	_	FW	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	undergo	_	_	VBP	O	-1	none	_	_
8	long-term	_	_	JJ	O	-1	none	_	_
9	proliferation	_	_	NN	O	-1	none	_	_
10	when	_	_	WRB	O	-1	none	_	_
11	activated	_	_	VBN	O	-1	none	_	_
12	through	_	_	IN	O	-1	none	_	_
13	CD40	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	expressed	_	_	VBN	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	their	_	_	PRP$	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	surface	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	nature	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	CD40	_	_	NN	Protein	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	signals	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	proliferating	_	_	VBG	O	-1	none	_	_
9	fresh	_	_	JJ	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	Epstein-Barr	_	_	JJ	O	-1	none	_	_
12	virus	_	_	NN	O	-1	none	_	_
13	negative	_	_	JJ	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	currently	_	_	RB	O	-1	none	_	_
18	unknown	_	_	JJ	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	CD40	_	_	NN	Protein	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	culture	_	_	NN	O	-1	none	_	_
11	system	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	used	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	examine	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	role	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	different	_	_	JJ	O	-1	none	_	_
20	signal	_	_	NN	O	-1	none	_	_
21	transduction	_	_	NN	O	-1	none	_	_
22	elements	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Protein	_	_	NN	O	-1	none	_	_
2	kinase	_	_	NN	O	-1	none	_	_
3	C	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	PKC	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	depletion	_	_	NN	O	-1	none	_	_
8	generated	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	long-term	_	_	JJ	O	-1	none	_	_
12	phorbol	_	_	NN	O	-1	none	_	_
13	12	_	_	CD	O	-1	none	_	_
14	myristate	_	_	NN	O	-1	none	_	_
15	13-acetate	_	_	NN	O	-1	none	_	_
16	treatment	_	_	NN	O	-1	none	_	_
17	had	_	_	VBD	O	-1	none	_	_
18	weak	_	_	JJ	O	-1	none	_	_
19	effects	_	_	NNS	O	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	proliferation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Rather	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	tyrosine	_	_	NN	O	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	directly	_	_	RB	O	-1	none	_	_
10	involved	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	mediating	_	_	VBG	O	-1	none	_	_
13	CD40	_	_	NN	Protein	-1	none	_	_
14	dependent	_	_	JJ	O	-1	none	_	_
15	signals	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	use	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	PTK	_	_	NN	O	-1	none	_	_
10	)-specific	_	_	JJ	O	-1	none	_	_
11	inhibitor	_	_	NN	O	-1	none	_	_
12	herbimycin	_	_	NN	O	-1	none	_	_
13	A	_	_	NN	O	-1	none	_	_
14	dramatically	_	_	RB	O	-1	none	_	_
15	decreased	_	_	VBD	O	-1	none	_	_
16	cellular	_	_	JJ	O	-1	none	_	_
17	proliferation	_	_	NN	O	-1	none	_	_
18	without	_	_	IN	O	-1	none	_	_
19	altering	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	immunodeficiency	_	_	NN	O	-1	none	_	_
26	virus-1	_	_	NN	O	-1	none	_	_
27	long	_	_	JJ	O	-1	none	_	_
28	terminal	_	_	JJ	O	-1	none	_	_
29	repeat	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	HIV-1	_	_	NN	O	-1	none	_	_
32	LTR	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	a	_	_	DT	O	-1	none	_	_
36	promoter	_	_	NN	O	-1	none	_	_
37	largely	_	_	RB	O	-1	none	_	_
38	dependent	_	_	JJ	O	-1	none	_	_
39	on	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	binding	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	nuclear	_	_	JJ	O	-1	none	_	_
44	factor	_	_	NN	O	-1	none	_	_
45	kappa	_	_	NN	O	-1	none	_	_
46	B	_	_	NN	O	-1	none	_	_
47	(	_	_	-LRB-	O	-1	none	_	_
48	NF-	_	_	NN	O	-1	none	_	_
49	kappa	_	_	NN	O	-1	none	_	_
50	B	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	cAMP	_	_	NN	O	-1	none	_	_
6	dependent	_	_	JJ	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	inhibitor	_	_	NN	O	-1	none	_	_
11	H-89	_	_	NN	O	-1	none	_	_
12	totally	_	_	RB	O	-1	none	_	_
13	inhibited	_	_	VBD	O	-1	none	_	_
14	HIV-1	_	_	NN	O	-1	none	_	_
15	LTR	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	concentration	_	_	NN	O	-1	none	_	_
20	as	_	_	RB	O	-1	none	_	_
21	low	_	_	JJ	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	100	_	_	CD	O	-1	none	_	_
24	nM	_	_	NN	O	-1	none	_	_
25	without	_	_	IN	O	-1	none	_	_
26	affecting	_	_	VBG	O	-1	none	_	_
27	cellular	_	_	JJ	O	-1	none	_	_
28	proliferation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Electrophoretic	_	_	JJ	O	-1	none	_	_
2	mobility	_	_	NN	O	-1	none	_	_
3	shift	_	_	NN	O	-1	none	_	_
4	assay	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	EMSA	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	supershift	_	_	NN	O	-1	none	_	_
10	assay	_	_	NN	O	-1	none	_	_
11	using	_	_	VBG	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	sequence	_	_	NN	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	kappa	_	_	NN	O	-1	none	_	_
20	light	_	_	JJ	O	-1	none	_	_
21	chain	_	_	NN	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	probe	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	revealed	_	_	VBD	O	-1	none	_	_
27	that	_	_	IN	O	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	p65	_	_	NN	Protein	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	RelA	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	c-Rel	_	_	NN	Protein	-1	none	_	_
35	were	_	_	VBD	O	-1	none	_	_
36	present	_	_	JJ	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	CD40	_	_	NN	Protein	-1	none	_	_
39	stimulated	_	_	VBN	O	-1	none	_	_
40	B	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	PKC	_	_	NN	O	-1	none	_	_
3	depletion	_	_	NN	O	-1	none	_	_
4	did	_	_	VBD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	alter	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	level	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	treatment	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	H-89	_	_	NN	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	herbimycin	_	_	NN	O	-1	none	_	_
20	A	_	_	NN	O	-1	none	_	_
21	provoked	_	_	VBD	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	decrease	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	NF-kappa	_	_	NN	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	level	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	establish	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	importance	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	different	_	_	JJ	O	-1	none	_	_
8	signal	_	_	NN	O	-1	none	_	_
9	transducing	_	_	NN	O	-1	none	_	_
10	pathways	_	_	NNS	O	-1	none	_	_
11	leading	_	_	VBG	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	CD40	_	_	NN	Protein	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	lymphocytes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	dexamethasone	_	_	NN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	glucocorticoid	_	_	NN	Protein	8	multitoken	_	_
8	receptor	_	_	NN	Protein	0	root	_	_
9	by	_	_	IN	O	-1	none	_	_
10	New	_	_	NNP	O	-1	none	_	_
11	World	_	_	NNP	O	-1	none	_	_
12	primate	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	extracts	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	if	_	_	IN	O	-1	none	_	_
4	New	_	_	NNP	O	-1	none	_	_
5	World	_	_	NNP	O	-1	none	_	_
6	primates	_	_	NNS	O	-1	none	_	_
7	express	_	_	VBP	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	inhibitor	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	influences	_	_	VBZ	O	-1	none	_	_
12	glucocorticoid	_	_	NN	Protein	13	multitoken	_	_
13	receptor	_	_	NN	Protein	0	root	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	GR	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	characteristics	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	examined	_	_	VBD	O	-1	none	_	_
22	[	_	_	CD	O	-1	none	_	_
23	3H	_	_	NN	O	-1	none	_	_
24	]	_	_	CD	O	-1	none	_	_
25	dexamethasone	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	cytosol	_	_	NN	O	-1	none	_	_
29	prepared	_	_	VBN	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	B95-8	_	_	NN	O	-1	none	_	_
32	lymphoid	_	_	JJ	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	derived	_	_	VBN	O	-1	none	_	_
36	from	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	cotton	_	_	NN	O	-1	none	_	_
39	top	_	_	JJ	O	-1	none	_	_
40	tamarin	_	_	NN	O	-1	none	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	Saguinus	_	_	FW	O	-1	none	_	_
43	oedipus	_	_	FW	O	-1	none	_	_
44	)	_	_	-RRB-	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	in	_	_	IN	O	-1	none	_	_
47	combination	_	_	NN	O	-1	none	_	_
48	with	_	_	IN	O	-1	none	_	_
49	cytosol	_	_	NN	O	-1	none	_	_
50	prepared	_	_	VBN	O	-1	none	_	_
51	from	_	_	IN	O	-1	none	_	_
52	human	_	_	NN	O	-1	none	_	_
53	or	_	_	CC	O	-1	none	_	_
54	rat	_	_	NN	O	-1	none	_	_
55	tissues	_	_	NNS	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	B95-8	_	_	NNP	O	-1	none	_	_
2	cytosol	_	_	NN	O	-1	none	_	_
3	inhibited	_	_	VBD	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	[	_	_	CD	O	-1	none	_	_
8	3H	_	_	NN	O	-1	none	_	_
9	]	_	_	CD	O	-1	none	_	_
10	dexamethasone	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	P	_	_	NN	O	-1	none	_	_
13	<	_	_	JJR	O	-1	none	_	_
14	0.01	_	_	CD	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	when	_	_	WRB	O	-1	none	_	_
17	mixed	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	cytosol	_	_	NN	O	-1	none	_	_
20	prepared	_	_	VBN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	either	_	_	CC	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	lymphoid	_	_	JJ	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	line	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	HL	_	_	NNS	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	rat	_	_	NN	O	-1	none	_	_
33	thymus	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	heat	_	_	NN	O	-1	none	_	_
6	labile	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	trypsin	_	_	NN	O	-1	none	_	_
9	sensitive	_	_	JJ	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Peak	_	_	JJ	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	150-200	_	_	CD	O	-1	none	_	_
9	kd	_	_	NN	O	-1	none	_	_
10	fractions	_	_	NNS	O	-1	none	_	_
11	after	_	_	IN	O	-1	none	_	_
12	Sephacryl	_	_	NN	O	-1	none	_	_
13	G-200	_	_	NN	O	-1	none	_	_
14	ultrafiltration	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Scatchard	_	_	NN	O	-1	none	_	_
2	analysis	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	[	_	_	CD	O	-1	none	_	_
5	3H	_	_	NN	O	-1	none	_	_
6	]	_	_	CD	O	-1	none	_	_
7	dexamethasone	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	using	_	_	VBG	O	-1	none	_	_
10	mixed	_	_	JJ	O	-1	none	_	_
11	cytosol	_	_	NN	O	-1	none	_	_
12	showed	_	_	VBD	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	diminished	_	_	JJ	O	-1	none	_	_
15	GR	_	_	NN	Protein	-1	none	_	_
16	apparent	_	_	JJ	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	affinity	_	_	NN	O	-1	none	_	_
19	when	_	_	WRB	O	-1	none	_	_
20	compared	_	_	VBN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	HL	_	_	NNS	O	-1	none	_	_
23	cytosol	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Kinetic	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	using	_	_	VBG	O	-1	none	_	_
4	mixed	_	_	JJ	O	-1	none	_	_
5	cytosol	_	_	NN	O	-1	none	_	_
6	indicated	_	_	VBD	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	B95-8	_	_	NN	O	-1	none	_	_
9	cytosol	_	_	NN	O	-1	none	_	_
10	did	_	_	VBD	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	affect	_	_	VB	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	apparent	_	_	JJ	O	-1	none	_	_
15	dissociation	_	_	NN	O	-1	none	_	_
16	rate	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	[	_	_	CD	O	-1	none	_	_
19	3H	_	_	NN	O	-1	none	_	_
20	]	_	_	CD	O	-1	none	_	_
21	dexamethasone	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	B95-8	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	contain	_	_	VBP	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	competitive	_	_	JJ	O	-1	none	_	_
10	inhibitor	_	_	NN	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	prevents	_	_	VBZ	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	dexamethasone	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	cognate	_	_	JJ	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	suppression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	function	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	NF	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	kappa	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	serine	_	_	NN	O	-1	none	_	_
16	protease	_	_	NN	O	-1	none	_	_
17	inhibitors	_	_	NNS	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	blocked	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	N-acetylcysteine	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Direct	_	_	JJ	O	-1	none	_	_
2	evidence	_	_	NN	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	N-acetylcysteine	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	NAC	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	enhances	_	_	VBZ	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	immune	_	_	JJ	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	peripheral	_	_	JJ	O	-1	none	_	_
14	blood	_	_	NN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	level	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	NF	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	kappa	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	presented	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	NAC	_	_	NN	O	-1	none	_	_
5	blocks	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	suppression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	mitogenesis	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	cytokine	_	_	NN	O	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	protease	_	_	NN	O	-1	none	_	_
17	inhibitors	_	_	NNS	O	-1	none	_	_
18	such	_	_	JJ	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	N-tosylphenylalanine	_	_	NN	O	-1	none	_	_
21	chloromethyl	_	_	NN	O	-1	none	_	_
22	ketone	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	TPCK	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	electrophoretic	_	_	JJ	O	-1	none	_	_
3	mobility	_	_	NN	O	-1	none	_	_
4	shift	_	_	NN	O	-1	none	_	_
5	assays	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	find	_	_	VBP	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	TPCK	_	_	NN	O	-1	none	_	_
11	virtually	_	_	RB	O	-1	none	_	_
12	abolishes	_	_	VBZ	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	less	_	_	JJR	O	-1	none	_	_
16	than	_	_	IN	O	-1	none	_	_
17	1	_	_	CD	O	-1	none	_	_
18	%	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	NF	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	kappa	_	_	NN	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	but	_	_	CC	O	-1	none	_	_
30	not	_	_	RB	O	-1	none	_	_
31	Oct-1	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	found	_	_	VBN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	nuclear	_	_	JJ	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	whole	_	_	JJ	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	extracts	_	_	NNS	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	activated	_	_	VBN	O	-1	none	_	_
42	T	_	_	NN	O	-1	none	_	_
43	cells	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Strikingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	immunosuppressive	_	_	JJ	O	-1	none	_	_
5	effects	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	TPCK	_	_	NN	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	blocked	_	_	VBN	O	-1	none	_	_
10	when	_	_	WRB	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	pretreated	_	_	VBN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	15	_	_	CD	O	-1	none	_	_
17	min	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	5	_	_	CD	O	-1	none	_	_
20	mM	_	_	NN	O	-1	none	_	_
21	NAC	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	NAC	_	_	NN	O	-1	none	_	_
2	not	_	_	RB	O	-1	none	_	_
3	only	_	_	RB	O	-1	none	_	_
4	blocks	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	TPCK	_	_	NN	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	enhances	_	_	VBZ	O	-1	none	_	_
11	mitogenesis	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	cytokine	_	_	NN	O	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	>	_	_	JJR	O	-1	none	_	_
17	2.5-fold	_	_	RB	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	some	_	_	DT	O	-1	none	_	_
20	cases	_	_	NNS	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	upon	_	_	IN	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	unsuppressed	_	_	JJ	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	support	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	notion	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	NF	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	kappa	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	I	_	_	PRP	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	kappa	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	proteases	_	_	NNS	O	-1	none	_	_
19	play	_	_	VBP	O	-1	none	_	_
20	obligate	_	_	JJ	O	-1	none	_	_
21	roles	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	activation	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	mitogenesis	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	roles	_	_	NNS	O	-1	none	_	_
30	that	_	_	WDT	O	-1	none	_	_
31	are	_	_	VBP	O	-1	none	_	_
32	enhanced	_	_	VBN	O	-1	none	_	_
33	significantly	_	_	RB	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	NAC	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	Protein	2	multitoken	_	_
2	receptors	_	_	NNS	Protein	0	root	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	down-regulated	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	inflamed	_	_	JJ	O	-1	none	_	_
7	colonic	_	_	JJ	O	-1	none	_	_
8	mucosa	_	_	NN	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	peripheral	_	_	JJ	O	-1	none	_	_
13	blood	_	_	NN	O	-1	none	_	_
14	mononuclear	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	inflammatory	_	_	JJ	O	-1	none	_	_
20	bowel	_	_	NN	O	-1	none	_	_
21	disease	_	_	NN	O	-1	none	_	_
22	[	_	_	CD	O	-1	none	_	_
23	see	_	_	VBP	O	-1	none	_	_
24	comments	_	_	NNS	O	-1	none	_	_
25	]	_	_	JJ	O	-1	none	_	_
26	BACKGROUND	_	_	NN	O	-1	none	_	_
27	:	_	_	:	O	-1	none	_	_
28	Growing	_	_	VBG	O	-1	none	_	_
29	evidence	_	_	NN	O	-1	none	_	_
30	indicates	_	_	VBZ	O	-1	none	_	_
31	that	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	immune	_	_	JJ	O	-1	none	_	_
34	system	_	_	NN	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
38	system	_	_	NN	O	-1	none	_	_
39	are	_	_	VBP	O	-1	none	_	_
40	linked	_	_	VBN	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	several	_	_	JJ	O	-1	none	_	_
43	mechanisms	_	_	NNS	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	for	_	_	IN	O	-1	none	_	_
46	example	_	_	NN	O	-1	none	_	_
47	intracellular	_	_	JJ	O	-1	none	_	_
48	glucocorticoid	_	_	NN	Protein	49	multitoken	_	_
49	receptors	_	_	NNS	Protein	0	root	_	_
50	(	_	_	-LRB-	O	-1	none	_	_
51	hGR	_	_	NN	Protein	-1	none	_	_
52	)	_	_	-RRB-	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Glucocorticoids	_	_	NNS	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	standard	_	_	JJ	O	-1	none	_	_
5	treatment	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	acute	_	_	JJ	O	-1	none	_	_
8	attacks	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	inflammatory	_	_	JJ	O	-1	none	_	_
11	bowel	_	_	NN	O	-1	none	_	_
12	disease	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	IBD	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	glucocorticoids	_	_	NNS	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	hGR	_	_	NN	Protein	-1	none	_	_
6	down-regulates	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	inflammatory	_	_	JJ	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	can	_	_	MD	O	-1	none	_	_
14	propagate	_	_	VB	O	-1	none	_	_
15	IBD	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	PATIENTS	_	_	NNS	O	-1	none	_	_
2	AND	_	_	CC	O	-1	none	_	_
3	METHODS	_	_	NNS	O	-1	none	_	_
4	:	_	_	:	O	-1	none	_	_
5	IBD	_	_	NN	O	-1	none	_	_
6	patients	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	either	_	_	RB	O	-1	none	_	_
9	treated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	5-60	_	_	CD	O	-1	none	_	_
12	mg	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	prednisolone	_	_	NN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	more	_	_	JJR	O	-1	none	_	_
17	than	_	_	IN	O	-1	none	_	_
18	1	_	_	CD	O	-1	none	_	_
19	week	_	_	NN	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	were	_	_	VBD	O	-1	none	_	_
22	without	_	_	IN	O	-1	none	_	_
23	glucocorticoid	_	_	NN	O	-1	none	_	_
24	treatment	_	_	NN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	more	_	_	JJR	O	-1	none	_	_
27	than	_	_	IN	O	-1	none	_	_
28	4	_	_	CD	O	-1	none	_	_
29	weeks	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	hGR	_	_	NN	Protein	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	determined	_	_	VBN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	isolated	_	_	VBN	O	-1	none	_	_
7	cytosol	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	peripheral	_	_	JJ	O	-1	none	_	_
10	blood	_	_	NN	O	-1	none	_	_
11	mononuclear	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	PBMCs	_	_	NNS	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	mucosal	_	_	JJ	O	-1	none	_	_
18	biopsies	_	_	NNS	O	-1	none	_	_
19	using	_	_	VBG	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	radioassay	_	_	NN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	[	_	_	CD	O	-1	none	_	_
24	3H	_	_	NN	O	-1	none	_	_
25	]-dexamethasone	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Interleukin	_	_	NN	Protein	5	multitoken	_	_
2	(	_	_	-LRB-	Protein	5	multitoken	_	_
3	IL	_	_	NN	Protein	5	multitoken	_	_
4	)	_	_	-RRB-	Protein	5	multitoken	_	_
5	6	_	_	CD	Protein	0	root	_	_
6	levels	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	determined	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	enzyme	_	_	NN	O	-1	none	_	_
11	linked	_	_	JJ	O	-1	none	_	_
12	immunosorbent	_	_	JJ	O	-1	none	_	_
13	assay	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	ELISA	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	systemic	_	_	JJ	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	PBMC	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	hGR	_	_	NN	Protein	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	corticosteroid	_	_	NN	O	-1	none	_	_
12	treated	_	_	VBN	O	-1	none	_	_
13	IBD	_	_	NN	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	significantly	_	_	RB	O	-1	none	_	_
17	lower	_	_	JJR	O	-1	none	_	_
18	than	_	_	IN	O	-1	none	_	_
19	those	_	_	DT	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	control	_	_	JJ	O	-1	none	_	_
22	subjects	_	_	NNS	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	59.6	_	_	CD	O	-1	none	_	_
25	+/-	_	_	CC	O	-1	none	_	_
26	57.1	_	_	CD	O	-1	none	_	_
27	dpm	_	_	NN	O	-1	none	_	_
28	mg-1	_	_	NN	O	-1	none	_	_
29	cytosol	_	_	NN	O	-1	none	_	_
30	protein	_	_	NN	O	-1	none	_	_
31	vs.	_	_	CC	O	-1	none	_	_
32	227.0	_	_	CD	O	-1	none	_	_
33	+/-	_	_	CC	O	-1	none	_	_
34	90.8	_	_	CD	O	-1	none	_	_
35	dpm	_	_	NN	O	-1	none	_	_
36	mg-1	_	_	NN	O	-1	none	_	_
37	cytosol	_	_	NN	O	-1	none	_	_
38	protein	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	P	_	_	NN	O	-1	none	_	_
41	=	_	_	JJ	O	-1	none	_	_
42	0.007	_	_	CD	O	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	IBD	_	_	NN	O	-1	none	_	_
46	patients	_	_	NNS	O	-1	none	_	_
47	not	_	_	RB	O	-1	none	_	_
48	receiving	_	_	VBG	O	-1	none	_	_
49	glucocorticoid	_	_	NN	O	-1	none	_	_
50	treatment	_	_	NN	O	-1	none	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	179.7	_	_	CD	O	-1	none	_	_
53	+/-	_	_	CC	O	-1	none	_	_
54	171.3	_	_	CD	O	-1	none	_	_
55	dpm	_	_	NN	O	-1	none	_	_
56	mg-1	_	_	NN	O	-1	none	_	_
57	cytosol	_	_	NN	O	-1	none	_	_
58	protein	_	_	NN	O	-1	none	_	_
59	,	_	_	,	O	-1	none	_	_
60	P	_	_	NN	O	-1	none	_	_
61	=	_	_	JJ	O	-1	none	_	_
62	0.002	_	_	CD	O	-1	none	_	_
63	)	_	_	-RRB-	O	-1	none	_	_
64	.	_	_	.	O	-1	none	_	_

1	Systemic	_	_	JJ	O	-1	none	_	_
2	hGR	_	_	NN	Protein	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	untreated	_	_	JJ	O	-1	none	_	_
6	IBD	_	_	NN	O	-1	none	_	_
7	patients	_	_	NNS	O	-1	none	_	_
8	did	_	_	VBD	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	differ	_	_	VB	O	-1	none	_	_
11	significantly	_	_	RB	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	those	_	_	DT	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	control	_	_	JJ	O	-1	none	_	_
16	subjects	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	patients	_	_	NNS	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	connective	_	_	JJ	O	-1	none	_	_
5	tissue	_	_	NN	O	-1	none	_	_
6	diseases	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	systemic	_	_	JJ	O	-1	none	_	_
9	hGR	_	_	NN	Protein	-1	none	_	_
10	levels	_	_	NNS	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	found	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	be	_	_	VB	O	-1	none	_	_
16	decreased	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	absence	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	glucocorticoid	_	_	NN	O	-1	none	_	_
22	treatment	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Systemic	_	_	JJ	O	-1	none	_	_
2	hGR	_	_	NN	Protein	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	Crohn	_	_	NN	O	-1	none	_	_
8	's	_	_	POS	O	-1	none	_	_
9	disease	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	CD	_	_	NNP	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	treated	_	_	VBN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	steroids	_	_	NNS	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	66.6	_	_	CD	O	-1	none	_	_
18	+/-	_	_	CC	O	-1	none	_	_
19	61.0	_	_	CD	O	-1	none	_	_
20	dpm	_	_	NN	O	-1	none	_	_
21	mg-1	_	_	NN	O	-1	none	_	_
22	cytosol	_	_	NN	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	were	_	_	VBD	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	different	_	_	JJ	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	those	_	_	DT	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	patients	_	_	NNS	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	ulcerative	_	_	JJ	O	-1	none	_	_
34	colitis	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	UC	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	56.1	_	_	CD	O	-1	none	_	_
40	+/-	_	_	CC	O	-1	none	_	_
41	51.6	_	_	CD	O	-1	none	_	_
42	dpm	_	_	NN	O	-1	none	_	_
43	mg-1	_	_	NN	O	-1	none	_	_
44	cytosol	_	_	NN	O	-1	none	_	_
45	protein	_	_	NN	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	findings	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	mucosal	_	_	JJ	O	-1	none	_	_
8	hGR	_	_	NN	Protein	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	significantly	_	_	RB	O	-1	none	_	_
12	decreased	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	steroid	_	_	NN	O	-1	none	_	_
16	treated	_	_	JJ	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	18.0	_	_	CD	O	-1	none	_	_
19	+/-	_	_	CC	O	-1	none	_	_
20	15.5	_	_	CD	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	steroid	_	_	NN	O	-1	none	_	_
25	treated	_	_	JJ	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	37.8	_	_	CD	O	-1	none	_	_
28	+/-	_	_	CC	O	-1	none	_	_
29	30.5	_	_	CD	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	patients	_	_	NNS	O	-1	none	_	_
32	compared	_	_	VBN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	control	_	_	JJ	O	-1	none	_	_
35	subjects	_	_	NNS	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	125.6	_	_	CD	O	-1	none	_	_
38	+/-	_	_	CC	O	-1	none	_	_
39	97.1	_	_	CD	O	-1	none	_	_
40	;	_	_	:	O	-1	none	_	_
41	P	_	_	NN	O	-1	none	_	_
42	=	_	_	JJ	O	-1	none	_	_
43	0.00009	_	_	CD	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	P	_	_	NN	O	-1	none	_	_
46	=	_	_	JJ	O	-1	none	_	_
47	0.0008	_	_	CD	O	-1	none	_	_
48	respectively	_	_	RB	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	IL-6	_	_	NNP	Protein	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	all	_	_	DT	O	-1	none	_	_
5	IBD	_	_	NN	O	-1	none	_	_
6	groups	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	without	_	_	IN	O	-1	none	_	_
10	steroids	_	_	NNS	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	significantly	_	_	RB	O	-1	none	_	_
13	different	_	_	JJ	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	those	_	_	DT	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	control	_	_	JJ	O	-1	none	_	_
18	subjects	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	CONCLUSION	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	In	_	_	IN	O	-1	none	_	_
4	IBD	_	_	NN	O	-1	none	_	_
5	there	_	_	EX	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	no	_	_	DT	O	-1	none	_	_
8	difference	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	systemic	_	_	JJ	O	-1	none	_	_
11	hGR	_	_	NN	Protein	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	between	_	_	IN	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	steroid	_	_	NN	O	-1	none	_	_
16	treated	_	_	JJ	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	control	_	_	JJ	O	-1	none	_	_
20	subjects	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	spite	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	inflammatory	_	_	JJ	O	-1	none	_	_
26	activity	_	_	NN	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	IL-6	_	_	NN	Protein	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Mucosal	_	_	JJ	O	-1	none	_	_
2	hGR	_	_	NN	Protein	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	decreased	_	_	VBN	O	-1	none	_	_
6	independently	_	_	RB	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	treatment	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	probably	_	_	RB	O	-1	none	_	_
11	leading	_	_	VBG	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	decreased	_	_	JJ	O	-1	none	_	_
15	protection	_	_	NN	O	-1	none	_	_
16	against	_	_	IN	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	action	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	intestinal	_	_	JJ	O	-1	none	_	_
22	mucosa	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Infection	_	_	NN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	Theileria	_	_	FW	O	-1	none	_	_
4	annulata	_	_	FW	O	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	matrix	_	_	NN	Protein	10	multitoken	_	_
9	metalloproteinase	_	_	NN	Protein	10	multitoken	_	_
10	9	_	_	CD	Protein	0	root	_	_
11	and	_	_	CC	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	AP-1	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	bovine	_	_	JJ	O	-1	none	_	_
17	leucocytes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Theileria	_	_	FW	O	-1	none	_	_
2	annulata	_	_	FW	O	-1	none	_	_
3	infects	_	_	VBZ	O	-1	none	_	_
4	bovine	_	_	JJ	O	-1	none	_	_
5	leucocytes	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	results	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	their	_	_	PRP$	O	-1	none	_	_
10	reversible	_	_	JJ	O	-1	none	_	_
11	transformation	_	_	NN	O	-1	none	_	_
12	such	_	_	JJ	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	they	_	_	PRP	O	-1	none	_	_
15	become	_	_	VBP	O	-1	none	_	_
16	immortalised	_	_	VBN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	metastatic	_	_	JJ	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	describes	_	_	VBZ	O	-1	none	_	_
5	parasite	_	_	NN	O	-1	none	_	_
6	induced	_	_	VBN	O	-1	none	_	_
7	changes	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	host	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	direct	_	_	JJ	O	-1	none	_	_
17	bearing	_	_	NN	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	this	_	_	DT	O	-1	none	_	_
20	transformation	_	_	NN	O	-1	none	_	_
21	process	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	T.	_	_	NNP	O	-1	none	_	_
2	annulata	_	_	FW	O	-1	none	_	_
3	infected	_	_	JJ	O	-1	none	_	_
4	leucocytes	_	_	NNS	O	-1	none	_	_
5	produce	_	_	VBP	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	number	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	novel	_	_	JJ	O	-1	none	_	_
10	metalloproteinase	_	_	NN	O	-1	none	_	_
11	activities	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	previously	_	_	RB	O	-1	none	_	_
6	called	_	_	VBN	O	-1	none	_	_
7	B1	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	97-kDa	_	_	JJ	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	secreted	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	large	_	_	JJ	O	-1	none	_	_
18	amounts	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	has	_	_	VBZ	O	-1	none	_	_
21	been	_	_	VBN	O	-1	none	_	_
22	purified	_	_	VBN	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	protein-free	_	_	JJ	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	conditioned	_	_	JJ	O	-1	none	_	_
27	medium	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	antiserum	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	enzyme	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	used	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	isolate	_	_	VB	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	cDNA	_	_	NN	O	-1	none	_	_
12	clone	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	predicted	_	_	JJ	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	sequence	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	B1	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	81	_	_	CD	O	-1	none	_	_
9	%	_	_	NN	O	-1	none	_	_
10	identical	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	matrix	_	_	NN	Protein	15	multitoken	_	_
14	metalloproteinase	_	_	NN	Protein	15	multitoken	_	_
15	9	_	_	CD	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	MMP9	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	demonstrating	_	_	VBG	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	it	_	_	PRP	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	bovine	_	_	JJ	O	-1	none	_	_
26	homologue	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	this	_	_	DT	O	-1	none	_	_
29	enzyme	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	RNAase	_	_	NN	O	-1	none	_	_
2	protection	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	demonstrated	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	MMP9	_	_	NN	Protein	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	unique	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	infected	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	due	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	increased	_	_	VBN	O	-1	none	_	_
19	MMP9	_	_	NN	Protein	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	assayed	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	levels	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	AP-1	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	demonstrated	_	_	VBD	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	it	_	_	PRP	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	constitutively	_	_	RB	O	-1	none	_	_
16	present	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	increased	_	_	VBN	O	-1	none	_	_
19	amounts	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	Theileria	_	_	FW	O	-1	none	_	_
22	infected	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	assayed	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	level	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	mRNA	_	_	NN	O	-1	none	_	_
9	encoding	_	_	VBG	O	-1	none	_	_
10	c-Fos	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	common	_	_	JJ	O	-1	none	_	_
14	component	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	observed	_	_	VBN	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	it	_	_	PRP	O	-1	none	_	_
21	was	_	_	VBD	O	-1	none	_	_
22	indeed	_	_	RB	O	-1	none	_	_
23	up-regulated	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	infected	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	AP-1	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	implicated	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	control	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	cycle	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	MMP9	_	_	NN	Protein	-1	none	_	_
15	can	_	_	MD	O	-1	none	_	_
16	confer	_	_	VB	O	-1	none	_	_
17	metastatic	_	_	JJ	O	-1	none	_	_
18	properties	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	these	_	_	DT	O	-1	none	_	_
21	results	_	_	NNS	O	-1	none	_	_
22	are	_	_	VBP	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	considerable	_	_	JJ	O	-1	none	_	_
25	significance	_	_	NN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	respect	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	transformed	_	_	JJ	O	-1	none	_	_
31	phenotype	_	_	NN	O	-1	none	_	_
32	induced	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	Theileria	_	_	FW	O	-1	none	_	_
35	infection	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Mutations	_	_	NNS	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	Pit-1	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	children	_	_	NNS	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	combined	_	_	JJ	O	-1	none	_	_
10	pituitary	_	_	JJ	O	-1	none	_	_
11	hormone	_	_	NN	O	-1	none	_	_
12	deficiency	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Pit-1	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	pituitary	_	_	JJ	O	-1	none	_	_
5	specific	_	_	JJ	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	binds	_	_	VBZ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	transactivates	_	_	VBZ	O	-1	none	_	_
13	promoters	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	growth	_	_	NN	O	-1	none	_	_
16	hormone	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	prolactin	_	_	NN	O	-1	none	_	_
19	genes	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	three	_	_	CD	O	-1	none	_	_
3	unrelated	_	_	JJ	O	-1	none	_	_
4	Japanese	_	_	JJ	O	-1	none	_	_
5	children	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	combined	_	_	JJ	O	-1	none	_	_
8	pituitary	_	_	JJ	O	-1	none	_	_
9	hormone	_	_	NN	O	-1	none	_	_
10	deficiency	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	we	_	_	PRP	O	-1	none	_	_
13	identified	_	_	VBD	O	-1	none	_	_
14	three	_	_	CD	O	-1	none	_	_
15	point	_	_	NN	O	-1	none	_	_
16	mutations	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	Pit-1	_	_	NN	Protein	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	Pro24Leu	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	Arg143Gln	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Arg271Trp	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	located	_	_	JJ	O	-1	none	_	_
30	on	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	major	_	_	JJ	O	-1	none	_	_
33	transactivation	_	_	NN	O	-1	none	_	_
34	region	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	POU	_	_	NN	O	-1	none	_	_
37	specific	_	_	JJ	O	-1	none	_	_
38	domain	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	POU-homeodomain	_	_	NN	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	respectively	_	_	RB	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Tumor	_	_	NN	Protein	3	multitoken	_	_
2	necrosis	_	_	NN	Protein	3	multitoken	_	_
3	factor-alpha	_	_	NN	Protein	0	root	_	_
4	mRNA	_	_	NN	O	-1	none	_	_
5	accumulation	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	myelomonocytic	_	_	JJ	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	lines	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Role	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	transcriptional	_	_	JJ	O	-1	none	_	_
4	regulation	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	motifs	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	mRNA	_	_	NN	O	-1	none	_	_
11	stabilization	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cytokine	_	_	NN	O	-1	none	_	_
3	TNF	_	_	NN	Protein	-1	none	_	_
4	mediates	_	_	VBZ	O	-1	none	_	_
5	many	_	_	JJ	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	pathologic	_	_	JJ	O	-1	none	_	_
9	signs	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cachexia	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	inflammation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	sepsis	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	current	_	_	JJ	O	-1	none	_	_
3	work	_	_	NN	O	-1	none	_	_
4	describes	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	regulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	TNF	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	myelomonocytic	_	_	JJ	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	lines	_	_	NNS	O	-1	none	_	_
14	after	_	_	IN	O	-1	none	_	_
15	PMA	_	_	NN	O	-1	none	_	_
16	stimulation	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	exhibit	_	_	VBP	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	low	_	_	JJ	O	-1	none	_	_
7	level	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	constitutive	_	_	JJ	O	-1	none	_	_
10	TNF	_	_	NN	Protein	-1	none	_	_
11	mRNA	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Within	_	_	IN	O	-1	none	_	_
2	2	_	_	CD	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	4	_	_	CD	O	-1	none	_	_
5	h	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	PMA	_	_	NN	O	-1	none	_	_
8	exposure	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	steady	_	_	JJ	O	-1	none	_	_
11	state	_	_	NN	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	TNF	_	_	NN	Protein	-1	none	_	_
15	mRNA	_	_	NN	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	markedly	_	_	RB	O	-1	none	_	_
18	elevated	_	_	JJ	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	all	_	_	DT	O	-1	none	_	_
21	myelomonocytic	_	_	JJ	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	lines	_	_	NNS	O	-1	none	_	_
24	studied	_	_	VBN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	rise	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	due	_	_	JJ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	increased	_	_	VBN	O	-1	none	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	stability	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	increased	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	almost	_	_	RB	O	-1	none	_	_
14	twofold	_	_	RB	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	overall	_	_	JJ	O	-1	none	_	_
20	increase	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	which	_	_	WDT	O	-1	none	_	_
25	rises	_	_	VBZ	O	-1	none	_	_
26	by	_	_	IN	O	-1	none	_	_
27	more	_	_	JJR	O	-1	none	_	_
28	than	_	_	IN	O	-1	none	_	_
29	sixfold	_	_	RB	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	level	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	genomic	_	_	JJ	O	-1	none	_	_
7	TNF	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	DNase	_	_	NN	O	-1	none	_	_
12	I	_	_	CD	O	-1	none	_	_
13	hypersensitive	_	_	JJ	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	detected	_	_	VBN	O	-1	none	_	_
17	within	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	TNF	_	_	NN	Protein	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	between	_	_	IN	O	-1	none	_	_
22	-200	_	_	CD	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	-100	_	_	CD	O	-1	none	_	_
25	bp	_	_	NN	O	-1	none	_	_
26	relative	_	_	JJ	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	initiation	_	_	NN	O	-1	none	_	_
31	site	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	absent	_	_	JJ	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	nonexpressing	_	_	JJ	O	-1	none	_	_
5	erythroleukemia	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	lines	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	DNase	_	_	NN	O	-1	none	_	_
11	I	_	_	CD	O	-1	none	_	_
12	site	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	present	_	_	JJ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	uninduced	_	_	JJ	O	-1	none	_	_
17	myelomonocytic	_	_	JJ	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	lines	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	changed	_	_	VBN	O	-1	none	_	_
24	after	_	_	IN	O	-1	none	_	_
25	PMA	_	_	NN	O	-1	none	_	_
26	induction	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	PMA	_	_	NN	O	-1	none	_	_
3	induction	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	c-fos	_	_	NN	Protein	-1	none	_	_
6	mRNA	_	_	NN	O	-1	none	_	_
7	correlated	_	_	VBD	O	-1	none	_	_
8	well	_	_	RB	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	TNF	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	;	_	_	:	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	encoding	_	_	VBG	O	-1	none	_	_
18	other	_	_	JJ	O	-1	none	_	_
19	proteins	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	AP-1	_	_	NN	O	-1	none	_	_
23	complex	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	junB	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	junD	_	_	NN	Protein	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	were	_	_	VBD	O	-1	none	_	_
30	also	_	_	RB	O	-1	none	_	_
31	induced	_	_	VBN	O	-1	none	_	_
32	by	_	_	IN	O	-1	none	_	_
33	PMA	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	nuclear	_	_	JJ	O	-1	none	_	_
3	extracts	_	_	NNS	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	resting	_	_	VBG	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	induced	_	_	VBN	O	-1	none	_	_
8	ML-1	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	contain	_	_	VBP	O	-1	none	_	_
11	proteins	_	_	NNS	O	-1	none	_	_
12	binding	_	_	VBG	O	-1	none	_	_
13	specifically	_	_	RB	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	AP-2	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	NF	_	_	NN	O	-1	none	_	_
22	kappa	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	sequence	_	_	NN	O	-1	none	_	_
25	located	_	_	JJ	O	-1	none	_	_
26	within	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	TNF	_	_	NN	Protein	-1	none	_	_
29	promoter	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	PMA	_	_	NN	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	increases	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	level	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	number	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	specific	_	_	JJ	O	-1	none	_	_
11	binding	_	_	VBG	O	-1	none	_	_
12	complexes	_	_	NNS	O	-1	none	_	_
13	relative	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	resting	_	_	VBG	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	regulatory	_	_	JJ	O	-1	none	_	_
3	mechanisms	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	murine	_	_	JJ	O	-1	none	_	_
9	TNF	_	_	NN	Protein	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	discussed	_	_	VBN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Interferon-beta	_	_	NN	Protein	-1	none	_	_
2	mediates	_	_	VBZ	O	-1	none	_	_
3	stromal	_	_	JJ	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	rescue	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	apoptosis	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	resolution	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	immune	_	_	JJ	O	-1	none	_	_
5	responses	_	_	NNS	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	characterized	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	extensive	_	_	JJ	O	-1	none	_	_
10	apoptosis	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	generate	_	_	VB	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	maintain	_	_	VB	O	-1	none	_	_
7	immunological	_	_	JJ	O	-1	none	_	_
8	memory	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	some	_	_	DT	O	-1	none	_	_
11	antigen	_	_	NN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	must	_	_	MD	O	-1	none	_	_
16	survive	_	_	VB	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	revert	_	_	VB	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	resting	_	_	VBG	O	-1	none	_	_
22	G0/G1	_	_	NN	O	-1	none	_	_
23	state	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Cytokines	_	_	NNS	O	-1	none	_	_
2	that	_	_	WDT	O	-1	none	_	_
3	bind	_	_	VBP	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	common	_	_	JJ	O	-1	none	_	_
7	gamma	_	_	NN	O	-1	none	_	_
8	chain	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	IL-2	_	_	NN	Protein	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	promote	_	_	VBP	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	survival	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	blasts	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	also	_	_	RB	O	-1	none	_	_
23	induce	_	_	VBP	O	-1	none	_	_
24	proliferation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	soluble	_	_	JJ	O	-1	none	_	_
5	factors	_	_	NNS	O	-1	none	_	_
6	secreted	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	stromal	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	induce	_	_	VBP	O	-1	none	_	_
11	Tcell	_	_	NN	O	-1	none	_	_
12	survival	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	resting	_	_	VBG	O	-1	none	_	_
16	G0/G1	_	_	NN	O	-1	none	_	_
17	state	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	interferon-beta	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	principal	_	_	JJ	O	-1	none	_	_
9	mediator	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	stromal	_	_	JJ	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	Tcell	_	_	NNP	O	-1	none	_	_
15	rescue	_	_	NN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	apoptosis	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Interferon-alpha	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	-beta	_	_	NN	O	-1	none	_	_
4	promote	_	_	VBP	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	reversion	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	blast	_	_	NN	O	-1	none	_	_
9	Tcells	_	_	NNS	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	resting	_	_	VBG	O	-1	none	_	_
13	G0/G1	_	_	NN	O	-1	none	_	_
14	configuration	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	all	_	_	PDT	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	characteristic	_	_	JJ	O	-1	none	_	_
19	features	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	stromal	_	_	JJ	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	rescue	_	_	NN	O	-1	none	_	_
24	;	_	_	:	O	-1	none	_	_
25	such	_	_	JJ	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	high	_	_	JJ	O	-1	none	_	_
28	Bcl-XL	_	_	NN	Protein	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	low	_	_	JJ	O	-1	none	_	_
32	Bcl-2	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Type	_	_	NN	O	-1	none	_	_
2	I	_	_	CD	O	-1	none	_	_
3	interferons	_	_	NNS	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	stromal	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	stimulate	_	_	VBP	O	-1	none	_	_
8	apparently	_	_	RB	O	-1	none	_	_
9	identical	_	_	JJ	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	pathways	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	leading	_	_	VBG	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	STAT-1	_	_	NN	Protein	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	mechanism	_	_	NN	O	-1	none	_	_
7	may	_	_	MD	O	-1	none	_	_
8	play	_	_	VB	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	fundamental	_	_	JJ	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	persistence	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	sites	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	chronic	_	_	JJ	O	-1	none	_	_
22	inflammation	_	_	NN	O	-1	none	_	_
23	;	_	_	:	O	-1	none	_	_
24	suggesting	_	_	VBG	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	chronic	_	_	JJ	O	-1	none	_	_
27	inflammation	_	_	NN	O	-1	none	_	_
28	is	_	_	VBZ	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	aberrant	_	_	JJ	O	-1	none	_	_
31	consequence	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	immunological	_	_	JJ	O	-1	none	_	_
34	memory	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Abnormalities	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cyclic	_	_	JJ	O	-1	none	_	_
4	adenosine	_	_	NN	O	-1	none	_	_
5	monophosphate	_	_	NN	O	-1	none	_	_
6	signaling	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	platelets	_	_	NNS	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	untreated	_	_	JJ	O	-1	none	_	_
11	patients	_	_	NNS	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	bipolar	_	_	JJ	O	-1	none	_	_
14	disorder	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Abnormalities	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cyclic	_	_	JJ	O	-1	none	_	_
7	adenosine	_	_	NN	O	-1	none	_	_
8	monophosphate	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	cAMP	_	_	NN	O	-1	none	_	_
11	)-dependent	_	_	JJ	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	system	_	_	NN	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	been	_	_	VBN	O	-1	none	_	_
16	recently	_	_	RB	O	-1	none	_	_
17	reported	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	bipolar	_	_	JJ	O	-1	none	_	_
22	disorder	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	evaluated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	immunoreactivity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	regulatory	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	catalytic	_	_	JJ	O	-1	none	_	_
10	subunits	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	cAMP	_	_	NN	O	-1	none	_	_
13	dependent	_	_	JJ	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	kinase	_	_	NN	O	-1	none	_	_
19	A	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	1	_	_	CD	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	its	_	_	PRP$	O	-1	none	_	_
25	substrates	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	Rap1	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	platelets	_	_	NNS	O	-1	none	_	_
31	from	_	_	IN	O	-1	none	_	_
32	untreated	_	_	JJ	O	-1	none	_	_
33	euthymic	_	_	JJ	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	manic	_	_	JJ	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	depressed	_	_	JJ	O	-1	none	_	_
39	patients	_	_	NNS	O	-1	none	_	_
40	with	_	_	IN	O	-1	none	_	_
41	bipolar	_	_	JJ	O	-1	none	_	_
42	disorder	_	_	NN	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	healthy	_	_	JJ	O	-1	none	_	_
45	subjects	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Platelets	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	collected	_	_	VBN	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	112	_	_	CD	O	-1	none	_	_
8	drug-free	_	_	JJ	O	-1	none	_	_
9	patients	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	bipolar	_	_	JJ	O	-1	none	_	_
12	disorder	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	52	_	_	CD	O	-1	none	_	_
15	euthymic	_	_	JJ	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	29	_	_	CD	O	-1	none	_	_
18	depressed	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	31	_	_	CD	O	-1	none	_	_
22	manic	_	_	JJ	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	62	_	_	CD	O	-1	none	_	_
26	healthy	_	_	JJ	O	-1	none	_	_
27	subjects	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	cAMP	_	_	NN	O	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Rap1	_	_	NN	Protein	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	assessed	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	Western	_	_	NN	O	-1	none	_	_
14	blot	_	_	NN	O	-1	none	_	_
15	analysis	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	immunostaining	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	computer	_	_	NN	O	-1	none	_	_
21	assisted	_	_	VBN	O	-1	none	_	_
22	imaging	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	immunolabeling	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	catalytic	_	_	JJ	O	-1	none	_	_
8	subunit	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	cAMP	_	_	NN	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	kinase	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	significantly	_	_	RB	O	-1	none	_	_
16	different	_	_	JJ	O	-1	none	_	_
17	among	_	_	IN	O	-1	none	_	_
18	groups	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	P	_	_	NN	O	-1	none	_	_
21	<	_	_	JJR	O	-1	none	_	_
22	.001	_	_	CD	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	higher	_	_	JJR	O	-1	none	_	_
27	values	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	untreated	_	_	JJ	O	-1	none	_	_
30	depressed	_	_	JJ	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	manic	_	_	JJ	O	-1	none	_	_
33	patients	_	_	NNS	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	bipolar	_	_	JJ	O	-1	none	_	_
36	disorder	_	_	NN	O	-1	none	_	_
37	compared	_	_	VBN	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	untreated	_	_	JJ	O	-1	none	_	_
40	euthymic	_	_	JJ	O	-1	none	_	_
41	patients	_	_	NNS	O	-1	none	_	_
42	with	_	_	IN	O	-1	none	_	_
43	bipolar	_	_	JJ	O	-1	none	_	_
44	disorder	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	healthy	_	_	JJ	O	-1	none	_	_
47	subjects	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	significant	_	_	JJ	O	-1	none	_	_
3	differences	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	immunolabeling	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	regulatory	_	_	JJ	O	-1	none	_	_
12	subunits	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	type	_	_	NN	O	-1	none	_	_
15	I	_	_	CD	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	type	_	_	NN	O	-1	none	_	_
18	II	_	_	CD	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	cAMP	_	_	NN	O	-1	none	_	_
22	dependent	_	_	JJ	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	kinase	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	immunolabeling	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Rap1	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	significantly	_	_	RB	O	-1	none	_	_
7	higher	_	_	JJR	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	P	_	_	NN	O	-1	none	_	_
10	<	_	_	JJR	O	-1	none	_	_
11	.001	_	_	CD	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	untreated	_	_	JJ	O	-1	none	_	_
15	euthymic	_	_	JJ	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	depressed	_	_	JJ	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	manic	_	_	JJ	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	than	_	_	IN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	healthy	_	_	JJ	O	-1	none	_	_
25	persons	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Levels	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	Rap1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	catalytic	_	_	JJ	O	-1	none	_	_
9	subunit	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cAMP	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	kinase	_	_	NN	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	altered	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	platelets	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	bipolar	_	_	JJ	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	may	_	_	MD	O	-1	none	_	_
4	provide	_	_	VB	O	-1	none	_	_
5	clues	_	_	NNS	O	-1	none	_	_
6	toward	_	_	IN	O	-1	none	_	_
7	understanding	_	_	VBG	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	involvement	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cAMP	_	_	NN	O	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	pathogenesis	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	bipolar	_	_	JJ	O	-1	none	_	_
18	disorder	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	characteristics	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	glucocorticoid	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	in	_	_	IN	O	-1	none	_	_
8	peripheral	_	_	JJ	O	-1	none	_	_
9	blood	_	_	NN	O	-1	none	_	_
10	lymphocytes	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	multiple	_	_	JJ	O	-1	none	_	_
13	sclerosis	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	exact	_	_	JJ	O	-1	none	_	_
4	etiology	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	multiple	_	_	JJ	O	-1	none	_	_
7	sclerosis	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	MS	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	remains	_	_	VBZ	O	-1	none	_	_
12	unresolved	_	_	JJ	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	immune	_	_	JJ	O	-1	none	_	_
15	reactions	_	_	NNS	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	believed	_	_	VBN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	central	_	_	JJ	O	-1	none	_	_
22	pathogenic	_	_	JJ	O	-1	none	_	_
23	mechanisms	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Endogenous	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	therapeutic	_	_	JJ	O	-1	none	_	_
4	steroid	_	_	NN	O	-1	none	_	_
5	hormones	_	_	NNS	O	-1	none	_	_
6	affect	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	immune	_	_	JJ	O	-1	none	_	_
9	system	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	inflammatory	_	_	JJ	O	-1	none	_	_
13	diseases	_	_	NNS	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	associated	_	_	VBN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
21	axis	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	providing	_	_	VBG	O	-1	none	_	_
24	evidence	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	an	_	_	DT	O	-1	none	_	_
27	immune-endocrine	_	_	JJ	O	-1	none	_	_
28	interplay	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Function	_	_	NN	O	-1	none	_	_
2	tests	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	MS	_	_	NN	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	revealed	_	_	VBN	O	-1	none	_	_
7	dysregulation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
11	system	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	substantial	_	_	JJ	O	-1	none	_	_
15	proportion	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	characterized	_	_	VBD	O	-1	none	_	_
3	glucocorticoid	_	_	NN	Protein	4	multitoken	_	_
4	receptor	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	GR	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	peripheral	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	39	_	_	CD	O	-1	none	_	_
15	MS	_	_	NN	O	-1	none	_	_
16	patients	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	14	_	_	CD	O	-1	none	_	_
19	age-	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	sex	_	_	NN	O	-1	none	_	_
22	matched	_	_	JJ	O	-1	none	_	_
23	controls	_	_	NNS	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	respect	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	dissociation	_	_	NN	O	-1	none	_	_
28	constant	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	capacity	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	using	_	_	VBG	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	whole-cell	_	_	JJ	O	-1	none	_	_
36	binding	_	_	NN	O	-1	none	_	_
37	assay	_	_	NN	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	[	_	_	NN	O	-1	none	_	_
40	3H	_	_	NN	O	-1	none	_	_
41	]	_	_	CD	O	-1	none	_	_
42	dexamethasone	_	_	NN	O	-1	none	_	_
43	as	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	ligand	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	GR	_	_	NN	Protein	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	parameters	_	_	NNS	O	-1	none	_	_
4	did	_	_	VBD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	differ	_	_	VB	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	between	_	_	IN	O	-1	none	_	_
9	patients	_	_	NNS	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	Kd	_	_	NN	O	-1	none	_	_
12	8.98	_	_	CD	O	-1	none	_	_
13	+/-	_	_	CC	O	-1	none	_	_
14	1.07	_	_	CD	O	-1	none	_	_
15	nM	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	Bmax	_	_	NN	O	-1	none	_	_
18	183	_	_	CD	O	-1	none	_	_
19	+/-	_	_	CC	O	-1	none	_	_
20	29.8	_	_	CD	O	-1	none	_	_
21	fmol/mg	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	controls	_	_	VBZ	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	Kd	_	_	NN	O	-1	none	_	_
27	9.36	_	_	CD	O	-1	none	_	_
28	+/-	_	_	CC	O	-1	none	_	_
29	1.17	_	_	CD	O	-1	none	_	_
30	nM	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	Bmax	_	_	NN	O	-1	none	_	_
33	158	_	_	CD	O	-1	none	_	_
34	+/-	_	_	CC	O	-1	none	_	_
35	16	_	_	CD	O	-1	none	_	_
36	fmol/mg	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	age	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	sex	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	course	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	duration	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	severity	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	disease	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	prior	_	_	RB	O	-1	none	_	_
18	steroid	_	_	NN	O	-1	none	_	_
19	treatments	_	_	NNS	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	detected	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	GR	_	_	NN	Protein	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	parameters	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	analyzed	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	relation	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	results	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	combined	_	_	JJ	O	-1	none	_	_
14	dexamethasone-CRH	_	_	JJ	Protein	-1	none	_	_
15	test	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	reflects	_	_	VBZ	O	-1	none	_	_
19	corticosteroid	_	_	NN	O	-1	none	_	_
20	receptor	_	_	NN	O	-1	none	_	_
21	function	_	_	NN	O	-1	none	_	_
22	at	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	hypothalamus	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	30	_	_	CD	O	-1	none	_	_
28	patients	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	9	_	_	CD	O	-1	none	_	_
31	controls	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	controls	_	_	NNS	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	moderate	_	_	JJ	O	-1	none	_	_
6	correlation	_	_	NN	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	affinity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	GR	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	regulatory	_	_	JJ	O	-1	none	_	_
17	function	_	_	NN	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	hypothalamic	_	_	JJ	O	-1	none	_	_
21	level	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	patients	_	_	NNS	O	-1	none	_	_
25	did	_	_	VBD	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	physiological	_	_	JJ	O	-1	none	_	_
7	relationship	_	_	NN	O	-1	none	_	_
8	between	_	_	IN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	function	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	glucocorticoid	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	disturbed	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	MS.	_	_	NNP	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	factor-kappaB	_	_	NN	O	-1	none	_	_
5	via	_	_	IN	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	requires	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	Raf	_	_	NN	O	-1	none	_	_
12	kinase	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	Ca2+	_	_	NN	O	-1	none	_	_
15	influx	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	synergy	_	_	NN	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	Raf	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	calcineurin	_	_	NN	O	-1	none	_	_
7	.	_	_	.	O	-1	none	_	_

1	Signals	_	_	NNS	O	-1	none	_	_
2	transduced	_	_	VBN	O	-1	none	_	_
3	via	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	TCR	_	_	NN	O	-1	none	_	_
6	activate	_	_	VBP	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	factor-kappaB	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	turn	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	critical	_	_	JJ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	transcriptional	_	_	JJ	O	-1	none	_	_
26	induction	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	many	_	_	JJ	O	-1	none	_	_
29	genes	_	_	NNS	O	-1	none	_	_
30	important	_	_	JJ	O	-1	none	_	_
31	for	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	proliferation	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	expression	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	differentiated	_	_	JJ	O	-1	none	_	_
39	phenotype	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	C	_	_	NN	O	-1	none	_	_
10	activator	_	_	NN	O	-1	none	_	_
11	PMA	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	combination	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	Ca2+	_	_	NN	O	-1	none	_	_
16	ionophores	_	_	NNS	O	-1	none	_	_
17	mimics	_	_	VBZ	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	process	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	two	_	_	CD	O	-1	none	_	_
24	agents	_	_	NNS	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	often	_	_	RB	O	-1	none	_	_
27	substituted	_	_	VBN	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	TCR	_	_	NN	O	-1	none	_	_
30	stimulation	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	bypassing	_	_	VBG	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	TCR	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	identify	_	_	VBP	O	-1	none	_	_
4	intracellular	_	_	JJ	O	-1	none	_	_
5	signaling	_	_	NN	O	-1	none	_	_
6	components	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	NF-kappaB	_	_	NN	O	-1	none	_	_
12	following	_	_	VBG	O	-1	none	_	_
13	TCR	_	_	NN	O	-1	none	_	_
14	stimulation	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	TCR	_	_	NN	O	-1	none	_	_
2	signaling	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	triggered	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	treating	_	_	VBG	O	-1	none	_	_
7	Jurkat	_	_	NN	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	PHA	_	_	NN	Protein	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	anti-CD3	_	_	JJ	Protein	-1	none	_	_
14	Abs	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	was	_	_	VBD	O	-1	none	_	_
20	monitored	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	electrophoretic	_	_	JJ	O	-1	none	_	_
23	mobility	_	_	NN	O	-1	none	_	_
24	shift	_	_	NN	O	-1	none	_	_
25	assays	_	_	NNS	O	-1	none	_	_
26	and/or	_	_	CC	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	kappaB	_	_	NN	O	-1	none	_	_
29	dependent	_	_	JJ	O	-1	none	_	_
30	reporter	_	_	NN	O	-1	none	_	_
31	assays	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Contrary	_	_	JJ	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	idea	_	_	NN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	C	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	involved	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	high	_	_	JJ	O	-1	none	_	_
19	doses	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	staurosporine	_	_	NN	O	-1	none	_	_
22	did	_	_	VBD	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	interfere	_	_	VB	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	NF-kappaB	_	_	NN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	PHA	_	_	NN	Protein	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	while	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	same	_	_	JJ	O	-1	none	_	_
35	dose	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	staurosporine	_	_	NN	O	-1	none	_	_
38	completely	_	_	RB	O	-1	none	_	_
39	blocked	_	_	VBD	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	PMA	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	PHA	_	_	NN	Protein	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	kappaB	_	_	NN	O	-1	none	_	_
4	dependent	_	_	JJ	O	-1	none	_	_
5	reporter	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	however	_	_	RB	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	effectively	_	_	RB	O	-1	none	_	_
12	blocked	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	dominant	_	_	JJ	O	-1	none	_	_
16	negative	_	_	JJ	O	-1	none	_	_
17	form	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	Raf-1	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	suggesting	_	_	VBG	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	critical	_	_	JJ	O	-1	none	_	_
24	role	_	_	NN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	Raf	_	_	NN	O	-1	none	_	_
28	kinase	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	TCR	_	_	NN	O	-1	none	_	_
3	mediated	_	_	JJ	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	NF-kappaB	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	dependent	_	_	JJ	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	Ca2+	_	_	NN	O	-1	none	_	_
13	influx	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	because	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	Ca2+	_	_	NN	O	-1	none	_	_
18	channel	_	_	NN	O	-1	none	_	_
19	blocker	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	SK&F	_	_	NN	O	-1	none	_	_
22	96365	_	_	CD	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	as	_	_	RB	O	-1	none	_	_
25	well	_	_	RB	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	other	_	_	JJ	O	-1	none	_	_
28	agents	_	_	NNS	O	-1	none	_	_
29	that	_	_	WDT	O	-1	none	_	_
30	prevented	_	_	VBD	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	Ca2+	_	_	NN	O	-1	none	_	_
33	influx	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	inhibited	_	_	VBD	O	-1	none	_	_
36	NF-kappaB	_	_	NN	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Cotransfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	constitutively	_	_	RB	O	-1	none	_	_
5	active	_	_	JJ	O	-1	none	_	_
6	form	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	calcineurin	_	_	NN	O	-1	none	_	_
9	largely	_	_	RB	O	-1	none	_	_
10	substituted	_	_	VBN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	Ca2+	_	_	NN	O	-1	none	_	_
14	requirement	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	reversed	_	_	VBD	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	blockade	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	SK&F	_	_	NN	O	-1	none	_	_
21	96365	_	_	CD	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Consistent	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	observations	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	coexpression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	constitutively	_	_	RB	O	-1	none	_	_
9	active	_	_	JJ	O	-1	none	_	_
10	forms	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	Raf-1	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	calcineurin	_	_	NN	O	-1	none	_	_
15	synergistically	_	_	RB	O	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	kappaB	_	_	NN	O	-1	none	_	_
18	dependent	_	_	JJ	O	-1	none	_	_
19	reporter	_	_	NN	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	physiologically	_	_	RB	O	-1	none	_	_
25	relevant	_	_	JJ	O	-1	none	_	_
26	functional	_	_	JJ	O	-1	none	_	_
27	interaction	_	_	NN	O	-1	none	_	_
28	between	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	kinase	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	phosphatase	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	distinct	_	_	JJ	O	-1	none	_	_
3	forms	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	active	_	_	JJ	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	CREB	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	cAMP	_	_	NN	Protein	14	multitoken	_	_
11	response	_	_	NN	Protein	14	multitoken	_	_
12	element	_	_	NN	Protein	14	multitoken	_	_
13	binding	_	_	NN	Protein	14	multitoken	_	_
14	protein	_	_	NN	Protein	0	root	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Mammalian	_	_	JJ	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	express	_	_	VBP	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	distinct	_	_	JJ	O	-1	none	_	_
6	forms	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	CREB	_	_	NN	Protein	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	cAMP	_	_	NN	Protein	16	multitoken	_	_
13	response	_	_	NN	Protein	16	multitoken	_	_
14	element	_	_	NN	Protein	16	multitoken	_	_
15	binding	_	_	NN	Protein	16	multitoken	_	_
16	protein	_	_	NN	Protein	0	root	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	apparently	_	_	RB	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	products	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	alternative	_	_	JJ	O	-1	none	_	_
25	splicing	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	CREB	_	_	NN	Protein	-1	none	_	_
29	gene	_	_	NN	O	-1	none	_	_
30	transcript	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	two	_	_	CD	O	-1	none	_	_
3	proteins	_	_	NNS	O	-1	none	_	_
4	differ	_	_	VBP	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	14-amino	_	_	NN	O	-1	none	_	_
8	acid	_	_	NN	O	-1	none	_	_
9	serine	_	_	NN	O	-1	none	_	_
10	rich	_	_	JJ	O	-1	none	_	_
11	insertion	_	_	NN	O	-1	none	_	_
12	present	_	_	JJ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	one	_	_	CD	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	CREB	_	_	NN	Protein	-1	none	_	_
18	isoforms	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	CREB	_	_	NN	Protein	-1	none	_	_
6	isoforms	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	many	_	_	JJ	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	types	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	mammalian	_	_	JJ	O	-1	none	_	_
15	species	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	encode	_	_	VBP	O	-1	none	_	_
3	proteins	_	_	NNS	O	-1	none	_	_
4	that	_	_	WDT	O	-1	none	_	_
5	bind	_	_	VBP	O	-1	none	_	_
6	specifically	_	_	RB	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cAMP	_	_	NN	O	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	element	_	_	NN	O	-1	none	_	_
12	in	_	_	FW	O	-1	none	_	_
13	vitro	_	_	FW	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	expected	_	_	VBN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	proteins	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	class	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	CREB	_	_	NN	Protein	-1	none	_	_
11	proteins	_	_	NNS	O	-1	none	_	_
12	bind	_	_	VBP	O	-1	none	_	_
13	DNA	_	_	NN	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	dimers	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	proteins	_	_	NNS	O	-1	none	_	_
3	impart	_	_	VBP	O	-1	none	_	_
4	cAMP	_	_	NN	O	-1	none	_	_
5	regulated	_	_	VBN	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	heterologous	_	_	JJ	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	domain	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	showing	_	_	VBG	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	cAMP	_	_	NN	O	-1	none	_	_
18	directly	_	_	RB	O	-1	none	_	_
19	modulates	_	_	VBZ	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	transcriptional	_	_	JJ	O	-1	none	_	_
22	stimulatory	_	_	JJ	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	CREB	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	presence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	multiple	_	_	JJ	O	-1	none	_	_
5	CREB	_	_	NN	Protein	-1	none	_	_
6	isoforms	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	identical	_	_	JJ	O	-1	none	_	_
9	DNA	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	specificities	_	_	NNS	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	differences	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	presumed	_	_	JJ	O	-1	none	_	_
17	regulatory	_	_	JJ	O	-1	none	_	_
18	domain	_	_	NN	O	-1	none	_	_
19	raises	_	_	VBZ	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	possibility	_	_	NN	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	CREB	_	_	NN	Protein	-1	none	_	_
24	proteins	_	_	NNS	O	-1	none	_	_
25	may	_	_	MD	O	-1	none	_	_
26	be	_	_	VB	O	-1	none	_	_
27	able	_	_	JJ	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	integrate	_	_	VB	O	-1	none	_	_
30	distinct	_	_	JJ	O	-1	none	_	_
31	regulatory	_	_	JJ	O	-1	none	_	_
32	signals	_	_	NNS	O	-1	none	_	_
33	at	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	level	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	gene	_	_	NN	O	-1	none	_	_
38	transcription	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Spi-C	_	_	NNP	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	novel	_	_	JJ	O	-1	none	_	_
5	Ets	_	_	NN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	temporally	_	_	RB	O	-1	none	_	_
10	regulated	_	_	VBN	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	lymphocyte	_	_	NN	O	-1	none	_	_
14	development	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	novel	_	_	JJ	O	-1	none	_	_
3	Ets	_	_	NN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	isolated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	yeast	_	_	NN	O	-1	none	_	_
9	one-hybrid	_	_	JJ	O	-1	none	_	_
10	screening	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	cDNA	_	_	NN	O	-1	none	_	_
14	library	_	_	NN	O	-1	none	_	_
15	made	_	_	VBN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	lipopolysaccharide	_	_	NN	O	-1	none	_	_
18	stimulated	_	_	VBD	O	-1	none	_	_
19	mouse	_	_	NN	O	-1	none	_	_
20	splenic	_	_	JJ	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	using	_	_	VBG	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	SP6	_	_	NN	O	-1	none	_	_
27	kappa	_	_	NN	O	-1	none	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	kappaY	_	_	NN	O	-1	none	_	_
30	element	_	_	NN	O	-1	none	_	_
31	as	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	bait	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	novel	_	_	JJ	O	-1	none	_	_
3	Ets	_	_	NN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	most	_	_	RBS	O	-1	none	_	_
7	closely	_	_	RB	O	-1	none	_	_
8	related	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	PU	_	_	NN	Protein	11	multitoken	_	_
11	.1	_	_	NN	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Spi-B	_	_	NN	Protein	-1	none	_	_
14	within	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	Ets	_	_	NN	O	-1	none	_	_
19	domain	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	was	_	_	VBD	O	-1	none	_	_
22	therefore	_	_	RB	O	-1	none	_	_
23	named	_	_	VBN	O	-1	none	_	_
24	Spi-C	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Spi-C	_	_	NN	Protein	-1	none	_	_
4	may	_	_	MD	O	-1	none	_	_
5	represent	_	_	VB	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	novel	_	_	JJ	O	-1	none	_	_
8	subgroup	_	_	NN	O	-1	none	_	_
9	within	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	Ets	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	family	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	it	_	_	PRP	O	-1	none	_	_
17	differed	_	_	VBD	O	-1	none	_	_
18	significantly	_	_	RB	O	-1	none	_	_
19	from	_	_	IN	O	-1	none	_	_
20	Spi-B	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	PU	_	_	NN	Protein	23	multitoken	_	_
23	.1	_	_	NN	Protein	0	root	_	_
24	within	_	_	IN	O	-1	none	_	_
25	helix	_	_	NN	O	-1	none	_	_
26	1	_	_	CD	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	Ets	_	_	NN	O	-1	none	_	_
30	domain	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Spi-C	_	_	NNP	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	encoded	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	single-copy	_	_	JJ	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	mapped	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	chromosome	_	_	NN	O	-1	none	_	_
13	10	_	_	CD	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	region	_	_	NN	O	-1	none	_	_
16	C.	_	_	NNP	O	-1	none	_	_
17	Spi-C	_	_	NN	Protein	-1	none	_	_
18	interacted	_	_	VBD	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	DNA	_	_	NN	O	-1	none	_	_
21	similarly	_	_	RB	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	PU	_	_	NN	Protein	24	multitoken	_	_
24	.1	_	_	NN	Protein	0	root	_	_
25	as	_	_	IN	O	-1	none	_	_
26	judged	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	methylation	_	_	NN	O	-1	none	_	_
29	interference	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	band-shift	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	site	_	_	NN	O	-1	none	_	_
34	selection	_	_	NN	O	-1	none	_	_
35	analysis	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	activated	_	_	VBD	O	-1	none	_	_
39	transcription	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	a	_	_	DT	O	-1	none	_	_
42	kappaY	_	_	NN	O	-1	none	_	_
43	element	_	_	NN	O	-1	none	_	_
44	reporter	_	_	NN	O	-1	none	_	_
45	gene	_	_	NN	O	-1	none	_	_
46	upon	_	_	IN	O	-1	none	_	_
47	co-transfection	_	_	NN	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	HeLa	_	_	NN	O	-1	none	_	_
50	cells	_	_	NNS	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	Spi-C	_	_	NNP	Protein	-1	none	_	_
2	RNA	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	expressed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	mature	_	_	JJ	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	lymphocytes	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	lower	_	_	JJR	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	macrophages	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Cloning	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	murine	_	_	JJ	O	-1	none	_	_
4	TCF-1	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	interacting	_	_	VBG	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	functional	_	_	JJ	O	-1	none	_	_
15	motifs	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	CD3-epsilon	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	alpha	_	_	NN	O	-1	none	_	_
24	enhancers	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	CD3-epsilon	_	_	NN	Protein	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	confined	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	lineage	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	identified	_	_	VBN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	cloned	_	_	VBN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	TCF-1	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	binds	_	_	VBZ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	functional	_	_	JJ	O	-1	none	_	_
19	element	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	lymphocyte	_	_	NN	O	-1	none	_	_
24	specific	_	_	JJ	O	-1	none	_	_
25	enhancer	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	CD3-epsilon	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	panel	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	lines	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	TCF-1	_	_	NN	Protein	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	restricted	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lineage	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	TCF-1	_	_	NNP	Protein	-1	none	_	_
2	belonged	_	_	VBD	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	novel	_	_	JJ	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	contain	_	_	VBP	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	so	_	_	RB	O	-1	none	_	_
13	called	_	_	VBN	O	-1	none	_	_
14	high	_	_	JJ	O	-1	none	_	_
15	mobility	_	_	NN	O	-1	none	_	_
16	group	_	_	NN	O	-1	none	_	_
17	1	_	_	CD	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	HMG	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	box	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	cloning	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	murine	_	_	JJ	O	-1	none	_	_
8	TCF-1	_	_	NN	Protein	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	splice	_	_	NN	O	-1	none	_	_
3	alternatives	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	identified	_	_	VBN	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	previously	_	_	RB	O	-1	none	_	_
10	observed	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	TCF-1	_	_	NN	Protein	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Murine	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	TCF-1	_	_	NN	Protein	-1	none	_	_
5	displayed	_	_	VBD	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	95.5	_	_	CD	O	-1	none	_	_
8	%	_	_	NN	O	-1	none	_	_
9	overall	_	_	JJ	O	-1	none	_	_
10	amino	_	_	NN	O	-1	none	_	_
11	acid	_	_	NN	O	-1	none	_	_
12	homology	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Recombinant	_	_	JJ	O	-1	none	_	_
2	murine	_	_	JJ	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	TCF-1	_	_	NN	Protein	-1	none	_	_
6	recognized	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	same	_	_	JJ	O	-1	none	_	_
9	sequence	_	_	NN	O	-1	none	_	_
10	motif	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	CD3-epsilon	_	_	NN	O	-1	none	_	_
14	enhancer	_	_	NN	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	judged	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	gel	_	_	NN	O	-1	none	_	_
19	retardation	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	methylation	_	_	NN	O	-1	none	_	_
22	interference	_	_	NN	O	-1	none	_	_
23	assays	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	With	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	murine	_	_	JJ	O	-1	none	_	_
4	cDNA	_	_	NN	O	-1	none	_	_
5	clones	_	_	NNS	O	-1	none	_	_
6	several	_	_	JJ	O	-1	none	_	_
7	aspects	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	TCF-1	_	_	NN	Protein	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	analyzed	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	First	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	deletion	_	_	NN	O	-1	none	_	_
4	analysis	_	_	NN	O	-1	none	_	_
5	revealed	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	region	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	TCF-1	_	_	NN	Protein	-1	none	_	_
11	containing	_	_	VBG	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	HMG	_	_	NN	O	-1	none	_	_
14	box	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	sufficient	_	_	JJ	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	sequence	_	_	NN	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Second	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	high	_	_	JJ	O	-1	none	_	_
5	stringency	_	_	NN	O	-1	none	_	_
6	Northern	_	_	NN	O	-1	none	_	_
7	blotting	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	in	_	_	FW	O	-1	none	_	_
10	situ	_	_	FW	O	-1	none	_	_
11	hybridization	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	TCF-1	_	_	NN	Protein	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	shown	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	confined	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	thymus	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	areas	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	spleen	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Third	_	_	NNP	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	TCF-1	_	_	NN	Protein	-1	none	_	_
4	bound	_	_	VBD	O	-1	none	_	_
5	specifically	_	_	RB	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	functional	_	_	JJ	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	element	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	T	_	_	NN	Protein	18	multitoken	_	_
16	cell	_	_	NN	Protein	18	multitoken	_	_
17	receptor	_	_	NN	Protein	18	multitoken	_	_
18	alpha	_	_	NN	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	TCR-alpha	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	enhancer	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	lineage	_	_	NN	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	affinity	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	functional	_	_	JJ	O	-1	none	_	_
11	motifs	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	TCR-alpha	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	CD3-epsilon	_	_	NN	Protein	-1	none	_	_
17	enhancers	_	_	NNS	O	-1	none	_	_
18	imply	_	_	VBP	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	important	_	_	JJ	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	TCF-1	_	_	NN	Protein	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	establishment	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	mature	_	_	JJ	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	phenotype	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Visualization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	endogenous	_	_	JJ	O	-1	none	_	_
5	NF-kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	p50	_	_	NN	Protein	-1	none	_	_
8	subunit	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	nucleus	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	follicular	_	_	JJ	O	-1	none	_	_
14	dendritic	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	germinal	_	_	JJ	O	-1	none	_	_
18	centers	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	50	_	_	CD	O	-1	none	_	_
6	kDa/65	_	_	CD	O	-1	none	_	_
7	kDa	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	p50	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p65	_	_	NN	Protein	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	heterodimer	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	ubiquitous	_	_	JJ	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	involved	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	positive	_	_	JJ	O	-1	none	_	_
24	regulation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	various	_	_	JJ	O	-1	none	_	_
27	immune	_	_	JJ	O	-1	none	_	_
28	genes	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aim	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	determine	_	_	VB	O	-1	none	_	_
9	whether	_	_	IN	O	-1	none	_	_
10	NF-kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	related	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	particular	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	type	_	_	NN	O	-1	none	_	_
19	and/or	_	_	CC	O	-1	none	_	_
20	differentiation	_	_	NN	O	-1	none	_	_
21	step	_	_	NN	O	-1	none	_	_
22	during	_	_	IN	O	-1	none	_	_
23	immunopoiesis	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	in	_	_	FW	O	-1	none	_	_
3	situ	_	_	FW	O	-1	none	_	_
4	hybridization	_	_	NN	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	sections	_	_	NNS	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	non	_	_	JJ	O	-1	none	_	_
9	HIV	_	_	NN	O	-1	none	_	_
10	hyperplastic	_	_	JJ	O	-1	none	_	_
11	lymph	_	_	NN	O	-1	none	_	_
12	nodes	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	found	_	_	VBD	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	105	_	_	CD	O	-1	none	_	_
22	kDa	_	_	NN	O	-1	none	_	_
23	precursor	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	p50	_	_	NN	Protein	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	overexpressed	_	_	VBN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	light	_	_	JJ	O	-1	none	_	_
31	zone	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	germinal	_	_	JJ	O	-1	none	_	_
34	centers	_	_	NNS	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	network	_	_	NN	O	-1	none	_	_
39	aspect	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	which	_	_	WDT	O	-1	none	_	_
42	suggested	_	_	VBD	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	involvement	_	_	NN	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	follicular	_	_	JJ	O	-1	none	_	_
47	dendritic	_	_	JJ	O	-1	none	_	_
48	cells	_	_	NNS	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	FDC	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	immunohistochemistry	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	p50	_	_	NN	Protein	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	detected	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cytoplasm	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	nucleus	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	FDC	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	confirming	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	involvement	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	FDC	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	p50	_	_	NN	Protein	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	detected	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	cytoplasm	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	all	_	_	DT	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	focused	_	_	VBD	O	-1	none	_	_
5	our	_	_	PRP$	O	-1	none	_	_
6	study	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	isolated	_	_	VBN	O	-1	none	_	_
9	FDC	_	_	NN	O	-1	none	_	_
10	clusters	_	_	NNS	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	normal	_	_	JJ	O	-1	none	_	_
13	tonsils	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	showed	_	_	VBN	O	-1	none	_	_
3	on	_	_	IN	O	-1	none	_	_
4	tissue	_	_	NN	O	-1	none	_	_
5	sections	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	detected	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	p50	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	both	_	_	CC	O	-1	none	_	_
13	cytoplasm	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	nucleus	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	FDC	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Nuclei	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	lymphocytes	_	_	NNS	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	FDC	_	_	NN	O	-1	none	_	_
6	clusters	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	negative	_	_	JJ	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	next	_	_	RB	O	-1	none	_	_
3	studied	_	_	VBD	O	-1	none	_	_
4	p65	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	c-Rel	_	_	NN	Protein	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	FDC	_	_	NN	O	-1	none	_	_
11	clusters	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	p65	_	_	NN	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	detected	_	_	VBN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	cytoplasm	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	FDC	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	whereas	_	_	IN	O	-1	none	_	_
11	nuclei	_	_	NNS	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	negative	_	_	JJ	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	p65	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	detected	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	nuclei	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	some	_	_	DT	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	c-Rel	_	_	NNP	Protein	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	detected	_	_	VBN	O	-1	none	_	_
5	only	_	_	RB	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	cytoplasm	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	lymphocytes	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	nucleus	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	cytoplasm	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	FDC	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	context	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	immunopoiesis	_	_	NN	O	-1	none	_	_
16	occurring	_	_	VBG	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	FDC	_	_	NN	O	-1	none	_	_
19	clusters	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	p50	_	_	NN	Protein	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	mainly	_	_	RB	O	-1	none	_	_
24	related	_	_	JJ	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	FDC	_	_	NN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	massive	_	_	JJ	O	-1	none	_	_
30	overexpression	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	nuclei	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	whereas	_	_	IN	O	-1	none	_	_
36	p65	_	_	NN	Protein	-1	none	_	_
37	is	_	_	VBZ	O	-1	none	_	_
38	expressed	_	_	VBN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	scattered	_	_	JJ	O	-1	none	_	_
42	manner	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	nuclei	_	_	NNS	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	lymphocytes	_	_	NNS	O	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	c-Rel	_	_	NN	Protein	-1	none	_	_
50	protein	_	_	NN	O	-1	none	_	_
51	exclusively	_	_	RB	O	-1	none	_	_
52	in	_	_	IN	O	-1	none	_	_
53	the	_	_	DT	O	-1	none	_	_
54	cytoplasm	_	_	NN	O	-1	none	_	_
55	of	_	_	IN	O	-1	none	_	_
56	lymphocytes	_	_	NNS	O	-1	none	_	_
57	from	_	_	IN	O	-1	none	_	_
58	FDC	_	_	NN	O	-1	none	_	_
59	clusters	_	_	NNS	O	-1	none	_	_
60	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggested	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	subunits	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	c-Rel	_	_	NN	Protein	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	have	_	_	VBP	O	-1	none	_	_
16	different	_	_	JJ	O	-1	none	_	_
17	roles	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	different	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	types	_	_	NNS	O	-1	none	_	_
22	during	_	_	IN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	immunopoiesis	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	O	-1	none	_	_
2	hormone	_	_	NN	O	-1	none	_	_
3	suppression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	neutrophil	_	_	NN	O	-1	none	_	_
7	mediated	_	_	VBN	O	-1	none	_	_
8	tumor	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	cytostasis	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	have	_	_	VBP	O	-1	none	_	_
8	investigated	_	_	VBN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	effect	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	glucocorticoid	_	_	NN	O	-1	none	_	_
13	hormones	_	_	NNS	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	neutrophil	_	_	NN	O	-1	none	_	_
16	mediated	_	_	VBN	O	-1	none	_	_
17	tumor	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	cytostasis	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	found	_	_	VBD	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	hydrocortisone	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	synthetic	_	_	JJ	O	-1	none	_	_
27	hormone	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	dexamethasone	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	Dex	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	inhibited	_	_	VBD	O	-1	none	_	_
35	cytostasis	_	_	NN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	presence	_	_	NN	O	-1	none	_	_
39	or	_	_	CC	O	-1	none	_	_
40	absence	_	_	NN	O	-1	none	_	_
41	of	_	_	IN	O	-1	none	_	_
42	tumor	_	_	NN	Protein	44	multitoken	_	_
43	necrosis	_	_	NN	Protein	44	multitoken	_	_
44	factor-alpha	_	_	NN	Protein	0	root	_	_
45	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Dex	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	completely	_	_	RB	O	-1	none	_	_
7	reversed	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	glucocorticoid	_	_	NN	Protein	11	multitoken	_	_
11	receptor	_	_	NN	Protein	0	root	_	_
12	antagonist	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	RU38486	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	clarify	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	underlying	_	_	JJ	O	-1	none	_	_
5	mechanisms	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	examined	_	_	VBD	O	-1	none	_	_
9	effects	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Dex	_	_	NN	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	avidity	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	beta2	_	_	NN	Protein	18	multitoken	_	_
18	integrin	_	_	NN	Protein	0	root	_	_
19	on	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	neutrophil	_	_	NN	O	-1	none	_	_
22	surface	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	how	_	_	WRB	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	might	_	_	MD	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	turn	_	_	NN	O	-1	none	_	_
29	affect	_	_	VBP	O	-1	none	_	_
30	neutrophil-to-tumor	_	_	JJ	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	binding	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Dex	_	_	NN	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	found	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	inhibit	_	_	VB	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	neutrophil	_	_	NN	O	-1	none	_	_
8	properties	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	RU38486	_	_	NN	O	-1	none	_	_
12	completely	_	_	RB	O	-1	none	_	_
13	suppressed	_	_	VBD	O	-1	none	_	_
14	both	_	_	DT	O	-1	none	_	_
15	forms	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	Dex	_	_	NN	O	-1	none	_	_
18	inhibition	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	findings	_	_	NNS	O	-1	none	_	_
6	suggest	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	glucocorticoid	_	_	NN	O	-1	none	_	_
9	hormone	_	_	NN	O	-1	none	_	_
10	inhibition	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	neutrophil	_	_	NN	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	tumor	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	cytostasis	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	least	_	_	JJS	O	-1	none	_	_
20	partially	_	_	RB	O	-1	none	_	_
21	due	_	_	JJ	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	lowering	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	ligand	_	_	NN	O	-1	none	_	_
28	binding	_	_	NN	O	-1	none	_	_
29	avidity	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	beta2	_	_	NN	Protein	32	multitoken	_	_
32	integrin	_	_	NN	Protein	0	root	_	_
33	on	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	neutrophil	_	_	NN	O	-1	none	_	_
36	surface	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	[	_	_	NN	O	-1	none	_	_
2	Glucocorticoid	_	_	NN	Protein	3	multitoken	_	_
3	receptors	_	_	NNS	Protein	0	root	_	_
4	on	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	peripheral	_	_	JJ	O	-1	none	_	_
7	mononuclear	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	polymorphonuclear	_	_	JJ	O	-1	none	_	_
10	leucocytes	_	_	NNS	O	-1	none	_	_
11	:	_	_	:	O	-1	none	_	_
12	changes	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	yang-deficiency	_	_	NN	O	-1	none	_	_
17	]	_	_	CD	O	-1	none	_	_
18	It	_	_	PRP	O	-1	none	_	_
19	was	_	_	VBD	O	-1	none	_	_
20	found	_	_	VBN	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	former	_	_	JJ	O	-1	none	_	_
25	works	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	glucocorticoid	_	_	NN	Protein	29	multitoken	_	_
29	receptors	_	_	NNS	Protein	0	root	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	GCR	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	on	_	_	IN	O	-1	none	_	_
34	peripheral	_	_	JJ	O	-1	none	_	_
35	mixed	_	_	JJ	O	-1	none	_	_
36	leucocytes	_	_	NNS	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	patients	_	_	NNS	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	Yang-deficiency	_	_	NN	O	-1	none	_	_
41	were	_	_	VBD	O	-1	none	_	_
42	decreased	_	_	VBN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	work	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	mixed	_	_	JJ	O	-1	none	_	_
7	leucocytes	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	further	_	_	JJ	O	-1	none	_	_
10	separated	_	_	VBN	O	-1	none	_	_
11	into	_	_	IN	O	-1	none	_	_
12	mononuclear	_	_	JJ	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	MNL	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	polymorphonuclear	_	_	JJ	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	PML	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	leucocytes	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	GCR	_	_	NN	Protein	-1	none	_	_
25	were	_	_	VBD	O	-1	none	_	_
26	determined	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	each	_	_	DT	O	-1	none	_	_
29	part	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	leucocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	GCR	_	_	NN	Protein	-1	none	_	_
2	on	_	_	IN	O	-1	none	_	_
3	MNL	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	PML	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	6	_	_	CD	O	-1	none	_	_
8	Yang	_	_	NN	O	-1	none	_	_
9	deficient	_	_	JJ	O	-1	none	_	_
10	patients	_	_	NNS	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	3473	_	_	CD	O	-1	none	_	_
13	+/-	_	_	CC	O	-1	none	_	_
14	413	_	_	CD	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	4433	_	_	CD	O	-1	none	_	_
17	+/-	_	_	CC	O	-1	none	_	_
18	651	_	_	CD	O	-1	none	_	_
19	sites	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	respectively	_	_	RB	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	statistically	_	_	RB	O	-1	none	_	_
25	significant	_	_	JJ	O	-1	none	_	_
26	from	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	normal	_	_	JJ	O	-1	none	_	_
29	control	_	_	NN	O	-1	none	_	_
30	group	_	_	NN	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	4462	_	_	CD	O	-1	none	_	_
33	+/-	_	_	CC	O	-1	none	_	_
34	962	_	_	CD	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	5622	_	_	CD	O	-1	none	_	_
37	+/-	_	_	CC	O	-1	none	_	_
38	782	_	_	CD	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	cell	_	_	NN	O	-1	none	_	_
42	respectively	_	_	RB	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	P	_	_	NN	O	-1	none	_	_
45	less	_	_	JJR	O	-1	none	_	_
46	than	_	_	IN	O	-1	none	_	_
47	0.05	_	_	CD	O	-1	none	_	_
48	)	_	_	-RRB-	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	GCR	_	_	NN	Protein	-1	none	_	_
2	on	_	_	IN	O	-1	none	_	_
3	MNL	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	PML	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	mixed	_	_	JJ	O	-1	none	_	_
8	leucocytes	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	5	_	_	CD	O	-1	none	_	_
11	patients	_	_	NNS	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	determined	_	_	VBN	O	-1	none	_	_
14	simultaneously	_	_	RB	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	all	_	_	DT	O	-1	none	_	_
18	lowered	_	_	VBN	O	-1	none	_	_
19	from	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	control	_	_	NN	O	-1	none	_	_
22	group	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	3369	_	_	CD	O	-1	none	_	_
5	+/-	_	_	CC	O	-1	none	_	_
6	370	_	_	CD	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	4986	_	_	CD	O	-1	none	_	_
9	+/-	_	_	CC	O	-1	none	_	_
10	419	_	_	CD	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	4524	_	_	CD	O	-1	none	_	_
13	+/-	_	_	CC	O	-1	none	_	_
14	852	_	_	CD	O	-1	none	_	_
15	sites	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	respectively	_	_	RB	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	lowest	_	_	JJS	O	-1	none	_	_
23	GCR	_	_	NN	Protein	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	MNL	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	highest	_	_	JJS	O	-1	none	_	_
28	on	_	_	IN	O	-1	none	_	_
29	PML	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Nonopsonic	_	_	JJ	O	-1	none	_	_
2	phagocytosis	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Pseudomonas	_	_	FW	O	-1	none	_	_
5	aeruginosa	_	_	FW	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	macrophages	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	polymorphonuclear	_	_	JJ	O	-1	none	_	_
10	leukocytes	_	_	NNS	O	-1	none	_	_
11	requires	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	presence	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	bacterial	_	_	JJ	O	-1	none	_	_
17	flagellum	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	mechanism	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	nonopsonic	_	_	JJ	O	-1	none	_	_
6	phagocytosis	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Pseudomonas	_	_	FW	O	-1	none	_	_
9	aeruginosa	_	_	FW	O	-1	none	_	_
10	has	_	_	VBZ	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	described	_	_	VBN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	bacterial	_	_	JJ	O	-1	none	_	_
16	ligands	_	_	NNS	O	-1	none	_	_
17	required	_	_	VBN	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	poorly	_	_	RB	O	-1	none	_	_
20	understood	_	_	VBN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	identify	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	requisite	_	_	JJ	O	-1	none	_	_
5	bacterial	_	_	JJ	O	-1	none	_	_
6	ligands	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	studies	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	isogenic	_	_	JJ	O	-1	none	_	_
11	mutants	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	P.	_	_	FW	O	-1	none	_	_
14	aeruginosa	_	_	FW	O	-1	none	_	_
15	PAK	_	_	NN	O	-1	none	_	_
16	lacking	_	_	VBG	O	-1	none	_	_
17	pili	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	flagella	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	RpoN	_	_	NN	Protein	25	multitoken	_	_
24	sigma	_	_	NN	Protein	25	multitoken	_	_
25	factor	_	_	NN	Protein	0	root	_	_
26	were	_	_	VBD	O	-1	none	_	_
27	undertaken	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	RpoN	_	_	NN	O	-1	none	_	_
3	mutant	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	lacking	_	_	VBG	O	-1	none	_	_
6	pili	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	flagella	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	nonpilus	_	_	JJ	O	-1	none	_	_
12	adhesins	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	bound	_	_	VBD	O	-1	none	_	_
15	poorly	_	_	RB	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	resistant	_	_	JJ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	ingestion	_	_	NN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	both	_	_	CC	O	-1	none	_	_
23	macrophages	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	neutrophils	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Pili	_	_	NNS	O	-1	none	_	_
2	were	_	_	VBD	O	-1	none	_	_
3	not	_	_	RB	O	-1	none	_	_
4	absolutely	_	_	RB	O	-1	none	_	_
5	required	_	_	VBN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	phagocytosis	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	P.	_	_	FW	O	-1	none	_	_
12	aeruginosa	_	_	FW	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	presence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	flagellum	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	required	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	P.	_	_	FW	O	-1	none	_	_
13	aeruginosa	_	_	FW	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	macrophages	_	_	NNS	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	critical	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	subsequent	_	_	JJ	O	-1	none	_	_
22	internalization	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	bacterium	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	suggesting	_	_	VBG	O	-1	none	_	_
28	that	_	_	IN	O	-1	none	_	_
29	this	_	_	DT	O	-1	none	_	_
30	factor	_	_	NN	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	surface	_	_	NN	O	-1	none	_	_
34	ligand	_	_	NN	O	-1	none	_	_
35	associated	_	_	VBN	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	its	_	_	PRP$	O	-1	none	_	_
38	assembly	_	_	NN	O	-1	none	_	_
39	was	_	_	VBD	O	-1	none	_	_
40	responsible	_	_	JJ	O	-1	none	_	_
41	for	_	_	IN	O	-1	none	_	_
42	stimulation	_	_	NN	O	-1	none	_	_
43	of	_	_	IN	O	-1	none	_	_
44	nonopsonic	_	_	JJ	O	-1	none	_	_
45	phagocytosis	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	c-fos	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	c-jun	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	jun	_	_	NN	Protein	8	multitoken	_	_
8	B	_	_	NN	Protein	0	root	_	_
9	in	_	_	IN	O	-1	none	_	_
10	peripheral	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	young	_	_	JJ	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	elderly	_	_	JJ	O	-1	none	_	_
17	adults	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	c-fos	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	c-jun	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	jun	_	_	NN	Protein	9	multitoken	_	_
9	B	_	_	NN	Protein	0	root	_	_
10	proto-oncogenes	_	_	NNS	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	studied	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	phytohemagglutinin	_	_	NN	Protein	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	PHA	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	peripheral	_	_	JJ	O	-1	none	_	_
20	blood	_	_	NN	O	-1	none	_	_
21	lymphocytes	_	_	NNS	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	PBL	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	from	_	_	IN	O	-1	none	_	_
26	young	_	_	JJ	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	aged	_	_	JJ	O	-1	none	_	_
29	humans	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Specific	_	_	JJ	O	-1	none	_	_
2	mRNAs	_	_	NNS	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	c-fos	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	c-jun	_	_	NN	Protein	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	detectable	_	_	JJ	O	-1	none	_	_
9	within	_	_	IN	O	-1	none	_	_
10	30	_	_	CD	O	-1	none	_	_
11	min	_	_	NN	O	-1	none	_	_
12	after	_	_	IN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	reached	_	_	VBD	O	-1	none	_	_
17	maximal	_	_	JJ	O	-1	none	_	_
18	levels	_	_	NNS	O	-1	none	_	_
19	within	_	_	IN	O	-1	none	_	_
20	2	_	_	CD	O	-1	none	_	_
21	h.	_	_	NN	O	-1	none	_	_
22	Both	_	_	CC	O	-1	none	_	_
23	c-fos	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	jun	_	_	NN	Protein	26	multitoken	_	_
26	B	_	_	NN	Protein	0	root	_	_
27	mRNAs	_	_	NNS	O	-1	none	_	_
28	decreased	_	_	VBD	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	pre-activation	_	_	NN	O	-1	none	_	_
31	levels	_	_	NNS	O	-1	none	_	_
32	within	_	_	IN	O	-1	none	_	_
33	6	_	_	CD	O	-1	none	_	_
34	h	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	while	_	_	IN	O	-1	none	_	_
37	c-jun	_	_	NN	Protein	-1	none	_	_
38	mRNA	_	_	NN	O	-1	none	_	_
39	remained	_	_	VBD	O	-1	none	_	_
40	elevated	_	_	JJ	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	PHA	_	_	NN	Protein	-1	none	_	_
3	activated	_	_	VBD	O	-1	none	_	_
4	PBL	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	no	_	_	DT	O	-1	none	_	_
7	age	_	_	NN	O	-1	none	_	_
8	related	_	_	JJ	O	-1	none	_	_
9	differences	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	observed	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	c-fos	_	_	NN	Protein	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	jun	_	_	NN	Protein	16	multitoken	_	_
16	B	_	_	NN	Protein	0	root	_	_
17	mRNA	_	_	NN	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	c-jun	_	_	NN	Protein	-1	none	_	_
4	mRNA	_	_	NN	O	-1	none	_	_
5	levels	_	_	NNS	O	-1	none	_	_
6	decreased	_	_	VBD	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	1.73	_	_	CD	O	-1	none	_	_
10	+/-	_	_	CC	O	-1	none	_	_
11	0.08	_	_	CD	O	-1	none	_	_
12	vs.	_	_	CC	O	-1	none	_	_
13	1.16	_	_	CD	O	-1	none	_	_
14	+/-	_	_	CC	O	-1	none	_	_
15	0.09	_	_	CD	O	-1	none	_	_
16	arbitrary	_	_	JJ	O	-1	none	_	_
17	units	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	P	_	_	NN	O	-1	none	_	_
20	<	_	_	JJR	O	-1	none	_	_
21	0.01	_	_	CD	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	young	_	_	JJ	O	-1	none	_	_
24	vs.	_	_	CC	O	-1	none	_	_
25	old	_	_	JJ	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	PBL	_	_	NN	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	elderly	_	_	JJ	O	-1	none	_	_
31	individuals	_	_	NNS	O	-1	none	_	_
32	activated	_	_	VBN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	PHA	_	_	NN	Protein	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	No	_	_	DT	O	-1	none	_	_
2	age	_	_	NN	O	-1	none	_	_
3	related	_	_	JJ	O	-1	none	_	_
4	differences	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	found	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	either	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	these	_	_	DT	O	-1	none	_	_
14	two	_	_	CD	O	-1	none	_	_
15	proto-oncogenes	_	_	NNS	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	anti-CD2	_	_	JJ	Protein	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	decreased	_	_	JJ	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	production	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	proliferative	_	_	JJ	O	-1	none	_	_
11	response	_	_	NN	O	-1	none	_	_
12	displayed	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	PHA	_	_	NN	Protein	-1	none	_	_
15	activated	_	_	VBD	O	-1	none	_	_
16	PBL	_	_	NN	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	elderly	_	_	JJ	O	-1	none	_	_
19	adults	_	_	NNS	O	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	be	_	_	VB	O	-1	none	_	_
22	related	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	age	_	_	NN	O	-1	none	_	_
25	related	_	_	JJ	O	-1	none	_	_
26	changes	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	c-jun	_	_	NN	Protein	-1	none	_	_
29	mRNA	_	_	NN	O	-1	none	_	_
30	expression	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	ratio	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	c-fos	_	_	NN	Protein	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	c-jun	_	_	NN	Protein	-1	none	_	_
39	mRNA	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	shared	_	_	JJ	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	motifs	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	common	_	_	JJ	O	-1	none	_	_
9	Stat	_	_	NN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	generation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	cytokine	_	_	NN	O	-1	none	_	_
16	pleiotropy	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	redundancy	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	IL-4	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	IL-7	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	IL-13	_	_	NN	Protein	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	IL-15	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	understand	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	bases	_	_	NNS	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	redundancy	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	pleiotropy	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	we	_	_	PRP	O	-1	none	_	_
13	have	_	_	VBP	O	-1	none	_	_
14	compared	_	_	VBN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	Stat	_	_	NN	O	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	peripheral	_	_	JJ	O	-1	none	_	_
21	blood	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	PBLs	_	_	NNS	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	by	_	_	IN	O	-1	none	_	_
27	cytokines	_	_	NNS	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	shared	_	_	JJ	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	distinct	_	_	JJ	O	-1	none	_	_
32	actions	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Interleukin-2	_	_	NNP	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	rapidly	_	_	RB	O	-1	none	_	_
6	activated	_	_	VBD	O	-1	none	_	_
7	Stat5	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	fresh	_	_	JJ	O	-1	none	_	_
10	PBL	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Stat3	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Stat5	_	_	NN	Protein	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	preactivated	_	_	JJ	O	-1	none	_	_
18	PBL	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	IL-7	_	_	NNP	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	IL-15	_	_	NN	Protein	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	same	_	_	JJ	O	-1	none	_	_
7	complexes	_	_	NNS	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	feature	_	_	NN	O	-1	none	_	_
13	explained	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	existence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	similar	_	_	JJ	O	-1	none	_	_
19	tyrosine	_	_	NN	O	-1	none	_	_
20	phosphorylated	_	_	JJ	O	-1	none	_	_
21	motifs	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	cytoplasmic	_	_	JJ	O	-1	none	_	_
25	domains	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	IL-2R	_	_	NN	Protein	28	multitoken	_	_
28	beta	_	_	NN	Protein	0	root	_	_
29	and	_	_	CC	O	-1	none	_	_
30	IL-7R	_	_	NN	Protein	-1	none	_	_
31	that	_	_	WDT	O	-1	none	_	_
32	can	_	_	MD	O	-1	none	_	_
33	serve	_	_	VB	O	-1	none	_	_
34	as	_	_	IN	O	-1	none	_	_
35	docking	_	_	NN	O	-1	none	_	_
36	sites	_	_	NNS	O	-1	none	_	_
37	for	_	_	IN	O	-1	none	_	_
38	Stat	_	_	NN	O	-1	none	_	_
39	proteins	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	IL-13	_	_	NNP	Protein	-1	none	_	_
2	Induced	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	same	_	_	JJ	O	-1	none	_	_
5	complexes	_	_	NNS	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	IL-4	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	finding	_	_	NN	O	-1	none	_	_
11	explained	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	our	_	_	PRP$	O	-1	none	_	_
14	studies	_	_	NNS	O	-1	none	_	_
15	implicating	_	_	VBG	O	-1	none	_	_
16	IL-4R	_	_	NN	Protein	-1	none	_	_
17	as	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	shared	_	_	JJ	O	-1	none	_	_
20	component	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	receptors	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	single	_	_	JJ	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	can	_	_	MD	O	-1	none	_	_
9	activate	_	_	VB	O	-1	none	_	_
10	different	_	_	JJ	O	-1	none	_	_
11	combinations	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Stat	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	under	_	_	IN	O	-1	none	_	_
16	different	_	_	JJ	O	-1	none	_	_
17	physiological	_	_	JJ	O	-1	none	_	_
18	conditions	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	indicate	_	_	VBP	O	-1	none	_	_
23	two	_	_	CD	O	-1	none	_	_
24	mechanisms	_	_	NNS	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	which	_	_	WDT	O	-1	none	_	_
27	distinct	_	_	JJ	O	-1	none	_	_
28	cytokines	_	_	NNS	O	-1	none	_	_
29	can	_	_	MD	O	-1	none	_	_
30	activate	_	_	VB	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	same	_	_	JJ	O	-1	none	_	_
33	Stat	_	_	NN	O	-1	none	_	_
34	protein	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	1,25-Dihydroxyvitamin	_	_	NN	O	-1	none	_	_
2	D3	_	_	NN	O	-1	none	_	_
3	induces	_	_	VBZ	O	-1	none	_	_
4	differentiation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	retinoic	_	_	JJ	O	-1	none	_	_
8	acid	_	_	NN	O	-1	none	_	_
9	resistant	_	_	JJ	O	-1	none	_	_
10	acute	_	_	JJ	O	-1	none	_	_
11	promyelocytic	_	_	JJ	O	-1	none	_	_
12	leukemia	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	line	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	UF-1	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	associated	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	p21	_	_	NN	Protein	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	WAF1	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	CIP1	_	_	NN	Protein	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	p27	_	_	NN	Protein	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	KIP1	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Retinoic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	RA	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	resistance	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	serious	_	_	JJ	O	-1	none	_	_
10	problem	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	acute	_	_	JJ	O	-1	none	_	_
15	promyelocytic	_	_	JJ	O	-1	none	_	_
16	leukemia	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	APL	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	who	_	_	WP	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	receiving	_	_	VBG	O	-1	none	_	_
23	all-trans	_	_	JJ	O	-1	none	_	_
24	RA	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	strategies	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	overcome	_	_	VB	O	-1	none	_	_
9	RA	_	_	NN	O	-1	none	_	_
10	resistance	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	APL	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	still	_	_	RB	O	-1	none	_	_
16	unclear	_	_	JJ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	biologic	_	_	JJ	O	-1	none	_	_
3	effects	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	RA	_	_	NN	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	mediated	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	two	_	_	CD	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	families	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	:	_	_	:	O	-1	none	_	_
16	RA	_	_	NN	O	-1	none	_	_
17	receptors	_	_	NNS	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	RARs	_	_	NNS	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	retinoid	_	_	NN	O	-1	none	_	_
23	X	_	_	NN	O	-1	none	_	_
24	receptors	_	_	NNS	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	RXRs	_	_	NNS	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	RXRs	_	_	NNS	O	-1	none	_	_
2	heterodimerize	_	_	VBP	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	1	_	_	CD	Protein	15	multitoken	_	_
5	,	_	_	,	Protein	15	multitoken	_	_
6	25-dihydroxyvitamin	_	_	NN	Protein	15	multitoken	_	_
7	D3	_	_	NN	Protein	15	multitoken	_	_
8	[	_	_	CD	Protein	15	multitoken	_	_
9	1,25	_	_	CD	Protein	15	multitoken	_	_
10	(	_	_	-LRB-	Protein	15	multitoken	_	_
11	OH	_	_	NN	Protein	15	multitoken	_	_
12	)	_	_	-RRB-	Protein	15	multitoken	_	_
13	2D3	_	_	NN	Protein	15	multitoken	_	_
14	]	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	VDR	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	enabling	_	_	VBG	O	-1	none	_	_
21	their	_	_	PRP$	O	-1	none	_	_
22	efficient	_	_	JJ	O	-1	none	_	_
23	transcriptional	_	_	JJ	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cyclin	_	_	NN	O	-1	none	_	_
3	dependent	_	_	JJ	O	-1	none	_	_
4	kinase	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	cdk	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	inhibitor	_	_	NN	O	-1	none	_	_
9	p21	_	_	NN	Protein	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	WAF1	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	CIP1	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	has	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	vitamin	_	_	NN	O	-1	none	_	_
18	D3	_	_	NN	O	-1	none	_	_
19	responsive	_	_	JJ	O	-1	none	_	_
20	element	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	VDRE	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	its	_	_	PRP$	O	-1	none	_	_
26	promoter	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	1,25	_	_	CD	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	OH	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	2D3	_	_	NN	O	-1	none	_	_
34	enhances	_	_	VBZ	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	expression	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	p21	_	_	NN	Protein	-1	none	_	_
39	(	_	_	-LRB-	O	-1	none	_	_
40	WAF1	_	_	NN	Protein	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	CIP1	_	_	NN	Protein	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	induces	_	_	VBZ	O	-1	none	_	_
46	differentiation	_	_	NN	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	selected	_	_	VBN	O	-1	none	_	_
49	myeloid	_	_	JJ	O	-1	none	_	_
50	leukemic	_	_	JJ	O	-1	none	_	_
51	cell	_	_	NN	O	-1	none	_	_
52	lines	_	_	NNS	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	established	_	_	VBN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	novel	_	_	JJ	O	-1	none	_	_
7	APL	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	line	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	UF-1	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	features	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	RA	_	_	NN	O	-1	none	_	_
17	resistance	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	1,25	_	_	CD	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	OH	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	2D3	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	induce	_	_	VB	O	-1	none	_	_
8	growth	_	_	NN	O	-1	none	_	_
9	inhibition	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	G1	_	_	NN	O	-1	none	_	_
12	arrest	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	UF-1	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	resulting	_	_	VBG	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	these	_	_	DT	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	toward	_	_	IN	O	-1	none	_	_
24	granulocytes	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	1	_	_	CD	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	25	_	_	CD	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	OH	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	2D3	_	_	NN	O	-1	none	_	_
9	induced	_	_	VBD	O	-1	none	_	_
10	G1	_	_	NN	O	-1	none	_	_
11	arrest	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	enhanced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	all-trans	_	_	JJ	O	-1	none	_	_
16	RA	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Also	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	1	_	_	CD	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	25	_	_	CD	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	OH	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	2D3	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	10	_	_	CD	O	-1	none	_	_
12	(-10)	_	_	CD	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	10	_	_	CD	O	-1	none	_	_
15	(-7)	_	_	CD	O	-1	none	_	_
16	mol/L	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	combination	_	_	NN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	RA	_	_	NN	O	-1	none	_	_
22	markedly	_	_	RB	O	-1	none	_	_
23	inhibits	_	_	VBZ	O	-1	none	_	_
24	cellular	_	_	JJ	O	-1	none	_	_
25	proliferation	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	dose-	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	time	_	_	NN	O	-1	none	_	_
31	dependent	_	_	JJ	O	-1	none	_	_
32	manner	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Associated	_	_	VBN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	p21	_	_	NN	Protein	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	WAF1	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	CIP1	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	p27	_	_	NN	Protein	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	KIP1	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	protein	_	_	NN	O	-1	none	_	_
23	increased	_	_	VBD	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	p21	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	WAF1	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CIP1	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	p27	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	KIP1	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	mRNA	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	protein	_	_	NN	O	-1	none	_	_
20	increased	_	_	VBD	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	these	_	_	DT	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	p21	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	WAF1	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CIP1	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	p27	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	KIP1	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	transcripts	_	_	NNS	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	induced	_	_	VBN	O	-1	none	_	_
20	after	_	_	IN	O	-1	none	_	_
21	6	_	_	CD	O	-1	none	_	_
22	hours	_	_	NNS	O	-1	none	_	_
23	'	_	_	POS	O	-1	none	_	_
24	exposure	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	1,25	_	_	CD	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	OH	_	_	NN	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	2D3	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	then	_	_	RB	O	-1	none	_	_
33	decreased	_	_	VBD	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	basal	_	_	JJ	O	-1	none	_	_
36	levels	_	_	NNS	O	-1	none	_	_
37	over	_	_	IN	O	-1	none	_	_
38	48	_	_	CD	O	-1	none	_	_
39	hours	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	p21	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	WAF1	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CIP1	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	levels	_	_	NNS	O	-1	none	_	_
14	increased	_	_	VBD	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	became	_	_	VBD	O	-1	none	_	_
17	detectable	_	_	JJ	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	12	_	_	CD	O	-1	none	_	_
20	hours	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	1,25	_	_	CD	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	OH	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	2D3	_	_	NN	O	-1	none	_	_
27	treatment	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	induction	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	p27	_	_	NN	Protein	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	KIP1	_	_	NN	Protein	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	protein	_	_	NN	O	-1	none	_	_
36	was	_	_	VBD	O	-1	none	_	_
37	much	_	_	RB	O	-1	none	_	_
38	more	_	_	RBR	O	-1	none	_	_
39	gradual	_	_	JJ	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	sustained	_	_	JJ	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	UF-1	_	_	NN	O	-1	none	_	_
44	cells	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	combination	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	25	_	_	CD	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	OH	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	2D3	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	RA	_	_	NN	O	-1	none	_	_
15	markedly	_	_	RB	O	-1	none	_	_
16	enhanced	_	_	VBD	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	levels	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	p27	_	_	NN	Protein	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	KIP1	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	transcript	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	protein	_	_	NN	O	-1	none	_	_
27	as	_	_	IN	O	-1	none	_	_
28	compared	_	_	VBN	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	levels	_	_	NNS	O	-1	none	_	_
31	induced	_	_	VBN	O	-1	none	_	_
32	by	_	_	IN	O	-1	none	_	_
33	1	_	_	CD	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	25	_	_	CD	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	OH	_	_	NN	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	2D3	_	_	NN	O	-1	none	_	_
40	alone	_	_	RB	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	exogenous	_	_	JJ	O	-1	none	_	_
5	p27	_	_	NN	Protein	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	KIP1	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	enhance	_	_	VB	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	level	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	CD11b	_	_	NN	Protein	-1	none	_	_
16	antigen	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	myeloid	_	_	JJ	O	-1	none	_	_
19	leukemic	_	_	JJ	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	RA	_	_	NN	O	-1	none	_	_
5	alone	_	_	RB	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	induce	_	_	VB	O	-1	none	_	_
8	G1	_	_	NN	O	-1	none	_	_
9	arrest	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	UF-1	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	;	_	_	:	O	-1	none	_	_
14	however	_	_	RB	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	it	_	_	PRP	O	-1	none	_	_
17	did	_	_	VBD	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	result	_	_	VB	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	increase	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	p21	_	_	NN	Protein	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	WAF1	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	CIP1	_	_	NN	Protein	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	p27	_	_	NN	Protein	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	KIP1	_	_	NN	Protein	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	transcript	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	protein	_	_	NN	O	-1	none	_	_
38	expression	_	_	NN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	RA	_	_	NN	O	-1	none	_	_
41	resistant	_	_	JJ	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	conclude	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	1,25	_	_	CD	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	OH	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	2D3	_	_	NN	O	-1	none	_	_
12	induces	_	_	VBZ	O	-1	none	_	_
13	increased	_	_	VBN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cdk	_	_	NN	O	-1	none	_	_
17	inhibitors	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	mediates	_	_	VBZ	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	G1	_	_	NN	O	-1	none	_	_
23	arrest	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	may	_	_	MD	O	-1	none	_	_
28	be	_	_	VB	O	-1	none	_	_
29	associated	_	_	VBN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	differentiation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	RA	_	_	NN	O	-1	none	_	_
34	resistant	_	_	JJ	O	-1	none	_	_
35	UF-1	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	toward	_	_	IN	O	-1	none	_	_
38	mature	_	_	JJ	O	-1	none	_	_
39	granulocytes	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Immunoprecipitation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	gp	_	_	NN	Protein	5	multitoken	_	_
5	160	_	_	CD	Protein	0	root	_	_
6	induced	_	_	VBD	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	extracts	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	polyclonal	_	_	JJ	O	-1	none	_	_
11	antibodies	_	_	NNS	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	Fos	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Jun	_	_	NN	O	-1	none	_	_
16	proteins	_	_	NNS	O	-1	none	_	_
17	indicates	_	_	VBZ	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	AP-1	_	_	NN	O	-1	none	_	_
20	complex	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	comprised	_	_	VBN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	members	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	these	_	_	DT	O	-1	none	_	_
27	family	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	proteins	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	gp160	_	_	NN	Protein	-1	none	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	AP-1	_	_	NN	O	-1	none	_	_
5	complex	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	upon	_	_	IN	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	tyrosine	_	_	NN	O	-1	none	_	_
11	phosphorylation	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	synthesis	_	_	NN	O	-1	none	_	_
16	independent	_	_	JJ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	stimulation	_	_	NN	O	-1	none	_	_
3	can	_	_	MD	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	abolished	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	inhibitors	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	C	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	it	_	_	PRP	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	unaffected	_	_	JJ	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	calcium	_	_	NN	O	-1	none	_	_
20	channel	_	_	NN	O	-1	none	_	_
21	blocker	_	_	NN	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	cyclosporine	_	_	NN	O	-1	none	_	_
24	A	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	similar	_	_	JJ	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	gp160	_	_	NN	Protein	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	seen	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	anti-CD4	_	_	JJ	Protein	-1	none	_	_
9	mAb	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aberrant	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	AP-1	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	gp160	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	CD4	_	_	NN	Protein	-1	none	_	_
10	positive	_	_	JJ	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	could	_	_	MD	O	-1	none	_	_
14	result	_	_	VB	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	up-regulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cytokines	_	_	NNS	O	-1	none	_	_
19	containing	_	_	VBG	O	-1	none	_	_
20	AP-1	_	_	NN	O	-1	none	_	_
21	sites	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	e.g.	_	_	FW	O	-1	none	_	_
24	interleukin-3	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	granulocyte	_	_	NN	Protein	30	multitoken	_	_
27	macrophage	_	_	NN	Protein	30	multitoken	_	_
28	colony	_	_	NN	Protein	30	multitoken	_	_
29	stimulating	_	_	NN	Protein	30	multitoken	_	_
30	factor	_	_	NN	Protein	0	root	_	_
31	,	_	_	,	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	concurrently	_	_	RB	O	-1	none	_	_
34	lead	_	_	VB	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	T	_	_	NN	O	-1	none	_	_
37	cell	_	_	NN	O	-1	none	_	_
38	unresponsiveness	_	_	NN	O	-1	none	_	_
39	by	_	_	IN	O	-1	none	_	_
40	inhibiting	_	_	VBG	O	-1	none	_	_
41	interleukin-2	_	_	NN	Protein	-1	none	_	_
42	secretion	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	Protein	2	multitoken	_	_
2	receptor	_	_	NN	Protein	0	root	_	_
3	in	_	_	IN	O	-1	none	_	_
4	patients	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	lupus	_	_	NN	O	-1	none	_	_
7	nephritis	_	_	NN	O	-1	none	_	_
8	:	_	_	:	O	-1	none	_	_
9	relationship	_	_	NN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	mononuclear	_	_	JJ	O	-1	none	_	_
15	leukocytes	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	effect	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	glucocorticoid	_	_	NN	O	-1	none	_	_
20	therapy	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	clinical	_	_	JJ	O	-1	none	_	_
5	significance	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	glucocorticoid	_	_	NN	Protein	8	multitoken	_	_
8	receptor	_	_	NN	Protein	0	root	_	_
9	determination	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	20	_	_	CD	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	systemic	_	_	JJ	O	-1	none	_	_
15	lupus	_	_	NN	O	-1	none	_	_
16	erythematosus	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	SLE	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	who	_	_	WP	O	-1	none	_	_
21	afterwards	_	_	RB	O	-1	none	_	_
22	developed	_	_	VBD	O	-1	none	_	_
23	nephrotic	_	_	JJ	O	-1	none	_	_
24	syndrome	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	Protein	2	multitoken	_	_
2	receptor	_	_	NN	Protein	0	root	_	_
3	concentrations	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	mononuclear	_	_	JJ	O	-1	none	_	_
6	leukocytes	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	MNL	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	comparable	_	_	JJ	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	those	_	_	DT	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	both	_	_	DT	O	-1	none	_	_
19	other	_	_	JJ	O	-1	none	_	_
20	patients	_	_	NNS	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	SLE	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	healthy	_	_	JJ	O	-1	none	_	_
25	persons	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Improvement	_	_	NN	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	urinary	_	_	JJ	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	excretion	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	disease	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	scored	_	_	VBN	O	-1	none	_	_
14	according	_	_	VBG	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	SLE	_	_	NN	O	-1	none	_	_
18	Disease	_	_	NN	O	-1	none	_	_
19	Activity	_	_	NN	O	-1	none	_	_
20	Index	_	_	NN	O	-1	none	_	_
21	system	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	University	_	_	NNP	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	Toronto	_	_	NNP	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	closely	_	_	RB	O	-1	none	_	_
29	related	_	_	JJ	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	glucocorticoid	_	_	NN	Protein	33	multitoken	_	_
33	receptor	_	_	NN	Protein	0	root	_	_
34	concentrations	_	_	NNS	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	MNL	_	_	NN	O	-1	none	_	_
37	isolated	_	_	VBN	O	-1	none	_	_
38	from	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	corresponding	_	_	JJ	O	-1	none	_	_
41	patients	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	summary	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	glucocorticoid	_	_	NN	Protein	5	multitoken	_	_
5	receptor	_	_	NN	Protein	0	root	_	_
6	determination	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	lupus	_	_	NN	O	-1	none	_	_
11	nephritis	_	_	NN	O	-1	none	_	_
12	may	_	_	MD	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	predictive	_	_	JJ	O	-1	none	_	_
16	clue	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	assessing	_	_	VBG	O	-1	none	_	_
19	responsiveness	_	_	NN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	glucocorticoid	_	_	NN	O	-1	none	_	_
22	therapy	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	induces	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	tyk2	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Jak1	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	differential	_	_	JJ	O	-1	none	_	_
13	assembly	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	STAT1	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	and	_	_	CC	O	-1	none	_	_
18	STAT3	_	_	NN	Protein	-1	none	_	_
19	complexes	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	monocytes	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	affects	_	_	VBZ	O	-1	none	_	_
3	monocytes	_	_	NNS	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	driving	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	progression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	immune	_	_	JJ	O	-1	none	_	_
13	responsiveness	_	_	NN	O	-1	none	_	_
14	such	_	_	JJ	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	Th2	_	_	NN	O	-1	none	_	_
17	lymphocyte	_	_	NN	O	-1	none	_	_
18	mediated	_	_	JJ	O	-1	none	_	_
19	effects	_	_	NNS	O	-1	none	_	_
20	predominate	_	_	VBP	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	report	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	show	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	monocytes	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	IL-10	_	_	NN	Protein	-1	none	_	_
14	stimulates	_	_	VBZ	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	signal	_	_	NN	O	-1	none	_	_
20	transducers	_	_	NNS	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	activators	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	STAT1	_	_	NN	Protein	27	multitoken	_	_
27	alpha	_	_	NN	Protein	0	root	_	_
28	and	_	_	CC	O	-1	none	_	_
29	STAT3	_	_	NN	Protein	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	differential	_	_	JJ	O	-1	none	_	_
34	manner	_	_	NN	O	-1	none	_	_
35	such	_	_	JJ	O	-1	none	_	_
36	that	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	relative	_	_	JJ	O	-1	none	_	_
39	formation	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	homo-	_	_	JJ	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	heterodimers	_	_	NNS	O	-1	none	_	_
44	varies	_	_	VBZ	O	-1	none	_	_
45	between	_	_	IN	O	-1	none	_	_
46	the	_	_	DT	O	-1	none	_	_
47	two	_	_	CD	O	-1	none	_	_
48	cell	_	_	NN	O	-1	none	_	_
49	types	_	_	NNS	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	IL-10	_	_	NNP	Protein	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	monocytes	_	_	NNS	O	-1	none	_	_
9	results	_	_	VBZ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	ligand	_	_	NN	O	-1	none	_	_
13	induced	_	_	VBD	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	phosphorylation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	tyk2	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Jak1	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	Jak2	_	_	NN	Protein	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	Jak3	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Selective	_	_	JJ	O	-1	none	_	_
2	modulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	immune	_	_	JJ	O	-1	none	_	_
5	responsiveness	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	IL-10	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	such	_	_	JJ	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	may	_	_	MD	O	-1	none	_	_
17	result	_	_	VB	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	part	_	_	NN	O	-1	none	_	_
20	from	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	differential	_	_	JJ	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	STAT	_	_	NN	O	-1	none	_	_
26	protein	_	_	NN	O	-1	none	_	_
27	pairs	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Acetylsalicylic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	sodium	_	_	NN	O	-1	none	_	_
5	salicylate	_	_	NN	O	-1	none	_	_
6	inhibit	_	_	VBP	O	-1	none	_	_
7	LPS	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B/c-Rel	_	_	JJ	Protein	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	translocation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	synthesis	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	tissue	_	_	NN	Protein	18	multitoken	_	_
18	factor	_	_	NN	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	TF	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	tumor	_	_	NN	Protein	26	multitoken	_	_
24	necrosis	_	_	NN	Protein	26	multitoken	_	_
25	factor	_	_	NN	Protein	26	multitoken	_	_
26	alfa	_	_	NN	Protein	0	root	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	TNF-alpha	_	_	NN	Protein	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	human	_	_	NN	O	-1	none	_	_
32	monocytes	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	investigated	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effects	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	acetylsalicylic	_	_	JJ	O	-1	none	_	_
8	acid	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	sodium	_	_	NN	O	-1	none	_	_
11	salicylate	_	_	NN	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	LPS	_	_	NN	O	-1	none	_	_
15	induced	_	_	VBD	O	-1	none	_	_
16	synthesis	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	pro	_	_	JJ	O	-1	none	_	_
20	coagulant	_	_	NN	O	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	tissue	_	_	NN	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	TF	_	_	NN	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	pro	_	_	JJ	O	-1	none	_	_
30	inflammatory	_	_	JJ	O	-1	none	_	_
31	protein	_	_	NN	O	-1	none	_	_
32	tumor	_	_	NN	Protein	34	multitoken	_	_
33	necrosis	_	_	NN	Protein	34	multitoken	_	_
34	factor-alpha	_	_	NN	Protein	0	root	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	TNF-alpha	_	_	NN	Protein	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	as	_	_	RB	O	-1	none	_	_
40	well	_	_	RB	O	-1	none	_	_
41	as	_	_	IN	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	prostaglandin	_	_	NN	O	-1	none	_	_
44	PGE2	_	_	NN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	human	_	_	NN	O	-1	none	_	_
47	monocytes	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	drugs	_	_	NNS	O	-1	none	_	_
3	dose-dependently	_	_	RB	O	-1	none	_	_
4	inhibited	_	_	VBD	O	-1	none	_	_
5	LPS	_	_	NN	O	-1	none	_	_
6	induced	_	_	VBD	O	-1	none	_	_
7	TF	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	TNF-alpha	_	_	NN	Protein	-1	none	_	_
10	synthesis	_	_	NN	O	-1	none	_	_
11	at	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	level	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	reduced	_	_	VBD	O	-1	none	_	_
21	PGE2	_	_	NN	O	-1	none	_	_
22	production	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	evidenced	_	_	VBN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	electro	_	_	NN	O	-1	none	_	_
5	mobility	_	_	NN	O	-1	none	_	_
6	shift	_	_	NN	O	-1	none	_	_
7	assay	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	EMSA	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	use	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	prototypic	_	_	JJ	O	-1	none	_	_
19	probe	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	these	_	_	DT	O	-1	none	_	_
22	drugs	_	_	NNS	O	-1	none	_	_
23	probably	_	_	RB	O	-1	none	_	_
24	exert	_	_	VBP	O	-1	none	_	_
25	their	_	_	PRP$	O	-1	none	_	_
26	inhibitory	_	_	JJ	O	-1	none	_	_
27	effects	_	_	NNS	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	interference	_	_	NN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	nuclear	_	_	JJ	O	-1	none	_	_
33	translocation	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	NF-kappa	_	_	NN	O	-1	none	_	_
36	B/c-Rel	_	_	NN	Protein	-1	none	_	_
37	proteins	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	may	_	_	MD	O	-1	none	_	_
4	expand	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	understanding	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	anti-thrombotic	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	anti-inflammatory	_	_	JJ	O	-1	none	_	_
12	effects	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	these	_	_	DT	O	-1	none	_	_
15	drugs	_	_	NNS	O	-1	none	_	_
16	when	_	_	WRB	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	monocytes	_	_	NNS	O	-1	none	_	_
20	occurs	_	_	VBZ	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Differential	_	_	JJ	O	-1	none	_	_
2	inhibition	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Smad6	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	Smad7	_	_	NN	Protein	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	bone	_	_	NN	O	-1	none	_	_
9	morphogenetic	_	_	JJ	O	-1	none	_	_
10	protein-	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	activin	_	_	NN	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	growth	_	_	NN	O	-1	none	_	_
15	arrest	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	apoptosis	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Smad6	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	Smad7	_	_	NN	Protein	-1	none	_	_
4	prevent	_	_	VBP	O	-1	none	_	_
5	ligand	_	_	NN	O	-1	none	_	_
6	induced	_	_	JJ	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	signal	_	_	NN	O	-1	none	_	_
10	transducing	_	_	NN	O	-1	none	_	_
11	Smad	_	_	NN	O	-1	none	_	_
12	proteins	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	transforming	_	_	VBG	O	-1	none	_	_
16	growth	_	_	NN	O	-1	none	_	_
17	factor-beta	_	_	NN	O	-1	none	_	_
18	family	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	previously	_	_	RB	O	-1	none	_	_
3	reported	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Smad7	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	activin	_	_	NN	Protein	9	multitoken	_	_
9	A	_	_	NN	Protein	0	root	_	_
10	inducible	_	_	JJ	O	-1	none	_	_
11	antagonist	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	activin	_	_	NN	Protein	14	multitoken	_	_
14	A	_	_	NN	Protein	0	root	_	_
15	induced	_	_	VBD	O	-1	none	_	_
16	growth	_	_	NN	O	-1	none	_	_
17	arrest	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	apoptosis	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	HS-72	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	although	_	_	IN	O	-1	none	_	_
4	mRNA	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Smad6	_	_	NN	Protein	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	activin	_	_	NN	Protein	12	multitoken	_	_
12	A	_	_	NN	Protein	0	root	_	_
13	in	_	_	IN	O	-1	none	_	_
14	HS-72	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	Smad6	_	_	NN	Protein	-1	none	_	_
18	showed	_	_	VBD	O	-1	none	_	_
19	no	_	_	DT	O	-1	none	_	_
20	antagonistic	_	_	JJ	O	-1	none	_	_
21	effect	_	_	NN	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	activin	_	_	NN	Protein	24	multitoken	_	_
24	A	_	_	NN	Protein	0	root	_	_
25	induced	_	_	VBD	O	-1	none	_	_
26	growth	_	_	NN	O	-1	none	_	_
27	arrest	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	apoptosis	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	found	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	ectopic	_	_	JJ	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Smad7	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	Smad6	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	inhibited	_	_	VBD	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	activin	_	_	NN	Protein	19	multitoken	_	_
19	A	_	_	NN	Protein	0	root	_	_
20	induced	_	_	VBD	O	-1	none	_	_
21	Smad2	_	_	NN	Protein	-1	none	_	_
22	phosphorylation	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	HS-72	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Alternative	_	_	JJ	O	-1	none	_	_
2	polyadenylation	_	_	NN	O	-1	none	_	_
3	events	_	_	NNS	O	-1	none	_	_
4	contribute	_	_	VBP	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-ATc	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	effector	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	NF-ATc	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	synthesized	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	three	_	_	CD	O	-1	none	_	_
9	prominent	_	_	JJ	O	-1	none	_	_
10	isoforms	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	differ	_	_	VBP	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	length	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	their	_	_	PRP$	O	-1	none	_	_
8	C	_	_	NN	O	-1	none	_	_
9	terminal	_	_	JJ	O	-1	none	_	_
10	peptides	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	mode	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	synthesis	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Due	_	_	JJ	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	switch	_	_	NN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	use	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	3	_	_	CD	O	-1	none	_	_
11	'	_	_	''	O	-1	none	_	_
12	polyA	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	more	_	_	RBR	O	-1	none	_	_
17	proximal	_	_	JJ	O	-1	none	_	_
18	polyA	_	_	NN	O	-1	none	_	_
19	site	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	NF-ATc	_	_	NN	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	switches	_	_	VBZ	O	-1	none	_	_
24	from	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	synthesis	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	two	_	_	CD	O	-1	none	_	_
30	longer	_	_	JJR	O	-1	none	_	_
31	isoforms	_	_	NNS	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	naive	_	_	JJ	O	-1	none	_	_
34	T	_	_	NN	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	that	_	_	DT	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	short	_	_	JJ	O	-1	none	_	_
40	isoform	_	_	NN	O	-1	none	_	_
41	A	_	_	NN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	T	_	_	NN	O	-1	none	_	_
44	effector	_	_	NN	O	-1	none	_	_
45	cells	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	relative	_	_	JJ	O	-1	none	_	_
3	low	_	_	JJ	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	affinity	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	cleavage	_	_	NN	O	-1	none	_	_
8	stimulation	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	CstF-64	_	_	NN	Protein	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	proximal	_	_	JJ	O	-1	none	_	_
14	polyA	_	_	NN	O	-1	none	_	_
15	site	_	_	NN	O	-1	none	_	_
16	seems	_	_	VBZ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	contribute	_	_	VB	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	its	_	_	PRP$	O	-1	none	_	_
21	neglect	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	naive	_	_	JJ	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	alternative	_	_	JJ	O	-1	none	_	_
3	polyadenylation	_	_	NN	O	-1	none	_	_
4	events	_	_	NNS	O	-1	none	_	_
5	ensure	_	_	VB	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	rapid	_	_	JJ	O	-1	none	_	_
8	accumulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	high	_	_	JJ	O	-1	none	_	_
11	concentrations	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-ATc	_	_	NN	O	-1	none	_	_
14	necessary	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	exceed	_	_	VB	O	-1	none	_	_
17	critical	_	_	JJ	O	-1	none	_	_
18	threshold	_	_	NN	O	-1	none	_	_
19	levels	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	NF-ATc	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	induction	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	effector	_	_	NN	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Cellular	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	molecular	_	_	JJ	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IFN-gamma	_	_	NN	Protein	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	IL-12	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	NK	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	line	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Interferon-gamma	_	_	NN	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	IFN-gamma	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	important	_	_	JJ	O	-1	none	_	_
8	immunoregulatory	_	_	JJ	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	produced	_	_	VBN	O	-1	none	_	_
11	predominantly	_	_	RB	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	large	_	_	JJ	O	-1	none	_	_
17	granular	_	_	JJ	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	LGL	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	response	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	different	_	_	JJ	O	-1	none	_	_
26	extracellular	_	_	JJ	O	-1	none	_	_
27	signals	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	particular	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	interleukins	_	_	NNS	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	ILs	_	_	NNS	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	IL-12	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	been	_	_	VBN	O	-1	none	_	_
16	shown	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	potent	_	_	JJ	O	-1	none	_	_
20	inducers	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	IFN-gamma	_	_	NN	Protein	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	expression	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	both	_	_	CC	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	LGL	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	it	_	_	PRP	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	reported	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	there	_	_	EX	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	some	_	_	DT	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	lines	_	_	NNS	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	produce	_	_	VBP	O	-1	none	_	_
15	IFN-gamma	_	_	NN	Protein	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	IL-2	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	IL-12	_	_	NN	O	-1	none	_	_
22	stimulation	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	there	_	_	EX	O	-1	none	_	_
25	has	_	_	VBZ	O	-1	none	_	_
26	as	_	_	RB	O	-1	none	_	_
27	yet	_	_	RB	O	-1	none	_	_
28	been	_	_	VBN	O	-1	none	_	_
29	no	_	_	DT	O	-1	none	_	_
30	report	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	natural	_	_	JJ	O	-1	none	_	_
34	killer	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	NK	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	line	_	_	NN	O	-1	none	_	_
40	that	_	_	WDT	O	-1	none	_	_
41	responds	_	_	VBZ	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	a	_	_	DT	O	-1	none	_	_
44	similar	_	_	JJ	O	-1	none	_	_
45	manner	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	report	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	present	_	_	VBP	O	-1	none	_	_
6	evidence	_	_	NN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	line	_	_	NN	O	-1	none	_	_
11	NK3	_	_	NN	O	-1	none	_	_
12	.3	_	_	NN	O	-1	none	_	_
13	derived	_	_	VBN	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	NK	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	responds	_	_	VBZ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	both	_	_	CC	O	-1	none	_	_
22	IL-2	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	IL-12	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	measured	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	increases	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	IFN-gamma	_	_	NN	Protein	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	granulocyte-macrophage	_	_	JJ	Protein	36	multitoken	_	_
34	colony	_	_	NN	Protein	36	multitoken	_	_
35	stimulating	_	_	NN	Protein	36	multitoken	_	_
36	factor	_	_	NN	Protein	0	root	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	GM-CSF	_	_	NN	Protein	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	cytoplasmic	_	_	JJ	O	-1	none	_	_
41	mRNA	_	_	NN	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	protein	_	_	NN	O	-1	none	_	_
44	expression	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	when	_	_	WRB	O	-1	none	_	_
5	used	_	_	VBN	O	-1	none	_	_
6	together	_	_	RB	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	IL-12	_	_	NN	O	-1	none	_	_
10	synergized	_	_	VBD	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	induction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	IFN-gamma	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	GM-CSF	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	this	_	_	DT	O	-1	none	_	_
20	synergy	_	_	NN	O	-1	none	_	_
21	was	_	_	VBD	O	-1	none	_	_
22	attributed	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	an	_	_	DT	O	-1	none	_	_
25	increased	_	_	JJ	O	-1	none	_	_
26	accumulation	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	stability	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	IFN-gamma	_	_	NN	Protein	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	GM-CSF	_	_	NN	Protein	-1	none	_	_
34	mRNAs	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	signaling	_	_	NN	O	-1	none	_	_
5	pathways	_	_	NNS	O	-1	none	_	_
6	involved	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	five	_	_	CD	O	-1	none	_	_
13	inhibitors	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	cyclosporin	_	_	NN	O	-1	none	_	_
16	A	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	CsA	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	transforming	_	_	VBG	Protein	23	multitoken	_	_
22	growth	_	_	NN	Protein	23	multitoken	_	_
23	factor-beta	_	_	NN	Protein	0	root	_	_
24	,	_	_	,	O	-1	none	_	_
25	cycloheximide	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	genistein	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	staurosporine	_	_	NN	O	-1	none	_	_
31	A	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	used	_	_	VBN	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	analyzing	_	_	VBG	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	effects	_	_	NNS	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	IL-2	_	_	NN	Protein	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	IL-12	_	_	NN	O	-1	none	_	_
43	on	_	_	IN	O	-1	none	_	_
44	NK3	_	_	NN	O	-1	none	_	_
45	.3	_	_	NN	O	-1	none	_	_
46	cells	_	_	NNS	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	C	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	new	_	_	JJ	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	synthesis	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	required	_	_	VBN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	induction	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	IFN-gamma	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	GM-CSF	_	_	NN	Protein	-1	none	_	_
26	cytoplasmic	_	_	JJ	O	-1	none	_	_
27	mRNA	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IL-12	_	_	NN	O	-1	none	_	_
5	induction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	IFN-gamma	_	_	NN	Protein	-1	none	_	_
8	cytoplasmic	_	_	JJ	O	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	appears	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	only	_	_	RB	O	-1	none	_	_
13	partially	_	_	RB	O	-1	none	_	_
14	depend	_	_	VB	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	kinase	_	_	NN	O	-1	none	_	_
20	C.	_	_	NN	O	-1	none	_	_
21	Furthermore	_	_	RB	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	both	_	_	DT	O	-1	none	_	_
24	transforming	_	_	VBG	O	-1	none	_	_
25	growth	_	_	NN	O	-1	none	_	_
26	factor-beta	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	genistein	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	a	_	_	DT	O	-1	none	_	_
31	tyrosine	_	_	NN	O	-1	none	_	_
32	kinase	_	_	NN	O	-1	none	_	_
33	inhibitor	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	could	_	_	MD	O	-1	none	_	_
36	suppress	_	_	VB	O	-1	none	_	_
37	IL-2	_	_	NN	Protein	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	IL-12	_	_	NN	O	-1	none	_	_
40	signaling	_	_	NN	O	-1	none	_	_
41	but	_	_	CC	O	-1	none	_	_
42	CsA	_	_	NN	O	-1	none	_	_
43	was	_	_	VBD	O	-1	none	_	_
44	generally	_	_	RB	O	-1	none	_	_
45	inactive	_	_	JJ	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	observed	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	suppression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	cytokine	_	_	NN	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	these	_	_	DT	O	-1	none	_	_
13	agents	_	_	NNS	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	independent	_	_	JJ	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	inhibition	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	proliferation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	but	_	_	CC	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	IL-12	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	AP1	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	regulation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	these	_	_	DT	O	-1	none	_	_
24	two	_	_	CD	O	-1	none	_	_
25	DNA	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	protein	_	_	NN	O	-1	none	_	_
28	complexes	_	_	NNS	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	correlated	_	_	VBN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	IFN-gamma	_	_	NN	Protein	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	GM-CSF	_	_	NN	Protein	-1	none	_	_
35	gene	_	_	NN	O	-1	none	_	_
36	expression	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-12	_	_	NN	O	-1	none	_	_
8	may	_	_	MD	O	-1	none	_	_
9	have	_	_	VB	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	leading	_	_	VBG	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	IFN-gamma	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	GM-CSF	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	NK3	_	_	NN	O	-1	none	_	_
28	.3	_	_	NN	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	line	_	_	NN	O	-1	none	_	_
31	may	_	_	MD	O	-1	none	_	_
32	serve	_	_	VB	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	novel	_	_	JJ	O	-1	none	_	_
36	model	_	_	NN	O	-1	none	_	_
37	for	_	_	IN	O	-1	none	_	_
38	dissecting	_	_	VBG	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	biochemical	_	_	JJ	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	molecular	_	_	JJ	O	-1	none	_	_
43	events	_	_	NNS	O	-1	none	_	_
44	involved	_	_	VBN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	these	_	_	DT	O	-1	none	_	_
47	pathways	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	monocytic	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	Treponema	_	_	FW	O	-1	none	_	_
8	pallidum	_	_	FW	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	Borrelia	_	_	FW	O	-1	none	_	_
11	burgdorferi	_	_	FW	O	-1	none	_	_
12	lipoproteins	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	synthetic	_	_	JJ	O	-1	none	_	_
15	lipopeptides	_	_	NNS	O	-1	none	_	_
16	proceeds	_	_	VBZ	O	-1	none	_	_
17	via	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	pathway	_	_	NN	O	-1	none	_	_
20	distinct	_	_	JJ	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	that	_	_	DT	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	lipopolysaccharide	_	_	NN	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	involves	_	_	VBZ	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	transcriptional	_	_	JJ	O	-1	none	_	_
29	activator	_	_	NN	O	-1	none	_	_
30	NF-kappa	_	_	NN	O	-1	none	_	_
31	B	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	increasing	_	_	VBG	O	-1	none	_	_
4	evidence	_	_	NN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	lipoproteins	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Treponema	_	_	FW	O	-1	none	_	_
9	pallidum	_	_	FW	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Borrelia	_	_	FW	O	-1	none	_	_
12	burgdorferi	_	_	FW	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	key	_	_	JJ	O	-1	none	_	_
15	inflammatory	_	_	JJ	O	-1	none	_	_
16	mediators	_	_	NNS	O	-1	none	_	_
17	during	_	_	IN	O	-1	none	_	_
18	syphilis	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	Lyme	_	_	NN	O	-1	none	_	_
21	disease	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	principal	_	_	JJ	O	-1	none	_	_
3	objective	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	present	_	_	JJ	O	-1	none	_	_
7	study	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	identify	_	_	VB	O	-1	none	_	_
11	more	_	_	RBR	O	-1	none	_	_
12	precisely	_	_	RB	O	-1	none	_	_
13	similarities	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	divergences	_	_	NNS	O	-1	none	_	_
16	among	_	_	IN	O	-1	none	_	_
17	lipopolysaccharide	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	LPS	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	-	_	_	:	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	lipoprotein-lipopeptide-induced	_	_	JJ	O	-1	none	_	_
24	immune	_	_	JJ	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	signaling	_	_	NN	O	-1	none	_	_
27	events	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Like	_	_	IN	O	-1	none	_	_
2	LPS	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	purified	_	_	VBN	O	-1	none	_	_
5	native	_	_	JJ	O	-1	none	_	_
6	B.	_	_	NNP	O	-1	none	_	_
7	burgdorferi	_	_	FW	O	-1	none	_	_
8	OspA	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	synthetic	_	_	JJ	O	-1	none	_	_
11	analogs	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	OspA	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	OspB	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	two	_	_	CD	O	-1	none	_	_
19	T.	_	_	FW	O	-1	none	_	_
20	pallidum	_	_	FW	O	-1	none	_	_
21	lipoproteins	_	_	NNS	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	Tpp47	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	Tpp17	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	all	_	_	DT	O	-1	none	_	_
28	induced	_	_	VBD	O	-1	none	_	_
29	NF-kappa	_	_	NN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	translocation	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	THP-1	_	_	NN	O	-1	none	_	_
34	human	_	_	NN	O	-1	none	_	_
35	monocytoid	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Acylation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	OspA	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	synthetic	_	_	JJ	O	-1	none	_	_
7	peptides	_	_	NNS	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	requisite	_	_	JJ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Polymyxin	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	abrogated	_	_	VBD	O	-1	none	_	_
4	only	_	_	RB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	response	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	LPS	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	70Z/3	_	_	NN	O	-1	none	_	_
4	derived	_	_	VBN	O	-1	none	_	_
5	pre-B-cell	_	_	NN	O	-1	none	_	_
6	lines	_	_	NNS	O	-1	none	_	_
7	either	_	_	CC	O	-1	none	_	_
8	lacking	_	_	VBG	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	expressing	_	_	VBG	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	CD14	_	_	NN	Protein	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	LPS	_	_	NN	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	it	_	_	PRP	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	observed	_	_	VBN	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	human	_	_	NN	O	-1	none	_	_
26	CD14	_	_	NN	Protein	-1	none	_	_
27	imparted	_	_	VBN	O	-1	none	_	_
28	responsiveness	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	LPS	_	_	NN	O	-1	none	_	_
31	but	_	_	CC	O	-1	none	_	_
32	not	_	_	RB	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	OspA	_	_	NN	Protein	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	spirochetal	_	_	JJ	O	-1	none	_	_
37	lipopeptides	_	_	NNS	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	assessed	_	_	VBN	O	-1	none	_	_
40	by	_	_	IN	O	-1	none	_	_
41	induction	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	NF-kappa	_	_	NN	O	-1	none	_	_
44	B	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	expression	_	_	NN	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	surface	_	_	NN	O	-1	none	_	_
49	immunoglobulin	_	_	NN	O	-1	none	_	_
50	M	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	biological	_	_	JJ	O	-1	none	_	_
5	relevance	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	observation	_	_	NN	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	T.	_	_	FW	O	-1	none	_	_
11	pallidum	_	_	FW	O	-1	none	_	_
12	lipoproteins-lipopeptides	_	_	NNS	O	-1	none	_	_
13	induce	_	_	VBP	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	cytokine	_	_	NN	O	-1	none	_	_
19	production	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	monocytes	_	_	NNS	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	supported	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	ability	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	synthetic	_	_	JJ	O	-1	none	_	_
30	analogs	_	_	NNS	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	promote	_	_	VB	O	-1	none	_	_
33	human	_	_	NN	O	-1	none	_	_
34	immunodeficiency	_	_	NN	O	-1	none	_	_
35	virus	_	_	NN	O	-1	none	_	_
36	replication	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	chronically	_	_	RB	O	-1	none	_	_
39	infected	_	_	JJ	O	-1	none	_	_
40	U1	_	_	NN	O	-1	none	_	_
41	monocytoid	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	;	_	_	:	O	-1	none	_	_
44	these	_	_	DT	O	-1	none	_	_
45	observations	_	_	NNS	O	-1	none	_	_
46	also	_	_	RB	O	-1	none	_	_
47	suggest	_	_	VBP	O	-1	none	_	_
48	a	_	_	DT	O	-1	none	_	_
49	potential	_	_	JJ	O	-1	none	_	_
50	mechanism	_	_	NN	O	-1	none	_	_
51	whereby	_	_	WRB	O	-1	none	_	_
52	a	_	_	DT	O	-1	none	_	_
53	syphilitic	_	_	JJ	O	-1	none	_	_
54	chancre	_	_	NN	O	-1	none	_	_
55	can	_	_	MD	O	-1	none	_	_
56	serve	_	_	VB	O	-1	none	_	_
57	as	_	_	IN	O	-1	none	_	_
58	a	_	_	DT	O	-1	none	_	_
59	cofactor	_	_	NN	O	-1	none	_	_
60	for	_	_	IN	O	-1	none	_	_
61	human	_	_	NN	O	-1	none	_	_
62	immunodeficiency	_	_	NN	O	-1	none	_	_
63	virus	_	_	NN	O	-1	none	_	_
64	transmission	_	_	NN	O	-1	none	_	_
65	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	combined	_	_	JJ	O	-1	none	_	_
3	data	_	_	NNS	O	-1	none	_	_
4	lend	_	_	VBP	O	-1	none	_	_
5	additional	_	_	JJ	O	-1	none	_	_
6	support	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	proposal	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	spirochetal	_	_	JJ	O	-1	none	_	_
12	lipoproteins	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	LPS	_	_	NN	O	-1	none	_	_
15	initiate	_	_	VBP	O	-1	none	_	_
16	monocyte	_	_	NN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	via	_	_	IN	O	-1	none	_	_
19	different	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	surface	_	_	NN	O	-1	none	_	_
22	events	_	_	NNS	O	-1	none	_	_
23	but	_	_	CC	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	signaling	_	_	NN	O	-1	none	_	_
27	pathways	_	_	NNS	O	-1	none	_	_
28	ultimately	_	_	RB	O	-1	none	_	_
29	converge	_	_	VBP	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	produce	_	_	VB	O	-1	none	_	_
32	qualitatively	_	_	RB	O	-1	none	_	_
33	similar	_	_	JJ	O	-1	none	_	_
34	cellular	_	_	JJ	O	-1	none	_	_
35	responses	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	chemokine	_	_	NN	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	BLR2	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	EBI1	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	specifically	_	_	RB	O	-1	none	_	_
11	transactivated	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	Epstein-Barr	_	_	JJ	Protein	17	multitoken	_	_
14	virus	_	_	NN	Protein	17	multitoken	_	_
15	nuclear	_	_	JJ	Protein	17	multitoken	_	_
16	antigen	_	_	NN	Protein	17	multitoken	_	_
17	2	_	_	CD	Protein	0	root	_	_
18	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	our	_	_	PRP$	O	-1	none	_	_
3	attempt	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	identify	_	_	VB	O	-1	none	_	_
6	chemokine	_	_	NN	O	-1	none	_	_
7	receptors	_	_	NNS	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	related	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	Burkitt	_	_	NN	Protein	16	multitoken	_	_
13	's	_	_	POS	Protein	16	multitoken	_	_
14	lymphoma	_	_	NN	Protein	16	multitoken	_	_
15	receptor	_	_	NN	Protein	16	multitoken	_	_
16	1	_	_	CD	Protein	0	root	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	BLR1	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	expressed	_	_	VBN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	activated	_	_	VBN	O	-1	none	_	_
25	lymphocytes	_	_	NNS	O	-1	none	_	_
26	we	_	_	PRP	O	-1	none	_	_
27	used	_	_	VBD	O	-1	none	_	_
28	RT-PCR	_	_	NN	O	-1	none	_	_
29	resulting	_	_	VBG	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	isolation	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	cDNA	_	_	NN	O	-1	none	_	_
36	encoding	_	_	VBG	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	seven	_	_	CD	O	-1	none	_	_
39	transmembrane	_	_	NN	O	-1	none	_	_
40	receptor	_	_	NN	O	-1	none	_	_
41	termed	_	_	VBN	O	-1	none	_	_
42	BLR2	_	_	NN	Protein	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	shows	_	_	VBZ	O	-1	none	_	_
4	significant	_	_	JJ	O	-1	none	_	_
5	sequence	_	_	NN	O	-1	none	_	_
6	similarities	_	_	NNS	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	G	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	coupled	_	_	VBN	O	-1	none	_	_
14	chemokine	_	_	NN	O	-1	none	_	_
15	receptors	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	turned	_	_	VBD	O	-1	none	_	_
18	out	_	_	RP	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	identical	_	_	JJ	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	recently	_	_	RB	O	-1	none	_	_
25	described	_	_	VBN	O	-1	none	_	_
26	receptor	_	_	NN	O	-1	none	_	_
27	EBI1	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	revealed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	BLR2	_	_	NN	Protein	-1	none	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	could	_	_	MD	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	highly	_	_	RB	O	-1	none	_	_
11	stimulated	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	mitogen-	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	anti-CD3-treated	_	_	JJ	O	-1	none	_	_
16	peripheral	_	_	JJ	O	-1	none	_	_
17	blood	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	BLR2	_	_	NN	Protein	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	mRNA	_	_	NN	O	-1	none	_	_
4	could	_	_	MD	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	detected	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	all	_	_	DT	O	-1	none	_	_
9	Epstein-Barr	_	_	JJ	O	-1	none	_	_
10	virus	_	_	NN	O	-1	none	_	_
11	positive	_	_	JJ	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	lines	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	BLR2	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	could	_	_	MD	O	-1	none	_	_
10	be	_	_	VB	O	-1	none	_	_
11	specifically	_	_	RB	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	Epstein-Barr	_	_	JJ	O	-1	none	_	_
15	virus	_	_	NN	O	-1	none	_	_
16	negative	_	_	JJ	O	-1	none	_	_
17	BL	_	_	NN	O	-1	none	_	_
18	41	_	_	CD	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	via	_	_	IN	O	-1	none	_	_
21	estrogen	_	_	NN	O	-1	none	_	_
22	mediated	_	_	JJ	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	Epstein-Barr	_	_	JJ	Protein	29	multitoken	_	_
26	virus	_	_	NN	Protein	29	multitoken	_	_
27	nuclear	_	_	JJ	Protein	29	multitoken	_	_
28	antigen	_	_	NN	Protein	29	multitoken	_	_
29	2	_	_	CD	Protein	0	root	_	_
30	,	_	_	,	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	key	_	_	JJ	O	-1	none	_	_
33	regulator	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	viral	_	_	JJ	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	cellular	_	_	JJ	O	-1	none	_	_
38	genes	_	_	NNS	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	immortalized	_	_	VBN	O	-1	none	_	_
41	B	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	involvement	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	BLR2	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	migration	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	activated	_	_	VBN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	viral	_	_	JJ	O	-1	none	_	_
19	pathogenesis	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Multiple	_	_	JJ	O	-1	none	_	_
2	proteins	_	_	NNS	O	-1	none	_	_
3	interact	_	_	VBP	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	inhibitory	_	_	JJ	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	repressor	_	_	NN	O	-1	none	_	_
10	element	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	interleukin-3	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	T	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	interleukin	_	_	NN	Protein	6	multitoken	_	_
6	3	_	_	CD	Protein	0	root	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	IL-3	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	directed	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	positive	_	_	JJ	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	negative	_	_	JJ	O	-1	none	_	_
16	cis	_	_	NN	O	-1	none	_	_
17	acting	_	_	VBG	O	-1	none	_	_
18	DNA	_	_	NN	O	-1	none	_	_
19	elements	_	_	NNS	O	-1	none	_	_
20	clustered	_	_	VBN	O	-1	none	_	_
21	within	_	_	IN	O	-1	none	_	_
22	300	_	_	CD	O	-1	none	_	_
23	base	_	_	NN	O	-1	none	_	_
24	pairs	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transcriptional	_	_	JJ	O	-1	none	_	_
28	start	_	_	NN	O	-1	none	_	_
29	site	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	strong	_	_	JJ	O	-1	none	_	_
3	repressor	_	_	NN	O	-1	none	_	_
4	element	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	termed	_	_	VBN	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	inhibitory	_	_	JJ	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	NIP	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	previously	_	_	RB	O	-1	none	_	_
16	mapped	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	segment	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	IL-3	_	_	NN	Protein	-1	none	_	_
23	promoter	_	_	NN	O	-1	none	_	_
24	between	_	_	IN	O	-1	none	_	_
25	nucleotides	_	_	NNS	O	-1	none	_	_
26	-271	_	_	CD	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	-250	_	_	CD	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	characterization	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	element	_	_	NN	O	-1	none	_	_
6	demonstrates	_	_	VBZ	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	it	_	_	PRP	O	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	mediate	_	_	VB	O	-1	none	_	_
11	repression	_	_	NN	O	-1	none	_	_
12	when	_	_	WRB	O	-1	none	_	_
13	linked	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	cis	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	heterologous	_	_	JJ	O	-1	none	_	_
19	promoter	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	DNA	_	_	NN	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	carried	_	_	VBN	O	-1	none	_	_
6	out	_	_	RP	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	characterize	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	repressor	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	varying	_	_	VBG	O	-1	none	_	_
3	conditions	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	three	_	_	CD	O	-1	none	_	_
6	distinct	_	_	JJ	O	-1	none	_	_
7	complexes	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	shown	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	interact	_	_	VB	O	-1	none	_	_
12	specifically	_	_	RB	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	NIP	_	_	NN	O	-1	none	_	_
16	region	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	although	_	_	IN	O	-1	none	_	_
19	only	_	_	RB	O	-1	none	_	_
20	one	_	_	CD	O	-1	none	_	_
21	correlates	_	_	VBZ	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	repressor	_	_	NN	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Complex	_	_	NN	O	-1	none	_	_
2	1	_	_	CD	O	-1	none	_	_
3	results	_	_	VBZ	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	ubiquitous	_	_	JJ	O	-1	none	_	_
9	polypeptide	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	recognizes	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	3	_	_	CD	O	-1	none	_	_
14	'	_	_	''	O	-1	none	_	_
15	portion	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	this	_	_	DT	O	-1	none	_	_
18	sequence	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	required	_	_	VBN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	repression	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Complex	_	_	NN	O	-1	none	_	_
2	2	_	_	CD	O	-1	none	_	_
3	corresponds	_	_	VBZ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	upstream	_	_	JJ	O	-1	none	_	_
11	stimulatory	_	_	JJ	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	E-box	_	_	NN	O	-1	none	_	_
17	motif	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	5	_	_	CD	O	-1	none	_	_
21	'	_	_	''	O	-1	none	_	_
22	portion	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	NIP	_	_	NN	O	-1	none	_	_
26	region	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	DNA	_	_	NN	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	specificity	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	complex	_	_	JJ	O	-1	none	_	_
6	3	_	_	CD	O	-1	none	_	_
7	overlaps	_	_	VBZ	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	that	_	_	DT	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	upstream	_	_	JJ	O	-1	none	_	_
12	stimulatory	_	_	JJ	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	clearly	_	_	RB	O	-1	none	_	_
17	distinct	_	_	JJ	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	which	_	_	WDT	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	latter	_	_	JJ	O	-1	none	_	_
7	two	_	_	CD	O	-1	none	_	_
8	complexes	_	_	NNS	O	-1	none	_	_
9	represents	_	_	VBZ	O	-1	none	_	_
10	NIP	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	we	_	_	PRP	O	-1	none	_	_
14	incorporated	_	_	VBD	O	-1	none	_	_
15	small	_	_	JJ	O	-1	none	_	_
16	alterations	_	_	NNS	O	-1	none	_	_
17	into	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	NIP	_	_	NN	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	an	_	_	DT	O	-1	none	_	_
23	IL-3	_	_	NN	Protein	-1	none	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	linked	_	_	VBN	O	-1	none	_	_
26	reporter	_	_	NN	O	-1	none	_	_
27	construct	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	examined	_	_	VBD	O	-1	none	_	_
30	their	_	_	PRP$	O	-1	none	_	_
31	effects	_	_	NNS	O	-1	none	_	_
32	on	_	_	IN	O	-1	none	_	_
33	NIP	_	_	NN	O	-1	none	_	_
34	mediated	_	_	VBD	O	-1	none	_	_
35	repression	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	specificity	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	repression	_	_	NN	O	-1	none	_	_
5	matches	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	DNA	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	specificity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	complex	_	_	JJ	O	-1	none	_	_
12	3	_	_	CD	O	-1	none	_	_
13	;	_	_	:	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	repressor	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	complex	_	_	NN	O	-1	none	_	_
19	3	_	_	CD	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	require	_	_	VBP	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	consensus	_	_	NN	O	-1	none	_	_
24	sequence	_	_	NN	O	-1	none	_	_
25	CTCACNTNC	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Legionella	_	_	NN	O	-1	none	_	_
3	pneumophila	_	_	NN	O	-1	none	_	_
4	rpoS	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	required	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	growth	_	_	NN	O	-1	none	_	_
10	within	_	_	IN	O	-1	none	_	_
11	Acanthamoeba	_	_	NN	O	-1	none	_	_
12	castellanii	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	regulatory	_	_	JJ	O	-1	none	_	_
4	networks	_	_	NNS	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	Legionella	_	_	NN	O	-1	none	_	_
7	pneumophila	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	encoding	_	_	VBG	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	homolog	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	Escherichia	_	_	FW	O	-1	none	_	_
17	coli	_	_	FW	O	-1	none	_	_
18	stress	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	stationary-phase	_	_	NN	O	-1	none	_	_
21	sigma	_	_	NN	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	RpoS	_	_	NN	Protein	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	identified	_	_	VBN	O	-1	none	_	_
26	by	_	_	IN	O	-1	none	_	_
27	complementation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	E.	_	_	FW	O	-1	none	_	_
31	coli	_	_	FW	O	-1	none	_	_
32	rpoS	_	_	NN	Protein	-1	none	_	_
33	mutation	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	open	_	_	JJ	O	-1	none	_	_
3	reading	_	_	NN	O	-1	none	_	_
4	frame	_	_	NN	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	approximately	_	_	RB	O	-1	none	_	_
8	60	_	_	CD	O	-1	none	_	_
9	%	_	_	NN	O	-1	none	_	_
10	identical	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	E.	_	_	FW	O	-1	none	_	_
14	coli	_	_	FW	O	-1	none	_	_
15	rpoS	_	_	NN	Protein	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	identified	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	level	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	L.	_	_	FW	O	-1	none	_	_
10	pneumophila	_	_	FW	O	-1	none	_	_
11	RpoS	_	_	NN	Protein	-1	none	_	_
12	increased	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	stationary	_	_	JJ	O	-1	none	_	_
15	phase	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	insertion	_	_	NN	O	-1	none	_	_
3	mutation	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	constructed	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	rpoS	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	chromosome	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	L.	_	_	FW	O	-1	none	_	_
15	pneumophila	_	_	FW	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	ability	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	this	_	_	DT	O	-1	none	_	_
22	mutant	_	_	NN	O	-1	none	_	_
23	strain	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	survive	_	_	VB	O	-1	none	_	_
26	various	_	_	JJ	O	-1	none	_	_
27	stress	_	_	NN	O	-1	none	_	_
28	conditions	_	_	NNS	O	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	assayed	_	_	VBN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	compared	_	_	VBN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	results	_	_	NNS	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	wild-type	_	_	JJ	O	-1	none	_	_
38	strain	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Both	_	_	CC	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	mutant	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	wild-type	_	_	JJ	O	-1	none	_	_
6	strains	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	more	_	_	RBR	O	-1	none	_	_
9	resistant	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	stress	_	_	NN	O	-1	none	_	_
12	when	_	_	WRB	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	stationary	_	_	JJ	O	-1	none	_	_
15	phase	_	_	NN	O	-1	none	_	_
16	than	_	_	IN	O	-1	none	_	_
17	when	_	_	WRB	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	logarithmic	_	_	JJ	O	-1	none	_	_
21	phase	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	growth	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	finding	_	_	NN	O	-1	none	_	_
3	indicates	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	L.	_	_	FW	O	-1	none	_	_
6	pneumophila	_	_	FW	O	-1	none	_	_
7	RpoS	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	required	_	_	VBN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	stationary-phase-dependent	_	_	JJ	O	-1	none	_	_
14	resistance	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	stress	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	mutant	_	_	NN	O	-1	none	_	_
4	strain	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	able	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	kill	_	_	VB	O	-1	none	_	_
9	HL-60-	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	THP-1-derived	_	_	JJ	O	-1	none	_	_
12	macrophages	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	it	_	_	PRP	O	-1	none	_	_
15	could	_	_	MD	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	replicate	_	_	VB	O	-1	none	_	_
18	within	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	protozoan	_	_	NN	O	-1	none	_	_
21	host	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	Acanthamoeba	_	_	NN	O	-1	none	_	_
24	castellanii	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	L.	_	_	FW	O	-1	none	_	_
6	pneumophila	_	_	FW	O	-1	none	_	_
7	possesses	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	growth	_	_	NN	O	-1	none	_	_
10	phase	_	_	NN	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	resistance	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	stress	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	independent	_	_	JJ	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	RpoS	_	_	NN	Protein	-1	none	_	_
20	control	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	RpoS	_	_	NN	Protein	-1	none	_	_
24	likely	_	_	JJ	O	-1	none	_	_
25	regulates	_	_	VBZ	O	-1	none	_	_
26	genes	_	_	NNS	O	-1	none	_	_
27	that	_	_	WDT	O	-1	none	_	_
28	enable	_	_	VBP	O	-1	none	_	_
29	it	_	_	PRP	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	survive	_	_	VB	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	environment	_	_	NN	O	-1	none	_	_
35	within	_	_	IN	O	-1	none	_	_
36	protozoa	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	rpoS	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	L.	_	_	FW	O	-1	none	_	_
11	pneumophila	_	_	FW	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	very	_	_	RB	O	-1	none	_	_
14	different	_	_	JJ	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	what	_	_	WP	O	-1	none	_	_
17	has	_	_	VBZ	O	-1	none	_	_
18	previously	_	_	RB	O	-1	none	_	_
19	been	_	_	VBN	O	-1	none	_	_
20	reported	_	_	VBN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	E.	_	_	FW	O	-1	none	_	_
23	coli	_	_	FW	O	-1	none	_	_
24	rpoS	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Apoptosis	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	growth	_	_	NN	O	-1	none	_	_
4	inhibition	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	malignant	_	_	JJ	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	after	_	_	IN	O	-1	none	_	_
9	treatment	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	arsenic	_	_	JJ	O	-1	none	_	_
12	trioxide	_	_	NN	O	-1	none	_	_
13	at	_	_	IN	O	-1	none	_	_
14	clinically	_	_	RB	O	-1	none	_	_
15	achievable	_	_	JJ	O	-1	none	_	_
16	concentrations	_	_	NNS	O	-1	none	_	_
17	[	_	_	VBP	O	-1	none	_	_
18	see	_	_	VB	O	-1	none	_	_
19	comments	_	_	NNS	O	-1	none	_	_
20	]	_	_	CD	O	-1	none	_	_
21	BACKGROUND	_	_	NN	O	-1	none	_	_
22	:	_	_	:	O	-1	none	_	_
23	Arsenic	_	_	JJ	O	-1	none	_	_
24	trioxide	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	As2O3	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	can	_	_	MD	O	-1	none	_	_
29	induce	_	_	VB	O	-1	none	_	_
30	clinical	_	_	JJ	O	-1	none	_	_
31	remission	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	patients	_	_	NNS	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	acute	_	_	JJ	O	-1	none	_	_
36	promyelocytic	_	_	JJ	O	-1	none	_	_
37	leukemia	_	_	NN	O	-1	none	_	_
38	via	_	_	IN	O	-1	none	_	_
39	induction	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	differentiation	_	_	NN	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	programmed	_	_	VBN	O	-1	none	_	_
44	cell	_	_	NN	O	-1	none	_	_
45	death	_	_	NN	O	-1	none	_	_
46	(	_	_	-LRB-	O	-1	none	_	_
47	apoptosis	_	_	NN	O	-1	none	_	_
48	)	_	_	-RRB-	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	As2O3	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	panel	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	malignant	_	_	JJ	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	determine	_	_	VB	O	-1	none	_	_
15	whether	_	_	IN	O	-1	none	_	_
16	growth-inhibitory	_	_	JJ	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	apoptotic	_	_	JJ	O	-1	none	_	_
19	effects	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	As2O3	_	_	NN	O	-1	none	_	_
22	can	_	_	MD	O	-1	none	_	_
23	be	_	_	VB	O	-1	none	_	_
24	observed	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	these	_	_	DT	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	clinically	_	_	RB	O	-1	none	_	_
30	achievable	_	_	JJ	O	-1	none	_	_
31	concentrations	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Eight	_	_	CD	O	-1	none	_	_
4	malignant	_	_	JJ	O	-1	none	_	_
5	lymphocytic	_	_	JJ	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	lines	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	primary	_	_	JJ	O	-1	none	_	_
10	cultures	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	lymphocytic	_	_	JJ	O	-1	none	_	_
13	leukemia	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	lymphoma	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	were	_	_	VBD	O	-1	none	_	_
18	treated	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	As2O3	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	without	_	_	IN	O	-1	none	_	_
25	dithiothreitol	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	DTT	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	or	_	_	CC	O	-1	none	_	_
30	buthionine	_	_	NN	O	-1	none	_	_
31	sulfoximine	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	BSO	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	an	_	_	DT	O	-1	none	_	_
37	inhibitor	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	glutathione	_	_	NN	O	-1	none	_	_
40	synthesis	_	_	NN	O	-1	none	_	_
41	)	_	_	-RRB-	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Apoptosis	_	_	NN	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	assessed	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	morphology	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	flow	_	_	NN	O	-1	none	_	_
9	cytometry	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	annexin	_	_	NN	Protein	12	multitoken	_	_
12	V	_	_	NN	Protein	0	root	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	level	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	terminal	_	_	JJ	Protein	19	multitoken	_	_
18	deoxynucleotidyl	_	_	NN	Protein	19	multitoken	_	_
19	transferase	_	_	NN	Protein	0	root	_	_
20	labeling	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	DNA	_	_	NN	O	-1	none	_	_
23	fragments	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Cellular	_	_	JJ	O	-1	none	_	_
2	proliferation	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	determined	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	5-bromo-2	_	_	JJ	O	-1	none	_	_
7	'-deoxyuridine	_	_	NN	O	-1	none	_	_
8	incorporation	_	_	NN	O	-1	none	_	_
9	into	_	_	IN	O	-1	none	_	_
10	DNA	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	flow	_	_	NN	O	-1	none	_	_
13	cytometry	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	use	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	mitotic	_	_	JJ	O	-1	none	_	_
20	arrest	_	_	NN	O	-1	none	_	_
21	assay	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Mitochondrial	_	_	JJ	O	-1	none	_	_
2	transmembrane	_	_	JJ	O	-1	none	_	_
3	potential	_	_	JJ	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	delta	_	_	NN	O	-1	none	_	_
6	psi	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	m	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	measured	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	means	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	rhodamine	_	_	NN	O	-1	none	_	_
17	123	_	_	CD	O	-1	none	_	_
18	staining	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	flow	_	_	NN	O	-1	none	_	_
21	cytometry	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Protein	_	_	NN	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	assessed	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	western	_	_	NN	O	-1	none	_	_
7	blot	_	_	NN	O	-1	none	_	_
8	analysis	_	_	NN	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	immunofluorescence	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Therapeutic	_	_	JJ	O	-1	none	_	_
4	concentrations	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	As2O3	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	1-2	_	_	CD	O	-1	none	_	_
9	microM	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	had	_	_	VBD	O	-1	none	_	_
12	dual	_	_	JJ	O	-1	none	_	_
13	effects	_	_	NNS	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	malignant	_	_	JJ	O	-1	none	_	_
16	lymphocytes	_	_	NNS	O	-1	none	_	_
17	:	_	_	:	O	-1	none	_	_
18	1	_	_	CD	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	inhibition	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	growth	_	_	NN	O	-1	none	_	_
23	through	_	_	IN	O	-1	none	_	_
24	adenosine	_	_	NN	O	-1	none	_	_
25	triphosphate	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	ATP	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	depletion	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	prolongation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	cell	_	_	NN	O	-1	none	_	_
34	cycle	_	_	NN	O	-1	none	_	_
35	time	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	2	_	_	CD	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	induction	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	apoptosis	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	As2O3	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	apoptosis	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	preceded	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	delta	_	_	NN	O	-1	none	_	_
8	psi	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	m	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	collapse	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	DTT	_	_	NN	O	-1	none	_	_
2	antagonized	_	_	VBD	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	BSO	_	_	NN	O	-1	none	_	_
5	enhanced	_	_	VBD	O	-1	none	_	_
6	As2O3	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	ATP	_	_	NN	O	-1	none	_	_
9	depletion	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	delta	_	_	NN	O	-1	none	_	_
12	psi	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	m	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	collapse	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	apoptosis	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Caspase-3	_	_	NNP	Protein	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	usually	_	_	RB	O	-1	none	_	_
5	resulting	_	_	VBG	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	delta	_	_	NN	O	-1	none	_	_
8	psi	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	m	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	collapse	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	always	_	_	RB	O	-1	none	_	_
17	associated	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	As2O3	_	_	NN	O	-1	none	_	_
20	induced	_	_	VBD	O	-1	none	_	_
21	apoptosis	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	As2O3	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	PML	_	_	NN	Protein	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	promyelocytic	_	_	JJ	O	-1	none	_	_
6	leukemia	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	degradation	_	_	NN	O	-1	none	_	_
10	but	_	_	CC	O	-1	none	_	_
11	did	_	_	VBD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	modulate	_	_	VB	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	cycle	_	_	NN	O	-1	none	_	_
18	related	_	_	JJ	O	-1	none	_	_
19	proteins	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	including	_	_	VBG	O	-1	none	_	_
22	c-myc	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	retinoblastoma	_	_	NN	Protein	25	multitoken	_	_
25	protein	_	_	NN	Protein	0	root	_	_
26	,	_	_	,	O	-1	none	_	_
27	cyclin	_	_	NN	Protein	30	multitoken	_	_
28	dependent	_	_	JJ	Protein	30	multitoken	_	_
29	kinase	_	_	NN	Protein	30	multitoken	_	_
30	4	_	_	CD	Protein	0	root	_	_
31	,	_	_	,	O	-1	none	_	_
32	cyclin	_	_	NN	Protein	33	multitoken	_	_
33	D1	_	_	NN	Protein	0	root	_	_
34	,	_	_	,	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	p53	_	_	NN	Protein	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	or	_	_	CC	O	-1	none	_	_
39	expression	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	differentiation	_	_	NN	O	-1	none	_	_
42	related	_	_	JJ	O	-1	none	_	_
43	antigens	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Substantial	_	_	JJ	O	-1	none	_	_
4	growth	_	_	NN	O	-1	none	_	_
5	inhibition	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	apoptosis	_	_	NN	O	-1	none	_	_
8	without	_	_	IN	O	-1	none	_	_
9	evidence	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	most	_	_	JJS	O	-1	none	_	_
16	malignant	_	_	JJ	O	-1	none	_	_
17	lymphocytic	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	treated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	1-2	_	_	CD	O	-1	none	_	_
22	microM	_	_	NN	O	-1	none	_	_
23	As2O3	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	As2O3	_	_	NN	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	prove	_	_	VB	O	-1	none	_	_
4	useful	_	_	JJ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	malignant	_	_	JJ	O	-1	none	_	_
10	lymphoproliferative	_	_	JJ	O	-1	none	_	_
11	disorders	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	UV	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	CYP1A1	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	mediated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	tryptophan	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cytochrome	_	_	NN	Protein	4	multitoken	_	_
4	P-4501A1	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	CYP1A1	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	UV	_	_	NN	O	-1	none	_	_
11	has	_	_	VBZ	O	-1	none	_	_
12	been	_	_	VBN	O	-1	none	_	_
13	observed	_	_	VBN	O	-1	none	_	_
14	earlier	_	_	RBR	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	animal	_	_	JJ	O	-1	none	_	_
17	studies	_	_	NNS	O	-1	none	_	_
18	via	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	mechanism	_	_	NN	O	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	yet	_	_	RB	O	-1	none	_	_
25	been	_	_	VBN	O	-1	none	_	_
26	resolved	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	previous	_	_	JJ	O	-1	none	_	_
3	data	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	indicated	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	formylated	_	_	VBN	O	-1	none	_	_
8	indolocarbazoles	_	_	NNS	O	-1	none	_	_
9	which	_	_	WDT	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	formed	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	UV	_	_	NN	O	-1	none	_	_
14	irradiation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	tryptophan	_	_	NN	O	-1	none	_	_
17	solutions	_	_	NNS	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	very	_	_	RB	O	-1	none	_	_
20	potent	_	_	JJ	O	-1	none	_	_
21	Ah-receptor	_	_	NN	Protein	-1	none	_	_
22	agonists	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	evaluate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	effect	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	UV	_	_	NN	O	-1	none	_	_
7	light	_	_	NN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	cytochrome	_	_	NN	Protein	10	multitoken	_	_
10	P4501A1	_	_	NN	Protein	0	root	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	studied	_	_	VBD	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	CYP1A1	_	_	NN	Protein	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	UV	_	_	NN	O	-1	none	_	_
23	irradiation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	cultured	_	_	VBN	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	keratinocytes	_	_	NNS	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	HaCaT	_	_	NN	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	line	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	primary	_	_	JJ	O	-1	none	_	_
35	human	_	_	NN	O	-1	none	_	_
36	blood	_	_	NN	O	-1	none	_	_
37	lymphocytes	_	_	NNS	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	mouse	_	_	NN	O	-1	none	_	_
40	Hepa-1	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	exposed	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	UV	_	_	NN	O	-1	none	_	_
7	light	_	_	NN	O	-1	none	_	_
8	delivered	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	bank	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	6	_	_	CD	O	-1	none	_	_
14	Philips	_	_	NN	O	-1	none	_	_
15	TL20/12RS	_	_	NN	O	-1	none	_	_
16	sun	_	_	NN	O	-1	none	_	_
17	lamps	_	_	NNS	O	-1	none	_	_
18	emitting	_	_	VBG	O	-1	none	_	_
19	primarily	_	_	RB	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	UVB	_	_	NN	O	-1	none	_	_
23	range	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	absence	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	presence	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	tryptophan	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	semiquantitative	_	_	JJ	O	-1	none	_	_
3	reverse	_	_	JJ	O	-1	none	_	_
4	transcriptase	_	_	NN	O	-1	none	_	_
5	linked	_	_	VBN	O	-1	none	_	_
6	polymerase	_	_	NN	O	-1	none	_	_
7	chain	_	_	NN	O	-1	none	_	_
8	reaction	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	RT-PCR	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	used	_	_	VBN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	analysis	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	treated	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	CYP1A1	_	_	NN	Protein	-1	none	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	level	_	_	NN	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	UV	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	presence	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	tryptophan	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	higher	_	_	JJR	O	-1	none	_	_
19	than	_	_	IN	O	-1	none	_	_
20	that	_	_	DT	O	-1	none	_	_
21	induced	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	UV	_	_	NN	O	-1	none	_	_
24	alone	_	_	RB	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	both	_	_	CC	O	-1	none	_	_
27	HaCaT	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	lymphocytes	_	_	NNS	O	-1	none	_	_
31	after	_	_	IN	O	-1	none	_	_
32	3	_	_	CD	O	-1	none	_	_
33	h	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	incubation	_	_	NN	O	-1	none	_	_
36	post-UV	_	_	JJ	O	-1	none	_	_
37	irradiation	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	find	_	_	VB	O	-1	none	_	_
3	out	_	_	RP	O	-1	none	_	_
4	if	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	UV	_	_	NN	O	-1	none	_	_
9	light	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	caused	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	formation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	an	_	_	DT	O	-1	none	_	_
17	Ah	_	_	NN	Protein	18	multitoken	_	_
18	receptor	_	_	NN	Protein	0	root	_	_
19	ligand	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	Hepa-1	_	_	NN	O	-1	none	_	_
22	wild-type	_	_	JJ	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	Ah	_	_	NN	Protein	25	multitoken	_	_
25	receptor	_	_	NN	Protein	0	root	_	_
26	deficient	_	_	JJ	O	-1	none	_	_
27	c12	_	_	NN	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	lines	_	_	NNS	O	-1	none	_	_
30	were	_	_	VBD	O	-1	none	_	_
31	applied	_	_	VBN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Wild-type	_	_	JJ	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	wt	_	_	JJ	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	inducible	_	_	JJ	O	-1	none	_	_
8	either	_	_	CC	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	tryptophan	_	_	NN	O	-1	none	_	_
12	photoproduct	_	_	NN	O	-1	none	_	_
13	6-formylindolo	_	_	JJ	O	-1	none	_	_
14	[	_	_	CD	O	-1	none	_	_
15	3,2-b	_	_	JJ	O	-1	none	_	_
16	]	_	_	NN	O	-1	none	_	_
17	carbazole	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	FICZ	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	UV	_	_	NN	O	-1	none	_	_
24	irradiation	_	_	NN	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	very	_	_	RB	O	-1	none	_	_
27	low	_	_	JJ	O	-1	none	_	_
28	or	_	_	CC	O	-1	none	_	_
29	undetectable	_	_	JJ	O	-1	none	_	_
30	levels	_	_	NNS	O	-1	none	_	_
31	were	_	_	VBD	O	-1	none	_	_
32	observed	_	_	VBN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	c12	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	shows	_	_	VBZ	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	induction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	FICZ	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	UV	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	Ah	_	_	NN	Protein	15	multitoken	_	_
15	receptor	_	_	NN	Protein	0	root	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	indicate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	UV	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	CYP1A1	_	_	NN	Protein	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	mammalian	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	mediated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	Ah	_	_	NN	Protein	20	multitoken	_	_
20	receptor	_	_	NN	Protein	0	root	_	_
21	ligand	_	_	NN	O	-1	none	_	_
22	formed	_	_	VBN	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	tryptophan	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	photoproducts	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	tryptophan	_	_	NN	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	suggested	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	be	_	_	VB	O	-1	none	_	_
11	mediators	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	light	_	_	JJ	O	-1	none	_	_
14	via	_	_	IN	O	-1	none	_	_
15	binding	_	_	VBG	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	Ah	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	and	_	_	CC	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	such	_	_	JJ	O	-1	none	_	_
23	also	_	_	RB	O	-1	none	_	_
24	could	_	_	MD	O	-1	none	_	_
25	have	_	_	VB	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	role	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	light	_	_	JJ	O	-1	none	_	_
30	regulated	_	_	VBN	O	-1	none	_	_
31	biological	_	_	JJ	O	-1	none	_	_
32	rhythms	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	Protein	2	multitoken	_	_
2	receptors	_	_	NNS	Protein	0	root	_	_
3	in	_	_	IN	O	-1	none	_	_
4	anorexia	_	_	NN	O	-1	none	_	_
5	nervosa	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	Cushing	_	_	NN	O	-1	none	_	_
8	's	_	_	POS	O	-1	none	_	_
9	disease	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Patients	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	anorexia	_	_	NN	O	-1	none	_	_
6	nervosa	_	_	NN	O	-1	none	_	_
7	do	_	_	VBP	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	display	_	_	VB	O	-1	none	_	_
10	cushingoid	_	_	JJ	O	-1	none	_	_
11	features	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	spite	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	elevated	_	_	JJ	O	-1	none	_	_
16	cortisol	_	_	NN	O	-1	none	_	_
17	plasma	_	_	NN	O	-1	none	_	_
18	levels	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Whether	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	cortisol	_	_	NN	O	-1	none	_	_
4	resistance	_	_	NN	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	reduced	_	_	JJ	O	-1	none	_	_
8	availability	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	metabolic	_	_	JJ	O	-1	none	_	_
12	substrates	_	_	NNS	O	-1	none	_	_
13	necessary	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	develop	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	effect	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	glucocorticoids	_	_	NNS	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	responsible	_	_	JJ	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	has	_	_	VBZ	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	been	_	_	VBN	O	-1	none	_	_
27	established	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Twenty-two	_	_	CD	O	-1	none	_	_
4	patients	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	severe	_	_	JJ	O	-1	none	_	_
7	restrictive	_	_	JJ	O	-1	none	_	_
8	anorexia	_	_	NN	O	-1	none	_	_
9	nervosa	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	10	_	_	CD	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	active	_	_	JJ	O	-1	none	_	_
15	Cushing	_	_	NN	O	-1	none	_	_
16	's	_	_	POS	O	-1	none	_	_
17	disease	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	24	_	_	CD	O	-1	none	_	_
21	healthy	_	_	JJ	O	-1	none	_	_
22	volunteers	_	_	NNS	O	-1	none	_	_
23	without	_	_	IN	O	-1	none	_	_
24	psychiatric	_	_	JJ	O	-1	none	_	_
25	disorders	_	_	NNS	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	mood	_	_	NN	O	-1	none	_	_
28	alterations	_	_	NNS	O	-1	none	_	_
29	were	_	_	VBD	O	-1	none	_	_
30	investigated	_	_	VBN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	Protein	2	multitoken	_	_
2	receptor	_	_	NN	Protein	0	root	_	_
3	characteristics	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	examined	_	_	VBN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	mononuclear	_	_	JJ	O	-1	none	_	_
8	leukocytes	_	_	NNS	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	measuring	_	_	VBG	O	-1	none	_	_
11	[	_	_	CD	O	-1	none	_	_
12	3H	_	_	NN	O	-1	none	_	_
13	]	_	_	CD	O	-1	none	_	_
14	dexamethasone	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	effect	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	dexamethasone	_	_	NN	O	-1	none	_	_
21	on	_	_	IN	O	-1	none	_	_
22	[	_	_	NN	O	-1	none	_	_
23	3H	_	_	NN	O	-1	none	_	_
24	]	_	_	CD	O	-1	none	_	_
25	thymidine	_	_	NN	O	-1	none	_	_
26	incorporation	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	represents	_	_	VBZ	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	index	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	DNA	_	_	NN	O	-1	none	_	_
34	synthesis	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	number	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	glucocorticoid	_	_	NN	Protein	7	multitoken	_	_
7	receptors	_	_	NNS	Protein	0	root	_	_
8	on	_	_	IN	O	-1	none	_	_
9	mononuclear	_	_	JJ	O	-1	none	_	_
10	leukocytes	_	_	NNS	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	MNL	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	comparable	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	anorexia	_	_	NN	O	-1	none	_	_
20	nervosa	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	active	_	_	JJ	O	-1	none	_	_
25	Cushing	_	_	NN	O	-1	none	_	_
26	's	_	_	POS	O	-1	none	_	_
27	disease	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	normal	_	_	JJ	O	-1	none	_	_
31	subjects	_	_	NNS	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	binding	_	_	NN	O	-1	none	_	_
34	capacity	_	_	NN	O	-1	none	_	_
35	3.3	_	_	CD	O	-1	none	_	_
36	+/-	_	_	CC	O	-1	none	_	_
37	0.23	_	_	CD	O	-1	none	_	_
38	vs.	_	_	CC	O	-1	none	_	_
39	3.7	_	_	CD	O	-1	none	_	_
40	+/-	_	_	CC	O	-1	none	_	_
41	0.30	_	_	CD	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	3.5	_	_	CD	O	-1	none	_	_
44	+/-	_	_	CC	O	-1	none	_	_
45	0.20	_	_	CD	O	-1	none	_	_
46	fmol/10	_	_	NN	O	-1	none	_	_
47	(	_	_	-LRB-	O	-1	none	_	_
48	6	_	_	CD	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	cells	_	_	NNS	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Conversely	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	glucocorticoid	_	_	NN	Protein	4	multitoken	_	_
4	receptor	_	_	NN	Protein	0	root	_	_
5	affinity	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	decreased	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	anorexia	_	_	NN	O	-1	none	_	_
11	nervosa	_	_	NN	O	-1	none	_	_
12	as	_	_	RB	O	-1	none	_	_
13	well	_	_	RB	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	Cushing	_	_	NN	O	-1	none	_	_
17	's	_	_	POS	O	-1	none	_	_
18	patients	_	_	NNS	O	-1	none	_	_
19	compared	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	control	_	_	JJ	O	-1	none	_	_
22	subjects	_	_	NNS	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	dissociation	_	_	NN	O	-1	none	_	_
25	constant	_	_	NN	O	-1	none	_	_
26	4.0	_	_	CD	O	-1	none	_	_
27	+/-	_	_	CC	O	-1	none	_	_
28	0.31	_	_	CD	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	4.1	_	_	CD	O	-1	none	_	_
31	+/-	_	_	CC	O	-1	none	_	_
32	0.34	_	_	CD	O	-1	none	_	_
33	vs.	_	_	CC	O	-1	none	_	_
34	2.9	_	_	CD	O	-1	none	_	_
35	+/-	_	_	CC	O	-1	none	_	_
36	0.29	_	_	CD	O	-1	none	_	_
37	nmol/L	_	_	NN	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	p	_	_	NN	O	-1	none	_	_
40	<	_	_	JJR	O	-1	none	_	_
41	.001	_	_	CD	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	inversely	_	_	RB	O	-1	none	_	_
45	correlated	_	_	VBD	O	-1	none	_	_
46	with	_	_	IN	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	levels	_	_	NNS	O	-1	none	_	_
49	of	_	_	IN	O	-1	none	_	_
50	urinary	_	_	JJ	O	-1	none	_	_
51	free	_	_	JJ	O	-1	none	_	_
52	cortisol	_	_	NN	O	-1	none	_	_
53	in	_	_	IN	O	-1	none	_	_
54	both	_	_	DT	O	-1	none	_	_
55	groups	_	_	NNS	O	-1	none	_	_
56	of	_	_	IN	O	-1	none	_	_
57	patients	_	_	NNS	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	Basal	_	_	JJ	O	-1	none	_	_
2	[	_	_	NN	O	-1	none	_	_
3	3H	_	_	NN	O	-1	none	_	_
4	]	_	_	CD	O	-1	none	_	_
5	thymidine	_	_	NN	O	-1	none	_	_
6	incorporation	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	MNL	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	significantly	_	_	RB	O	-1	none	_	_
11	reduced	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	anorexia	_	_	NN	O	-1	none	_	_
14	nervosa	_	_	NN	O	-1	none	_	_
15	as	_	_	RB	O	-1	none	_	_
16	well	_	_	RB	O	-1	none	_	_
17	as	_	_	IN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	Cushing	_	_	NN	O	-1	none	_	_
20	's	_	_	POS	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	compared	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	control	_	_	JJ	O	-1	none	_	_
25	subjects	_	_	NNS	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	p	_	_	NN	O	-1	none	_	_
28	<	_	_	JJR	O	-1	none	_	_
29	.001	_	_	CD	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	was	_	_	VBD	O	-1	none	_	_
33	diminished	_	_	VBN	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	dexamethasone	_	_	NN	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	an	_	_	DT	O	-1	none	_	_
38	extent	_	_	NN	O	-1	none	_	_
39	similar	_	_	JJ	O	-1	none	_	_
40	to	_	_	TO	O	-1	none	_	_
41	control	_	_	JJ	O	-1	none	_	_
42	subjects	_	_	NNS	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	patients	_	_	NNS	O	-1	none	_	_
45	with	_	_	IN	O	-1	none	_	_
46	anorexia	_	_	NN	O	-1	none	_	_
47	nervosa	_	_	NN	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	but	_	_	CC	O	-1	none	_	_
50	significantly	_	_	RB	O	-1	none	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	p	_	_	NN	O	-1	none	_	_
53	<	_	_	JJR	O	-1	none	_	_
54	.001	_	_	CD	O	-1	none	_	_
55	)	_	_	-RRB-	O	-1	none	_	_
56	less	_	_	RBR	O	-1	none	_	_
57	in	_	_	IN	O	-1	none	_	_
58	those	_	_	DT	O	-1	none	_	_
59	with	_	_	IN	O	-1	none	_	_
60	Cushing	_	_	NN	O	-1	none	_	_
61	's	_	_	POS	O	-1	none	_	_
62	disease	_	_	NN	O	-1	none	_	_
63	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	patients	_	_	NNS	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	anorexia	_	_	NN	O	-1	none	_	_
5	nervosa	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	incorporation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	[	_	_	CD	O	-1	none	_	_
11	3H	_	_	NN	O	-1	none	_	_
12	]	_	_	CD	O	-1	none	_	_
13	thymidine	_	_	NN	O	-1	none	_	_
14	into	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	MNL	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	inversely	_	_	RB	O	-1	none	_	_
19	correlated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	urinary	_	_	JJ	O	-1	none	_	_
22	free	_	_	JJ	O	-1	none	_	_
23	cortisol	_	_	NN	O	-1	none	_	_
24	levels	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	These	_	_	DT	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	indicate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	lack	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	cushingoid	_	_	JJ	O	-1	none	_	_
11	features	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	anorexia	_	_	NN	O	-1	none	_	_
16	nervosa	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	ascribable	_	_	JJ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	reduced	_	_	JJ	O	-1	none	_	_
23	sensitivity	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	glucocorticoids	_	_	NNS	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	more	_	_	RBR	O	-1	none	_	_
29	likely	_	_	JJ	O	-1	none	_	_
30	due	_	_	JJ	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	paucity	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	metabolic	_	_	JJ	O	-1	none	_	_
36	substrates	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	diesel	_	_	NN	O	-1	none	_	_
4	organic	_	_	JJ	O	-1	none	_	_
5	extracts	_	_	NNS	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	chemokine	_	_	NN	O	-1	none	_	_
8	production	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	peripheral	_	_	JJ	O	-1	none	_	_
11	blood	_	_	NN	O	-1	none	_	_
12	mononuclear	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Polyaromatic	_	_	NN	O	-1	none	_	_
4	hydrocarbons	_	_	NNS	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	PAHs	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	associated	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	diesel	_	_	NN	O	-1	none	_	_
11	exhaust	_	_	NN	O	-1	none	_	_
12	particles	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	DEPs	_	_	NNS	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	found	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	atmospheric	_	_	JJ	O	-1	none	_	_
21	urban	_	_	JJ	O	-1	none	_	_
22	pollution	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Such	_	_	JJ	O	-1	none	_	_
2	compounds	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	favor	_	_	VB	O	-1	none	_	_
8	IgE	_	_	NN	O	-1	none	_	_
9	production	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	bronchial	_	_	JJ	O	-1	none	_	_
12	hyperresponsiveness	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	airway	_	_	NN	O	-1	none	_	_
16	inflammation	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Chemokines	_	_	NNS	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	group	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	chemotactic	_	_	JJ	O	-1	none	_	_
7	cytokines	_	_	NNS	O	-1	none	_	_
8	involved	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	recruitment	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	inflammatory	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	OBJECTIVE	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	We	_	_	PRP	O	-1	none	_	_
4	investigated	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	DEP-PAHs	_	_	NNS	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	release	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-8	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	MCP-1	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	RANTES	_	_	NN	Protein	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	PBMCs	_	_	NNS	O	-1	none	_	_
24	obtained	_	_	VBN	O	-1	none	_	_
25	from	_	_	IN	O	-1	none	_	_
26	healthy	_	_	JJ	O	-1	none	_	_
27	subjects	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Protein	_	_	NN	O	-1	none	_	_
4	production	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	supernatants	_	_	NNS	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	assessed	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	ELISA	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	evaluated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	semiquantitative	_	_	JJ	O	-1	none	_	_
19	RT-PCR	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Secretion	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	IL-8	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	RANTES	_	_	NN	Protein	-1	none	_	_
8	increased	_	_	VBD	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	dose	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	manner	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	increasing	_	_	VBG	O	-1	none	_	_
16	concentrations	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	DEP-PAHs	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	range	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	0.5	_	_	CD	O	-1	none	_	_
23	ng	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	50	_	_	CD	O	-1	none	_	_
26	ng/mL	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	contrary	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	release	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	MCP-1	_	_	NN	Protein	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	significantly	_	_	RB	O	-1	none	_	_
11	inhibited	_	_	VBN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	also	_	_	RB	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	dose	_	_	NN	O	-1	none	_	_
17	dependent	_	_	JJ	O	-1	none	_	_
18	manner	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Messenger	_	_	NN	O	-1	none	_	_
2	RNA	_	_	NN	O	-1	none	_	_
3	production	_	_	NN	O	-1	none	_	_
4	coding	_	_	VBG	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	IL-8	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	RANTES	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	MCP-1	_	_	NN	Protein	-1	none	_	_
12	showed	_	_	VBD	O	-1	none	_	_
13	parallel	_	_	JJ	O	-1	none	_	_
14	variations	_	_	NNS	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	production	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	correspondent	_	_	NN	O	-1	none	_	_
21	proteins	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	DEP-PAHs	_	_	NNS	O	-1	none	_	_
4	became	_	_	VBD	O	-1	none	_	_
5	significant	_	_	JJ	O	-1	none	_	_
6	at	_	_	IN	O	-1	none	_	_
7	7	_	_	CD	O	-1	none	_	_
8	hours	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	up	_	_	RB	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	48	_	_	CD	O	-1	none	_	_
13	hours	_	_	NNS	O	-1	none	_	_
14	time	_	_	NN	O	-1	none	_	_
15	culture	_	_	NN	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	MCP-1	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	up	_	_	RB	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	24	_	_	CD	O	-1	none	_	_
23	hours	_	_	NNS	O	-1	none	_	_
24	time	_	_	NN	O	-1	none	_	_
25	culture	_	_	NN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	IL-8	_	_	NN	Protein	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	RANTES	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	supernatants	_	_	NNS	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	DEP-PAH-activated	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	compared	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	those	_	_	DT	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	controls	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	exhibited	_	_	VBD	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	significantly	_	_	RB	O	-1	none	_	_
17	enhanced	_	_	VBN	O	-1	none	_	_
18	chemotactic	_	_	JJ	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	neutrophils	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	eosinophils	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	significantly	_	_	RB	O	-1	none	_	_
28	inhibited	_	_	VBN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	pretreatment	_	_	NN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	anti-IL-8	_	_	NN	Protein	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	anti-RANTES	_	_	JJ	Protein	-1	none	_	_
35	neutralizing	_	_	VBG	O	-1	none	_	_
36	antibodies	_	_	NNS	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	respectively	_	_	RB	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	CONCLUSION	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	These	_	_	DT	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	chemokine	_	_	NN	O	-1	none	_	_
9	pathways	_	_	NNS	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	modulated	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	DEP-PAHs	_	_	NNS	O	-1	none	_	_
14	at	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	transcriptional	_	_	JJ	O	-1	none	_	_
17	level	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	reinforcing	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	idea	_	_	NN	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	development	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	inflammatory	_	_	JJ	O	-1	none	_	_
27	reactions	_	_	NNS	O	-1	none	_	_
28	might	_	_	MD	O	-1	none	_	_
29	be	_	_	VB	O	-1	none	_	_
30	affected	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	diesel	_	_	NN	O	-1	none	_	_
33	exhaust	_	_	NN	O	-1	none	_	_
34	emission	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	DR-nm23	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	encoded	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	member	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	nm23	_	_	NN	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	family	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	inhibits	_	_	VBZ	O	-1	none	_	_
18	granulocyte	_	_	NN	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	induces	_	_	VBZ	O	-1	none	_	_
22	apoptosis	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	32Dc13	_	_	NN	O	-1	none	_	_
25	myeloid	_	_	JJ	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Chronic	_	_	JJ	O	-1	none	_	_
2	myelogenous	_	_	JJ	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	evolves	_	_	VBZ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	clinically	_	_	RB	O	-1	none	_	_
8	distinct	_	_	JJ	O	-1	none	_	_
9	stages	_	_	NNS	O	-1	none	_	_
10	:	_	_	:	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	chronic	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	blast	_	_	NN	O	-1	none	_	_
16	crisis	_	_	NN	O	-1	none	_	_
17	phase	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	molecular	_	_	JJ	O	-1	none	_	_
3	changes	_	_	NNS	O	-1	none	_	_
4	associated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	chronic	_	_	JJ	O	-1	none	_	_
7	phase	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	blast	_	_	NN	O	-1	none	_	_
10	crisis	_	_	NN	O	-1	none	_	_
11	transition	_	_	NN	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	largely	_	_	RB	O	-1	none	_	_
14	unknown	_	_	JJ	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	identified	_	_	VBN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	cDNA	_	_	NN	O	-1	none	_	_
6	clone	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	DR-nm23	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	differentially	_	_	RB	O	-1	none	_	_
11	expressed	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	blast-crisis	_	_	JJ	O	-1	none	_	_
15	cDNA	_	_	NN	O	-1	none	_	_
16	library	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	has	_	_	VBZ	O	-1	none	_	_
20	approximately	_	_	RB	O	-1	none	_	_
21	70	_	_	CD	O	-1	none	_	_
22	%	_	_	NN	O	-1	none	_	_
23	sequence	_	_	NN	O	-1	none	_	_
24	similarity	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	putative	_	_	JJ	O	-1	none	_	_
28	metastatic	_	_	JJ	O	-1	none	_	_
29	suppressor	_	_	NN	O	-1	none	_	_
30	genes	_	_	NNS	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	nm23-H1	_	_	NN	Protein	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	nm23-H2	_	_	NN	Protein	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	deduced	_	_	JJ	O	-1	none	_	_
3	amino	_	_	NN	O	-1	none	_	_
4	acid	_	_	NN	O	-1	none	_	_
5	sequence	_	_	NN	O	-1	none	_	_
6	similarity	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	encoded	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	these	_	_	DT	O	-1	none	_	_
13	two	_	_	CD	O	-1	none	_	_
14	latter	_	_	JJ	O	-1	none	_	_
15	genes	_	_	NNS	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	approximately	_	_	RB	O	-1	none	_	_
18	65	_	_	CD	O	-1	none	_	_
19	%	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	includes	_	_	VBZ	O	-1	none	_	_
22	domains	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	amino	_	_	NN	O	-1	none	_	_
25	acid	_	_	NN	O	-1	none	_	_
26	residues	_	_	NNS	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	leucine	_	_	NN	O	-1	none	_	_
30	zipper	_	_	NN	O	-1	none	_	_
31	like	_	_	IN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	RGD	_	_	NN	O	-1	none	_	_
35	domain	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	serine	_	_	NN	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	histidine	_	_	NN	O	-1	none	_	_
42	residue	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	NH2-	_	_	NN	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	in	_	_	IN	O	-1	none	_	_
48	the	_	_	DT	O	-1	none	_	_
49	COOH-terminal	_	_	JJ	O	-1	none	_	_
50	portion	_	_	NN	O	-1	none	_	_
51	of	_	_	IN	O	-1	none	_	_
52	the	_	_	DT	O	-1	none	_	_
53	protein	_	_	NN	O	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	respectively	_	_	RB	O	-1	none	_	_
56	)	_	_	-RRB-	O	-1	none	_	_
57	postulated	_	_	VBN	O	-1	none	_	_
58	to	_	_	TO	O	-1	none	_	_
59	be	_	_	VB	O	-1	none	_	_
60	important	_	_	JJ	O	-1	none	_	_
61	for	_	_	IN	O	-1	none	_	_
62	nm23	_	_	NN	O	-1	none	_	_
63	function	_	_	NN	O	-1	none	_	_
64	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Its	_	_	PRP$	O	-1	none	_	_
2	constitutive	_	_	JJ	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	myeloid	_	_	JJ	O	-1	none	_	_
7	precursor	_	_	NN	O	-1	none	_	_
8	32Dc13	_	_	NN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	line	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	growth-factor	_	_	NN	O	-1	none	_	_
15	dependent	_	_	JJ	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	both	_	_	DT	O	-1	none	_	_
18	proliferation	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	differentiation	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	results	_	_	VBZ	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	inhibition	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	granulocytic	_	_	JJ	O	-1	none	_	_
27	differentiation	_	_	NN	O	-1	none	_	_
28	induced	_	_	VBN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	granulocyte	_	_	NN	Protein	33	multitoken	_	_
31	colony	_	_	NN	Protein	33	multitoken	_	_
32	stimulating	_	_	NN	Protein	33	multitoken	_	_
33	factor	_	_	NN	Protein	0	root	_	_
34	and	_	_	CC	O	-1	none	_	_
35	causes	_	_	VBZ	O	-1	none	_	_
36	apoptotic	_	_	JJ	O	-1	none	_	_
37	cell	_	_	NN	O	-1	none	_	_
38	death	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	consistent	_	_	JJ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	DR-nm23	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	normal	_	_	JJ	O	-1	none	_	_
12	hematopoiesis	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	raise	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	possibility	_	_	NN	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	its	_	_	PRP$	O	-1	none	_	_
19	overexpression	_	_	NN	O	-1	none	_	_
20	contributes	_	_	VBZ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	arrest	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	feature	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	blastic	_	_	JJ	O	-1	none	_	_
29	transformation	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	chronic	_	_	JJ	O	-1	none	_	_
32	myelogenous	_	_	JJ	O	-1	none	_	_
33	leukemia	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Attenuation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	gamma	_	_	NN	Protein	4	multitoken	_	_
4	interferon	_	_	NN	Protein	0	root	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	phosphorylation	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	mononuclear	_	_	JJ	O	-1	none	_	_
10	phagocytes	_	_	NNS	O	-1	none	_	_
11	infected	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	Leishmania	_	_	NN	O	-1	none	_	_
14	donovani	_	_	NNS	O	-1	none	_	_
15	:	_	_	:	O	-1	none	_	_
16	selective	_	_	JJ	O	-1	none	_	_
17	inhibition	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	signaling	_	_	NN	O	-1	none	_	_
20	through	_	_	IN	O	-1	none	_	_
21	Janus	_	_	NN	O	-1	none	_	_
22	kinases	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	Stat1	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	transcription	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	response	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	gamma	_	_	NN	Protein	10	multitoken	_	_
10	interferon	_	_	NN	Protein	0	root	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	impaired	_	_	JJ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	mononuclear	_	_	JJ	O	-1	none	_	_
15	phagocytes	_	_	NNS	O	-1	none	_	_
16	infected	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	Leishmania	_	_	NN	O	-1	none	_	_
19	donovani	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	mechanisms	_	_	NNS	O	-1	none	_	_
24	involved	_	_	VBN	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	fully	_	_	RB	O	-1	none	_	_
28	understood	_	_	VBN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	changes	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	brought	_	_	VBD	O	-1	none	_	_
7	about	_	_	RB	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	gamma	_	_	NN	Protein	10	multitoken	_	_
10	interferon	_	_	NN	Protein	0	root	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	thought	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	involve	_	_	VB	O	-1	none	_	_
15	transient	_	_	JJ	O	-1	none	_	_
16	increases	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	activities	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	cellular	_	_	JJ	O	-1	none	_	_
22	protein	_	_	NN	O	-1	none	_	_
23	tyrosine	_	_	NN	O	-1	none	_	_
24	kinases	_	_	NNS	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	including	_	_	VBG	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	Janus	_	_	NN	O	-1	none	_	_
29	kinases	_	_	NNS	O	-1	none	_	_
30	Jak1	_	_	NN	Protein	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	Jak2	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	leading	_	_	VBG	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	tyrosine	_	_	NN	O	-1	none	_	_
37	phosphorylation	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	transcription	_	_	NN	O	-1	none	_	_
41	factor	_	_	NN	O	-1	none	_	_
42	Stat1	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	investigate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	accounting	_	_	VBG	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	impaired	_	_	JJ	O	-1	none	_	_
9	responses	_	_	NNS	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	gamma	_	_	VB	Protein	12	multitoken	_	_
12	interferon	_	_	NN	Protein	0	root	_	_
13	,	_	_	,	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	model	_	_	NN	O	-1	none	_	_
16	system	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	examining	_	_	VBG	O	-1	none	_	_
19	overall	_	_	JJ	O	-1	none	_	_
20	changes	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	protein	_	_	NN	O	-1	none	_	_
23	tyrosine	_	_	NN	O	-1	none	_	_
24	phosphorylation	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	Jak1	_	_	NN	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	Jak2	_	_	NN	Protein	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	phosphorylation	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	Stat1	_	_	NN	O	-1	none	_	_
35	was	_	_	VBD	O	-1	none	_	_
36	developed	_	_	VBN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	phorbol	_	_	NN	O	-1	none	_	_
39	12-myristate	_	_	NN	O	-1	none	_	_
40	13-acetate-differentiated	_	_	JJ	O	-1	none	_	_
41	U-937	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	whole-cell	_	_	JJ	O	-1	none	_	_
4	lysates	_	_	NNS	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	antiphosphotyrosine	_	_	JJ	O	-1	none	_	_
7	immunoblotting	_	_	NN	O	-1	none	_	_
8	showed	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	incubation	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	gamma	_	_	NN	Protein	13	multitoken	_	_
13	interferon	_	_	NN	Protein	0	root	_	_
14	brought	_	_	VBD	O	-1	none	_	_
15	about	_	_	RB	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	increases	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	phosphotyrosine	_	_	NN	O	-1	none	_	_
20	labeling	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	several	_	_	JJ	O	-1	none	_	_
23	proteins	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Increased	_	_	VBN	O	-1	none	_	_
2	labeling	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	occurred	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	similar	_	_	JJ	O	-1	none	_	_
9	extents	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	control	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	had	_	_	VBD	O	-1	none	_	_
18	been	_	_	VBN	O	-1	none	_	_
19	infected	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	L.	_	_	NNP	O	-1	none	_	_
22	donovani	_	_	NNS	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	16	_	_	CD	O	-1	none	_	_
25	h.	_	_	NN	O	-1	none	_	_
26	Jak1	_	_	NN	Protein	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	Jak2	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	Stat1	_	_	NN	O	-1	none	_	_
32	were	_	_	VBD	O	-1	none	_	_
33	immunoprecipitated	_	_	VBN	O	-1	none	_	_
34	from	_	_	IN	O	-1	none	_	_
35	control	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	interferon	_	_	NN	O	-1	none	_	_
38	treated	_	_	JJ	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	tyrosine	_	_	NN	O	-1	none	_	_
43	phosphorylation	_	_	NN	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	these	_	_	DT	O	-1	none	_	_
46	proteins	_	_	NNS	O	-1	none	_	_
47	,	_	_	,	O	-1	none	_	_
48	detected	_	_	VBN	O	-1	none	_	_
49	by	_	_	IN	O	-1	none	_	_
50	antiphosphotyrosine	_	_	JJ	O	-1	none	_	_
51	immunoblotting	_	_	NN	O	-1	none	_	_
52	was	_	_	VBD	O	-1	none	_	_
53	used	_	_	VBN	O	-1	none	_	_
54	to	_	_	TO	O	-1	none	_	_
55	measured	_	_	VBN	O	-1	none	_	_
56	their	_	_	PRP$	O	-1	none	_	_
57	activation	_	_	NN	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	Tyrosine	_	_	NN	O	-1	none	_	_
2	phosphorylation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Jak1	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	Jak2	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Stat1	_	_	NN	O	-1	none	_	_
10	increased	_	_	VBD	O	-1	none	_	_
11	markedly	_	_	RB	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	dose	_	_	NN	O	-1	none	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	manner	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	U-937	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	incubated	_	_	VBN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	gamma	_	_	NN	Protein	25	multitoken	_	_
25	interferon	_	_	NN	Protein	0	root	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	infected	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	L.	_	_	NNP	O	-1	none	_	_
9	donovani	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	tyrosine	_	_	NN	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	Jak1	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	Jak2	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Stat1	_	_	NN	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	markedly	_	_	RB	O	-1	none	_	_
22	impaired	_	_	JJ	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	dependent	_	_	JJ	O	-1	none	_	_
5	upon	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	duration	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	exposure	_	_	NN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	L.	_	_	NNP	O	-1	none	_	_
12	donovani	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	maximal	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	complete	_	_	JJ	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	16	_	_	CD	O	-1	none	_	_
20	h.	_	_	NN	O	-1	none	_	_
21	Results	_	_	NNS	O	-1	none	_	_
22	similar	_	_	JJ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	those	_	_	DT	O	-1	none	_	_
25	observed	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	U-937	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	were	_	_	VBD	O	-1	none	_	_
30	also	_	_	RB	O	-1	none	_	_
31	obtained	_	_	VBN	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	human	_	_	NN	O	-1	none	_	_
34	peripheral	_	_	JJ	O	-1	none	_	_
35	blood	_	_	NN	O	-1	none	_	_
36	monocytes	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	infection	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	mononuclear	_	_	JJ	O	-1	none	_	_
9	phagocytes	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	L.	_	_	NNP	O	-1	none	_	_
12	donovani	_	_	NNS	O	-1	none	_	_
13	leads	_	_	VBZ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	impaired	_	_	JJ	O	-1	none	_	_
16	gamma	_	_	NN	Protein	17	multitoken	_	_
17	interferon	_	_	NN	Protein	0	root	_	_
18	mediated	_	_	VBD	O	-1	none	_	_
19	tyrosine	_	_	NN	O	-1	none	_	_
20	phosphorylation	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	selective	_	_	JJ	O	-1	none	_	_
23	effects	_	_	NNS	O	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	Jak-Stat1	_	_	NN	O	-1	none	_	_
27	pathway	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Unresponsiveness	_	_	NN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	gamma	_	_	NN	Protein	4	multitoken	_	_
4	interferon	_	_	NN	Protein	0	root	_	_
5	for	_	_	IN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	pathway	_	_	NN	O	-1	none	_	_
10	may	_	_	MD	O	-1	none	_	_
11	explain	_	_	VB	O	-1	none	_	_
12	impaired	_	_	JJ	O	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	responses	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	leishmania	_	_	NN	O	-1	none	_	_
17	infected	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	DNA	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	properties	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	heat	_	_	NN	O	-1	none	_	_
8	shock	_	_	NN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	HSF1	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	HSF3	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	induced	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	avian	_	_	JJ	O	-1	none	_	_
20	erythroblast	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	line	_	_	NN	O	-1	none	_	_
23	HD6	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Avian	_	_	JJ	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	express	_	_	VBP	O	-1	none	_	_
4	three	_	_	CD	O	-1	none	_	_
5	heat	_	_	NN	O	-1	none	_	_
6	shock	_	_	NN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	HSF	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	genes	_	_	NNS	O	-1	none	_	_
13	corresponding	_	_	VBG	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	novel	_	_	JJ	O	-1	none	_	_
17	factor	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	HSF3	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	homologs	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	mouse	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	HSF1	_	_	NN	Protein	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	HSF2	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	biochemical	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	biological	_	_	JJ	O	-1	none	_	_
8	properties	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	these	_	_	DT	O	-1	none	_	_
11	HSFs	_	_	NNS	O	-1	none	_	_
12	reveals	_	_	VBZ	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	HSF3	_	_	NN	Protein	-1	none	_	_
15	has	_	_	VBZ	O	-1	none	_	_
16	properties	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	common	_	_	JJ	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	both	_	_	CC	O	-1	none	_	_
21	HSF1	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	HSF2	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	yet	_	_	RB	O	-1	none	_	_
26	has	_	_	VBZ	O	-1	none	_	_
27	features	_	_	NNS	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	are	_	_	VBP	O	-1	none	_	_
30	distinct	_	_	JJ	O	-1	none	_	_
31	from	_	_	IN	O	-1	none	_	_
32	both	_	_	DT	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	HSF3	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	constitutively	_	_	RB	O	-1	none	_	_
4	expressed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	erythroblast	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	line	_	_	NN	O	-1	none	_	_
10	HD6	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	lymphoblast	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	line	_	_	NN	O	-1	none	_	_
16	MSB	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	embryo	_	_	NN	O	-1	none	_	_
20	fibroblasts	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	yet	_	_	RB	O	-1	none	_	_
24	its	_	_	PRP$	O	-1	none	_	_
25	DNA	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	activity	_	_	NN	O	-1	none	_	_
28	is	_	_	VBZ	O	-1	none	_	_
29	induced	_	_	VBN	O	-1	none	_	_
30	only	_	_	RB	O	-1	none	_	_
31	upon	_	_	IN	O	-1	none	_	_
32	exposure	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	HD6	_	_	NN	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	heat	_	_	NN	O	-1	none	_	_
38	shock	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Acquisition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HSF3	_	_	NN	Protein	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	HD6	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	accompanied	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	oligomerization	_	_	NN	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	non	_	_	JJ	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	DNA	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	dimer	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	DNA	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	trimer	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	whereas	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	effect	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	heat	_	_	NN	O	-1	none	_	_
34	shock	_	_	NN	O	-1	none	_	_
35	on	_	_	IN	O	-1	none	_	_
36	HSF1	_	_	NN	Protein	-1	none	_	_
37	is	_	_	VBZ	O	-1	none	_	_
38	oligomerization	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	an	_	_	DT	O	-1	none	_	_
41	inert	_	_	JJ	O	-1	none	_	_
42	monomer	_	_	NN	O	-1	none	_	_
43	to	_	_	TO	O	-1	none	_	_
44	a	_	_	DT	O	-1	none	_	_
45	DNA	_	_	NN	O	-1	none	_	_
46	binding	_	_	NN	O	-1	none	_	_
47	trimer	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HSF3	_	_	NN	Protein	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	delayed	_	_	VBN	O	-1	none	_	_
9	compared	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	that	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	HSF1	_	_	NN	Protein	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	occurs	_	_	VBZ	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	HSF1	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	heat	_	_	NN	O	-1	none	_	_
7	shock	_	_	NN	O	-1	none	_	_
8	leads	_	_	VBZ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	translocation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	HSF3	_	_	NN	Protein	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	nucleus	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	reveal	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	HSF3	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	negatively	_	_	RB	O	-1	none	_	_
8	regulated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	avian	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	acquires	_	_	VBZ	O	-1	none	_	_
14	DNA	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	certain	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	upon	_	_	IN	O	-1	none	_	_
21	heat	_	_	NN	O	-1	none	_	_
22	shock	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	Jak-STAT	_	_	NN	Protein	6	multitoken	_	_
6	1	_	_	CD	Protein	0	root	_	_
7	signaling	_	_	NN	O	-1	none	_	_
8	pathway	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	IL-5	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	eosinophils	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	intracellular	_	_	JJ	O	-1	none	_	_
3	signal	_	_	NN	O	-1	none	_	_
4	transduction	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IL-5	_	_	NN	Protein	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	eosinophils	_	_	NNS	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	unknown	_	_	JJ	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	objective	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	investigate	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	involvement	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	newly	_	_	RB	O	-1	none	_	_
14	discovered	_	_	VBN	O	-1	none	_	_
15	Jak-STAT	_	_	NN	O	-1	none	_	_
16	pathway	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-5	_	_	NN	Protein	-1	none	_	_
20	signal	_	_	NN	O	-1	none	_	_
21	transduction	_	_	NN	O	-1	none	_	_
22	mechanism	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Eosinophils	_	_	NNS	O	-1	none	_	_
2	were	_	_	VBD	O	-1	none	_	_
3	purified	_	_	VBN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	peripheral	_	_	JJ	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	discontinuous	_	_	JJ	O	-1	none	_	_
9	Percoll	_	_	NN	O	-1	none	_	_
10	gradients	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	stimulated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	IL-5	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	involvement	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Jak	_	_	NN	Protein	5	multitoken	_	_
5	2	_	_	CD	Protein	0	root	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	investigated	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	immunoprecipitation	_	_	NN	O	-1	none	_	_
10	followed	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	immunoblotting	_	_	VBG	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	phosphorylation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Jak	_	_	NN	Protein	5	multitoken	_	_
5	2	_	_	CD	Protein	0	root	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	studied	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	autophosphorylation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	immunoprecipitated	_	_	JJ	O	-1	none	_	_
13	kinase	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Jak	_	_	NN	Protein	2	multitoken	_	_
2	2	_	_	CD	Protein	0	root	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylated	_	_	JJ	O	-1	none	_	_
6	within	_	_	IN	O	-1	none	_	_
7	1	_	_	CD	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	3	_	_	CD	O	-1	none	_	_
10	min	_	_	NN	O	-1	none	_	_
11	after	_	_	IN	O	-1	none	_	_
12	stimulation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	eosinophils	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	IL-5	_	_	NN	Protein	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Jak	_	_	NN	Protein	2	multitoken	_	_
2	2	_	_	CD	Protein	0	root	_	_
3	coprecipitated	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	beta-subunit	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	IL-5	_	_	NN	O	-1	none	_	_
10	receptor	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	suggesting	_	_	VBG	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	physical	_	_	JJ	O	-1	none	_	_
15	association	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	kinase	_	_	NN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	receptor	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	nuclear	_	_	JJ	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	STAT-1	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	p91	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	investigated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	immunoprecipitation	_	_	NN	O	-1	none	_	_
12	followed	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	immunoblotting	_	_	VBG	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	tyrosine	_	_	NN	O	-1	none	_	_
17	phosphorylation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	STAT-1	_	_	NNP	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	tyrosine	_	_	NN	O	-1	none	_	_
4	phosphorylated	_	_	JJ	O	-1	none	_	_
5	within	_	_	IN	O	-1	none	_	_
6	15	_	_	CD	O	-1	none	_	_
7	min	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	IL-5	_	_	NN	Protein	-1	none	_	_
10	stimulation	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	presence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STAT-1	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	extract	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	studied	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	electrophoretic	_	_	JJ	O	-1	none	_	_
13	mobility	_	_	NN	O	-1	none	_	_
14	shift	_	_	NN	O	-1	none	_	_
15	assay	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	IL-5	_	_	NNP	Protein	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	two	_	_	CD	O	-1	none	_	_
4	proteins	_	_	NNS	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	bound	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	gamma	_	_	NN	O	-1	none	_	_
10	activating	_	_	NN	O	-1	none	_	_
11	sequence	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	presence	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	anti-STAT-1	_	_	JJ	Protein	-1	none	_	_
7	Ab	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	band	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	supershifted	_	_	VBN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Latent	_	_	JJ	Protein	3	multitoken	_	_
2	membrane	_	_	NN	Protein	3	multitoken	_	_
3	protein-1	_	_	NN	Protein	0	root	_	_
4	induces	_	_	VBZ	O	-1	none	_	_
5	cyclin	_	_	NN	Protein	6	multitoken	_	_
6	D2	_	_	NN	Protein	0	root	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	pRb	_	_	NN	Protein	-1	none	_	_
10	hyperphosphorylation	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	loss	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	TGF-beta	_	_	NN	Protein	16	multitoken	_	_
16	1	_	_	CD	Protein	0	root	_	_
17	mediated	_	_	VBN	O	-1	none	_	_
18	growth	_	_	NN	O	-1	none	_	_
19	inhibition	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	EBV	_	_	NN	O	-1	none	_	_
22	positive	_	_	JJ	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	normal	_	_	JJ	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	cycle	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	regulated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	several	_	_	JJ	O	-1	none	_	_
9	molecules	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	such	_	_	JJ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	tumor-suppressor	_	_	JJ	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	pRb	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	G1	_	_	NN	O	-1	none	_	_
20	cyclins	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	cyclin	_	_	NN	O	-1	none	_	_
24	dependent	_	_	JJ	O	-1	none	_	_
25	kinases	_	_	NNS	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	their	_	_	PRP$	O	-1	none	_	_
29	inhibitors	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	regulators	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	targeted	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	negative	_	_	JJ	O	-1	none	_	_
7	growth	_	_	NN	O	-1	none	_	_
8	regulatory	_	_	JJ	O	-1	none	_	_
9	signals	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	such	_	_	JJ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	that	_	_	DT	O	-1	none	_	_
14	provided	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	TGF-beta	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	presence	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	either	_	_	CC	O	-1	none	_	_
10	wild-type	_	_	JJ	O	-1	none	_	_
11	EBV	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	its	_	_	PRP$	O	-1	none	_	_
14	transforming	_	_	VBG	O	-1	none	_	_
15	latent	_	_	JJ	Protein	17	multitoken	_	_
16	membrane	_	_	NN	Protein	17	multitoken	_	_
17	protein-1	_	_	NN	Protein	0	root	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	LMP-1	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	results	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	loss	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	TGF-beta	_	_	NN	Protein	27	multitoken	_	_
27	1	_	_	CD	Protein	0	root	_	_
28	mediated	_	_	VBN	O	-1	none	_	_
29	growth	_	_	NN	O	-1	none	_	_
30	inhibition	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	human	_	_	NN	O	-1	none	_	_
33	B	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Chemical	_	_	NNP	O	-1	none	_	_
2	cross	_	_	VB	O	-1	none	_	_
3	linking	_	_	VBG	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	125I	_	_	NN	O	-1	none	_	_
6	labeled	_	_	VBN	O	-1	none	_	_
7	TGF-beta	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	essentially	_	_	RB	O	-1	none	_	_
12	normal	_	_	JJ	O	-1	none	_	_
13	TGF-beta	_	_	NN	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	profile	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	EBV	_	_	NN	O	-1	none	_	_
18	positive	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	EBV	_	_	NN	O	-1	none	_	_
21	negative	_	_	JJ	O	-1	none	_	_
22	Burkitt	_	_	NN	O	-1	none	_	_
23	's	_	_	POS	O	-1	none	_	_
24	lymphoma	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	lines	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	these	_	_	DT	O	-1	none	_	_
30	receptors	_	_	NNS	O	-1	none	_	_
31	were	_	_	VBD	O	-1	none	_	_
32	shown	_	_	VBN	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	be	_	_	VB	O	-1	none	_	_
35	functional	_	_	JJ	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	transducing	_	_	VBG	O	-1	none	_	_
38	signals	_	_	NNS	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	as	_	_	IN	O	-1	none	_	_
41	evidenced	_	_	VBN	O	-1	none	_	_
42	by	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	TGF-beta	_	_	NN	Protein	45	multitoken	_	_
45	1	_	_	CD	Protein	0	root	_	_
46	mediated	_	_	VBN	O	-1	none	_	_
47	modulation	_	_	NN	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	junB	_	_	NN	Protein	-1	none	_	_
50	gene	_	_	NN	O	-1	none	_	_
51	expression	_	_	NN	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	TGF-beta	_	_	NN	Protein	4	multitoken	_	_
4	1	_	_	CD	Protein	0	root	_	_
5	did	_	_	VBD	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	induce	_	_	VB	O	-1	none	_	_
8	dephosphorylation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	pRb	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	EBV	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	LMP-1	_	_	NN	Protein	-1	none	_	_
16	)-positive	_	_	JJ	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	as	_	_	IN	O	-1	none	_	_
19	opposed	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	EBV	_	_	NN	O	-1	none	_	_
22	negative	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	suggesting	_	_	VBG	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	dichotomy	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	TGF-beta	_	_	NN	Protein	31	multitoken	_	_
31	1	_	_	CD	Protein	0	root	_	_
32	signaling	_	_	NN	O	-1	none	_	_
33	pathway	_	_	NN	O	-1	none	_	_
34	leading	_	_	VBG	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	separable	_	_	JJ	O	-1	none	_	_
37	gene	_	_	NN	O	-1	none	_	_
38	regulatory	_	_	JJ	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	growth	_	_	NN	O	-1	none	_	_
41	inhibitory	_	_	JJ	O	-1	none	_	_
42	responses	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	LMP-1	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	induce	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cyclin	_	_	NN	Protein	12	multitoken	_	_
12	D2	_	_	NN	Protein	0	root	_	_
13	;	_	_	:	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	EBV	_	_	NN	O	-1	none	_	_
19	negative	_	_	JJ	O	-1	none	_	_
20	Burkitt	_	_	NN	O	-1	none	_	_
21	's	_	_	POS	O	-1	none	_	_
22	lymphoma	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	do	_	_	VBP	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	express	_	_	VB	O	-1	none	_	_
27	D-type	_	_	JJ	O	-1	none	_	_
28	cyclins	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	data	_	_	NNS	O	-1	none	_	_
6	point	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	potential	_	_	JJ	O	-1	none	_	_
10	mechanism	_	_	NN	O	-1	none	_	_
11	underlying	_	_	VBG	O	-1	none	_	_
12	EBV	_	_	NN	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	transformation	_	_	NN	O	-1	none	_	_
17	whereby	_	_	IN	O	-1	none	_	_
18	constitutive	_	_	JJ	O	-1	none	_	_
19	induction	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	key	_	_	JJ	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	cycle	_	_	NN	O	-1	none	_	_
24	regulators	_	_	NNS	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	LMP-1	_	_	NN	Protein	-1	none	_	_
27	can	_	_	MD	O	-1	none	_	_
28	lead	_	_	VB	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	pRb	_	_	NN	Protein	-1	none	_	_
31	hyperphosphorylation	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	uncontrolled	_	_	JJ	O	-1	none	_	_
34	cell	_	_	NN	O	-1	none	_	_
35	proliferation	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	interleukin-2	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	alpha	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	beta	_	_	NN	O	-1	none	_	_
12	isoforms	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	glucocorticoid	_	_	NN	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	immunosuppressive	_	_	JJ	O	-1	none	_	_
3	effects	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	glucocorticoids	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	largely	_	_	RB	O	-1	none	_	_
8	due	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	transcriptional	_	_	JJ	O	-1	none	_	_
11	inhibition	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	immunologically	_	_	RB	O	-1	none	_	_
14	relevant	_	_	JJ	O	-1	none	_	_
15	genes	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	such	_	_	JJ	O	-1	none	_	_
18	as	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	interleukin-2	_	_	NN	Protein	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	IL-2	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	mediated	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	intracellular	_	_	JJ	O	-1	none	_	_
8	glucocorticoid	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	GR	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	humans	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	alternative	_	_	JJ	O	-1	none	_	_
5	splicing	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	GR	_	_	NN	O	-1	none	_	_
9	precursor	_	_	NN	O	-1	none	_	_
10	mRNA	_	_	NN	O	-1	none	_	_
11	gives	_	_	VBZ	O	-1	none	_	_
12	rise	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	two	_	_	CD	O	-1	none	_	_
15	receptor	_	_	NN	O	-1	none	_	_
16	isoforms	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	termed	_	_	VBN	O	-1	none	_	_
19	GRalpha	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	GRbeta	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	previously	_	_	RB	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	GRbeta	_	_	NN	Protein	-1	none	_	_
6	could	_	_	MD	O	-1	none	_	_
7	antagonize	_	_	VB	O	-1	none	_	_
8	GRalpha	_	_	NN	Protein	-1	none	_	_
9	mediated	_	_	JJ	O	-1	none	_	_
10	transactivation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	glucocorticoid	_	_	NN	O	-1	none	_	_
14	responsive	_	_	JJ	O	-1	none	_	_
15	element	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	GRE	_	_	NN	O	-1	none	_	_
18	)-driven	_	_	JJ	O	-1	none	_	_
19	reporter	_	_	NN	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	COS-7	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	designed	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	analyze	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	roles	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	two	_	_	CD	O	-1	none	_	_
13	GR	_	_	NN	O	-1	none	_	_
14	isoforms	_	_	NNS	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	glucocorticoid	_	_	NN	Protein	-1	none	_	_
17	mediated	_	_	VBD	O	-1	none	_	_
18	transrepression	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	developed	_	_	VBN	O	-1	none	_	_
5	transfection	_	_	NN	O	-1	none	_	_
6	technique	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	demonstrate	_	_	VBP	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	primary	_	_	JJ	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	stimulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	548	_	_	CD	O	-1	none	_	_
20	bp	_	_	NN	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	promoter-luciferase	_	_	NN	O	-1	none	_	_
23	reporter	_	_	NN	O	-1	none	_	_
24	construct	_	_	NN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	phorbol	_	_	NN	O	-1	none	_	_
27	ester	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	calcium	_	_	NN	O	-1	none	_	_
30	ionophore	_	_	NN	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	reversed	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	dexamethasone	_	_	NN	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	a	_	_	DT	O	-1	none	_	_
37	similar	_	_	JJ	O	-1	none	_	_
38	extent	_	_	NN	O	-1	none	_	_
39	as	_	_	IN	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	Jurkat	_	_	NN	O	-1	none	_	_
42	T	_	_	NN	O	-1	none	_	_
43	lymphoma	_	_	NN	O	-1	none	_	_
44	cells	_	_	NNS	O	-1	none	_	_
45	transfected	_	_	VBN	O	-1	none	_	_
46	with	_	_	IN	O	-1	none	_	_
47	a	_	_	DT	O	-1	none	_	_
48	GRalpha	_	_	NN	Protein	-1	none	_	_
49	expression	_	_	NN	O	-1	none	_	_
50	vector	_	_	NN	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	Transfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	GRbeta	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	vector	_	_	NN	O	-1	none	_	_
7	alone	_	_	RB	O	-1	none	_	_
8	did	_	_	VBD	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	result	_	_	VB	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	IL-2	_	_	NN	Protein	-1	none	_	_
13	promoter	_	_	NN	O	-1	none	_	_
14	repression	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	response	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	glucocorticoids	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	GRbeta	_	_	NN	Protein	-1	none	_	_
4	did	_	_	VBD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	antagonize	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	repressive	_	_	JJ	O	-1	none	_	_
9	effects	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	GRalpha	_	_	NN	Protein	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Surprisingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	overexpression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	GRbeta	_	_	NN	Protein	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	Jurkat	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	did	_	_	VBD	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	cause	_	_	VB	O	-1	none	_	_
12	significant	_	_	JJ	O	-1	none	_	_
13	inhibition	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	GRalpha	_	_	NN	Protein	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	transactivation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	GRE	_	_	NN	O	-1	none	_	_
21	dependent	_	_	JJ	O	-1	none	_	_
22	luciferase	_	_	NN	O	-1	none	_	_
23	reporter	_	_	NN	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	either	_	_	CC	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	transrepressive	_	_	JJ	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	glucocorticoids	_	_	NNS	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	exclusively	_	_	RB	O	-1	none	_	_
15	mediated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	GRalpha	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	GRbeta	_	_	NN	Protein	-1	none	_	_
2	can	_	_	MD	O	-1	none	_	_
3	neither	_	_	CC	O	-1	none	_	_
4	antagonize	_	_	VB	O	-1	none	_	_
5	GRalpha	_	_	NN	Protein	-1	none	_	_
6	mediated	_	_	JJ	O	-1	none	_	_
7	transactivation	_	_	NN	O	-1	none	_	_
8	nor	_	_	CC	O	-1	none	_	_
9	transrepression	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	Jurkat	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	indicating	_	_	VBG	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	type	_	_	NN	O	-1	none	_	_
18	specific	_	_	JJ	O	-1	none	_	_
19	pattern	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	GRbeta	_	_	NN	Protein	-1	none	_	_
22	mediated	_	_	VBD	O	-1	none	_	_
23	antiglucocorticoid	_	_	JJ	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	apoptosis	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	mononucleated	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	physiological	_	_	JJ	O	-1	none	_	_
10	process	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	regulating	_	_	VBG	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	intensity	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	immune	_	_	JJ	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	female	_	_	JJ	O	-1	none	_	_
3	steroid	_	_	NN	O	-1	none	_	_
4	hormones	_	_	NNS	O	-1	none	_	_
5	estrogen	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	E2	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	progesterone	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	Prog	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	known	_	_	VBN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	modulate	_	_	VB	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	reactivity	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	immune	_	_	JJ	O	-1	none	_	_
23	system	_	_	NN	O	-1	none	_	_
24	;	_	_	:	O	-1	none	_	_
25	recently	_	_	RB	O	-1	none	_	_
26	it	_	_	PRP	O	-1	none	_	_
27	has	_	_	VBZ	O	-1	none	_	_
28	been	_	_	VBN	O	-1	none	_	_
29	demonstrated	_	_	VBN	O	-1	none	_	_
30	that	_	_	IN	O	-1	none	_	_
31	they	_	_	PRP	O	-1	none	_	_
32	can	_	_	MD	O	-1	none	_	_
33	regulate	_	_	VB	O	-1	none	_	_
34	induction	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	apoptosis	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	endothelial	_	_	JJ	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	osteoblasts	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	E2	_	_	NN	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	Prog	_	_	NN	O	-1	none	_	_
6	increased	_	_	VBD	O	-1	none	_	_
7	survival	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	prevented	_	_	VBD	O	-1	none	_	_
10	apoptosis	_	_	NN	O	-1	none	_	_
11	induced	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	TNF-alpha	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	undifferentiated	_	_	JJ	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	macrophage	_	_	NN	O	-1	none	_	_
19	like	_	_	IN	O	-1	none	_	_
20	PMA	_	_	NN	O	-1	none	_	_
21	differentiated	_	_	VBN	O	-1	none	_	_
22	U937	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	as	_	_	IN	O	-1	none	_	_
26	assessed	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	trypan	_	_	NN	O	-1	none	_	_
29	blue	_	_	JJ	O	-1	none	_	_
30	exclusion	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	counting	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	thymidine	_	_	NN	O	-1	none	_	_
35	incorporation	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	AnnexinV	_	_	NN	O	-1	none	_	_
38	labeling	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	followed	_	_	VBN	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	flow	_	_	NN	O	-1	none	_	_
43	cytometry	_	_	NN	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	DNA	_	_	NN	O	-1	none	_	_
46	fragmentation	_	_	NN	O	-1	none	_	_
47	studies	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	can	_	_	MD	O	-1	none	_	_
4	be	_	_	VB	O	-1	none	_	_
5	associated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	specific	_	_	JJ	O	-1	none	_	_
11	hormone	_	_	NN	O	-1	none	_	_
12	receptors	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	since	_	_	IN	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	observed	_	_	VBD	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	estrogen	_	_	NN	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	alpha	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	ER-alpha	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	ER-beta	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	progesterone	_	_	NN	Protein	32	multitoken	_	_
32	receptor	_	_	NN	Protein	0	root	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	PR	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	mRNAs	_	_	NNS	O	-1	none	_	_
37	;	_	_	:	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	ER-alpha	_	_	NN	Protein	-1	none	_	_
40	protein	_	_	NN	O	-1	none	_	_
41	expression	_	_	NN	O	-1	none	_	_
42	was	_	_	VBD	O	-1	none	_	_
43	confirmed	_	_	VBN	O	-1	none	_	_
44	by	_	_	IN	O	-1	none	_	_
45	immunocytochemical	_	_	JJ	O	-1	none	_	_
46	analysis	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	hormone	_	_	NN	O	-1	none	_	_
5	mediated	_	_	VBD	O	-1	none	_	_
6	survival	_	_	NN	O	-1	none	_	_
7	against	_	_	IN	O	-1	none	_	_
8	apoptosis	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	concentration	_	_	NN	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	reaching	_	_	VBG	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	half-maximal	_	_	JJ	O	-1	none	_	_
16	effect	_	_	NN	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	10	_	_	CD	O	-1	none	_	_
19	nM	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	blocked	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	ER	_	_	NN	O	-1	none	_	_
25	antagonist	_	_	NN	O	-1	none	_	_
26	ICI	_	_	NN	O	-1	none	_	_
27	182,780	_	_	CD	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	undifferentiated	_	_	JJ	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	further	_	_	RB	O	-1	none	_	_
33	supporting	_	_	VBG	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	receptor	_	_	NN	O	-1	none	_	_
36	mediated	_	_	VBN	O	-1	none	_	_
37	mechanism	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	survival	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	E2	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	associated	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	time	_	_	NN	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	decrease	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	mRNA	_	_	NN	O	-1	none	_	_
15	level	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	proapoptotic	_	_	JJ	O	-1	none	_	_
19	Nip-2	_	_	NN	O	-1	none	_	_
20	protein	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	supporting	_	_	VBG	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	hypothesis	_	_	NN	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	hormone	_	_	NN	O	-1	none	_	_
27	responsiveness	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	U937	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	mediated	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	target	_	_	NN	O	-1	none	_	_
35	gene	_	_	NN	O	-1	none	_	_
36	transcription	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	presented	_	_	VBN	O	-1	none	_	_
4	here	_	_	RB	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	female	_	_	JJ	O	-1	none	_	_
9	steroid	_	_	NN	O	-1	none	_	_
10	receptors	_	_	NNS	O	-1	none	_	_
11	play	_	_	VBP	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	regulation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	immune	_	_	JJ	O	-1	none	_	_
19	response	_	_	NN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	preventing	_	_	VBG	O	-1	none	_	_
22	apoptosis	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	monoblastoid	_	_	JJ	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	;	_	_	:	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	effect	_	_	NN	O	-1	none	_	_
29	might	_	_	MD	O	-1	none	_	_
30	have	_	_	VB	O	-1	none	_	_
31	important	_	_	JJ	O	-1	none	_	_
32	consequences	_	_	NNS	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	clinical	_	_	JJ	O	-1	none	_	_
36	use	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	steroid	_	_	NN	O	-1	none	_	_
39	receptor	_	_	NN	O	-1	none	_	_
40	drugs	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Characterization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	CD43	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	leukosialin	_	_	NN	Protein	-1	none	_	_
7	mediated	_	_	JJ	O	-1	none	_	_
8	pathway	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	inducing	_	_	VBG	O	-1	none	_	_
11	apoptosis	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	T-lymphoblastoid	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	monoclonal	_	_	JJ	O	-1	none	_	_
3	antibody	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	mAb	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	J393	_	_	NN	O	-1	none	_	_
8	induces	_	_	VBZ	O	-1	none	_	_
9	apoptosis	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	Jurkat	_	_	NN	O	-1	none	_	_
12	T-cells	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	NH2-terminal	_	_	JJ	O	-1	none	_	_
2	amino	_	_	NN	O	-1	none	_	_
3	acid	_	_	NN	O	-1	none	_	_
4	sequence	_	_	NN	O	-1	none	_	_
5	analysis	_	_	NN	O	-1	none	_	_
6	identified	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	140-kDa	_	_	JJ	O	-1	none	_	_
9	surface	_	_	NN	O	-1	none	_	_
10	antigen	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	mAb	_	_	NN	O	-1	none	_	_
13	J393	_	_	NN	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	CD43	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	leukosialin	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	major	_	_	JJ	O	-1	none	_	_
21	sialoglycoprotein	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	leukocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	Jurkat	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	co-expressed	_	_	VBD	O	-1	none	_	_
5	two	_	_	CD	O	-1	none	_	_
6	discrete	_	_	JJ	O	-1	none	_	_
7	cell-surface	_	_	JJ	O	-1	none	_	_
8	isoforms	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	CD43	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	recognized	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	mAb	_	_	NN	O	-1	none	_	_
15	J393	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	mAb	_	_	NN	O	-1	none	_	_
18	G10-2	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	respectively	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	only	_	_	RB	O	-1	none	_	_
23	J393	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	CD43	_	_	NN	Protein	-1	none	_	_
26	signaled	_	_	VBD	O	-1	none	_	_
27	apoptosis	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	J393	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	CD43	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	hyposialylated	_	_	VBN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	bearing	_	_	VBG	O	-1	none	_	_
11	predominantly	_	_	RB	O	-1	none	_	_
12	O	_	_	NNP	O	-1	none	_	_
13	linked	_	_	VBD	O	-1	none	_	_
14	monosaccharide	_	_	NN	O	-1	none	_	_
15	glycans	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	whereas	_	_	IN	O	-1	none	_	_
18	G10-2	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	CD43	_	_	NN	Protein	-1	none	_	_
21	bore	_	_	VBD	O	-1	none	_	_
22	complex	_	_	JJ	O	-1	none	_	_
23	sialylated	_	_	VBN	O	-1	none	_	_
24	tetra-	_	_	JJ	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	hexasaccharide	_	_	NN	O	-1	none	_	_
27	chains	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	soluble	_	_	JJ	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	bivalent	_	_	JJ	O	-1	none	_	_
6	mAb	_	_	NN	O	-1	none	_	_
7	J393	_	_	NN	O	-1	none	_	_
8	killed	_	_	VBD	O	-1	none	_	_
9	25-50	_	_	CD	O	-1	none	_	_
10	%	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	population	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	while	_	_	IN	O	-1	none	_	_
17	concomitant	_	_	JJ	O	-1	none	_	_
18	engagement	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	either	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	CD3.TcR	_	_	NN	O	-1	none	_	_
23	complex	_	_	NN	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	integrins	_	_	NNS	O	-1	none	_	_
27	CD18	_	_	NN	Protein	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	CD29	_	_	NN	Protein	-1	none	_	_
30	significantly	_	_	RB	O	-1	none	_	_
31	potentiated	_	_	VBD	O	-1	none	_	_
32	this	_	_	DT	O	-1	none	_	_
33	effect	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Jurkat	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	mAb	_	_	NN	O	-1	none	_	_
7	J393	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	tyrosine	_	_	NN	O	-1	none	_	_
10	phosphorylation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	substrates	_	_	NNS	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	underwent	_	_	VBD	O	-1	none	_	_
17	hyperphosphorylation	_	_	NN	O	-1	none	_	_
18	upon	_	_	IN	O	-1	none	_	_
19	antigen	_	_	NN	O	-1	none	_	_
20	receptor	_	_	NN	O	-1	none	_	_
21	costimulation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Tyrosine	_	_	NN	O	-1	none	_	_
2	kinase	_	_	NN	O	-1	none	_	_
3	inhibition	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	herbimycin	_	_	NN	O	-1	none	_	_
6	A	_	_	NN	O	-1	none	_	_
7	diminished	_	_	VBD	O	-1	none	_	_
8	J393	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	CD43	_	_	NN	Protein	-1	none	_	_
11	mediated	_	_	JJ	O	-1	none	_	_
12	apoptosis	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	whereas	_	_	IN	O	-1	none	_	_
15	inhibition	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	phosphotyrosine	_	_	NN	O	-1	none	_	_
18	phosphatase	_	_	NN	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	bis	_	_	FW	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	maltolato	_	_	FW	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	oxovanadium-IV	_	_	NN	O	-1	none	_	_
26	enhanced	_	_	VBD	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	death	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Signal	_	_	NN	O	-1	none	_	_
2	transduction	_	_	NN	O	-1	none	_	_
3	through	_	_	IN	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	may	_	_	MD	O	-1	none	_	_
8	lead	_	_	VB	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	altered	_	_	JJ	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	J393	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	CD43	_	_	NN	Protein	-1	none	_	_
18	ligation	_	_	NN	O	-1	none	_	_
19	prompted	_	_	VBD	O	-1	none	_	_
20	decreases	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	nuclear	_	_	JJ	O	-1	none	_	_
24	localization	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transcriptional	_	_	JJ	O	-1	none	_	_
28	regulatory	_	_	JJ	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	NF-kappaB	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	proteins	_	_	NNS	O	-1	none	_	_
33	binding	_	_	VBG	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	interferon	_	_	NN	O	-1	none	_	_
36	inducible	_	_	JJ	O	-1	none	_	_
37	regulatory	_	_	JJ	O	-1	none	_	_
38	element	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	peripheral	_	_	JJ	O	-1	none	_	_
3	blood	_	_	NN	O	-1	none	_	_
4	T-lymphocytes	_	_	NNS	O	-1	none	_	_
5	express	_	_	VBP	O	-1	none	_	_
6	cryptic	_	_	JJ	O	-1	none	_	_
7	epitopes	_	_	NNS	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	mAb	_	_	NN	O	-1	none	_	_
10	J393	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	these	_	_	DT	O	-1	none	_	_
13	findings	_	_	NNS	O	-1	none	_	_
14	demonstrate	_	_	VBP	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	existence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	tightly	_	_	RB	O	-1	none	_	_
20	regulated	_	_	VBN	O	-1	none	_	_
21	CD43	_	_	NN	Protein	-1	none	_	_
22	mediated	_	_	JJ	O	-1	none	_	_
23	pathway	_	_	NN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	inducing	_	_	VBG	O	-1	none	_	_
26	apoptosis	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	T-cell	_	_	NN	O	-1	none	_	_
30	lineages	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	glucocorticoid	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	sites	_	_	NNS	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	glucocorticoid	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Glucocorticoids	_	_	NNS	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	known	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	have	_	_	VB	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	lytic	_	_	JJ	O	-1	none	_	_
8	effect	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	leukemic	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	via	_	_	IN	O	-1	none	_	_
13	interactions	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	glucocorticoid	_	_	NN	Protein	17	multitoken	_	_
17	receptor	_	_	NN	Protein	0	root	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	GR	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Cortisol	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	various	_	_	JJ	O	-1	none	_	_
4	synthetic	_	_	JJ	O	-1	none	_	_
5	glucocorticoids	_	_	NNS	O	-1	none	_	_
6	bind	_	_	VBP	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	GR	_	_	NN	Protein	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	one-site	_	_	JJ	O	-1	none	_	_
12	kinetics	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Cortivazol	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	CVZ	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	unique	_	_	JJ	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	high	_	_	JJ	O	-1	none	_	_
10	potency	_	_	NN	O	-1	none	_	_
11	synthetic	_	_	JJ	O	-1	none	_	_
12	glucocorticoid	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	has	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	phenylpyrazol	_	_	JJ	O	-1	none	_	_
18	fused	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	A	_	_	NN	O	-1	none	_	_
22	ring	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	steroid	_	_	NN	O	-1	none	_	_
26	nucleus	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	displays	_	_	VBZ	O	-1	none	_	_
29	binding	_	_	NN	O	-1	none	_	_
30	consistent	_	_	JJ	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	two	_	_	CD	O	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	more	_	_	JJR	O	-1	none	_	_
35	sites	_	_	NNS	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	cytosol	_	_	NN	O	-1	none	_	_
39	from	_	_	IN	O	-1	none	_	_
40	CEM	_	_	NN	O	-1	none	_	_
41	C7	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	a	_	_	DT	O	-1	none	_	_
45	human	_	_	NN	O	-1	none	_	_
46	acute	_	_	JJ	O	-1	none	_	_
47	lymphoblastic	_	_	JJ	O	-1	none	_	_
48	T-cell	_	_	NN	O	-1	none	_	_
49	line	_	_	NN	O	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	has	_	_	VBZ	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	lower	_	_	JJR	O	-1	none	_	_
9	affinity	_	_	NN	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	sites	_	_	NNS	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	similar	_	_	JJ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	affinity	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	site	_	_	NN	O	-1	none	_	_
19	molarity	_	_	NN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	those	_	_	DT	O	-1	none	_	_
22	recognized	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	dexamethasone	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	higher	_	_	JJR	O	-1	none	_	_
3	affinity	_	_	NN	O	-1	none	_	_
4	sites	_	_	NNS	O	-1	none	_	_
5	bind	_	_	VBP	O	-1	none	_	_
6	CVZ	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	20-	_	_	CD	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	50-fold	_	_	RB	O	-1	none	_	_
11	greater	_	_	JJR	O	-1	none	_	_
12	affinity	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	consistent	_	_	JJ	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	CVZ	_	_	NN	O	-1	none	_	_
17	's	_	_	POS	O	-1	none	_	_
18	enhanced	_	_	VBN	O	-1	none	_	_
19	biological	_	_	JJ	O	-1	none	_	_
20	effects	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	mutant	_	_	NN	O	-1	none	_	_
3	leukemic	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	resistant	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	lytic	_	_	JJ	O	-1	none	_	_
9	effects	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	dexamethasone	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	CVZ	_	_	NN	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	lyses	_	_	VBZ	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	recognizes	_	_	VBZ	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	single	_	_	JJ	O	-1	none	_	_
22	class	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	sites	_	_	NNS	O	-1	none	_	_
25	similar	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	high	_	_	JJ	O	-1	none	_	_
29	affinity	_	_	NN	O	-1	none	_	_
30	site	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	CEM	_	_	NN	O	-1	none	_	_
33	C7	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	carried	_	_	VBN	O	-1	none	_	_
4	out	_	_	RP	O	-1	none	_	_
5	experiments	_	_	NNS	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	define	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	nature	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	higher	_	_	JJR	O	-1	none	_	_
13	affinity	_	_	NN	O	-1	none	_	_
14	CVZ	_	_	NN	O	-1	none	_	_
15	binding	_	_	VBG	O	-1	none	_	_
16	site	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	:	_	_	:	O	-1	none	_	_
6	1	_	_	LS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	CVZ	_	_	NN	O	-1	none	_	_
9	has	_	_	VBZ	O	-1	none	_	_
10	more	_	_	JJR	O	-1	none	_	_
11	than	_	_	IN	O	-1	none	_	_
12	one	_	_	CD	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	second	_	_	JJ	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	independent	_	_	JJ	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	B-cell	_	_	NN	O	-1	none	_	_
22	line	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	IM-9	_	_	NN	O	-1	none	_	_
25	;	_	_	:	O	-1	none	_	_
26	2	_	_	CD	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	antiglucocorticoid	_	_	JJ	O	-1	none	_	_
30	RU	_	_	NN	O	-1	none	_	_
31	38486	_	_	CD	O	-1	none	_	_
32	is	_	_	VBZ	O	-1	none	_	_
33	able	_	_	JJ	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	block	_	_	VB	O	-1	none	_	_
36	both	_	_	CC	O	-1	none	_	_
37	CVZ	_	_	NN	O	-1	none	_	_
38	's	_	_	POS	O	-1	none	_	_
39	higher	_	_	JJR	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	lower	_	_	JJR	O	-1	none	_	_
42	affinity	_	_	NN	O	-1	none	_	_
43	sites	_	_	NNS	O	-1	none	_	_
44	;	_	_	:	O	-1	none	_	_
45	3	_	_	CD	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	all	_	_	DT	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	CVZ	_	_	NN	O	-1	none	_	_
50	's	_	_	POS	O	-1	none	_	_
51	binding	_	_	NN	O	-1	none	_	_
52	sites	_	_	NNS	O	-1	none	_	_
53	are	_	_	VBP	O	-1	none	_	_
54	on	_	_	IN	O	-1	none	_	_
55	a	_	_	DT	O	-1	none	_	_
56	protein	_	_	NN	O	-1	none	_	_
57	immunologically	_	_	RB	O	-1	none	_	_
58	indistinguishable	_	_	JJ	O	-1	none	_	_
59	from	_	_	IN	O	-1	none	_	_
60	the	_	_	DT	O	-1	none	_	_
61	human	_	_	NN	O	-1	none	_	_
62	GR	_	_	NN	Protein	-1	none	_	_
63	;	_	_	:	O	-1	none	_	_
64	and	_	_	CC	O	-1	none	_	_
65	4	_	_	CD	O	-1	none	_	_
66	)	_	_	-RRB-	O	-1	none	_	_
67	freshly	_	_	RB	O	-1	none	_	_
68	isolated	_	_	VBN	O	-1	none	_	_
69	clones	_	_	NNS	O	-1	none	_	_
70	of	_	_	IN	O	-1	none	_	_
71	CVZ	_	_	NN	O	-1	none	_	_
72	resistant	_	_	JJ	O	-1	none	_	_
73	cells	_	_	NNS	O	-1	none	_	_
74	have	_	_	VBP	O	-1	none	_	_
75	lost	_	_	VBN	O	-1	none	_	_
76	all	_	_	DT	O	-1	none	_	_
77	binding	_	_	VBG	O	-1	none	_	_
78	sites	_	_	NNS	O	-1	none	_	_
79	for	_	_	IN	O	-1	none	_	_
80	CVZ	_	_	NN	O	-1	none	_	_
81	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	CVZ	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	recognizing	_	_	VBG	O	-1	none	_	_
8	two	_	_	CD	O	-1	none	_	_
9	glucocorticoid	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	sites	_	_	NNS	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	GR	_	_	NN	Protein	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	very	_	_	RB	O	-1	none	_	_
20	similar	_	_	JJ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	it	_	_	PRP	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Increased	_	_	VBN	O	-1	none	_	_
2	glucocorticoid	_	_	NN	Protein	4	multitoken	_	_
3	receptor	_	_	NN	Protein	4	multitoken	_	_
4	beta	_	_	NN	Protein	0	root	_	_
5	in	_	_	IN	O	-1	none	_	_
6	airway	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	glucocorticoid-insensitive	_	_	JJ	O	-1	none	_	_
10	asthma	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	GC	_	_	NN	O	-1	none	_	_
4	)-insensitive	_	_	JJ	O	-1	none	_	_
5	asthma	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	challenging	_	_	JJ	O	-1	none	_	_
9	clinical	_	_	JJ	O	-1	none	_	_
10	problem	_	_	NN	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	can	_	_	MD	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	associated	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	life	_	_	NN	O	-1	none	_	_
17	threatening	_	_	JJ	O	-1	none	_	_
18	disease	_	_	NN	O	-1	none	_	_
19	progression	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	molecular	_	_	JJ	O	-1	none	_	_
3	basis	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	GC	_	_	NN	O	-1	none	_	_
6	insensitivity	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	unknown	_	_	JJ	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Alternative	_	_	JJ	O	-1	none	_	_
2	splicing	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	GC	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	GCR	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	pre-mRNA	_	_	NN	O	-1	none	_	_
11	generates	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	second	_	_	JJ	O	-1	none	_	_
14	GCR	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	termed	_	_	VBN	O	-1	none	_	_
17	GCRbeta	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	does	_	_	VBZ	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	bind	_	_	VB	O	-1	none	_	_
23	GC	_	_	NN	O	-1	none	_	_
24	but	_	_	CC	O	-1	none	_	_
25	antagonizes	_	_	VBZ	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	transactivating	_	_	NN	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	classic	_	_	JJ	O	-1	none	_	_
32	GCR	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	increased	_	_	VBN	O	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	GCRbeta	_	_	NN	Protein	-1	none	_	_
6	could	_	_	MD	O	-1	none	_	_
7	account	_	_	VB	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	glucocorticoid	_	_	NN	O	-1	none	_	_
10	insensitivity	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Bronchoalveolar	_	_	JJ	O	-1	none	_	_
2	lavage	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	BAL	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	peripheral	_	_	JJ	O	-1	none	_	_
9	blood	_	_	NN	O	-1	none	_	_
10	mononuclear	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	PBMC	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	examined	_	_	VBN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	GCRbeta	_	_	NN	Protein	-1	none	_	_
19	immunoreactivity	_	_	NN	O	-1	none	_	_
20	using	_	_	VBG	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	GCRbeta	_	_	NN	Protein	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	antibody	_	_	NN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	immunohistochemical	_	_	JJ	O	-1	none	_	_
27	staining	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Cell	_	_	NN	O	-1	none	_	_
2	localization	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	GCRbeta	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	performed	_	_	VBN	O	-1	none	_	_
8	using	_	_	VBG	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	double	_	_	JJ	O	-1	none	_	_
11	immunostaining	_	_	NN	O	-1	none	_	_
12	technique	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	GCRbeta	_	_	NN	Protein	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	GC-insensitive	_	_	JJ	O	-1	none	_	_
7	asthma	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	particularly	_	_	RB	O	-1	none	_	_
10	high	_	_	JJ	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	airway	_	_	NN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	thought	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	play	_	_	VB	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	major	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	pathogenesis	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	asthma	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	GCRbeta	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	specimens	_	_	NNS	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	airways	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	chronic	_	_	JJ	O	-1	none	_	_
17	bronchitis	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	chronic	_	_	JJ	O	-1	none	_	_
3	bronchitis	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	few	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	GCRbeta	_	_	NN	Protein	-1	none	_	_
9	positive	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	their	_	_	PRP$	O	-1	none	_	_
12	numbers	_	_	NNS	O	-1	none	_	_
13	did	_	_	VBD	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	differ	_	_	VB	O	-1	none	_	_
16	significantly	_	_	RB	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	normal	_	_	JJ	O	-1	none	_	_
19	control	_	_	JJ	O	-1	none	_	_
20	subjects	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	GC-insensitive	_	_	JJ	O	-1	none	_	_
5	asthma	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	associated	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	increased	_	_	VBN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	GCRbeta	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	airway	_	_	NN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Monoallelic	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Pax5	_	_	NN	Protein	-1	none	_	_
5	:	_	_	:	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	paradigm	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	haploinsufficiency	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	mammalian	_	_	JJ	O	-1	none	_	_
13	Pax	_	_	NN	O	-1	none	_	_
14	genes	_	_	NNS	O	-1	none	_	_
15	?	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	generally	_	_	RB	O	-1	none	_	_
4	assumed	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	most	_	_	JJS	O	-1	none	_	_
7	mammalian	_	_	JJ	O	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	transcribed	_	_	VBN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	both	_	_	DT	O	-1	none	_	_
13	alleles	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Hence	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	diploid	_	_	JJ	O	-1	none	_	_
5	state	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	genome	_	_	NN	O	-1	none	_	_
9	offers	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	advantage	_	_	NN	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	loss-of-function	_	_	JJ	O	-1	none	_	_
15	mutation	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	one	_	_	CD	O	-1	none	_	_
18	allele	_	_	NN	O	-1	none	_	_
19	can	_	_	MD	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	compensated	_	_	VBN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	remaining	_	_	VBG	O	-1	none	_	_
26	wild-type	_	_	JJ	O	-1	none	_	_
27	allele	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	same	_	_	JJ	O	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Indeed	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	vast	_	_	JJ	O	-1	none	_	_
5	majority	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	disease	_	_	NN	O	-1	none	_	_
9	syndromes	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	engineered	_	_	VBN	O	-1	none	_	_
12	mutations	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	mouse	_	_	NN	O	-1	none	_	_
16	genome	_	_	NN	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	recessive	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	indicating	_	_	VBG	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	recessiveness	_	_	NN	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	'	_	_	''	O	-1	none	_	_
26	default	_	_	NN	O	-1	none	_	_
27	'	_	_	''	O	-1	none	_	_
28	state	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	minority	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	genes	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	semi-dominant	_	_	JJ	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	heterozygous	_	_	JJ	O	-1	none	_	_
12	loss-of-function	_	_	JJ	O	-1	none	_	_
13	mutation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	these	_	_	DT	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	leads	_	_	VBZ	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	phenotypic	_	_	JJ	O	-1	none	_	_
20	abnormalities	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	condition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	known	_	_	VBN	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	haploinsufficiency	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	described	_	_	VBN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	five	_	_	CD	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	nine	_	_	CD	O	-1	none	_	_
16	mammalian	_	_	JJ	O	-1	none	_	_
17	Pax	_	_	NN	O	-1	none	_	_
18	genes	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	associated	_	_	VBN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	mouse	_	_	NN	O	-1	none	_	_
25	developmental	_	_	JJ	O	-1	none	_	_
26	mutants	_	_	NNS	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	disease	_	_	NN	O	-1	none	_	_
30	syndromes	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	reported	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	Pax5	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	subject	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	allele	_	_	NN	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	regulation	_	_	NN	O	-1	none	_	_
15	during	_	_	IN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	development	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Pax5	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	predominantly	_	_	RB	O	-1	none	_	_
4	transcribed	_	_	VBN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	only	_	_	RB	O	-1	none	_	_
7	one	_	_	CD	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	its	_	_	PRP$	O	-1	none	_	_
10	two	_	_	CD	O	-1	none	_	_
11	alleles	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	early	_	_	JJ	O	-1	none	_	_
14	B-lymphoid	_	_	JJ	O	-1	none	_	_
15	progenitors	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	mature	_	_	JJ	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	while	_	_	IN	O	-1	none	_	_
22	it	_	_	PRP	O	-1	none	_	_
23	transiently	_	_	RB	O	-1	none	_	_
24	switches	_	_	VBZ	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	biallelic	_	_	JJ	O	-1	none	_	_
28	mode	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	pre-B	_	_	JJ	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	immature	_	_	JJ	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	consequence	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	B-lymphoid	_	_	JJ	O	-1	none	_	_
6	tissues	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	mosaic	_	_	JJ	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	regard	_	_	NN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	transcribed	_	_	JJ	O	-1	none	_	_
14	allele	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	heterozygous	_	_	JJ	O	-1	none	_	_
18	mutation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	Pax5	_	_	NN	Protein	-1	none	_	_
21	therefore	_	_	RB	O	-1	none	_	_
22	results	_	_	VBZ	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	deletion	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	lymphocytes	_	_	NNS	O	-1	none	_	_
28	expressing	_	_	VBG	O	-1	none	_	_
29	only	_	_	RB	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	mutant	_	_	NN	O	-1	none	_	_
32	allele	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	allele	_	_	NN	O	-1	none	_	_
3	specific	_	_	JJ	O	-1	none	_	_
4	regulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Pax5	_	_	NN	Protein	-1	none	_	_
7	raises	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	intriguing	_	_	JJ	O	-1	none	_	_
10	possibility	_	_	NN	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	monoallelic	_	_	JJ	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	may	_	_	MD	O	-1	none	_	_
15	also	_	_	RB	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	causing	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	haploinsufficiency	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	other	_	_	JJ	O	-1	none	_	_
24	Pax	_	_	NN	O	-1	none	_	_
25	genes	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	review	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	discuss	_	_	VBP	O	-1	none	_	_
7	different	_	_	JJ	O	-1	none	_	_
8	models	_	_	NNS	O	-1	none	_	_
9	accounting	_	_	VBG	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	haploinsufficiency	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	mammalian	_	_	JJ	O	-1	none	_	_
15	Pax	_	_	NN	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	provide	_	_	VBP	O	-1	none	_	_
19	further	_	_	JJ	O	-1	none	_	_
20	evidence	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	support	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	allele	_	_	NN	O	-1	none	_	_
26	specific	_	_	JJ	O	-1	none	_	_
27	regulation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	Pax5	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	discuss	_	_	VB	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	implication	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	these	_	_	DT	O	-1	none	_	_
36	findings	_	_	NNS	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	context	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	recent	_	_	JJ	O	-1	none	_	_
43	literature	_	_	NN	O	-1	none	_	_
44	describing	_	_	VBG	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	stochastic	_	_	JJ	O	-1	none	_	_
47	and	_	_	CC	O	-1	none	_	_
48	monoallelic	_	_	JJ	O	-1	none	_	_
49	activation	_	_	NN	O	-1	none	_	_
50	of	_	_	IN	O	-1	none	_	_
51	other	_	_	JJ	O	-1	none	_	_
52	hematopoietic	_	_	JJ	O	-1	none	_	_
53	genes	_	_	NNS	O	-1	none	_	_
54	.	_	_	.	O	-1	none	_	_

1	Interleukin	_	_	NN	Protein	2	multitoken	_	_
2	2	_	_	CD	Protein	0	root	_	_
3	signaling	_	_	NN	O	-1	none	_	_
4	involves	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Stat	_	_	NN	O	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	most	_	_	RBS	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	cytokines	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	immune	_	_	JJ	O	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	regulation	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	interleukin	_	_	NN	Protein	14	multitoken	_	_
14	2	_	_	CD	Protein	0	root	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	potent	_	_	JJ	O	-1	none	_	_
21	activator	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	proliferation	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	function	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	T	_	_	NN	O	-1	none	_	_
29	lymphocytes	_	_	NNS	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	natural	_	_	JJ	O	-1	none	_	_
32	killer	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanisms	_	_	NNS	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	effects	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	propagated	_	_	VBN	O	-1	none	_	_
11	within	_	_	IN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	understood	_	_	VBN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	its	_	_	PRP$	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	recently	_	_	RB	O	-1	none	_	_
11	shown	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	lead	_	_	VB	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	two	_	_	CD	O	-1	none	_	_
19	kinases	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	Jak-1	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	Jak-3	_	_	CD	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	subsequent	_	_	JJ	O	-1	none	_	_
26	steps	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	signaling	_	_	NN	O	-1	none	_	_
30	pathway	_	_	NN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	nucleus	_	_	NN	O	-1	none	_	_
34	that	_	_	WDT	O	-1	none	_	_
35	lead	_	_	VBP	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	activation	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	specific	_	_	JJ	O	-1	none	_	_
41	genes	_	_	NNS	O	-1	none	_	_
42	had	_	_	VBD	O	-1	none	_	_
43	not	_	_	RB	O	-1	none	_	_
44	been	_	_	VBN	O	-1	none	_	_
45	characterized	_	_	VBN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	many	_	_	JJ	O	-1	none	_	_
3	cytokines	_	_	NNS	O	-1	none	_	_
4	that	_	_	WDT	O	-1	none	_	_
5	activate	_	_	VBP	O	-1	none	_	_
6	Jak	_	_	NN	O	-1	none	_	_
7	kinases	_	_	NNS	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	lead	_	_	VBP	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	tyrosine	_	_	NN	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	members	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	Stat	_	_	NN	O	-1	none	_	_
21	family	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	factors	_	_	NNS	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	ability	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	IL-2	_	_	NN	Protein	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	trigger	_	_	VB	O	-1	none	_	_
32	Stat	_	_	NN	O	-1	none	_	_
33	phosphorylation	_	_	NN	O	-1	none	_	_
34	was	_	_	VBD	O	-1	none	_	_
35	examined	_	_	VBN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Exposure	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	or	_	_	CC	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	natural	_	_	JJ	O	-1	none	_	_
11	killer	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	line	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	NKL	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	IL-2	_	_	NN	Protein	-1	none	_	_
19	leads	_	_	VBZ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	phosphorylation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	Stat1	_	_	NN	Protein	25	multitoken	_	_
25	alpha	_	_	NN	Protein	0	root	_	_
26	,	_	_	,	O	-1	none	_	_
27	Stat1	_	_	NN	Protein	28	multitoken	_	_
28	beta	_	_	NN	Protein	0	root	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	Stat3	_	_	NN	Protein	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	as	_	_	RB	O	-1	none	_	_
34	well	_	_	RB	O	-1	none	_	_
35	as	_	_	IN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	two	_	_	CD	O	-1	none	_	_
38	Stat	_	_	NN	O	-1	none	_	_
39	related	_	_	JJ	O	-1	none	_	_
40	proteins	_	_	NNS	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	p94	_	_	NN	Protein	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	p95	_	_	NN	Protein	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	p94	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	p95	_	_	NN	Protein	-1	none	_	_
4	share	_	_	NN	O	-1	none	_	_
5	homology	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	Stat1	_	_	NN	Protein	-1	none	_	_
8	at	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	phosphorylation	_	_	NN	O	-1	none	_	_
11	site	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	Src	_	_	NN	O	-1	none	_	_
16	homology	_	_	NN	O	-1	none	_	_
17	2	_	_	CD	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	SH2	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	domain	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	but	_	_	CC	O	-1	none	_	_
24	otherwise	_	_	RB	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	immunologically	_	_	RB	O	-1	none	_	_
27	distinct	_	_	JJ	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	Stat1	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	Stat	_	_	NN	O	-1	none	_	_
3	proteins	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	translocate	_	_	VB	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	nucleus	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	bind	_	_	VB	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	sequence	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	mechanism	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	its	_	_	PRP$	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	activate	_	_	VB	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	involved	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	immune	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	function	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	CD4	_	_	NN	Protein	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	.	_	_	.	O	-1	none	_	_

1	Interaction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	fibronectin	_	_	NN	Protein	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	VLA-5	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	on	_	_	IN	O	-1	none	_	_
8	CD4	_	_	NN	Protein	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	induces	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Fibronectin	_	_	NN	Protein	-1	none	_	_
2	synergized	_	_	VBD	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	anti-CD3	_	_	JJ	O	-1	none	_	_
5	antibody	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	promote	_	_	VB	O	-1	none	_	_
8	CD4	_	_	NN	Protein	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	proliferation	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	serum-free	_	_	JJ	O	-1	none	_	_
14	culture	_	_	NN	O	-1	none	_	_
15	system	_	_	NN	O	-1	none	_	_
16	whereas	_	_	IN	O	-1	none	_	_
17	no	_	_	DT	O	-1	none	_	_
18	proliferation	_	_	NN	O	-1	none	_	_
19	was	_	_	VBD	O	-1	none	_	_
20	observed	_	_	VBN	O	-1	none	_	_
21	when	_	_	WRB	O	-1	none	_	_
22	CD4	_	_	NN	Protein	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	were	_	_	VBD	O	-1	none	_	_
25	cultured	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	anti-CD3	_	_	NN	O	-1	none	_	_
28	alone	_	_	RB	O	-1	none	_	_
29	or	_	_	CC	O	-1	none	_	_
30	fibronectin	_	_	NN	Protein	-1	none	_	_
31	alone	_	_	RB	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	anti-CD29	_	_	JJ	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	integrin	_	_	NN	Protein	8	multitoken	_	_
7	beta	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	as	_	_	RB	O	-1	none	_	_
11	well	_	_	RB	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	anti-VLA-5	_	_	JJ	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	fibronectin	_	_	NN	O	-1	none	_	_
17	receptor	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	antibodies	_	_	NNS	O	-1	none	_	_
20	blocked	_	_	VBD	O	-1	none	_	_
21	this	_	_	DT	O	-1	none	_	_
22	CD4	_	_	NN	Protein	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	activation	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	this	_	_	DT	O	-1	none	_	_
27	system	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	anti-CD3	_	_	NN	O	-1	none	_	_
3	alone	_	_	RB	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	fibronectin	_	_	NN	Protein	-1	none	_	_
6	alone	_	_	RB	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	induce	_	_	VB	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	message	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	CD4	_	_	NN	Protein	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	combination	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	anti-CD3	_	_	NN	O	-1	none	_	_
20	plus	_	_	CC	O	-1	none	_	_
21	fibronectin	_	_	NN	Protein	-1	none	_	_
22	induced	_	_	VBD	O	-1	none	_	_
23	IL-2	_	_	NN	Protein	-1	none	_	_
24	message	_	_	NN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	CD4	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	VLA-5	_	_	NN	Protein	5	multitoken	_	_
4	fibronectin	_	_	NN	Protein	5	multitoken	_	_
5	receptor	_	_	NN	Protein	0	root	_	_
6	on	_	_	IN	O	-1	none	_	_
7	CD4	_	_	NN	Protein	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	play	_	_	VB	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	complementary	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	CD3-TCR-mediated	_	_	JJ	O	-1	none	_	_
16	signal	_	_	NN	O	-1	none	_	_
17	transduction	_	_	NN	O	-1	none	_	_
18	through	_	_	IN	O	-1	none	_	_
19	its	_	_	PRP$	O	-1	none	_	_
20	interaction	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	fibronectin	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Glucocorticoids	_	_	NNS	O	-1	none	_	_
2	promote	_	_	VBP	O	-1	none	_	_
3	nonphlogistic	_	_	JJ	O	-1	none	_	_
4	phagocytosis	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	apoptotic	_	_	JJ	O	-1	none	_	_
7	leukocytes	_	_	NNS	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	Phagocyte	_	_	NN	O	-1	none	_	_
2	recognition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	uptake	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	nonphlogistic	_	_	JJ	O	-1	none	_	_
8	degradation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	neutrophils	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	other	_	_	JJ	O	-1	none	_	_
13	leukocytes	_	_	NNS	O	-1	none	_	_
14	undergoing	_	_	VBG	O	-1	none	_	_
15	apoptosis	_	_	NN	O	-1	none	_	_
16	promote	_	_	VBP	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	resolution	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	inflammation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	assessed	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effects	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	anti-inflammatory	_	_	JJ	O	-1	none	_	_
8	glucocorticoids	_	_	NNS	O	-1	none	_	_
9	on	_	_	IN	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	leukocyte	_	_	NN	O	-1	none	_	_
12	clearance	_	_	NN	O	-1	none	_	_
13	mechanism	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Pretreatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	"	_	_	``	O	-1	none	_	_
4	semimature	_	_	JJ	O	-1	none	_	_
5	"	_	_	''	O	-1	none	_	_
6	5-day	_	_	JJ	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	monocyte	_	_	NN	O	-1	none	_	_
9	derived	_	_	VBN	O	-1	none	_	_
10	macrophages	_	_	NNS	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	M	_	_	NN	O	-1	none	_	_
13	phi	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	24	_	_	CD	O	-1	none	_	_
17	h	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	methylprednisolone	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	dexamethasone	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	hydrocortisone	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	nonglucocorticoid	_	_	NN	O	-1	none	_	_
30	steroids	_	_	NNS	O	-1	none	_	_
31	aldosterone	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	estradiol	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	progesterone	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	potentiated	_	_	VBD	O	-1	none	_	_
39	phagocytosis	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	apoptotic	_	_	JJ	O	-1	none	_	_
42	neutrophils	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	potentiated	_	_	JJ	O	-1	none	_	_
9	phagocytosis	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	apoptotic	_	_	JJ	O	-1	none	_	_
12	neutrophils	_	_	NNS	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	completely	_	_	RB	O	-1	none	_	_
15	blocked	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	glucocorticoid	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	antagonist	_	_	NN	O	-1	none	_	_
21	RU38486	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	glucocorticoids	_	_	NNS	O	-1	none	_	_
25	did	_	_	VBD	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	promote	_	_	VB	O	-1	none	_	_
28	5-day	_	_	JJ	O	-1	none	_	_
29	M	_	_	NN	O	-1	none	_	_
30	phi	_	_	NN	O	-1	none	_	_
31	ingestion	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	opsonized	_	_	VBN	O	-1	none	_	_
34	erythrocytes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Similar	_	_	JJ	O	-1	none	_	_
2	glucocorticoid	_	_	NN	O	-1	none	_	_
3	mediated	_	_	VBN	O	-1	none	_	_
4	potentiation	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	5-day	_	_	JJ	O	-1	none	_	_
9	M	_	_	NN	O	-1	none	_	_
10	phi	_	_	NN	O	-1	none	_	_
11	uptake	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	alternative	_	_	JJ	O	-1	none	_	_
14	apoptotic	_	_	JJ	O	-1	none	_	_
15	"	_	_	``	O	-1	none	_	_
16	targets	_	_	NNS	O	-1	none	_	_
17	"	_	_	''	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	eosinophils	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	Jurkat	_	_	NN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	uptake	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	apoptotic	_	_	JJ	O	-1	none	_	_
30	neutrophils	_	_	NNS	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	alternative	_	_	JJ	O	-1	none	_	_
33	phagocytes	_	_	NNS	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	human	_	_	NN	O	-1	none	_	_
36	glomerular	_	_	JJ	O	-1	none	_	_
37	mesangial	_	_	JJ	O	-1	none	_	_
38	cells	_	_	NNS	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	murine	_	_	JJ	O	-1	none	_	_
41	M	_	_	NN	O	-1	none	_	_
42	phi	_	_	NN	O	-1	none	_	_
43	elicited	_	_	VBN	O	-1	none	_	_
44	into	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	peritoneum	_	_	NN	O	-1	none	_	_
47	or	_	_	CC	O	-1	none	_	_
48	derived	_	_	VBN	O	-1	none	_	_
49	from	_	_	IN	O	-1	none	_	_
50	bone	_	_	NN	O	-1	none	_	_
51	marrow	_	_	NN	O	-1	none	_	_
52	)	_	_	-RRB-	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Importantly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	methylprednisolone	_	_	NN	O	-1	none	_	_
4	mediated	_	_	VBD	O	-1	none	_	_
5	enhancement	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	uptake	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	apoptotic	_	_	JJ	O	-1	none	_	_
11	neutrophils	_	_	NNS	O	-1	none	_	_
12	did	_	_	VBD	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	trigger	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	release	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	chemokines	_	_	NNS	O	-1	none	_	_
20	IL-8	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	monocyte	_	_	NN	Protein	24	multitoken	_	_
23	chemoattractant	_	_	NN	Protein	24	multitoken	_	_
24	protein-1	_	_	NN	Protein	0	root	_	_
25	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	longer-term	_	_	JJ	O	-1	none	_	_
4	potentiation	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	methylprednisolone	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	observed	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	maturing	_	_	VBG	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	monocyte	_	_	NN	O	-1	none	_	_
13	derived	_	_	VBN	O	-1	none	_	_
14	M	_	_	NN	O	-1	none	_	_
15	phi	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	greater	_	_	JJR	O	-1	none	_	_
19	increases	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	5-day	_	_	JJ	O	-1	none	_	_
22	M	_	_	NN	O	-1	none	_	_
23	phi	_	_	NN	O	-1	none	_	_
24	uptake	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	apoptotic	_	_	JJ	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	being	_	_	VBG	O	-1	none	_	_
29	observed	_	_	VBN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	earlier	_	_	JJR	O	-1	none	_	_
32	glucocorticoids	_	_	NNS	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	added	_	_	VBN	O	-1	none	_	_
35	during	_	_	IN	O	-1	none	_	_
36	monocyte	_	_	NN	O	-1	none	_	_
37	maturation	_	_	NN	O	-1	none	_	_
38	into	_	_	IN	O	-1	none	_	_
39	M	_	_	NN	O	-1	none	_	_
40	phi	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	potentiation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	nonphlogistic	_	_	JJ	O	-1	none	_	_
7	clearance	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	apoptotic	_	_	JJ	O	-1	none	_	_
10	leukocytes	_	_	NNS	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	phagocytes	_	_	NNS	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	hitherto	_	_	RB	O	-1	none	_	_
16	unrecognized	_	_	JJ	O	-1	none	_	_
17	property	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	glucocorticoids	_	_	NNS	O	-1	none	_	_
20	that	_	_	WDT	O	-1	none	_	_
21	has	_	_	VBZ	O	-1	none	_	_
22	potential	_	_	JJ	O	-1	none	_	_
23	implications	_	_	NNS	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	therapies	_	_	NNS	O	-1	none	_	_
26	aimed	_	_	VBN	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	promoting	_	_	VBG	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	resolution	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	inflammatory	_	_	JJ	O	-1	none	_	_
33	diseases	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	murine	_	_	JJ	O	-1	none	_	_
3	BCL6	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	induced	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	activated	_	_	VBN	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	immediate	_	_	JJ	O	-1	none	_	_
13	early	_	_	JJ	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	chromosomal	_	_	JJ	O	-1	none	_	_
3	translocation	_	_	NN	O	-1	none	_	_
4	involving	_	_	VBG	O	-1	none	_	_
5	3q27	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	often	_	_	RB	O	-1	none	_	_
8	detected	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	B-cell	_	_	NN	O	-1	none	_	_
12	lymphomas	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	especially	_	_	RB	O	-1	none	_	_
15	diffuse	_	_	JJ	O	-1	none	_	_
16	lymphomas	_	_	NNS	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	large-cell	_	_	JJ	O	-1	none	_	_
20	component	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	BCL6	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	has	_	_	VBZ	O	-1	none	_	_
5	been	_	_	VBN	O	-1	none	_	_
6	isolated	_	_	VBN	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	chromosomal	_	_	JJ	O	-1	none	_	_
10	breakpoint	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	these	_	_	DT	O	-1	none	_	_
13	lymphomas	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	cloned	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	murine	_	_	JJ	O	-1	none	_	_
6	BCL6	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	mBCL6	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	cDNA	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	muscle	_	_	NN	O	-1	none	_	_
14	cDNA	_	_	NN	O	-1	none	_	_
15	library	_	_	NN	O	-1	none	_	_
16	using	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	BCL6	_	_	NN	Protein	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	hBCL6	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	cDNA	_	_	NN	O	-1	none	_	_
24	as	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	probe	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	predicted	_	_	JJ	O	-1	none	_	_
3	amino	_	_	NN	O	-1	none	_	_
4	acid	_	_	NN	O	-1	none	_	_
5	sequence	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	95	_	_	CD	O	-1	none	_	_
8	%	_	_	NN	O	-1	none	_	_
9	identical	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	that	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	hBCL6	_	_	NN	Protein	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	contains	_	_	VBZ	O	-1	none	_	_
3	six	_	_	CD	O	-1	none	_	_
4	repeats	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	Kruppel	_	_	NNP	O	-1	none	_	_
8	like	_	_	IN	O	-1	none	_	_
9	zinc-finger	_	_	JJ	O	-1	none	_	_
10	motif	_	_	NN	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	completely	_	_	RB	O	-1	none	_	_
14	identical	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	those	_	_	DT	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	hBCL6	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	indicating	_	_	VBG	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	BCL6	_	_	NN	Protein	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	well	_	_	RB	O	-1	none	_	_
27	conserved	_	_	VBN	O	-1	none	_	_
28	between	_	_	IN	O	-1	none	_	_
29	humans	_	_	NNS	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	mice	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mBCL6	_	_	NN	Protein	-1	none	_	_
5	gene	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	ubiquitously	_	_	RB	O	-1	none	_	_
8	detected	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	adult	_	_	JJ	O	-1	none	_	_
11	mouse	_	_	NN	O	-1	none	_	_
12	tissues	_	_	NNS	O	-1	none	_	_
13	including	_	_	VBG	O	-1	none	_	_
14	lymphatic	_	_	JJ	O	-1	none	_	_
15	organs	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	activated	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	phorbol	_	_	NN	O	-1	none	_	_
11	ester	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Ca2+	_	_	NN	O	-1	none	_	_
14	ionophore	_	_	NN	O	-1	none	_	_
15	within	_	_	IN	O	-1	none	_	_
16	30	_	_	CD	O	-1	none	_	_
17	min	_	_	NN	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	stimulation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	inhibited	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	synthesis	_	_	NN	O	-1	none	_	_
15	inhibitor	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	cycloheximide	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	BCL6	_	_	NN	Protein	-1	none	_	_
6	plays	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	activated	_	_	VBN	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	immediate	_	_	JJ	O	-1	none	_	_
15	early	_	_	JJ	O	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	functional	_	_	JJ	O	-1	none	_	_
3	synergy	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	IL-12	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	involves	_	_	VBZ	O	-1	none	_	_
9	p38	_	_	NN	O	-1	none	_	_
10	mitogen	_	_	NN	O	-1	none	_	_
11	activated	_	_	VBN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	kinase	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	associated	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	augmentation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	STAT	_	_	NN	O	-1	none	_	_
22	serine	_	_	NN	O	-1	none	_	_
23	phosphorylation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	IL-12	_	_	NNP	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	can	_	_	MD	O	-1	none	_	_
5	stimulate	_	_	VB	O	-1	none	_	_
6	mitogen-	_	_	NN	O	-1	none	_	_
7	or	_	_	CC	O	-1	none	_	_
8	CD3	_	_	NN	O	-1	none	_	_
9	activated	_	_	VBN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	proliferate	_	_	VB	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	produce	_	_	VB	O	-1	none	_	_
16	IFN-gamma	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	kill	_	_	VB	O	-1	none	_	_
20	tumor	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	magnitude	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	functional	_	_	JJ	O	-1	none	_	_
6	responses	_	_	NNS	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	greatly	_	_	RB	O	-1	none	_	_
9	augmented	_	_	JJ	O	-1	none	_	_
10	when	_	_	WRB	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	activated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	combination	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	IL-12	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	functional	_	_	JJ	O	-1	none	_	_
3	synergy	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-12	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	associated	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	prominent	_	_	JJ	O	-1	none	_	_
14	increase	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	STAT1	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	STAT3	_	_	NN	Protein	-1	none	_	_
19	serine	_	_	NN	O	-1	none	_	_
20	phosphorylation	_	_	NN	O	-1	none	_	_
21	over	_	_	IN	O	-1	none	_	_
22	that	_	_	DT	O	-1	none	_	_
23	observed	_	_	VBN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	IL-12	_	_	NN	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	IL-2	_	_	NN	Protein	-1	none	_	_
28	alone	_	_	RB	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	STAT	_	_	NN	O	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	augmented	_	_	JJ	O	-1	none	_	_
10	over	_	_	IN	O	-1	none	_	_
11	that	_	_	DT	O	-1	none	_	_
12	seen	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	either	_	_	CC	O	-1	none	_	_
15	cytokine	_	_	NN	O	-1	none	_	_
16	alone	_	_	RB	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	inhibitor	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	p38	_	_	NN	O	-1	none	_	_
6	MAP	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	completely	_	_	RB	O	-1	none	_	_
9	inhibits	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	serine	_	_	NN	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	STAT1	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	STAT3	_	_	NN	Protein	-1	none	_	_
17	induced	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	IL-12	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	abrogates	_	_	VBZ	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	functional	_	_	JJ	O	-1	none	_	_
26	synergy	_	_	NN	O	-1	none	_	_
27	between	_	_	IN	O	-1	none	_	_
28	IL-12	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	IL-2	_	_	NN	Protein	-1	none	_	_
31	without	_	_	IN	O	-1	none	_	_
32	affecting	_	_	VBG	O	-1	none	_	_
33	STAT	_	_	NN	O	-1	none	_	_
34	tyrosine	_	_	NN	O	-1	none	_	_
35	phosphorylation	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	suggests	_	_	VBZ	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	p38	_	_	NN	O	-1	none	_	_
5	MAP	_	_	NN	O	-1	none	_	_
6	kinase	_	_	NN	O	-1	none	_	_
7	may	_	_	MD	O	-1	none	_	_
8	play	_	_	VB	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	important	_	_	JJ	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	regulating	_	_	VBG	O	-1	none	_	_
14	STAT	_	_	NN	O	-1	none	_	_
15	serine	_	_	NN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	combination	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	IL-12	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	IL-2	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	indicate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	optimal	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	IL-12	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	may	_	_	MD	O	-1	none	_	_
18	depend	_	_	VB	O	-1	none	_	_
19	on	_	_	IN	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	interaction	_	_	NN	O	-1	none	_	_
22	between	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	p38	_	_	NN	O	-1	none	_	_
25	MAP	_	_	NN	O	-1	none	_	_
26	kinase	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	Janus	_	_	NN	O	-1	none	_	_
29	kinase	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	STAT	_	_	NN	O	-1	none	_	_
32	signaling	_	_	NN	O	-1	none	_	_
33	pathways	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	[	_	_	NN	O	-1	none	_	_
2	The	_	_	DT	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	24,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
6	D3	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	dioxyvit	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	Ca	_	_	NN	O	-1	none	_	_
12	metabolism	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	immune	_	_	JJ	O	-1	none	_	_
15	status	_	_	NN	O	-1	none	_	_
16	during	_	_	IN	O	-1	none	_	_
17	chronic	_	_	JJ	O	-1	none	_	_
18	kidney	_	_	NN	O	-1	none	_	_
19	failure	_	_	NN	O	-1	none	_	_
20	]	_	_	CD	O	-1	none	_	_
21	Active	_	_	JJ	O	-1	none	_	_
22	metabolite	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	vitamin	_	_	NN	O	-1	none	_	_
25	D3	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	24R	_	_	NN	O	-1	none	_	_
28	,25	_	_	CD	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	OH	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	2D3	_	_	NN	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	dioxyvit	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	was	_	_	VBD	O	-1	none	_	_
37	used	_	_	VBN	O	-1	none	_	_
38	at	_	_	IN	O	-1	none	_	_
39	a	_	_	DT	O	-1	none	_	_
40	daily	_	_	JJ	O	-1	none	_	_
41	dose	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	100	_	_	CD	O	-1	none	_	_
44	micrograms	_	_	NNS	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	treatment	_	_	NN	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	children	_	_	NNS	O	-1	none	_	_
49	affected	_	_	VBN	O	-1	none	_	_
50	with	_	_	IN	O	-1	none	_	_
51	tubulointerstitial	_	_	JJ	O	-1	none	_	_
52	disease	_	_	NN	O	-1	none	_	_
53	of	_	_	IN	O	-1	none	_	_
54	kidney	_	_	NN	O	-1	none	_	_
55	and	_	_	CC	O	-1	none	_	_
56	with	_	_	IN	O	-1	none	_	_
57	chronic	_	_	JJ	O	-1	none	_	_
58	glomerulonephritis	_	_	NN	O	-1	none	_	_
59	under	_	_	IN	O	-1	none	_	_
60	conditions	_	_	NNS	O	-1	none	_	_
61	of	_	_	IN	O	-1	none	_	_
62	kidney	_	_	NN	O	-1	none	_	_
63	insufficiency	_	_	NN	O	-1	none	_	_
64	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	drug	_	_	NN	O	-1	none	_	_
3	exhibited	_	_	VBD	O	-1	none	_	_
4	distinct	_	_	JJ	O	-1	none	_	_
5	normalizing	_	_	NN	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	patterns	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	calcium	_	_	NN	O	-1	none	_	_
11	metabolism	_	_	NN	O	-1	none	_	_
12	:	_	_	:	O	-1	none	_	_
13	increase	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	total	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	ionized	_	_	VBN	O	-1	none	_	_
18	Ca2+	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	25-OHD	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	decrease	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	concentration	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	parath	_	_	NN	O	-1	none	_	_
28	hormone	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	osteocalcine	_	_	NN	Protein	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	blood	_	_	NN	O	-1	none	_	_
33	serum	_	_	NN	O	-1	none	_	_
34	as	_	_	RB	O	-1	none	_	_
35	well	_	_	RB	O	-1	none	_	_
36	as	_	_	IN	O	-1	none	_	_
37	on	_	_	IN	O	-1	none	_	_
38	immunological	_	_	JJ	O	-1	none	_	_
39	parameters	_	_	NNS	O	-1	none	_	_
40	:	_	_	:	O	-1	none	_	_
41	restoration	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	decreased	_	_	VBN	O	-1	none	_	_
44	content	_	_	NN	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	T-	_	_	NN	O	-1	none	_	_
47	and	_	_	CC	O	-1	none	_	_
48	0-lymphocytes	_	_	NNS	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	Concentration	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	receptors	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	hormonal	_	_	JJ	O	-1	none	_	_
6	form	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	1,25	_	_	CD	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	OH	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	2D3	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	minimal	_	_	JJ	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	lymphocytes	_	_	NNS	O	-1	none	_	_
20	under	_	_	IN	O	-1	none	_	_
21	conditions	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	chronic	_	_	JJ	O	-1	none	_	_
24	kidney	_	_	NN	O	-1	none	_	_
25	insufficiency	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	while	_	_	IN	O	-1	none	_	_
28	their	_	_	PRP$	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	after	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	dioxyvit	_	_	NN	O	-1	none	_	_
34	action	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	was	_	_	VBD	O	-1	none	_	_
37	detected	_	_	VBN	O	-1	none	_	_
38	only	_	_	RB	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	patients	_	_	NNS	O	-1	none	_	_
41	with	_	_	IN	O	-1	none	_	_
42	glomerulonephritis	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Specific	_	_	JJ	O	-1	none	_	_
2	calcitropic	_	_	JJ	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	dioxyvit	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	simultaneous	_	_	JJ	O	-1	none	_	_
8	correction	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	vitamin	_	_	NN	O	-1	none	_	_
11	D	_	_	NN	O	-1	none	_	_
12	deficiency	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	apparently	_	_	RB	O	-1	none	_	_
15	responsible	_	_	JJ	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	high	_	_	JJ	O	-1	none	_	_
18	efficacy	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	drug	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	treatment	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	calcium	_	_	NN	O	-1	none	_	_
26	metabolism	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	immunity	_	_	NN	O	-1	none	_	_
29	impairments	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	children	_	_	NNS	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	renal	_	_	JJ	O	-1	none	_	_
34	deteriorations	_	_	NNS	O	-1	none	_	_
35	at	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	step	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	chronic	_	_	JJ	O	-1	none	_	_
40	kidney	_	_	NN	O	-1	none	_	_
41	insufficiency	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Tyloxapol	_	_	NN	O	-1	none	_	_
2	inhibits	_	_	VBZ	O	-1	none	_	_
3	NF-kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	cytokine	_	_	NN	O	-1	none	_	_
7	release	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	scavenges	_	_	VBZ	O	-1	none	_	_
10	HOCI	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	reduces	_	_	VBZ	O	-1	none	_	_
14	viscosity	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cystic	_	_	JJ	O	-1	none	_	_
17	fibrosis	_	_	NN	O	-1	none	_	_
18	sputum	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Cystic	_	_	JJ	O	-1	none	_	_
2	fibrosis	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	CF	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	patients	_	_	NNS	O	-1	none	_	_
7	develop	_	_	VBP	O	-1	none	_	_
8	progressive	_	_	JJ	O	-1	none	_	_
9	cytokine	_	_	NN	O	-1	none	_	_
10	mediated	_	_	VBN	O	-1	none	_	_
11	inflammatory	_	_	JJ	O	-1	none	_	_
12	lung	_	_	NN	O	-1	none	_	_
13	disease	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	abundant	_	_	JJ	O	-1	none	_	_
17	production	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	thick	_	_	JJ	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	tenacious	_	_	JJ	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	protease-	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	oxidant	_	_	JJ	O	-1	none	_	_
26	rich	_	_	JJ	O	-1	none	_	_
27	purulent	_	_	JJ	O	-1	none	_	_
28	airway	_	_	NN	O	-1	none	_	_
29	secretions	_	_	NNS	O	-1	none	_	_
30	that	_	_	WDT	O	-1	none	_	_
31	are	_	_	VBP	O	-1	none	_	_
32	difficult	_	_	JJ	O	-1	none	_	_
33	to	_	_	TO	O	-1	none	_	_
34	clear	_	_	VB	O	-1	none	_	_
35	even	_	_	RB	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	physiotherapy	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	search	_	_	NN	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	potential	_	_	JJ	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	we	_	_	PRP	O	-1	none	_	_
10	have	_	_	VBP	O	-1	none	_	_
11	tested	_	_	VBN	O	-1	none	_	_
12	tyloxapol	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	alkylaryl	_	_	NN	O	-1	none	_	_
16	polyether	_	_	JJ	O	-1	none	_	_
17	alcohol	_	_	NN	O	-1	none	_	_
18	polymer	_	_	NN	O	-1	none	_	_
19	detergent	_	_	NN	O	-1	none	_	_
20	previously	_	_	RB	O	-1	none	_	_
21	used	_	_	VBN	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	mucolytic	_	_	JJ	O	-1	none	_	_
25	agent	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	adult	_	_	JJ	O	-1	none	_	_
28	chronic	_	_	JJ	O	-1	none	_	_
29	bronchitis	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Tyloxapol	_	_	NN	O	-1	none	_	_
2	inhibits	_	_	VBZ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	factor-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	NK-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	reduces	_	_	VBZ	O	-1	none	_	_
17	resting	_	_	VBG	O	-1	none	_	_
18	secretion	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	cytokine	_	_	NN	O	-1	none	_	_
22	interleukin-8	_	_	NN	Protein	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	IL-8	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	cultured	_	_	VBN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	monocytes	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	inhibits	_	_	VBZ	O	-1	none	_	_
33	lipopolysaccharide	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	LPS	_	_	NN	O	-1	none	_	_
36	)-stimulated	_	_	JJ	O	-1	none	_	_
37	release	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	tumor	_	_	NN	Protein	41	multitoken	_	_
40	necrosis	_	_	NN	Protein	41	multitoken	_	_
41	factor-alpha	_	_	NN	Protein	0	root	_	_
42	(	_	_	-LRB-	O	-1	none	_	_
43	TNF-alpha	_	_	NN	Protein	-1	none	_	_
44	)	_	_	-RRB-	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	IL-1	_	_	NN	Protein	47	multitoken	_	_
47	beta	_	_	NN	Protein	0	root	_	_
48	,	_	_	,	O	-1	none	_	_
49	IL-6	_	_	NN	Protein	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	IL-8	_	_	NN	Protein	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	granulocyte-macrophage	_	_	JJ	Protein	56	multitoken	_	_
54	colony	_	_	NN	Protein	56	multitoken	_	_
55	stimulating	_	_	NN	Protein	56	multitoken	_	_
56	factor	_	_	NN	Protein	0	root	_	_
57	(	_	_	-LRB-	O	-1	none	_	_
58	GM-CSF	_	_	NN	Protein	-1	none	_	_
59	)	_	_	-RRB-	O	-1	none	_	_
60	,	_	_	,	O	-1	none	_	_
61	and	_	_	CC	O	-1	none	_	_
62	the	_	_	DT	O	-1	none	_	_
63	eiconsanoids	_	_	NNS	O	-1	none	_	_
64	thromboxane	_	_	NN	O	-1	none	_	_
65	A2	_	_	NN	O	-1	none	_	_
66	and	_	_	CC	O	-1	none	_	_
67	leukotriene	_	_	NN	O	-1	none	_	_
68	B4	_	_	NN	O	-1	none	_	_
69	(	_	_	-LRB-	O	-1	none	_	_
70	LTB4	_	_	NN	O	-1	none	_	_
71	)	_	_	-RRB-	O	-1	none	_	_
72	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	tyloxapol	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	potent	_	_	JJ	O	-1	none	_	_
10	antioxidant	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	hydroxyl	_	_	NN	O	-1	none	_	_
13	radicals	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	OH	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Tyloxapol	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	0.05	_	_	CD	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	0.1	_	_	CD	O	-1	none	_	_
6	%	_	_	NN	O	-1	none	_	_
7	wt/vol	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	effectively	_	_	RB	O	-1	none	_	_
10	scavenges	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	oxidant	_	_	JJ	O	-1	none	_	_
13	hypochlorous	_	_	JJ	O	-1	none	_	_
14	acid	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	HOCl	_	_	NN	O	-1	none	_	_
17	;	_	_	:	O	-1	none	_	_
18	1	_	_	CD	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	7.5	_	_	CD	O	-1	none	_	_
21	mM	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	in	_	_	FW	O	-1	none	_	_
24	vitro	_	_	FW	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	protects	_	_	VBZ	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	HOCl	_	_	NN	O	-1	none	_	_
30	mediated	_	_	VBD	O	-1	none	_	_
31	lung	_	_	NN	O	-1	none	_	_
32	injury	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	rats	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Tyloxapol	_	_	NN	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	reduces	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	viscosity	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	CF	_	_	NN	O	-1	none	_	_
8	sputum	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	463	_	_	CD	O	-1	none	_	_
12	+/-	_	_	CC	O	-1	none	_	_
13	133	_	_	CD	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	128	_	_	CD	O	-1	none	_	_
16	+/-	_	_	CC	O	-1	none	_	_
17	52	_	_	CD	O	-1	none	_	_
18	centipoise	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	tyloxapol	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	potentially	_	_	RB	O	-1	none	_	_
7	useful	_	_	JJ	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	new	_	_	JJ	O	-1	none	_	_
11	antiinflammatory	_	_	JJ	O	-1	none	_	_
12	therapy	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	CF	_	_	NN	O	-1	none	_	_
15	lung	_	_	NN	O	-1	none	_	_
16	disease	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	could	_	_	MD	O	-1	none	_	_
20	possibly	_	_	RB	O	-1	none	_	_
21	promote	_	_	VB	O	-1	none	_	_
22	clearance	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	secretions	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	CF	_	_	NN	O	-1	none	_	_
28	airway	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	erythroid	_	_	JJ	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	genes	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	acute	_	_	JJ	O	-1	none	_	_
8	megakaryoblastic	_	_	JJ	O	-1	none	_	_
9	leukaemia	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	transient	_	_	JJ	O	-1	none	_	_
12	myeloproliferative	_	_	JJ	O	-1	none	_	_
13	disorder	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	Down	_	_	NN	O	-1	none	_	_
16	's	_	_	POS	O	-1	none	_	_
17	syndrome	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Acute	_	_	JJ	O	-1	none	_	_
2	megakaryoblastic	_	_	JJ	O	-1	none	_	_
3	leukaemia	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	M7	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	transient	_	_	JJ	O	-1	none	_	_
9	myeloproliferative	_	_	JJ	O	-1	none	_	_
10	disorder	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	Down	_	_	NN	O	-1	none	_	_
13	's	_	_	POS	O	-1	none	_	_
14	syndrome	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	TMD	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	characterized	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	rapid	_	_	JJ	O	-1	none	_	_
22	growth	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	abnormal	_	_	JJ	O	-1	none	_	_
25	blast	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	which	_	_	WDT	O	-1	none	_	_
28	express	_	_	VBP	O	-1	none	_	_
29	megakaryocytic	_	_	JJ	O	-1	none	_	_
30	markers	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	clarify	_	_	VB	O	-1	none	_	_
3	properties	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	blast	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	M7	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	TMD	_	_	NN	O	-1	none	_	_
12	cases	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	examined	_	_	VBD	O	-1	none	_	_
16	erythroid	_	_	JJ	O	-1	none	_	_
17	markers	_	_	NNS	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	blasts	_	_	NNS	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	six	_	_	CD	O	-1	none	_	_
23	cases	_	_	NNS	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	M7	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	seven	_	_	CD	O	-1	none	_	_
28	cases	_	_	NNS	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	TMD	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	this	_	_	DT	O	-1	none	_	_
33	study	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Erythroid	_	_	JJ	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	mRNAs	_	_	NNS	O	-1	none	_	_
4	encoding	_	_	VBG	O	-1	none	_	_
5	gamma-globin	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	erythroid	_	_	JJ	O	-1	none	_	_
8	delta-aminolevulinate	_	_	JJ	Protein	9	multitoken	_	_
9	synthase	_	_	NN	Protein	0	root	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	found	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	expressed	_	_	VBN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	blasts	_	_	NNS	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	most	_	_	JJS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	these	_	_	DT	O	-1	none	_	_
21	cases	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	indicating	_	_	VBG	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	majorities	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	blasts	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	M7	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	TMD	_	_	NN	O	-1	none	_	_
33	cases	_	_	NNS	O	-1	none	_	_
34	have	_	_	VBP	O	-1	none	_	_
35	erythroid	_	_	JJ	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	megakaryocytic	_	_	JJ	O	-1	none	_	_
38	phenotypes	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	found	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	mRNAs	_	_	NNS	O	-1	none	_	_
6	encoding	_	_	VBG	O	-1	none	_	_
7	GATA-1	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	GATA-2	_	_	NN	Protein	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	expressed	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	all	_	_	DT	O	-1	none	_	_
14	these	_	_	DT	O	-1	none	_	_
15	cases	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	M7	_	_	NN	O	-1	none	_	_
6	blasts	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	TMD	_	_	NN	O	-1	none	_	_
9	blasts	_	_	NNS	O	-1	none	_	_
10	correspond	_	_	VBP	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	erythroid	_	_	JJ	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	megakaryocytic	_	_	JJ	O	-1	none	_	_
16	bipotential	_	_	JJ	O	-1	none	_	_
17	progenitor	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Formation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	reactive	_	_	JJ	O	-1	none	_	_
4	oxygen	_	_	NN	O	-1	none	_	_
5	intermediates	_	_	NNS	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	ROI	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	after	_	_	IN	O	-1	none	_	_
10	oxidative	_	_	JJ	O	-1	none	_	_
11	stress	_	_	NN	O	-1	none	_	_
12	has	_	_	VBZ	O	-1	none	_	_
13	been	_	_	VBN	O	-1	none	_	_
14	shown	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	signal	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	e.g.	_	_	FW	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	IL-2	_	_	NN	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	its	_	_	PRP$	O	-1	none	_	_
31	receptor	_	_	NN	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	induced	_	_	VBN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	ROI	_	_	NNS	O	-1	none	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	can	_	_	MD	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	large	_	_	JJ	O	-1	none	_	_
10	extent	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	attributed	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	NF-kappaB	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Now	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	examined	_	_	VBN	O	-1	none	_	_
5	whether	_	_	IN	O	-1	none	_	_
6	naive	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	memory	_	_	NN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	lymphocytes	_	_	NNS	O	-1	none	_	_
11	differ	_	_	VBP	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	their	_	_	PRP$	O	-1	none	_	_
14	sensitivity	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	ROI	_	_	NN	O	-1	none	_	_
17	mediated	_	_	VBD	O	-1	none	_	_
18	signals	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	composition	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	p50	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	RelA	_	_	NN	Protein	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	similar	_	_	JJ	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	these	_	_	DT	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	types	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	magnitude	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	kinetics	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	intracellular	_	_	JJ	O	-1	none	_	_
7	ROI	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	similar	_	_	JJ	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	suggesting	_	_	VBG	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	there	_	_	EX	O	-1	none	_	_
14	were	_	_	VBD	O	-1	none	_	_
15	no	_	_	DT	O	-1	none	_	_
16	differences	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	ROI	_	_	NN	O	-1	none	_	_
19	forming	_	_	VBG	O	-1	none	_	_
20	mechanisms	_	_	NNS	O	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	antioxidative	_	_	JJ	O	-1	none	_	_
23	capacities	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	representing	_	_	VBG	O	-1	none	_	_
8	different	_	_	JJ	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	and/or	_	_	CC	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	stages	_	_	NNS	O	-1	none	_	_
13	can	_	_	MD	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	differentially	_	_	RB	O	-1	none	_	_
16	responsive	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	ROI	_	_	NN	O	-1	none	_	_
19	mediated	_	_	VBD	O	-1	none	_	_
20	signals	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	Protein	5	multitoken	_	_
2	factor-90	_	_	NN	Protein	5	multitoken	_	_
3	of	_	_	IN	Protein	5	multitoken	_	_
4	activated	_	_	VBN	Protein	5	multitoken	_	_
5	T-cells	_	_	NNS	Protein	0	root	_	_
6	:	_	_	:	O	-1	none	_	_
7	A	_	_	DT	O	-1	none	_	_
8	double	_	_	JJ	O	-1	none	_	_
9	stranded	_	_	JJ	O	-1	none	_	_
10	RNA	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	substrate	_	_	NN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	double	_	_	JJ	O	-1	none	_	_
18	stranded	_	_	JJ	O	-1	none	_	_
19	RNA	_	_	NN	O	-1	none	_	_
20	dependent	_	_	JJ	O	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	kinase	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	PKR	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	NFAT	_	_	NN	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	play	_	_	VBP	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	central	_	_	JJ	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	initiating	_	_	VBG	O	-1	none	_	_
10	T-cell	_	_	NN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	through	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	immediate-early	_	_	JJ	O	-1	none	_	_
17	T-cell	_	_	NN	O	-1	none	_	_
18	specific	_	_	JJ	O	-1	none	_	_
19	genes	_	_	NNS	O	-1	none	_	_
20	including	_	_	VBG	O	-1	none	_	_
21	interleukin-2	_	_	NN	Protein	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	IL-2	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	NFAT	_	_	NN	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	bind	_	_	VBP	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	enhancer	_	_	NN	O	-1	none	_	_
12	known	_	_	VBN	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	antigen	_	_	NN	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	element	_	_	NN	O	-1	none	_	_
19	2	_	_	CD	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	ARRE-2	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Multiple	_	_	JJ	O	-1	none	_	_
2	proteins	_	_	NNS	O	-1	none	_	_
3	exhibiting	_	_	VBG	O	-1	none	_	_
4	ARRE-2	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	have	_	_	VBP	O	-1	none	_	_
8	been	_	_	VBN	O	-1	none	_	_
9	isolated	_	_	VBN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	including	_	_	VBG	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	heterodimer	_	_	NN	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	stimulated	_	_	VBN	O	-1	none	_	_
16	T-cell	_	_	NN	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	extracts	_	_	NNS	O	-1	none	_	_
19	consisting	_	_	VBG	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	Mr	_	_	NN	O	-1	none	_	_
22	=	_	_	JJ	O	-1	none	_	_
23	90	_	_	CD	O	-1	none	_	_
24	000	_	_	CD	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	NF90	_	_	NN	Protein	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	Mr	_	_	NN	O	-1	none	_	_
30	=	_	_	JJ	O	-1	none	_	_
31	45	_	_	CD	O	-1	none	_	_
32	000	_	_	CD	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	NF45	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	subunits	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	subunits	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	heterodimer	_	_	NN	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	cloned	_	_	VBN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	NF90	_	_	NN	Protein	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	found	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	encode	_	_	VB	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	containing	_	_	VBG	O	-1	none	_	_
19	two	_	_	CD	O	-1	none	_	_
20	domains	_	_	NNS	O	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	are	_	_	VBP	O	-1	none	_	_
23	predicted	_	_	VBN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	form	_	_	VB	O	-1	none	_	_
26	motifs	_	_	NNS	O	-1	none	_	_
27	capable	_	_	JJ	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	binding	_	_	VBG	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	double	_	_	VB	O	-1	none	_	_
32	stranded	_	_	JJ	O	-1	none	_	_
33	RNA	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	in	_	_	FW	O	-1	none	_	_
3	vitro	_	_	FW	O	-1	none	_	_
4	translated	_	_	VBN	O	-1	none	_	_
5	polypeptides	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	have	_	_	VBP	O	-1	none	_	_
9	demonstrated	_	_	VBN	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	NF90	_	_	NN	Protein	-1	none	_	_
12	specifically	_	_	RB	O	-1	none	_	_
13	binds	_	_	VBZ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	double	_	_	VB	O	-1	none	_	_
16	stranded	_	_	JJ	O	-1	none	_	_
17	RNA	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	NF90	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	phosphorylated	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	double	_	_	JJ	O	-1	none	_	_
9	stranded	_	_	JJ	O	-1	none	_	_
10	RNA	_	_	NN	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	manner	_	_	NN	O	-1	none	_	_
13	likely	_	_	JJ	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	interferon	_	_	NN	Protein	24	multitoken	_	_
17	induced	_	_	VBD	Protein	24	multitoken	_	_
18	,	_	_	,	Protein	24	multitoken	_	_
19	double	_	_	JJ	Protein	24	multitoken	_	_
20	stranded	_	_	JJ	Protein	24	multitoken	_	_
21	RNA	_	_	NN	Protein	24	multitoken	_	_
22	dependent	_	_	JJ	Protein	24	multitoken	_	_
23	protein	_	_	NN	Protein	24	multitoken	_	_
24	kinase	_	_	NN	Protein	0	root	_	_
25	,	_	_	,	O	-1	none	_	_
26	PKR	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NF90	_	_	NN	Protein	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	only	_	_	RB	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	T-cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	also	_	_	RB	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	nonimmune	_	_	JJ	O	-1	none	_	_
18	HeLa	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	HeLa	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	almost	_	_	RB	O	-1	none	_	_
9	exclusively	_	_	RB	O	-1	none	_	_
10	localized	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	ribosome	_	_	NN	O	-1	none	_	_
14	salt	_	_	NN	O	-1	none	_	_
15	wash	_	_	NN	O	-1	none	_	_
16	fraction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	lysates	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Disruption	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	SCL	_	_	NN	Protein	-1	none	_	_
6	locus	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	"	_	_	``	O	-1	none	_	_
9	illegitimate	_	_	JJ	O	-1	none	_	_
10	"	_	_	''	O	-1	none	_	_
11	V-(	_	_	NN	O	-1	none	_	_
12	D	_	_	NN	O	-1	none	_	_
13	)-J	_	_	NN	O	-1	none	_	_
14	recombinase	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	fusion	_	_	NN	O	-1	none	_	_
3	complementary	_	_	JJ	O	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	line	_	_	NN	O	-1	none	_	_
10	HSB-2	_	_	NN	O	-1	none	_	_
11	elucidates	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	provocative	_	_	JJ	O	-1	none	_	_
14	mechanism	_	_	NN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	disruption	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	putative	_	_	JJ	O	-1	none	_	_
21	hematopoietic	_	_	JJ	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	SCL	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	fusion	_	_	NN	O	-1	none	_	_
3	cDNA	_	_	NN	O	-1	none	_	_
4	results	_	_	VBZ	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	interstitial	_	_	JJ	O	-1	none	_	_
8	deletion	_	_	NN	O	-1	none	_	_
9	between	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	previously	_	_	RB	O	-1	none	_	_
12	unknown	_	_	JJ	O	-1	none	_	_
13	locus	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	SIL	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	SCL	_	_	NN	Protein	-1	none	_	_
18	interrupting	_	_	VBG	O	-1	none	_	_
19	locus	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	5	_	_	CD	O	-1	none	_	_
25	'	_	_	''	O	-1	none	_	_
26	untranslated	_	_	JJ	O	-1	none	_	_
27	region	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	SCL	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Similar	_	_	JJ	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	1	_	_	CD	O	-1	none	_	_
4	;	_	_	:	O	-1	none	_	_
5	14	_	_	CD	O	-1	none	_	_
6	translocations	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	deletion	_	_	NN	O	-1	none	_	_
10	disrupts	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	SCL	_	_	NN	Protein	-1	none	_	_
13	5	_	_	CD	O	-1	none	_	_
14	'	_	_	''	O	-1	none	_	_
15	regulatory	_	_	JJ	O	-1	none	_	_
16	region	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	event	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	probably	_	_	RB	O	-1	none	_	_
5	mediated	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	V-(	_	_	NN	O	-1	none	_	_
8	D	_	_	NN	O	-1	none	_	_
9	)-J	_	_	NN	O	-1	none	_	_
10	recombinase	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	although	_	_	IN	O	-1	none	_	_
14	neither	_	_	DT	O	-1	none	_	_
15	locus	_	_	NN	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	an	_	_	DT	O	-1	none	_	_
18	immunoglobulin	_	_	NN	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	receptor	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	other	_	_	JJ	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	lines	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	CEM	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	RPMI	_	_	NN	O	-1	none	_	_
10	8402	_	_	CD	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	have	_	_	VBP	O	-1	none	_	_
13	essentially	_	_	RB	O	-1	none	_	_
14	identical	_	_	JJ	O	-1	none	_	_
15	deletions	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	lymphocytes	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	growth	_	_	NN	O	-1	none	_	_
7	affecting	_	_	VBG	O	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	other	_	_	JJ	O	-1	none	_	_
10	than	_	_	IN	O	-1	none	_	_
11	immune	_	_	JJ	O	-1	none	_	_
12	receptors	_	_	NNS	O	-1	none	_	_
13	risk	_	_	VBP	O	-1	none	_	_
14	rearrangements	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	[	_	_	NN	O	-1	none	_	_
2	Effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	regimen	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	kidney	_	_	NN	O	-1	none	_	_
8	tonifying	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	qi	_	_	NN	O	-1	none	_	_
11	invigorating	_	_	JJ	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	aging	_	_	VBG	O	-1	none	_	_
14	changes	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	glucocorticoid	_	_	NN	Protein	17	multitoken	_	_
17	receptor	_	_	NN	Protein	0	root	_	_
18	]	_	_	CD	O	-1	none	_	_
19	The	_	_	DT	O	-1	none	_	_
20	plasma	_	_	NN	O	-1	none	_	_
21	cortisol	_	_	NN	O	-1	none	_	_
22	concentration	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	sites	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	glucocorticoid	_	_	NN	Protein	28	multitoken	_	_
28	receptor	_	_	NN	Protein	0	root	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	GCR	_	_	NN	Protein	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	peripheral	_	_	JJ	O	-1	none	_	_
35	lymphocytes	_	_	NNS	O	-1	none	_	_
36	were	_	_	VBD	O	-1	none	_	_
37	measured	_	_	VBN	O	-1	none	_	_
38	in	_	_	IN	O	-1	none	_	_
39	32	_	_	CD	O	-1	none	_	_
40	healthy	_	_	JJ	O	-1	none	_	_
41	aged	_	_	JJ	O	-1	none	_	_
42	persons	_	_	NNS	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	13	_	_	CD	O	-1	none	_	_
45	young	_	_	JJ	O	-1	none	_	_
46	adults	_	_	NNS	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	animal	_	_	NN	O	-1	none	_	_
3	experiment	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	GCR	_	_	NN	Protein	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	spleen	_	_	NN	O	-1	none	_	_
8	lymphocytic	_	_	JJ	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	measured	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	18	_	_	CD	O	-1	none	_	_
15	aged	_	_	JJ	O	-1	none	_	_
16	rats	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	9	_	_	CD	O	-1	none	_	_
19	young	_	_	JJ	O	-1	none	_	_
20	rats	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	GCR	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	lower	_	_	JJR	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	aged	_	_	JJ	O	-1	none	_	_
12	persons	_	_	NNS	O	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	rats	_	_	NNS	O	-1	none	_	_
15	than	_	_	IN	O	-1	none	_	_
16	that	_	_	DT	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	young	_	_	JJ	O	-1	none	_	_
20	while	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	plasma	_	_	NN	O	-1	none	_	_
23	cortisol	_	_	NN	O	-1	none	_	_
24	level	_	_	NN	O	-1	none	_	_
25	did	_	_	VBD	O	-1	none	_	_
26	n't	_	_	RB	O	-1	none	_	_
27	change	_	_	VB	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	aging	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	So	_	_	IN	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	think	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	GCR	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	more	_	_	RBR	O	-1	none	_	_
8	sensitive	_	_	JJ	O	-1	none	_	_
9	than	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	plasma	_	_	NN	O	-1	none	_	_
12	cortisol	_	_	NN	O	-1	none	_	_
13	level	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	reflect	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	aging	_	_	NN	O	-1	none	_	_
18	change	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	adrenal	_	_	JJ	O	-1	none	_	_
22	cortex	_	_	NN	O	-1	none	_	_
23	function	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	treatment	_	_	NN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	regimen	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Kidney	_	_	NN	O	-1	none	_	_
9	tonifying	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Qi	_	_	NN	O	-1	none	_	_
12	invigorating	_	_	JJ	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	GCR	_	_	NN	Protein	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	aged	_	_	JJ	O	-1	none	_	_
19	persons	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	rats	_	_	NNS	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	enhanced	_	_	VBN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	way	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	function	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	aged	_	_	JJ	O	-1	none	_	_
35	adrenal	_	_	JJ	O	-1	none	_	_
36	cortex	_	_	NN	O	-1	none	_	_
37	was	_	_	VBD	O	-1	none	_	_
38	improved	_	_	VBN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Modulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	normal	_	_	JJ	O	-1	none	_	_
4	erythroid	_	_	JJ	O	-1	none	_	_
5	differentiation	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	endogenous	_	_	JJ	O	-1	none	_	_
9	thyroid	_	_	NN	O	-1	none	_	_
10	hormone	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	retinoic	_	_	JJ	O	-1	none	_	_
13	acid	_	_	NN	O	-1	none	_	_
14	receptors	_	_	NNS	O	-1	none	_	_
15	:	_	_	:	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	possible	_	_	JJ	O	-1	none	_	_
18	target	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	v-erbA	_	_	NN	Protein	-1	none	_	_
21	oncogene	_	_	NN	O	-1	none	_	_
22	action	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	v-erbA	_	_	NN	Protein	-1	none	_	_
3	oncogene	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	mutated	_	_	JJ	O	-1	none	_	_
7	version	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	thyroid	_	_	NN	Protein	13	multitoken	_	_
11	hormone	_	_	NN	Protein	13	multitoken	_	_
12	receptor	_	_	NN	Protein	13	multitoken	_	_
13	alpha	_	_	NN	Protein	0	root	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	c-erbA	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	TR-alpha	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	inhibits	_	_	VBZ	O	-1	none	_	_
21	erythroid	_	_	JJ	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	constitutively	_	_	RB	O	-1	none	_	_
25	represses	_	_	VBZ	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	certain	_	_	JJ	O	-1	none	_	_
29	erythrocyte	_	_	NN	O	-1	none	_	_
30	genes	_	_	NNS	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	suggesting	_	_	VBG	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	normal	_	_	JJ	O	-1	none	_	_
35	function	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	proto-oncogene	_	_	NN	O	-1	none	_	_
39	c-erbA	_	_	NN	Protein	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	erythropoiesis	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	endogenous	_	_	JJ	O	-1	none	_	_
7	thyroid	_	_	NN	Protein	10	multitoken	_	_
8	hormone	_	_	NN	Protein	10	multitoken	_	_
9	receptor	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	c-erbA	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	TR-alpha	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	closely	_	_	RB	O	-1	none	_	_
19	related	_	_	JJ	O	-1	none	_	_
20	retinoic	_	_	JJ	Protein	23	multitoken	_	_
21	acid	_	_	NN	Protein	23	multitoken	_	_
22	receptor	_	_	NN	Protein	23	multitoken	_	_
23	alpha	_	_	NN	Protein	0	root	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	RAR-alpha	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	play	_	_	VBP	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	role	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	regulation	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	normal	_	_	JJ	O	-1	none	_	_
35	erythroid	_	_	JJ	O	-1	none	_	_
36	differentiation	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Retinoic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	RA	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	distinctly	_	_	RB	O	-1	none	_	_
7	modulated	_	_	VBD	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	erythroid	_	_	JJ	O	-1	none	_	_
10	differentiation	_	_	NN	O	-1	none	_	_
11	program	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	normal	_	_	JJ	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	progenitors	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	erythroblasts	_	_	NNS	O	-1	none	_	_
18	reversibly	_	_	RB	O	-1	none	_	_
19	transformed	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	conditional	_	_	JJ	O	-1	none	_	_
23	tyrosine	_	_	NN	O	-1	none	_	_
24	kinase	_	_	NN	O	-1	none	_	_
25	oncogene	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	added	_	_	VBN	O	-1	none	_	_
3	pulsewise	_	_	RB	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	immature	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	differentiation	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	accelerated	_	_	VBN	O	-1	none	_	_
11	while	_	_	IN	O	-1	none	_	_
12	more	_	_	RBR	O	-1	none	_	_
13	mature	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	underwent	_	_	VBD	O	-1	none	_	_
16	premature	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	death	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Thyroid	_	_	NN	O	-1	none	_	_
2	hormone	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	T3	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	alone	_	_	RB	O	-1	none	_	_
7	caused	_	_	VBD	O	-1	none	_	_
8	similar	_	_	JJ	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	weaker	_	_	JJR	O	-1	none	_	_
11	effects	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	T3	_	_	NN	O	-1	none	_	_
4	strongly	_	_	RB	O	-1	none	_	_
5	enhanced	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	action	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	RA	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	suggesting	_	_	VBG	O	-1	none	_	_
12	cooperative	_	_	JJ	O	-1	none	_	_
13	action	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	two	_	_	CD	O	-1	none	_	_
17	receptors	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	modulating	_	_	VBG	O	-1	none	_	_
20	erythroid	_	_	JJ	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	RAR-alpha	_	_	NN	Protein	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	negative	_	_	JJ	O	-1	none	_	_
9	erythroblasts	_	_	NNS	O	-1	none	_	_
10	conferred	_	_	VBD	O	-1	none	_	_
11	RA	_	_	NN	O	-1	none	_	_
12	induced	_	_	JJ	O	-1	none	_	_
13	regulation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	otherwise	_	_	RB	O	-1	none	_	_
19	unresponsive	_	_	JJ	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	thus	_	_	RB	O	-1	none	_	_
23	showing	_	_	VBG	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	RAR-alpha	_	_	NN	Protein	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	essential	_	_	JJ	O	-1	none	_	_
29	for	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	RA	_	_	NN	O	-1	none	_	_
32	effect	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Likewise	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	enhanced	_	_	VBN	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	exogenous	_	_	JJ	O	-1	none	_	_
7	c-erbA	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	TR-alpha	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	erythroblasts	_	_	NNS	O	-1	none	_	_
12	rendered	_	_	VBD	O	-1	none	_	_
13	them	_	_	PRP	O	-1	none	_	_
14	susceptible	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	modulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	differentiation	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	T3	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	similar	_	_	JJ	O	-1	none	_	_
25	function	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	both	_	_	DT	O	-1	none	_	_
28	receptors	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	novel	_	_	JJ	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	derived	_	_	VBN	O	-1	none	_	_
6	coactivator	_	_	NN	O	-1	none	_	_
7	potentiates	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	immunoglobulin	_	_	NN	O	-1	none	_	_
12	promoters	_	_	NNS	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	octamer	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	novel	_	_	JJ	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	restricted	_	_	JJ	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	required	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	high	_	_	JJ	O	-1	none	_	_
11	levels	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	octamer	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Oct	_	_	NN	O	-1	none	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	from	_	_	IN	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	immunoglobulin	_	_	NN	O	-1	none	_	_
21	heavy	_	_	JJ	O	-1	none	_	_
22	chain	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	IgH	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	promoter	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	detected	_	_	VBN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	an	_	_	DT	O	-1	none	_	_
32	in	_	_	FW	O	-1	none	_	_
33	vitro	_	_	FW	O	-1	none	_	_
34	system	_	_	NN	O	-1	none	_	_
35	consisting	_	_	VBG	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	HeLa	_	_	NN	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	derived	_	_	VBN	O	-1	none	_	_
40	extracts	_	_	NNS	O	-1	none	_	_
41	complemented	_	_	VBD	O	-1	none	_	_
42	with	_	_	IN	O	-1	none	_	_
43	fractionated	_	_	VBN	O	-1	none	_	_
44	B	_	_	NN	O	-1	none	_	_
45	cell	_	_	NN	O	-1	none	_	_
46	nuclear	_	_	JJ	O	-1	none	_	_
47	proteins	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	responsible	_	_	JJ	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	designated	_	_	VBN	O	-1	none	_	_
9	Oct	_	_	NN	O	-1	none	_	_
10	coactivator	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	OCA-B	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	suggest	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	OCA-B	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	tissue-,	_	_	JJ	O	-1	none	_	_
12	promoter-,	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	factor	_	_	NN	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	coactivator	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	OCA-B	_	_	NN	Protein	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	be	_	_	VB	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	major	_	_	JJ	O	-1	none	_	_
24	determinant	_	_	NN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	specific	_	_	JJ	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	immunoglobulin	_	_	NN	O	-1	none	_	_
32	promoters	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	light	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	evidence	_	_	NN	O	-1	none	_	_
6	showing	_	_	VBG	O	-1	none	_	_
7	physical	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	functional	_	_	JJ	O	-1	none	_	_
10	interactions	_	_	NNS	O	-1	none	_	_
11	between	_	_	IN	O	-1	none	_	_
12	Oct	_	_	NN	O	-1	none	_	_
13	factors	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	OCA-B	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	we	_	_	PRP	O	-1	none	_	_
18	propose	_	_	VBP	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	mechanism	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	action	_	_	NN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	OCA-B	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	discuss	_	_	VB	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	implications	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	OCA-B	_	_	NN	Protein	-1	none	_	_
31	for	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	transcriptional	_	_	JJ	O	-1	none	_	_
34	regulation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	other	_	_	JJ	O	-1	none	_	_
37	tissue	_	_	NN	O	-1	none	_	_
38	specific	_	_	JJ	O	-1	none	_	_
39	promoters	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Lymphocyte	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	vitamin	_	_	NN	O	-1	none	_	_
6	D	_	_	NN	O	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	rickets	_	_	NN	O	-1	none	_	_
9	type	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	show	_	_	VBP	O	-1	none	_	_
12	functional	_	_	JJ	O	-1	none	_	_
13	defects	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	1	_	_	CD	Protein	19	multitoken	_	_
17	alpha,25-dihydroxyvitamin	_	_	NN	Protein	19	multitoken	_	_
18	D3	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	.	_	_	.	O	-1	none	_	_

1	Lymphocyte	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	established	_	_	VBN	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	five	_	_	CD	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	vitamin	_	_	NN	O	-1	none	_	_
11	D	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	rickets	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	type	_	_	NN	O	-1	none	_	_
16	II	_	_	CD	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	VDDR-II	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	lines	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	established	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	infection	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	T-lymphotrophic	_	_	JJ	O	-1	none	_	_
10	virus	_	_	NN	O	-1	none	_	_
11	type	_	_	NN	O	-1	none	_	_
12	I	_	_	CD	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	HTLV-I	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	[	_	_	CD	O	-1	none	_	_
4	3H	_	_	NN	O	-1	none	_	_
5	]	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	alpha,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
8	D3	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	1,25	_	_	CD	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	OH	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	2D3	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	these	_	_	DT	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	lines	_	_	NNS	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	compared	_	_	VBN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	studies	_	_	NNS	O	-1	none	_	_
28	using	_	_	VBG	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	T-lymphocyte	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	line	_	_	NN	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	S-LB1	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	from	_	_	IN	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	normal	_	_	JJ	O	-1	none	_	_
39	individual	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	1,25	_	_	CD	Protein	7	multitoken	_	_
3	(	_	_	-LRB-	Protein	7	multitoken	_	_
4	OH	_	_	NN	Protein	7	multitoken	_	_
5	)	_	_	-RRB-	Protein	7	multitoken	_	_
6	2D3	_	_	NN	Protein	7	multitoken	_	_
7	receptor	_	_	NN	Protein	0	root	_	_
8	of	_	_	IN	O	-1	none	_	_
9	S-LB1	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	comparable	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	well	_	_	RB	O	-1	none	_	_
15	characterized	_	_	VBN	O	-1	none	_	_
16	chick	_	_	NN	O	-1	none	_	_
17	intestinal	_	_	JJ	O	-1	none	_	_
18	1,25	_	_	CD	Protein	23	multitoken	_	_
19	(	_	_	-LRB-	Protein	23	multitoken	_	_
20	OH	_	_	NN	Protein	23	multitoken	_	_
21	)	_	_	-RRB-	Protein	23	multitoken	_	_
22	2D3	_	_	NN	Protein	23	multitoken	_	_
23	receptor	_	_	NN	Protein	0	root	_	_
24	in	_	_	IN	O	-1	none	_	_
25	terms	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	its	_	_	PRP$	O	-1	none	_	_
28	ligand	_	_	NN	O	-1	none	_	_
29	binding	_	_	NN	O	-1	none	_	_
30	affinity	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	capacity	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	its	_	_	PRP$	O	-1	none	_	_
35	mobility	_	_	NN	O	-1	none	_	_
36	on	_	_	IN	O	-1	none	_	_
37	5-20	_	_	CD	O	-1	none	_	_
38	%	_	_	NN	O	-1	none	_	_
39	sucrose	_	_	NN	O	-1	none	_	_
40	gradients	_	_	NNS	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	its	_	_	PRP$	O	-1	none	_	_
44	adsorption	_	_	NN	O	-1	none	_	_
45	to	_	_	TO	O	-1	none	_	_
46	and	_	_	CC	O	-1	none	_	_
47	elution	_	_	NN	O	-1	none	_	_
48	properties	_	_	NNS	O	-1	none	_	_
49	from	_	_	IN	O	-1	none	_	_
50	DNA-cellulose	_	_	NN	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	Three	_	_	CD	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	lines	_	_	NNS	O	-1	none	_	_
4	established	_	_	VBN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	patients	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	VDDR-II	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	Rh-VDR	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	Sh-VDR	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Ab-VDR	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	showed	_	_	VBD	O	-1	none	_	_
18	no	_	_	DT	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	1,25	_	_	CD	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	OH	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	2D3	_	_	NN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	receptor	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	treatment	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	cultured	_	_	JJ	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	1,25	_	_	CD	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	OH	_	_	NN	O	-1	none	_	_
40	)	_	_	-RRB-	O	-1	none	_	_
41	2D3	_	_	NN	O	-1	none	_	_
42	did	_	_	VBD	O	-1	none	_	_
43	not	_	_	RB	O	-1	none	_	_
44	stimulate	_	_	VB	O	-1	none	_	_
45	production	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	24,25-dihydroxy-vitamin	_	_	NN	O	-1	none	_	_
48	D3	_	_	NN	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	24,25	_	_	CD	O	-1	none	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	OH	_	_	NN	O	-1	none	_	_
53	)	_	_	-RRB-	O	-1	none	_	_
54	2D3	_	_	NN	O	-1	none	_	_
55	)	_	_	-RRB-	O	-1	none	_	_
56	,	_	_	,	O	-1	none	_	_
57	a	_	_	DT	O	-1	none	_	_
58	response	_	_	NN	O	-1	none	_	_
59	which	_	_	WDT	O	-1	none	_	_
60	is	_	_	VBZ	O	-1	none	_	_
61	diagnostic	_	_	JJ	O	-1	none	_	_
62	of	_	_	IN	O	-1	none	_	_
63	the	_	_	DT	O	-1	none	_	_
64	presence	_	_	NN	O	-1	none	_	_
65	of	_	_	IN	O	-1	none	_	_
66	a	_	_	DT	O	-1	none	_	_
67	functional	_	_	JJ	O	-1	none	_	_
68	1,25	_	_	CD	Protein	73	multitoken	_	_
69	(	_	_	-LRB-	Protein	73	multitoken	_	_
70	OH	_	_	NN	Protein	73	multitoken	_	_
71	)	_	_	-RRB-	Protein	73	multitoken	_	_
72	2D3	_	_	NN	Protein	73	multitoken	_	_
73	receptor	_	_	NN	Protein	0	root	_	_
74	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	fourth	_	_	JJ	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	line	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	A1-VDR	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	receptor	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	1,25	_	_	CD	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	OH	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	2D3	_	_	NN	O	-1	none	_	_
17	had	_	_	VBD	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	low	_	_	JJ	O	-1	none	_	_
20	binding	_	_	NN	O	-1	none	_	_
21	capacity	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	25	_	_	CD	Protein	27	multitoken	_	_
24	(	_	_	-LRB-	Protein	27	multitoken	_	_
25	OH	_	_	NN	Protein	27	multitoken	_	_
26	)	_	_	-RRB-	Protein	27	multitoken	_	_
27	D3-24-hydroxylase	_	_	NN	Protein	0	root	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	not	_	_	RB	O	-1	none	_	_
31	detectable	_	_	JJ	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	24,25-(	_	_	CD	O	-1	none	_	_
4	OH	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	2D3	_	_	NN	O	-1	none	_	_
7	synthesis	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	1,25	_	_	CD	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	OH	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	2D3	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	observed	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	fifth	_	_	JJ	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	line	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	designated	_	_	VBN	O	-1	none	_	_
23	Ro-VDR	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	although	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	sensitivity	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	hormone	_	_	NN	O	-1	none	_	_
30	treatment	_	_	NN	O	-1	none	_	_
31	was	_	_	VBD	O	-1	none	_	_
32	lower	_	_	JJR	O	-1	none	_	_
33	than	_	_	IN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	control	_	_	NN	O	-1	none	_	_
37	cell	_	_	NN	O	-1	none	_	_
38	line	_	_	NN	O	-1	none	_	_
39	from	_	_	IN	O	-1	none	_	_
40	a	_	_	DT	O	-1	none	_	_
41	normal	_	_	JJ	O	-1	none	_	_
42	donor	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	capacity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	1,25	_	_	CD	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	OH	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	2D3	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	low	_	_	JJ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	Ro-VDR	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	all	_	_	DT	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	lines	_	_	NNS	O	-1	none	_	_
5	where	_	_	WRB	O	-1	none	_	_
6	1,25	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	OH	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	2D3	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	detectable	_	_	JJ	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	had	_	_	VBD	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	typical	_	_	JJ	O	-1	none	_	_
23	sedimentation	_	_	NN	O	-1	none	_	_
24	coefficient	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	3.7	_	_	CD	O	-1	none	_	_
27	S	_	_	NN	O	-1	none	_	_
28	on	_	_	IN	O	-1	none	_	_
29	sucrose	_	_	NN	O	-1	none	_	_
30	density	_	_	NN	O	-1	none	_	_
31	gradient	_	_	NN	O	-1	none	_	_
32	analysis	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	elution	_	_	NN	O	-1	none	_	_
4	properties	_	_	NNS	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	DNA-cellulose	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	however	_	_	RB	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	differed	_	_	VBD	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	normal	_	_	JJ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	both	_	_	CC	O	-1	none	_	_
15	Ro-VDR	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	A1-VDR	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	where	_	_	WRB	O	-1	none	_	_
20	elution	_	_	NN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	DNA-cellulose	_	_	NN	O	-1	none	_	_
23	occurred	_	_	VBD	O	-1	none	_	_
24	at	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	lower	_	_	JJR	O	-1	none	_	_
27	salt	_	_	NN	O	-1	none	_	_
28	concentration	_	_	NN	O	-1	none	_	_
29	than	_	_	IN	O	-1	none	_	_
30	is	_	_	VBZ	O	-1	none	_	_
31	typical	_	_	JJ	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	1,25	_	_	CD	Protein	39	multitoken	_	_
35	(	_	_	-LRB-	Protein	39	multitoken	_	_
36	OH	_	_	NN	Protein	39	multitoken	_	_
37	)	_	_	-RRB-	Protein	39	multitoken	_	_
38	2D3	_	_	NN	Protein	39	multitoken	_	_
39	receptor	_	_	NN	Protein	0	root	_	_
40	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	Ro-VDR	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	typical	_	_	JJ	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	localization	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	unoccupied	_	_	JJ	O	-1	none	_	_
11	1,25	_	_	CD	Protein	16	multitoken	_	_
12	(	_	_	-LRB-	Protein	16	multitoken	_	_
13	OH	_	_	NN	Protein	16	multitoken	_	_
14	)	_	_	-RRB-	Protein	16	multitoken	_	_
15	2D3	_	_	NN	Protein	16	multitoken	_	_
16	receptor	_	_	NN	Protein	0	root	_	_
17	,	_	_	,	O	-1	none	_	_
18	neither	_	_	CC	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	unoccupied	_	_	JJ	O	-1	none	_	_
21	nor	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	occupied	_	_	JJ	O	-1	none	_	_
24	receptor	_	_	NN	O	-1	none	_	_
25	from	_	_	IN	O	-1	none	_	_
26	A1-VDR	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	completely	_	_	RB	O	-1	none	_	_
30	localized	_	_	JJ	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	nucleus	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	series	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	functional	_	_	JJ	O	-1	none	_	_
6	studies	_	_	NNS	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	found	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	modulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	level	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	mRNAs	_	_	NNS	O	-1	none	_	_
17	coding	_	_	VBG	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	both	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	c-myc	_	_	NN	Protein	-1	none	_	_
22	oncogene	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	growth	_	_	NN	O	-1	none	_	_
26	factor	_	_	NN	O	-1	none	_	_
27	known	_	_	VBN	O	-1	none	_	_
28	as	_	_	IN	O	-1	none	_	_
29	granulocyte-monocyte	_	_	JJ	O	-1	none	_	_
30	colony	_	_	NN	O	-1	none	_	_
31	stimulating	_	_	NN	O	-1	none	_	_
32	activity	_	_	NN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	1,25	_	_	CD	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	OH	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	2D3	_	_	NN	O	-1	none	_	_
39	correlated	_	_	VBD	O	-1	none	_	_
40	with	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	1,25	_	_	CD	Protein	47	multitoken	_	_
43	(	_	_	-LRB-	Protein	47	multitoken	_	_
44	OH	_	_	NN	Protein	47	multitoken	_	_
45	)	_	_	-RRB-	Protein	47	multitoken	_	_
46	2D3	_	_	NN	Protein	47	multitoken	_	_
47	receptor	_	_	NN	Protein	0	root	_	_
48	status	_	_	NN	O	-1	none	_	_
49	of	_	_	IN	O	-1	none	_	_
50	these	_	_	DT	O	-1	none	_	_
51	cells	_	_	NNS	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Use	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	lines	_	_	NNS	O	-1	none	_	_
6	will	_	_	MD	O	-1	none	_	_
7	facilitate	_	_	VB	O	-1	none	_	_
8	further	_	_	JJ	O	-1	none	_	_
9	study	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	molecular	_	_	JJ	O	-1	none	_	_
13	defect	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	s	_	_	NNS	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	receptor	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	1,25	_	_	CD	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	OH	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	2D3	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	vitamin	_	_	NN	O	-1	none	_	_
28	D	_	_	NN	O	-1	none	_	_
29	dependent	_	_	JJ	O	-1	none	_	_
30	rickets	_	_	NN	O	-1	none	_	_
31	type	_	_	NN	O	-1	none	_	_
32	II	_	_	CD	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	will	_	_	MD	O	-1	none	_	_
35	allow	_	_	VB	O	-1	none	_	_
36	a	_	_	DT	O	-1	none	_	_
37	correlation	_	_	NN	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	impairment	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	cellular	_	_	JJ	O	-1	none	_	_
42	functions	_	_	NNS	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	1	_	_	CD	O	-1	none	_	_
4	alpha	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
7	D3	_	_	NN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	chronic	_	_	JJ	O	-1	none	_	_
12	myelogenous	_	_	JJ	O	-1	none	_	_
13	leukemia	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	line	_	_	NN	O	-1	none	_	_
16	RWLeu-4	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	1	_	_	CD	O	-1	none	_	_
5	alpha	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
8	D3	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	VD3	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	proliferation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	macromolecular	_	_	JJ	O	-1	none	_	_
19	synthesis	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	new	_	_	JJ	O	-1	none	_	_
23	Philadelphia	_	_	NN	O	-1	none	_	_
24	chromosome	_	_	NN	O	-1	none	_	_
25	positive	_	_	JJ	O	-1	none	_	_
26	chronic	_	_	JJ	O	-1	none	_	_
27	myelogenous	_	_	JJ	O	-1	none	_	_
28	leukemia	_	_	NN	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	line	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	RWLeu-4	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	were	_	_	VBD	O	-1	none	_	_
35	investigated	_	_	VBN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	[	_	_	CD	O	-1	none	_	_
4	3H	_	_	NN	O	-1	none	_	_
5	]	_	_	CD	O	-1	none	_	_
6	VD3	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	saturable	_	_	JJ	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	approximately	_	_	RB	O	-1	none	_	_
12	2000-3000	_	_	CD	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	half-maximal	_	_	JJ	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	occurring	_	_	VBG	O	-1	none	_	_
21	at	_	_	IN	O	-1	none	_	_
22	0.21-0	_	_	CD	O	-1	none	_	_
23	.33	_	_	CD	O	-1	none	_	_
24	nM	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	RWLeu-4	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	VD3	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	24R-hydroxylase	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	marker	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	vitamin	_	_	NN	O	-1	none	_	_
15	D3	_	_	NN	O	-1	none	_	_
16	responsiveness	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	many	_	_	JJ	O	-1	none	_	_
19	tissues	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Exposure	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	RWLeu-4	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	VD3	_	_	NN	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	inhibited	_	_	VBD	O	-1	none	_	_
9	proliferation	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	synthesis	_	_	NN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	50	_	_	CD	O	-1	none	_	_
16	%	_	_	NN	O	-1	none	_	_
17	effective	_	_	JJ	O	-1	none	_	_
18	dose	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	3.5-10	_	_	CD	O	-1	none	_	_
21	nM	_	_	NN	O	-1	none	_	_
22	within	_	_	IN	O	-1	none	_	_
23	72	_	_	CD	O	-1	none	_	_
24	h	_	_	NN	O	-1	none	_	_
25	;	_	_	:	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	addition	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	RNA	_	_	NN	O	-1	none	_	_
32	synthesis	_	_	NN	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	inhibited	_	_	VBN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	VD3	_	_	NN	O	-1	none	_	_
37	treatment	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Exposure	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	RWLeu-4	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	5	_	_	CD	O	-1	none	_	_
7	nM	_	_	NN	O	-1	none	_	_
8	VD3	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	72	_	_	CD	O	-1	none	_	_
11	h	_	_	NN	O	-1	none	_	_
12	caused	_	_	VBD	O	-1	none	_	_
13	50	_	_	CD	O	-1	none	_	_
14	%	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	differentiate	_	_	VB	O	-1	none	_	_
20	into	_	_	IN	O	-1	none	_	_
21	macrophage	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	monocyte	_	_	NN	O	-1	none	_	_
24	type	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	judged	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	nitroblue	_	_	JJ	O	-1	none	_	_
30	tetrazolium	_	_	NN	O	-1	none	_	_
31	staining	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	adherence	_	_	NN	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	plastic	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Progressive	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	surface	_	_	NN	O	-1	none	_	_
6	maturation	_	_	NN	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	antigens	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	monocyte	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	macrophage	_	_	NN	O	-1	none	_	_
14	lineage	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	induced	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	treatment	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	RWLeu-4	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	VD3	_	_	NN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	24	_	_	CD	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	72	_	_	CD	O	-1	none	_	_
28	h	_	_	NN	O	-1	none	_	_
29	at	_	_	IN	O	-1	none	_	_
30	doses	_	_	NNS	O	-1	none	_	_
31	that	_	_	WDT	O	-1	none	_	_
32	inhibited	_	_	VBD	O	-1	none	_	_
33	cellular	_	_	JJ	O	-1	none	_	_
34	proliferation	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	c-myc	_	_	NN	Protein	-1	none	_	_
2	RNA	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	which	_	_	WDT	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	constitutively	_	_	RB	O	-1	none	_	_
7	expressed	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	RWLeu-4	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	increased	_	_	VBN	O	-1	none	_	_
13	after	_	_	IN	O	-1	none	_	_
14	0.5	_	_	CD	O	-1	none	_	_
15	h	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	treatment	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	50	_	_	CD	O	-1	none	_	_
20	nM	_	_	NN	O	-1	none	_	_
21	VD3	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	then	_	_	RB	O	-1	none	_	_
24	rapidly	_	_	RB	O	-1	none	_	_
25	decreased	_	_	VBD	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	barely	_	_	RB	O	-1	none	_	_
28	detectable	_	_	JJ	O	-1	none	_	_
29	levels	_	_	NNS	O	-1	none	_	_
30	after	_	_	IN	O	-1	none	_	_
31	4	_	_	CD	O	-1	none	_	_
32	h	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	treatment	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	in	_	_	FW	O	-1	none	_	_
5	vitro	_	_	FW	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	kinase	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	p210bcr-abl	_	_	NN	Protein	13	multitoken	_	_
13	oncogene	_	_	NN	Protein	0	root	_	_
14	product	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	decreased	_	_	VBN	O	-1	none	_	_
17	approximately	_	_	RB	O	-1	none	_	_
18	50	_	_	CD	O	-1	none	_	_
19	%	_	_	NN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	VD3	_	_	NN	O	-1	none	_	_
22	treatment	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	presence	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	functional	_	_	JJ	O	-1	none	_	_
8	receptor-effector	_	_	JJ	O	-1	none	_	_
9	system	_	_	NN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	VD3	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	multiple	_	_	JJ	O	-1	none	_	_
14	biological	_	_	JJ	O	-1	none	_	_
15	responses	_	_	NNS	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	hormone	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	these	_	_	DT	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	provide	_	_	VBP	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	unique	_	_	JJ	O	-1	none	_	_
25	model	_	_	NN	O	-1	none	_	_
26	system	_	_	NN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	probe	_	_	VB	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	specific	_	_	JJ	O	-1	none	_	_
33	effects	_	_	NNS	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	VD3	_	_	NN	O	-1	none	_	_
36	on	_	_	IN	O	-1	none	_	_
37	cell	_	_	NN	O	-1	none	_	_
38	growth	_	_	NN	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	differentiation	_	_	NN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	chronic	_	_	JJ	O	-1	none	_	_
43	myelogenous	_	_	JJ	O	-1	none	_	_
44	leukemia	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	O	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	death	_	_	NN	O	-1	none	_	_
5	requires	_	_	VBZ	O	-1	none	_	_
6	autoinduction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	glucocorticoid	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	leukemic	_	_	JJ	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	negative	_	_	JJ	O	-1	none	_	_
6	autoregulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	glucocorticoid	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	GR	_	_	NN	Protein	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	seen	_	_	VBN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	most	_	_	JJS	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	tissues	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	GR	_	_	NN	Protein	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	positively	_	_	RB	O	-1	none	_	_
25	autoregulated	_	_	VBN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	human	_	_	NN	O	-1	none	_	_
28	leukemic	_	_	JJ	O	-1	none	_	_
29	T	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	other	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	sensitive	_	_	JJ	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	glucocorticoid	_	_	NN	O	-1	none	_	_
38	induced	_	_	VBD	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	death	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	positive	_	_	JJ	O	-1	none	_	_
5	autoregulation	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	necessary	_	_	JJ	O	-1	none	_	_
9	component	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	glucocorticoid	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	death	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	wild-type	_	_	JJ	O	-1	none	_	_
18	GR	_	_	NN	Protein	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	under	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	control	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	tetracycline	_	_	NN	O	-1	none	_	_
26	regulated	_	_	VBD	O	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	stably	_	_	RB	O	-1	none	_	_
30	transfected	_	_	VBN	O	-1	none	_	_
31	into	_	_	IN	O	-1	none	_	_
32	glucocorticoid	_	_	NN	O	-1	none	_	_
33	resistant	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	lacking	_	_	VBG	O	-1	none	_	_
36	endogenous	_	_	JJ	O	-1	none	_	_
37	functional	_	_	JJ	O	-1	none	_	_
38	receptor	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Transfectants	_	_	NNS	O	-1	none	_	_
2	grown	_	_	VBN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	presence	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	tetracycline	_	_	NN	O	-1	none	_	_
8	contained	_	_	VBD	O	-1	none	_	_
9	about	_	_	RB	O	-1	none	_	_
10	15,000	_	_	CD	O	-1	none	_	_
11	receptors	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	value	_	_	NN	O	-1	none	_	_
17	approximately	_	_	RB	O	-1	none	_	_
18	equal	_	_	JJ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	basal	_	_	JJ	O	-1	none	_	_
21	level	_	_	NN	O	-1	none	_	_
22	GR	_	_	NN	Protein	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	glucocorticoid	_	_	NN	O	-1	none	_	_
26	sensitive	_	_	JJ	O	-1	none	_	_
27	6TG1	_	_	NN	O	-1	none	_	_
28	.1	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	before	_	_	IN	O	-1	none	_	_
31	steroid	_	_	NN	O	-1	none	_	_
32	treatment	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Under	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	conditions	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	dexamethasone	_	_	NN	O	-1	none	_	_
6	had	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	minimal	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	growth	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	elicited	_	_	VBD	O	-1	none	_	_
15	little	_	_	JJ	O	-1	none	_	_
16	internucleosomal	_	_	JJ	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	fragmentation	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	induced	_	_	VBD	O	-1	none	_	_
22	no	_	_	DT	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	cycle	_	_	NN	O	-1	none	_	_
25	perturbation	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	absence	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	tetracycline	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	GR	_	_	NN	Protein	-1	none	_	_
8	mRNA	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	increased	_	_	VBD	O	-1	none	_	_
13	2-3-fold	_	_	RB	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	expressed	_	_	VBD	O	-1	none	_	_
18	48,000	_	_	CD	O	-1	none	_	_
19	receptors	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	level	_	_	NN	O	-1	none	_	_
23	nearly	_	_	RB	O	-1	none	_	_
24	equivalent	_	_	JJ	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	that	_	_	DT	O	-1	none	_	_
27	present	_	_	JJ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	6TG1	_	_	NN	O	-1	none	_	_
30	.1	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	after	_	_	IN	O	-1	none	_	_
33	18	_	_	CD	O	-1	none	_	_
34	h	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	autoinduction	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Under	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	conditions	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	dexamethasone	_	_	NN	O	-1	none	_	_
6	markedly	_	_	RB	O	-1	none	_	_
7	inhibited	_	_	VBD	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	growth	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	caused	_	_	VBD	O	-1	none	_	_
12	G1	_	_	NN	O	-1	none	_	_
13	arrest	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	significant	_	_	JJ	O	-1	none	_	_
18	internucleosomal	_	_	JJ	O	-1	none	_	_
19	DNA	_	_	NN	O	-1	none	_	_
20	fragmentation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	therefore	_	_	RB	O	-1	none	_	_
4	suggest	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	basal	_	_	JJ	O	-1	none	_	_
7	level	_	_	NN	O	-1	none	_	_
8	GR	_	_	NN	Protein	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	inadequate	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	mediate	_	_	VB	O	-1	none	_	_
14	glucocorticoid	_	_	NN	O	-1	none	_	_
15	induced	_	_	JJ	O	-1	none	_	_
16	apoptosis	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	glucocorticoid	_	_	NN	O	-1	none	_	_
19	sensitive	_	_	JJ	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	positive	_	_	JJ	O	-1	none	_	_
25	autoregulation	_	_	NN	O	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	necessary	_	_	JJ	O	-1	none	_	_
29	component	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	this	_	_	DT	O	-1	none	_	_
32	process	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Genes	_	_	NNS	O	-1	none	_	_
2	that	_	_	WDT	O	-1	none	_	_
3	regulate	_	_	VBP	O	-1	none	_	_
4	interleukin-4	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Interleukin-4	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	immunomodulatory	_	_	JJ	O	-1	none	_	_
5	cytokine	_	_	NN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	plays	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	central	_	_	JJ	O	-1	none	_	_
10	role	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	regulation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	allergic	_	_	JJ	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	atopic	_	_	JJ	O	-1	none	_	_
18	immune	_	_	JJ	O	-1	none	_	_
19	responses	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Significant	_	_	JJ	O	-1	none	_	_
2	progress	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	made	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	gaining	_	_	VBG	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	detailed	_	_	JJ	O	-1	none	_	_
10	understanding	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	regulation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	interleukin-4	_	_	NN	Protein	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	recent	_	_	JJ	O	-1	none	_	_
3	identification	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	characterization	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	several	_	_	JJ	O	-1	none	_	_
8	key	_	_	JJ	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	has	_	_	VBZ	O	-1	none	_	_
12	helped	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	elucidate	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	molecular	_	_	JJ	O	-1	none	_	_
17	mechanisms	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	helper	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	cytokine	_	_	NN	O	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	expression	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	modulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	myelopoiesis	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	leukemogenesis	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Acute	_	_	JJ	O	-1	none	_	_
2	myeloid	_	_	JJ	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	AML	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	still	_	_	RB	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	mortality	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	60	_	_	CD	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	80	_	_	CD	O	-1	none	_	_
17	%	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	AML	_	_	NN	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	characterized	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	block	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	myeloid	_	_	JJ	O	-1	none	_	_
9	differentiation	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	PU	_	_	NN	Protein	5	multitoken	_	_
5	.1	_	_	NN	Protein	0	root	_	_
6	and	_	_	CC	O	-1	none	_	_
7	C/EBPalpha	_	_	NN	Protein	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	responsible	_	_	JJ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	normal	_	_	JJ	O	-1	none	_	_
12	myeloid	_	_	JJ	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	from	_	_	IN	O	-1	none	_	_
15	stem	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	granulocytes	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	particular	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	PU	_	_	NN	Protein	5	multitoken	_	_
5	.1	_	_	NN	Protein	0	root	_	_
6	induces	_	_	VBZ	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	macrophage	_	_	NN	Protein	13	multitoken	_	_
11	colony	_	_	NN	Protein	13	multitoken	_	_
12	stimulating	_	_	NN	Protein	13	multitoken	_	_
13	factor	_	_	NN	Protein	0	root	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	M-CSF	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	receptor	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	development	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	monocytes	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	whereas	_	_	IN	O	-1	none	_	_
25	C/EBPalpha	_	_	NN	Protein	-1	none	_	_
26	increases	_	_	VBZ	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	granulocyte	_	_	NN	Protein	38	multitoken	_	_
32	colony	_	_	NN	Protein	38	multitoken	_	_
33	stimulating	_	_	NN	Protein	38	multitoken	_	_
34	factor	_	_	NN	Protein	38	multitoken	_	_
35	(	_	_	-LRB-	Protein	38	multitoken	_	_
36	G-CSF	_	_	NN	Protein	38	multitoken	_	_
37	)	_	_	-RRB-	Protein	38	multitoken	_	_
38	receptor	_	_	NN	Protein	0	root	_	_
39	and	_	_	CC	O	-1	none	_	_
40	leads	_	_	VBZ	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	mature	_	_	VB	O	-1	none	_	_
43	granulocytes	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	AML	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	chromosomal	_	_	JJ	O	-1	none	_	_
5	aberrations	_	_	NNS	O	-1	none	_	_
6	result	_	_	VBP	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	oncoproteins	_	_	NNS	O	-1	none	_	_
9	such	_	_	JJ	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	AML1	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	ETO	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	PML	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	RARalpha	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	activated	_	_	VBN	O	-1	none	_	_
21	Ras	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	can	_	_	MD	O	-1	none	_	_
25	deregulate	_	_	VB	O	-1	none	_	_
26	genes	_	_	NNS	O	-1	none	_	_
27	important	_	_	JJ	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	normal	_	_	JJ	O	-1	none	_	_
30	myelopoiesis	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	AML1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	ETO	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	bind	_	_	VB	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	C/EBPalpha	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	inhibit	_	_	VBP	O	-1	none	_	_
15	C/EBPalpha	_	_	NN	Protein	-1	none	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	block	_	_	VB	O	-1	none	_	_
21	granulocytic	_	_	JJ	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	AML1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	ETO	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	synergize	_	_	VB	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	AML1	_	_	NN	Protein	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	enhance	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	M-CSF	_	_	NN	Protein	-1	none	_	_
21	receptor	_	_	NN	O	-1	none	_	_
22	promoter	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	hand	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	PML	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	RARalpha	_	_	NN	Protein	-1	none	_	_
10	fusion	_	_	NN	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	causes	_	_	VBZ	O	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	repression	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	recruiting	_	_	VBG	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	corepressor	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	N-CoR	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	histone	_	_	NN	O	-1	none	_	_
24	deacetylase	_	_	NN	O	-1	none	_	_
25	complex	_	_	NN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	DNA	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	which	_	_	WDT	O	-1	none	_	_
31	results	_	_	VBZ	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	decreased	_	_	VBN	O	-1	none	_	_
34	histone	_	_	NN	O	-1	none	_	_
35	acetylation	_	_	NN	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	repressive	_	_	JJ	O	-1	none	_	_
39	chromatin	_	_	NN	O	-1	none	_	_
40	organization	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	describe	_	_	VBP	O	-1	none	_	_
4	methods	_	_	NNS	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	investigate	_	_	VB	O	-1	none	_	_
7	whether	_	_	IN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	how	_	_	WRB	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	agonists	_	_	NNS	O	-1	none	_	_
12	induce	_	_	VBP	O	-1	none	_	_
13	myeloid	_	_	JJ	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	how	_	_	WRB	O	-1	none	_	_
17	oncoproteins	_	_	NNS	O	-1	none	_	_
18	might	_	_	MD	O	-1	none	_	_
19	cause	_	_	VB	O	-1	none	_	_
20	AML	_	_	NN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	modulating	_	_	VBG	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	factors	_	_	NNS	O	-1	none	_	_
28	that	_	_	WDT	O	-1	none	_	_
29	are	_	_	VBP	O	-1	none	_	_
30	pivotal	_	_	JJ	O	-1	none	_	_
31	for	_	_	IN	O	-1	none	_	_
32	normal	_	_	JJ	O	-1	none	_	_
33	myeloid	_	_	JJ	O	-1	none	_	_
34	development	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Copyright	_	_	NN	O	-1	none	_	_
2	1999	_	_	CD	O	-1	none	_	_
3	Academic	_	_	NNP	O	-1	none	_	_
4	Press	_	_	NNP	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	Heterogeneity	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	antigen	_	_	NN	O	-1	none	_	_
4	molecules	_	_	NNS	O	-1	none	_	_
5	recognized	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	anti-tax1	_	_	JJ	Protein	-1	none	_	_
8	monoclonal	_	_	JJ	O	-1	none	_	_
9	antibody	_	_	NN	O	-1	none	_	_
10	Lt-4	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	lines	_	_	NNS	O	-1	none	_	_
14	bearing	_	_	VBG	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	leukemia	_	_	NN	O	-1	none	_	_
19	virus	_	_	NN	O	-1	none	_	_
20	type	_	_	NN	O	-1	none	_	_
21	I	_	_	CD	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	related	_	_	JJ	O	-1	none	_	_
24	retroviruses	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	monoclonal	_	_	JJ	O	-1	none	_	_
4	antibody	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	Lt-4	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	directed	_	_	VBN	O	-1	none	_	_
9	against	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	leukemia	_	_	NN	O	-1	none	_	_
14	virus	_	_	NN	O	-1	none	_	_
15	type	_	_	NN	O	-1	none	_	_
16	I	_	_	CD	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	HTLV-I	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	trans-activator	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	tax1	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	antigen	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	we	_	_	PRP	O	-1	none	_	_
27	examined	_	_	VBD	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	tax1	_	_	NN	Protein	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	related	_	_	JJ	O	-1	none	_	_
34	antigens	_	_	NNS	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	a	_	_	DT	O	-1	none	_	_
37	variety	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	T	_	_	NN	O	-1	none	_	_
40	cell	_	_	NN	O	-1	none	_	_
41	lines	_	_	NNS	O	-1	none	_	_
42	bearing	_	_	VBG	O	-1	none	_	_
43	HTLV-I	_	_	NN	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	related	_	_	JJ	O	-1	none	_	_
46	retroviruses	_	_	NNS	O	-1	none	_	_
47	,	_	_	,	O	-1	none	_	_
48	simian	_	_	JJ	O	-1	none	_	_
49	T	_	_	NN	O	-1	none	_	_
50	cell	_	_	NN	O	-1	none	_	_
51	leukemia	_	_	NN	O	-1	none	_	_
52	virus	_	_	NN	O	-1	none	_	_
53	type	_	_	NN	O	-1	none	_	_
54	I	_	_	CD	O	-1	none	_	_
55	(	_	_	-LRB-	O	-1	none	_	_
56	STLV-I	_	_	NN	O	-1	none	_	_
57	)	_	_	-RRB-	O	-1	none	_	_
58	and	_	_	CC	O	-1	none	_	_
59	HTLV-II	_	_	NN	O	-1	none	_	_
60	,	_	_	,	O	-1	none	_	_
61	by	_	_	IN	O	-1	none	_	_
62	immunofluorescence	_	_	NN	O	-1	none	_	_
63	and	_	_	CC	O	-1	none	_	_
64	immunoblot	_	_	NN	O	-1	none	_	_
65	assays	_	_	NNS	O	-1	none	_	_
66	.	_	_	.	O	-1	none	_	_

1	Lt-4	_	_	NNP	O	-1	none	_	_
2	reacted	_	_	VBD	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	all	_	_	DT	O	-1	none	_	_
5	HTLV-I-bearing	_	_	JJ	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	lines	_	_	NNS	O	-1	none	_	_
8	tested	_	_	VBN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	five	_	_	CD	O	-1	none	_	_
11	out	_	_	IN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	eight	_	_	CD	O	-1	none	_	_
14	simian	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	lines	_	_	NNS	O	-1	none	_	_
17	bearing	_	_	VBG	O	-1	none	_	_
18	STLV-I	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	HTLV-II-bearing	_	_	JJ	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	line	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Lt-4	_	_	NNP	O	-1	none	_	_
2	detected	_	_	VBD	O	-1	none	_	_
3	40	_	_	CD	O	-1	none	_	_
4	kd	_	_	NN	O	-1	none	_	_
5	tax1	_	_	NN	Protein	-1	none	_	_
6	antigen	_	_	NN	O	-1	none	_	_
7	molecules	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	most	_	_	JJS	O	-1	none	_	_
10	HTLV-I-bearing	_	_	JJ	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	lines	_	_	NNS	O	-1	none	_	_
13	except	_	_	IN	O	-1	none	_	_
14	one	_	_	CD	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	line	_	_	NN	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	expressed	_	_	VBD	O	-1	none	_	_
19	39	_	_	CD	O	-1	none	_	_
20	kd	_	_	NN	O	-1	none	_	_
21	tax1	_	_	NN	Protein	-1	none	_	_
22	antigen	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	STLV-I-bearing	_	_	JJ	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	lines	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	tax1	_	_	NN	Protein	-1	none	_	_
9	related	_	_	JJ	O	-1	none	_	_
10	antigen	_	_	NN	O	-1	none	_	_
11	molecules	_	_	NNS	O	-1	none	_	_
12	detected	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	Lt-4	_	_	NN	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	heterogeneous	_	_	JJ	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	having	_	_	VBG	O	-1	none	_	_
19	molecular	_	_	JJ	O	-1	none	_	_
20	weights	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	range	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	36-41	_	_	CD	O	-1	none	_	_
26	kd	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	balance	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	cytokine	_	_	NN	O	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transducer	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	activator	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	STAT	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	cytokines	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	inflammatory	_	_	JJ	O	-1	none	_	_
26	synovial	_	_	JJ	O	-1	none	_	_
27	fluids	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	balance	_	_	NN	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	type	_	_	NN	O	-1	none	_	_
5	1	_	_	CD	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	2	_	_	CD	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	helper	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	cytokine	_	_	NN	O	-1	none	_	_
12	production	_	_	NN	O	-1	none	_	_
13	plays	_	_	VBZ	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	important	_	_	JJ	O	-1	none	_	_
16	role	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	several	_	_	JJ	O	-1	none	_	_
19	animal	_	_	NN	O	-1	none	_	_
20	models	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	autoimmunity	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	skewed	_	_	JJ	O	-1	none	_	_
26	patterns	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	cytokine	_	_	NN	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	have	_	_	VBP	O	-1	none	_	_
31	been	_	_	VBN	O	-1	none	_	_
32	described	_	_	VBN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	human	_	_	NN	O	-1	none	_	_
35	inflammatory	_	_	JJ	O	-1	none	_	_
36	diseases	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Many	_	_	JJ	O	-1	none	_	_
2	cytokines	_	_	NNS	O	-1	none	_	_
3	activate	_	_	VBP	O	-1	none	_	_
4	signal	_	_	NN	O	-1	none	_	_
5	transducer	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	STAT	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	turn	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	activate	_	_	VBP	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	inflammatory	_	_	JJ	O	-1	none	_	_
25	effector	_	_	NN	O	-1	none	_	_
26	genes	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	used	_	_	VBD	O	-1	none	_	_
3	mononuclear	_	_	JJ	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	priming	_	_	NN	O	-1	none	_	_
6	cultures	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	inflammatory	_	_	JJ	O	-1	none	_	_
9	synovial	_	_	JJ	O	-1	none	_	_
10	fluids	_	_	NNS	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	SFs	_	_	NNS	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	derived	_	_	VBN	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	arthritis	_	_	NN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	examine	_	_	VB	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	regulation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	cytokine	_	_	NN	O	-1	none	_	_
24	production	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	STAT	_	_	NN	O	-1	none	_	_
27	activity	_	_	NN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	inflammatory	_	_	JJ	O	-1	none	_	_
31	synovial	_	_	JJ	O	-1	none	_	_
32	microenvironment	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Exposure	_	_	NN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	SFs	_	_	NNS	O	-1	none	_	_
4	during	_	_	IN	O	-1	none	_	_
5	priming	_	_	NN	O	-1	none	_	_
6	resulted	_	_	VBD	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	81	_	_	CD	O	-1	none	_	_
10	%	_	_	NN	O	-1	none	_	_
11	inhibition	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	interferon	_	_	NN	Protein	16	multitoken	_	_
14	(	_	_	-LRB-	Protein	16	multitoken	_	_
15	IFN	_	_	NN	Protein	16	multitoken	_	_
16	)-gamma	_	_	NN	Protein	0	root	_	_
17	,	_	_	,	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	interleukin	_	_	NN	Protein	24	multitoken	_	_
21	(	_	_	-LRB-	Protein	24	multitoken	_	_
22	IL	_	_	NN	Protein	24	multitoken	_	_
23	)	_	_	-RRB-	Protein	24	multitoken	_	_
24	4	_	_	CD	Protein	0	root	_	_
25	,	_	_	,	O	-1	none	_	_
26	production	_	_	NN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	effector	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	generated	_	_	VBN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	priming	_	_	NN	O	-1	none	_	_
33	cultures	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	SF	_	_	NN	O	-1	none	_	_
2	suppression	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	mediated	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	IL-4	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	inhibition	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	IL-12	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	it	_	_	PRP	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	reversed	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	dominant	_	_	JJ	O	-1	none	_	_
22	fashion	_	_	NN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	exogenous	_	_	JJ	O	-1	none	_	_
25	IL-12	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	SFs	_	_	NNS	O	-1	none	_	_
2	blocked	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	sustained	_	_	JJ	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	Stat1	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	Stat3	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	during	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	priming	_	_	NN	O	-1	none	_	_
18	period	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	Stat1	_	_	NN	Protein	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	differentially	_	_	RB	O	-1	none	_	_
25	regulated	_	_	VBN	O	-1	none	_	_
26	by	_	_	IN	O	-1	none	_	_
27	cytokines	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	parallel	_	_	NN	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	their	_	_	PRP$	O	-1	none	_	_
32	positive	_	_	JJ	O	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	negative	_	_	JJ	O	-1	none	_	_
35	regulation	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	IFN-gamma	_	_	NN	Protein	-1	none	_	_
38	production	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Active	_	_	JJ	O	-1	none	_	_
2	Stat3	_	_	NN	Protein	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	but	_	_	CC	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	Stat1	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	detected	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	inflamed	_	_	JJ	O	-1	none	_	_
14	joints	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	role	_	_	NN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	altered	_	_	JJ	O	-1	none	_	_
8	balance	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Stat1	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Stat3	_	_	NN	Protein	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	regulation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	pathogenesis	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	inflammatory	_	_	JJ	O	-1	none	_	_
28	synovitis	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	conserved	_	_	JJ	O	-1	none	_	_
3	motif	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	promoters	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	several	_	_	JJ	O	-1	none	_	_
9	cytokines	_	_	NNS	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	Th2-type	_	_	JJ	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	recently	_	_	RB	O	-1	none	_	_
4	found	_	_	VBN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	novel	_	_	JJ	O	-1	none	_	_
7	conserved	_	_	VBN	O	-1	none	_	_
8	motif	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	promoters	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	several	_	_	JJ	O	-1	none	_	_
14	T-cell-expressed	_	_	JJ	O	-1	none	_	_
15	cytokines	_	_	NNS	O	-1	none	_	_
16	[	_	_	VBP	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	interleukin-2	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	-4	_	_	CD	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	-5	_	_	CD	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	-13	_	_	CD	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	mouse	_	_	NN	O	-1	none	_	_
29	granulocyte	_	_	NN	Protein	33	multitoken	_	_
30	and	_	_	CC	Protein	33	multitoken	_	_
31	macrophage-colony	_	_	NN	Protein	33	multitoken	_	_
32	stimulating	_	_	NN	Protein	33	multitoken	_	_
33	factor	_	_	NN	Protein	0	root	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	GM-CSF	_	_	NN	Protein	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	]	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	contains	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	core	_	_	NN	O	-1	none	_	_
5	sequence	_	_	NN	O	-1	none	_	_
6	CTTGG	_	_	NN	O	-1	none	_	_
7	...	_	_	:	O	-1	none	_	_
8	CCAAG	_	_	NN	O	-1	none	_	_
9	which	_	_	WDT	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	present	_	_	JJ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	part	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	larger	_	_	JJR	O	-1	none	_	_
16	palindromic	_	_	JJ	O	-1	none	_	_
17	sequences	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	each	_	_	DT	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	suggest	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	they	_	_	PRP	O	-1	none	_	_
5	may	_	_	MD	O	-1	none	_	_
6	interact	_	_	VB	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	new	_	_	JJ	O	-1	none	_	_
10	family	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	trans-acting	_	_	JJ	O	-1	none	_	_
13	factors	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	transfection	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	GM-CSF	_	_	NN	Protein	-1	none	_	_
8	element	_	_	NN	O	-1	none	_	_
9	has	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	strong	_	_	JJ	O	-1	none	_	_
12	positive	_	_	JJ	O	-1	none	_	_
13	effect	_	_	NN	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	reporter	_	_	NN	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	human	_	_	NN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	line	_	_	NN	O	-1	none	_	_
27	Jurkat	_	_	NN	O	-1	none	_	_
28	J6	_	_	NN	O	-1	none	_	_
29	upon	_	_	IN	O	-1	none	_	_
30	stimulation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	DNA	_	_	NN	O	-1	none	_	_
3	mobility	_	_	NN	O	-1	none	_	_
4	shift	_	_	NN	O	-1	none	_	_
5	assays	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	this	_	_	DT	O	-1	none	_	_
8	sequence	_	_	NN	O	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	give	_	_	VB	O	-1	none	_	_
11	either	_	_	CC	O	-1	none	_	_
12	six	_	_	CD	O	-1	none	_	_
13	different	_	_	JJ	O	-1	none	_	_
14	specific	_	_	JJ	O	-1	none	_	_
15	bands	_	_	NNS	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	competed	_	_	VBN	O	-1	none	_	_
19	out	_	_	RP	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	different	_	_	JJ	O	-1	none	_	_
22	parts	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	sequence	_	_	NN	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	one	_	_	CD	O	-1	none	_	_
28	specific	_	_	JJ	O	-1	none	_	_
29	band	_	_	NN	O	-1	none	_	_
30	which	_	_	WDT	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	competed	_	_	VBN	O	-1	none	_	_
33	out	_	_	RP	O	-1	none	_	_
34	by	_	_	IN	O	-1	none	_	_
35	each	_	_	DT	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	inverted	_	_	JJ	O	-1	none	_	_
39	repeats	_	_	NNS	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	depending	_	_	VBG	O	-1	none	_	_
42	on	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	reconstitution	_	_	NN	O	-1	none	_	_
45	conditions	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	different	_	_	JJ	O	-1	none	_	_
3	genes	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	core	_	_	NN	O	-1	none	_	_
7	sequences	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	separated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	integer	_	_	NN	O	-1	none	_	_
12	numbers	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	helical	_	_	JJ	O	-1	none	_	_
15	turns	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Considering	_	_	VBG	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	strong	_	_	JJ	O	-1	none	_	_
4	positive	_	_	JJ	O	-1	none	_	_
5	regulatory	_	_	JJ	O	-1	none	_	_
6	effect	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	element	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	its	_	_	PRP$	O	-1	none	_	_
12	presence	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	several	_	_	JJ	O	-1	none	_	_
15	T-cell-expressed	_	_	JJ	O	-1	none	_	_
16	cytokine	_	_	NN	O	-1	none	_	_
17	genes	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	it	_	_	PRP	O	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	be	_	_	VB	O	-1	none	_	_
22	crucial	_	_	JJ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	coordinated	_	_	JJ	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	these	_	_	DT	O	-1	none	_	_
29	cytokines	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	T	_	_	NN	O	-1	none	_	_
32	helper	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	PU	_	_	NN	Protein	2	multitoken	_	_
2	.1	_	_	CD	Protein	0	root	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	Spi-1	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	C/EBP	_	_	NN	Protein	8	multitoken	_	_
8	alpha	_	_	NN	Protein	0	root	_	_
9	regulate	_	_	VBP	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	granulocyte-macrophage	_	_	JJ	Protein	18	multitoken	_	_
14	colony	_	_	NN	Protein	18	multitoken	_	_
15	stimulating	_	_	NN	Protein	18	multitoken	_	_
16	factor	_	_	NN	Protein	18	multitoken	_	_
17	receptor	_	_	NN	Protein	18	multitoken	_	_
18	alpha	_	_	NN	Protein	0	root	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Growth	_	_	NN	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	receptors	_	_	NNS	O	-1	none	_	_
4	play	_	_	VBP	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	important	_	_	JJ	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	hematopoiesis	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	further	_	_	RB	O	-1	none	_	_
5	understand	_	_	VB	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	mechanisms	_	_	NNS	O	-1	none	_	_
8	directing	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	these	_	_	DT	O	-1	none	_	_
13	key	_	_	JJ	O	-1	none	_	_
14	regulators	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	hematopoiesis	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	we	_	_	PRP	O	-1	none	_	_
19	initiated	_	_	VBD	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	study	_	_	NN	O	-1	none	_	_
22	investigating	_	_	VBG	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	factors	_	_	NNS	O	-1	none	_	_
26	activating	_	_	VBG	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	granulocyte-macrophage	_	_	JJ	Protein	39	multitoken	_	_
32	colony	_	_	NN	Protein	39	multitoken	_	_
33	stimulating	_	_	NN	Protein	39	multitoken	_	_
34	factor	_	_	NN	Protein	39	multitoken	_	_
35	(	_	_	-LRB-	Protein	39	multitoken	_	_
36	GM-CSF	_	_	NN	Protein	39	multitoken	_	_
37	)	_	_	-RRB-	Protein	39	multitoken	_	_
38	receptor	_	_	NN	Protein	39	multitoken	_	_
39	alpha	_	_	NN	Protein	0	root	_	_
40	gene	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	GM-CSF	_	_	NN	Protein	10	multitoken	_	_
9	receptor	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	directs	_	_	VBZ	O	-1	none	_	_
13	reporter	_	_	NN	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	tissue	_	_	NN	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	fashion	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	myelomonocytic	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	correlates	_	_	VBZ	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	its	_	_	PRP$	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	pattern	_	_	NN	O	-1	none	_	_
31	as	_	_	IN	O	-1	none	_	_
32	analyzed	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	reverse	_	_	JJ	O	-1	none	_	_
35	transcription	_	_	NN	O	-1	none	_	_
36	PCR	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	GM-CSF	_	_	NN	Protein	4	multitoken	_	_
3	receptor	_	_	NN	Protein	4	multitoken	_	_
4	alpha	_	_	NN	Protein	0	root	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	contains	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	important	_	_	JJ	O	-1	none	_	_
9	functional	_	_	JJ	O	-1	none	_	_
10	site	_	_	NN	O	-1	none	_	_
11	between	_	_	IN	O	-1	none	_	_
12	positions	_	_	NNS	O	-1	none	_	_
13	-53	_	_	CD	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	-41	_	_	CD	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	identified	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	deletion	_	_	NN	O	-1	none	_	_
20	analysis	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	reporter	_	_	NN	O	-1	none	_	_
23	constructs	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	myeloid	_	_	JJ	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	PU	_	_	NN	Protein	12	multitoken	_	_
12	.1	_	_	NN	Protein	0	root	_	_
13	binds	_	_	VBZ	O	-1	none	_	_
14	specifically	_	_	RB	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	this	_	_	DT	O	-1	none	_	_
17	site	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	CCAAT	_	_	NN	O	-1	none	_	_
8	site	_	_	NN	O	-1	none	_	_
9	located	_	_	JJ	O	-1	none	_	_
10	upstream	_	_	RB	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	PU	_	_	NN	Protein	14	multitoken	_	_
14	.1	_	_	NN	Protein	0	root	_	_
15	site	_	_	NN	O	-1	none	_	_
16	between	_	_	IN	O	-1	none	_	_
17	positions	_	_	NNS	O	-1	none	_	_
18	-70	_	_	CD	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	-54	_	_	CD	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	involved	_	_	VBN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	positive	_	_	JJ	O	-1	none	_	_
25	negative	_	_	JJ	O	-1	none	_	_
26	regulation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	GM-CSF	_	_	NN	Protein	31	multitoken	_	_
30	receptor	_	_	NN	Protein	31	multitoken	_	_
31	alpha	_	_	NN	Protein	0	root	_	_
32	promoter	_	_	NN	O	-1	none	_	_
33	activity	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	C/EBP	_	_	NN	Protein	2	multitoken	_	_
2	alpha	_	_	NN	Protein	0	root	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	major	_	_	JJ	O	-1	none	_	_
6	CCAAT	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	enhancer	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	C/EBP	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	form	_	_	NN	O	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	this	_	_	DT	O	-1	none	_	_
18	site	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	extracts	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	U937	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Point	_	_	NN	O	-1	none	_	_
2	mutations	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	either	_	_	CC	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	PU	_	_	NN	Protein	7	multitoken	_	_
7	.1	_	_	NN	Protein	0	root	_	_
8	site	_	_	NN	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	C/EBP	_	_	NN	O	-1	none	_	_
12	site	_	_	NN	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	abolish	_	_	VBP	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	respective	_	_	JJ	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	result	_	_	VBP	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	significant	_	_	JJ	O	-1	none	_	_
25	decrease	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	GM-CSF	_	_	NN	Protein	29	multitoken	_	_
28	receptor	_	_	NN	Protein	29	multitoken	_	_
29	alpha	_	_	NN	Protein	0	root	_	_
30	promoter	_	_	NN	O	-1	none	_	_
31	activity	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	myelomonocytic	_	_	JJ	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	only	_	_	RB	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	myeloid	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	extracts	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	PU	_	_	NN	Protein	14	multitoken	_	_
14	.1	_	_	NN	Protein	0	root	_	_
15	forms	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	novel	_	_	JJ	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	more	_	_	RBR	O	-1	none	_	_
22	slowly	_	_	RB	O	-1	none	_	_
23	migrating	_	_	VBG	O	-1	none	_	_
24	complex	_	_	JJ	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	PU-SF	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	when	_	_	WRB	O	-1	none	_	_
29	binding	_	_	VBG	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	GM-CSF	_	_	NN	Protein	33	multitoken	_	_
32	receptor	_	_	NN	Protein	33	multitoken	_	_
33	alpha	_	_	NN	Protein	0	root	_	_
34	promoter	_	_	NN	O	-1	none	_	_
35	PU	_	_	NN	Protein	36	multitoken	_	_
36	.1	_	_	NN	Protein	0	root	_	_
37	site	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	first	_	_	JJ	O	-1	none	_	_
5	demonstration	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	interaction	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	PU	_	_	NN	Protein	12	multitoken	_	_
12	.1	_	_	NN	Protein	0	root	_	_
13	on	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	myeloid	_	_	JJ	O	-1	none	_	_
16	PU	_	_	NN	Protein	17	multitoken	_	_
17	.1	_	_	NN	Protein	0	root	_	_
18	binding	_	_	VBG	O	-1	none	_	_
19	site	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	novel	_	_	JJ	O	-1	none	_	_
3	complex	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	distinct	_	_	JJ	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	that	_	_	DT	O	-1	none	_	_
8	described	_	_	VBN	O	-1	none	_	_
9	previously	_	_	RB	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	binding	_	_	VBG	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	enhancer	_	_	NN	O	-1	none	_	_
16	sites	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	can	_	_	MD	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	formed	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	addition	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	PU	_	_	NN	Protein	25	multitoken	_	_
25	.1	_	_	CD	Protein	0	root	_	_
26	to	_	_	TO	O	-1	none	_	_
27	extracts	_	_	NNS	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	certain	_	_	JJ	O	-1	none	_	_
30	nonmyeloid	_	_	JJ	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	types	_	_	NNS	O	-1	none	_	_
33	which	_	_	WDT	O	-1	none	_	_
34	do	_	_	VBP	O	-1	none	_	_
35	not	_	_	RB	O	-1	none	_	_
36	express	_	_	VB	O	-1	none	_	_
37	PU	_	_	NN	Protein	38	multitoken	_	_
38	.1	_	_	NN	Protein	0	root	_	_
39	,	_	_	,	O	-1	none	_	_
40	including	_	_	VBG	O	-1	none	_	_
41	T	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	epithelial	_	_	JJ	O	-1	none	_	_
45	cells	_	_	NNS	O	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	but	_	_	CC	O	-1	none	_	_
48	not	_	_	RB	O	-1	none	_	_
49	from	_	_	IN	O	-1	none	_	_
50	erythroid	_	_	JJ	O	-1	none	_	_
51	cells	_	_	NNS	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	PU-SF	_	_	NN	O	-1	none	_	_
8	complex	_	_	NN	O	-1	none	_	_
9	binds	_	_	VBZ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	PU	_	_	NN	Protein	12	multitoken	_	_
12	.1	_	_	NN	Protein	0	root	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	number	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	myeloid	_	_	JJ	O	-1	none	_	_
20	promoters	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	formation	_	_	NN	O	-1	none	_	_
25	requires	_	_	VBZ	O	-1	none	_	_
26	an	_	_	DT	O	-1	none	_	_
27	intact	_	_	JJ	O	-1	none	_	_
28	PU	_	_	NN	Protein	29	multitoken	_	_
29	.1	_	_	NN	Protein	0	root	_	_
30	site	_	_	NN	O	-1	none	_	_
31	adjacent	_	_	JJ	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	single	_	_	JJ	O	-1	none	_	_
35	stranded	_	_	JJ	O	-1	none	_	_
36	region	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	PU	_	_	NN	Protein	4	multitoken	_	_
4	.1	_	_	NN	Protein	0	root	_	_
5	in	_	_	IN	O	-1	none	_	_
6	nonmyeloid	_	_	JJ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	can	_	_	MD	O	-1	none	_	_
9	activate	_	_	VB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	GM-CSF	_	_	NN	Protein	13	multitoken	_	_
12	receptor	_	_	NN	Protein	13	multitoken	_	_
13	alpha	_	_	NN	Protein	0	root	_	_
14	promoter	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Deletion	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	amino-terminal	_	_	JJ	O	-1	none	_	_
5	region	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	PU	_	_	NN	Protein	8	multitoken	_	_
8	.1	_	_	CD	Protein	0	root	_	_
9	results	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	failure	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	form	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	PU-SF	_	_	NN	O	-1	none	_	_
17	complex	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	concomitant	_	_	JJ	O	-1	none	_	_
22	loss	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	transactivation	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	suggesting	_	_	VBG	O	-1	none	_	_
27	that	_	_	IN	O	-1	none	_	_
28	formation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	PU-SF	_	_	NN	O	-1	none	_	_
32	complex	_	_	NN	O	-1	none	_	_
33	is	_	_	VBZ	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	functional	_	_	JJ	O	-1	none	_	_
36	importance	_	_	NN	O	-1	none	_	_
37	for	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	activity	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	GM-CSF	_	_	NN	Protein	44	multitoken	_	_
43	receptor	_	_	NN	Protein	44	multitoken	_	_
44	alpha	_	_	NN	Protein	0	root	_	_
45	promoter	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	C/EBP	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	can	_	_	MD	O	-1	none	_	_
9	also	_	_	RB	O	-1	none	_	_
10	active	_	_	JJ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	GM-CSF	_	_	NN	Protein	14	multitoken	_	_
13	receptor	_	_	NN	Protein	14	multitoken	_	_
14	alpha	_	_	NN	Protein	0	root	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	nonmyeloid	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ABSTRACT	_	_	NN	O	-1	none	_	_
3	TRUNCATED	_	_	VBD	O	-1	none	_	_
4	AT	_	_	IN	O	-1	none	_	_
5	400	_	_	CD	O	-1	none	_	_
6	WORDS	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_

1	p70	_	_	NN	Protein	4	multitoken	_	_
2	(	_	_	-LRB-	Protein	4	multitoken	_	_
3	s6k	_	_	NN	Protein	4	multitoken	_	_
4	)	_	_	-RRB-	Protein	0	root	_	_
5	integrates	_	_	VBZ	O	-1	none	_	_
6	phosphatidylinositol	_	_	NN	O	-1	none	_	_
7	3-kinase	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	rapamycin	_	_	NN	O	-1	none	_	_
10	regulated	_	_	VBD	O	-1	none	_	_
11	signals	_	_	NNS	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	E2F	_	_	NN	O	-1	none	_	_
14	regulation	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	lymphocytes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	lymphocytes	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	hematopoietic	_	_	JJ	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	interleukin-2	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	uses	_	_	VBZ	O	-1	none	_	_
13	phosphatidylinositol	_	_	NN	O	-1	none	_	_
14	3-kinase	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	PI	_	_	NN	O	-1	none	_	_
17	3-kinase	_	_	NN	O	-1	none	_	_
18	)-induced	_	_	JJ	O	-1	none	_	_
19	signaling	_	_	NN	O	-1	none	_	_
20	pathways	_	_	NNS	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	regulate	_	_	VB	O	-1	none	_	_
23	E2F	_	_	NN	O	-1	none	_	_
24	transcriptional	_	_	JJ	O	-1	none	_	_
25	activity	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	critical	_	_	JJ	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	cycle	_	_	NN	O	-1	none	_	_
31	checkpoint	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	PI	_	_	NN	O	-1	none	_	_
2	3-kinase	_	_	NN	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	regulates	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p70	_	_	NN	Protein	11	multitoken	_	_
9	(	_	_	-LRB-	Protein	11	multitoken	_	_
10	s6k	_	_	NN	Protein	11	multitoken	_	_
11	)	_	_	-RRB-	Protein	0	root	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	40S	_	_	NN	O	-1	none	_	_
15	ribosomal	_	_	JJ	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	S6	_	_	NN	O	-1	none	_	_
18	kinase	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	response	_	_	NN	O	-1	none	_	_
22	that	_	_	WDT	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	abrogated	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	macrolide	_	_	NN	O	-1	none	_	_
28	rapamycin	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	immunosuppressive	_	_	JJ	O	-1	none	_	_
3	drug	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	known	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	prevent	_	_	VB	O	-1	none	_	_
8	T-cell	_	_	NN	O	-1	none	_	_
9	proliferation	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	precise	_	_	JJ	O	-1	none	_	_
14	point	_	_	NN	O	-1	none	_	_
15	at	_	_	IN	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	rapamycin	_	_	NN	O	-1	none	_	_
18	regulates	_	_	VBZ	O	-1	none	_	_
19	T-cell	_	_	NN	O	-1	none	_	_
20	cycle	_	_	NN	O	-1	none	_	_
21	progression	_	_	NN	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	yet	_	_	RB	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	be	_	_	VB	O	-1	none	_	_
26	elucidated	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	rapamycin	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	p70	_	_	NN	Protein	16	multitoken	_	_
14	(	_	_	-LRB-	Protein	16	multitoken	_	_
15	s6k	_	_	NN	Protein	16	multitoken	_	_
16	)	_	_	-RRB-	Protein	0	root	_	_
17	in	_	_	IN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	IL-2	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	PI	_	_	NN	O	-1	none	_	_
22	3-kinase	_	_	NN	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	E2Fs	_	_	NNS	O	-1	none	_	_
26	have	_	_	VBP	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	been	_	_	VBN	O	-1	none	_	_
29	characterized	_	_	VBN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	rapamycin	_	_	NN	O	-1	none	_	_
5	resistant	_	_	JJ	O	-1	none	_	_
6	mutant	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p70	_	_	NN	Protein	11	multitoken	_	_
9	(	_	_	-LRB-	Protein	11	multitoken	_	_
10	s6k	_	_	NN	Protein	11	multitoken	_	_
11	)	_	_	-RRB-	Protein	0	root	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	could	_	_	MD	O	-1	none	_	_
16	restore	_	_	VB	O	-1	none	_	_
17	rapamycin	_	_	NN	O	-1	none	_	_
18	suppressed	_	_	VBD	O	-1	none	_	_
19	E2F	_	_	NN	O	-1	none	_	_
20	responses	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	rapamycin	_	_	NN	O	-1	none	_	_
5	controlled	_	_	VBN	O	-1	none	_	_
6	processes	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	E2F	_	_	NN	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	appear	_	_	VBP	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	mediated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	p70	_	_	NN	Protein	19	multitoken	_	_
17	(	_	_	-LRB-	Protein	19	multitoken	_	_
18	s6k	_	_	NN	Protein	19	multitoken	_	_
19	)	_	_	-RRB-	Protein	0	root	_	_
20	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	rapamycin	_	_	NN	O	-1	none	_	_
5	resistant	_	_	JJ	O	-1	none	_	_
6	p70	_	_	NN	Protein	9	multitoken	_	_
7	(	_	_	-LRB-	Protein	9	multitoken	_	_
8	s6k	_	_	NN	Protein	9	multitoken	_	_
9	)	_	_	-RRB-	Protein	0	root	_	_
10	could	_	_	MD	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	rescue	_	_	VB	O	-1	none	_	_
13	rapamycin	_	_	NN	O	-1	none	_	_
14	inhibition	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	T-cell	_	_	NN	O	-1	none	_	_
17	cycle	_	_	NN	O	-1	none	_	_
18	entry	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	consistent	_	_	JJ	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	involvement	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	additional	_	_	JJ	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	rapamycin	_	_	NN	O	-1	none	_	_
28	sensitive	_	_	JJ	O	-1	none	_	_
29	pathways	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	control	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	T-cell	_	_	NN	O	-1	none	_	_
35	cycle	_	_	NN	O	-1	none	_	_
36	progression	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	results	_	_	NNS	O	-1	none	_	_
4	thus	_	_	RB	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	p70	_	_	NN	Protein	10	multitoken	_	_
8	(	_	_	-LRB-	Protein	10	multitoken	_	_
9	s6k	_	_	NN	Protein	10	multitoken	_	_
10	)	_	_	-RRB-	Protein	0	root	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	able	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	regulate	_	_	VB	O	-1	none	_	_
15	E2F	_	_	NN	O	-1	none	_	_
16	transcriptional	_	_	JJ	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	provide	_	_	VB	O	-1	none	_	_
20	direct	_	_	JJ	O	-1	none	_	_
21	evidence	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	first	_	_	JJ	O	-1	none	_	_
25	time	_	_	NN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	link	_	_	NN	O	-1	none	_	_
29	between	_	_	IN	O	-1	none	_	_
30	IL-2	_	_	NN	Protein	-1	none	_	_
31	receptors	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	PI	_	_	NN	O	-1	none	_	_
34	3-kinase	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	p70	_	_	NN	Protein	40	multitoken	_	_
38	(	_	_	-LRB-	Protein	40	multitoken	_	_
39	s6k	_	_	NN	Protein	40	multitoken	_	_
40	)	_	_	-RRB-	Protein	0	root	_	_
41	that	_	_	WDT	O	-1	none	_	_
42	regulates	_	_	VBZ	O	-1	none	_	_
43	a	_	_	DT	O	-1	none	_	_
44	crucial	_	_	JJ	O	-1	none	_	_
45	G1	_	_	NN	O	-1	none	_	_
46	checkpoint	_	_	NN	O	-1	none	_	_
47	in	_	_	IN	O	-1	none	_	_
48	T	_	_	NN	O	-1	none	_	_
49	lymphocytes	_	_	NNS	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	Heterogeneous	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Epstein-Barr	_	_	JJ	O	-1	none	_	_
5	virus	_	_	NN	O	-1	none	_	_
6	latent	_	_	JJ	O	-1	none	_	_
7	proteins	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	endemic	_	_	JJ	O	-1	none	_	_
10	Burkitt	_	_	NN	O	-1	none	_	_
11	's	_	_	POS	O	-1	none	_	_
12	lymphoma	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Epstein-Barr	_	_	NNP	O	-1	none	_	_
2	virus	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	EBV	_	_	NN	O	-1	none	_	_
5	)-infected	_	_	JJ	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	may	_	_	MD	O	-1	none	_	_
8	sustain	_	_	VB	O	-1	none	_	_
9	three	_	_	CD	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	forms	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	virus	_	_	NN	O	-1	none	_	_
14	latency	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	lymphoblastoid	_	_	JJ	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	lines	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	six	_	_	CD	O	-1	none	_	_
7	EBV	_	_	NN	O	-1	none	_	_
8	encoded	_	_	VBN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	antigens	_	_	NNS	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	EBNA1	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	2	_	_	CD	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	3A	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	3B	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	3C	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	-LP	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	three	_	_	CD	O	-1	none	_	_
26	latent	_	_	JJ	O	-1	none	_	_
27	membrane	_	_	NN	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	LMP1	_	_	NN	Protein	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	2A	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	2B	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	two	_	_	CD	O	-1	none	_	_
39	nuclear	_	_	JJ	O	-1	none	_	_
40	RNAs	_	_	NNS	O	-1	none	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	EBERs	_	_	NNS	O	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	are	_	_	VBP	O	-1	none	_	_
45	expressed	_	_	VBN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	form	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	latency	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	termed	_	_	VBN	O	-1	none	_	_
7	latency	_	_	NN	O	-1	none	_	_
8	III	_	_	CD	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	encountered	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	some	_	_	DT	O	-1	none	_	_
15	posttransplant	_	_	JJ	O	-1	none	_	_
16	lymphoproliferative	_	_	JJ	O	-1	none	_	_
17	disorders	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	EBV	_	_	NN	O	-1	none	_	_
3	positive	_	_	JJ	O	-1	none	_	_
4	cases	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Hodgkin	_	_	NN	O	-1	none	_	_
7	's	_	_	POS	O	-1	none	_	_
8	disease	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	EBERs	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	EBNA1	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	LMPs	_	_	NNS	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	expressed	_	_	VBN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	latency	_	_	NN	O	-1	none	_	_
22	II	_	_	CD	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	whereas	_	_	IN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	Burkitt	_	_	NN	O	-1	none	_	_
28	's	_	_	POS	O	-1	none	_	_
29	lymphoma	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	BL	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	only	_	_	RB	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	EBERs	_	_	NNS	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	EBNA1	_	_	NN	Protein	-1	none	_	_
38	have	_	_	VBP	O	-1	none	_	_
39	been	_	_	VBN	O	-1	none	_	_
40	detected	_	_	VBN	O	-1	none	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	latency	_	_	NN	O	-1	none	_	_
43	I	_	_	PRP	O	-1	none	_	_
44	)	_	_	-RRB-	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	studied	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	EBV	_	_	NN	O	-1	none	_	_
8	proteins	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	17	_	_	CD	O	-1	none	_	_
11	cases	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	EBV	_	_	NN	O	-1	none	_	_
14	positive	_	_	JJ	O	-1	none	_	_
15	endemic	_	_	JJ	O	-1	none	_	_
16	BL	_	_	NN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	immunohistology	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	LMP1	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	seen	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	variable	_	_	JJ	O	-1	none	_	_
8	proportions	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	tumor	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	two	_	_	CD	O	-1	none	_	_
14	cases	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	EBNA2	_	_	NN	Protein	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	detected	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	some	_	_	DT	O	-1	none	_	_
21	tumor	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	three	_	_	CD	O	-1	none	_	_
25	other	_	_	JJ	O	-1	none	_	_
26	cases	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Also	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	BZLF1	_	_	NN	Protein	6	multitoken	_	_
5	trans-activator	_	_	NN	Protein	6	multitoken	_	_
6	protein	_	_	NN	Protein	0	root	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	few	_	_	JJ	O	-1	none	_	_
12	tumor	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	6	_	_	CD	O	-1	none	_	_
16	cases	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	indicating	_	_	VBG	O	-1	none	_	_
19	entry	_	_	NN	O	-1	none	_	_
20	into	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	lytic	_	_	JJ	O	-1	none	_	_
23	cycle	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	phenotypic	_	_	JJ	O	-1	none	_	_
3	drift	_	_	NN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	latency	_	_	NN	O	-1	none	_	_
6	I	_	_	CD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	latency	_	_	NN	O	-1	none	_	_
9	III	_	_	CD	O	-1	none	_	_
10	has	_	_	VBZ	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	observed	_	_	VBN	O	-1	none	_	_
13	previously	_	_	RB	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	some	_	_	DT	O	-1	none	_	_
16	BL	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	lines	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	similar	_	_	JJ	O	-1	none	_	_
7	phenomenon	_	_	NN	O	-1	none	_	_
8	may	_	_	MD	O	-1	none	_	_
9	occur	_	_	VB	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	BL	_	_	NN	O	-1	none	_	_
12	in	_	_	FW	O	-1	none	_	_
13	vivo	_	_	FW	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	indicate	_	_	VBP	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	operational	_	_	JJ	O	-1	none	_	_
19	definition	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	EBV	_	_	NN	O	-1	none	_	_
22	latencies	_	_	NNS	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	not	_	_	RB	O	-1	none	_	_
25	easily	_	_	RB	O	-1	none	_	_
26	applied	_	_	VBN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	tumors	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Jeg-3	_	_	NNP	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	choriocarcinoma	_	_	NN	O	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	immunosuppression	_	_	NN	O	-1	none	_	_
6	:	_	_	:	O	-1	none	_	_
7	downregulation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	interleukin-2	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	interleukin-2	_	_	NN	Protein	13	multitoken	_	_
12	receptor	_	_	NN	Protein	13	multitoken	_	_
13	alpha-chain	_	_	NN	Protein	0	root	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	its	_	_	PRP$	O	-1	none	_	_
17	Jak	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Stat	_	_	NN	O	-1	none	_	_
20	signaling	_	_	NN	O	-1	none	_	_
21	pathway	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	PROBLEM	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	immunosuppressive	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	immunosuppression	_	_	NN	O	-1	none	_	_
10	inducing	_	_	VBG	O	-1	none	_	_
11	capacities	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Jeg-3	_	_	NN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	choriocarcinoma	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	line	_	_	NN	O	-1	none	_	_
18	supernatants	_	_	NNS	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	HCSs	_	_	NNS	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	are	_	_	VBP	O	-1	none	_	_
23	not	_	_	RB	O	-1	none	_	_
24	yet	_	_	RB	O	-1	none	_	_
25	completely	_	_	RB	O	-1	none	_	_
26	understood	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	METHOD	_	_	NN	O	-1	none	_	_
2	OF	_	_	IN	O	-1	none	_	_
3	STUDY	_	_	NN	O	-1	none	_	_
4	:	_	_	:	O	-1	none	_	_
5	For	_	_	IN	O	-1	none	_	_
6	assessment	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IL	_	_	NN	O	-1	none	_	_
9	production	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	whole	_	_	JJ	O	-1	none	_	_
12	peripheral	_	_	JJ	O	-1	none	_	_
13	venous	_	_	JJ	O	-1	none	_	_
14	blood	_	_	NN	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	healthy	_	_	JJ	O	-1	none	_	_
17	donors	_	_	NNS	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	stimulated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	phorbol-myristate-acetate	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	ionomycine	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Secretion	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	ILs	_	_	NNS	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	blocked	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	monensine	_	_	NN	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	Intracellular	_	_	JJ	O	-1	none	_	_
2	ILs	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	analyzed	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	flow	_	_	NN	O	-1	none	_	_
7	cytometry	_	_	NN	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	For	_	_	IN	O	-1	none	_	_
2	IL-2R	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	signaling	_	_	NN	O	-1	none	_	_
5	pathway	_	_	NN	O	-1	none	_	_
6	molecule	_	_	NN	O	-1	none	_	_
7	analysis	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	peripheral	_	_	JJ	O	-1	none	_	_
10	blood	_	_	NN	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	stimulated	_	_	VBN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	phytohemagglutinin	_	_	NN	Protein	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	PHA	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	IL-2R	_	_	NNP	O	-1	none	_	_
2	chains	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	measured	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	flow	_	_	NN	O	-1	none	_	_
7	cytometry	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	Jaks	_	_	NNP	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Stats	_	_	NNS	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	sodium	_	_	NN	O	-1	none	_	_
15	dodecyl	_	_	NN	O	-1	none	_	_
16	sulfate	_	_	NN	O	-1	none	_	_
17	polyacrylamide	_	_	NN	O	-1	none	_	_
18	gel	_	_	NN	O	-1	none	_	_
19	electrophoresis	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	SDS-PAGE	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	Western	_	_	NN	O	-1	none	_	_
25	blot	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	IFN-gamma	_	_	NN	Protein	-1	none	_	_
2	production	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	strongly	_	_	RB	O	-1	none	_	_
5	decreased	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	HCSs	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	some	_	_	DT	O	-1	none	_	_
10	cases	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	others	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	50	_	_	CD	O	-1	none	_	_
2	%	_	_	NN	O	-1	none	_	_
3	HCS	_	_	NN	O	-1	none	_	_
4	downregulates	_	_	VBZ	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	alpha-chain	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	slightly	_	_	RB	O	-1	none	_	_
9	upregulates	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	beta-chain	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Jak1	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Jak3	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	Stat1	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	Stat3	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	Stat5	_	_	NN	Protein	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	suppressed	_	_	VBN	O	-1	none	_	_
14	approximately	_	_	RB	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	below	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	level	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	unstimulated	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	HCS	_	_	NN	O	-1	none	_	_
4	forcefully	_	_	RB	O	-1	none	_	_
5	blocks	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	;	_	_	:	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	IL-2R	_	_	NN	Protein	13	multitoken	_	_
13	alpha-chain	_	_	NN	Protein	0	root	_	_
14	;	_	_	:	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	Jak1	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	Jak3	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	Stat1	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	Stat3	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	Stat5	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	observed	_	_	JJ	O	-1	none	_	_
3	phenomena	_	_	NNS	O	-1	none	_	_
4	might	_	_	MD	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	caused	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	downregulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	IL-2R	_	_	NN	O	-1	none	_	_
12	regulation	_	_	NN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	might	_	_	MD	O	-1	none	_	_
17	play	_	_	VB	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	key	_	_	JJ	O	-1	none	_	_
20	role	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	expansion	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	choriocarcinoma	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	possibly	_	_	RB	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	survival	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	fetal	_	_	JJ	O	-1	none	_	_
35	allograft	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Constitutively	_	_	RB	O	-1	none	_	_
2	activated	_	_	VBN	O	-1	none	_	_
3	Jak-STAT	_	_	NN	O	-1	none	_	_
4	pathway	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	transformed	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	HTLV-I	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	lymphotropic	_	_	JJ	O	-1	none	_	_
5	virus	_	_	NN	O	-1	none	_	_
6	I	_	_	PRP	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	etiological	_	_	JJ	O	-1	none	_	_
13	agent	_	_	NN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	adult	_	_	JJ	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	leukemia	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	tropical	_	_	JJ	O	-1	none	_	_
21	spastic	_	_	JJ	O	-1	none	_	_
22	paraparesis	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	also	_	_	RB	O	-1	none	_	_
25	termed	_	_	VBN	O	-1	none	_	_
26	HTLV-I-associated	_	_	JJ	O	-1	none	_	_
27	myelopathy	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	Jak	_	_	NN	O	-1	none	_	_
4	kinases	_	_	NNS	O	-1	none	_	_
5	Jak1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	Jak3	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transducer	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	activator	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	proteins	_	_	NNS	O	-1	none	_	_
17	Stat3	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Stat5	_	_	NN	Protein	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	activated	_	_	VBN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	normal	_	_	JJ	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	response	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	IL-2	_	_	NN	Protein	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	this	_	_	DT	O	-1	none	_	_
32	signaling	_	_	NN	O	-1	none	_	_
33	pathway	_	_	NN	O	-1	none	_	_
34	was	_	_	VBD	O	-1	none	_	_
35	constitutively	_	_	RB	O	-1	none	_	_
36	activated	_	_	VBN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	HTLV-I-transformed	_	_	JJ	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	immunodeficiency	_	_	NN	O	-1	none	_	_
3	viruses	_	_	NNS	O	-1	none	_	_
4	containing	_	_	VBG	O	-1	none	_	_
5	heterologous	_	_	JJ	O	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	promoters	_	_	NNS	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	replication	_	_	NN	O	-1	none	_	_
11	competent	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	exhibit	_	_	VBP	O	-1	none	_	_
14	different	_	_	JJ	O	-1	none	_	_
15	lymphocyte	_	_	NN	O	-1	none	_	_
16	tropisms	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	immunodeficiency	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	HIV	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	type	_	_	NN	O	-1	none	_	_
9	1	_	_	CD	O	-1	none	_	_
10	long	_	_	JJ	O	-1	none	_	_
11	terminal	_	_	JJ	O	-1	none	_	_
12	repeat	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	LTR	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	contains	_	_	VBZ	O	-1	none	_	_
17	binding	_	_	VBG	O	-1	none	_	_
18	sites	_	_	NNS	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	kappa	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	NF-kappa	_	_	NN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	constitutively	_	_	RB	O	-1	none	_	_
31	expressed	_	_	VBN	O	-1	none	_	_
32	transcription	_	_	NN	O	-1	none	_	_
33	factor	_	_	NN	O	-1	none	_	_
34	Sp1	_	_	NN	Protein	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	both	_	_	DT	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	which	_	_	WDT	O	-1	none	_	_
39	are	_	_	VBP	O	-1	none	_	_
40	highly	_	_	RB	O	-1	none	_	_
41	conserved	_	_	VBN	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	HIV	_	_	NN	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	simian	_	_	JJ	O	-1	none	_	_
46	immunodeficiency	_	_	NN	O	-1	none	_	_
47	virus	_	_	NN	O	-1	none	_	_
48	isolates	_	_	NNS	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	delineate	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	motifs	_	_	NNS	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	replicative	_	_	JJ	O	-1	none	_	_
11	capacity	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	HIV	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	explore	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	possibility	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	extending	_	_	VBG	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	virus	_	_	NN	O	-1	none	_	_
23	host	_	_	NN	O	-1	none	_	_
24	range	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	known	_	_	VBN	O	-1	none	_	_
27	heterologous	_	_	JJ	O	-1	none	_	_
28	enhancer	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	promoters	_	_	NNS	O	-1	none	_	_
31	were	_	_	VBD	O	-1	none	_	_
32	inserted	_	_	VBN	O	-1	none	_	_
33	into	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	HIV-1	_	_	NN	O	-1	none	_	_
36	LTR	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	place	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	NF-kappa	_	_	NN	O	-1	none	_	_
42	B	_	_	NN	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	Sp1	_	_	NN	Protein	-1	none	_	_
45	binding	_	_	NN	O	-1	none	_	_
46	sites	_	_	NNS	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	substitutions	_	_	NNS	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	viral	_	_	JJ	O	-1	none	_	_
8	replication	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	transfected	_	_	VBN	O	-1	none	_	_
11	HeLa	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	HIV	_	_	NN	O	-1	none	_	_
16	infection	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	peripheral	_	_	JJ	O	-1	none	_	_
20	blood	_	_	NN	O	-1	none	_	_
21	lymphocytes	_	_	NNS	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	continuous	_	_	JJ	O	-1	none	_	_
24	T-leukemia	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	lines	_	_	NNS	O	-1	none	_	_
27	were	_	_	VBD	O	-1	none	_	_
28	evaluated	_	_	VBN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	HIVs	_	_	NNS	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	which	_	_	WDT	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	NF-kappa	_	_	NN	O	-1	none	_	_
6	B/Sp1	_	_	NN	Protein	-1	none	_	_
7	enhancer	_	_	NN	O	-1	none	_	_
8	plus	_	_	CC	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	downstream	_	_	JJ	O	-1	none	_	_
11	TATA	_	_	NN	O	-1	none	_	_
12	element	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	replaced	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	heterologous	_	_	JJ	O	-1	none	_	_
17	enhancer	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	promoters	_	_	NNS	O	-1	none	_	_
20	were	_	_	VBD	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	constructed	_	_	VBN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Viruses	_	_	NNS	O	-1	none	_	_
2	containing	_	_	VBG	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	cytomegalovirus	_	_	NN	O	-1	none	_	_
6	immediate-early	_	_	JJ	O	-1	none	_	_
7	enhancer	_	_	NN	O	-1	none	_	_
8	exhibited	_	_	VBD	O	-1	none	_	_
9	infectious	_	_	JJ	O	-1	none	_	_
10	kinetics	_	_	NNS	O	-1	none	_	_
11	similar	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	that	_	_	DT	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	wild-type	_	_	JJ	O	-1	none	_	_
16	HIV	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	peripheral	_	_	JJ	O	-1	none	_	_
21	blood	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	AA2	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	replicated	_	_	VBD	O	-1	none	_	_
28	less	_	_	RBR	O	-1	none	_	_
29	efficiently	_	_	RB	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	H9	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	CEM	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	heterologous	_	_	JJ	O	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	elements	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	capable	_	_	JJ	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	restoring	_	_	VBG	O	-1	none	_	_
12	Tat	_	_	NN	Protein	-1	none	_	_
13	responsiveness	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	HIV	_	_	NN	O	-1	none	_	_
17	LTR	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	context	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	directing	_	_	VBG	O	-1	none	_	_
23	reporter	_	_	NN	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	as	_	_	RB	O	-1	none	_	_
27	well	_	_	RB	O	-1	none	_	_
28	as	_	_	IN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	production	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	infectious	_	_	JJ	O	-1	none	_	_
34	progeny	_	_	NN	O	-1	none	_	_
35	virions	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Prolactin	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	interleukin-2	_	_	NN	O	-1	none	_	_
4	receptors	_	_	NNS	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	signal	_	_	NN	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	MGF-STAT5-like	_	_	JJ	O	-1	none	_	_
12	transcription	_	_	NN	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	surface	_	_	NN	O	-1	none	_	_
4	receptors	_	_	NNS	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	PRL	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	interleukin-2	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	structurally	_	_	RB	O	-1	none	_	_
14	distinct	_	_	JJ	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	share	_	_	NN	O	-1	none	_	_
18	regulatory	_	_	JJ	O	-1	none	_	_
19	tasks	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	They	_	_	PRP	O	-1	none	_	_
2	can	_	_	MD	O	-1	none	_	_
3	stimulate	_	_	VB	O	-1	none	_	_
4	proliferation	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	activate	_	_	VBP	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	over-lapping	_	_	JJ	O	-1	none	_	_
10	sets	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	genes	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	PRL	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	IL-2	_	_	NN	O	-1	none	_	_
4	receptor	_	_	NN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	both	_	_	DT	O	-1	none	_	_
8	linked	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	Jak	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Stat	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	signal	_	_	NN	O	-1	none	_	_
16	transducer	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	activator	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	pathway	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	ability	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	PRL	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	activate	_	_	VB	O	-1	none	_	_
11	Stat	_	_	NN	O	-1	none	_	_
12	proteins	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	different	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	lines	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	comparison	_	_	NN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	Stat	_	_	NN	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	induced	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	interferon-gamma	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	PRL	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	IL-6	_	_	NN	Protein	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	T47D	_	_	NN	O	-1	none	_	_
17	mammary	_	_	JJ	O	-1	none	_	_
18	tumor	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	made	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	closely	_	_	RB	O	-1	none	_	_
5	related	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	mammary	_	_	JJ	O	-1	none	_	_
8	gland	_	_	NN	O	-1	none	_	_
9	factor-Stat5	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	rapidly	_	_	RB	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	upon	_	_	IN	O	-1	none	_	_
14	interaction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	PRL	_	_	NN	Protein	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	their	_	_	PRP$	O	-1	none	_	_
21	respective	_	_	JJ	O	-1	none	_	_
22	receptors	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	second	_	_	JJ	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	related	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	Stat1	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	observed	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	emphasize	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	role	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	PRL	_	_	NN	Protein	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	regulator	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	immune	_	_	JJ	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	indicate	_	_	VBP	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	Stat	_	_	NN	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	mammary	_	_	JJ	O	-1	none	_	_
22	gland	_	_	NN	O	-1	none	_	_
23	factor-Stat5	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	Stat1	_	_	NN	O	-1	none	_	_
26	play	_	_	VBP	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	role	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	regulation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	gene	_	_	NN	O	-1	none	_	_
34	expression	_	_	NN	O	-1	none	_	_
35	during	_	_	IN	O	-1	none	_	_
36	T	_	_	NN	O	-1	none	_	_
37	cell	_	_	NN	O	-1	none	_	_
38	development	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Modulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	CD28	_	_	NN	Protein	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	:	_	_	:	O	-1	none	_	_
6	distinct	_	_	JJ	O	-1	none	_	_
7	regulatory	_	_	JJ	O	-1	none	_	_
8	pathways	_	_	NNS	O	-1	none	_	_
9	during	_	_	IN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	replicative	_	_	JJ	O	-1	none	_	_
13	senescence	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	costimulatory	_	_	JJ	O	-1	none	_	_
3	molecule	_	_	NN	O	-1	none	_	_
4	CD28	_	_	NN	Protein	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	restricted	_	_	JJ	O	-1	none	_	_
8	tissue	_	_	NN	O	-1	none	_	_
9	distribution	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	expressed	_	_	VBN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	some	_	_	DT	O	-1	none	_	_
18	plasmacytoma	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	CD28	_	_	NN	Protein	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	constitutively	_	_	RB	O	-1	none	_	_
5	expressed	_	_	VBN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	its	_	_	PRP$	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	transiently	_	_	RB	O	-1	none	_	_
11	down-regulated	_	_	VBN	O	-1	none	_	_
12	following	_	_	VBG	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	declines	_	_	VBZ	O	-1	none	_	_
18	progressively	_	_	RB	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	in	_	_	FW	O	-1	none	_	_
21	vitro	_	_	FW	O	-1	none	_	_
22	senescence	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vivo	_	_	FW	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	CD8+	_	_	JJ	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	less	_	_	RBR	O	-1	none	_	_
10	frequently	_	_	RB	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	CD4+	_	_	JJ	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	completely	_	_	RB	O	-1	none	_	_
17	lose	_	_	VB	O	-1	none	_	_
18	CD28	_	_	NN	Protein	-1	none	_	_
19	surface	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	during	_	_	IN	O	-1	none	_	_
22	chronic	_	_	JJ	O	-1	none	_	_
23	infections	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	aging	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	correlates	_	_	VBZ	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	changes	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	activities	_	_	NNS	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	two	_	_	CD	O	-1	none	_	_
12	motifs	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	alpha	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	beta	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	within	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	CD28	_	_	NN	Protein	-1	none	_	_
22	minimal	_	_	JJ	O	-1	none	_	_
23	promoter	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	complexes	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	coordinately	_	_	RB	O	-1	none	_	_
5	expressed	_	_	VBN	O	-1	none	_	_
6	except	_	_	IN	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	replicative	_	_	JJ	O	-1	none	_	_
9	senescence	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	characterized	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	down-modulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	site	_	_	NN	O	-1	none	_	_
19	beta-	_	_	NN	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	site	_	_	NN	O	-1	none	_	_
23	alpha	_	_	NN	O	-1	none	_	_
24	binding	_	_	NN	O	-1	none	_	_
25	activities	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	induces	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	parallel	_	_	JJ	O	-1	none	_	_
10	decline	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	both	_	_	CC	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	alpha-	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	beta	_	_	NN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	activities	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	new	_	_	JJ	O	-1	none	_	_
3	member	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	leucine	_	_	NN	O	-1	none	_	_
7	zipper	_	_	NN	O	-1	none	_	_
8	class	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	binds	_	_	VBZ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	HLA	_	_	NN	Protein	17	multitoken	_	_
16	DR	_	_	NN	Protein	17	multitoken	_	_
17	alpha	_	_	NN	Protein	0	root	_	_
18	promoter	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	mutants	_	_	NNS	O	-1	none	_	_
3	derived	_	_	VBN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	transformed	_	_	VBN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	lines	_	_	NNS	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	defective	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	expressing	_	_	VBG	O	-1	none	_	_
14	major	_	_	JJ	O	-1	none	_	_
15	histocompatibility	_	_	NN	O	-1	none	_	_
16	complex	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	MHC	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	class	_	_	NN	O	-1	none	_	_
21	II	_	_	CD	O	-1	none	_	_
22	genes	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	failure	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	express	_	_	VB	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	class	_	_	NN	O	-1	none	_	_
7	II	_	_	CD	O	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	least	_	_	JJS	O	-1	none	_	_
12	one	_	_	CD	O	-1	none	_	_
13	such	_	_	JJ	O	-1	none	_	_
14	mutant	_	_	NN	O	-1	none	_	_
15	line	_	_	NN	O	-1	none	_	_
16	has	_	_	VBZ	O	-1	none	_	_
17	been	_	_	VBN	O	-1	none	_	_
18	mapped	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	MHC	_	_	NN	O	-1	none	_	_
22	class	_	_	NN	O	-1	none	_	_
23	II	_	_	CD	O	-1	none	_	_
24	X	_	_	NN	O	-1	none	_	_
25	box	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	conserved	_	_	VBN	O	-1	none	_	_
29	transcriptional	_	_	JJ	O	-1	none	_	_
30	element	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	promoter	_	_	NN	O	-1	none	_	_
34	region	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	complementary	_	_	JJ	O	-1	none	_	_
3	DNA	_	_	NN	O	-1	none	_	_
4	encoding	_	_	VBG	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	human	_	_	NN	Protein	14	multitoken	_	_
11	X	_	_	NN	Protein	14	multitoken	_	_
12	box	_	_	NN	Protein	14	multitoken	_	_
13	binding	_	_	NN	Protein	14	multitoken	_	_
14	protein	_	_	NN	Protein	0	root	_	_
15	,	_	_	,	O	-1	none	_	_
16	hXBP-1	_	_	NN	Protein	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	whose	_	_	WP$	O	-1	none	_	_
19	target	_	_	NN	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	DR	_	_	NN	Protein	24	multitoken	_	_
24	alpha	_	_	NN	Protein	0	root	_	_
25	X	_	_	NN	O	-1	none	_	_
26	box	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	3	_	_	CD	O	-1	none	_	_
30	'	_	_	''	O	-1	none	_	_
31	flanking	_	_	JJ	O	-1	none	_	_
32	region	_	_	NN	O	-1	none	_	_
33	has	_	_	VBZ	O	-1	none	_	_
34	now	_	_	RB	O	-1	none	_	_
35	been	_	_	VBN	O	-1	none	_	_
36	cloned	_	_	VBN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	complementary	_	_	JJ	O	-1	none	_	_
3	DNA	_	_	NN	O	-1	none	_	_
4	encoded	_	_	VBD	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	structural	_	_	JJ	O	-1	none	_	_
9	similarities	_	_	NNS	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	c-jun	_	_	NN	Protein	-1	none	_	_
13	proto-oncogene	_	_	NN	O	-1	none	_	_
14	product	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	target	_	_	NN	O	-1	none	_	_
19	sequence	_	_	NN	O	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	closely	_	_	RB	O	-1	none	_	_
22	related	_	_	JJ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	palindromic	_	_	JJ	O	-1	none	_	_
26	target	_	_	NN	O	-1	none	_	_
27	sequence	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	c-jun	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Mutation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	hXBP-1	_	_	NN	Protein	-1	none	_	_
5	DNA	_	_	NN	O	-1	none	_	_
6	target	_	_	NN	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	decreased	_	_	VBD	O	-1	none	_	_
9	DR	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	in	_	_	FW	O	-1	none	_	_
14	vivo	_	_	FW	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	hXBP-1	_	_	NN	Protein	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	acts	_	_	VBZ	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Synergistic	_	_	JJ	O	-1	none	_	_
2	interactions	_	_	NNS	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	overlapping	_	_	VBG	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	sites	_	_	NNS	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	serum	_	_	NN	Protein	11	multitoken	_	_
10	response	_	_	NN	Protein	11	multitoken	_	_
11	factor	_	_	NN	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	ELK-1	_	_	NN	Protein	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	mediate	_	_	VBP	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	basal	_	_	JJ	O	-1	none	_	_
18	enhancement	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	phorbol	_	_	NN	O	-1	none	_	_
21	ester	_	_	NN	O	-1	none	_	_
22	responsiveness	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	primate	_	_	JJ	O	-1	none	_	_
25	cytomegalovirus	_	_	NN	O	-1	none	_	_
26	major	_	_	JJ	O	-1	none	_	_
27	immediate-early	_	_	JJ	O	-1	none	_	_
28	promoters	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	monocyte	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	T-lymphocyte	_	_	NN	O	-1	none	_	_
33	cell	_	_	NN	O	-1	none	_	_
34	types	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Cytomegalovirus	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	CMV	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	infection	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	nonpermissive	_	_	JJ	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	persistent	_	_	JJ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	many	_	_	JJ	O	-1	none	_	_
12	lymphoid	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	myeloid	_	_	JJ	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	types	_	_	NNS	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	can	_	_	MD	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	activated	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	differentiated	_	_	VBN	O	-1	none	_	_
23	macrophages	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	shown	_	_	VBN	O	-1	none	_	_
4	elsewhere	_	_	RB	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	both	_	_	CC	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	major	_	_	JJ	O	-1	none	_	_
9	immediate-early	_	_	JJ	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	MIE	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	lytic	_	_	JJ	O	-1	none	_	_
16	cycle	_	_	NN	O	-1	none	_	_
17	infectious	_	_	JJ	O	-1	none	_	_
18	progeny	_	_	NN	O	-1	none	_	_
19	virus	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	can	_	_	MD	O	-1	none	_	_
22	be	_	_	VB	O	-1	none	_	_
23	induced	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	otherwise	_	_	RB	O	-1	none	_	_
26	nonpermissive	_	_	JJ	O	-1	none	_	_
27	monocyte	_	_	NN	O	-1	none	_	_
28	like	_	_	IN	O	-1	none	_	_
29	U-937	_	_	NN	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	cultures	_	_	NNS	O	-1	none	_	_
32	infected	_	_	VBN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	either	_	_	CC	O	-1	none	_	_
35	human	_	_	NN	O	-1	none	_	_
36	CMV	_	_	NN	O	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	HCMV	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	or	_	_	CC	O	-1	none	_	_
41	simian	_	_	JJ	O	-1	none	_	_
42	CMV	_	_	NN	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	SCMV	_	_	NN	O	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	by	_	_	IN	O	-1	none	_	_
47	treatment	_	_	NN	O	-1	none	_	_
48	with	_	_	IN	O	-1	none	_	_
49	the	_	_	DT	O	-1	none	_	_
50	phorbol	_	_	NN	O	-1	none	_	_
51	ester	_	_	NN	O	-1	none	_	_
52	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
53	(	_	_	-LRB-	O	-1	none	_	_
54	TPA	_	_	NN	O	-1	none	_	_
55	)	_	_	-RRB-	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	Two	_	_	CD	O	-1	none	_	_
2	multicopy	_	_	JJ	O	-1	none	_	_
3	basal	_	_	JJ	O	-1	none	_	_
4	enhancer	_	_	NN	O	-1	none	_	_
5	motifs	_	_	NNS	O	-1	none	_	_
6	within	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	SCMV	_	_	NNP	O	-1	none	_	_
9	MIE	_	_	NNP	O	-1	none	_	_
10	enhancer	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	namely	_	_	RB	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	11	_	_	CD	O	-1	none	_	_
15	copies	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	16-bp	_	_	JJ	O	-1	none	_	_
19	cyclic	_	_	JJ	O	-1	none	_	_
20	AMP	_	_	NN	O	-1	none	_	_
21	response	_	_	NN	O	-1	none	_	_
22	element	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	CRE	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	3	_	_	CD	O	-1	none	_	_
28	copies	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	novel	_	_	JJ	O	-1	none	_	_
31	17-bp	_	_	JJ	O	-1	none	_	_
32	serum	_	_	NN	Protein	34	multitoken	_	_
33	response	_	_	NN	Protein	34	multitoken	_	_
34	factor	_	_	NN	Protein	0	root	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	SRF	_	_	NN	Protein	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	binding	_	_	VBG	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	referred	_	_	VBN	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	as	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	SNE	_	_	NN	O	-1	none	_	_
45	(	_	_	-LRB-	O	-1	none	_	_
46	SRF	_	_	NN	Protein	-1	none	_	_
47	and	_	_	CC	O	-1	none	_	_
48	NFkappaB	_	_	NN	O	-1	none	_	_
49	like	_	_	IN	O	-1	none	_	_
50	element	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	as	_	_	RB	O	-1	none	_	_
54	well	_	_	RB	O	-1	none	_	_
55	as	_	_	IN	O	-1	none	_	_
56	four	_	_	CD	O	-1	none	_	_
57	classical	_	_	JJ	O	-1	none	_	_
58	NFkappaB	_	_	NN	O	-1	none	_	_
59	sites	_	_	NNS	O	-1	none	_	_
60	within	_	_	IN	O	-1	none	_	_
61	the	_	_	DT	O	-1	none	_	_
62	HCMV	_	_	NN	O	-1	none	_	_
63	version	_	_	NN	O	-1	none	_	_
64	,	_	_	,	O	-1	none	_	_
65	contribute	_	_	VBP	O	-1	none	_	_
66	to	_	_	TO	O	-1	none	_	_
67	TPA	_	_	NN	O	-1	none	_	_
68	responsiveness	_	_	NN	O	-1	none	_	_
69	in	_	_	IN	O	-1	none	_	_
70	transient	_	_	JJ	O	-1	none	_	_
71	assays	_	_	NNS	O	-1	none	_	_
72	in	_	_	IN	O	-1	none	_	_
73	monocyte	_	_	NN	O	-1	none	_	_
74	and	_	_	CC	O	-1	none	_	_
75	T-cell	_	_	NN	O	-1	none	_	_
76	types	_	_	NNS	O	-1	none	_	_
77	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	SCMV	_	_	NN	O	-1	none	_	_
3	SNE	_	_	NN	O	-1	none	_	_
4	sites	_	_	NNS	O	-1	none	_	_
5	contain	_	_	VBP	O	-1	none	_	_
6	potential	_	_	JJ	O	-1	none	_	_
7	overlapping	_	_	VBG	O	-1	none	_	_
8	core	_	_	NN	O	-1	none	_	_
9	recognition	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	motifs	_	_	NNS	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	SRF	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	Rel	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	NFkappaB	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	ETS	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	YY1	_	_	NN	O	-1	none	_	_
23	class	_	_	NN	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	factors	_	_	NNS	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	fail	_	_	VBP	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	respond	_	_	VB	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	either	_	_	CC	O	-1	none	_	_
32	serum	_	_	NN	O	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	tumor	_	_	NN	Protein	37	multitoken	_	_
35	necrosis	_	_	NN	Protein	37	multitoken	_	_
36	factor	_	_	NN	Protein	37	multitoken	_	_
37	alpha	_	_	NN	Protein	0	root	_	_
38	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	evaluate	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	mechanism	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	TPA	_	_	NN	O	-1	none	_	_
9	responsiveness	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	SNE	_	_	NN	O	-1	none	_	_
13	motifs	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	related	_	_	JJ	O	-1	none	_	_
18	16-bp	_	_	JJ	O	-1	none	_	_
19	SEE	_	_	VBP	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	SRF	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	ETS	_	_	NN	O	-1	none	_	_
24	element	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	motif	_	_	NN	O	-1	none	_	_
27	found	_	_	VBN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	HCMV	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	chimpanzee	_	_	NN	O	-1	none	_	_
33	CMV	_	_	NN	O	-1	none	_	_
34	MIE	_	_	NN	O	-1	none	_	_
35	enhancers	_	_	NNS	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	we	_	_	PRP	O	-1	none	_	_
38	have	_	_	VBP	O	-1	none	_	_
39	examined	_	_	VBN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	functional	_	_	JJ	O	-1	none	_	_
42	responses	_	_	NNS	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	protein	_	_	NN	O	-1	none	_	_
45	binding	_	_	NN	O	-1	none	_	_
46	properties	_	_	NNS	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	multimerized	_	_	JJ	O	-1	none	_	_
49	wild-type	_	_	JJ	O	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	mutant	_	_	NN	O	-1	none	_	_
52	elements	_	_	NNS	O	-1	none	_	_
53	added	_	_	VBD	O	-1	none	_	_
54	upstream	_	_	JJ	O	-1	none	_	_
55	to	_	_	TO	O	-1	none	_	_
56	the	_	_	DT	O	-1	none	_	_
57	SCMV	_	_	NNP	O	-1	none	_	_
58	MIE	_	_	NNP	O	-1	none	_	_
59	or	_	_	CC	O	-1	none	_	_
60	simian	_	_	JJ	O	-1	none	_	_
61	virus	_	_	NN	O	-1	none	_	_
62	40	_	_	CD	O	-1	none	_	_
63	minimal	_	_	JJ	O	-1	none	_	_
64	promoter	_	_	NN	O	-1	none	_	_
65	regions	_	_	NNS	O	-1	none	_	_
66	in	_	_	IN	O	-1	none	_	_
67	the	_	_	DT	O	-1	none	_	_
68	U-937	_	_	NN	O	-1	none	_	_
69	,	_	_	,	O	-1	none	_	_
70	K-562	_	_	NN	O	-1	none	_	_
71	,	_	_	,	O	-1	none	_	_
72	HL-60	_	_	NN	O	-1	none	_	_
73	,	_	_	,	O	-1	none	_	_
74	THP-1	_	_	NN	O	-1	none	_	_
75	,	_	_	,	O	-1	none	_	_
76	and	_	_	CC	O	-1	none	_	_
77	Jurkat	_	_	NN	O	-1	none	_	_
78	cell	_	_	NN	O	-1	none	_	_
79	lines	_	_	NNS	O	-1	none	_	_
80	.	_	_	.	O	-1	none	_	_

1	Unlike	_	_	IN	O	-1	none	_	_
2	classical	_	_	JJ	O	-1	none	_	_
3	NFkappaB	_	_	NN	O	-1	none	_	_
4	sites	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	neither	_	_	CC	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	SNE	_	_	NN	O	-1	none	_	_
9	nor	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	SEE	_	_	VBP	O	-1	none	_	_
12	motif	_	_	NN	O	-1	none	_	_
13	responded	_	_	VBD	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	phosphatase	_	_	NN	O	-1	none	_	_
16	inhibition	_	_	NN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	okadaic	_	_	JJ	O	-1	none	_	_
19	acid	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	TPA	_	_	NN	O	-1	none	_	_
5	responsiveness	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	both	_	_	CC	O	-1	none	_	_
8	CMV	_	_	NN	O	-1	none	_	_
9	elements	_	_	NNS	O	-1	none	_	_
10	proved	_	_	VBD	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	involve	_	_	VB	O	-1	none	_	_
13	synergistic	_	_	JJ	O	-1	none	_	_
14	interactions	_	_	NNS	O	-1	none	_	_
15	between	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	core	_	_	NN	O	-1	none	_	_
18	SRF	_	_	NN	Protein	-1	none	_	_
19	binding	_	_	VBG	O	-1	none	_	_
20	site	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	CCATATATGG	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	adjacent	_	_	JJ	O	-1	none	_	_
27	inverted	_	_	JJ	O	-1	none	_	_
28	ETS	_	_	NN	O	-1	none	_	_
29	binding	_	_	NN	O	-1	none	_	_
30	motifs	_	_	NNS	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	TTCC	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	which	_	_	WDT	O	-1	none	_	_
36	correlated	_	_	VBD	O	-1	none	_	_
37	directly	_	_	RB	O	-1	none	_	_
38	with	_	_	IN	O	-1	none	_	_
39	formation	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	a	_	_	DT	O	-1	none	_	_
42	bound	_	_	JJ	O	-1	none	_	_
43	tripartite	_	_	NN	O	-1	none	_	_
44	complex	_	_	NN	O	-1	none	_	_
45	containing	_	_	VBG	O	-1	none	_	_
46	both	_	_	CC	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	cellular	_	_	JJ	O	-1	none	_	_
49	SRF	_	_	NN	Protein	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	ELK-1	_	_	NN	Protein	-1	none	_	_
52	proteins	_	_	NNS	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	complex	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	more	_	_	RBR	O	-1	none	_	_
6	abundant	_	_	JJ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	U-937	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	K-562	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	HeLa	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	extracts	_	_	NNS	O	-1	none	_	_
16	than	_	_	IN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	Raji	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	HF	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	BALB/c	_	_	NN	O	-1	none	_	_
23	3T3	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	HL-60	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	but	_	_	CC	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	binding	_	_	NN	O	-1	none	_	_
32	activity	_	_	NN	O	-1	none	_	_
33	was	_	_	VBD	O	-1	none	_	_
34	altered	_	_	VBN	O	-1	none	_	_
35	only	_	_	RB	O	-1	none	_	_
36	twofold	_	_	RB	O	-1	none	_	_
37	after	_	_	IN	O	-1	none	_	_
38	TPA	_	_	NN	O	-1	none	_	_
39	treatment	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	40-fold	_	_	RB	O	-1	none	_	_
3	stimulation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	chloramphenicol	_	_	NN	Protein	6	multitoken	_	_
6	acetyltransferase	_	_	NN	Protein	0	root	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	mediated	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	four	_	_	CD	O	-1	none	_	_
11	tandem	_	_	JJ	O	-1	none	_	_
12	repeats	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	SNE	_	_	NN	O	-1	none	_	_
16	could	_	_	MD	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	induced	_	_	VBN	O	-1	none	_	_
19	within	_	_	IN	O	-1	none	_	_
20	2	_	_	CD	O	-1	none	_	_
21	h	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	up	_	_	IN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	250-fold	_	_	JJ	O	-1	none	_	_
27	within	_	_	IN	O	-1	none	_	_
28	6	_	_	CD	O	-1	none	_	_
29	h	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	after	_	_	IN	O	-1	none	_	_
32	addition	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	TPA	_	_	NN	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	DNA	_	_	NN	O	-1	none	_	_
37	transfected	_	_	VBN	O	-1	none	_	_
38	U-937	_	_	NN	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	indicating	_	_	VBG	O	-1	none	_	_
42	that	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	stimulation	_	_	NN	O	-1	none	_	_
45	appeared	_	_	VBD	O	-1	none	_	_
46	likely	_	_	JJ	O	-1	none	_	_
47	to	_	_	TO	O	-1	none	_	_
48	be	_	_	VB	O	-1	none	_	_
49	a	_	_	DT	O	-1	none	_	_
50	true	_	_	JJ	O	-1	none	_	_
51	protein	_	_	NN	O	-1	none	_	_
52	kinase	_	_	NN	O	-1	none	_	_
53	C	_	_	NN	O	-1	none	_	_
54	mediated	_	_	JJ	O	-1	none	_	_
55	signal	_	_	NN	O	-1	none	_	_
56	transduction	_	_	NN	O	-1	none	_	_
57	event	_	_	NN	O	-1	none	_	_
58	rather	_	_	RB	O	-1	none	_	_
59	than	_	_	IN	O	-1	none	_	_
60	a	_	_	DT	O	-1	none	_	_
61	differentiation	_	_	NN	O	-1	none	_	_
62	response	_	_	NN	O	-1	none	_	_
63	.	_	_	.	O	-1	none	_	_

1	Slight	_	_	JJ	O	-1	none	_	_
2	differences	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	sequence	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	core	_	_	NN	O	-1	none	_	_
9	SRF	_	_	NN	Protein	-1	none	_	_
10	binding	_	_	VBG	O	-1	none	_	_
11	site	_	_	NN	O	-1	none	_	_
12	compared	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	that	_	_	DT	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	classical	_	_	JJ	O	-1	none	_	_
18	c-Fos	_	_	NN	Protein	-1	none	_	_
19	promoter	_	_	NN	O	-1	none	_	_
20	serum	_	_	NN	O	-1	none	_	_
21	response	_	_	NN	O	-1	none	_	_
22	element	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	together	_	_	RB	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	differences	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	spacing	_	_	NN	O	-1	none	_	_
30	between	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	SRF	_	_	NN	Protein	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	ETS	_	_	NN	O	-1	none	_	_
35	motifs	_	_	NNS	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	appear	_	_	VBP	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	account	_	_	VB	O	-1	none	_	_
40	for	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	inability	_	_	NN	O	-1	none	_	_
43	of	_	_	IN	O	-1	none	_	_
44	the	_	_	DT	O	-1	none	_	_
45	SCMV	_	_	NN	O	-1	none	_	_
46	SNEs	_	_	NNS	O	-1	none	_	_
47	to	_	_	TO	O	-1	none	_	_
48	respond	_	_	VB	O	-1	none	_	_
49	to	_	_	TO	O	-1	none	_	_
50	serum	_	_	NN	O	-1	none	_	_
51	induction	_	_	NN	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	Osteoclast	_	_	NN	O	-1	none	_	_
2	markers	_	_	NNS	O	-1	none	_	_
3	accumulate	_	_	VBP	O	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	developing	_	_	VBG	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	peripheral	_	_	JJ	O	-1	none	_	_
10	blood	_	_	NN	O	-1	none	_	_
11	mononuclear	_	_	JJ	O	-1	none	_	_
12	precursors	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Recent	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	osteoclasts	_	_	NNS	O	-1	none	_	_
7	develop	_	_	VBP	O	-1	none	_	_
8	in	_	_	FW	O	-1	none	_	_
9	vitro	_	_	FW	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	hematopoietic	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	;	_	_	:	O	-1	none	_	_
14	however	_	_	RB	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	special	_	_	JJ	O	-1	none	_	_
17	cultures	_	_	NNS	O	-1	none	_	_
18	conditions	_	_	NNS	O	-1	none	_	_
19	and/or	_	_	CC	O	-1	none	_	_
20	cytokine	_	_	NN	O	-1	none	_	_
21	mobilized	_	_	VBN	O	-1	none	_	_
22	peripheral	_	_	JJ	O	-1	none	_	_
23	blood	_	_	NN	O	-1	none	_	_
24	are	_	_	VBP	O	-1	none	_	_
25	apparently	_	_	RB	O	-1	none	_	_
26	required	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	report	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	expressing	_	_	VBG	O	-1	none	_	_
8	osteoclast	_	_	NN	O	-1	none	_	_
9	markers	_	_	NNS	O	-1	none	_	_
10	differentiate	_	_	VBP	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	precursors	_	_	NNS	O	-1	none	_	_
13	present	_	_	JJ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	nonmobilized	_	_	JJ	O	-1	none	_	_
16	peripheral	_	_	JJ	O	-1	none	_	_
17	blood	_	_	NN	O	-1	none	_	_
18	mononuclear	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	PBMC	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	without	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	addition	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	stromal	_	_	JJ	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	growth	_	_	NN	O	-1	none	_	_
32	factors	_	_	NNS	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	cytokines	_	_	NNS	O	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	steroids	_	_	NNS	O	-1	none	_	_
37	;	_	_	:	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	characterize	_	_	VBP	O	-1	none	_	_
40	their	_	_	PRP$	O	-1	none	_	_
41	phenotype	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	adherent	_	_	JJ	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	eccentrically	_	_	RB	O	-1	none	_	_
7	placed	_	_	VBN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	round	_	_	JJ	O	-1	none	_	_
10	nucleus	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	express	_	_	VB	O	-1	none	_	_
14	low	_	_	JJ	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	TRAP	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	sodium	_	_	NN	O	-1	none	_	_
20	fluoride	_	_	NN	O	-1	none	_	_
21	resistant-	_	_	JJ	O	-1	none	_	_
22	alpha-naphthyl-acetate-esterase	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	NaF-R-NSE	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Over	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	next	_	_	JJ	O	-1	none	_	_
4	week	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	population	_	_	NN	O	-1	none	_	_
9	accumulates	_	_	VBZ	O	-1	none	_	_
10	phenotypic	_	_	JJ	O	-1	none	_	_
11	markers	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	osteoclasts	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	vitronectin	_	_	NN	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	[	_	_	CD	O	-1	none	_	_
18	VR	_	_	NN	O	-1	none	_	_
19	]	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	calcitonin	_	_	NN	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	TRAP	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	cathepsin	_	_	NN	Protein	27	multitoken	_	_
27	K	_	_	NN	Protein	0	root	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	mRNA	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	increased	_	_	VBN	O	-1	none	_	_
35	nuclearity	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	covering	_	_	VBG	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	entire	_	_	JJ	O	-1	none	_	_
40	surface	_	_	NN	O	-1	none	_	_
41	by	_	_	IN	O	-1	none	_	_
42	15	_	_	CD	O	-1	none	_	_
43	days	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Resorption	_	_	NN	O	-1	none	_	_
2	lacunae	_	_	NNS	O	-1	none	_	_
3	can	_	_	MD	O	-1	none	_	_
4	be	_	_	VB	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	day	_	_	NN	O	-1	none	_	_
8	22	_	_	CD	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	pits	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	nearly	_	_	RB	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	numerous	_	_	JJ	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	preosteoclast	_	_	JJ	O	-1	none	_	_
14	phenotype	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	they	_	_	PRP	O	-1	none	_	_
17	do	_	_	VBP	O	-1	none	_	_
18	represent	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	subset	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	osteoclast	_	_	NN	O	-1	none	_	_
26	like	_	_	IN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	that	_	_	WDT	O	-1	none	_	_
29	has	_	_	VBZ	O	-1	none	_	_
30	achieved	_	_	VBN	O	-1	none	_	_
31	osteoclastic	_	_	JJ	O	-1	none	_	_
32	maturity	_	_	NN	O	-1	none	_	_
33	under	_	_	IN	O	-1	none	_	_
34	these	_	_	DT	O	-1	none	_	_
35	culture	_	_	NN	O	-1	none	_	_
36	conditions	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Transcripts	_	_	NNS	O	-1	none	_	_
2	for	_	_	IN	O	-1	none	_	_
3	osteoprotegerin	_	_	NN	Protein	4	multitoken	_	_
4	ligand	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	OPGL	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	osteoclast	_	_	NN	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	also	_	_	RB	O	-1	none	_	_
15	known	_	_	VBN	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	RANKL	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	TRANCE	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	expressed	_	_	VBN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	likely	_	_	RB	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	adherent	_	_	JJ	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	adherent	_	_	JJ	O	-1	none	_	_
5	population	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	preosteoclast	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	osteoclast	_	_	JJ	O	-1	none	_	_
13	phenotypic	_	_	JJ	O	-1	none	_	_
14	properties	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	arises	_	_	VBZ	O	-1	none	_	_
17	selectively	_	_	RB	O	-1	none	_	_
18	under	_	_	IN	O	-1	none	_	_
19	simple	_	_	JJ	O	-1	none	_	_
20	culture	_	_	NN	O	-1	none	_	_
21	conditions	_	_	NNS	O	-1	none	_	_
22	from	_	_	IN	O	-1	none	_	_
23	normal	_	_	JJ	O	-1	none	_	_
24	PBMC	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Further	_	_	JJ	O	-1	none	_	_
2	characterization	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	should	_	_	MD	O	-1	none	_	_
7	identify	_	_	VB	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	involved	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	growth	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	terminal	_	_	JJ	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	osteoclasts	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	HTLV-1	_	_	NNP	O	-1	none	_	_
2	Tax	_	_	NN	Protein	-1	none	_	_
3	induces	_	_	VBZ	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	various	_	_	JJ	O	-1	none	_	_
7	immediate	_	_	JJ	O	-1	none	_	_
8	early	_	_	JJ	O	-1	none	_	_
9	serum	_	_	NN	O	-1	none	_	_
10	responsive	_	_	JJ	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	1	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-1	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	etiological	_	_	JJ	O	-1	none	_	_
13	agent	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	adult	_	_	JJ	O	-1	none	_	_
16	T-cell	_	_	NN	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	ATL	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	showed	_	_	VBD	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	mobility-shift	_	_	JJ	O	-1	none	_	_
6	assay	_	_	NN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	T-cell	_	_	NN	O	-1	none	_	_
9	lines	_	_	NNS	O	-1	none	_	_
10	transformed	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	virus	_	_	NN	O	-1	none	_	_
14	contained	_	_	VBD	O	-1	none	_	_
15	high	_	_	JJ	O	-1	none	_	_
16	levels	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	AP-1	_	_	NN	O	-1	none	_	_
19	activities	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Consistent	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	result	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	lines	_	_	NNS	O	-1	none	_	_
9	expressed	_	_	VBD	O	-1	none	_	_
10	increased	_	_	VBN	O	-1	none	_	_
11	levels	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	mRNAs	_	_	NNS	O	-1	none	_	_
14	encoding	_	_	VBG	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	AP-1	_	_	NN	O	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	c-Fos	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	Fra-1	_	_	NN	Protein	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	c-Jun	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	JunB	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	JunD	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Previously	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	c-fos	_	_	NN	Protein	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	reported	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	transactivated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	viral	_	_	JJ	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	Tax1	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	T-cell	_	_	NN	O	-1	none	_	_
6	line	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	JPX-9	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	Tax1	_	_	NN	Protein	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	inducible	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	showed	_	_	VBD	O	-1	none	_	_
22	that	_	_	IN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	mRNAs	_	_	NNS	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	Fra-1	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	c-Jun	_	_	NN	Protein	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	JunD	_	_	NN	Protein	-1	none	_	_
33	was	_	_	VBD	O	-1	none	_	_
34	also	_	_	RB	O	-1	none	_	_
35	transactivated	_	_	VBN	O	-1	none	_	_
36	by	_	_	IN	O	-1	none	_	_
37	Tax1	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Tax1	_	_	NN	Protein	-1	none	_	_
4	activated	_	_	VBN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	two	_	_	CD	O	-1	none	_	_
8	other	_	_	JJ	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	having	_	_	VBG	O	-1	none	_	_
12	zinc	_	_	NN	O	-1	none	_	_
13	finger	_	_	NN	O	-1	none	_	_
14	motifs	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	Egr-1	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	Egr-2	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	same	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Tax1	_	_	NN	Protein	-1	none	_	_
3	inducible	_	_	JJ	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factors	_	_	NNS	O	-1	none	_	_
6	identified	_	_	VBN	O	-1	none	_	_
7	here	_	_	RB	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	encoded	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	members	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	immediate	_	_	JJ	O	-1	none	_	_
15	early	_	_	JJ	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	under	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	control	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	growth	_	_	NN	O	-1	none	_	_
22	signals	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Tax1	_	_	NN	Protein	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	suggested	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	replace	_	_	VB	O	-1	none	_	_
8	growth	_	_	NN	O	-1	none	_	_
9	signals	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	at	_	_	IN	O	-1	none	_	_
12	least	_	_	JJS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	part	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	this	_	_	DT	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Bik	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	novel	_	_	JJ	O	-1	none	_	_
5	death	_	_	NN	O	-1	none	_	_
6	inducing	_	_	VBG	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	shares	_	_	NNS	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	distinct	_	_	JJ	O	-1	none	_	_
11	sequence	_	_	NN	O	-1	none	_	_
12	motif	_	_	NN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	Bcl-2	_	_	NN	O	-1	none	_	_
15	family	_	_	NN	O	-1	none	_	_
16	proteins	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	interacts	_	_	VBZ	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	viral	_	_	JJ	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	cellular	_	_	JJ	O	-1	none	_	_
23	survival	_	_	NN	O	-1	none	_	_
24	promoting	_	_	VBG	O	-1	none	_	_
25	proteins	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	survival	_	_	NN	O	-1	none	_	_
3	promoting	_	_	VBG	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	Bcl-2	_	_	NN	O	-1	none	_	_
8	family	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	appears	_	_	VBZ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	modulated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	interactions	_	_	NNS	O	-1	none	_	_
17	between	_	_	IN	O	-1	none	_	_
18	various	_	_	JJ	O	-1	none	_	_
19	cellular	_	_	JJ	O	-1	none	_	_
20	proteins	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	identified	_	_	VBN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	novel	_	_	JJ	O	-1	none	_	_
6	cellular	_	_	JJ	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	Bik	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	that	_	_	WDT	O	-1	none	_	_
12	interacts	_	_	VBZ	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cellular	_	_	JJ	O	-1	none	_	_
16	survival	_	_	NN	O	-1	none	_	_
17	promoting	_	_	VBG	O	-1	none	_	_
18	proteins	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	Bcl-2	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	Bcl-xL	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	as	_	_	RB	O	-1	none	_	_
25	well	_	_	RB	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	viral	_	_	JJ	O	-1	none	_	_
29	survival	_	_	NN	O	-1	none	_	_
30	promoting	_	_	VBG	O	-1	none	_	_
31	proteins	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	Epstein	_	_	NN	O	-1	none	_	_
34	Barr	_	_	NN	O	-1	none	_	_
35	virus-BHRF1	_	_	NN	Protein	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	adenovirus	_	_	NN	O	-1	none	_	_
38	E1B-19	_	_	NN	Protein	39	multitoken	_	_
39	kDa	_	_	NN	Protein	0	root	_	_
40	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	transient	_	_	JJ	O	-1	none	_	_
3	transfection	_	_	NN	O	-1	none	_	_
4	assays	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	Bik	_	_	NN	Protein	-1	none	_	_
7	promotes	_	_	VBZ	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	death	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	manner	_	_	NN	O	-1	none	_	_
13	similar	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	death	_	_	NN	O	-1	none	_	_
17	promoting	_	_	VBG	O	-1	none	_	_
18	members	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	Bcl-2	_	_	NN	O	-1	none	_	_
22	family	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	Bax	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	Bak	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	death	_	_	NN	O	-1	none	_	_
3	promoting	_	_	VBG	O	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Bik	_	_	NN	Protein	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	suppressed	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	coexpression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Bcl-2	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	Bcl-XL	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	EBV-BHRF1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	E1B-19	_	_	NN	O	-1	none	_	_
20	kDa	_	_	NN	O	-1	none	_	_
21	proteins	_	_	NNS	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	Bik	_	_	NN	Protein	-1	none	_	_
25	may	_	_	MD	O	-1	none	_	_
26	be	_	_	VB	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	common	_	_	JJ	O	-1	none	_	_
29	target	_	_	NN	O	-1	none	_	_
30	for	_	_	IN	O	-1	none	_	_
31	both	_	_	DT	O	-1	none	_	_
32	cellular	_	_	JJ	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	viral	_	_	JJ	O	-1	none	_	_
35	anti-apoptotic	_	_	JJ	O	-1	none	_	_
36	proteins	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	While	_	_	IN	O	-1	none	_	_
2	Bik	_	_	NN	Protein	-1	none	_	_
3	does	_	_	VBZ	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	show	_	_	VB	O	-1	none	_	_
6	overt	_	_	JJ	O	-1	none	_	_
7	homology	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	BH1	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	BH2	_	_	NN	Protein	-1	none	_	_
13	conserved	_	_	VBN	O	-1	none	_	_
14	domains	_	_	NNS	O	-1	none	_	_
15	characteristic	_	_	JJ	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	Bcl-2	_	_	NN	O	-1	none	_	_
19	family	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	it	_	_	PRP	O	-1	none	_	_
22	does	_	_	VBZ	O	-1	none	_	_
23	share	_	_	VB	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	9	_	_	CD	O	-1	none	_	_
26	amino	_	_	NN	O	-1	none	_	_
27	acid	_	_	NN	O	-1	none	_	_
28	domain	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	BH3	_	_	NN	Protein	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	Bax	_	_	NN	Protein	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	Bak	_	_	NN	Protein	-1	none	_	_
36	which	_	_	WDT	O	-1	none	_	_
37	may	_	_	MD	O	-1	none	_	_
38	be	_	_	VB	O	-1	none	_	_
39	a	_	_	DT	O	-1	none	_	_
40	critical	_	_	JJ	O	-1	none	_	_
41	determinant	_	_	NN	O	-1	none	_	_
42	for	_	_	IN	O	-1	none	_	_
43	the	_	_	DT	O	-1	none	_	_
44	death	_	_	NN	O	-1	none	_	_
45	promoting	_	_	VBG	O	-1	none	_	_
46	activity	_	_	NN	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	these	_	_	DT	O	-1	none	_	_
49	proteins	_	_	NNS	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Janus	_	_	NN	Protein	3	multitoken	_	_
2	kinase	_	_	NN	Protein	3	multitoken	_	_
3	3	_	_	CD	Protein	0	root	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	JAK3	_	_	NN	Protein	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	cytoplasmic	_	_	JJ	O	-1	none	_	_
10	tyrosine	_	_	NN	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	required	_	_	VBN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	development	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	cytokines	_	_	NNS	O	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	utilize	_	_	VBP	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	interleukin-2	_	_	NN	Protein	31	multitoken	_	_
25	(	_	_	-LRB-	Protein	31	multitoken	_	_
26	IL-2	_	_	NN	Protein	31	multitoken	_	_
27	)	_	_	-RRB-	Protein	31	multitoken	_	_
28	receptor	_	_	NN	Protein	31	multitoken	_	_
29	common	_	_	JJ	Protein	31	multitoken	_	_
30	gamma	_	_	NN	Protein	31	multitoken	_	_
31	chain	_	_	NN	Protein	0	root	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	gamma	_	_	NN	Protein	36	multitoken	_	_
34	(	_	_	-LRB-	Protein	36	multitoken	_	_
35	c	_	_	NN	Protein	36	multitoken	_	_
36	)	_	_	-RRB-	Protein	0	root	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Genetic	_	_	JJ	O	-1	none	_	_
2	inactivation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	JAK3	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	manifested	_	_	VBN	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	severe	_	_	JJ	O	-1	none	_	_
9	combined	_	_	JJ	O	-1	none	_	_
10	immunodeficiency	_	_	NN	O	-1	none	_	_
11	disease	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	SCID	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	humans	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	mice	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	suggested	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	JAK3	_	_	NN	Protein	-1	none	_	_
7	represents	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	pharmacological	_	_	JJ	O	-1	none	_	_
10	target	_	_	NN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	control	_	_	VB	O	-1	none	_	_
13	certain	_	_	JJ	O	-1	none	_	_
14	lymphoid	_	_	JJ	O	-1	none	_	_
15	derived	_	_	VBN	O	-1	none	_	_
16	diseases	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Similar	_	_	JJ	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	effects	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	other	_	_	JJ	O	-1	none	_	_
8	cytokines	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	use	_	_	VBP	O	-1	none	_	_
11	gamma	_	_	NN	Protein	14	multitoken	_	_
12	(	_	_	-LRB-	Protein	14	multitoken	_	_
13	c	_	_	NN	Protein	14	multitoken	_	_
14	)	_	_	-RRB-	Protein	0	root	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	inhibitor	_	_	NN	O	-1	none	_	_
8	prevented	_	_	VBD	O	-1	none	_	_
9	tetanus	_	_	NN	O	-1	none	_	_
10	toxoid	_	_	NN	O	-1	none	_	_
11	antigen	_	_	NN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	proliferation	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	expansion	_	_	NN	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	failed	_	_	VBD	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	block	_	_	VB	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	Zap70	_	_	NN	Protein	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	p56Lck	_	_	NN	Protein	-1	none	_	_
27	after	_	_	IN	O	-1	none	_	_
28	anti-CD3	_	_	JJ	O	-1	none	_	_
29	stimulation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	human	_	_	NN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Taken	_	_	VBN	O	-1	none	_	_
2	together	_	_	RB	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	findings	_	_	NNS	O	-1	none	_	_
6	suggest	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	AG-490	_	_	NN	O	-1	none	_	_
9	inhibits	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	JAK3	_	_	NN	Protein	-1	none	_	_
12	mediated	_	_	VBD	O	-1	none	_	_
13	Type	_	_	NN	O	-1	none	_	_
14	II	_	_	CD	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	pathway	_	_	NN	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	derived	_	_	VBN	O	-1	none	_	_
24	Type	_	_	NN	O	-1	none	_	_
25	I	_	_	CD	O	-1	none	_	_
26	pathway	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	possesses	_	_	VBZ	O	-1	none	_	_
29	therapeutic	_	_	JJ	O	-1	none	_	_
30	potential	_	_	NN	O	-1	none	_	_
31	for	_	_	IN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cell	_	_	NN	O	-1	none	_	_
34	derived	_	_	VBN	O	-1	none	_	_
35	pathologies	_	_	NNS	O	-1	none	_	_
36	such	_	_	JJ	O	-1	none	_	_
37	as	_	_	IN	O	-1	none	_	_
38	graft-versus-host	_	_	JJ	O	-1	none	_	_
39	disease	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	allergy	_	_	NN	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	autoimmune	_	_	JJ	O	-1	none	_	_
45	disorders	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Megakaryocytic	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	erythrocytic	_	_	JJ	O	-1	none	_	_
4	lineages	_	_	NNS	O	-1	none	_	_
5	share	_	_	VBP	O	-1	none	_	_
6	specific	_	_	JJ	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Erythroid	_	_	JJ	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	genes	_	_	NNS	O	-1	none	_	_
4	contain	_	_	VBP	O	-1	none	_	_
5	binding	_	_	VBG	O	-1	none	_	_
6	sites	_	_	NNS	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	NF-E1	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	called	_	_	VBD	O	-1	none	_	_
12	GF-1	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	Eryf-1	_	_	NN	Protein	-1	none	_	_
15	;	_	_	:	O	-1	none	_	_
16	refs	_	_	NNS	O	-1	none	_	_
17	1-3	_	_	CD	O	-1	none	_	_
18	respectively	_	_	RB	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	principal	_	_	JJ	O	-1	none	_	_
23	DNA	_	_	NN	O	-1	none	_	_
24	binding	_	_	NN	O	-1	none	_	_
25	protein	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	erythrocytic	_	_	JJ	O	-1	none	_	_
29	lineage	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	NF-E1	_	_	NNP	Protein	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	seems	_	_	VBZ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	restricted	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	erythrocytic	_	_	JJ	O	-1	none	_	_
10	lineage	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	closely	_	_	RB	O	-1	none	_	_
3	related	_	_	JJ	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	if	_	_	IN	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	identical	_	_	JJ	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	found	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	megakaryocytic	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	line	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	purified	_	_	VBN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	megakaryocytes	_	_	NNS	O	-1	none	_	_
23	;	_	_	:	O	-1	none	_	_
24	it	_	_	PRP	O	-1	none	_	_
25	binds	_	_	VBZ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	regions	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	two	_	_	CD	O	-1	none	_	_
31	megakaryocytic	_	_	JJ	O	-1	none	_	_
32	specific	_	_	JJ	O	-1	none	_	_
33	genes	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	sites	_	_	NNS	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	partial	_	_	JJ	O	-1	none	_	_
6	proteolysis	_	_	NN	O	-1	none	_	_
7	profile	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	this	_	_	DT	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	indistinguishable	_	_	JJ	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	those	_	_	DT	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	erythroid	_	_	JJ	O	-1	none	_	_
18	protein	_	_	NN	O	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	also	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	NF-E1	_	_	NN	Protein	-1	none	_	_
23	messenger	_	_	NN	O	-1	none	_	_
24	RNA	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	same	_	_	JJ	O	-1	none	_	_
28	size	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	both	_	_	CC	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	megakaryocytic	_	_	JJ	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	erythroid	_	_	JJ	O	-1	none	_	_
35	cell	_	_	NN	O	-1	none	_	_
36	lines	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	point	_	_	NN	O	-1	none	_	_
4	mutations	_	_	NNS	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	abolish	_	_	VBP	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-E1	_	_	NN	Protein	-1	none	_	_
10	result	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	70	_	_	CD	O	-1	none	_	_
14	%	_	_	NN	O	-1	none	_	_
15	decrease	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	transcriptional	_	_	JJ	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	megakaryocytic	_	_	JJ	O	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	promoter	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	find	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	NF-E2	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	another	_	_	DT	O	-1	none	_	_
8	trans-acting	_	_	JJ	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	erythrocytic	_	_	JJ	O	-1	none	_	_
13	lineage	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	present	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	megakaryocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	both	_	_	DT	O	-1	none	_	_
5	lineages	_	_	NNS	O	-1	none	_	_
6	might	_	_	MD	O	-1	none	_	_
7	then	_	_	RB	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	mediated	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	part	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	same	_	_	JJ	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	trans-acting	_	_	JJ	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	strengthen	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	idea	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	close	_	_	JJ	O	-1	none	_	_
9	association	_	_	NN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	erythrocytic	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	megakaryocytic	_	_	JJ	O	-1	none	_	_
16	lineages	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	could	_	_	MD	O	-1	none	_	_
19	also	_	_	RB	O	-1	none	_	_
20	explain	_	_	VB	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	markers	_	_	NNS	O	-1	none	_	_
25	specific	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	erythrocytic	_	_	JJ	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	megakaryocytic	_	_	JJ	O	-1	none	_	_
31	lineages	_	_	NNS	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	most	_	_	JJS	O	-1	none	_	_
34	erythroblastic	_	_	JJ	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	megakaryoblastic	_	_	JJ	O	-1	none	_	_
37	permanent	_	_	JJ	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	lines	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	differentiation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	myeloid	_	_	JJ	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	lines	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	redox	_	_	NN	O	-1	none	_	_
12	changes	_	_	NNS	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	through	_	_	IN	O	-1	none	_	_
15	glutathione	_	_	NN	O	-1	none	_	_
16	depletion	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	investigated	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effect	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	redox	_	_	NN	O	-1	none	_	_
8	changes	_	_	NNS	O	-1	none	_	_
9	in	_	_	FW	O	-1	none	_	_
10	vivo	_	_	FW	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	two	_	_	CD	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	myeloid	_	_	JJ	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	lines	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	HL-60	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	KG-1	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	glutathione	_	_	NN	O	-1	none	_	_
3	depleting	_	_	VBG	O	-1	none	_	_
4	agent	_	_	NN	O	-1	none	_	_
5	diethyl	_	_	NN	O	-1	none	_	_
6	maleate	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	DEM	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	prevented	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	development	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	differentiated	_	_	VBN	O	-1	none	_	_
15	features	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	phorbol	_	_	NN	O	-1	none	_	_
20	esters	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	including	_	_	VBG	O	-1	none	_	_
23	adherence	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	plastic	_	_	JJ	O	-1	none	_	_
29	surfaces	_	_	NNS	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	repression	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	myeloperoxidase	_	_	NN	Protein	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	CD34	_	_	NN	Protein	-1	none	_	_
37	genes	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	DEM	_	_	NN	O	-1	none	_	_
4	abolished	_	_	VBD	O	-1	none	_	_
5	phorbol	_	_	NN	O	-1	none	_	_
6	12-myristate	_	_	NN	O	-1	none	_	_
7	13-acetate-induced	_	_	JJ	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	factors	_	_	NNS	O	-1	none	_	_
13	AP-1	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Egr-1	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	suggesting	_	_	VBG	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	inhibition	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	may	_	_	MD	O	-1	none	_	_
23	be	_	_	VB	O	-1	none	_	_
24	due	_	_	JJ	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	at	_	_	IN	O	-1	none	_	_
27	least	_	_	JJS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	part	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	redox	_	_	NN	O	-1	none	_	_
33	modifications	_	_	NNS	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	these	_	_	DT	O	-1	none	_	_
36	proteins	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	p105	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	p98	_	_	NN	Protein	-1	none	_	_
4	precursor	_	_	NN	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	play	_	_	VBP	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	active	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	NF-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	mediated	_	_	JJ	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	transduction	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Rel	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	NF-kappa	_	_	NN	O	-1	none	_	_
5	B	_	_	NN	O	-1	none	_	_
6	family	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	composed	_	_	VBN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	two	_	_	CD	O	-1	none	_	_
14	distinct	_	_	JJ	O	-1	none	_	_
15	subgroups	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	undergo	_	_	VBP	O	-1	none	_	_
20	proteolytic	_	_	JJ	O	-1	none	_	_
21	processing	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	contain	_	_	VBP	O	-1	none	_	_
24	SWI6	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	ankyrin	_	_	NN	O	-1	none	_	_
27	repeats	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	their	_	_	PRP$	O	-1	none	_	_
30	carboxyl	_	_	NN	O	-1	none	_	_
31	termini	_	_	NNS	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	p105	_	_	NN	Protein	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	p98	_	_	NN	Protein	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	those	_	_	DT	O	-1	none	_	_
40	without	_	_	IN	O	-1	none	_	_
41	such	_	_	JJ	O	-1	none	_	_
42	repeats	_	_	NNS	O	-1	none	_	_
43	that	_	_	WDT	O	-1	none	_	_
44	do	_	_	VBP	O	-1	none	_	_
45	not	_	_	RB	O	-1	none	_	_
46	require	_	_	VB	O	-1	none	_	_
47	processing	_	_	NN	O	-1	none	_	_
48	(	_	_	-LRB-	O	-1	none	_	_
49	p65	_	_	NN	Protein	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	c-Rel	_	_	NN	Protein	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	RelB	_	_	NN	Protein	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	and	_	_	CC	O	-1	none	_	_
56	Dorsal	_	_	NN	Protein	-1	none	_	_
57	)	_	_	-RRB-	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	p105	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	p98	_	_	NN	Protein	-1	none	_	_
8	precursors	_	_	NNS	O	-1	none	_	_
9	share	_	_	VBP	O	-1	none	_	_
10	functional	_	_	JJ	O	-1	none	_	_
11	properties	_	_	NNS	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	I	_	_	NN	O	-1	none	_	_
15	kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	proteins	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	also	_	_	RB	O	-1	none	_	_
21	contain	_	_	VBP	O	-1	none	_	_
22	SWI6	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	ankyrin	_	_	NN	O	-1	none	_	_
25	repeats	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	p105	_	_	NN	Protein	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	p98	_	_	NN	Protein	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	found	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	form	_	_	VB	O	-1	none	_	_
9	stable	_	_	JJ	O	-1	none	_	_
10	complexes	_	_	NNS	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	other	_	_	JJ	O	-1	none	_	_
13	Rel	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	family	_	_	NN	O	-1	none	_	_
18	members	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	including	_	_	VBG	O	-1	none	_	_
21	p65	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	c-Rel	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Association	_	_	NNP	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	precursors	_	_	NNS	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	sufficient	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	cytoplasmic	_	_	JJ	O	-1	none	_	_
9	retention	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	either	_	_	CC	O	-1	none	_	_
12	p65	_	_	NN	Protein	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	c-Rel	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	both	_	_	DT	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	otherwise	_	_	RB	O	-1	none	_	_
21	nuclear	_	_	JJ	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	complexes	_	_	NNS	O	-1	none	_	_
3	undergo	_	_	VBP	O	-1	none	_	_
4	stimulus	_	_	NN	O	-1	none	_	_
5	responsive	_	_	JJ	O	-1	none	_	_
6	processing	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	produce	_	_	VB	O	-1	none	_	_
9	active	_	_	JJ	O	-1	none	_	_
10	p50	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	c-Rel	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	p55	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	c-Rel	_	_	NN	Protein	-1	none	_	_
17	complexes	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	second	_	_	JJ	O	-1	none	_	_
6	pathway	_	_	NN	O	-1	none	_	_
7	leading	_	_	VBG	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	processing	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	precursors	_	_	NNS	O	-1	none	_	_
19	rather	_	_	RB	O	-1	none	_	_
20	than	_	_	IN	O	-1	none	_	_
21	phosphorylation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	I	_	_	NN	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	plays	_	_	VBZ	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	major	_	_	JJ	O	-1	none	_	_
29	role	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	c-Rel	_	_	NN	Protein	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	STAT5	_	_	NN	O	-1	none	_	_
6	target	_	_	NN	O	-1	none	_	_
7	sequences	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	HTLV-I-transformed	_	_	JJ	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	type	_	_	NN	O	-1	none	_	_
3	I	_	_	CD	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	T-cell	_	_	NN	O	-1	none	_	_
6	leukemia	_	_	NN	O	-1	none	_	_
7	virus	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	HTLV-I	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	induces	_	_	VBZ	O	-1	none	_	_
12	abnormal	_	_	JJ	O	-1	none	_	_
13	growth	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	subsequent	_	_	JJ	O	-1	none	_	_
16	transformation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	associated	_	_	VBN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	development	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	an	_	_	DT	O	-1	none	_	_
29	acute	_	_	JJ	O	-1	none	_	_
30	T-cell	_	_	NN	O	-1	none	_	_
31	malignancy	_	_	NN	O	-1	none	_	_
32	termed	_	_	VBN	O	-1	none	_	_
33	adult	_	_	JJ	O	-1	none	_	_
34	T-cell	_	_	NN	O	-1	none	_	_
35	leukemia	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	characteristic	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	HTLV-I-transformed	_	_	JJ	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	constitutive	_	_	JJ	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	Rel	_	_	NN	O	-1	none	_	_
16	family	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factors	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	appears	_	_	VBZ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	be	_	_	VB	O	-1	none	_	_
25	essential	_	_	JJ	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	growth	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	these	_	_	DT	O	-1	none	_	_
31	transformed	_	_	JJ	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Reporter	_	_	NN	O	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	reveal	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	c-Rel	_	_	NN	Protein	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	STAT5	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	present	_	_	JJ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	Fc	_	_	NN	Protein	18	multitoken	_	_
18	gammaR1	_	_	NN	Protein	0	root	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	leads	_	_	VBZ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	potent	_	_	JJ	O	-1	none	_	_
23	transactivation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	this	_	_	DT	O	-1	none	_	_
26	enhancer	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	c-Rel	_	_	NN	Protein	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	Fc	_	_	NN	Protein	7	multitoken	_	_
7	gammaR1	_	_	NN	Protein	0	root	_	_
8	STAT	_	_	NN	O	-1	none	_	_
9	site	_	_	NN	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	occurs	_	_	VBZ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	peripheral	_	_	JJ	O	-1	none	_	_
15	blood	_	_	NN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	immortalized	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	HTLV-I	_	_	NN	O	-1	none	_	_
21	in	_	_	FW	O	-1	none	_	_
22	vitro	_	_	FW	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	correlated	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	enhanced	_	_	VBN	O	-1	none	_	_
28	levels	_	_	NNS	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	proliferation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	these	_	_	DT	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	raise	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	possibility	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	NF-kappaB	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Rel	_	_	NN	O	-1	none	_	_
10	may	_	_	MD	O	-1	none	_	_
11	participate	_	_	VB	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	growth	_	_	NN	O	-1	none	_	_
15	control	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	HTLV-I-transformed	_	_	JJ	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	regulating	_	_	VBG	O	-1	none	_	_
22	genes	_	_	NNS	O	-1	none	_	_
23	driven	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	both	_	_	CC	O	-1	none	_	_
26	kappaB	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	certain	_	_	JJ	O	-1	none	_	_
29	STAT	_	_	NN	O	-1	none	_	_
30	enhancers	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Direct	_	_	JJ	O	-1	none	_	_
2	demonstration	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NFATp	_	_	NN	Protein	-1	none	_	_
5	dephosphorylation	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	localization	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	activated	_	_	VBN	O	-1	none	_	_
11	HT-2	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	using	_	_	VBG	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	NFATp	_	_	NN	Protein	-1	none	_	_
17	polyclonal	_	_	JJ	O	-1	none	_	_
18	antibody	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	activated	_	_	VBN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	NFAT	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	regulates	_	_	VBZ	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	number	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cytokine	_	_	NN	O	-1	none	_	_
17	genes	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	NFAT	_	_	NN	O	-1	none	_	_
21	DNA	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	stimulated	_	_	VBN	O	-1	none	_	_
26	following	_	_	VBG	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	lines	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	evidence	_	_	NN	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	suggested	_	_	VBN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	NFAT	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	substrate	_	_	NN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	calcineurin	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	serine/threonine	_	_	NN	O	-1	none	_	_
17	phosphatase	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	polyclonal	_	_	JJ	O	-1	none	_	_
4	antibody	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	murine	_	_	JJ	O	-1	none	_	_
7	NFATp	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	Western	_	_	NN	O	-1	none	_	_
10	blot	_	_	NN	O	-1	none	_	_
11	analysis	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	various	_	_	JJ	O	-1	none	_	_
14	mouse	_	_	NN	O	-1	none	_	_
15	tissues	_	_	NNS	O	-1	none	_	_
16	demonstrated	_	_	VBD	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	110-130-kDa	_	_	JJ	O	-1	none	_	_
20	NFATp	_	_	NN	Protein	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	highly	_	_	RB	O	-1	none	_	_
24	expressed	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	thymus	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	spleen	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	immunoprecipitated	_	_	VBN	O	-1	none	_	_
4	NFATp	_	_	NN	Protein	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	untreated	_	_	JJ	O	-1	none	_	_
7	HT-2	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	calcineurin	_	_	NN	O	-1	none	_	_
11	resulted	_	_	VBD	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	dephosphorylation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	NFATp	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	demonstrating	_	_	VBG	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	NFATp	_	_	NN	Protein	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	an	_	_	DT	O	-1	none	_	_
23	in	_	_	FW	O	-1	none	_	_
24	vitro	_	_	FW	O	-1	none	_	_
25	substrate	_	_	NN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	calcineurin	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	NFATp	_	_	NN	Protein	-1	none	_	_
2	immunoprecipitated	_	_	VBN	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	32P	_	_	NN	O	-1	none	_	_
5	labeled	_	_	VBN	O	-1	none	_	_
6	HT-2	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	migrated	_	_	VBD	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	approximately	_	_	RB	O	-1	none	_	_
12	120-kDa	_	_	JJ	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	localized	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	cytosol	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	ionomycin	_	_	NN	O	-1	none	_	_
7	resulted	_	_	VBD	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	decrease	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	molecular	_	_	JJ	O	-1	none	_	_
14	weight	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	NFATp	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	loss	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	32P	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	consistent	_	_	JJ	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	NFATp	_	_	NN	Protein	-1	none	_	_
26	dephosphorylation	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	dephosphorylation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NFATp	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	accompanied	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	localization	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	protein	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	nuclear	_	_	JJ	O	-1	none	_	_
15	fraction	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	events	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	blocked	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	preincubation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	FK506	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	calcineurin	_	_	NN	O	-1	none	_	_
17	inhibitor	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	consistent	_	_	JJ	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	hypothesis	_	_	NN	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	NFATp	_	_	NN	Protein	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	calcineurin	_	_	NN	O	-1	none	_	_
28	substrate	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Transcription	_	_	NN	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	Sp1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	AP-2	_	_	NN	O	-1	none	_	_
6	mediate	_	_	VBP	O	-1	none	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	acid	_	_	NN	O	-1	none	_	_
10	sphingomyelinase	_	_	NN	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	monocytic	_	_	JJ	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Cells	_	_	NNS	O	-1	none	_	_
2	from	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	monocytic	_	_	JJ	O	-1	none	_	_
6	leukemia	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	line	_	_	NN	O	-1	none	_	_
9	THP-1	_	_	NN	O	-1	none	_	_
10	differentiate	_	_	VBP	O	-1	none	_	_
11	towards	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	macrophage	_	_	NN	O	-1	none	_	_
14	like	_	_	IN	O	-1	none	_	_
15	phenotype	_	_	NN	O	-1	none	_	_
16	when	_	_	WRB	O	-1	none	_	_
17	stimulated	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	phorbol	_	_	NN	O	-1	none	_	_
20	12-myristate	_	_	NN	O	-1	none	_	_
21	-13-	_	_	CD	O	-1	none	_	_
22	acetate	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	PMA	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	1,25-dihydroxy-vitamin	_	_	NN	O	-1	none	_	_
28	D3	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	various	_	_	JJ	O	-1	none	_	_
32	other	_	_	JJ	O	-1	none	_	_
33	agents	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	lysosomal	_	_	JJ	O	-1	none	_	_
10	enzyme	_	_	NN	O	-1	none	_	_
11	acid	_	_	NN	O	-1	none	_	_
12	sphingomyelinase	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	ASM	_	_	NN	O	-1	none	_	_
15	;	_	_	:	O	-1	none	_	_
16	E.C.	_	_	NNP	O	-1	none	_	_
17	3.1.4.12	_	_	CD	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	induced	_	_	VBN	O	-1	none	_	_
21	during	_	_	IN	O	-1	none	_	_
22	this	_	_	DT	O	-1	none	_	_
23	process	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	strongly	_	_	RB	O	-1	none	_	_
27	elevated	_	_	JJ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	differentiated	_	_	VBN	O	-1	none	_	_
30	THP-1	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	as	_	_	RB	O	-1	none	_	_
34	well	_	_	RB	O	-1	none	_	_
35	as	_	_	IN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	differentiated	_	_	VBN	O	-1	none	_	_
38	human	_	_	NN	O	-1	none	_	_
39	mononuclear	_	_	JJ	O	-1	none	_	_
40	phagocytes	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	Northern	_	_	NN	O	-1	none	_	_
3	blotting	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	RNase	_	_	NN	O	-1	none	_	_
6	protection	_	_	NN	O	-1	none	_	_
7	assay	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	run-on	_	_	JJ	O	-1	none	_	_
12	analyses	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	show	_	_	VBP	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	up-regulation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	ASM	_	_	NN	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	regulated	_	_	VBN	O	-1	none	_	_
24	mainly	_	_	RB	O	-1	none	_	_
25	at	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	level	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	that	_	_	IN	O	-1	none	_	_
32	new	_	_	JJ	O	-1	none	_	_
33	protein	_	_	NN	O	-1	none	_	_
34	synthesis	_	_	NN	O	-1	none	_	_
35	is	_	_	VBZ	O	-1	none	_	_
36	required	_	_	VBN	O	-1	none	_	_
37	for	_	_	IN	O	-1	none	_	_
38	enhanced	_	_	VBN	O	-1	none	_	_
39	ASM	_	_	NN	O	-1	none	_	_
40	activity	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	cell-type	_	_	JJ	O	-1	none	_	_
3	specific	_	_	JJ	O	-1	none	_	_
4	induction	_	_	NN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	PMA	_	_	NN	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	further	_	_	RB	O	-1	none	_	_
10	investigated	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	respect	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	transcriptional	_	_	JJ	O	-1	none	_	_
15	control	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	series	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	5	_	_	CD	O	-1	none	_	_
5	'	_	_	''	O	-1	none	_	_
6	deletion	_	_	NN	O	-1	none	_	_
7	derivatives	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	upstream	_	_	JJ	O	-1	none	_	_
11	regulatory	_	_	JJ	O	-1	none	_	_
12	region	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	used	_	_	VBN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	transient	_	_	JJ	O	-1	none	_	_
17	transfection	_	_	NN	O	-1	none	_	_
18	assays	_	_	NNS	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	identify	_	_	VB	O	-1	none	_	_
21	promoter	_	_	NN	O	-1	none	_	_
22	elements	_	_	NNS	O	-1	none	_	_
23	required	_	_	VBN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	basal	_	_	JJ	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	inducible	_	_	JJ	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	PMA	_	_	NN	O	-1	none	_	_
3	responsive	_	_	JJ	O	-1	none	_	_
4	element	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	localized	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	region	_	_	NN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	-319	_	_	CD	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	-219	_	_	CD	O	-1	none	_	_
14	bp	_	_	NN	O	-1	none	_	_
15	upstream	_	_	JJ	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	initiation	_	_	NN	O	-1	none	_	_
19	codon	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	co-transfections	_	_	NNS	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	factor	_	_	NN	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	plasmids	_	_	NNS	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	AP-2	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	Sp1	_	_	NN	Protein	-1	none	_	_
31	resulted	_	_	VBD	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	augmented	_	_	JJ	O	-1	none	_	_
34	ASM	_	_	NN	O	-1	none	_	_
35	promoter	_	_	NN	O	-1	none	_	_
36	activity	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	which	_	_	WDT	O	-1	none	_	_
39	was	_	_	VBD	O	-1	none	_	_
40	abolished	_	_	VBN	O	-1	none	_	_
41	when	_	_	WRB	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	binding	_	_	NN	O	-1	none	_	_
44	sites	_	_	NNS	O	-1	none	_	_
45	for	_	_	IN	O	-1	none	_	_
46	these	_	_	DT	O	-1	none	_	_
47	two	_	_	CD	O	-1	none	_	_
48	factors	_	_	NNS	O	-1	none	_	_
49	were	_	_	VBD	O	-1	none	_	_
50	deleted	_	_	VBN	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	electrophoretic	_	_	JJ	O	-1	none	_	_
3	mobility	_	_	NN	O	-1	none	_	_
4	shift	_	_	NN	O	-1	none	_	_
5	assays	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	supershift	_	_	NN	O	-1	none	_	_
8	assays	_	_	NNS	O	-1	none	_	_
9	we	_	_	PRP	O	-1	none	_	_
10	demonstrate	_	_	VBP	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	this	_	_	DT	O	-1	none	_	_
13	region	_	_	NN	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	specifically	_	_	RB	O	-1	none	_	_
16	bound	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	Sp1	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	AP-2	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	present	_	_	JJ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	extracts	_	_	NNS	O	-1	none	_	_
8	prepared	_	_	VBN	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	both	_	_	DT	O	-1	none	_	_
11	induced	_	_	VBN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	uninduced	_	_	JJ	O	-1	none	_	_
14	THP-1	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	intensity	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	complex	_	_	NN	O	-1	none	_	_
8	formed	_	_	VBN	O	-1	none	_	_
9	appeared	_	_	VBD	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	increase	_	_	VB	O	-1	none	_	_
12	when	_	_	WRB	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	extracts	_	_	NNS	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	PMA	_	_	NN	O	-1	none	_	_
17	treated	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	used	_	_	VBN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	From	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	conclude	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	concerted	_	_	JJ	O	-1	none	_	_
10	action	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	AP-2	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	Sp1	_	_	NN	Protein	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	essential	_	_	JJ	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	up	_	_	RB	O	-1	none	_	_
23	-regulation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	ASM	_	_	NN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	during	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	process	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	macrophage	_	_	NN	O	-1	none	_	_
32	differentiation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	direct	_	_	JJ	O	-1	none	_	_
3	interaction	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	adaptor	_	_	NN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	Cbl-b	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	zap-70	_	_	NN	Protein	-1	none	_	_
13	induces	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	positive	_	_	JJ	O	-1	none	_	_
16	signal	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	activated	_	_	JJ	O	-1	none	_	_
3	kinases	_	_	NNS	O	-1	none	_	_
4	then	_	_	RB	O	-1	none	_	_
5	induce	_	_	VBP	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	tyrosine	_	_	NN	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	multiple	_	_	JJ	O	-1	none	_	_
11	intracellular	_	_	JJ	O	-1	none	_	_
12	proteins	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	eventually	_	_	RB	O	-1	none	_	_
15	leading	_	_	VBG	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	T-cell	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	prominent	_	_	JJ	O	-1	none	_	_
5	substrates	_	_	NNS	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	kinases	_	_	NNS	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	adaptor	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	Cbl	_	_	NN	O	-1	none	_	_
14	[	_	_	CD	O	-1	none	_	_
15	3	_	_	CD	O	-1	none	_	_
16	]	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	recent	_	_	JJ	O	-1	none	_	_
19	studies	_	_	NNS	O	-1	none	_	_
20	suggest	_	_	VBP	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	Cbl	_	_	NN	O	-1	none	_	_
23	negatively	_	_	RB	O	-1	none	_	_
24	regulates	_	_	VBZ	O	-1	none	_	_
25	upstream	_	_	JJ	O	-1	none	_	_
26	kinases	_	_	NNS	O	-1	none	_	_
27	such	_	_	JJ	O	-1	none	_	_
28	as	_	_	IN	O	-1	none	_	_
29	Syk	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	Zap-70	_	_	NN	Protein	-1	none	_	_
32	[	_	_	CD	O	-1	none	_	_
33	4	_	_	CD	O	-1	none	_	_
34	]	_	_	NN	O	-1	none	_	_
35	[	_	_	CD	O	-1	none	_	_
36	5	_	_	CD	O	-1	none	_	_
37	]	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Cbl-b	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	homologue	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Cbl	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	widely	_	_	RB	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	many	_	_	JJ	O	-1	none	_	_
13	tissues	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	including	_	_	VBG	O	-1	none	_	_
17	hematopoietic	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	[	_	_	VBP	O	-1	none	_	_
20	6	_	_	CD	O	-1	none	_	_
21	]	_	_	CD	O	-1	none	_	_
22	[	_	_	NN	O	-1	none	_	_
23	7	_	_	CD	O	-1	none	_	_
24	]	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Cbl-b	_	_	NN	Protein	-1	none	_	_
2	undergoes	_	_	VBZ	O	-1	none	_	_
3	rapid	_	_	JJ	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylation	_	_	NN	O	-1	none	_	_
6	upon	_	_	IN	O	-1	none	_	_
7	stimulation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	TCR	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	cytokine	_	_	NN	O	-1	none	_	_
13	receptors	_	_	NNS	O	-1	none	_	_
14	[	_	_	VBP	O	-1	none	_	_
15	8	_	_	CD	O	-1	none	_	_
16	]	_	_	CD	O	-1	none	_	_
17	[	_	_	CD	O	-1	none	_	_
18	9	_	_	CD	O	-1	none	_	_
19	]	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Cbl-b	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	unclear	_	_	JJ	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	however	_	_	RB	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	overexpression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Cbl-b	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	constitutive	_	_	JJ	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	NFAT	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Unlike	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	proposed	_	_	JJ	O	-1	none	_	_
4	role	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Cbl	_	_	NN	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	negative	_	_	JJ	O	-1	none	_	_
10	regulator	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	our	_	_	PRP$	O	-1	none	_	_
13	results	_	_	NNS	O	-1	none	_	_
14	suggest	_	_	VBP	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	Cbl	_	_	NN	O	-1	none	_	_
18	homologue	_	_	NN	O	-1	none	_	_
19	Cbl-b	_	_	NN	Protein	-1	none	_	_
20	has	_	_	VBZ	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	positive	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	T-cell	_	_	NN	O	-1	none	_	_
26	signaling	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	most	_	_	RBS	O	-1	none	_	_
29	likely	_	_	JJ	O	-1	none	_	_
30	via	_	_	IN	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	direct	_	_	JJ	O	-1	none	_	_
33	interaction	_	_	NN	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	upstream	_	_	JJ	O	-1	none	_	_
37	kinase	_	_	NN	O	-1	none	_	_
38	Zap-70	_	_	NN	Protein	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Molecular	_	_	JJ	O	-1	none	_	_
2	mechanisms	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	steroid	_	_	NN	O	-1	none	_	_
5	action	_	_	NN	O	-1	none	_	_
6	:	_	_	:	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	novel	_	_	JJ	O	-1	none	_	_
9	type	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cross-talk	_	_	NN	O	-1	none	_	_
12	between	_	_	IN	O	-1	none	_	_
13	glucocorticoids	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	NF-kappa	_	_	NN	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factors	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Despite	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	widespread	_	_	JJ	O	-1	none	_	_
4	use	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	glucocorticoids	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	treatment	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	diseases	_	_	NNS	O	-1	none	_	_
12	characterized	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	inflammation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	molecular	_	_	JJ	O	-1	none	_	_
18	mechanism	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	s	_	_	VBZ	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	these	_	_	DT	O	-1	none	_	_
25	hormones	_	_	NNS	O	-1	none	_	_
26	exert	_	_	VBP	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	beneficial	_	_	JJ	O	-1	none	_	_
29	effect	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	patients	_	_	NNS	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	asthma	_	_	NN	O	-1	none	_	_
34	remains	_	_	VBZ	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	be	_	_	VB	O	-1	none	_	_
37	elucidated	_	_	VBN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	studied	_	_	VBN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	transcriptional	_	_	JJ	O	-1	none	_	_
8	regulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	intercellular	_	_	JJ	Protein	12	multitoken	_	_
11	adhesion	_	_	NN	Protein	12	multitoken	_	_
12	molecule-1	_	_	NN	Protein	0	root	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	ICAM-1	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	adhesion	_	_	NN	O	-1	none	_	_
18	molecules	_	_	NNS	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	likely	_	_	JJ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	play	_	_	VB	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	causal	_	_	JJ	O	-1	none	_	_
25	role	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	inflammation	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	promoting	_	_	VBG	O	-1	none	_	_
30	cell-cell	_	_	JJ	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	cell-matrix	_	_	JJ	O	-1	none	_	_
33	interactions	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	observed	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	monocytic	_	_	JJ	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	U937	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	bronchial	_	_	JJ	O	-1	none	_	_
13	epithelial	_	_	JJ	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	H292	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	cell-line	_	_	JJ	O	-1	none	_	_
18	dexamethasone	_	_	NN	O	-1	none	_	_
19	strongly	_	_	RB	O	-1	none	_	_
20	suppressed	_	_	VBD	O	-1	none	_	_
21	basal	_	_	JJ	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	induced	_	_	JJ	O	-1	none	_	_
24	ICAM-1	_	_	NN	Protein	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Subsequent	_	_	JJ	O	-1	none	_	_
2	analysis	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	ICAM-1	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	revealed	_	_	VBN	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	12-O-tetradecanoylphorbol	_	_	NN	O	-1	none	_	_
13	13-acetate	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	TPA	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	tumour	_	_	NN	Protein	20	multitoken	_	_
19	necrosis	_	_	NN	Protein	20	multitoken	_	_
20	factor-alpha	_	_	NN	Protein	0	root	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	TNF-alpha	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	upregulate	_	_	VBP	O	-1	none	_	_
25	ICAM-1	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	through	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	presence	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	nuclear	_	_	JJ	O	-1	none	_	_
33	factor	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	NF-kappa	_	_	NN	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	target	_	_	NN	O	-1	none	_	_
39	sequence	_	_	NN	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	TGGAAATTCC	_	_	NN	O	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	glucocorticoid	_	_	NN	O	-1	none	_	_
3	recognition	_	_	NN	O	-1	none	_	_
4	sequences	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	present	_	_	JJ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	promoter	_	_	NN	O	-1	none	_	_
10	region	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	dexamethasone	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	still	_	_	RB	O	-1	none	_	_
15	able	_	_	JJ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	repress	_	_	VB	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	when	_	_	WRB	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	multimerized	_	_	JJ	O	-1	none	_	_
22	NF-kappa	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	sequence	_	_	NN	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	transactivated	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	TNF-alpha	_	_	NN	Protein	-1	none	_	_
29	upon	_	_	IN	O	-1	none	_	_
30	transfection	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	293	_	_	CD	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	direct	_	_	JJ	O	-1	none	_	_
5	interaction	_	_	NN	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	glucocorticoid	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	and	_	_	CC	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	factor-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	at	_	_	IN	O	-1	none	_	_
17	least	_	_	JJS	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	partial	_	_	JJ	O	-1	none	_	_
20	explanation	_	_	NN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	effects	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	this	_	_	DT	O	-1	none	_	_
26	hormone	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	inflammatory	_	_	JJ	O	-1	none	_	_
29	diseases	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Block	_	_	NNP	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	granulocytic	_	_	JJ	O	-1	none	_	_
4	differentiation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	32Dcl3	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	AML1	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	ETO	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	MTG8	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	but	_	_	CC	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	highly	_	_	RB	O	-1	none	_	_
19	expressed	_	_	VBN	O	-1	none	_	_
20	Bcl-2	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	chimeric	_	_	JJ	O	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	AML1	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	ETO	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	MTG8	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	generated	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	t	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	8	_	_	CD	O	-1	none	_	_
17	;	_	_	:	O	-1	none	_	_
18	21	_	_	CD	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	acute	_	_	JJ	O	-1	none	_	_
21	myeloid	_	_	JJ	O	-1	none	_	_
22	leukemia	_	_	NN	O	-1	none	_	_
23	enhances	_	_	VBZ	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	Bcl-2	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	evaluate	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	enhancement	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	primary	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	AML1	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	ETO	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	leukemogenesis	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	effects	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	over-expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	Bcl-2	_	_	NN	Protein	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	murine	_	_	JJ	O	-1	none	_	_
25	myeloid	_	_	JJ	O	-1	none	_	_
26	precursor	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	line	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	32Dcl3	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	were	_	_	VBD	O	-1	none	_	_
33	examined	_	_	VBN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	32Dcl3	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	expressing	_	_	VBG	O	-1	none	_	_
5	exogenous	_	_	JJ	O	-1	none	_	_
6	Bcl-2	_	_	NN	Protein	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	induced	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	differentiate	_	_	VB	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	onset	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	morphological	_	_	JJ	O	-1	none	_	_
16	differentiation	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	delayed	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	even	_	_	RB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	expressing	_	_	VBG	O	-1	none	_	_
7	very	_	_	RB	O	-1	none	_	_
8	high	_	_	JJ	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	exogenous	_	_	JJ	O	-1	none	_	_
12	Bcl-2	_	_	NN	Protein	-1	none	_	_
13	eventually	_	_	RB	O	-1	none	_	_
14	underwent	_	_	VBD	O	-1	none	_	_
15	differentiation	_	_	NN	O	-1	none	_	_
16	without	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	significant	_	_	JJ	O	-1	none	_	_
19	decrease	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	synthesis	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	Bcl-2	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	contrary	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	32Dcl3	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	stably	_	_	RB	O	-1	none	_	_
8	expressing	_	_	VBG	O	-1	none	_	_
9	AML1	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	ETO	_	_	NN	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	completely	_	_	RB	O	-1	none	_	_
14	resistant	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	differentiation	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	continued	_	_	VBD	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	grow	_	_	VB	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	presence	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	G-CSF	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	consistent	_	_	JJ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	interpretation	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	stimulation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Bcl-2	_	_	NN	Protein	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	primary	_	_	JJ	O	-1	none	_	_
17	target	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	AML1	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	ETO	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Phosphorylation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	NFATp	_	_	NN	Protein	-1	none	_	_
7	inhibits	_	_	VBZ	O	-1	none	_	_
8	its	_	_	PRP$	O	-1	none	_	_
9	DNA	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	cyclosporin	_	_	NN	O	-1	none	_	_
14	A	_	_	NN	O	-1	none	_	_
15	treated	_	_	VBN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Cyclosporin	_	_	NN	O	-1	none	_	_
2	A	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	CsA	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	exerts	_	_	VBZ	O	-1	none	_	_
7	its	_	_	PRP$	O	-1	none	_	_
8	immunosuppressive	_	_	JJ	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	inhibiting	_	_	VBG	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	factor	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	activated	_	_	VBN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	NFAT	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	thus	_	_	RB	O	-1	none	_	_
26	preventing	_	_	VBG	O	-1	none	_	_
27	transcriptional	_	_	JJ	O	-1	none	_	_
28	induction	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	several	_	_	JJ	O	-1	none	_	_
31	cytokine	_	_	NN	O	-1	none	_	_
32	genes	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	thought	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	largely	_	_	RB	O	-1	none	_	_
8	mediated	_	_	VBN	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	inactivation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	phosphatase	_	_	NN	O	-1	none	_	_
14	calcineurin	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	turn	_	_	NN	O	-1	none	_	_
19	inhibits	_	_	VBZ	O	-1	none	_	_
20	translocation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	an	_	_	DT	O	-1	none	_	_
23	NFAT	_	_	NN	O	-1	none	_	_
24	component	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	nucleus	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	CsA	_	_	NN	O	-1	none	_	_
6	treatment	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Raji	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Jurkat	_	_	NN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	lines	_	_	NNS	O	-1	none	_	_
15	yields	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	phosphorylated	_	_	JJ	O	-1	none	_	_
18	form	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	NFATp	_	_	NN	Protein	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	inhibited	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	DNA	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	its	_	_	PRP$	O	-1	none	_	_
30	ability	_	_	NN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	form	_	_	VB	O	-1	none	_	_
33	an	_	_	DT	O	-1	none	_	_
34	NFAT	_	_	NN	O	-1	none	_	_
35	complex	_	_	NN	O	-1	none	_	_
36	with	_	_	IN	O	-1	none	_	_
37	Fos	_	_	NN	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	Jun.	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Immunoblot	_	_	NN	O	-1	none	_	_
2	analyses	_	_	NNS	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	metabolic	_	_	JJ	O	-1	none	_	_
5	labeling	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	[	_	_	CD	O	-1	none	_	_
8	32P	_	_	NN	O	-1	none	_	_
9	]	_	_	NN	O	-1	none	_	_
10	orthophosphate	_	_	NN	O	-1	none	_	_
11	show	_	_	VBP	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	CsA	_	_	NN	O	-1	none	_	_
14	alters	_	_	VBZ	O	-1	none	_	_
15	NFATp	_	_	NN	Protein	-1	none	_	_
16	migration	_	_	NN	O	-1	none	_	_
17	on	_	_	IN	O	-1	none	_	_
18	SDS-polyacrylamide	_	_	NN	O	-1	none	_	_
19	gel	_	_	NN	O	-1	none	_	_
20	electrophoresis	_	_	NN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	increasing	_	_	VBG	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	phosphorylation	_	_	NN	O	-1	none	_	_
25	level	_	_	NN	O	-1	none	_	_
26	without	_	_	IN	O	-1	none	_	_
27	affecting	_	_	VBG	O	-1	none	_	_
28	subcellular	_	_	JJ	O	-1	none	_	_
29	distribution	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Dephosphorylation	_	_	NN	O	-1	none	_	_
2	by	_	_	IN	O	-1	none	_	_
3	in	_	_	FW	O	-1	none	_	_
4	vitro	_	_	FW	O	-1	none	_	_
5	treatment	_	_	NN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	calcineurin	_	_	NN	O	-1	none	_	_
8	or	_	_	CC	O	-1	none	_	_
9	alkaline	_	_	NN	Protein	10	multitoken	_	_
10	phosphatase	_	_	NN	Protein	0	root	_	_
11	restores	_	_	VBZ	O	-1	none	_	_
12	NFATp	_	_	NN	Protein	-1	none	_	_
13	DNA	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	ability	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	reconstitute	_	_	VB	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	NFAT	_	_	NN	O	-1	none	_	_
23	complex	_	_	NN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	Fos	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Jun	_	_	NN	O	-1	none	_	_
28	proteins	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	point	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	new	_	_	JJ	O	-1	none	_	_
7	mechanism	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	CsA	_	_	NN	O	-1	none	_	_
10	sensitive	_	_	JJ	O	-1	none	_	_
11	regulation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	NFATp	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	dephosphorylation	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	critical	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	DNA	_	_	NN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Interleukin-6	_	_	NNP	Protein	-1	none	_	_
2	production	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	hemorrhagic	_	_	JJ	O	-1	none	_	_
5	shock	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	accompanied	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	neutrophil	_	_	NN	O	-1	none	_	_
10	recruitment	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	lung	_	_	NN	O	-1	none	_	_
13	injury	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Hemorrhagic	_	_	JJ	O	-1	none	_	_
2	shock	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	HS	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	initiates	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	inflammatory	_	_	JJ	O	-1	none	_	_
9	cascade	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	includes	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	production	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	cytokines	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	recruitment	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	neutrophils	_	_	NNS	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	PMN	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	may	_	_	MD	O	-1	none	_	_
25	progress	_	_	VB	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	organ	_	_	NN	O	-1	none	_	_
28	failure	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	inducing	_	_	VBG	O	-1	none	_	_
31	acute	_	_	JJ	O	-1	none	_	_
32	respiratory	_	_	JJ	O	-1	none	_	_
33	distress	_	_	NN	O	-1	none	_	_
34	syndrome	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	ARDS	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	examine	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	hypothesis	_	_	NN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	interleukin-6	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	IL-6	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	contributes	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	PMN	_	_	NN	O	-1	none	_	_
13	infiltration	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	lung	_	_	NN	O	-1	none	_	_
16	damage	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	HS	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	examined	_	_	VBD	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	lungs	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	rats	_	_	NNS	O	-1	none	_	_
26	subjected	_	_	VBN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	unresuscitated	_	_	JJ	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	resuscitated	_	_	VBN	O	-1	none	_	_
31	HS	_	_	NN	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	production	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	IL-6	_	_	NN	Protein	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	activation	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	Stat3	_	_	NN	Protein	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	semiquantitative	_	_	JJ	O	-1	none	_	_
3	RT-PCR	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	found	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	striking	_	_	JJ	O	-1	none	_	_
9	increase	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	IL-6	_	_	NN	Protein	-1	none	_	_
12	mRNA	_	_	NN	O	-1	none	_	_
13	levels	_	_	NNS	O	-1	none	_	_
14	only	_	_	RB	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	resuscitated	_	_	VBN	O	-1	none	_	_
17	HS	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	peak	_	_	JJ	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	observed	_	_	VBN	O	-1	none	_	_
23	1	_	_	CD	O	-1	none	_	_
24	h	_	_	NN	O	-1	none	_	_
25	after	_	_	IN	O	-1	none	_	_
26	initiation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	resuscitation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Increased	_	_	VBN	O	-1	none	_	_
2	IL-6	_	_	NN	Protein	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	localized	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	bronchial	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	alveolar	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Electrophoretic	_	_	JJ	O	-1	none	_	_
2	mobility	_	_	NN	O	-1	none	_	_
3	shift	_	_	NN	O	-1	none	_	_
4	assay	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	extracts	_	_	NNS	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	shock	_	_	NN	O	-1	none	_	_
10	lungs	_	_	NNS	O	-1	none	_	_
11	exhibited	_	_	VBD	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	increase	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	Stat3	_	_	NN	Protein	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	kinetics	_	_	NNS	O	-1	none	_	_
19	similar	_	_	JJ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	IL-6	_	_	NN	Protein	-1	none	_	_
22	mRNA	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	FW	O	-1	none	_	_
2	situ	_	_	FW	O	-1	none	_	_
3	DNA	_	_	NN	O	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	assay	_	_	NN	O	-1	none	_	_
6	determined	_	_	VBD	O	-1	none	_	_
7	Stat3	_	_	NN	Protein	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	predominantly	_	_	RB	O	-1	none	_	_
10	within	_	_	IN	O	-1	none	_	_
11	alveoli	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Intratracheal	_	_	JJ	O	-1	none	_	_
2	instillation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	alone	_	_	RB	O	-1	none	_	_
6	into	_	_	IN	O	-1	none	_	_
7	normal	_	_	JJ	O	-1	none	_	_
8	rats	_	_	NNS	O	-1	none	_	_
9	resulted	_	_	VBD	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	PMN	_	_	NN	O	-1	none	_	_
12	infiltration	_	_	NN	O	-1	none	_	_
13	into	_	_	IN	O	-1	none	_	_
14	lung	_	_	NN	O	-1	none	_	_
15	interstitium	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	alveoli	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	marked	_	_	JJ	O	-1	none	_	_
20	elevation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	bronchoalveolar	_	_	JJ	O	-1	none	_	_
23	lavage	_	_	NN	O	-1	none	_	_
24	cellularity	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	increased	_	_	VBD	O	-1	none	_	_
28	wet-to-dry	_	_	JJ	O	-1	none	_	_
29	ratio	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IL-6	_	_	NN	Protein	-1	none	_	_
6	production	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	Stat3	_	_	NN	Protein	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	occur	_	_	VBP	O	-1	none	_	_
11	early	_	_	RB	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	HS	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	contribute	_	_	VB	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	PMN	_	_	NN	O	-1	none	_	_
19	mediated	_	_	VBD	O	-1	none	_	_
20	lung	_	_	NN	O	-1	none	_	_
21	injury	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	including	_	_	VBG	O	-1	none	_	_
24	ARDS	_	_	NN	O	-1	none	_	_
25	after	_	_	IN	O	-1	none	_	_
26	HS	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Tumor	_	_	NN	O	-1	none	_	_
2	necrosis	_	_	NN	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	receptor	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	signal	_	_	NN	O	-1	none	_	_
8	transduction	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	HIV-1-infected	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	OBJECTIVE	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	To	_	_	TO	O	-1	none	_	_
4	examine	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	inter-relationship	_	_	NN	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	HIV-1	_	_	NN	O	-1	none	_	_
9	infection	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	surface	_	_	NN	O	-1	none	_	_
14	receptors	_	_	NNS	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	tumor	_	_	NN	Protein	21	multitoken	_	_
17	necrosis	_	_	NN	Protein	21	multitoken	_	_
18	factor	_	_	NN	Protein	21	multitoken	_	_
19	(	_	_	-LRB-	Protein	21	multitoken	_	_
20	TNF	_	_	NN	Protein	21	multitoken	_	_
21	)-alpha	_	_	NN	Protein	0	root	_	_
22	,	_	_	,	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	immunoregulatory	_	_	JJ	O	-1	none	_	_
25	cytokine	_	_	NN	O	-1	none	_	_
26	that	_	_	WDT	O	-1	none	_	_
27	can	_	_	MD	O	-1	none	_	_
28	enhance	_	_	VB	O	-1	none	_	_
29	HIV-1	_	_	NN	O	-1	none	_	_
30	replication	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	DESIGN	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Infected	_	_	JJ	O	-1	none	_	_
4	promyelocytic	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	promonocytic	_	_	JJ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	examined	_	_	VBN	O	-1	none	_	_
10	because	_	_	IN	O	-1	none	_	_
11	they	_	_	PRP	O	-1	none	_	_
12	normally	_	_	RB	O	-1	none	_	_
13	express	_	_	VBP	O	-1	none	_	_
14	both	_	_	DT	O	-1	none	_	_
15	types	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	TNF	_	_	NN	O	-1	none	_	_
18	receptors	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	TNF	_	_	NN	O	-1	none	_	_
4	receptor	_	_	NN	O	-1	none	_	_
5	surface	_	_	NN	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	determined	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	specific	_	_	JJ	O	-1	none	_	_
11	monoclonal	_	_	JJ	O	-1	none	_	_
12	antibody	_	_	NN	O	-1	none	_	_
13	recognition	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	flow	_	_	NN	O	-1	none	_	_
16	cytometry	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	signal	_	_	NN	O	-1	none	_	_
20	transduction	_	_	NN	O	-1	none	_	_
21	was	_	_	VBD	O	-1	none	_	_
22	detected	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	gel	_	_	NN	O	-1	none	_	_
25	shift	_	_	NN	O	-1	none	_	_
26	analysis	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	HIV-1	_	_	NNP	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	quantitated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	reverse	_	_	JJ	Protein	9	multitoken	_	_
9	transcriptase	_	_	NN	Protein	0	root	_	_
10	assay	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	series	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	uninfected	_	_	JJ	O	-1	none	_	_
5	parental	_	_	JJ	O	-1	none	_	_
6	HL-60	_	_	NN	O	-1	none	_	_
7	subclones	_	_	NNS	O	-1	none	_	_
8	all	_	_	DT	O	-1	none	_	_
9	reduced	_	_	VBD	O	-1	none	_	_
10	TR75	_	_	NN	Protein	-1	none	_	_
11	surface	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	TNF-alpha	_	_	NN	Protein	-1	none	_	_
17	treatment	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	An	_	_	DT	O	-1	none	_	_
2	increase	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	TR75	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	evident	_	_	JJ	O	-1	none	_	_
9	during	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	peak	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	acute	_	_	JJ	O	-1	none	_	_
15	HIV-1	_	_	NN	O	-1	none	_	_
16	infection	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	HL-60	_	_	NN	O	-1	none	_	_
19	promyelocytes	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Antibody	_	_	NN	O	-1	none	_	_
2	cross	_	_	NN	O	-1	none	_	_
3	linking	_	_	VBG	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	TR55	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	absence	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	exogenous	_	_	JJ	O	-1	none	_	_
12	TNF-alpha	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	induced	_	_	VBD	O	-1	none	_	_
15	maximal	_	_	JJ	O	-1	none	_	_
16	HIV-1	_	_	NN	O	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	up-modulation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	surface	_	_	NN	O	-1	none	_	_
23	TR75	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	nuclear	_	_	JJ	O	-1	none	_	_
27	NF-kappa	_	_	NN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	activity	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	OM-10	_	_	NN	O	-1	none	_	_
32	.1	_	_	CD	O	-1	none	_	_
33	cultures	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Surprisingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	case	_	_	NN	O	-1	none	_	_
7	even	_	_	RB	O	-1	none	_	_
8	when	_	_	WRB	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	antagonistic	_	_	JJ	O	-1	none	_	_
11	anti-TR55	_	_	JJ	Protein	-1	none	_	_
12	antibody	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	used	_	_	VBN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Our	_	_	PRP$	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	demonstrated	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	HIV-1	_	_	NN	O	-1	none	_	_
8	infection	_	_	NN	O	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	selectively	_	_	RB	O	-1	none	_	_
11	influence	_	_	VB	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	surface	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	TNF	_	_	NN	O	-1	none	_	_
17	receptors	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	potentially	_	_	RB	O	-1	none	_	_
20	influencing	_	_	VBG	O	-1	none	_	_
21	its	_	_	PRP$	O	-1	none	_	_
22	own	_	_	JJ	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	altering	_	_	VBG	O	-1	none	_	_
26	normal	_	_	JJ	O	-1	none	_	_
27	immunoregulatory	_	_	JJ	O	-1	none	_	_
28	signal	_	_	NN	O	-1	none	_	_
29	transduction	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Association	_	_	NNP	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	interleukin-4	_	_	NN	Protein	7	multitoken	_	_
5	receptor	_	_	NN	Protein	7	multitoken	_	_
6	alpha	_	_	NN	Protein	7	multitoken	_	_
7	chain	_	_	NN	Protein	0	root	_	_
8	with	_	_	IN	O	-1	none	_	_
9	p47phox	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	activator	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	phagocyte	_	_	NN	O	-1	none	_	_
16	NADPH	_	_	NN	O	-1	none	_	_
17	oxidase	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Interleukin	_	_	NN	Protein	5	multitoken	_	_
2	(	_	_	-LRB-	Protein	5	multitoken	_	_
3	IL	_	_	NN	Protein	5	multitoken	_	_
4	)	_	_	-RRB-	Protein	5	multitoken	_	_
5	-4	_	_	CD	Protein	0	root	_	_
6	plays	_	_	VBZ	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	important	_	_	JJ	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	IgE	_	_	NN	O	-1	none	_	_
12	synthesis	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	Th2	_	_	NN	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	IL-4	_	_	NNP	Protein	-1	none	_	_
2	conducts	_	_	VBZ	O	-1	none	_	_
3	its	_	_	PRP$	O	-1	none	_	_
4	biological	_	_	JJ	O	-1	none	_	_
5	activities	_	_	NNS	O	-1	none	_	_
6	through	_	_	IN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	IL-4	_	_	NN	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	IL-4R	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	surface	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	target	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	IL-4R	_	_	NNP	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	thought	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	composed	_	_	VBN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	IL-4R	_	_	NN	Protein	11	multitoken	_	_
10	alpha	_	_	NN	Protein	11	multitoken	_	_
11	chain	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	IL-4R	_	_	NN	Protein	14	multitoken	_	_
14	alpha	_	_	NN	Protein	0	root	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	either	_	_	CC	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-2R	_	_	NN	Protein	21	multitoken	_	_
20	gamma	_	_	NN	Protein	21	multitoken	_	_
21	chain	_	_	NN	Protein	0	root	_	_
22	or	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	IL-13R	_	_	NN	Protein	26	multitoken	_	_
25	alpha	_	_	NN	Protein	26	multitoken	_	_
26	chain	_	_	NN	Protein	0	root	_	_
27	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	found	_	_	VBD	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	p47phox	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	activator	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	phagocyte	_	_	NN	O	-1	none	_	_
15	NADPH	_	_	NN	O	-1	none	_	_
16	oxidase	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	binds	_	_	VBZ	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	this	_	_	DT	O	-1	none	_	_
21	portion	_	_	NN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	two-hybrid	_	_	JJ	O	-1	none	_	_
25	system	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	observed	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	association	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p47phox	_	_	NN	Protein	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	hIL-4R	_	_	NN	Protein	12	multitoken	_	_
12	alpha	_	_	NN	Protein	0	root	_	_
13	in	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	derived	_	_	VBN	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	normal	_	_	JJ	O	-1	none	_	_
20	donor	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	p47phox	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transduction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	IL-4	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	STAT6	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	CD23	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	IgE	_	_	NN	O	-1	none	_	_
12	synthesis	_	_	NN	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	IL-4	_	_	NN	Protein	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	affected	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	p47phox	_	_	NN	Protein	-1	none	_	_
21	deficient	_	_	JJ	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	which	_	_	WDT	O	-1	none	_	_
25	raises	_	_	VBZ	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	possibility	_	_	NN	O	-1	none	_	_
28	that	_	_	IN	O	-1	none	_	_
29	p47phox	_	_	NN	Protein	-1	none	_	_
30	may	_	_	MD	O	-1	none	_	_
31	be	_	_	VB	O	-1	none	_	_
32	important	_	_	JJ	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	other	_	_	JJ	O	-1	none	_	_
35	signaling	_	_	NN	O	-1	none	_	_
36	activities	_	_	NNS	O	-1	none	_	_
37	as	_	_	RB	O	-1	none	_	_
38	well	_	_	RB	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	B	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	[	_	_	RB	O	-1	none	_	_
2	Hormonal	_	_	JJ	O	-1	none	_	_
3	metabolic	_	_	JJ	O	-1	none	_	_
4	status	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	breast	_	_	NN	O	-1	none	_	_
7	cancer	_	_	NN	O	-1	none	_	_
8	patients	_	_	NNS	O	-1	none	_	_
9	after	_	_	IN	O	-1	none	_	_
10	conservative	_	_	JJ	O	-1	none	_	_
11	surgery	_	_	NN	O	-1	none	_	_
12	:	_	_	:	O	-1	none	_	_
13	comparison	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	known	_	_	JJ	O	-1	none	_	_
16	prognostic	_	_	JJ	O	-1	none	_	_
17	criteria	_	_	NNS	O	-1	none	_	_
18	]	_	_	VBD	O	-1	none	_	_
19	Body	_	_	NN	O	-1	none	_	_
20	weight	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	body	_	_	NN	O	-1	none	_	_
23	mass	_	_	NN	O	-1	none	_	_
24	index	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	body	_	_	NN	O	-1	none	_	_
27	fat	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	lean	_	_	JJ	O	-1	none	_	_
30	body	_	_	NN	O	-1	none	_	_
31	mass	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	blood-glucose	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	cholesterol	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	HDL-cholesterol	_	_	NN	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	triglyceride	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	beta-lipoproteins	_	_	NNS	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	insulin	_	_	NN	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	gonadotropin	_	_	NN	O	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	estradiol	_	_	NN	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	testosterone	_	_	NN	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	SHBG	_	_	NN	Protein	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	T3	_	_	NN	O	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	T4	_	_	NN	O	-1	none	_	_
56	and	_	_	CC	O	-1	none	_	_
57	TSH	_	_	NN	O	-1	none	_	_
58	levels	_	_	NNS	O	-1	none	_	_
59	as	_	_	RB	O	-1	none	_	_
60	well	_	_	RB	O	-1	none	_	_
61	as	_	_	IN	O	-1	none	_	_
62	estradiol	_	_	NN	Protein	-1	none	_	_
63	and	_	_	CC	O	-1	none	_	_
64	progesterone	_	_	NN	Protein	65	multitoken	_	_
65	receptor	_	_	NN	Protein	0	root	_	_
66	levels	_	_	NNS	O	-1	none	_	_
67	in	_	_	IN	O	-1	none	_	_
68	excised	_	_	VBN	O	-1	none	_	_
69	tumor	_	_	NN	O	-1	none	_	_
70	were	_	_	VBD	O	-1	none	_	_
71	studied	_	_	VBN	O	-1	none	_	_
72	in	_	_	IN	O	-1	none	_	_
73	40	_	_	CD	O	-1	none	_	_
74	patients	_	_	NNS	O	-1	none	_	_
75	with	_	_	IN	O	-1	none	_	_
76	breast	_	_	NN	O	-1	none	_	_
77	cancer	_	_	NN	O	-1	none	_	_
78	prior	_	_	RB	O	-1	none	_	_
79	to	_	_	TO	O	-1	none	_	_
80	conservative	_	_	JJ	O	-1	none	_	_
81	treatment	_	_	NN	O	-1	none	_	_
82	.	_	_	.	O	-1	none	_	_

1	Said	_	_	NNP	O	-1	none	_	_
2	anthropometric	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	metabolic	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	hormonal	_	_	JJ	O	-1	none	_	_
7	parameters	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	compared	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	index	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	lymphocytic	_	_	JJ	O	-1	none	_	_
15	infiltration	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	tumor	_	_	NN	O	-1	none	_	_
18	selected	_	_	VBN	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	prognostic	_	_	JJ	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	significant	_	_	JJ	O	-1	none	_	_
3	correlation	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	high	_	_	JJ	O	-1	none	_	_
6	lymphocytic	_	_	JJ	O	-1	none	_	_
7	infiltration	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	2.5	_	_	CD	O	-1	none	_	_
10	points	_	_	NNS	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	low	_	_	JJ	O	-1	none	_	_
14	body	_	_	NN	O	-1	none	_	_
15	mass	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	fat	_	_	NN	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	identified	_	_	VBN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Also	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	smoking	_	_	NN	O	-1	none	_	_
4	contributed	_	_	VBD	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	loss	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	body	_	_	NN	O	-1	none	_	_
9	mass	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	fat	_	_	NN	O	-1	none	_	_
12	;	_	_	:	O	-1	none	_	_
13	however	_	_	RB	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	it	_	_	PRP	O	-1	none	_	_
16	caused	_	_	VBD	O	-1	none	_	_
17	lymphocytic	_	_	JJ	O	-1	none	_	_
18	infiltration	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	rise	_	_	VB	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Moderate	_	_	JJ	O	-1	none	_	_
2	body	_	_	NN	O	-1	none	_	_
3	mass	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	relatively	_	_	RB	O	-1	none	_	_
6	low	_	_	JJ	O	-1	none	_	_
7	fat	_	_	JJ	O	-1	none	_	_
8	level	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	positive	_	_	JJ	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	status	_	_	NN	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	among	_	_	IN	O	-1	none	_	_
15	factors	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	good	_	_	JJ	O	-1	none	_	_
18	prognosis	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	breast	_	_	NN	O	-1	none	_	_
21	cancer	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	early	_	_	JJ	O	-1	none	_	_
24	stages	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	HLA	_	_	NN	O	-1	none	_	_
2	class	_	_	NN	O	-1	none	_	_
3	I	_	_	CD	O	-1	none	_	_
4	mediated	_	_	JJ	O	-1	none	_	_
5	induction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	proliferation	_	_	NN	O	-1	none	_	_
9	involves	_	_	VBZ	O	-1	none	_	_
10	cyclin	_	_	NN	O	-1	none	_	_
11	E	_	_	NN	O	-1	none	_	_
12	mediated	_	_	VBD	O	-1	none	_	_
13	inactivation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	Rb	_	_	NN	Protein	-1	none	_	_
16	function	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	induction	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	E2F	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Chronic	_	_	JJ	O	-1	none	_	_
2	rejection	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	transplanted	_	_	VBN	O	-1	none	_	_
5	organs	_	_	NNS	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	manifested	_	_	VBN	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	atherosclerosis	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	blood	_	_	NN	O	-1	none	_	_
13	vessels	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	allograft	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	HLA	_	_	NN	O	-1	none	_	_
2	class	_	_	NN	O	-1	none	_	_
3	I	_	_	CD	O	-1	none	_	_
4	Ags	_	_	NNS	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	implicated	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	play	_	_	VB	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	major	_	_	JJ	O	-1	none	_	_
12	role	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	this	_	_	DT	O	-1	none	_	_
15	process	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	since	_	_	IN	O	-1	none	_	_
18	signaling	_	_	NN	O	-1	none	_	_
19	via	_	_	IN	O	-1	none	_	_
20	HLA	_	_	NN	O	-1	none	_	_
21	class	_	_	NN	O	-1	none	_	_
22	I	_	_	CD	O	-1	none	_	_
23	molecules	_	_	NNS	O	-1	none	_	_
24	can	_	_	MD	O	-1	none	_	_
25	induce	_	_	VB	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	proliferation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	aortic	_	_	JJ	O	-1	none	_	_
30	endothelial	_	_	JJ	O	-1	none	_	_
31	as	_	_	RB	O	-1	none	_	_
32	well	_	_	RB	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	smooth	_	_	JJ	O	-1	none	_	_
35	muscle	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	show	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	HLA	_	_	NN	O	-1	none	_	_
9	class	_	_	NN	O	-1	none	_	_
10	I	_	_	CD	O	-1	none	_	_
11	mediated	_	_	JJ	O	-1	none	_	_
12	induction	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	proliferation	_	_	NN	O	-1	none	_	_
16	correlates	_	_	VBZ	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	inactivation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	Rb	_	_	NN	Protein	-1	none	_	_
22	protein	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	line	_	_	NN	O	-1	none	_	_
28	Jurkat	_	_	NN	O	-1	none	_	_
29	as	_	_	RB	O	-1	none	_	_
30	well	_	_	RB	O	-1	none	_	_
31	as	_	_	IN	O	-1	none	_	_
32	human	_	_	NN	O	-1	none	_	_
33	aortic	_	_	JJ	O	-1	none	_	_
34	endothelial	_	_	JJ	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	HLA	_	_	NN	O	-1	none	_	_
2	class	_	_	NN	O	-1	none	_	_
3	I	_	_	CD	O	-1	none	_	_
4	mediated	_	_	VBD	O	-1	none	_	_
5	inactivation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Rb	_	_	NN	Protein	-1	none	_	_
8	can	_	_	MD	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	inhibited	_	_	VBN	O	-1	none	_	_
11	specifically	_	_	RB	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	neutralizing	_	_	VBG	O	-1	none	_	_
14	Abs	_	_	NNS	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	basic	_	_	JJ	O	-1	none	_	_
17	fibroblast	_	_	NN	O	-1	none	_	_
18	growth	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	bFGF	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	suggesting	_	_	VBG	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	role	_	_	NN	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	FGF	_	_	NN	O	-1	none	_	_
29	receptors	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	signaling	_	_	NN	O	-1	none	_	_
33	process	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Signaling	_	_	NN	O	-1	none	_	_
2	through	_	_	IN	O	-1	none	_	_
3	HLA	_	_	NN	O	-1	none	_	_
4	class	_	_	NN	O	-1	none	_	_
5	I	_	_	CD	O	-1	none	_	_
6	molecules	_	_	NNS	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	cyclin	_	_	NN	O	-1	none	_	_
9	E	_	_	NN	O	-1	none	_	_
10	associated	_	_	JJ	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	within	_	_	IN	O	-1	none	_	_
14	4	_	_	CD	O	-1	none	_	_
15	h	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	quiescent	_	_	JJ	O	-1	none	_	_
18	endothelial	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	appeared	_	_	VBD	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	mediate	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	inactivation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	Rb	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	cdk2	_	_	NN	Protein	-1	none	_	_
3	inhibitor	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	Olomoucine	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	as	_	_	RB	O	-1	none	_	_
8	well	_	_	RB	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	dominant	_	_	JJ	O	-1	none	_	_
12	negative	_	_	JJ	O	-1	none	_	_
13	cdk2	_	_	NN	Protein	-1	none	_	_
14	construct	_	_	NN	O	-1	none	_	_
15	prevented	_	_	VBD	O	-1	none	_	_
16	HLA	_	_	NN	O	-1	none	_	_
17	class	_	_	NN	O	-1	none	_	_
18	I	_	_	CD	O	-1	none	_	_
19	mediated	_	_	VBD	O	-1	none	_	_
20	inactivation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	Rb	_	_	NN	Protein	-1	none	_	_
23	;	_	_	:	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	contrast	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	dominant	_	_	JJ	O	-1	none	_	_
28	negative	_	_	JJ	O	-1	none	_	_
29	cdk4	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	cdk6	_	_	NN	Protein	-1	none	_	_
32	constructs	_	_	NNS	O	-1	none	_	_
33	had	_	_	VBD	O	-1	none	_	_
34	no	_	_	DT	O	-1	none	_	_
35	effect	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	there	_	_	EX	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	no	_	_	DT	O	-1	none	_	_
6	increase	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	cyclin	_	_	NN	O	-1	none	_	_
9	D	_	_	NN	O	-1	none	_	_
10	associated	_	_	JJ	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	upon	_	_	IN	O	-1	none	_	_
14	HLA	_	_	NN	O	-1	none	_	_
15	class	_	_	NN	O	-1	none	_	_
16	I	_	_	CD	O	-1	none	_	_
17	ligation	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	suggesting	_	_	VBG	O	-1	none	_	_
20	that	_	_	IN	O	-1	none	_	_
21	cyclin	_	_	NN	O	-1	none	_	_
22	E	_	_	NN	O	-1	none	_	_
23	dependent	_	_	JJ	O	-1	none	_	_
24	kinase	_	_	NN	O	-1	none	_	_
25	activity	_	_	NN	O	-1	none	_	_
26	mediates	_	_	VBZ	O	-1	none	_	_
27	Rb	_	_	NN	Protein	-1	none	_	_
28	inactivation	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	leading	_	_	VBG	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	E2F	_	_	NN	O	-1	none	_	_
33	activation	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	cell	_	_	NN	O	-1	none	_	_
36	proliferation	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	central	_	_	JJ	O	-1	none	_	_
3	role	_	_	NN	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	single	_	_	JJ	O	-1	none	_	_
7	c-Myb	_	_	NN	Protein	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	site	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	thymic	_	_	JJ	O	-1	none	_	_
13	locus	_	_	NN	O	-1	none	_	_
14	control	_	_	NN	O	-1	none	_	_
15	region	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Locus	_	_	NN	O	-1	none	_	_
2	control	_	_	NN	O	-1	none	_	_
3	regions	_	_	NNS	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	LCRs	_	_	NNS	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	powerful	_	_	JJ	O	-1	none	_	_
9	assemblies	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cis	_	_	NN	O	-1	none	_	_
12	elements	_	_	NNS	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	organize	_	_	VBP	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	actions	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cell-type-specific	_	_	JJ	O	-1	none	_	_
19	trans-acting	_	_	JJ	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	2.3-kb	_	_	JJ	O	-1	none	_	_
3	LCR	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	adenosine	_	_	NN	Protein	8	multitoken	_	_
8	deaminase	_	_	NN	Protein	0	root	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	ADA	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	first	_	_	JJ	O	-1	none	_	_
14	intron	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	controls	_	_	VBZ	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	thymocytes	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	composed	_	_	VBN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	200-bp	_	_	JJ	O	-1	none	_	_
27	enhancer	_	_	NN	O	-1	none	_	_
28	domain	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	extended	_	_	VBD	O	-1	none	_	_
31	flanking	_	_	JJ	O	-1	none	_	_
32	sequences	_	_	NNS	O	-1	none	_	_
33	that	_	_	WDT	O	-1	none	_	_
34	facilitate	_	_	VBP	O	-1	none	_	_
35	activation	_	_	NN	O	-1	none	_	_
36	from	_	_	IN	O	-1	none	_	_
37	within	_	_	IN	O	-1	none	_	_
38	chromatin	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Prior	_	_	RB	O	-1	none	_	_
2	analyses	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	enhancer	_	_	NN	O	-1	none	_	_
8	contains	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	28-bp	_	_	JJ	O	-1	none	_	_
11	core	_	_	NN	O	-1	none	_	_
12	region	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	local	_	_	JJ	O	-1	none	_	_
15	adjacent	_	_	JJ	O	-1	none	_	_
16	augmentative	_	_	JJ	O	-1	none	_	_
17	cis	_	_	NN	O	-1	none	_	_
18	elements	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	core	_	_	NN	O	-1	none	_	_
7	contains	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	single	_	_	JJ	O	-1	none	_	_
10	critical	_	_	JJ	O	-1	none	_	_
11	c-Myb	_	_	NN	Protein	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	both	_	_	DT	O	-1	none	_	_
3	transiently	_	_	RB	O	-1	none	_	_
4	cotransfected	_	_	VBN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	stable	_	_	JJ	O	-1	none	_	_
9	chromatin	_	_	NN	O	-1	none	_	_
10	integrated	_	_	VBN	O	-1	none	_	_
11	yeast	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	c-Myb	_	_	NN	Protein	-1	none	_	_
15	strongly	_	_	RB	O	-1	none	_	_
16	transactivated	_	_	VBD	O	-1	none	_	_
17	reporter	_	_	NN	O	-1	none	_	_
18	constructs	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	contained	_	_	VBD	O	-1	none	_	_
21	polymerized	_	_	JJ	O	-1	none	_	_
22	core	_	_	NN	O	-1	none	_	_
23	sequences	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	c-Myb	_	_	NNP	Protein	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	strongly	_	_	RB	O	-1	none	_	_
5	evident	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	lymphoblasts	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	enhancer	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	active	_	_	JJ	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	localized	_	_	JJ	O	-1	none	_	_
18	within	_	_	IN	O	-1	none	_	_
19	discrete	_	_	JJ	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	structures	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Fetal	_	_	JJ	O	-1	none	_	_
2	murine	_	_	JJ	O	-1	none	_	_
3	thymus	_	_	NN	O	-1	none	_	_
4	exhibited	_	_	VBD	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	striking	_	_	JJ	O	-1	none	_	_
7	concordance	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	endogenous	_	_	JJ	O	-1	none	_	_
10	c-myb	_	_	NN	Protein	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	that	_	_	DT	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	mouse	_	_	NN	O	-1	none	_	_
16	ADA	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	ADA	_	_	NN	Protein	-1	none	_	_
20	LCR	_	_	NN	O	-1	none	_	_
21	directed	_	_	VBD	O	-1	none	_	_
22	transgene	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Point	_	_	NN	O	-1	none	_	_
2	mutation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	c-Myb	_	_	NN	Protein	-1	none	_	_
6	site	_	_	NN	O	-1	none	_	_
7	within	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	intact	_	_	JJ	O	-1	none	_	_
10	2.3-kb	_	_	JJ	O	-1	none	_	_
11	LCR	_	_	NN	O	-1	none	_	_
12	severely	_	_	RB	O	-1	none	_	_
13	attenuated	_	_	VBD	O	-1	none	_	_
14	enhancer	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	transfections	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	LCR	_	_	NN	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	transgenic	_	_	JJ	O	-1	none	_	_
23	thymocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Within	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	context	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	complex	_	_	NN	O	-1	none	_	_
7	enhancer	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	LCR	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	c-Myb	_	_	NN	Protein	-1	none	_	_
12	can	_	_	MD	O	-1	none	_	_
13	act	_	_	VB	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	an	_	_	DT	O	-1	none	_	_
16	organizer	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	thymocyte	_	_	NN	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	gene	_	_	NN	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	via	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	single	_	_	JJ	O	-1	none	_	_
25	binding	_	_	NN	O	-1	none	_	_
26	site	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Minimally	_	_	RB	O	-1	none	_	_
2	modified	_	_	VBN	O	-1	none	_	_
3	low	_	_	JJ	O	-1	none	_	_
4	density	_	_	NN	O	-1	none	_	_
5	lipoprotein	_	_	NN	O	-1	none	_	_
6	induced	_	_	VBD	O	-1	none	_	_
7	inflammatory	_	_	JJ	O	-1	none	_	_
8	responses	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	endothelial	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	cyclic	_	_	JJ	O	-1	none	_	_
16	adenosine	_	_	NN	O	-1	none	_	_
17	monophosphate	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	minimally	_	_	RB	O	-1	none	_	_
7	oxidized	_	_	VBN	O	-1	none	_	_
8	LDL	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	MM-LDL	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	activated	_	_	VBD	O	-1	none	_	_
13	endothelial	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	increase	_	_	VB	O	-1	none	_	_
17	their	_	_	PRP$	O	-1	none	_	_
18	interaction	_	_	NN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	monocytes	_	_	NNS	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	neutrophils	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	inducing	_	_	VBG	O	-1	none	_	_
26	monocyte	_	_	NN	O	-1	none	_	_
27	but	_	_	CC	O	-1	none	_	_
28	not	_	_	RB	O	-1	none	_	_
29	neutrophil	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	synthesis	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	monocyte	_	_	NN	Protein	36	multitoken	_	_
35	chemotactic	_	_	JJ	Protein	36	multitoken	_	_
36	protein-1	_	_	NN	Protein	0	root	_	_
37	and	_	_	CC	O	-1	none	_	_
38	monocyte	_	_	NN	Protein	41	multitoken	_	_
39	colony	_	_	NN	Protein	41	multitoken	_	_
40	stimulating	_	_	NN	Protein	41	multitoken	_	_
41	factor	_	_	NN	Protein	0	root	_	_
42	(	_	_	-LRB-	O	-1	none	_	_
43	M-CSF	_	_	NN	Protein	-1	none	_	_
44	)	_	_	-RRB-	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	examined	_	_	VBN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	signaling	_	_	NN	O	-1	none	_	_
10	pathways	_	_	NNS	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	this	_	_	DT	O	-1	none	_	_
14	monocyte	_	_	NN	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	response	_	_	NN	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	induced	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Both	_	_	CC	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	monocyte	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	levels	_	_	NNS	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	M-CSF	_	_	NN	Protein	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	MM-LDL	_	_	NN	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	inhibited	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	kinase	_	_	NN	O	-1	none	_	_
19	C	_	_	NN	O	-1	none	_	_
20	depleted	_	_	VBN	O	-1	none	_	_
21	endothelial	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	number	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	our	_	_	PRP$	O	-1	none	_	_
5	studies	_	_	NNS	O	-1	none	_	_
6	indicate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	cAMP	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	second	_	_	JJ	O	-1	none	_	_
12	messenger	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	effects	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	MM-LDL	_	_	NN	O	-1	none	_	_
18	cited	_	_	VBD	O	-1	none	_	_
19	above	_	_	RB	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Incubation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	endothelial	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	MM-LDL	_	_	NN	O	-1	none	_	_
7	caused	_	_	VBD	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	173	_	_	CD	O	-1	none	_	_
10	%	_	_	NN	O	-1	none	_	_
11	increase	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	intracellular	_	_	JJ	O	-1	none	_	_
14	cAMP	_	_	NN	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Agents	_	_	NNS	O	-1	none	_	_
2	which	_	_	WDT	O	-1	none	_	_
3	increased	_	_	VBD	O	-1	none	_	_
4	cAMP	_	_	NN	O	-1	none	_	_
5	levels	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	including	_	_	VBG	O	-1	none	_	_
8	cholera	_	_	NN	O	-1	none	_	_
9	toxin	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	pertussis	_	_	NN	O	-1	none	_	_
12	toxin	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	dibutyryl	_	_	NN	O	-1	none	_	_
15	cAMP	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	isoproterenol	_	_	NN	O	-1	none	_	_
19	mimicked	_	_	VBD	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	actions	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	MM-LDL	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Agents	_	_	NNS	O	-1	none	_	_
2	which	_	_	WDT	O	-1	none	_	_
3	elevated	_	_	VBD	O	-1	none	_	_
4	cAMP	_	_	NN	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	shown	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	activate	_	_	VB	O	-1	none	_	_
10	NF	_	_	NN	O	-1	none	_	_
11	kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	suggesting	_	_	VBG	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	role	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	monocyte-endothelial	_	_	JJ	O	-1	none	_	_
25	interactions	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	endothelial	_	_	JJ	Protein	5	multitoken	_	_
3	leukocyte	_	_	NN	Protein	5	multitoken	_	_
4	adhesion	_	_	NN	Protein	5	multitoken	_	_
5	molecule	_	_	NN	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	ELAM	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	synthesis	_	_	NN	O	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	regulated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	NF	_	_	NN	O	-1	none	_	_
16	kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	ELAM	_	_	NN	Protein	-1	none	_	_
20	was	_	_	VBD	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	expressed	_	_	VBN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	ELAM	_	_	NN	Protein	-1	none	_	_
25	mRNA	_	_	NN	O	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	only	_	_	RB	O	-1	none	_	_
28	slightly	_	_	RB	O	-1	none	_	_
29	elevated	_	_	JJ	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	response	_	_	NN	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	MM-LDL	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	present	_	_	VBP	O	-1	none	_	_
3	evidence	_	_	NN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	induction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	neutrophil	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	LPS	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	actually	_	_	RB	O	-1	none	_	_
13	suppressed	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	agents	_	_	NNS	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	elevated	_	_	VBD	O	-1	none	_	_
18	cAMP	_	_	NN	O	-1	none	_	_
19	levels	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	rel	_	_	NN	Protein	-1	none	_	_
2	Is	_	_	VBZ	O	-1	none	_	_
3	rapidly	_	_	RB	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylated	_	_	JJ	O	-1	none	_	_
6	following	_	_	VBG	O	-1	none	_	_
7	granulocyte-colony	_	_	JJ	Protein	9	multitoken	_	_
8	stimulating	_	_	NN	Protein	9	multitoken	_	_
9	factor	_	_	NN	Protein	0	root	_	_
10	treatment	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	neutrophils	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Stimulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	neutrophils	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	granulocyte-colony	_	_	JJ	Protein	7	multitoken	_	_
6	stimulating	_	_	NN	Protein	7	multitoken	_	_
7	factor	_	_	NN	Protein	0	root	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	G-CSF	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	results	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	enhanced	_	_	VBN	O	-1	none	_	_
15	respiratory	_	_	JJ	O	-1	none	_	_
16	burst	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	prolonged	_	_	JJ	O	-1	none	_	_
19	survival	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	increased	_	_	VBD	O	-1	none	_	_
23	tumor	_	_	NN	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	killing	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	G-CSF	_	_	NN	Protein	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	mediated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	binding	_	_	VBG	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	specific	_	_	JJ	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	high	_	_	JJ	O	-1	none	_	_
13	affinity	_	_	NN	O	-1	none	_	_
14	receptors	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	G-CSF	_	_	NNP	Protein	-1	none	_	_
2	receptors	_	_	NNS	O	-1	none	_	_
3	lack	_	_	VBP	O	-1	none	_	_
4	intrinsic	_	_	JJ	O	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	kinase	_	_	NN	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	results	_	_	VBZ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	rapid	_	_	JJ	O	-1	none	_	_
18	induction	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	tyrosine	_	_	NN	O	-1	none	_	_
21	kinase	_	_	NN	O	-1	none	_	_
22	activity	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Antiphosphotyrosine	_	_	JJ	O	-1	none	_	_
2	immunoblots	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	whole	_	_	JJ	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	lysates	_	_	NNS	O	-1	none	_	_
7	prepared	_	_	VBN	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	neutrophils	_	_	NNS	O	-1	none	_	_
10	show	_	_	VBP	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	G-CSF	_	_	NN	Protein	-1	none	_	_
14	rapidly	_	_	RB	O	-1	none	_	_
15	induces	_	_	VBZ	O	-1	none	_	_
16	prominent	_	_	JJ	O	-1	none	_	_
17	tyrosine	_	_	NN	O	-1	none	_	_
18	phosphorylation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	relative	_	_	JJ	O	-1	none	_	_
25	molecular	_	_	JJ	O	-1	none	_	_
26	mass	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	80	_	_	CD	O	-1	none	_	_
29	kDa	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	monospecific	_	_	JJ	O	-1	none	_	_
3	antibodies	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	80-kDa	_	_	JJ	O	-1	none	_	_
7	tyrosine	_	_	NN	O	-1	none	_	_
8	phosphorylated	_	_	JJ	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	has	_	_	VBZ	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	shown	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	p80c-rel	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	proto-oncogene	_	_	NN	O	-1	none	_	_
19	belonging	_	_	VBG	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	family	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	transcriptional	_	_	JJ	O	-1	none	_	_
25	regulators	_	_	NNS	O	-1	none	_	_
26	which	_	_	WDT	O	-1	none	_	_
27	include	_	_	VBP	O	-1	none	_	_
28	NF-kB	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	phosphorylation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	p80c-rel	_	_	NN	Protein	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	unique	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	G-CSF	_	_	NN	Protein	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	that	_	_	DT	O	-1	none	_	_
14	granulocyte-macrophage	_	_	JJ	Protein	17	multitoken	_	_
15	colony	_	_	NN	Protein	17	multitoken	_	_
16	stimulating	_	_	NN	Protein	17	multitoken	_	_
17	factor	_	_	NN	Protein	0	root	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	also	_	_	RB	O	-1	none	_	_
20	stimulates	_	_	VBZ	O	-1	none	_	_
21	neutrophils	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	induces	_	_	VBZ	O	-1	none	_	_
24	tyrosine	_	_	NN	O	-1	none	_	_
25	phosphorylation	_	_	NN	O	-1	none	_	_
26	does	_	_	VBZ	O	-1	none	_	_
27	not	_	_	RB	O	-1	none	_	_
28	result	_	_	VB	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	tyrosine	_	_	NN	O	-1	none	_	_
31	phosphorylation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	p80c-rel	_	_	NN	Protein	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	consequences	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	p80c-rel	_	_	NN	Protein	-1	none	_	_
5	tyrosine	_	_	NN	O	-1	none	_	_
6	phosphorylation	_	_	NN	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	yet	_	_	RB	O	-1	none	_	_
10	known	_	_	VBN	O	-1	none	_	_
11	;	_	_	:	O	-1	none	_	_
12	however	_	_	RB	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	phosphorylated	_	_	JJ	O	-1	none	_	_
16	p80c-rel	_	_	NN	Protein	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	capable	_	_	JJ	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	binding	_	_	VBG	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	DNA	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	G-CSF	_	_	NN	Protein	-1	none	_	_
26	stimulation	_	_	NN	O	-1	none	_	_
27	results	_	_	VBZ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	increase	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	amount	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	p80c-rel	_	_	NN	Protein	-1	none	_	_
36	which	_	_	WDT	O	-1	none	_	_
37	binds	_	_	VBZ	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	DNA	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	one	_	_	CD	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	first	_	_	JJ	O	-1	none	_	_
9	biochemical	_	_	JJ	O	-1	none	_	_
10	events	_	_	NNS	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	occurs	_	_	VBZ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	neutrophils	_	_	NNS	O	-1	none	_	_
15	following	_	_	VBG	O	-1	none	_	_
16	G-CSF	_	_	NN	Protein	-1	none	_	_
17	stimulation	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	tyrosine	_	_	NN	O	-1	none	_	_
23	kinase	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	leads	_	_	VBZ	O	-1	none	_	_
26	directly	_	_	RB	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	tyrosine	_	_	NN	O	-1	none	_	_
30	phosphorylation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	p80c-rel	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	activated	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	G-CSF	_	_	NN	Protein	-1	none	_	_
9	appears	_	_	VBZ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	directly	_	_	RB	O	-1	none	_	_
12	transduce	_	_	VB	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	functions	_	_	VBZ	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	transcriptional	_	_	JJ	O	-1	none	_	_
23	regulator	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	immunodeficiency	_	_	NN	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	associated	_	_	VBN	O	-1	none	_	_
5	Hodgkin	_	_	NN	O	-1	none	_	_
6	's	_	_	POS	O	-1	none	_	_
7	disease	_	_	NN	O	-1	none	_	_
8	derives	_	_	VBZ	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	post-germinal	_	_	JJ	O	-1	none	_	_
11	center	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	immunodeficiency	_	_	NN	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	associated	_	_	VBN	O	-1	none	_	_
5	Hodgkin	_	_	NN	O	-1	none	_	_
6	's	_	_	POS	O	-1	none	_	_
7	disease	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	HIV-HD	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	displays	_	_	NNS	O	-1	none	_	_
12	several	_	_	JJ	O	-1	none	_	_
13	peculiarities	_	_	NNS	O	-1	none	_	_
14	when	_	_	WRB	O	-1	none	_	_
15	compared	_	_	VBN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	HD	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	general	_	_	JJ	O	-1	none	_	_
21	population	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	include	_	_	VBP	O	-1	none	_	_
3	overrepresentation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	clinically	_	_	RB	O	-1	none	_	_
6	aggressive	_	_	JJ	O	-1	none	_	_
7	histologic	_	_	JJ	O	-1	none	_	_
8	types	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	frequent	_	_	JJ	O	-1	none	_	_
11	infection	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Reed-Sternberg	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	RS	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	Epstein-Barr	_	_	JJ	O	-1	none	_	_
20	virus	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	EBV	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	reported	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	histogenesis	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	HD	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	general	_	_	JJ	O	-1	none	_	_
14	population	_	_	NN	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	assessed	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	monitoring	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	pattern	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	BCL-6	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factor	_	_	NN	O	-1	none	_	_
29	expressed	_	_	VBN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	germinal	_	_	JJ	O	-1	none	_	_
32	center	_	_	NN	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	GC	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	cells	_	_	NNS	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	CD138	_	_	NN	Protein	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	syndecan	_	_	NN	Protein	44	multitoken	_	_
44	-1	_	_	CD	Protein	0	root	_	_
45	(	_	_	-LRB-	O	-1	none	_	_
46	syn-1	_	_	NN	Protein	-1	none	_	_
47	)	_	_	-RRB-	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	a	_	_	DT	O	-1	none	_	_
50	proteoglycan	_	_	NN	O	-1	none	_	_
51	associated	_	_	VBN	O	-1	none	_	_
52	with	_	_	IN	O	-1	none	_	_
53	post-GC	_	_	JJ	O	-1	none	_	_
54	,	_	_	,	O	-1	none	_	_
55	terminal	_	_	JJ	O	-1	none	_	_
56	B-cell	_	_	NN	O	-1	none	_	_
57	differentiation	_	_	NN	O	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	applied	_	_	VBN	O	-1	none	_	_
8	these	_	_	DT	O	-1	none	_	_
9	two	_	_	CD	O	-1	none	_	_
10	markers	_	_	NNS	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	study	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	HIV-HD	_	_	NN	O	-1	none	_	_
16	histogenesis	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	correlated	_	_	VBD	O	-1	none	_	_
19	their	_	_	PRP$	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	status	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	virologic	_	_	JJ	O	-1	none	_	_
25	features	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	this	_	_	DT	O	-1	none	_	_
28	disease	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	found	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	RS	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	all	_	_	DT	O	-1	none	_	_
9	histologic	_	_	JJ	O	-1	none	_	_
10	categories	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	HIV-HD	_	_	NN	O	-1	none	_	_
13	consistently	_	_	RB	O	-1	none	_	_
14	display	_	_	VBP	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	BCL-6	_	_	NN	Protein	-1	none	_	_
17	(-)/syn-1	_	_	NN	Protein	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	+	_	_	CC	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	phenotype	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	thus	_	_	RB	O	-1	none	_	_
24	reflect	_	_	VBP	O	-1	none	_	_
25	post-GC	_	_	JJ	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Conversely	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	RS	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	virtually	_	_	RB	O	-1	none	_	_
7	all	_	_	DT	O	-1	none	_	_
8	HIV-HD	_	_	NN	O	-1	none	_	_
9	express	_	_	VBP	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	EBV	_	_	NN	O	-1	none	_	_
12	encoded	_	_	VBD	O	-1	none	_	_
13	latent	_	_	JJ	Protein	16	multitoken	_	_
14	membrane	_	_	NN	Protein	16	multitoken	_	_
15	protein	_	_	NN	Protein	16	multitoken	_	_
16	1	_	_	CD	Protein	0	root	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	LMP1	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	being	_	_	VBG	O	-1	none	_	_
24	functionally	_	_	RB	O	-1	none	_	_
25	homologous	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	CD40	_	_	NN	Protein	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	may	_	_	MD	O	-1	none	_	_
30	contribute	_	_	VB	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	at	_	_	IN	O	-1	none	_	_
33	least	_	_	JJS	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	part	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	modulation	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	HIV-HD	_	_	NN	O	-1	none	_	_
43	phenotype	_	_	NN	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	USF	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	c-Myc	_	_	NN	Protein	-1	none	_	_
4	enhances	_	_	VBZ	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	while	_	_	IN	O	-1	none	_	_
7	Yin-Yang	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	suppresses	_	_	VBZ	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	promoter	_	_	NN	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	CXCR4	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	coreceptor	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	HIV-1	_	_	NN	O	-1	none	_	_
21	entry	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Transcription	_	_	NN	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	USF1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	USF2	_	_	NN	Protein	-1	none	_	_
6	up-regulate	_	_	VBP	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	i.e.	_	_	FW	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	HIV-1	_	_	NN	O	-1	none	_	_
13	long	_	_	JJ	O	-1	none	_	_
14	terminal	_	_	JJ	O	-1	none	_	_
15	repeats	_	_	NNS	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	via	_	_	IN	O	-1	none	_	_
18	interaction	_	_	NN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	E	_	_	NN	O	-1	none	_	_
22	box	_	_	NN	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	their	_	_	PRP$	O	-1	none	_	_
25	target	_	_	NN	O	-1	none	_	_
26	promoters	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	also	_	_	RB	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	binding	_	_	NN	O	-1	none	_	_
33	site	_	_	NN	O	-1	none	_	_
34	for	_	_	IN	O	-1	none	_	_
35	c-Myc	_	_	NN	Protein	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	c-Myc	_	_	NN	Protein	-1	none	_	_
3	oncoprotein	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	control	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	cellular	_	_	JJ	O	-1	none	_	_
10	proliferation	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	differentiation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	while	_	_	IN	O	-1	none	_	_
15	Yin-Yang	_	_	NN	Protein	16	multitoken	_	_
16	1	_	_	CD	Protein	0	root	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	YY1	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	has	_	_	VBZ	O	-1	none	_	_
21	been	_	_	VBN	O	-1	none	_	_
22	shown	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	control	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	number	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	cellular	_	_	JJ	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	viral	_	_	JJ	O	-1	none	_	_
34	genes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	two	_	_	CD	O	-1	none	_	_
3	proteins	_	_	NNS	O	-1	none	_	_
4	physically	_	_	RB	O	-1	none	_	_
5	interact	_	_	VBP	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	each	_	_	DT	O	-1	none	_	_
8	other	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	mutually	_	_	RB	O	-1	none	_	_
11	inhibit	_	_	VBP	O	-1	none	_	_
12	their	_	_	PRP$	O	-1	none	_	_
13	respective	_	_	JJ	O	-1	none	_	_
14	biological	_	_	JJ	O	-1	none	_	_
15	functions	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	show	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	USF	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	c-Myc	_	_	NN	Protein	-1	none	_	_
11	up-regulates	_	_	VBZ	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	while	_	_	IN	O	-1	none	_	_
14	YY1	_	_	NN	Protein	-1	none	_	_
15	down-regulates	_	_	VBZ	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	CXCR4	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	coreceptor	_	_	NN	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cell-tropic	_	_	JJ	O	-1	none	_	_
27	HIV-1	_	_	NN	O	-1	none	_	_
28	entry	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	identified	_	_	VBN	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	E	_	_	NN	O	-1	none	_	_
6	box	_	_	NN	O	-1	none	_	_
7	around	_	_	IN	O	-1	none	_	_
8	-260	_	_	CD	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	YY1	_	_	NN	Protein	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	site	_	_	NN	O	-1	none	_	_
14	around	_	_	IN	O	-1	none	_	_
15	-300	_	_	CD	O	-1	none	_	_
16	relative	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	start	_	_	NN	O	-1	none	_	_
21	site	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	USF	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	c-Myc	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	YY1	_	_	NN	Protein	-1	none	_	_
10	may	_	_	MD	O	-1	none	_	_
11	play	_	_	VB	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	important	_	_	JJ	O	-1	none	_	_
14	role	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	HIV-1-replicative	_	_	JJ	O	-1	none	_	_
18	cycle	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	modulating	_	_	VBG	O	-1	none	_	_
22	both	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	viral	_	_	JJ	O	-1	none	_	_
25	fusion	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	entry	_	_	NN	O	-1	none	_	_
28	process	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	viral	_	_	JJ	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	but	_	_	CC	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	lipopolysaccharide	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	anti-IgM	_	_	JJ	Protein	-1	none	_	_
8	stimulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	primary	_	_	JJ	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	leads	_	_	VBZ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	persistent	_	_	JJ	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	accumulation	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	RelB	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	analyzed	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	CD40	_	_	NN	Protein	-1	none	_	_
10	stimulation	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	nuclear	_	_	JJ	O	-1	none	_	_
16	appearance	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	Rel	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	factor	_	_	NN	O	-1	none	_	_
22	kappaB	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	NF-kappaB	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	factors	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	primary	_	_	JJ	O	-1	none	_	_
29	murine	_	_	JJ	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	lymphocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	triggering	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	CD40	_	_	NN	Protein	-1	none	_	_
7	signaling	_	_	NN	O	-1	none	_	_
8	pathway	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	s	_	_	NNS	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	CD40	_	_	NN	Protein	-1	none	_	_
14	ligands	_	_	NNS	O	-1	none	_	_
15	expressed	_	_	VBN	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	L	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	led	_	_	VBD	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	strong	_	_	JJ	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	an	_	_	DT	O	-1	none	_	_
25	NF-kappaB-controlled	_	_	JJ	O	-1	none	_	_
26	beta-globin	_	_	NN	Protein	-1	none	_	_
27	reporter	_	_	NN	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	primary	_	_	JJ	O	-1	none	_	_
31	B	_	_	NN	O	-1	none	_	_
32	lymphocytes	_	_	NNS	O	-1	none	_	_
33	from	_	_	IN	O	-1	none	_	_
34	transgenic	_	_	JJ	O	-1	none	_	_
35	mice	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Analyses	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	translocation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	individual	_	_	JJ	O	-1	none	_	_
7	members	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	Rel	_	_	NN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	after	_	_	IN	O	-1	none	_	_
12	CD40	_	_	NN	Protein	-1	none	_	_
13	induction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	primary	_	_	JJ	O	-1	none	_	_
16	B	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	showed	_	_	VBD	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	strong	_	_	JJ	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	long	_	_	JJ	O	-1	none	_	_
23	lasting	_	_	JJ	O	-1	none	_	_
24	accumulation	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	RelB	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	less	_	_	RBR	O	-1	none	_	_
30	pronounced	_	_	JJ	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	c-Rel	_	_	NN	Protein	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	LPS	_	_	NN	O	-1	none	_	_
2	stimulation	_	_	NN	O	-1	none	_	_
3	did	_	_	VBD	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	give	_	_	VB	O	-1	none	_	_
6	rise	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	persistent	_	_	JJ	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	accumulation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	RelB	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	c-Rel	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	whereas	_	_	IN	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	c-Rel	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	RelB	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	accumulated	_	_	VBN	O	-1	none	_	_
26	after	_	_	IN	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	receptor	_	_	NN	O	-1	none	_	_
30	stimulation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	induced	_	_	VBD	O	-1	none	_	_
3	not	_	_	RB	O	-1	none	_	_
4	only	_	_	RB	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	translocation	_	_	NN	O	-1	none	_	_
7	but	_	_	CC	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	de	_	_	FW	O	-1	none	_	_
10	novo	_	_	FW	O	-1	none	_	_
11	synthesis	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	RelB	_	_	NN	Protein	-1	none	_	_
14	RNA	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	protein	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	S107	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	stably	_	_	RB	O	-1	none	_	_
5	transfected	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	relB	_	_	NN	Protein	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	stimulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	RelB	_	_	NN	Protein	-1	none	_	_
14	translocation	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	CD40	_	_	NN	Protein	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	observed	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	stimulation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	CD40	_	_	NN	Protein	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	pathways	_	_	NNS	O	-1	none	_	_
10	exerts	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	long	_	_	JJ	O	-1	none	_	_
13	lasting	_	_	JJ	O	-1	none	_	_
14	stimulatory	_	_	JJ	O	-1	none	_	_
15	effect	_	_	NN	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	nuclear	_	_	JJ	O	-1	none	_	_
22	translocation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	RelB	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	LPS	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	anti-IgM	_	_	NN	Protein	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	unable	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	activate	_	_	VB	O	-1	none	_	_
9	RelB	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	CD40	_	_	NN	Protein	-1	none	_	_
12	appears	_	_	VBZ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	trigger	_	_	VB	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	special	_	_	JJ	O	-1	none	_	_
17	program	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	involved	_	_	VBN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	proliferation	_	_	NN	O	-1	none	_	_
25	and/or	_	_	CC	O	-1	none	_	_
26	differentiation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	lymphocytes	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	activity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	core	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	factor-alpha	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	AML1	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	beta	_	_	NN	O	-1	none	_	_
12	subunits	_	_	NNS	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	murine	_	_	JJ	O	-1	none	_	_
15	leukemia	_	_	NN	O	-1	none	_	_
16	virus	_	_	NN	O	-1	none	_	_
17	enhancer	_	_	NN	O	-1	none	_	_
18	cores	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Core	_	_	NN	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	CBF	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	known	_	_	VBN	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	polyomavirus	_	_	NN	O	-1	none	_	_
12	enhancer	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	2	_	_	CD	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	SL3	_	_	NN	O	-1	none	_	_
18	enhancer	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	1	_	_	CD	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	is	_	_	VBZ	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	mammalian	_	_	JJ	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	factor	_	_	NN	O	-1	none	_	_
27	that	_	_	WDT	O	-1	none	_	_
28	binds	_	_	VBZ	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	element	_	_	NN	O	-1	none	_	_
32	termed	_	_	VBN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	core	_	_	NN	O	-1	none	_	_
35	within	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	enhancers	_	_	NNS	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	murine	_	_	JJ	O	-1	none	_	_
41	leukemia	_	_	NN	O	-1	none	_	_
42	virus	_	_	NN	O	-1	none	_	_
43	family	_	_	NN	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	retroviruses	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	core	_	_	NN	O	-1	none	_	_
3	elements	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	SL3	_	_	NN	O	-1	none	_	_
7	virus	_	_	NN	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	important	_	_	JJ	O	-1	none	_	_
10	genetic	_	_	JJ	O	-1	none	_	_
11	determinants	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	ability	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	this	_	_	DT	O	-1	none	_	_
17	virus	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	induce	_	_	VB	O	-1	none	_	_
20	T-cell	_	_	NN	O	-1	none	_	_
21	lymphomas	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	transcriptional	_	_	JJ	O	-1	none	_	_
25	activity	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	viral	_	_	JJ	O	-1	none	_	_
29	long	_	_	JJ	O	-1	none	_	_
30	terminal	_	_	JJ	O	-1	none	_	_
31	repeat	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	T	_	_	NN	O	-1	none	_	_
34	lymphocytes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	CBF	_	_	NN	O	-1	none	_	_
2	consists	_	_	VBZ	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	subunits	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	DNA	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	subunit	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	CBF	_	_	NN	Protein	13	multitoken	_	_
13	alpha	_	_	NN	Protein	0	root	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	second	_	_	JJ	O	-1	none	_	_
18	subunit	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	CBF	_	_	NN	Protein	21	multitoken	_	_
21	beta	_	_	NN	Protein	0	root	_	_
22	,	_	_	,	O	-1	none	_	_
23	that	_	_	WDT	O	-1	none	_	_
24	stimulates	_	_	VBZ	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	DNA	_	_	NN	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	CBF	_	_	NN	Protein	31	multitoken	_	_
31	alpha	_	_	NN	Protein	0	root	_	_
32	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	genes	_	_	NNS	O	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	encodes	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	CBF	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	subunit	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	AML1	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	also	_	_	RB	O	-1	none	_	_
15	called	_	_	VBN	O	-1	none	_	_
16	Cbf	_	_	NN	Protein	18	multitoken	_	_
17	alpha	_	_	NN	Protein	18	multitoken	_	_
18	2	_	_	CD	Protein	0	root	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	locus	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	rearranged	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	chromosomal	_	_	JJ	O	-1	none	_	_
7	translocations	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	myeloproliferative	_	_	JJ	O	-1	none	_	_
11	disorders	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	leukemias	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	exogenously	_	_	RB	O	-1	none	_	_
3	expressed	_	_	VBN	O	-1	none	_	_
4	Cbf	_	_	NN	Protein	6	multitoken	_	_
5	alpha	_	_	NN	Protein	6	multitoken	_	_
6	2	_	_	CD	Protein	0	root	_	_
7	encoded	_	_	VBN	O	-1	none	_	_
8	subunit	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	CBF	_	_	NN	Protein	11	multitoken	_	_
11	alpha	_	_	NN	Protein	0	root	_	_
12	2-451	_	_	CD	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	stimulated	_	_	VBD	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	SL3	_	_	NN	O	-1	none	_	_
19	enhancer	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	P19	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	HeLa	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Activity	_	_	NN	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	mediated	_	_	VBN	O	-1	none	_	_
4	through	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	core	_	_	NN	O	-1	none	_	_
7	elements	_	_	NNS	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	Three	_	_	CD	O	-1	none	_	_
2	different	_	_	JJ	O	-1	none	_	_
3	isoforms	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	CBF	_	_	NN	Protein	6	multitoken	_	_
6	beta	_	_	NN	Protein	0	root	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	tested	_	_	VBN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	transcriptional	_	_	JJ	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	SL3	_	_	NN	O	-1	none	_	_
16	enhancer	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	least	_	_	JJS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	certain	_	_	JJ	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	types	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	maximum	_	_	NN	O	-1	none	_	_
14	activity	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	CBF	_	_	NN	O	-1	none	_	_
17	required	_	_	VBD	O	-1	none	_	_
18	both	_	_	DT	O	-1	none	_	_
19	subunits	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	They	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	provided	_	_	VBD	O	-1	none	_	_
4	support	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	hypothesis	_	_	NN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	CBF	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	factor	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lymphocytes	_	_	NNS	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	responsible	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	recognition	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	SL3	_	_	NN	O	-1	none	_	_
24	cores	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	whether	_	_	IN	O	-1	none	_	_
5	CBF	_	_	NN	O	-1	none	_	_
6	could	_	_	MD	O	-1	none	_	_
7	distinguish	_	_	VB	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	1-bp	_	_	JJ	O	-1	none	_	_
10	difference	_	_	NN	O	-1	none	_	_
11	between	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	enhancer	_	_	NN	O	-1	none	_	_
14	core	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	SL3	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	core	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	nonleukemogenic	_	_	JJ	O	-1	none	_	_
23	virus	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	Akv	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	difference	_	_	NN	O	-1	none	_	_
3	strongly	_	_	RB	O	-1	none	_	_
4	affects	_	_	VBZ	O	-1	none	_	_
5	transcription	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	leukemogenicity	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	SL3	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	no	_	_	DT	O	-1	none	_	_
4	combination	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	CBF	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	and	_	_	CC	O	-1	none	_	_
9	CBF	_	_	NN	Protein	10	multitoken	_	_
10	beta	_	_	NN	Protein	0	root	_	_
11	subunits	_	_	NNS	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	we	_	_	PRP	O	-1	none	_	_
14	tested	_	_	VBD	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	able	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	distinguish	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	1-bp	_	_	JJ	O	-1	none	_	_
21	difference	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	assays	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	complete	_	_	JJ	O	-1	none	_	_
5	understanding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	how	_	_	WRB	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	recognize	_	_	VBP	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	SL3	_	_	NN	O	-1	none	_	_
13	core	_	_	NN	O	-1	none	_	_
14	remains	_	_	VBZ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	elucidated	_	_	VBN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Interleukin-7	_	_	NNP	Protein	-1	none	_	_
2	can	_	_	MD	O	-1	none	_	_
3	induce	_	_	VB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Jak	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	,	_	_	,	O	-1	none	_	_
10	Jak	_	_	NN	Protein	11	multitoken	_	_
11	3	_	_	CD	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	STAT	_	_	NN	Protein	14	multitoken	_	_
14	5	_	_	CD	Protein	0	root	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	murine	_	_	JJ	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Janus	_	_	NN	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	kinases	_	_	NNS	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	Jak	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	STAT	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	transducer	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	activator	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	proteins	_	_	NNS	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	recently	_	_	RB	O	-1	none	_	_
24	been	_	_	VBN	O	-1	none	_	_
25	linked	_	_	VBN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	signal	_	_	NN	O	-1	none	_	_
29	transduction	_	_	NN	O	-1	none	_	_
30	mechanism	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	several	_	_	JJ	O	-1	none	_	_
33	cytokines	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	IL-7	_	_	NNP	Protein	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	observed	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	induce	_	_	VB	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	rapid	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	dose	_	_	NN	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	tyrosine	_	_	NN	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	Jak	_	_	NN	Protein	15	multitoken	_	_
15	1	_	_	CD	Protein	0	root	_	_
16	and	_	_	CC	O	-1	none	_	_
17	Jak	_	_	NN	Protein	18	multitoken	_	_
18	3	_	_	CD	Protein	0	root	_	_
19	and	_	_	CC	O	-1	none	_	_
20	concomitantly	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	tyrosine	_	_	NN	O	-1	none	_	_
24	phosphorylation	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	DNA	_	_	NN	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	multiple	_	_	JJ	O	-1	none	_	_
31	STAT	_	_	NN	O	-1	none	_	_
32	proteins	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	STAT	_	_	NN	O	-1	none	_	_
3	proteins	_	_	NNS	O	-1	none	_	_
4	utilized	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	IL-7	_	_	NN	Protein	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	identical	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	those	_	_	DT	O	-1	none	_	_
11	induced	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	could	_	_	MD	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	identified	_	_	VBN	O	-1	none	_	_
18	as	_	_	IN	O	-1	none	_	_
19	various	_	_	JJ	O	-1	none	_	_
20	STAT	_	_	NN	O	-1	none	_	_
21	5	_	_	CD	O	-1	none	_	_
22	isoforms	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	FW	O	-1	none	_	_
2	vivo	_	_	FW	O	-1	none	_	_
3	modulation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	glucocorticoid	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	inhaled	_	_	VBN	O	-1	none	_	_
10	fluticasone	_	_	NN	O	-1	none	_	_
11	propionate	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	bronchial	_	_	JJ	O	-1	none	_	_
14	mucosa	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	blood	_	_	NN	O	-1	none	_	_
17	lymphocytes	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	subjects	_	_	NNS	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	mild	_	_	JJ	O	-1	none	_	_
22	asthma	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	In	_	_	FW	O	-1	none	_	_
4	vivo	_	_	FW	O	-1	none	_	_
5	regulation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	glucocorticoid	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	GR	_	_	NN	Protein	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	glucocorticoids	_	_	NNS	O	-1	none	_	_
15	provides	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	means	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	modulating	_	_	VBG	O	-1	none	_	_
20	sensitivity	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	targeted	_	_	VBN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	OBJECTIVE	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	We	_	_	PRP	O	-1	none	_	_
4	sought	_	_	VBD	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	determine	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	in	_	_	FW	O	-1	none	_	_
9	vivo	_	_	FW	O	-1	none	_	_
10	modulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	GR	_	_	NN	Protein	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	fluticasone	_	_	NN	O	-1	none	_	_
17	propionate	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	FP	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	subjects	_	_	NNS	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	mild	_	_	JJ	O	-1	none	_	_
25	asthma	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Ten	_	_	CD	O	-1	none	_	_
4	atopic	_	_	JJ	O	-1	none	_	_
5	asthmatic	_	_	JJ	O	-1	none	_	_
6	subjects	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	treated	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	FP	_	_	NN	O	-1	none	_	_
11	250	_	_	CD	O	-1	none	_	_
12	microg	_	_	NN	O	-1	none	_	_
13	twice	_	_	RB	O	-1	none	_	_
14	daily	_	_	RB	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	4	_	_	CD	O	-1	none	_	_
17	weeks	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Before	_	_	IN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	after	_	_	IN	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	patients	_	_	NNS	O	-1	none	_	_
8	underwent	_	_	VBD	O	-1	none	_	_
9	fiberoptic	_	_	JJ	O	-1	none	_	_
10	bronchoscopy	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	endobronchial	_	_	JJ	O	-1	none	_	_
13	biopsy	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	sampling	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	venous	_	_	JJ	O	-1	none	_	_
18	blood	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	measurements	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	GR	_	_	NN	Protein	-1	none	_	_
23	mRNA	_	_	NN	O	-1	none	_	_
24	levels	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	solution	_	_	NN	O	-1	none	_	_
3	hybridization	_	_	NN	O	-1	none	_	_
4	assay	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	used	_	_	VBN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	quantitative	_	_	JJ	O	-1	none	_	_
9	analysis	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	GR	_	_	NN	Protein	-1	none	_	_
12	mRNA	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	24-hour	_	_	JJ	O	-1	none	_	_
6	urinary	_	_	JJ	O	-1	none	_	_
7	cortisol	_	_	NN	O	-1	none	_	_
8	excretion	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	adrenocorticotropic	_	_	JJ	Protein	12	multitoken	_	_
12	hormone	_	_	NN	Protein	0	root	_	_
13	test	_	_	NN	O	-1	none	_	_
14	before	_	_	IN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	after	_	_	IN	O	-1	none	_	_
17	treatment	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	FP	_	_	NN	O	-1	none	_	_
20	were	_	_	VBD	O	-1	none	_	_
21	performed	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	A	_	_	DT	O	-1	none	_	_
4	high	_	_	JJ	O	-1	none	_	_
5	interindividual	_	_	JJ	O	-1	none	_	_
6	variation	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	GR	_	_	NN	Protein	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	seen	_	_	VBN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	detected	_	_	VBD	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	significant	_	_	JJ	O	-1	none	_	_
7	reduction	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	GR	_	_	NN	Protein	-1	none	_	_
11	mRNA	_	_	NN	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	endobronchial	_	_	JJ	O	-1	none	_	_
16	biopsy	_	_	NN	O	-1	none	_	_
17	specimens	_	_	NNS	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	FP	_	_	NN	O	-1	none	_	_
20	treatment	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	36.6	_	_	CD	O	-1	none	_	_
23	+/-	_	_	CC	O	-1	none	_	_
24	23.1	_	_	CD	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	25.0	_	_	CD	O	-1	none	_	_
27	+/-	_	_	CC	O	-1	none	_	_
28	10.9	_	_	CD	O	-1	none	_	_
29	amol	_	_	NN	O	-1	none	_	_
30	GR	_	_	NN	Protein	-1	none	_	_
31	mRNA	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	microg	_	_	NN	O	-1	none	_	_
34	RNA	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	respectively	_	_	RB	O	-1	none	_	_
37	;	_	_	:	O	-1	none	_	_
38	P	_	_	NN	O	-1	none	_	_
39	<	_	_	JJR	O	-1	none	_	_
40	.01	_	_	CD	O	-1	none	_	_
41	)	_	_	-RRB-	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	peripheral	_	_	JJ	O	-1	none	_	_
4	blood	_	_	NN	O	-1	none	_	_
5	lymphocytes	_	_	NNS	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	even	_	_	RB	O	-1	none	_	_
8	more	_	_	RBR	O	-1	none	_	_
9	striking	_	_	JJ	O	-1	none	_	_
10	downregulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	GR	_	_	NN	Protein	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	its	_	_	PRP$	O	-1	none	_	_
16	cognate	_	_	JJ	O	-1	none	_	_
17	ligand	_	_	NN	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	documented	_	_	VBN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	30.3	_	_	CD	O	-1	none	_	_
22	+/-	_	_	CC	O	-1	none	_	_
23	26.5	_	_	CD	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	8.8	_	_	CD	O	-1	none	_	_
26	+/-	_	_	CC	O	-1	none	_	_
27	5	_	_	CD	O	-1	none	_	_
28	amol	_	_	NN	O	-1	none	_	_
29	GR	_	_	NN	Protein	-1	none	_	_
30	mRNA	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	microg	_	_	NN	O	-1	none	_	_
33	RNA	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	respectively	_	_	RB	O	-1	none	_	_
36	;	_	_	:	O	-1	none	_	_
37	P	_	_	NN	O	-1	none	_	_
38	<	_	_	JJR	O	-1	none	_	_
39	.001	_	_	CD	O	-1	none	_	_
40	)	_	_	-RRB-	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	possibly	_	_	RB	O	-1	none	_	_
43	reflecting	_	_	VBG	O	-1	none	_	_
44	differences	_	_	NNS	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	glucocorticoid	_	_	NN	O	-1	none	_	_
47	sensitivity	_	_	NN	O	-1	none	_	_
48	between	_	_	IN	O	-1	none	_	_
49	tissues	_	_	NNS	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	small	_	_	JJ	O	-1	none	_	_
3	but	_	_	CC	O	-1	none	_	_
4	significant	_	_	JJ	O	-1	none	_	_
5	reduction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	24-hour	_	_	JJ	O	-1	none	_	_
9	urinary	_	_	JJ	O	-1	none	_	_
10	cortisol	_	_	NN	O	-1	none	_	_
11	excretion	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	observed	_	_	VBN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	233	_	_	CD	O	-1	none	_	_
16	+/-	_	_	CC	O	-1	none	_	_
17	109	_	_	CD	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	157	_	_	CD	O	-1	none	_	_
20	+/-	_	_	CC	O	-1	none	_	_
21	66	_	_	CD	O	-1	none	_	_
22	nmol/L	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	respectively	_	_	RB	O	-1	none	_	_
25	;	_	_	:	O	-1	none	_	_
26	P	_	_	NN	O	-1	none	_	_
27	<	_	_	JJR	O	-1	none	_	_
28	.01	_	_	CD	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	whereas	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	feedback	_	_	NN	O	-1	none	_	_
34	regulation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	glucocorticoid	_	_	NN	O	-1	none	_	_
37	synthesis	_	_	NN	O	-1	none	_	_
38	by	_	_	IN	O	-1	none	_	_
39	means	_	_	NNS	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
43	axis	_	_	NN	O	-1	none	_	_
44	as	_	_	IN	O	-1	none	_	_
45	assessed	_	_	VBN	O	-1	none	_	_
46	by	_	_	IN	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	adrenocorticotropic	_	_	JJ	Protein	49	multitoken	_	_
49	hormone	_	_	NN	Protein	0	root	_	_
50	test	_	_	NN	O	-1	none	_	_
51	remained	_	_	VBD	O	-1	none	_	_
52	normal	_	_	JJ	O	-1	none	_	_
53	after	_	_	IN	O	-1	none	_	_
54	treatment	_	_	NN	O	-1	none	_	_
55	with	_	_	IN	O	-1	none	_	_
56	FP	_	_	NN	O	-1	none	_	_
57	.	_	_	.	O	-1	none	_	_

1	CONCLUSION	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	study	_	_	NN	O	-1	none	_	_
8	confirm	_	_	VBP	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	potency	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	inhaled	_	_	JJ	O	-1	none	_	_
14	corticosteroid	_	_	NN	O	-1	none	_	_
15	FP	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	provide	_	_	VBP	O	-1	none	_	_
18	evidence	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	considerable	_	_	JJ	O	-1	none	_	_
22	tissue	_	_	NN	O	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	interindividual	_	_	JJ	O	-1	none	_	_
25	variation	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	GR	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	gamma	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	delta	_	_	NN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	positive	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	pregnancy	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	PROBLEM	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Due	_	_	JJ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	lack	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	classical	_	_	JJ	O	-1	none	_	_
9	HLA	_	_	NN	O	-1	none	_	_
10	antigens	_	_	NNS	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	trophoblast	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	fetal	_	_	JJ	O	-1	none	_	_
16	antigens	_	_	NNS	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	possibly	_	_	RB	O	-1	none	_	_
19	presented	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	non	_	_	JJ	O	-1	none	_	_
23	major	_	_	JJ	O	-1	none	_	_
24	histocompatibility	_	_	NN	O	-1	none	_	_
25	complex	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	MHC	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	restricted	_	_	JJ	O	-1	none	_	_
30	way	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Decidual	_	_	JJ	O	-1	none	_	_
2	gammadelta	_	_	NN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	increase	_	_	VBP	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	number	_	_	NN	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	pregnancy	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	might	_	_	MD	O	-1	none	_	_
15	play	_	_	VB	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	role	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	recognition	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	fetal	_	_	JJ	O	-1	none	_	_
22	antigens	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	also	_	_	RB	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	determining	_	_	VBG	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	quality	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	response	_	_	NN	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	these	_	_	DT	O	-1	none	_	_
34	antigens	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	aimed	_	_	VBN	O	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	investigating	_	_	VBG	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	population	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	progesterone	_	_	NN	O	-1	none	_	_
15	dependent	_	_	JJ	O	-1	none	_	_
16	immunomodulation	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	METHOD	_	_	NN	O	-1	none	_	_
2	OF	_	_	IN	O	-1	none	_	_
3	STUDY	_	_	NN	O	-1	none	_	_
4	:	_	_	:	O	-1	none	_	_
5	Peripheral	_	_	JJ	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	healthy	_	_	JJ	O	-1	none	_	_
9	pregnant	_	_	JJ	O	-1	none	_	_
10	women	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	habitual	_	_	JJ	O	-1	none	_	_
14	aborters	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	tested	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	immunocytochemistry	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	presence	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	gamma	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	delta	_	_	NN	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	receptor	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	TCR	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	progesterone	_	_	NN	Protein	34	multitoken	_	_
34	receptor	_	_	NN	Protein	0	root	_	_
35	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	In	_	_	IN	O	-1	none	_	_
4	peripheral	_	_	JJ	O	-1	none	_	_
5	blood	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	healthy	_	_	JJ	O	-1	none	_	_
8	pregnant	_	_	JJ	O	-1	none	_	_
9	women	_	_	NNS	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	percentage	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	gamma	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	delta	_	_	NN	O	-1	none	_	_
16	TCR+	_	_	JJ	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	significantly	_	_	RB	O	-1	none	_	_
20	higher	_	_	JJR	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	P	_	_	NN	O	-1	none	_	_
23	<	_	_	JJR	O	-1	none	_	_
24	0.001	_	_	CD	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	than	_	_	IN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	that	_	_	DT	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	recurrent	_	_	JJ	O	-1	none	_	_
31	aborters	_	_	NNS	O	-1	none	_	_
32	or	_	_	CC	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	non	_	_	JJ	O	-1	none	_	_
35	pregnant	_	_	JJ	O	-1	none	_	_
36	individuals	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Ninety-seven	_	_	CD	O	-1	none	_	_
2	percent	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	gamma	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	delta	_	_	NN	O	-1	none	_	_
7	TCR+	_	_	JJ	O	-1	none	_	_
8	pregnancy	_	_	NN	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	expressed	_	_	VBD	O	-1	none	_	_
11	progesterone	_	_	NN	Protein	12	multitoken	_	_
12	receptor	_	_	NN	Protein	0	root	_	_
13	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	CONCLUSIONS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	These	_	_	DT	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	gamma	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	delta	_	_	NN	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	bearing	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	progesterone	_	_	NN	O	-1	none	_	_
17	dependent	_	_	JJ	O	-1	none	_	_
18	immunomodulation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Bacterial	_	_	JJ	O	-1	none	_	_
2	peptidoglycan	_	_	NN	O	-1	none	_	_
3	induces	_	_	VBZ	O	-1	none	_	_
4	CD14	_	_	NN	Protein	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factors	_	_	NNS	O	-1	none	_	_
10	CREB	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	ATF	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	AP-1	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Peptidoglycan	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	PGN	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	major	_	_	JJ	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	wall	_	_	NN	O	-1	none	_	_
10	component	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	Gram	_	_	NN	O	-1	none	_	_
13	positive	_	_	JJ	O	-1	none	_	_
14	bacteria	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	induces	_	_	VBZ	O	-1	none	_	_
17	secretion	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	cytokines	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	macrophages	_	_	NNS	O	-1	none	_	_
22	through	_	_	IN	O	-1	none	_	_
23	CD14	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	pattern	_	_	NN	O	-1	none	_	_
27	recognition	_	_	NN	O	-1	none	_	_
28	receptor	_	_	NN	O	-1	none	_	_
29	that	_	_	WDT	O	-1	none	_	_
30	binds	_	_	VBZ	O	-1	none	_	_
31	lipopolysaccharide	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	other	_	_	JJ	O	-1	none	_	_
34	microbial	_	_	JJ	O	-1	none	_	_
35	products	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	begin	_	_	VB	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	elucidate	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	mechanisms	_	_	NNS	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	regulate	_	_	VBP	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	cytokine	_	_	NN	O	-1	none	_	_
13	genes	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	wanted	_	_	VBD	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	determine	_	_	VB	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	factors	_	_	NNS	O	-1	none	_	_
22	are	_	_	VBP	O	-1	none	_	_
23	activated	_	_	VBN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	PGN	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	mouse	_	_	NN	O	-1	none	_	_
28	RAW264	_	_	NN	O	-1	none	_	_
29	.7	_	_	CD	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	human	_	_	NN	O	-1	none	_	_
32	THP-1	_	_	NN	O	-1	none	_	_
33	macrophage	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	:	_	_	:	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	i	_	_	FW	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	PGN	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	phosphorylation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	factors	_	_	NNS	O	-1	none	_	_
16	ATF-1	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	CREB	_	_	NN	Protein	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	ii	_	_	LS	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	ATF-1	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	CREB	_	_	NN	Protein	-1	none	_	_
26	bound	_	_	VBD	O	-1	none	_	_
27	DNA	_	_	NN	O	-1	none	_	_
28	as	_	_	IN	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	dimer	_	_	NN	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	induced	_	_	VBD	O	-1	none	_	_
33	transcriptional	_	_	JJ	O	-1	none	_	_
34	activation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	a	_	_	DT	O	-1	none	_	_
37	CRE	_	_	NN	O	-1	none	_	_
38	reporter	_	_	NN	O	-1	none	_	_
39	plasmid	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	which	_	_	WDT	O	-1	none	_	_
42	was	_	_	VBD	O	-1	none	_	_
43	inhibited	_	_	VBN	O	-1	none	_	_
44	by	_	_	IN	O	-1	none	_	_
45	dominant	_	_	JJ	O	-1	none	_	_
46	negative	_	_	JJ	O	-1	none	_	_
47	CREB	_	_	NN	Protein	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	ATF-1	_	_	NN	Protein	-1	none	_	_
50	;	_	_	:	O	-1	none	_	_
51	(	_	_	-LRB-	O	-1	none	_	_
52	iii	_	_	LS	O	-1	none	_	_
53	)	_	_	-RRB-	O	-1	none	_	_
54	PGN	_	_	NN	O	-1	none	_	_
55	induced	_	_	VBD	O	-1	none	_	_
56	phosphorylation	_	_	NN	O	-1	none	_	_
57	of	_	_	IN	O	-1	none	_	_
58	c-Jun	_	_	NN	Protein	-1	none	_	_
59	,	_	_	,	O	-1	none	_	_
60	protein	_	_	NN	O	-1	none	_	_
61	synthesis	_	_	NN	O	-1	none	_	_
62	of	_	_	IN	O	-1	none	_	_
63	JunB	_	_	NN	Protein	-1	none	_	_
64	and	_	_	CC	O	-1	none	_	_
65	c-Fos	_	_	NN	Protein	-1	none	_	_
66	,	_	_	,	O	-1	none	_	_
67	and	_	_	CC	O	-1	none	_	_
68	transcriptional	_	_	JJ	O	-1	none	_	_
69	activation	_	_	NN	O	-1	none	_	_
70	of	_	_	IN	O	-1	none	_	_
71	the	_	_	DT	O	-1	none	_	_
72	AP-1	_	_	NN	O	-1	none	_	_
73	reporter	_	_	NN	O	-1	none	_	_
74	plasmid	_	_	NN	O	-1	none	_	_
75	,	_	_	,	O	-1	none	_	_
76	which	_	_	WDT	O	-1	none	_	_
77	was	_	_	VBD	O	-1	none	_	_
78	inhibited	_	_	VBN	O	-1	none	_	_
79	by	_	_	IN	O	-1	none	_	_
80	dominant	_	_	JJ	O	-1	none	_	_
81	negative	_	_	JJ	O	-1	none	_	_
82	c-Fos	_	_	NN	Protein	-1	none	_	_
83	;	_	_	:	O	-1	none	_	_
84	and	_	_	CC	O	-1	none	_	_
85	(	_	_	-LRB-	O	-1	none	_	_
86	iv	_	_	NN	O	-1	none	_	_
87	)	_	_	-RRB-	O	-1	none	_	_
88	PGN	_	_	NN	O	-1	none	_	_
89	induced	_	_	VBD	O	-1	none	_	_
90	activation	_	_	NN	O	-1	none	_	_
91	of	_	_	IN	O	-1	none	_	_
92	CREB	_	_	NN	O	-1	none	_	_
93	and	_	_	CC	O	-1	none	_	_
94	ATF	_	_	NN	O	-1	none	_	_
95	and	_	_	CC	O	-1	none	_	_
96	AP-1	_	_	NN	O	-1	none	_	_
97	was	_	_	VBD	O	-1	none	_	_
98	mediated	_	_	VBN	O	-1	none	_	_
99	through	_	_	IN	O	-1	none	_	_
100	CD14	_	_	NN	Protein	-1	none	_	_
101	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	first	_	_	JJ	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	demonstrate	_	_	VB	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	CREB	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	ATF	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	AP-1	_	_	NN	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	factors	_	_	NNS	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	PGN	_	_	NN	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	any	_	_	DT	O	-1	none	_	_
22	other	_	_	JJ	O	-1	none	_	_
23	component	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	Gram	_	_	NN	O	-1	none	_	_
26	positive	_	_	JJ	O	-1	none	_	_
27	bacteria	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	C/EBP	_	_	NN	Protein	2	multitoken	_	_
2	beta	_	_	NN	Protein	0	root	_	_
3	in	_	_	IN	O	-1	none	_	_
4	rheumatoid	_	_	JJ	O	-1	none	_	_
5	arthritis	_	_	NN	O	-1	none	_	_
6	:	_	_	:	O	-1	none	_	_
7	correlation	_	_	NN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	inflammation	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	disease	_	_	NN	O	-1	none	_	_
13	specificity	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Rheumatoid	_	_	JJ	O	-1	none	_	_
2	arthritis	_	_	NN	O	-1	none	_	_
3	synovial	_	_	JJ	O	-1	none	_	_
4	tissue	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	examined	_	_	VBN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	compared	_	_	VBN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	osteoarthritis	_	_	NN	O	-1	none	_	_
11	tissue	_	_	NN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	presence	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	C/EBP	_	_	NN	Protein	21	multitoken	_	_
21	beta	_	_	NN	Protein	0	root	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	NF-IL-6	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	region	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	lining	_	_	JJ	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	sublining	_	_	JJ	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	type	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	subcellular	_	_	JJ	O	-1	none	_	_
14	distribution	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	cytoplasmic	_	_	JJ	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	C/EBP	_	_	NN	O	-1	none	_	_
25	beta	_	_	NN	O	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	characterized	_	_	VBN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Rheumatoid	_	_	JJ	O	-1	none	_	_
2	arthritis	_	_	NN	O	-1	none	_	_
3	synovial	_	_	JJ	O	-1	none	_	_
4	fluid	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	normal	_	_	JJ	O	-1	none	_	_
9	peripheral	_	_	JJ	O	-1	none	_	_
10	blood	_	_	NN	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	examined	_	_	VBN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	C/EBP	_	_	NN	Protein	2	multitoken	_	_
2	beta	_	_	NN	Protein	0	root	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	detected	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	synovial	_	_	JJ	O	-1	none	_	_
8	lining	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	sublining	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	synovial	_	_	JJ	O	-1	none	_	_
15	tissue	_	_	NN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	both	_	_	DT	O	-1	none	_	_
20	rheumatoid	_	_	JJ	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	osteoarthritis	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	significant	_	_	JJ	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	P	_	_	NN	O	-1	none	_	_
5	<	_	_	VBG	O	-1	none	_	_
6	0.001	_	_	CD	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	<	_	_	JJR	O	-1	none	_	_
9	0.05	_	_	CD	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	respectively	_	_	RB	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	increase	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	percentage	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	nuclear	_	_	JJ	O	-1	none	_	_
21	staining	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	seen	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	lining	_	_	JJ	O	-1	none	_	_
27	layer	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	compared	_	_	VBN	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	sublining	_	_	JJ	O	-1	none	_	_
35	region	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	rheumatoid	_	_	JJ	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	osteoarthritis	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	both	_	_	DT	O	-1	none	_	_
3	diseases	_	_	NNS	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	strong	_	_	JJ	O	-1	none	_	_
6	correlation	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	r	_	_	NN	O	-1	none	_	_
9	=	_	_	JJ	O	-1	none	_	_
10	0.79	_	_	CD	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	P	_	_	NN	O	-1	none	_	_
13	<	_	_	JJR	O	-1	none	_	_
14	0.001	_	_	CD	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	observed	_	_	VBN	O	-1	none	_	_
18	between	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	percentage	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	synovial	_	_	JJ	O	-1	none	_	_
26	lining	_	_	NN	O	-1	none	_	_
27	that	_	_	WDT	O	-1	none	_	_
28	were	_	_	VBD	O	-1	none	_	_
29	positive	_	_	JJ	O	-1	none	_	_
30	for	_	_	IN	O	-1	none	_	_
31	nuclear	_	_	JJ	O	-1	none	_	_
32	C/EBP	_	_	NN	Protein	33	multitoken	_	_
33	beta	_	_	NN	Protein	0	root	_	_
34	and	_	_	CC	O	-1	none	_	_
35	lining	_	_	JJ	O	-1	none	_	_
36	cell	_	_	NN	O	-1	none	_	_
37	depth	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Two-color	_	_	JJ	O	-1	none	_	_
2	immunohistochemistry	_	_	NN	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	both	_	_	CC	O	-1	none	_	_
6	macrophages	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	fibroblast	_	_	NN	O	-1	none	_	_
9	like	_	_	IN	O	-1	none	_	_
10	synoviocytes	_	_	NNS	O	-1	none	_	_
11	were	_	_	VBD	O	-1	none	_	_
12	positive	_	_	JJ	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	nuclear	_	_	JJ	O	-1	none	_	_
15	C/EBP	_	_	NN	Protein	16	multitoken	_	_
16	beta	_	_	NN	Protein	0	root	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	presence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	C/EBP	_	_	NN	Protein	5	multitoken	_	_
5	beta	_	_	NN	Protein	0	root	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	confirmed	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	immunohistochemistry	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Western	_	_	NN	O	-1	none	_	_
12	blot	_	_	NN	O	-1	none	_	_
13	analysis	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	isolated	_	_	VBN	O	-1	none	_	_
16	synovial	_	_	JJ	O	-1	none	_	_
17	fibroblasts	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	C/EBP	_	_	NN	Protein	3	multitoken	_	_
3	beta	_	_	NN	Protein	0	root	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	detected	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	rheumatoid	_	_	JJ	O	-1	none	_	_
9	synovial	_	_	JJ	O	-1	none	_	_
10	fluid	_	_	NN	O	-1	none	_	_
11	monocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	macrophages	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	but	_	_	CC	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	neutrophils	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	confirmed	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	presence	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	C/EBP	_	_	NN	Protein	9	multitoken	_	_
9	beta	_	_	NN	Protein	0	root	_	_
10	in	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	intensity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	C/EBP	_	_	NN	Protein	5	multitoken	_	_
5	beta	_	_	NN	Protein	0	root	_	_
6	staining	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	greater	_	_	JJR	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	P	_	_	NN	O	-1	none	_	_
11	<	_	_	JJR	O	-1	none	_	_
12	0.001	_	_	CD	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	synovial	_	_	JJ	O	-1	none	_	_
16	fluid	_	_	NN	O	-1	none	_	_
17	monocytes	_	_	NNS	O	-1	none	_	_
18	than	_	_	IN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	those	_	_	DT	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	normal	_	_	JJ	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	rheumatoid	_	_	JJ	O	-1	none	_	_
25	peripheral	_	_	JJ	O	-1	none	_	_
26	blood	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	enhanced	_	_	VBN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	staining	_	_	NN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	C/EBP	_	_	NN	Protein	10	multitoken	_	_
10	beta	_	_	NN	Protein	0	root	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	synovial	_	_	JJ	O	-1	none	_	_
14	lining	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	compared	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	sublining	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	suggesting	_	_	VBG	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	lining	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	positive	_	_	JJ	O	-1	none	_	_
30	correlation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	lining	_	_	JJ	O	-1	none	_	_
33	layer	_	_	NN	O	-1	none	_	_
34	depth	_	_	NN	O	-1	none	_	_
35	with	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	percentage	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	lining	_	_	JJ	O	-1	none	_	_
43	positive	_	_	JJ	O	-1	none	_	_
44	for	_	_	IN	O	-1	none	_	_
45	nuclear	_	_	JJ	O	-1	none	_	_
46	C/EBP	_	_	NN	Protein	47	multitoken	_	_
47	beta	_	_	NN	Protein	0	root	_	_
48	,	_	_	,	O	-1	none	_	_
49	suggest	_	_	VBP	O	-1	none	_	_
50	a	_	_	DT	O	-1	none	_	_
51	potential	_	_	JJ	O	-1	none	_	_
52	role	_	_	NN	O	-1	none	_	_
53	for	_	_	IN	O	-1	none	_	_
54	C/EBP	_	_	NN	Protein	55	multitoken	_	_
55	beta	_	_	NN	Protein	0	root	_	_
56	in	_	_	IN	O	-1	none	_	_
57	chronic	_	_	JJ	O	-1	none	_	_
58	inflammation	_	_	NN	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	production	_	_	NN	O	-1	none	_	_
6	or	_	_	CC	O	-1	none	_	_
7	activity	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	C/EBP	_	_	NN	Protein	10	multitoken	_	_
10	beta	_	_	NN	Protein	0	root	_	_
11	,	_	_	,	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	inhibit	_	_	VB	O	-1	none	_	_
14	inflammatory	_	_	JJ	O	-1	none	_	_
15	mediator	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	synovial	_	_	JJ	O	-1	none	_	_
19	macrophages	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	fibroblasts	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	offers	_	_	VBZ	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	novel	_	_	JJ	O	-1	none	_	_
26	approach	_	_	NN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	therapeutic	_	_	JJ	O	-1	none	_	_
29	intervention	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Identification	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	essential	_	_	JJ	O	-1	none	_	_
4	GATA	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	Ets	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	motifs	_	_	NNS	O	-1	none	_	_
9	within	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	promoter	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	platelet	_	_	NN	Protein	17	multitoken	_	_
15	glycoprotein	_	_	NN	Protein	17	multitoken	_	_
16	Ib	_	_	NN	Protein	17	multitoken	_	_
17	alpha	_	_	NN	Protein	0	root	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Platelet	_	_	NN	O	-1	none	_	_
2	glycoprotein	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	GP	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	Ib-IX-V	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	multisubunit	_	_	JJ	O	-1	none	_	_
10	adhesion	_	_	NN	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	supports	_	_	VBZ	O	-1	none	_	_
14	platelet	_	_	NN	O	-1	none	_	_
15	attachment	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	thrombogenic	_	_	JJ	O	-1	none	_	_
18	surfaces	_	_	NNS	O	-1	none	_	_
19	at	_	_	IN	O	-1	none	_	_
20	sites	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	vascular	_	_	JJ	O	-1	none	_	_
23	injury	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	congenital	_	_	JJ	O	-1	none	_	_
3	absence	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	receptor	_	_	NN	O	-1	none	_	_
7	results	_	_	VBZ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	bleeding	_	_	JJ	O	-1	none	_	_
11	disorder	_	_	NN	O	-1	none	_	_
12	associated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	"	_	_	``	O	-1	none	_	_
15	giant	_	_	JJ	O	-1	none	_	_
16	"	_	_	''	O	-1	none	_	_
17	platelets	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	condition	_	_	NN	O	-1	none	_	_
21	linking	_	_	VBG	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	complex	_	_	NN	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	platelet	_	_	NN	O	-1	none	_	_
29	morphogenesis	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	understand	_	_	VB	O	-1	none	_	_
3	better	_	_	JJR	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	GP	_	_	NN	O	-1	none	_	_
9	Ib-IX-V	_	_	NN	O	-1	none	_	_
10	complex	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	studies	_	_	NNS	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	undertaken	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	define	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	essential	_	_	JJ	O	-1	none	_	_
19	genetic	_	_	JJ	O	-1	none	_	_
20	elements	_	_	NNS	O	-1	none	_	_
21	supporting	_	_	VBG	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	alpha-subunit	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	complex	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	GP	_	_	NN	Protein	33	multitoken	_	_
32	Ib	_	_	NN	Protein	33	multitoken	_	_
33	alpha	_	_	NN	Protein	0	root	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	GP	_	_	NN	Protein	3	multitoken	_	_
2	Ib	_	_	NN	Protein	3	multitoken	_	_
3	alpha	_	_	NN	Protein	0	root	_	_
4	promoter	_	_	NN	O	-1	none	_	_
5	activity	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	evaluated	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	transfection	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	erythroleukemia	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	reporter	_	_	NN	O	-1	none	_	_
16	plasmids	_	_	NNS	O	-1	none	_	_
17	coding	_	_	VBG	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	enzyme	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	luciferase	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	were	_	_	VBD	O	-1	none	_	_
3	initiated	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	fragment	_	_	NN	O	-1	none	_	_
7	extending	_	_	VBG	O	-1	none	_	_
8	2,738	_	_	CD	O	-1	none	_	_
9	nucleotides	_	_	NNS	O	-1	none	_	_
10	5	_	_	CD	O	-1	none	_	_
11	'	_	_	''	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	start	_	_	NN	O	-1	none	_	_
16	site	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	lead	_	_	VB	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	identification	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	253	_	_	CD	O	-1	none	_	_
24	nucleotides	_	_	NNS	O	-1	none	_	_
25	retaining	_	_	VBG	O	-1	none	_	_
26	full	_	_	JJ	O	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	human	_	_	NN	O	-1	none	_	_
31	erythroleukemia	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	nonhematopoietic	_	_	JJ	O	-1	none	_	_
5	lineage	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	endothelial	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	HeLa	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	GP	_	_	NN	Protein	16	multitoken	_	_
15	Ib	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	was	_	_	VBD	O	-1	none	_	_
20	no	_	_	DT	O	-1	none	_	_
21	greater	_	_	JJR	O	-1	none	_	_
22	than	_	_	IN	O	-1	none	_	_
23	background	_	_	NN	O	-1	none	_	_
24	levels	_	_	NNS	O	-1	none	_	_
25	obtained	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	promoterless	_	_	JJ	O	-1	none	_	_
28	constructs	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Gel	_	_	NN	O	-1	none	_	_
2	shift	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	site	_	_	NN	O	-1	none	_	_
6	directed	_	_	JJ	O	-1	none	_	_
7	mutagenesis	_	_	NN	O	-1	none	_	_
8	studies	_	_	NNS	O	-1	none	_	_
9	defined	_	_	VBD	O	-1	none	_	_
10	essential	_	_	JJ	O	-1	none	_	_
11	GATA	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Ets	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	motifs	_	_	NNS	O	-1	none	_	_
16	93	_	_	CD	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	150	_	_	CD	O	-1	none	_	_
19	nucleotides	_	_	NNS	O	-1	none	_	_
20	upstream	_	_	RB	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	start	_	_	NN	O	-1	none	_	_
25	site	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	finding	_	_	NN	O	-1	none	_	_
29	which	_	_	WDT	O	-1	none	_	_
30	further	_	_	RB	O	-1	none	_	_
31	substantiates	_	_	VBZ	O	-1	none	_	_
32	these	_	_	DT	O	-1	none	_	_
33	elements	_	_	NNS	O	-1	none	_	_
34	as	_	_	IN	O	-1	none	_	_
35	important	_	_	JJ	O	-1	none	_	_
36	determinants	_	_	NNS	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	megakaryocytic	_	_	JJ	O	-1	none	_	_
39	gene	_	_	NN	O	-1	none	_	_
40	expression	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	define	_	_	VBP	O	-1	none	_	_
4	essential	_	_	JJ	O	-1	none	_	_
5	cis	_	_	NN	O	-1	none	_	_
6	acting	_	_	VBG	O	-1	none	_	_
7	elements	_	_	NNS	O	-1	none	_	_
8	responsible	_	_	JJ	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	GP	_	_	NN	Protein	15	multitoken	_	_
14	Ib	_	_	NN	Protein	15	multitoken	_	_
15	alpha	_	_	NN	Protein	0	root	_	_
16	and	_	_	CC	O	-1	none	_	_
17	provide	_	_	VB	O	-1	none	_	_
18	insights	_	_	NNS	O	-1	none	_	_
19	into	_	_	IN	O	-1	none	_	_
20	molecular	_	_	JJ	O	-1	none	_	_
21	events	_	_	NNS	O	-1	none	_	_
22	coinciding	_	_	VBG	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	release	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	normal	_	_	JJ	O	-1	none	_	_
28	platelets	_	_	NNS	O	-1	none	_	_
29	into	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	bloodstream	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	[	_	_	NN	O	-1	none	_	_
2	The	_	_	DT	O	-1	none	_	_
3	role	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	glucocorticoid	_	_	NN	Protein	6	multitoken	_	_
6	receptors	_	_	NNS	Protein	0	root	_	_
7	and	_	_	CC	O	-1	none	_	_
8	HLA	_	_	NN	O	-1	none	_	_
9	antigens	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	pathogenesis	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	Cushing	_	_	NN	O	-1	none	_	_
15	's	_	_	POS	O	-1	none	_	_
16	syndrome	_	_	NN	O	-1	none	_	_
17	]	_	_	CD	O	-1	none	_	_
18	Lymphocytic	_	_	JJ	O	-1	none	_	_
19	levels	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	glucocorticoid	_	_	NN	Protein	22	multitoken	_	_
22	receptors	_	_	NNS	Protein	0	root	_	_
23	were	_	_	VBD	O	-1	none	_	_
24	evaluated	_	_	VBN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	114	_	_	CD	O	-1	none	_	_
27	patients	_	_	NNS	O	-1	none	_	_
28	suffering	_	_	VBG	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	Icenko	_	_	NNP	O	-1	none	_	_
31	Cushing	_	_	NN	O	-1	none	_	_
32	's	_	_	POS	O	-1	none	_	_
33	syndrome	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Incidence	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HLA	_	_	NN	O	-1	none	_	_
4	antigens	_	_	NNS	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	determined	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	94	_	_	CD	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	them	_	_	PRP	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	significant	_	_	JJ	O	-1	none	_	_
3	rise	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	A10	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	B27	_	_	NN	Protein	8	multitoken	_	_
8	antigen	_	_	NN	Protein	0	root	_	_
9	incidence	_	_	NN	O	-1	none	_	_
10	compared	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	that	_	_	DT	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	subjects	_	_	NNS	O	-1	none	_	_
16	allows	_	_	VBZ	O	-1	none	_	_
17	these	_	_	DT	O	-1	none	_	_
18	antigens	_	_	NNS	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	be	_	_	VB	O	-1	none	_	_
21	considered	_	_	VBN	O	-1	none	_	_
22	genetic	_	_	JJ	O	-1	none	_	_
23	markers	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	Icenko	_	_	NNP	O	-1	none	_	_
26	Cushing	_	_	NN	O	-1	none	_	_
27	's	_	_	POS	O	-1	none	_	_
28	syndrome	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	levels	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	glucocorticoid	_	_	NN	Protein	5	multitoken	_	_
5	receptors	_	_	NNS	Protein	0	root	_	_
6	in	_	_	IN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	patients	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	lower	_	_	JJR	O	-1	none	_	_
13	than	_	_	IN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	normal	_	_	JJ	O	-1	none	_	_
16	subjects	_	_	NNS	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	active	_	_	JJ	O	-1	none	_	_
21	stage	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	disease	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	following	_	_	VBG	O	-1	none	_	_
27	bilateral	_	_	JJ	O	-1	none	_	_
28	total	_	_	JJ	O	-1	none	_	_
29	adrenalectomy	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	patients	_	_	NNS	O	-1	none	_	_
3	carrying	_	_	VBG	O	-1	none	_	_
4	B27	_	_	NN	Protein	5	multitoken	_	_
5	antigen	_	_	NN	Protein	0	root	_	_
6	had	_	_	VBD	O	-1	none	_	_
7	lymphocytic	_	_	JJ	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	concentrations	_	_	NNS	O	-1	none	_	_
10	under	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	levels	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	such	_	_	JJ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	patients	_	_	NNS	O	-1	none	_	_
17	free	_	_	JJ	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	antigen	_	_	NN	O	-1	none	_	_
21	carriage	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Antigen	_	_	NN	Protein	2	multitoken	_	_
2	B27	_	_	NN	Protein	0	root	_	_
3	seems	_	_	VBZ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	be	_	_	VB	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	cause	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	lower	_	_	JJR	O	-1	none	_	_
10	levels	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	glucocorticoid	_	_	NN	Protein	13	multitoken	_	_
13	receptors	_	_	NNS	Protein	0	root	_	_
14	in	_	_	IN	O	-1	none	_	_
15	blood	_	_	NN	O	-1	none	_	_
16	lymphocytes	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Retinoic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	activates	_	_	VBZ	O	-1	none	_	_
4	interferon	_	_	NN	Protein	6	multitoken	_	_
5	regulatory	_	_	JJ	Protein	6	multitoken	_	_
6	factor-1	_	_	NN	Protein	0	root	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	myeloid	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	All-trans-retinoic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	ATRA	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	drug	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	choice	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	treatment	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	acute	_	_	JJ	O	-1	none	_	_
16	promyelocytic	_	_	JJ	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	APL	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	ATRA	_	_	NN	O	-1	none	_	_
2	induces	_	_	VBZ	O	-1	none	_	_
3	both	_	_	CC	O	-1	none	_	_
4	in	_	_	FW	O	-1	none	_	_
5	vitro	_	_	FW	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	in	_	_	FW	O	-1	none	_	_
8	vivo	_	_	FW	O	-1	none	_	_
9	differentiation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	APL	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	into	_	_	IN	O	-1	none	_	_
14	mature	_	_	JJ	O	-1	none	_	_
15	granulocytes	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	molecular	_	_	JJ	O	-1	none	_	_
5	mechanisms	_	_	NNS	O	-1	none	_	_
6	involved	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	ATRA	_	_	NN	O	-1	none	_	_
9	dependent	_	_	JJ	O	-1	none	_	_
10	growth	_	_	NN	O	-1	none	_	_
11	inhibition	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	cellular	_	_	JJ	O	-1	none	_	_
14	differentiation	_	_	NN	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	presently	_	_	RB	O	-1	none	_	_
18	understood	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NB4	_	_	NN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	line	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	derived	_	_	VBN	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	bone	_	_	NN	O	-1	none	_	_
12	marrow	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	patient	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	APL	_	_	NN	O	-1	none	_	_
18	during	_	_	IN	O	-1	none	_	_
19	relapse	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	can	_	_	MD	O	-1	none	_	_
22	be	_	_	VB	O	-1	none	_	_
23	used	_	_	VBN	O	-1	none	_	_
24	as	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	model	_	_	NN	O	-1	none	_	_
27	system	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	study	_	_	VB	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	growth	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	differentiation	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	APL	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	interferon	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	IFN	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	regulatory	_	_	JJ	O	-1	none	_	_
7	factors	_	_	NNS	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	IRF-1	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	IRF-2	_	_	NN	Protein	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	other	_	_	JJ	O	-1	none	_	_
15	IFN	_	_	NN	O	-1	none	_	_
16	inducible	_	_	JJ	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	products	_	_	NNS	O	-1	none	_	_
19	regulate	_	_	VBP	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	growth	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	we	_	_	PRP	O	-1	none	_	_
24	analyzed	_	_	VBD	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	effects	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	ATRA	_	_	NN	O	-1	none	_	_
29	on	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	these	_	_	DT	O	-1	none	_	_
34	genes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	ATRA	_	_	NN	O	-1	none	_	_
5	directly	_	_	RB	O	-1	none	_	_
6	activates	_	_	VBZ	O	-1	none	_	_
7	IRF-1	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	followed	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	IRF-2	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	2	_	_	CD	O	-1	none	_	_
18	'-5'	_	_	CD	O	-1	none	_	_
19	oligoadenylate	_	_	NN	O	-1	none	_	_
20	synthetase	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	OAS	_	_	NNP	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	slower	_	_	JJR	O	-1	none	_	_
28	kinetics	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	NB4	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	ATRA	_	_	NN	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	activated	_	_	VBD	O	-1	none	_	_
10	IRF-1	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	HL-60	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	U937	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	THP-1	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	which	_	_	WDT	O	-1	none	_	_
23	all	_	_	DT	O	-1	none	_	_
24	respond	_	_	VBP	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	ATRA	_	_	NN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	growth	_	_	NN	O	-1	none	_	_
29	inhibition	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	more	_	_	JJR	O	-1	none	_	_
3	than	_	_	IN	O	-1	none	_	_
4	additive	_	_	JJ	O	-1	none	_	_
5	increase	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	IRF-1	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	seen	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	ATRA	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	IFN-gamma	_	_	NN	Protein	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	NB4	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	ATRA	_	_	NN	O	-1	none	_	_
2	did	_	_	VBD	O	-1	none	_	_
3	not	_	_	RB	O	-1	none	_	_
4	activate	_	_	VB	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	factor	_	_	NN	O	-1	none	_	_
7	kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	signal	_	_	NN	O	-1	none	_	_
11	transducer	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	activator	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	STAT	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	pathways	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	an	_	_	DT	O	-1	none	_	_
25	alternate	_	_	JJ	O	-1	none	_	_
26	mechanism	_	_	NN	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	involved	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	IRF-1	_	_	NN	Protein	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ATRA	_	_	NN	O	-1	none	_	_
3	induced	_	_	VBN	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	IRF-1	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	activator	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	repressor	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	transformation	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	may	_	_	MD	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	one	_	_	CD	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	molecular	_	_	JJ	O	-1	none	_	_
23	mechanisms	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	ATRA	_	_	NN	O	-1	none	_	_
26	induced	_	_	VBD	O	-1	none	_	_
27	growth	_	_	NN	O	-1	none	_	_
28	inhibition	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	basis	_	_	NN	O	-1	none	_	_
33	for	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	synergistic	_	_	JJ	O	-1	none	_	_
36	actions	_	_	NNS	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	ATRA	_	_	NN	O	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	IFNs	_	_	NNS	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	myeloid	_	_	JJ	O	-1	none	_	_
43	leukemia	_	_	NN	O	-1	none	_	_
44	cells	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	roles	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	in	_	_	FW	O	-1	none	_	_
5	vivo	_	_	FW	O	-1	none	_	_
6	footprinted	_	_	VBN	O	-1	none	_	_
7	DNA	_	_	NN	O	-1	none	_	_
8	motifs	_	_	NNS	O	-1	none	_	_
9	within	_	_	IN	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	alpha-globin	_	_	NN	Protein	-1	none	_	_
12	enhancer	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Erythroid	_	_	JJ	O	-1	none	_	_
2	lineage	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	developmental	_	_	JJ	O	-1	none	_	_
5	stage	_	_	NN	O	-1	none	_	_
6	specificities	_	_	NNS	O	-1	none	_	_
7	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	alpha	_	_	NN	O	-1	none	_	_
7	like	_	_	IN	O	-1	none	_	_
8	globin	_	_	NN	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	embryonic	_	_	JJ	O	-1	none	_	_
12	zeta	_	_	NN	O	-1	none	_	_
13	2	_	_	CD	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	adult	_	_	JJ	O	-1	none	_	_
16	alpha	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	during	_	_	IN	O	-1	none	_	_
19	erythroid	_	_	JJ	O	-1	none	_	_
20	development	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	mediated	_	_	VBN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	distal	_	_	JJ	O	-1	none	_	_
26	enhancer	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	HS-40	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	protein-DNA	_	_	JJ	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	have	_	_	VBP	O	-1	none	_	_
6	shown	_	_	VBN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	HS-40	_	_	NN	Protein	-1	none	_	_
9	consists	_	_	VBZ	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	multiple	_	_	JJ	O	-1	none	_	_
12	nuclear	_	_	JJ	O	-1	none	_	_
13	factor	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	motifs	_	_	NNS	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	occupied	_	_	VBN	O	-1	none	_	_
19	in	_	_	FW	O	-1	none	_	_
20	vivo	_	_	FW	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	an	_	_	DT	O	-1	none	_	_
23	erythroid	_	_	JJ	O	-1	none	_	_
24	lineage-	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	developmental	_	_	JJ	O	-1	none	_	_
27	stage	_	_	NN	O	-1	none	_	_
28	specific	_	_	JJ	O	-1	none	_	_
29	manner	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	systematically	_	_	RB	O	-1	none	_	_
4	analyzed	_	_	VBN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	functional	_	_	JJ	O	-1	none	_	_
7	roles	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	these	_	_	DT	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	motifs	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	HS-40	_	_	NN	Protein	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	site	_	_	NN	O	-1	none	_	_
17	directed	_	_	JJ	O	-1	none	_	_
18	mutagenesis	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	transient	_	_	JJ	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	assay	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	erythroid	_	_	JJ	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	cultures	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Three	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	HS-40	_	_	NN	Protein	-1	none	_	_
5	enhancer	_	_	NN	O	-1	none	_	_
6	motifs	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	5	_	_	CD	O	-1	none	_	_
9	'	_	_	''	O	-1	none	_	_
10	NF-E2	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	AP1	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	GT	_	_	NN	O	-1	none	_	_
15	II	_	_	CD	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	GATA-1	_	_	NN	Protein	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	c	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	positively	_	_	RB	O	-1	none	_	_
24	regulate	_	_	VBP	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	zeta	_	_	NN	Protein	27	multitoken	_	_
27	2-globin	_	_	NN	Protein	0	root	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	activity	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	embryonic	_	_	JJ	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	fetal	_	_	JJ	O	-1	none	_	_
34	erythroid	_	_	JJ	O	-1	none	_	_
35	K562	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	adult	_	_	JJ	Protein	40	multitoken	_	_
40	alpha-globin	_	_	NN	Protein	0	root	_	_
41	promoter	_	_	NN	O	-1	none	_	_
42	activity	_	_	NN	O	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	adult	_	_	JJ	O	-1	none	_	_
45	erythroid	_	_	JJ	O	-1	none	_	_
46	MEL	_	_	NN	O	-1	none	_	_
47	cells	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	hand	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	3	_	_	CD	O	-1	none	_	_
8	'	_	_	''	O	-1	none	_	_
9	NF-E2	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	AP1	_	_	NN	O	-1	none	_	_
12	motif	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	able	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	exert	_	_	VB	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	positive	_	_	JJ	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	negative	_	_	JJ	O	-1	none	_	_
21	regulatory	_	_	JJ	O	-1	none	_	_
22	effects	_	_	NNS	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	zeta	_	_	NN	Protein	26	multitoken	_	_
26	2-globin	_	_	NN	Protein	0	root	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	K562	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	this	_	_	DT	O	-1	none	_	_
35	dual	_	_	JJ	O	-1	none	_	_
36	function	_	_	NN	O	-1	none	_	_
37	appears	_	_	VBZ	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	be	_	_	VB	O	-1	none	_	_
40	modulated	_	_	VBN	O	-1	none	_	_
41	through	_	_	IN	O	-1	none	_	_
42	differential	_	_	JJ	O	-1	none	_	_
43	binding	_	_	NN	O	-1	none	_	_
44	of	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	ubiquitous	_	_	JJ	O	-1	none	_	_
47	AP1	_	_	NN	O	-1	none	_	_
48	factors	_	_	NNS	O	-1	none	_	_
49	and	_	_	CC	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	erythroid	_	_	JJ	O	-1	none	_	_
52	enriched	_	_	JJ	O	-1	none	_	_
53	NF-E2	_	_	NN	O	-1	none	_	_
54	factor	_	_	NN	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	Mutation	_	_	NN	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	GATA-1	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	d	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	motif	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	exhibits	_	_	VBZ	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	adult	_	_	JJ	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	genomic	_	_	JJ	O	-1	none	_	_
17	footprint	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	decreases	_	_	VBZ	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	HS-40	_	_	NN	Protein	-1	none	_	_
22	enhancer	_	_	NN	O	-1	none	_	_
23	function	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	dimethyl	_	_	JJ	O	-1	none	_	_
26	sulfoxide	_	_	NN	O	-1	none	_	_
27	induced	_	_	VBD	O	-1	none	_	_
28	MEL	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	but	_	_	CC	O	-1	none	_	_
31	not	_	_	RB	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	K562	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	defined	_	_	VBN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	regulatory	_	_	JJ	O	-1	none	_	_
7	roles	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	different	_	_	JJ	O	-1	none	_	_
11	HS-40	_	_	NN	Protein	-1	none	_	_
12	motifs	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	remarkable	_	_	JJ	O	-1	none	_	_
3	correlation	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	genomic	_	_	JJ	O	-1	none	_	_
6	footprinting	_	_	NN	O	-1	none	_	_
7	data	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	mutagenesis	_	_	NN	O	-1	none	_	_
11	results	_	_	VBZ	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	suggests	_	_	VBZ	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	erythroid	_	_	JJ	O	-1	none	_	_
17	lineage-	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	developmental	_	_	JJ	O	-1	none	_	_
20	stage	_	_	NN	O	-1	none	_	_
21	specific	_	_	JJ	O	-1	none	_	_
22	regulation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	human	_	_	NN	O	-1	none	_	_
25	alpha	_	_	NN	O	-1	none	_	_
26	like	_	_	IN	O	-1	none	_	_
27	globin	_	_	NN	O	-1	none	_	_
28	promoters	_	_	NNS	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	indeed	_	_	RB	O	-1	none	_	_
31	modulated	_	_	VBN	O	-1	none	_	_
32	by	_	_	IN	O	-1	none	_	_
33	stable	_	_	JJ	O	-1	none	_	_
34	binding	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	specific	_	_	JJ	O	-1	none	_	_
37	nuclear	_	_	JJ	O	-1	none	_	_
38	factors	_	_	NNS	O	-1	none	_	_
39	in	_	_	FW	O	-1	none	_	_
40	vivo	_	_	FW	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Comparative	_	_	JJ	O	-1	none	_	_
2	analysis	_	_	NN	O	-1	none	_	_
3	identifies	_	_	VBZ	O	-1	none	_	_
4	conserved	_	_	VBN	O	-1	none	_	_
5	tumor	_	_	NN	Protein	11	multitoken	_	_
6	necrosis	_	_	NN	Protein	11	multitoken	_	_
7	factor	_	_	NN	Protein	11	multitoken	_	_
8	receptor	_	_	NN	Protein	11	multitoken	_	_
9	associated	_	_	JJ	Protein	11	multitoken	_	_
10	factor	_	_	NN	Protein	11	multitoken	_	_
11	3	_	_	CD	Protein	0	root	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	simian	_	_	JJ	O	-1	none	_	_
19	Epstein-Barr	_	_	JJ	O	-1	none	_	_
20	virus	_	_	NN	O	-1	none	_	_
21	oncogene	_	_	NN	O	-1	none	_	_
22	LMP1	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Nonhuman	_	_	JJ	O	-1	none	_	_
2	primates	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	naturally	_	_	RB	O	-1	none	_	_
5	infected	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	B-lymphotropic	_	_	JJ	O	-1	none	_	_
9	herpesvirus	_	_	NN	O	-1	none	_	_
10	closely	_	_	RB	O	-1	none	_	_
11	related	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	Epstein-Barr	_	_	JJ	O	-1	none	_	_
14	virus	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	EBV	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	simian	_	_	JJ	O	-1	none	_	_
3	EBV	_	_	NN	O	-1	none	_	_
4	share	_	_	NN	O	-1	none	_	_
5	considerable	_	_	JJ	O	-1	none	_	_
6	genetic	_	_	JJ	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	biologic	_	_	JJ	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	epidemiologic	_	_	JJ	O	-1	none	_	_
12	features	_	_	NNS	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	EBV	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	including	_	_	VBG	O	-1	none	_	_
18	virus	_	_	NN	O	-1	none	_	_
19	induced	_	_	VBD	O	-1	none	_	_
20	tumorigenesis	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	latent	_	_	JJ	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	transformation	_	_	NN	O	-1	none	_	_
6	associated	_	_	VBD	O	-1	none	_	_
7	viral	_	_	JJ	O	-1	none	_	_
8	genes	_	_	NNS	O	-1	none	_	_
9	demonstrate	_	_	VBP	O	-1	none	_	_
10	marked	_	_	JJ	O	-1	none	_	_
11	sequence	_	_	NN	O	-1	none	_	_
12	divergence	_	_	NN	O	-1	none	_	_
13	among	_	_	IN	O	-1	none	_	_
14	species	_	_	NNS	O	-1	none	_	_
15	despite	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	conserved	_	_	JJ	O	-1	none	_	_
18	functions	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	cloned	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	latent	_	_	JJ	Protein	8	multitoken	_	_
6	membrane	_	_	NN	Protein	8	multitoken	_	_
7	protein	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	LMP1	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	homologs	_	_	NNS	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	simian	_	_	JJ	O	-1	none	_	_
16	EBV	_	_	NN	O	-1	none	_	_
17	naturally	_	_	RB	O	-1	none	_	_
18	infecting	_	_	VBG	O	-1	none	_	_
19	baboons	_	_	NNS	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	cercopithicine	_	_	NN	O	-1	none	_	_
22	herpesvirus	_	_	NN	O	-1	none	_	_
23	12	_	_	CD	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	herpesvirus	_	_	NN	O	-1	none	_	_
26	papio	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	rhesus	_	_	NN	O	-1	none	_	_
30	monkeys	_	_	NNS	O	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	cercopithicine	_	_	NN	O	-1	none	_	_
33	herpesvirus	_	_	NN	O	-1	none	_	_
34	15	_	_	CD	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	for	_	_	IN	O	-1	none	_	_
37	a	_	_	DT	O	-1	none	_	_
38	comparative	_	_	JJ	O	-1	none	_	_
39	study	_	_	NN	O	-1	none	_	_
40	with	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	human	_	_	NN	O	-1	none	_	_
43	EBV	_	_	NN	O	-1	none	_	_
44	oncogene	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transmembrane	_	_	JJ	O	-1	none	_	_
3	domains	_	_	NNS	O	-1	none	_	_
4	are	_	_	VBP	O	-1	none	_	_
5	well	_	_	RB	O	-1	none	_	_
6	conserved	_	_	VBN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	but	_	_	CC	O	-1	none	_	_
9	there	_	_	EX	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	striking	_	_	JJ	O	-1	none	_	_
12	sequence	_	_	NN	O	-1	none	_	_
13	divergence	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	carboxy-terminal	_	_	JJ	O	-1	none	_	_
17	cytoplasmic	_	_	JJ	O	-1	none	_	_
18	domain	_	_	NN	O	-1	none	_	_
19	essential	_	_	JJ	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	B-cell	_	_	NN	O	-1	none	_	_
22	immortalization	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	interaction	_	_	NN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	tumor	_	_	NN	O	-1	none	_	_
28	necrosis	_	_	NN	O	-1	none	_	_
29	factor	_	_	NN	O	-1	none	_	_
30	receptor	_	_	NN	O	-1	none	_	_
31	signaling	_	_	NN	O	-1	none	_	_
32	pathway	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	A	_	_	DT	O	-1	none	_	_
2	PXQXT/S	_	_	NN	O	-1	none	_	_
3	containing	_	_	VBG	O	-1	none	_	_
4	sequence	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	present	_	_	JJ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cytoplasmic	_	_	JJ	O	-1	none	_	_
11	domain	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	Hodgkin	_	_	NN	O	-1	none	_	_
15	's	_	_	POS	O	-1	none	_	_
16	disease	_	_	NN	O	-1	none	_	_
17	marker	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	CD30	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	binds	_	_	VBZ	O	-1	none	_	_
23	TRAF3	_	_	NN	Protein	-1	none	_	_
24	in	_	_	FW	O	-1	none	_	_
25	vitro	_	_	FW	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	last	_	_	JJ	O	-1	none	_	_
3	13	_	_	CD	O	-1	none	_	_
4	amino	_	_	NN	O	-1	none	_	_
5	acids	_	_	NNS	O	-1	none	_	_
6	containing	_	_	VBG	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	PXQXT/S	_	_	NN	O	-1	none	_	_
9	sequence	_	_	NN	O	-1	none	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	highly	_	_	RB	O	-1	none	_	_
12	conserved	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	simian	_	_	JJ	O	-1	none	_	_
17	EBV	_	_	NN	O	-1	none	_	_
18	LMP1	_	_	NN	Protein	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	do	_	_	VBP	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	bind	_	_	VB	O	-1	none	_	_
23	TRAF3	_	_	NN	Protein	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	suggesting	_	_	VBG	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	distinct	_	_	JJ	O	-1	none	_	_
28	role	_	_	NN	O	-1	none	_	_
29	for	_	_	IN	O	-1	none	_	_
30	this	_	_	DT	O	-1	none	_	_
31	conserved	_	_	JJ	O	-1	none	_	_
32	region	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	LMP1	_	_	NN	Protein	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	conserved	_	_	JJ	O	-1	none	_	_
3	TRAF3	_	_	NN	Protein	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	sites	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	LMP1	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	CD30	_	_	NN	Protein	-1	none	_	_
11	Hodgkin	_	_	NN	O	-1	none	_	_
12	's	_	_	POS	O	-1	none	_	_
13	disease	_	_	NN	O	-1	none	_	_
14	marker	_	_	NN	O	-1	none	_	_
15	provides	_	_	VBZ	O	-1	none	_	_
16	further	_	_	JJ	O	-1	none	_	_
17	evidence	_	_	NN	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	TRAF3	_	_	NN	Protein	-1	none	_	_
21	mediated	_	_	JJ	O	-1	none	_	_
22	signal	_	_	NN	O	-1	none	_	_
23	transduction	_	_	NN	O	-1	none	_	_
24	pathway	_	_	NN	O	-1	none	_	_
25	may	_	_	MD	O	-1	none	_	_
26	be	_	_	VB	O	-1	none	_	_
27	important	_	_	JJ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	malignant	_	_	JJ	O	-1	none	_	_
30	transformation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Increased	_	_	VBN	O	-1	none	_	_
2	proliferation	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	cytotoxicity	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	after	_	_	IN	O	-1	none	_	_
10	stimulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	peripheral	_	_	JJ	O	-1	none	_	_
14	blood	_	_	NN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	lymphocytes	_	_	NNS	O	-1	none	_	_
17	through	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	surface	_	_	NN	O	-1	none	_	_
20	ganglioside	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	GD3	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	[	_	_	CD	O	-1	none	_	_
25	published	_	_	VBN	O	-1	none	_	_
26	erratum	_	_	NN	O	-1	none	_	_
27	appears	_	_	VBZ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	J	_	_	NNP	O	-1	none	_	_
30	Immunol	_	_	NNP	O	-1	none	_	_
31	1994	_	_	CD	O	-1	none	_	_
32	Jul	_	_	NNP	O	-1	none	_	_
33	15	_	_	CD	O	-1	none	_	_
34	;	_	_	:	O	-1	none	_	_
35	153	_	_	CD	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	2	_	_	CD	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	:910	_	_	CD	O	-1	none	_	_
40	]	_	_	CD	O	-1	none	_	_
41	Previous	_	_	JJ	O	-1	none	_	_
42	studies	_	_	NNS	O	-1	none	_	_
43	have	_	_	VBP	O	-1	none	_	_
44	suggested	_	_	VBN	O	-1	none	_	_
45	that	_	_	IN	O	-1	none	_	_
46	gangliosides	_	_	NNS	O	-1	none	_	_
47	have	_	_	VBP	O	-1	none	_	_
48	an	_	_	DT	O	-1	none	_	_
49	important	_	_	JJ	O	-1	none	_	_
50	role	_	_	NN	O	-1	none	_	_
51	in	_	_	IN	O	-1	none	_	_
52	cell	_	_	NN	O	-1	none	_	_
53	signaling	_	_	NN	O	-1	none	_	_
54	and	_	_	CC	O	-1	none	_	_
55	recognition	_	_	NN	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	their	_	_	PRP$	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	function	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	processes	_	_	NNS	O	-1	none	_	_
9	has	_	_	VBZ	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	clearly	_	_	RB	O	-1	none	_	_
13	defined	_	_	VBN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	mAb	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	R24	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	reacts	_	_	VBZ	O	-1	none	_	_
8	specifically	_	_	RB	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	surface	_	_	NN	O	-1	none	_	_
13	ganglioside	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	GD3	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	has	_	_	VBZ	O	-1	none	_	_
18	been	_	_	VBN	O	-1	none	_	_
19	demonstrated	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	stimulate	_	_	VB	O	-1	none	_	_
22	proliferation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	derived	_	_	VBN	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	peripheral	_	_	JJ	O	-1	none	_	_
30	blood	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	investigated	_	_	VBN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	mechanisms	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	R24	_	_	NN	O	-1	none	_	_
14	mAb	_	_	NN	O	-1	none	_	_
15	affects	_	_	VBZ	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	functions	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Additionally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	IFN-gamma	_	_	NN	Protein	-1	none	_	_
4	activity	_	_	NN	O	-1	none	_	_
5	but	_	_	CC	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	IL-1	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	IL-4	_	_	NN	Protein	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	present	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	culture	_	_	NN	O	-1	none	_	_
18	supernatants	_	_	NNS	O	-1	none	_	_
19	72	_	_	CD	O	-1	none	_	_
20	h	_	_	NN	O	-1	none	_	_
21	after	_	_	IN	O	-1	none	_	_
22	R24	_	_	NN	O	-1	none	_	_
23	stimulation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	some	_	_	DT	O	-1	none	_	_
3	donors	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	increased	_	_	VBD	O	-1	none	_	_
6	IL-6	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	TNF-alpha	_	_	NN	Protein	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	detected	_	_	VBN	O	-1	none	_	_
13	after	_	_	IN	O	-1	none	_	_
14	R24	_	_	NN	O	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	R24	_	_	NN	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	resulted	_	_	VBD	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	translocation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	c-rel	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	little	_	_	JJ	O	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	no	_	_	DT	O	-1	none	_	_
15	NF	_	_	NN	O	-1	none	_	_
16	kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	p50	_	_	NN	Protein	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	p65	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	from	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	cytoplasm	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	nucleus	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	increase	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	NF	_	_	NN	O	-1	none	_	_
33	kappa	_	_	NN	O	-1	none	_	_
34	B	_	_	NN	O	-1	none	_	_
35	binding	_	_	NN	O	-1	none	_	_
36	complexes	_	_	NNS	O	-1	none	_	_
37	containing	_	_	VBG	O	-1	none	_	_
38	c-rel	_	_	NN	Protein	-1	none	_	_
39	and	_	_	CC	O	-1	none	_	_
40	p50	_	_	NN	Protein	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	caused	_	_	VBD	O	-1	none	_	_
5	increased	_	_	VBN	O	-1	none	_	_
6	tyrosine	_	_	NN	O	-1	none	_	_
7	phosphorylation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	substrates	_	_	NNS	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	R24	_	_	NN	O	-1	none	_	_
2	stimulated	_	_	VBD	O	-1	none	_	_
3	increases	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	proliferation	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	cytotoxicity	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	surface	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	could	_	_	MD	O	-1	none	_	_
15	be	_	_	VB	O	-1	none	_	_
16	blocked	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	cyclosporin	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	staurosporin	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	indicating	_	_	VBG	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	cyclophilin	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	calcineurin	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	kinase	_	_	NN	O	-1	none	_	_
30	C	_	_	NN	O	-1	none	_	_
31	may	_	_	MD	O	-1	none	_	_
32	be	_	_	VB	O	-1	none	_	_
33	involved	_	_	VBN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	R24	_	_	NN	O	-1	none	_	_
37	signaling	_	_	NN	O	-1	none	_	_
38	pathway	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Additionally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	herbimycin	_	_	NN	O	-1	none	_	_
4	A	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	tyrosine	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	inhibitor	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	blocked	_	_	VBD	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	R24	_	_	NN	O	-1	none	_	_
14	stimulated	_	_	VBD	O	-1	none	_	_
15	increase	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	proliferation	_	_	NN	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	cytotoxicity	_	_	NN	O	-1	none	_	_
21	at	_	_	IN	O	-1	none	_	_
22	concentrations	_	_	NNS	O	-1	none	_	_
23	consistent	_	_	JJ	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	specificity	_	_	NN	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	tyrosine	_	_	NN	O	-1	none	_	_
28	kinases	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	multiple	_	_	JJ	O	-1	none	_	_
6	biochemical	_	_	JJ	O	-1	none	_	_
7	pathways	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	involved	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	R24	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Does	_	_	VBZ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	TAL1	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	occur	_	_	VBP	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	majority	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	T-cell	_	_	NN	O	-1	none	_	_
15	acute	_	_	JJ	O	-1	none	_	_
16	lymphoblastic	_	_	JJ	O	-1	none	_	_
17	leukemia	_	_	NN	O	-1	none	_	_
18	?	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	pediatric	_	_	JJ	O	-1	none	_	_
3	oncology	_	_	NN	O	-1	none	_	_
4	group	_	_	NN	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	.	_	_	.	O	-1	none	_	_

1	Almost	_	_	RB	O	-1	none	_	_
2	25	_	_	CD	O	-1	none	_	_
3	%	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	T-cell	_	_	NN	O	-1	none	_	_
8	acute	_	_	JJ	O	-1	none	_	_
9	lymphoblastic	_	_	JJ	O	-1	none	_	_
10	leukemia	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	T-ALL	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	have	_	_	VBP	O	-1	none	_	_
15	tumor	_	_	NN	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	rearrangements	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	TAL1	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	TAL1	_	_	NN	Protein	-1	none	_	_
3	expression	_	_	NN	O	-1	none	_	_
4	has	_	_	VBZ	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	observed	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	lymphocytes	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	TAL1	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	products	_	_	NNS	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	readily	_	_	RB	O	-1	none	_	_
17	detected	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	leukemic	_	_	JJ	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	that	_	_	WDT	O	-1	none	_	_
22	harbor	_	_	VBP	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	rearranged	_	_	JJ	O	-1	none	_	_
25	TAL1	_	_	NN	Protein	-1	none	_	_
26	allele	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Hence	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	has	_	_	VBZ	O	-1	none	_	_
5	been	_	_	VBN	O	-1	none	_	_
6	proposed	_	_	VBN	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	ectopic	_	_	JJ	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TAL1	_	_	NN	Protein	-1	none	_	_
12	promotes	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	development	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	T-ALL	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	report	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	show	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	TAL1	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	leukemic	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	most	_	_	JJS	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	T-ALL	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	including	_	_	VBG	O	-1	none	_	_
22	many	_	_	JJ	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	do	_	_	VBP	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	display	_	_	VB	O	-1	none	_	_
27	an	_	_	DT	O	-1	none	_	_
28	apparent	_	_	JJ	O	-1	none	_	_
29	TAL1	_	_	NN	Protein	-1	none	_	_
30	gene	_	_	NN	O	-1	none	_	_
31	alteration	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	polymorphic	_	_	JJ	O	-1	none	_	_
3	dinucleotide	_	_	NN	O	-1	none	_	_
4	repeat	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	transcribed	_	_	JJ	O	-1	none	_	_
8	sequences	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	TAL1	_	_	NN	Protein	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	used	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	determine	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	allele	_	_	NN	O	-1	none	_	_
17	specificity	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	TAL1	_	_	NN	Protein	-1	none	_	_
20	transcription	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	primary	_	_	JJ	O	-1	none	_	_
23	T-ALL	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Monoallelic	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TAL1	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	leukemic	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	all	_	_	DT	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	8	_	_	CD	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	8	_	_	CD	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	bearing	_	_	VBG	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	TAL1	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	rearrangement	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	leukemic	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	patients	_	_	NNS	O	-1	none	_	_
7	without	_	_	IN	O	-1	none	_	_
8	detectable	_	_	JJ	O	-1	none	_	_
9	TAL1	_	_	NN	Protein	-1	none	_	_
10	rearrangements	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	TAL1	_	_	NN	Protein	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	occurred	_	_	VBD	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	either	_	_	CC	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	monoallelic	_	_	JJ	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	3	_	_	CD	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	7	_	_	CD	O	-1	none	_	_
23	patients	_	_	NNS	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	biallelic	_	_	JJ	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	4	_	_	CD	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	7	_	_	CD	O	-1	none	_	_
32	patients	_	_	NNS	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	fashion	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	TAL1	_	_	NN	Protein	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	these	_	_	DT	O	-1	none	_	_
7	patients	_	_	NNS	O	-1	none	_	_
8	may	_	_	MD	O	-1	none	_	_
9	result	_	_	VB	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	subtle	_	_	JJ	O	-1	none	_	_
12	alterations	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	cis	_	_	NN	O	-1	none	_	_
15	acting	_	_	VBG	O	-1	none	_	_
16	regulatory	_	_	JJ	O	-1	none	_	_
17	sequences	_	_	NNS	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	affecting	_	_	VBG	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	single	_	_	JJ	O	-1	none	_	_
24	TAL1	_	_	NN	Protein	-1	none	_	_
25	allele	_	_	NN	O	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	or	_	_	CC	O	-1	none	_	_
28	changes	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	trans-acting	_	_	JJ	O	-1	none	_	_
31	factors	_	_	NNS	O	-1	none	_	_
32	that	_	_	WDT	O	-1	none	_	_
33	control	_	_	VBP	O	-1	none	_	_
34	TAL1	_	_	NN	Protein	-1	none	_	_
35	transcription	_	_	NN	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	affecting	_	_	VBG	O	-1	none	_	_
38	expression	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	both	_	_	DT	O	-1	none	_	_
41	TAL1	_	_	NN	Protein	-1	none	_	_
42	alleles	_	_	NNS	O	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Detection	_	_	NN	O	-1	none	_	_
2	in	_	_	IN	O	-1	none	_	_
3	non	_	_	JJ	O	-1	none	_	_
4	erythroid	_	_	JJ	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	characteristics	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	erythroid	_	_	JJ	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	EF1	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	erythroid	_	_	JJ	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factor	_	_	NN	O	-1	none	_	_
5	erythroid	_	_	JJ	Protein	6	multitoken	_	_
6	factor-1	_	_	NN	Protein	0	root	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	EF1	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	plays	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	critical	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	erythroid	_	_	JJ	O	-1	none	_	_
19	specific	_	_	JJ	O	-1	none	_	_
20	genes	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	presence	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mobility	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	sequence	_	_	NN	O	-1	none	_	_
14	specific	_	_	JJ	O	-1	none	_	_
15	DNA	_	_	NN	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	characteristics	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	EF1	_	_	NN	Protein	-1	none	_	_
20	at	_	_	IN	O	-1	none	_	_
21	low	_	_	JJ	O	-1	none	_	_
22	abundance	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	wide	_	_	JJ	O	-1	none	_	_
26	variety	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	non	_	_	JJ	O	-1	none	_	_
29	erythroid	_	_	JJ	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	types	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	first	_	_	JJ	O	-1	none	_	_
5	report	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	EF1	_	_	NN	Protein	-1	none	_	_
9	like	_	_	IN	O	-1	none	_	_
10	activity	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	non	_	_	JJ	O	-1	none	_	_
13	erythroid	_	_	JJ	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	indicates	_	_	VBZ	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	play	_	_	VB	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	regulation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	genes	_	_	NNS	O	-1	none	_	_
29	expressed	_	_	VBN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	such	_	_	JJ	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	role	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NFATp	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	cyclosporin	_	_	NN	O	-1	none	_	_
7	A	_	_	NN	O	-1	none	_	_
8	sensitive	_	_	JJ	O	-1	none	_	_
9	tumor	_	_	NN	Protein	11	multitoken	_	_
10	necrosis	_	_	NN	Protein	11	multitoken	_	_
11	factor-alpha	_	_	NN	Protein	0	root	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	tumor	_	_	NN	Protein	4	multitoken	_	_
3	necrosis	_	_	NN	Protein	4	multitoken	_	_
4	factor-alpha	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	TNF	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	immediate	_	_	JJ	O	-1	none	_	_
13	early	_	_	JJ	O	-1	none	_	_
14	gene	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	activated	_	_	VBN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	it	_	_	PRP	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	rapidly	_	_	RB	O	-1	none	_	_
25	induced	_	_	VBN	O	-1	none	_	_
26	without	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	requirement	_	_	NN	O	-1	none	_	_
29	for	_	_	IN	O	-1	none	_	_
30	protein	_	_	NN	O	-1	none	_	_
31	synthesis	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Maximal	_	_	JJ	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TNF	_	_	NN	Protein	5	multitoken	_	_
5	alpha	_	_	NN	Protein	0	root	_	_
6	mRNA	_	_	NN	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	be	_	_	VB	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	treatment	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	calcium	_	_	NN	O	-1	none	_	_
17	ionophores	_	_	NNS	O	-1	none	_	_
18	alone	_	_	RB	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	via	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	calcineurin	_	_	NN	O	-1	none	_	_
23	dependent	_	_	JJ	O	-1	none	_	_
24	process	_	_	NN	O	-1	none	_	_
25	that	_	_	WDT	O	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	blocked	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	cyclosporin	_	_	NN	O	-1	none	_	_
30	A	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	identified	_	_	VBN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	promoter	_	_	NN	O	-1	none	_	_
7	element	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	kappa	_	_	NN	O	-1	none	_	_
10	3	_	_	CD	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	that	_	_	DT	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	required	_	_	VBN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	calcium	_	_	NN	O	-1	none	_	_
17	stimulated	_	_	VBN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	cyclosporin	_	_	NN	O	-1	none	_	_
20	A	_	_	NN	O	-1	none	_	_
21	sensitive	_	_	JJ	O	-1	none	_	_
22	induction	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	TNF	_	_	NN	Protein	26	multitoken	_	_
26	alpha	_	_	NN	Protein	0	root	_	_
27	gene	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	activated	_	_	VBN	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	demonstrate	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	kappa	_	_	NN	O	-1	none	_	_
8	3	_	_	CD	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	contains	_	_	VBZ	O	-1	none	_	_
12	NFATp	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	cyclosporin	_	_	NN	O	-1	none	_	_
16	sensitive	_	_	JJ	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	protein	_	_	NN	O	-1	none	_	_
20	required	_	_	VBN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	interleukin-2	_	_	NN	Protein	-1	none	_	_
23	gene	_	_	NN	O	-1	none	_	_
24	transcription	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	NFATp	_	_	NN	Protein	-1	none	_	_
2	binds	_	_	VBZ	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	sites	_	_	NNS	O	-1	none	_	_
6	within	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	kappa	_	_	NN	O	-1	none	_	_
9	3	_	_	CD	O	-1	none	_	_
10	element	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	occupancy	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	both	_	_	DT	O	-1	none	_	_
16	sites	_	_	NNS	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	required	_	_	VBN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	TNF	_	_	NN	Protein	21	multitoken	_	_
21	alpha	_	_	NN	Protein	0	root	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	induction	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	although	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	kappa	_	_	NN	O	-1	none	_	_
6	3	_	_	CD	O	-1	none	_	_
7	element	_	_	NN	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	little	_	_	JJ	O	-1	none	_	_
10	sequence	_	_	NN	O	-1	none	_	_
11	similarity	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	other	_	_	JJ	O	-1	none	_	_
14	NFATp	_	_	NN	Protein	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	sites	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	it	_	_	PRP	O	-1	none	_	_
19	appears	_	_	VBZ	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	function	_	_	VB	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	cyclosporin	_	_	NN	O	-1	none	_	_
25	sensitive	_	_	JJ	O	-1	none	_	_
26	promoter	_	_	NN	O	-1	none	_	_
27	element	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	T	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	virtue	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	its	_	_	PRP$	O	-1	none	_	_
35	ability	_	_	NN	O	-1	none	_	_
36	to	_	_	TO	O	-1	none	_	_
37	bind	_	_	VB	O	-1	none	_	_
38	NFATp	_	_	NN	Protein	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	involvement	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NFATp	_	_	NN	Protein	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	both	_	_	CC	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	interleukin-2	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	TNF	_	_	NN	Protein	14	multitoken	_	_
14	alpha	_	_	NN	Protein	0	root	_	_
15	genes	_	_	NNS	O	-1	none	_	_
16	suggests	_	_	VBZ	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	plays	_	_	VBZ	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	important	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	coordinate	_	_	JJ	O	-1	none	_	_
27	induction	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	multiple	_	_	JJ	O	-1	none	_	_
30	cytokine	_	_	NN	O	-1	none	_	_
31	genes	_	_	NNS	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	starting	_	_	VBG	O	-1	none	_	_
34	at	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	earliest	_	_	JJS	O	-1	none	_	_
37	stages	_	_	NNS	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	T	_	_	NN	O	-1	none	_	_
40	cell	_	_	NN	O	-1	none	_	_
41	activation	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NF-kappa	_	_	NN	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	inhibitor	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	tepoxalin	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	suppresses	_	_	VBZ	O	-1	none	_	_
9	surface	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	adhesion	_	_	NN	O	-1	none	_	_
15	molecules	_	_	NNS	O	-1	none	_	_
16	CD62E	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	CD11b	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	CD18	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	CD106	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Tepoxalin	_	_	NNP	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	dual	_	_	JJ	O	-1	none	_	_
5	enzyme	_	_	NN	O	-1	none	_	_
6	inhibitor	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	cyclooxygenase	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	5-lipoxygenase	_	_	NN	O	-1	none	_	_
11	has	_	_	VBZ	O	-1	none	_	_
12	been	_	_	VBN	O	-1	none	_	_
13	shown	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	inhibit	_	_	VB	O	-1	none	_	_
16	T-cell	_	_	NN	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Its	_	_	PRP$	O	-1	none	_	_
2	immunosuppressive	_	_	JJ	O	-1	none	_	_
3	property	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	distinct	_	_	JJ	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	cyclosporin	_	_	NN	O	-1	none	_	_
8	because	_	_	IN	O	-1	none	_	_
9	only	_	_	RB	O	-1	none	_	_
10	tepoxalin	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	cyclosporin	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	suppresses	_	_	VBZ	O	-1	none	_	_
17	NF-kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	tepoxalin	_	_	NN	O	-1	none	_	_
6	selectively	_	_	RB	O	-1	none	_	_
7	inhibits	_	_	VBZ	O	-1	none	_	_
8	intercellular	_	_	JJ	Protein	10	multitoken	_	_
9	adhesion	_	_	NN	Protein	10	multitoken	_	_
10	molecule-1	_	_	NN	Protein	0	root	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	ICAM-1	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	CD54	_	_	NN	Protein	-1	none	_	_
15	)/MAC-1	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	CD11b	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	CD18	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	dependent	_	_	JJ	O	-1	none	_	_
22	adhesion	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	polymorphonuclear	_	_	JJ	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	IL-1	_	_	NN	Protein	-1	none	_	_
28	activated	_	_	VBD	O	-1	none	_	_
29	human	_	_	NN	O	-1	none	_	_
30	umbilical	_	_	JJ	O	-1	none	_	_
31	vein	_	_	NN	O	-1	none	_	_
32	endothelial	_	_	JJ	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	inhibition	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	related	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	surface	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	several	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	adhesion	_	_	NN	O	-1	none	_	_
15	molecules	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Flow	_	_	NN	O	-1	none	_	_
2	cytometry	_	_	NN	O	-1	none	_	_
3	analyses	_	_	NNS	O	-1	none	_	_
4	on	_	_	IN	O	-1	none	_	_
5	cultured	_	_	VBN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	treated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	tepoxalin	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	antisense	_	_	JJ	O	-1	none	_	_
14	oligonucleotides	_	_	NNS	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	P65	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	p50	_	_	NN	Protein	-1	none	_	_
20	subunit	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	NF-kappa	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	then	_	_	RB	O	-1	none	_	_
27	stimulated	_	_	VBN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	PMA	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	revealed	_	_	VBD	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	reduced	_	_	JJ	O	-1	none	_	_
34	expression	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	CD11b	_	_	NN	Protein	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	CD18	_	_	NN	Protein	-1	none	_	_
39	on	_	_	IN	O	-1	none	_	_
40	monocytic	_	_	JJ	O	-1	none	_	_
41	HL60	_	_	NN	O	-1	none	_	_
42	cells	_	_	NNS	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	endothelial	_	_	JJ	Protein	47	multitoken	_	_
46	adhesion	_	_	NN	Protein	47	multitoken	_	_
47	molecule-1	_	_	NN	Protein	0	root	_	_
48	(	_	_	-LRB-	O	-1	none	_	_
49	CD62E	_	_	NN	Protein	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	and	_	_	CC	O	-1	none	_	_
52	vascular	_	_	JJ	Protein	54	multitoken	_	_
53	adhesion	_	_	NN	Protein	54	multitoken	_	_
54	molecule-1	_	_	NN	Protein	0	root	_	_
55	(	_	_	-LRB-	O	-1	none	_	_
56	CD106	_	_	NN	Protein	-1	none	_	_
57	)	_	_	-RRB-	O	-1	none	_	_
58	on	_	_	IN	O	-1	none	_	_
59	human	_	_	NN	O	-1	none	_	_
60	umbilical	_	_	JJ	O	-1	none	_	_
61	vein	_	_	NN	O	-1	none	_	_
62	endothelial	_	_	JJ	O	-1	none	_	_
63	cells	_	_	NNS	O	-1	none	_	_
64	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	other	_	_	JJ	O	-1	none	_	_
4	adhesion	_	_	NN	O	-1	none	_	_
5	molecules	_	_	NNS	O	-1	none	_	_
6	such	_	_	JJ	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	lymphocyte	_	_	NN	O	-1	none	_	_
9	function	_	_	NN	O	-1	none	_	_
10	associated-antigen-1	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	CD11a	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	CD18	_	_	NN	Protein	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	CD54	_	_	NN	Protein	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	unaffected	_	_	JJ	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Tepoxalin	_	_	NN	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	inhibited	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	secretion	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	regulated	_	_	VBN	O	-1	none	_	_
11	chemokine	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	IL-8	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	known	_	_	JJ	O	-1	none	_	_
17	inducer	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	CD11b	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	CD18	_	_	NN	Protein	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	suppression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	CD11b	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	CD18	_	_	NN	Protein	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	tepoxalin	_	_	NN	O	-1	none	_	_
11	may	_	_	MD	O	-1	none	_	_
12	involve	_	_	VB	O	-1	none	_	_
13	IL-8	_	_	NN	Protein	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	inhibiting	_	_	VBG	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	surface	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	several	_	_	JJ	O	-1	none	_	_
15	adhesion	_	_	NN	O	-1	none	_	_
16	molecules	_	_	NNS	O	-1	none	_	_
17	can	_	_	MD	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	modulated	_	_	VBN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	tepoxalin	_	_	NN	O	-1	none	_	_
23	may	_	_	MD	O	-1	none	_	_
24	be	_	_	VB	O	-1	none	_	_
25	useful	_	_	JJ	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	treating	_	_	VBG	O	-1	none	_	_
28	selected	_	_	VBN	O	-1	none	_	_
29	adhesion	_	_	NN	O	-1	none	_	_
30	mediated	_	_	VBN	O	-1	none	_	_
31	events	_	_	NNS	O	-1	none	_	_
32	such	_	_	JJ	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	leukocyte	_	_	NN	O	-1	none	_	_
35	migration	_	_	NN	O	-1	none	_	_
36	or	_	_	CC	O	-1	none	_	_
37	atherosclerotic	_	_	JJ	O	-1	none	_	_
38	plaque	_	_	NN	O	-1	none	_	_
39	formation	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CD20	_	_	NN	Protein	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	B1	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	encodes	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	involved	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	regulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	proliferation	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	differentiation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	5	_	_	CD	O	-1	none	_	_
4	'	_	_	''	O	-1	none	_	_
5	deletion	_	_	NN	O	-1	none	_	_
6	CD20	_	_	NN	Protein	-1	none	_	_
7	promoter-CAT	_	_	NN	Protein	-1	none	_	_
8	constructs	_	_	NNS	O	-1	none	_	_
9	have	_	_	VBP	O	-1	none	_	_
10	previously	_	_	RB	O	-1	none	_	_
11	revealed	_	_	VBN	O	-1	none	_	_
12	two	_	_	CD	O	-1	none	_	_
13	regions	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	promoter	_	_	NN	O	-1	none	_	_
17	between	_	_	IN	O	-1	none	_	_
18	bases	_	_	NNS	O	-1	none	_	_
19	-186	_	_	CD	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	-280	_	_	CD	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	between	_	_	IN	O	-1	none	_	_
24	bases	_	_	NNS	O	-1	none	_	_
25	-280	_	_	CD	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	-454	_	_	CD	O	-1	none	_	_
28	which	_	_	WDT	O	-1	none	_	_
29	contained	_	_	VBD	O	-1	none	_	_
30	positive	_	_	JJ	O	-1	none	_	_
31	regulatory	_	_	JJ	O	-1	none	_	_
32	elements	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	identified	_	_	VBD	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	element	_	_	NN	O	-1	none	_	_
9	present	_	_	JJ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	most	_	_	RBS	O	-1	none	_	_
13	proximal	_	_	JJ	O	-1	none	_	_
14	region	_	_	NN	O	-1	none	_	_
15	located	_	_	JJ	O	-1	none	_	_
16	between	_	_	IN	O	-1	none	_	_
17	bases	_	_	NNS	O	-1	none	_	_
18	-214	_	_	CD	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	-201	_	_	CD	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	TTCTTCTAATTAA	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	which	_	_	WDT	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	important	_	_	JJ	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	high	_	_	JJ	O	-1	none	_	_
30	constitutive	_	_	JJ	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	CD20	_	_	NN	Protein	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	mature	_	_	JJ	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	cells	_	_	NNS	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	the	_	_	DT	O	-1	none	_	_
40	induction	_	_	NN	O	-1	none	_	_
41	of	_	_	IN	O	-1	none	_	_
42	CD20	_	_	NN	Protein	-1	none	_	_
43	in	_	_	IN	O	-1	none	_	_
44	pre-B	_	_	JJ	O	-1	none	_	_
45	cells	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	sequence	_	_	NN	O	-1	none	_	_
3	element	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	referred	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	BAT	_	_	NN	O	-1	none	_	_
10	box	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	its	_	_	PRP$	O	-1	none	_	_
13	deletion	_	_	NN	O	-1	none	_	_
14	significantly	_	_	RB	O	-1	none	_	_
15	reduced	_	_	VBD	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	CD20	_	_	NN	Protein	-1	none	_	_
21	promoter-CAT	_	_	NN	Protein	-1	none	_	_
22	construct	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	B	_	_	NN	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Mobility	_	_	NN	O	-1	none	_	_
2	shift	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	various	_	_	JJ	O	-1	none	_	_
6	mutant	_	_	NN	O	-1	none	_	_
7	probes	_	_	NNS	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	nuclear	_	_	JJ	O	-1	none	_	_
12	extracts	_	_	NNS	O	-1	none	_	_
13	demonstrated	_	_	VBD	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	core	_	_	NN	O	-1	none	_	_
17	sequence	_	_	NN	O	-1	none	_	_
18	TAAT	_	_	NN	O	-1	none	_	_
19	was	_	_	VBD	O	-1	none	_	_
20	essential	_	_	JJ	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	binding	_	_	VBG	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	this	_	_	DT	O	-1	none	_	_
25	site	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Cross	_	_	NNP	O	-1	none	_	_
2	competition	_	_	NN	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	octamer	_	_	NN	O	-1	none	_	_
7	sequence	_	_	NN	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	Ig	_	_	NN	O	-1	none	_	_
11	heavy	_	_	JJ	O	-1	none	_	_
12	chain	_	_	NN	O	-1	none	_	_
13	promoter	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	BAT	_	_	NN	O	-1	none	_	_
17	box	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	TA	_	_	NNP	O	-1	none	_	_
22	rich	_	_	JJ	O	-1	none	_	_
23	sequence	_	_	NN	O	-1	none	_	_
24	present	_	_	JJ	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	CD21	_	_	NN	Protein	-1	none	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	revealed	_	_	VBD	O	-1	none	_	_
30	that	_	_	IN	O	-1	none	_	_
31	all	_	_	DT	O	-1	none	_	_
32	three	_	_	CD	O	-1	none	_	_
33	sequences	_	_	NNS	O	-1	none	_	_
34	bound	_	_	VBD	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	same	_	_	JJ	O	-1	none	_	_
37	nuclear	_	_	JJ	O	-1	none	_	_
38	proteins	_	_	NNS	O	-1	none	_	_
39	suggesting	_	_	VBG	O	-1	none	_	_
40	that	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	BAT	_	_	NN	O	-1	none	_	_
43	box	_	_	NN	O	-1	none	_	_
44	binding	_	_	NN	O	-1	none	_	_
45	proteins	_	_	NNS	O	-1	none	_	_
46	were	_	_	VBD	O	-1	none	_	_
47	Oct-1	_	_	NN	Protein	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	Oct-2	_	_	NN	Protein	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	Southwestern	_	_	NN	O	-1	none	_	_
2	blotting	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	UV	_	_	NN	O	-1	none	_	_
5	cross	_	_	VBP	O	-1	none	_	_
6	linking	_	_	VBG	O	-1	none	_	_
7	studies	_	_	NNS	O	-1	none	_	_
8	confirmed	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	BAT	_	_	NN	O	-1	none	_	_
12	box	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	Oct-1	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	Oct-2	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	affinity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	BAT	_	_	NN	O	-1	none	_	_
6	box	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	proteins	_	_	NNS	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	BAT	_	_	NN	O	-1	none	_	_
12	box	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	approximately	_	_	RB	O	-1	none	_	_
15	25-fold	_	_	RB	O	-1	none	_	_
16	less	_	_	JJR	O	-1	none	_	_
17	than	_	_	IN	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	octamer	_	_	NN	O	-1	none	_	_
21	sequence	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	BAT	_	_	NN	O	-1	none	_	_
25	box	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	proteins	_	_	NNS	O	-1	none	_	_
28	dissociated	_	_	VBN	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	BAT	_	_	NN	O	-1	none	_	_
32	box	_	_	NN	O	-1	none	_	_
33	10-fold	_	_	RB	O	-1	none	_	_
34	more	_	_	RBR	O	-1	none	_	_
35	rapidly	_	_	RB	O	-1	none	_	_
36	than	_	_	IN	O	-1	none	_	_
37	from	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	octamer	_	_	NN	O	-1	none	_	_
40	sequence	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Despite	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	lower	_	_	JJR	O	-1	none	_	_
4	affinity	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	trimer	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	BAT	_	_	NN	O	-1	none	_	_
11	box	_	_	NN	O	-1	none	_	_
12	sequence	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	efficiently	_	_	RB	O	-1	none	_	_
16	transactivated	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	an	_	_	DT	O	-1	none	_	_
19	Oct-2	_	_	NN	Protein	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	vector	_	_	NN	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	trimer	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	octamer	_	_	NN	O	-1	none	_	_
29	sequence	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	HeLa	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	BAT	_	_	NN	O	-1	none	_	_
3	box	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	Oct-2	_	_	NN	Protein	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	implicated	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	CD20	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	pre-B	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	line	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	PB-697	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	via	_	_	IN	O	-1	none	_	_
23	phorbol	_	_	NN	O	-1	none	_	_
24	esters	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	results	_	_	NNS	O	-1	none	_	_
4	suggest	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	BAT	_	_	NN	O	-1	none	_	_
8	box	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	proteins	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	important	_	_	JJ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	specific	_	_	JJ	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	CD20	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	perhaps	_	_	RB	O	-1	none	_	_
23	CD21	_	_	NN	Protein	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	IL-10	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	IL-4	_	_	NN	Protein	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	LPS	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	NF-IL6	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	NF-kappa	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	involved	_	_	VBN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	IL-6	_	_	NN	Protein	-1	none	_	_
24	regulation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Interleukin-10	_	_	NNP	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	IL-10	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	like	_	_	IN	O	-1	none	_	_
7	IL-4	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	known	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	inhibit	_	_	VB	O	-1	none	_	_
13	cytokine	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	activated	_	_	VBN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	showed	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	IL-10	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-4	_	_	NN	Protein	-1	none	_	_
8	inhibit	_	_	VBP	O	-1	none	_	_
9	LPS	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	IL-6	_	_	NN	Protein	-1	none	_	_
12	mRNA	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	inhibiting	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	rate	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	IL-6	_	_	NN	Protein	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	strong	_	_	JJ	O	-1	none	_	_
3	inhibition	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	IL-6	_	_	NN	Protein	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	rate	_	_	NN	O	-1	none	_	_
9	prompted	_	_	VBD	O	-1	none	_	_
10	us	_	_	PRP	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	study	_	_	VB	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	effect	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-10	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	IL-4	_	_	NN	Protein	-1	none	_	_
19	on	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	transcription	_	_	NN	O	-1	none	_	_
24	factors	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	questioned	_	_	VBD	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	or	_	_	CC	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	IL-10	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	IL-4	_	_	NN	Protein	-1	none	_	_
9	affected	_	_	VBD	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	transcription	_	_	NN	O	-1	none	_	_
14	factors	_	_	NNS	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	known	_	_	VBN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	involved	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	control	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	IL-6	_	_	NN	Protein	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	rate	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	namely	_	_	RB	O	-1	none	_	_
31	activator	_	_	NN	O	-1	none	_	_
32	protein-1	_	_	NN	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	AP-1	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	nuclear	_	_	JJ	Protein	39	multitoken	_	_
38	factor	_	_	NN	Protein	39	multitoken	_	_
39	IL-6	_	_	NN	Protein	0	root	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	NF-IL6	_	_	NN	Protein	-1	none	_	_
42	)	_	_	-RRB-	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	nuclear	_	_	JJ	O	-1	none	_	_
46	factor	_	_	NN	O	-1	none	_	_
47	kappa	_	_	NN	O	-1	none	_	_
48	B	_	_	NN	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	NF-kappaB	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	electrophoretic	_	_	JJ	O	-1	none	_	_
3	mobility	_	_	NN	O	-1	none	_	_
4	shift	_	_	NN	O	-1	none	_	_
5	assays	_	_	NNS	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	EMSAs	_	_	NNS	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	we	_	_	PRP	O	-1	none	_	_
10	showed	_	_	VBD	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	IL-10	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	IL-4	_	_	NN	Protein	-1	none	_	_
15	inhibited	_	_	VBD	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	induced	_	_	VBD	O	-1	none	_	_
18	AP-1	_	_	NN	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inhibiting	_	_	JJ	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	IL-4	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	slightly	_	_	RB	O	-1	none	_	_
8	more	_	_	RBR	O	-1	none	_	_
9	pronounced	_	_	JJ	O	-1	none	_	_
10	than	_	_	IN	O	-1	none	_	_
11	that	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	IL-10	_	_	NN	Protein	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Downregulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	LPS	_	_	NN	O	-1	none	_	_
4	induced	_	_	VBD	O	-1	none	_	_
5	AP-1	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	accompanied	_	_	VBN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	thus	_	_	RB	O	-1	none	_	_
11	possibly	_	_	RB	O	-1	none	_	_
12	explained	_	_	VBN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	reduced	_	_	JJ	O	-1	none	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	mRNA	_	_	NN	O	-1	none	_	_
20	level	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	two	_	_	CD	O	-1	none	_	_
24	major	_	_	JJ	O	-1	none	_	_
25	components	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	AP-1	_	_	NN	O	-1	none	_	_
29	complex	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	namely	_	_	RB	O	-1	none	_	_
32	c-fos	_	_	NN	Protein	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	c-jun	_	_	NN	Protein	-1	none	_	_
35	as	_	_	IN	O	-1	none	_	_
36	determined	_	_	VBN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	Northern	_	_	NN	O	-1	none	_	_
39	experiments	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	activity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	NF-IL6	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	strongly	_	_	RB	O	-1	none	_	_
8	inhibited	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	IL-4	_	_	NN	Protein	-1	none	_	_
11	whereas	_	_	IN	O	-1	none	_	_
12	IL-10	_	_	NN	Protein	-1	none	_	_
13	showed	_	_	VBD	O	-1	none	_	_
14	no	_	_	DT	O	-1	none	_	_
15	effect	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	NF-IL6	_	_	NNP	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	affected	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	IL-4	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	suggesting	_	_	VBG	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	IL-4	_	_	NN	Protein	-1	none	_	_
15	affects	_	_	VBZ	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	preexisting	_	_	VBG	O	-1	none	_	_
20	NF-IL6	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Neither	_	_	CC	O	-1	none	_	_
2	IL-10	_	_	NN	Protein	-1	none	_	_
3	nor	_	_	CC	O	-1	none	_	_
4	IL-4	_	_	NN	Protein	-1	none	_	_
5	inhibited	_	_	VBD	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	agreement	_	_	NN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	finding	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	Northern	_	_	NN	O	-1	none	_	_
8	experiments	_	_	NNS	O	-1	none	_	_
9	where	_	_	WRB	O	-1	none	_	_
10	p65	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	p105	_	_	NN	Protein	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	levels	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	determined	_	_	VBN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	demonstrated	_	_	VBD	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	these	_	_	DT	O	-1	none	_	_
23	components	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	NF-kappa	_	_	NN	O	-1	none	_	_
27	B	_	_	NN	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	factor	_	_	NN	O	-1	none	_	_
30	were	_	_	VBD	O	-1	none	_	_
31	not	_	_	RB	O	-1	none	_	_
32	affected	_	_	VBN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	IL-10	_	_	NN	Protein	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	IL-4	_	_	NN	Protein	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	neither	_	_	CC	O	-1	none	_	_
4	IL-10	_	_	NN	Protein	-1	none	_	_
5	nor	_	_	CC	O	-1	none	_	_
6	IL-4	_	_	NN	Protein	-1	none	_	_
7	showed	_	_	VBD	O	-1	none	_	_
8	any	_	_	DT	O	-1	none	_	_
9	effect	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	I-kappa	_	_	NN	O	-1	none	_	_
12	B	_	_	NN	O	-1	none	_	_
13	mRNA	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	determined	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	Northern	_	_	NN	O	-1	none	_	_
19	experiments	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	IL-10	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	IL-4	_	_	NN	Protein	-1	none	_	_
6	similarly	_	_	RB	O	-1	none	_	_
7	affect	_	_	VBP	O	-1	none	_	_
8	IL-6	_	_	NN	Protein	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	IL-4	_	_	NN	Protein	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	accompanied	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	reduction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	AP-1	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	NF-IL6	_	_	NN	Protein	-1	none	_	_
15	binding	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	whereas	_	_	IN	O	-1	none	_	_
18	IL-10	_	_	NN	Protein	-1	none	_	_
19	only	_	_	RB	O	-1	none	_	_
20	inhibited	_	_	VBD	O	-1	none	_	_
21	AP-1	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	HIV-1	_	_	NNP	O	-1	none	_	_
2	LTR	_	_	NN	O	-1	none	_	_
3	activity	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	CD40	_	_	NN	Protein	-1	none	_	_
7	activated	_	_	VBN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	lymphocytes	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	CD40	_	_	NN	Protein	-1	none	_	_
2	stimulated	_	_	VBD	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	lymphocytes	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	highly	_	_	RB	O	-1	none	_	_
8	permissive	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	productive	_	_	JJ	O	-1	none	_	_
12	infection	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	immunodeficiency	_	_	NN	O	-1	none	_	_
17	virus	_	_	NN	O	-1	none	_	_
18	type	_	_	NN	O	-1	none	_	_
19	1	_	_	CD	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	factors	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	HIV-1	_	_	NN	O	-1	none	_	_
13	LTR	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	which	_	_	WDT	O	-1	none	_	_
16	contains	_	_	VBZ	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	transcriptional	_	_	JJ	O	-1	none	_	_
19	control	_	_	NN	O	-1	none	_	_
20	elements	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	virus	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	unknown	_	_	JJ	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	plasmids	_	_	NNS	O	-1	none	_	_
6	containing	_	_	VBG	O	-1	none	_	_
7	deleted	_	_	VBN	O	-1	none	_	_
8	parts	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	LTR	_	_	NN	O	-1	none	_	_
12	region	_	_	NN	O	-1	none	_	_
13	linked	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	reporter	_	_	NN	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	showed	_	_	VBD	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	NF-kappaB	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	site	_	_	NN	O	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	essential	_	_	JJ	O	-1	none	_	_
26	for	_	_	IN	O	-1	none	_	_
27	HIV-1	_	_	NN	O	-1	none	_	_
28	LTR	_	_	NN	O	-1	none	_	_
29	activity	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	CD40	_	_	NN	Protein	-1	none	_	_
32	stimulated	_	_	VBN	O	-1	none	_	_
33	B	_	_	NN	O	-1	none	_	_
34	lymphocytes	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	electrophoretic	_	_	JJ	O	-1	none	_	_
5	mobility	_	_	NN	O	-1	none	_	_
6	shift	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	supershift	_	_	NN	O	-1	none	_	_
9	assays	_	_	NNS	O	-1	none	_	_
10	revealed	_	_	VBD	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	important	_	_	JJ	O	-1	none	_	_
13	NF-kappaB	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	composed	_	_	VBN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	at	_	_	IN	O	-1	none	_	_
19	least	_	_	JJS	O	-1	none	_	_
20	p50	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	p65	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	c-Rel	_	_	NN	Protein	-1	none	_	_
26	NF-kappaB	_	_	NN	O	-1	none	_	_
27	subunits	_	_	NNS	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	present	_	_	JJ	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	nuclei	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	CD40	_	_	NN	Protein	-1	none	_	_
34	stimulated	_	_	VBN	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	confirm	_	_	VBP	O	-1	none	_	_
4	at	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	molecular	_	_	JJ	O	-1	none	_	_
7	level	_	_	NN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	ability	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	HIV-1	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	replicate	_	_	VB	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	that	_	_	IN	O	-1	none	_	_
19	this	_	_	DT	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	strongly	_	_	RB	O	-1	none	_	_
23	associated	_	_	VBN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	NF-kappaB	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Growth	_	_	NN	O	-1	none	_	_
2	regulation	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	cellular	_	_	JJ	O	-1	none	_	_
5	changes	_	_	NNS	O	-1	none	_	_
6	during	_	_	IN	O	-1	none	_	_
7	differentiation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	prostatic	_	_	JJ	O	-1	none	_	_
11	cancer	_	_	NN	O	-1	none	_	_
12	LNCaP	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	induced	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	lymphocyte	_	_	NN	O	-1	none	_	_
19	conditioned	_	_	JJ	O	-1	none	_	_
20	medium	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	prostatic	_	_	JJ	O	-1	none	_	_
3	epithelial	_	_	JJ	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	androgen	_	_	NN	O	-1	none	_	_
8	dependent	_	_	JJ	O	-1	none	_	_
9	LNCaP	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	line	_	_	NN	O	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	examined	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	conditioned	_	_	JJ	O	-1	none	_	_
18	medium	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	CM	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	derived	_	_	VBN	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	phytohemagglutinin	_	_	NN	Protein	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	PHA	_	_	NN	Protein	-1	none	_	_
27	)-stimulated	_	_	JJ	O	-1	none	_	_
28	lymphocytes	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Addition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	CM	_	_	NN	O	-1	none	_	_
4	caused	_	_	VBD	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	greater	_	_	JJR	O	-1	none	_	_
7	than	_	_	IN	O	-1	none	_	_
8	70	_	_	CD	O	-1	none	_	_
9	%	_	_	NN	O	-1	none	_	_
10	reduction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	proliferation	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	counting	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	cycle	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	G1	_	_	NN	O	-1	none	_	_
5	phase	_	_	NN	O	-1	none	_	_
6	arrest	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	clonogenicity	_	_	NN	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	reduced	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	growth	_	_	NN	O	-1	none	_	_
3	modulating	_	_	NN	O	-1	none	_	_
4	effect	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	dose	_	_	NN	O	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	due	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	lysis	_	_	NN	O	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	apoptosis	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	androgen	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	androgen	_	_	NN	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	these	_	_	DT	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	showed	_	_	VBD	O	-1	none	_	_
12	approximately	_	_	RB	O	-1	none	_	_
13	50	_	_	CD	O	-1	none	_	_
14	%	_	_	NN	O	-1	none	_	_
15	reduction	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	underlining	_	_	VBG	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	proliferation	_	_	NN	O	-1	none	_	_
20	reduction	_	_	NN	O	-1	none	_	_
21	mechanism	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	prostate	_	_	NN	Protein	4	multitoken	_	_
3	specific	_	_	JJ	Protein	4	multitoken	_	_
4	antigen	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	PSA	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	downregulated	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	approximately	_	_	RB	O	-1	none	_	_
12	75	_	_	CD	O	-1	none	_	_
13	%	_	_	NN	O	-1	none	_	_
14	during	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	process	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Cell	_	_	NN	O	-1	none	_	_
2	morphology	_	_	NN	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	dendritic	_	_	JJ	O	-1	none	_	_
5	processes	_	_	NNS	O	-1	none	_	_
6	extending	_	_	VBG	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	cytoplasm	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	other	_	_	JJ	O	-1	none	_	_
11	neuroendocrine	_	_	JJ	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	characteristics	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	several	_	_	JJ	O	-1	none	_	_
5	cytoskeleton	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	intracellular	_	_	JJ	O	-1	none	_	_
8	proteins	_	_	NNS	O	-1	none	_	_
9	increased	_	_	VBD	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	determined	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	immunostaining	_	_	NN	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	slides	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	ELISA	_	_	NN	O	-1	none	_	_
19	procedures	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	included	_	_	VBD	O	-1	none	_	_
3	vimentin	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	correlating	_	_	VBG	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	shape	_	_	NN	O	-1	none	_	_
9	changes	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	cytokeratins	_	_	NNS	O	-1	none	_	_
12	8	_	_	CD	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	18	_	_	CD	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	associated	_	_	VBN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	differentiated	_	_	VBN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	types	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	prostate	_	_	NN	O	-1	none	_	_
23	epithelia	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	neuron	_	_	NN	Protein	28	multitoken	_	_
27	specific	_	_	JJ	Protein	28	multitoken	_	_
28	enolase	_	_	NN	Protein	0	root	_	_
29	and	_	_	CC	O	-1	none	_	_
30	serotonin	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	associated	_	_	VBN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	neuroendocrine	_	_	NN	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	From	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	cellular	_	_	JJ	O	-1	none	_	_
4	changes	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	infer	_	_	VB	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	growth	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	modulated	_	_	VBN	O	-1	none	_	_
15	along	_	_	IN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	induction	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	terminal	_	_	JJ	O	-1	none	_	_
20	differentiation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Activated	_	_	VBN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	demonstrated	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	important	_	_	JJ	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	providing	_	_	VBG	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	modulating	_	_	NN	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	growth	_	_	NN	O	-1	none	_	_
3	modulator	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	semipurified	_	_	VBN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	had	_	_	VBD	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	estimated	_	_	VBN	O	-1	none	_	_
10	molecular	_	_	JJ	O	-1	none	_	_
11	weight	_	_	NN	O	-1	none	_	_
12	13,000	_	_	CD	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	24,000	_	_	CD	O	-1	none	_	_
15	Da	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activity	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	determined	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	distinct	_	_	JJ	O	-1	none	_	_
8	from	_	_	IN	O	-1	none	_	_
9	TGF	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	TNF	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	some	_	_	DT	O	-1	none	_	_
15	commonly	_	_	RB	O	-1	none	_	_
16	known	_	_	VBN	O	-1	none	_	_
17	lymphokines	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	interaction	_	_	NN	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	lymphoid	_	_	JJ	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	prostatic	_	_	JJ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	growth	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	development	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	described	_	_	VBN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	C/EBP	_	_	NN	O	-1	none	_	_
2	proteins	_	_	NNS	O	-1	none	_	_
3	activate	_	_	VBP	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	immunodeficiency	_	_	NN	O	-1	none	_	_
9	virus	_	_	NN	O	-1	none	_	_
10	type	_	_	NN	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	long	_	_	JJ	O	-1	none	_	_
13	terminal	_	_	JJ	O	-1	none	_	_
14	repeat	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	macrophages	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Three	_	_	CD	O	-1	none	_	_
2	binding	_	_	VBG	O	-1	none	_	_
3	sites	_	_	NNS	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	C/EBP	_	_	NN	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	found	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	immunodeficiency	_	_	NN	O	-1	none	_	_
13	virus	_	_	NN	O	-1	none	_	_
14	type	_	_	NN	O	-1	none	_	_
15	1	_	_	CD	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	HIV-1	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	long	_	_	JJ	O	-1	none	_	_
20	terminal	_	_	JJ	O	-1	none	_	_
21	repeat	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	LTR	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	V.M.	_	_	NNP	O	-1	none	_	_
27	Tesmer	_	_	NNP	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	A.Rajadhyaksha	_	_	NNP	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	J.Babin	_	_	NNP	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	M.Bina	_	_	NNP	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	Proc.Natl.Acad.Sci	_	_	NNP	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	USA	_	_	NNP	O	-1	none	_	_
2	90:7298-7302,	_	_	CD	O	-1	none	_	_
3	1993	_	_	CD	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	determined	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	functional	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	C/EBP	_	_	NN	O	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	C/EBP	_	_	NN	O	-1	none	_	_
12	sites	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	regulating	_	_	VBG	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	from	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	HIV-	_	_	NN	O	-1	none	_	_
19	1	_	_	CD	O	-1	none	_	_
20	LTR	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	monocytes	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	macrophages	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	endogenous	_	_	JJ	O	-1	none	_	_
4	C/EBP	_	_	NN	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	using	_	_	VBG	O	-1	none	_	_
8	either	_	_	CC	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	excess	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	C/EBP	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	sites	_	_	NNS	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	trans-	_	_	JJ	O	-1	none	_	_
18	dominant	_	_	JJ	O	-1	none	_	_
19	negative	_	_	JJ	O	-1	none	_	_
20	inhibitor	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	demonstrated	_	_	VBD	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	C/EBP	_	_	NN	O	-1	none	_	_
25	proteins	_	_	NNS	O	-1	none	_	_
26	are	_	_	VBP	O	-1	none	_	_
27	required	_	_	VBN	O	-1	none	_	_
28	for	_	_	IN	O	-1	none	_	_
29	basal	_	_	JJ	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	activated	_	_	VBN	O	-1	none	_	_
32	levels	_	_	NNS	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	HIV-1	_	_	NN	O	-1	none	_	_
35	LTR	_	_	NN	O	-1	none	_	_
36	transcription	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	promonocytic	_	_	JJ	O	-1	none	_	_
40	cell	_	_	NN	O	-1	none	_	_
41	line	_	_	NN	O	-1	none	_	_
42	U937	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	JJ	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	RNA	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	blots	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	assays	_	_	NNS	O	-1	none	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	NF-IL6	_	_	NN	Protein	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	only	_	_	RB	O	-1	none	_	_
15	known	_	_	JJ	O	-1	none	_	_
16	C/EBP	_	_	NN	O	-1	none	_	_
17	family	_	_	NN	O	-1	none	_	_
18	member	_	_	NN	O	-1	none	_	_
19	which	_	_	WDT	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	increased	_	_	VBN	O	-1	none	_	_
22	when	_	_	WRB	O	-1	none	_	_
23	U937	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	activated	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Mutational	_	_	JJ	O	-1	none	_	_
2	analyses	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	HIV-1	_	_	NN	O	-1	none	_	_
6	LTR	_	_	NN	O	-1	none	_	_
7	showed	_	_	VBD	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	one	_	_	CD	O	-1	none	_	_
10	C/EBP	_	_	NN	O	-1	none	_	_
11	site	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	required	_	_	VBN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	normal	_	_	JJ	O	-1	none	_	_
16	LTR	_	_	NN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	both	_	_	CC	O	-1	none	_	_
19	before	_	_	IN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	after	_	_	IN	O	-1	none	_	_
22	cellular	_	_	JJ	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	two	_	_	CD	O	-1	none	_	_
28	3	_	_	CD	O	-1	none	_	_
29	'	_	_	''	O	-1	none	_	_
30	C/EBP	_	_	NN	O	-1	none	_	_
31	sites	_	_	NNS	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	functionally	_	_	RB	O	-1	none	_	_
34	equivalent	_	_	JJ	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	crippled	_	_	VBN	O	-1	none	_	_
6	HIV-1	_	_	NN	O	-1	none	_	_
7	LTRs	_	_	NNS	O	-1	none	_	_
8	lacking	_	_	VBG	O	-1	none	_	_
9	C/EBP	_	_	NN	O	-1	none	_	_
10	sites	_	_	NNS	O	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	still	_	_	RB	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	induced	_	_	VBN	O	-1	none	_	_
15	following	_	_	VBG	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	U937	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	models	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	suggested	_	_	VBN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	how	_	_	WRB	O	-1	none	_	_
7	elevated	_	_	JJ	O	-1	none	_	_
8	NF-IL6	_	_	NN	Protein	-1	none	_	_
9	may	_	_	MD	O	-1	none	_	_
10	participate	_	_	VB	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	autostimulatory	_	_	JJ	O	-1	none	_	_
14	loop	_	_	NN	O	-1	none	_	_
15	involving	_	_	VBG	O	-1	none	_	_
16	HIV	_	_	NN	O	-1	none	_	_
17	infection	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	macrophage	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	cytokine	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	HIV	_	_	NN	O	-1	none	_	_
27	replication	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Immune	_	_	JJ	O	-1	none	_	_
2	functions	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	clinical	_	_	JJ	O	-1	none	_	_
5	parameters	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	hormone	_	_	NN	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	status	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	breast	_	_	NN	O	-1	none	_	_
12	cancer	_	_	NN	O	-1	none	_	_
13	patients	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	carried	_	_	VBN	O	-1	none	_	_
4	out	_	_	RP	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	detailed	_	_	JJ	O	-1	none	_	_
7	analysis	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	cellular	_	_	JJ	O	-1	none	_	_
11	immune	_	_	JJ	O	-1	none	_	_
12	functions	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	breast	_	_	NN	O	-1	none	_	_
15	cancer	_	_	NN	O	-1	none	_	_
16	patients	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	comparison	_	_	NN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	healthy	_	_	JJ	O	-1	none	_	_
21	controls	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	possible	_	_	JJ	O	-1	none	_	_
3	correlation	_	_	NN	O	-1	none	_	_
4	between	_	_	IN	O	-1	none	_	_
5	immune	_	_	JJ	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	clinical	_	_	JJ	O	-1	none	_	_
8	parameters	_	_	NNS	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	analysed	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	50	_	_	CD	O	-1	none	_	_
13	breast	_	_	NN	O	-1	none	_	_
14	cancer	_	_	NN	O	-1	none	_	_
15	patients	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Immune	_	_	JJ	O	-1	none	_	_
2	parameters	_	_	NNS	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	natural	_	_	JJ	O	-1	none	_	_
5	killer	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	T	_	_	NN	O	-1	none	_	_
9	lymphocyte	_	_	NN	O	-1	none	_	_
10	functions	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	numbers	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	circulating	_	_	VBG	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	lymphocytes	_	_	NNS	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	analysed	_	_	VBN	O	-1	none	_	_
20	against	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	clinical	_	_	JJ	O	-1	none	_	_
23	parameters	_	_	NNS	O	-1	none	_	_
24	comprising	_	_	VBG	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	tumour	_	_	NN	O	-1	none	_	_
27	burden	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	stage	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	disease	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	expression	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	hormone	_	_	NN	O	-1	none	_	_
39	receptors	_	_	NNS	O	-1	none	_	_
40	on	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	tumour	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	analyse	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	immune	_	_	JJ	O	-1	none	_	_
7	function	_	_	NN	O	-1	none	_	_
8	data	_	_	NNS	O	-1	none	_	_
9	effectively	_	_	RB	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	low	_	_	JJ	O	-1	none	_	_
12	responders	_	_	NNS	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	identified	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	stringent	_	_	JJ	O	-1	none	_	_
17	cut-off	_	_	JJ	O	-1	none	_	_
18	values	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Considerably	_	_	RB	O	-1	none	_	_
2	higher	_	_	JJR	O	-1	none	_	_
3	proportions	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	low	_	_	JJ	O	-1	none	_	_
6	responders	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	found	_	_	VBN	O	-1	none	_	_
9	among	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	patient	_	_	NN	O	-1	none	_	_
12	population	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Elevated	_	_	JJ	O	-1	none	_	_
2	numbers	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	circulating	_	_	VBG	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	CD3	_	_	NN	O	-1	none	_	_
9	directed	_	_	VBD	O	-1	none	_	_
10	cytolysis	_	_	NN	O	-1	none	_	_
11	correlated	_	_	VBD	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	oestrogen	_	_	NN	Protein	17	multitoken	_	_
17	receptors	_	_	NNS	Protein	0	root	_	_
18	independently	_	_	RB	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	clinical	_	_	JJ	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	histological	_	_	JJ	O	-1	none	_	_
24	parameters	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Elevated	_	_	JJ	O	-1	none	_	_
2	cyclic	_	_	JJ	O	-1	none	_	_
3	AMP	_	_	NN	O	-1	none	_	_
4	inhibits	_	_	VBZ	O	-1	none	_	_
5	NF-kappaB-mediated	_	_	JJ	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	monocytic	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	endothelial	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	NF-kappaB	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	Rel	_	_	NN	O	-1	none	_	_
5	family	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	regulates	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	inducible	_	_	JJ	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	many	_	_	JJ	O	-1	none	_	_
15	genes	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	activated	_	_	VBN	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	monocytes	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	endothelial	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	examined	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	molecular	_	_	JJ	O	-1	none	_	_
9	mechanism	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	agents	_	_	NNS	O	-1	none	_	_
13	that	_	_	WDT	O	-1	none	_	_
14	elevate	_	_	VBP	O	-1	none	_	_
15	intracellular	_	_	JJ	O	-1	none	_	_
16	cAMP	_	_	NN	O	-1	none	_	_
17	inhibit	_	_	VBP	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	tumor	_	_	NN	Protein	25	multitoken	_	_
23	necrosis	_	_	NN	Protein	25	multitoken	_	_
24	factor	_	_	NN	Protein	25	multitoken	_	_
25	alpha	_	_	NN	Protein	0	root	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	TNFalpha	_	_	NN	Protein	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	tissue	_	_	NN	Protein	31	multitoken	_	_
31	factor	_	_	NN	Protein	0	root	_	_
32	,	_	_	,	O	-1	none	_	_
33	endothelial	_	_	JJ	Protein	36	multitoken	_	_
34	leukocyte	_	_	NN	Protein	36	multitoken	_	_
35	adhesion	_	_	NN	Protein	36	multitoken	_	_
36	molecule-1	_	_	NN	Protein	0	root	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	vascular	_	_	JJ	Protein	42	multitoken	_	_
40	cell	_	_	NN	Protein	42	multitoken	_	_
41	adhesion	_	_	NN	Protein	42	multitoken	_	_
42	molecule-1	_	_	NN	Protein	0	root	_	_
43	genes	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	forskolin	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	dibutyryl	_	_	NN	O	-1	none	_	_
5	cAMP	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	elevate	_	_	VBP	O	-1	none	_	_
9	intracellular	_	_	JJ	O	-1	none	_	_
10	cAMP	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	independent	_	_	JJ	O	-1	none	_	_
13	mechanisms	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	inhibited	_	_	VBD	O	-1	none	_	_
16	TNFalpha	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	tissue	_	_	NN	Protein	19	multitoken	_	_
19	factor	_	_	NN	Protein	0	root	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	at	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	level	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-kappaB-dependent	_	_	JJ	O	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	transiently	_	_	RB	O	-1	none	_	_
8	transfected	_	_	VBN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	monocytic	_	_	JJ	O	-1	none	_	_
11	THP-1	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	umbilical	_	_	JJ	O	-1	none	_	_
16	vein	_	_	NN	O	-1	none	_	_
17	endothelial	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	was	_	_	VBD	O	-1	none	_	_
20	inhibited	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	elevated	_	_	JJ	O	-1	none	_	_
23	cAMP	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	overexpression	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	catalytic	_	_	JJ	O	-1	none	_	_
30	subunit	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	protein	_	_	NN	O	-1	none	_	_
33	kinase	_	_	NN	O	-1	none	_	_
34	A	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	PKA	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Elevated	_	_	JJ	O	-1	none	_	_
2	cAMP	_	_	NN	O	-1	none	_	_
3	did	_	_	VBD	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	prevent	_	_	VB	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	translocation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	p50	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p65	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	c-Rel	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	p65	_	_	NN	Protein	-1	none	_	_
16	heterodimers	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	decrease	_	_	VB	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	translocation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	p65	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	or	_	_	CC	O	-1	none	_	_
25	significantly	_	_	RB	O	-1	none	_	_
26	modify	_	_	VB	O	-1	none	_	_
27	TNFalpha	_	_	NN	Protein	-1	none	_	_
28	induced	_	_	VBD	O	-1	none	_	_
29	phosphorylation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	p65	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	transcriptional	_	_	JJ	O	-1	none	_	_
6	activation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	plasmid	_	_	NN	O	-1	none	_	_
10	containing	_	_	VBG	O	-1	none	_	_
11	multimerized	_	_	JJ	O	-1	none	_	_
12	kappaB	_	_	NN	O	-1	none	_	_
13	sites	_	_	NNS	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	p65	_	_	NN	Protein	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	inhibited	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	agents	_	_	NNS	O	-1	none	_	_
20	that	_	_	WDT	O	-1	none	_	_
21	elevate	_	_	VBP	O	-1	none	_	_
22	cAMP	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	overexpression	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	catalytic	_	_	JJ	O	-1	none	_	_
29	subunit	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	PKA	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	indicates	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	PKA	_	_	NN	O	-1	none	_	_
8	reduces	_	_	VBZ	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	induction	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	distinct	_	_	JJ	O	-1	none	_	_
14	set	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	endothelial	_	_	JJ	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	inhibiting	_	_	VBG	O	-1	none	_	_
24	NF-kappaB-mediated	_	_	JJ	O	-1	none	_	_
25	transcription	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Ah	_	_	NN	Protein	3	multitoken	_	_
3	receptor	_	_	NN	Protein	0	root	_	_
4	recognizes	_	_	VBZ	O	-1	none	_	_
5	DNA	_	_	NN	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	sites	_	_	NNS	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	B	_	_	NN	Protein	13	multitoken	_	_
11	cell	_	_	NN	Protein	13	multitoken	_	_
12	transcription	_	_	NN	Protein	13	multitoken	_	_
13	factor	_	_	NN	Protein	0	root	_	_
14	,	_	_	,	O	-1	none	_	_
15	BSAP	_	_	NN	Protein	-1	none	_	_
16	:	_	_	:	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	possible	_	_	JJ	O	-1	none	_	_
19	mechanism	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	dioxin	_	_	NN	O	-1	none	_	_
22	mediated	_	_	VBD	O	-1	none	_	_
23	alteration	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	CD19	_	_	NN	Protein	-1	none	_	_
26	gene	_	_	NN	O	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	human	_	_	NN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	lymphocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	2,3,7,8-tetrachlorodibenzo-p-dioxin	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	TCDD	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	inhibits	_	_	VBZ	O	-1	none	_	_
6	murine	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	lymphocyte	_	_	NN	O	-1	none	_	_
11	immunoglobulin	_	_	NN	O	-1	none	_	_
12	production	_	_	NN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	unknown	_	_	JJ	O	-1	none	_	_
16	mechanism	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	investigated	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	effect	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	TCDD	_	_	NN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	CD19	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	B	_	_	NN	O	-1	none	_	_
18	lymphocyte	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	line	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	TCDD	_	_	NN	O	-1	none	_	_
7	treatment	_	_	NN	O	-1	none	_	_
8	decreased	_	_	VBD	O	-1	none	_	_
9	steady	_	_	JJ	O	-1	none	_	_
10	state	_	_	NN	O	-1	none	_	_
11	levels	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	CD19	_	_	NN	Protein	-1	none	_	_
14	mRNA	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	67	_	_	CD	O	-1	none	_	_
17	%	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	IM-9	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	line	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	gel	_	_	NN	O	-1	none	_	_
4	mobility	_	_	NN	O	-1	none	_	_
5	shift	_	_	NN	O	-1	none	_	_
6	assay	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	identified	_	_	VBD	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	complex	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	IM-9	_	_	NN	O	-1	none	_	_
16	nuclear	_	_	JJ	O	-1	none	_	_
17	extracts	_	_	NNS	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	several	_	_	JJ	O	-1	none	_	_
21	criteria	_	_	NNS	O	-1	none	_	_
22	appears	_	_	VBZ	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	be	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	Ah	_	_	NN	Protein	27	multitoken	_	_
27	receptor	_	_	NN	Protein	0	root	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	Ah	_	_	NN	Protein	6	multitoken	_	_
6	receptor	_	_	NN	Protein	0	root	_	_
7	complex	_	_	NN	O	-1	none	_	_
8	recognized	_	_	VBD	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	DNA	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	site	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	B	_	_	NN	Protein	19	multitoken	_	_
15	cell	_	_	NN	Protein	19	multitoken	_	_
16	lineage	_	_	NN	Protein	19	multitoken	_	_
17	specific	_	_	JJ	Protein	19	multitoken	_	_
18	activator	_	_	NN	Protein	19	multitoken	_	_
19	protein	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	BSAP	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	region	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	human	_	_	NN	O	-1	none	_	_
30	CD19	_	_	NN	Protein	-1	none	_	_
31	gene	_	_	NN	O	-1	none	_	_
32	which	_	_	WDT	O	-1	none	_	_
33	is	_	_	VBZ	O	-1	none	_	_
34	similar	_	_	JJ	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	consensus	_	_	NN	O	-1	none	_	_
38	Ah	_	_	NN	Protein	39	multitoken	_	_
39	receptor	_	_	NN	Protein	0	root	_	_
40	DNA	_	_	NN	O	-1	none	_	_
41	binding	_	_	NN	O	-1	none	_	_
42	site	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	AhR	_	_	NN	Protein	-1	none	_	_
7	could	_	_	MD	O	-1	none	_	_
8	interfere	_	_	VB	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	BSAP	_	_	NN	Protein	-1	none	_	_
11	stimulated	_	_	VBD	O	-1	none	_	_
12	CD19	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	transcription	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	competition	_	_	NN	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	common	_	_	JJ	O	-1	none	_	_
20	DNA	_	_	NN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	site	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	G	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	Anh	_	_	NNP	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	MTetra	_	_	NNP	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	natural	_	_	JJ	O	-1	none	_	_
9	bacterial	_	_	JJ	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	wall	_	_	NN	O	-1	none	_	_
12	breakdown	_	_	NN	O	-1	none	_	_
13	product	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	induces	_	_	VBZ	O	-1	none	_	_
16	interleukin-1	_	_	NN	Protein	17	multitoken	_	_
17	beta	_	_	NN	Protein	0	root	_	_
18	and	_	_	CC	O	-1	none	_	_
19	interleukin-6	_	_	NN	Protein	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	monocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	molecular	_	_	JJ	O	-1	none	_	_
6	mechanisms	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	inflammatory	_	_	JJ	O	-1	none	_	_
10	cytokine	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	[	_	_	CD	O	-1	none	_	_
13	published	_	_	VBN	O	-1	none	_	_
14	erratum	_	_	NN	O	-1	none	_	_
15	appears	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	J	_	_	NNP	O	-1	none	_	_
18	Biol	_	_	NNP	O	-1	none	_	_
19	Chem	_	_	NNP	O	-1	none	_	_
20	1994	_	_	CD	O	-1	none	_	_
21	Jun	_	_	NN	O	-1	none	_	_
22	17	_	_	CD	O	-1	none	_	_
23	;	_	_	:	O	-1	none	_	_
24	269	_	_	CD	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	24	_	_	CD	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	:16983	_	_	CD	O	-1	none	_	_
29	]	_	_	CD	O	-1	none	_	_
30	It	_	_	PRP	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	believed	_	_	VBN	O	-1	none	_	_
33	that	_	_	IN	O	-1	none	_	_
34	induction	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	cytokine	_	_	NN	O	-1	none	_	_
37	expression	_	_	NN	O	-1	none	_	_
38	by	_	_	IN	O	-1	none	_	_
39	bacterial	_	_	JJ	O	-1	none	_	_
40	cell	_	_	NN	O	-1	none	_	_
41	wall	_	_	NN	O	-1	none	_	_
42	components	_	_	NNS	O	-1	none	_	_
43	plays	_	_	VBZ	O	-1	none	_	_
44	a	_	_	DT	O	-1	none	_	_
45	role	_	_	NN	O	-1	none	_	_
46	in	_	_	IN	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	development	_	_	NN	O	-1	none	_	_
49	and	_	_	CC	O	-1	none	_	_
50	course	_	_	NN	O	-1	none	_	_
51	of	_	_	IN	O	-1	none	_	_
52	sepsis	_	_	NN	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	most	_	_	JJS	O	-1	none	_	_
4	attention	_	_	NN	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	focused	_	_	VBN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	lipopolysaccharide	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	LPS	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	studied	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	ability	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	N-acetylglucosaminyl-1	_	_	NN	O	-1	none	_	_
7	,6-anhydro-N-acetylmuramyl-L-alanyl-D-	_	_	NN	O	-1	none	_	_
8	isoglutamyl-m-diaminopimelyl-D-alanine	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	G	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	Anh	_	_	NNP	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	MTetra	_	_	NNP	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	naturally	_	_	RB	O	-1	none	_	_
19	occurring	_	_	VBG	O	-1	none	_	_
20	breakdown	_	_	NN	O	-1	none	_	_
21	product	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	peptidoglycan	_	_	NN	O	-1	none	_	_
24	that	_	_	WDT	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	produced	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	soluble	_	_	JJ	O	-1	none	_	_
29	lytic	_	_	JJ	O	-1	none	_	_
30	transglycosylase	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	Escherichia	_	_	FW	O	-1	none	_	_
33	coli	_	_	FW	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	induce	_	_	VB	O	-1	none	_	_
37	cytokine	_	_	NN	O	-1	none	_	_
38	expression	_	_	NN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	human	_	_	NN	O	-1	none	_	_
41	monocytes	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	G	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	Anh	_	_	NNP	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	MTetra	_	_	NNP	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	found	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	strongly	_	_	RB	O	-1	none	_	_
10	induce	_	_	VB	O	-1	none	_	_
11	interleukin	_	_	NN	Protein	16	multitoken	_	_
12	(	_	_	-LRB-	Protein	16	multitoken	_	_
13	IL	_	_	NN	Protein	16	multitoken	_	_
14	)	_	_	-RRB-	Protein	16	multitoken	_	_
15	-1	_	_	CD	Protein	16	multitoken	_	_
16	beta	_	_	NN	Protein	0	root	_	_
17	and	_	_	CC	O	-1	none	_	_
18	IL-6	_	_	NN	Protein	-1	none	_	_
19	mRNA	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	after	_	_	IN	O	-1	none	_	_
22	2	_	_	CD	O	-1	none	_	_
23	h	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	IL-1	_	_	NN	Protein	26	multitoken	_	_
26	beta	_	_	NN	Protein	0	root	_	_
27	and	_	_	CC	O	-1	none	_	_
28	IL-6	_	_	NN	Protein	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	secretion	_	_	NN	O	-1	none	_	_
31	after	_	_	IN	O	-1	none	_	_
32	48	_	_	CD	O	-1	none	_	_
33	h	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	activation	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	increase	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	mRNA	_	_	NN	O	-1	none	_	_
5	accumulation	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	at	_	_	IN	O	-1	none	_	_
8	least	_	_	JJS	O	-1	none	_	_
9	partly	_	_	RB	O	-1	none	_	_
10	due	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	increase	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	rates	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	respective	_	_	JJ	O	-1	none	_	_
21	genes	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	accompanied	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	strong	_	_	JJ	O	-1	none	_	_
28	induction	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	nuclear	_	_	JJ	O	-1	none	_	_
31	factor-kappa	_	_	NN	O	-1	none	_	_
32	B	_	_	NN	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	activator	_	_	NN	O	-1	none	_	_
35	protein-1	_	_	NN	O	-1	none	_	_
36	transcription	_	_	NN	O	-1	none	_	_
37	factor	_	_	NN	O	-1	none	_	_
38	expression	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Experiments	_	_	NNS	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	inhibitors	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	kinase	_	_	NN	O	-1	none	_	_
7	C	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	kinase	_	_	NN	O	-1	none	_	_
11	A	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	dependent	_	_	JJ	O	-1	none	_	_
17	pathways	_	_	NNS	O	-1	none	_	_
18	revealed	_	_	VBD	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	G	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	Anh	_	_	NNP	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	MTetra	_	_	NN	O	-1	none	_	_
25	induced	_	_	VBD	O	-1	none	_	_
26	IL-1	_	_	NN	Protein	27	multitoken	_	_
27	beta	_	_	NN	Protein	0	root	_	_
28	and	_	_	CC	O	-1	none	_	_
29	IL-6	_	_	NN	Protein	-1	none	_	_
30	mRNA	_	_	NN	O	-1	none	_	_
31	expression	_	_	NN	O	-1	none	_	_
32	involves	_	_	VBZ	O	-1	none	_	_
33	activation	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	an	_	_	DT	O	-1	none	_	_
36	H7-inhibitable	_	_	JJ	O	-1	none	_	_
37	pathway	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	synthesis	_	_	NN	O	-1	none	_	_
6	inhibitor	_	_	NN	O	-1	none	_	_
7	cycloheximide	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	it	_	_	PRP	O	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	shown	_	_	VBN	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	G	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	Anh	_	_	NNP	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	MTetra	_	_	NN	O	-1	none	_	_
18	induced	_	_	VBD	O	-1	none	_	_
19	IL-6	_	_	NN	Protein	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	expression	_	_	NN	O	-1	none	_	_
22	depends	_	_	VBZ	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	synthesis	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	new	_	_	JJ	O	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	whereas	_	_	IN	O	-1	none	_	_
31	G	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	Anh	_	_	NNP	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	MTetra	_	_	NN	O	-1	none	_	_
36	induced	_	_	VBD	O	-1	none	_	_
37	IL-1	_	_	NN	Protein	38	multitoken	_	_
38	beta	_	_	NN	Protein	0	root	_	_
39	mRNA	_	_	NN	O	-1	none	_	_
40	accumulation	_	_	NN	O	-1	none	_	_
41	does	_	_	VBZ	O	-1	none	_	_
42	not	_	_	RB	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	responses	_	_	NNS	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	G	_	_	NNP	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	Anh	_	_	NNP	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	MTetra	_	_	NNP	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	compared	_	_	VBN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	those	_	_	DT	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	LPS	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	muramyldipeptide	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	MDP	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	it	_	_	PRP	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	found	_	_	VBN	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	optimal	_	_	JJ	O	-1	none	_	_
27	response	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	G	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	Anh	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	MTetra	_	_	NN	O	-1	none	_	_
34	induction	_	_	NN	O	-1	none	_	_
35	was	_	_	VBD	O	-1	none	_	_
36	similar	_	_	JJ	O	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	that	_	_	DT	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	LPS	_	_	NN	O	-1	none	_	_
41	but	_	_	CC	O	-1	none	_	_
42	significantly	_	_	RB	O	-1	none	_	_
43	higher	_	_	JJR	O	-1	none	_	_
44	than	_	_	IN	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	response	_	_	NN	O	-1	none	_	_
47	to	_	_	TO	O	-1	none	_	_
48	MDP	_	_	NN	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	maximal	_	_	JJ	O	-1	none	_	_
4	G	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	Anh	_	_	NNP	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	MTetra	_	_	NN	O	-1	none	_	_
9	induced	_	_	VBD	O	-1	none	_	_
10	IL-1	_	_	NN	Protein	11	multitoken	_	_
11	beta	_	_	NN	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	IL-6	_	_	NN	Protein	-1	none	_	_
14	mRNA	_	_	NN	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	could	_	_	MD	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	enhanced	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	co-stimulation	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	LPS	_	_	NN	O	-1	none	_	_
23	or	_	_	CC	O	-1	none	_	_
24	MDP	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	suggesting	_	_	VBG	O	-1	none	_	_
27	that	_	_	IN	O	-1	none	_	_
28	different	_	_	JJ	O	-1	none	_	_
29	receptors	_	_	NNS	O	-1	none	_	_
30	and/or	_	_	CC	O	-1	none	_	_
31	transduction	_	_	NN	O	-1	none	_	_
32	pathways	_	_	NNS	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	involved	_	_	VBN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	G	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	Anh	_	_	NNP	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	MTetra	_	_	NN	O	-1	none	_	_
10	induces	_	_	VBZ	O	-1	none	_	_
11	IL-1	_	_	NN	Protein	12	multitoken	_	_
12	beta	_	_	NN	Protein	0	root	_	_
13	and	_	_	CC	O	-1	none	_	_
14	IL-6	_	_	NN	Protein	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	suggesting	_	_	VBG	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	possible	_	_	JJ	O	-1	none	_	_
22	role	_	_	NN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	G	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	Anh	_	_	NNP	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	MTetra	_	_	NNP	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	release	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	cytokines	_	_	NNS	O	-1	none	_	_
34	during	_	_	IN	O	-1	none	_	_
35	sepsis	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	zinc	_	_	NN	O	-1	none	_	_
3	finger	_	_	NN	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	factor	_	_	NN	O	-1	none	_	_
6	Egr-1	_	_	NN	Protein	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	essential	_	_	JJ	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	restricts	_	_	VBZ	O	-1	none	_	_
12	differentiation	_	_	NN	O	-1	none	_	_
13	along	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	macrophage	_	_	NN	O	-1	none	_	_
16	lineage	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	isolated	_	_	VBN	O	-1	none	_	_
4	cDNA	_	_	NN	O	-1	none	_	_
5	clones	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	myeloid	_	_	JJ	O	-1	none	_	_
8	differentiation	_	_	NN	O	-1	none	_	_
9	primary	_	_	JJ	O	-1	none	_	_
10	response	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	MyD	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	genes	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	activated	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	absence	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	de	_	_	FW	O	-1	none	_	_
22	novo	_	_	FW	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	synthesis	_	_	NN	O	-1	none	_	_
25	following	_	_	VBG	O	-1	none	_	_
26	induction	_	_	NN	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	differentiation	_	_	NN	O	-1	none	_	_
29	along	_	_	IN	O	-1	none	_	_
30	either	_	_	CC	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	macrophage	_	_	NN	O	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	granulocyte	_	_	NN	O	-1	none	_	_
35	lineage	_	_	NN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	human	_	_	NN	O	-1	none	_	_
38	myeloblastic	_	_	JJ	O	-1	none	_	_
39	leukemia	_	_	NN	O	-1	none	_	_
40	HL-60	_	_	NN	O	-1	none	_	_
41	cells	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	cDNA	_	_	NN	O	-1	none	_	_
3	clone	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	primary	_	_	JJ	O	-1	none	_	_
7	response	_	_	NN	O	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	upon	_	_	IN	O	-1	none	_	_
12	macrophage	_	_	NN	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	encoded	_	_	VBN	O	-1	none	_	_
16	for	_	_	IN	O	-1	none	_	_
17	Egr-1	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	zinc	_	_	NN	O	-1	none	_	_
21	finger	_	_	NN	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Egr-1	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	transcriptionally	_	_	RB	O	-1	none	_	_
9	silent	_	_	JJ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	HL-60	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	but	_	_	CC	O	-1	none	_	_
15	active	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	U-937	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	M1	_	_	NN	O	-1	none	_	_
20	cells	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	latter	_	_	JJ	O	-1	none	_	_
24	two	_	_	CD	O	-1	none	_	_
25	being	_	_	VBG	O	-1	none	_	_
26	predetermined	_	_	VBN	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	macrophage	_	_	NN	O	-1	none	_	_
29	differentiation	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Egr-1	_	_	NNP	Protein	-1	none	_	_
2	antisense	_	_	JJ	O	-1	none	_	_
3	oligomers	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	culture	_	_	NN	O	-1	none	_	_
7	media	_	_	NNS	O	-1	none	_	_
8	blocked	_	_	VBD	O	-1	none	_	_
9	macrophage	_	_	NN	O	-1	none	_	_
10	differentiation	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	both	_	_	CC	O	-1	none	_	_
13	myeloid	_	_	JJ	O	-1	none	_	_
14	leukemia	_	_	NN	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	lines	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	normal	_	_	JJ	O	-1	none	_	_
19	myeloblasts	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	HL-60	_	_	NNP	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	constitutively	_	_	RB	O	-1	none	_	_
4	expressing	_	_	VBG	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	Egr-1	_	_	NN	Protein	-1	none	_	_
7	transgene	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	HL-60Egr-1	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	could	_	_	MD	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	macrophage	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	but	_	_	CC	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	granulocyte	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Egr-1	_	_	NN	Protein	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	essential	_	_	JJ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	restricts	_	_	VBZ	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	myeloblasts	_	_	NNS	O	-1	none	_	_
16	along	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	macrophage	_	_	NN	O	-1	none	_	_
19	lineage	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Cutting	_	_	JJ	O	-1	none	_	_
2	edge	_	_	NN	O	-1	none	_	_
3	:	_	_	:	O	-1	none	_	_
4	TCR	_	_	NN	O	-1	none	_	_
5	stimulation	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	antibody	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	bacterial	_	_	JJ	O	-1	none	_	_
10	superantigen	_	_	NN	O	-1	none	_	_
11	induces	_	_	VBZ	O	-1	none	_	_
12	Stat3	_	_	NN	Protein	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Recent	_	_	JJ	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	TCR	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	CD3	_	_	NN	O	-1	none	_	_
8	stimulation	_	_	NN	O	-1	none	_	_
9	induces	_	_	VBZ	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	Stat5	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	murine	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	CD3	_	_	NN	O	-1	none	_	_
7	ligation	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	mAb	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Staphylococcal	_	_	JJ	O	-1	none	_	_
12	enterotoxin	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	SE	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	induce	_	_	VBP	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	rapid	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	gradually	_	_	RB	O	-1	none	_	_
21	accumulating	_	_	VBG	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	long	_	_	JJ	O	-1	none	_	_
24	lasting	_	_	JJ	O	-1	none	_	_
25	tyrosine	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	serine	_	_	NN	O	-1	none	_	_
29	phosphorylation	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	Stat3	_	_	NN	Protein	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	but	_	_	CC	O	-1	none	_	_
34	not	_	_	RB	O	-1	none	_	_
35	Stat5	_	_	NN	Protein	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	allogen	_	_	NN	O	-1	none	_	_
39	specific	_	_	JJ	O	-1	none	_	_
40	human	_	_	NN	O	-1	none	_	_
41	CD4+	_	_	JJ	O	-1	none	_	_
42	T	_	_	NN	O	-1	none	_	_
43	cell	_	_	NN	O	-1	none	_	_
44	lines	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	rapid	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	transient	_	_	JJ	O	-1	none	_	_
10	tyrosine	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	serine	_	_	NN	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	Stat3	_	_	NN	Protein	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Compared	_	_	VBN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	CD3	_	_	NN	Protein	-1	none	_	_
6	ligation	_	_	NN	O	-1	none	_	_
7	induces	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	delayed	_	_	JJ	O	-1	none	_	_
10	Stat3	_	_	NN	Protein	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	oligonucleotide	_	_	NN	O	-1	none	_	_
14	probes	_	_	NNS	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	ICAM-1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	IL-2R	_	_	NN	Protein	20	multitoken	_	_
20	alpha	_	_	NN	Protein	0	root	_	_
21	promoter	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	CD3	_	_	NN	Protein	-1	none	_	_
8	ligation	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	mAb	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	SE	_	_	NN	O	-1	none	_	_
13	triggers	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	rapid	_	_	JJ	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	PP1	_	_	NN	O	-1	none	_	_
18	sensitive	_	_	JJ	O	-1	none	_	_
19	tyrosine	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	serine	_	_	NN	O	-1	none	_	_
22	phosphorylation	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	Stat3	_	_	NN	Protein	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	CD4+	_	_	JJ	O	-1	none	_	_
28	T	_	_	NN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	provide	_	_	VBP	O	-1	none	_	_
5	evidence	_	_	NN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	TCR	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	CD3	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	IL-2	_	_	NN	Protein	-1	none	_	_
12	induce	_	_	VBP	O	-1	none	_	_
13	Stat3	_	_	NN	Protein	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	via	_	_	IN	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	signaling	_	_	NN	O	-1	none	_	_
18	pathways	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Mononuclear	_	_	JJ	O	-1	none	_	_
2	leukocyte	_	_	NN	O	-1	none	_	_
3	glucocorticoid	_	_	NN	Protein	4	multitoken	_	_
4	receptor	_	_	NN	Protein	0	root	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	characteristics	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	down-regulation	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	major	_	_	JJ	O	-1	none	_	_
11	depression	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Some	_	_	DT	O	-1	none	_	_
2	patients	_	_	NNS	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	major	_	_	JJ	O	-1	none	_	_
5	depressive	_	_	JJ	O	-1	none	_	_
6	disorder	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	MDD	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	have	_	_	VBP	O	-1	none	_	_
11	elevated	_	_	JJ	O	-1	none	_	_
12	plasma	_	_	NN	O	-1	none	_	_
13	cortisol	_	_	NN	O	-1	none	_	_
14	concentrations	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	show	_	_	VBP	O	-1	none	_	_
17	failure	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	suppress	_	_	VB	O	-1	none	_	_
20	cortisol	_	_	NN	O	-1	none	_	_
21	secretion	_	_	NN	O	-1	none	_	_
22	upon	_	_	IN	O	-1	none	_	_
23	administration	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	dexamethasone	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	DEX	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	yet	_	_	RB	O	-1	none	_	_
31	they	_	_	PRP	O	-1	none	_	_
32	do	_	_	VBP	O	-1	none	_	_
33	not	_	_	RB	O	-1	none	_	_
34	have	_	_	VB	O	-1	none	_	_
35	Cushingoid	_	_	JJ	O	-1	none	_	_
36	features	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	study	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	represents	_	_	VBZ	O	-1	none	_	_
6	glucocorticoid	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	GC	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	resistance	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	[	_	_	CD	O	-1	none	_	_
13	3H	_	_	NN	O	-1	none	_	_
14	]-DEX-binding	_	_	JJ	O	-1	none	_	_
15	assays	_	_	NNS	O	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	used	_	_	VBN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	measure	_	_	VB	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	in	_	_	FW	O	-1	none	_	_
22	vitro	_	_	FW	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	GC	_	_	NN	O	-1	none	_	_
26	receptor	_	_	NN	O	-1	none	_	_
27	affinity	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	1/Kd	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	number	_	_	NN	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	Bmax	_	_	NN	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	mononuclear	_	_	JJ	O	-1	none	_	_
38	leukocytes	_	_	NNS	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	11	_	_	CD	O	-1	none	_	_
41	MDD	_	_	NN	O	-1	none	_	_
42	patients	_	_	NNS	O	-1	none	_	_
43	and	_	_	CC	O	-1	none	_	_
44	15	_	_	CD	O	-1	none	_	_
45	control	_	_	JJ	O	-1	none	_	_
46	subjects	_	_	NNS	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	receptor	_	_	NN	O	-1	none	_	_
3	abnormalities	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	detected	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	MDD	_	_	NN	O	-1	none	_	_
9	group	_	_	NN	O	-1	none	_	_
10	;	_	_	:	O	-1	none	_	_
11	thus	_	_	RB	O	-1	none	_	_
12	any	_	_	DT	O	-1	none	_	_
13	cellular	_	_	JJ	O	-1	none	_	_
14	defect	_	_	NN	O	-1	none	_	_
15	leading	_	_	VBG	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	lack	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	responsiveness	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	GC	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	MDD	_	_	NN	O	-1	none	_	_
26	patients	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	if	_	_	IN	O	-1	none	_	_
29	present	_	_	JJ	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	probably	_	_	RB	O	-1	none	_	_
32	lies	_	_	VBZ	O	-1	none	_	_
33	beyond	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	initial	_	_	JJ	O	-1	none	_	_
36	receptor	_	_	NN	O	-1	none	_	_
37	binding	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	DEX	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	1.0	_	_	CD	O	-1	none	_	_
4	mg	_	_	NN	O	-1	none	_	_
5	orally	_	_	RB	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	administered	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	study	_	_	VB	O	-1	none	_	_
11	in	_	_	FW	O	-1	none	_	_
12	vivo	_	_	FW	O	-1	none	_	_
13	GC	_	_	NN	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	down-regulation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Compared	_	_	VBN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	control	_	_	NN	O	-1	none	_	_
5	group	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	fewer	_	_	JJR	O	-1	none	_	_
8	depressed	_	_	JJ	O	-1	none	_	_
9	subjects	_	_	NNS	O	-1	none	_	_
10	down-regulated	_	_	VBD	O	-1	none	_	_
11	Bmax	_	_	NN	O	-1	none	_	_
12	after	_	_	IN	O	-1	none	_	_
13	DEX	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	paired	_	_	JJ	O	-1	none	_	_
3	t-test	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	Bmax	_	_	NN	O	-1	none	_	_
6	decreased	_	_	VBD	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	control	_	_	NN	O	-1	none	_	_
11	group	_	_	NN	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	depressed	_	_	JJ	O	-1	none	_	_
17	group	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Receptor	_	_	NN	O	-1	none	_	_
2	number	_	_	NN	O	-1	none	_	_
3	on	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	control	_	_	NN	O	-1	none	_	_
6	day	_	_	NN	O	-1	none	_	_
7	did	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	correlate	_	_	VB	O	-1	none	_	_
10	significantly	_	_	RB	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	degree	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	receptor	_	_	NN	O	-1	none	_	_
16	down-regulation	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	severity	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	depression	_	_	NN	O	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	cortisol	_	_	NN	O	-1	none	_	_
23	concentrations	_	_	NNS	O	-1	none	_	_
24	across	_	_	IN	O	-1	none	_	_
25	all	_	_	PDT	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	subjects	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	do	_	_	VBP	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	lend	_	_	VB	O	-1	none	_	_
6	support	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	previous	_	_	JJ	O	-1	none	_	_
9	reports	_	_	NNS	O	-1	none	_	_
10	suggesting	_	_	VBG	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	GC	_	_	NN	O	-1	none	_	_
13	resistance	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	MDD	_	_	NN	O	-1	none	_	_
16	results	_	_	VBZ	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	GC	_	_	NN	O	-1	none	_	_
20	receptor	_	_	NN	O	-1	none	_	_
21	binding	_	_	NN	O	-1	none	_	_
22	abnormality	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	they	_	_	PRP	O	-1	none	_	_
26	emphasize	_	_	VBP	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	importance	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	considering	_	_	VBG	O	-1	none	_	_
31	receptor	_	_	NN	O	-1	none	_	_
32	studies	_	_	NNS	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	context	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	GC	_	_	NN	O	-1	none	_	_
38	mediated	_	_	VBN	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	processes	_	_	NNS	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	order	_	_	NN	O	-1	none	_	_
43	to	_	_	TO	O	-1	none	_	_
44	identify	_	_	VB	O	-1	none	_	_
45	the	_	_	DT	O	-1	none	_	_
46	exact	_	_	JJ	O	-1	none	_	_
47	cellular	_	_	JJ	O	-1	none	_	_
48	defect	_	_	NN	O	-1	none	_	_
49	(	_	_	-LRB-	O	-1	none	_	_
50	s	_	_	VBZ	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	leading	_	_	VBG	O	-1	none	_	_
53	to	_	_	TO	O	-1	none	_	_
54	GC	_	_	NN	O	-1	none	_	_
55	resistance	_	_	NN	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	has	_	_	VBZ	O	-1	none	_	_
3	been	_	_	VBN	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	interferon-gamma	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	IFN-gamma	_	_	NN	Protein	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	interleukin-10	_	_	NN	Protein	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	IL-10	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	have	_	_	VBP	O	-1	none	_	_
16	various	_	_	JJ	O	-1	none	_	_
17	reverse	_	_	JJ	O	-1	none	_	_
18	effects	_	_	NNS	O	-1	none	_	_
19	on	_	_	IN	O	-1	none	_	_
20	macrophages	_	_	NNS	O	-1	none	_	_
21	;	_	_	:	O	-1	none	_	_
22	however	_	_	RB	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	molecular	_	_	JJ	O	-1	none	_	_
26	mechanism	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	this	_	_	DT	O	-1	none	_	_
29	difference	_	_	NN	O	-1	none	_	_
30	has	_	_	VBZ	O	-1	none	_	_
31	not	_	_	RB	O	-1	none	_	_
32	been	_	_	VBN	O	-1	none	_	_
33	fully	_	_	RB	O	-1	none	_	_
34	understood	_	_	VBN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	This	_	_	DT	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	explain	_	_	VB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	difference	_	_	NN	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	IL-10	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	IFN-gamma	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	biological	_	_	JJ	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	inhibitory	_	_	JJ	O	-1	none	_	_
17	effect	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	IL-10	_	_	NN	Protein	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	IFN-gamma	_	_	NN	Protein	-1	none	_	_
22	activities	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	RB	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	novel	_	_	JJ	O	-1	none	_	_
5	E2F-1	_	_	NN	Protein	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	MHC	_	_	NN	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	deficient	_	_	JJ	O	-1	none	_	_
13	B-cell	_	_	NN	O	-1	none	_	_
14	lines	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	normal	_	_	JJ	O	-1	none	_	_
17	IFN-gamma	_	_	NN	Protein	-1	none	_	_
18	induction	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	class	_	_	NN	O	-1	none	_	_
22	IL	_	_	NN	O	-1	none	_	_
23	transactivator	_	_	NN	O	-1	none	_	_
24	CIITA	_	_	NN	Protein	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	class	_	_	NN	O	-1	none	_	_
27	II	_	_	CD	O	-1	none	_	_
28	non	_	_	JJ	O	-1	none	_	_
29	inducible	_	_	JJ	O	-1	none	_	_
30	RB	_	_	NN	Protein	-1	none	_	_
31	defective	_	_	JJ	O	-1	none	_	_
32	tumor	_	_	NN	O	-1	none	_	_
33	lines	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	major	_	_	JJ	O	-1	none	_	_
3	histocompatibility	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	MHC	_	_	NN	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	class	_	_	NN	O	-1	none	_	_
8	II	_	_	CD	O	-1	none	_	_
9	genes	_	_	NNS	O	-1	none	_	_
10	encode	_	_	VBP	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	surface	_	_	NN	O	-1	none	_	_
13	proteins	_	_	NNS	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	bind	_	_	VBP	O	-1	none	_	_
16	antigenic	_	_	JJ	O	-1	none	_	_
17	peptide	_	_	NN	O	-1	none	_	_
18	for	_	_	IN	O	-1	none	_	_
19	presentation	_	_	NN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	T-cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	class	_	_	NN	O	-1	none	_	_
3	II	_	_	CD	O	-1	none	_	_
4	proteins	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	expressed	_	_	VBN	O	-1	none	_	_
7	constitutively	_	_	RB	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	B-cells	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	EBV	_	_	NN	O	-1	none	_	_
12	transformed	_	_	VBN	O	-1	none	_	_
13	B-cells	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	inducible	_	_	JJ	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	IFN-gamma	_	_	NN	Protein	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	wide	_	_	JJ	O	-1	none	_	_
23	variety	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	types	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Retinoblastoma	_	_	NN	Protein	2	multitoken	_	_
2	protein	_	_	NN	Protein	0	root	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	RB	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	tumor	_	_	NN	O	-1	none	_	_
9	suppressor	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	functions	_	_	VBZ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	transcriptional	_	_	JJ	O	-1	none	_	_
15	repressor	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	inactivating	_	_	VBG	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	transactivator	_	_	NN	O	-1	none	_	_
22	E2F-I	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	RB	_	_	NN	Protein	-1	none	_	_
2	defective	_	_	JJ	O	-1	none	_	_
3	tumor	_	_	NN	O	-1	none	_	_
4	lines	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	non	_	_	JJ	O	-1	none	_	_
7	inducible	_	_	JJ	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	MHC	_	_	NN	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	II	_	_	CD	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	IFN-gamma	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	very	_	_	RB	O	-1	none	_	_
17	weakly	_	_	RB	O	-1	none	_	_
18	inducible	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	transfection	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	2	_	_	CD	O	-1	none	_	_
24	different	_	_	JJ	O	-1	none	_	_
25	lines	_	_	NNS	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	RB	_	_	NN	Protein	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	vectors	_	_	NNS	O	-1	none	_	_
30	re-establishes	_	_	VBZ	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	substantially	_	_	RB	O	-1	none	_	_
33	enhances	_	_	VBZ	O	-1	none	_	_
34	class	_	_	NN	O	-1	none	_	_
35	II	_	_	CD	O	-1	none	_	_
36	inducibility	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	examined	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	RB	_	_	NN	Protein	-1	none	_	_
7	status	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	series	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	B-cell	_	_	NN	O	-1	none	_	_
13	mutants	_	_	NNS	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	defective	_	_	JJ	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	class	_	_	NN	O	-1	none	_	_
19	II	_	_	CD	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	generated	_	_	VBD	O	-1	none	_	_
23	either	_	_	CC	O	-1	none	_	_
24	in	_	_	FW	O	-1	none	_	_
25	vitro	_	_	FW	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	derived	_	_	VBN	O	-1	none	_	_
28	from	_	_	IN	O	-1	none	_	_
29	Bare	_	_	JJ	O	-1	none	_	_
30	Lymphocyte	_	_	NN	O	-1	none	_	_
31	Syndrome	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	BLS	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	patients	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	matrix	_	_	NN	O	-1	none	_	_
3	bound	_	_	VBD	O	-1	none	_	_
4	RB	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	detectable	_	_	JJ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	all	_	_	DT	O	-1	none	_	_
9	cases	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	indicating	_	_	VBG	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	loss	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	RB	_	_	NN	Protein	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	responsible	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	decreased	_	_	VBN	O	-1	none	_	_
21	class	_	_	NN	O	-1	none	_	_
22	II	_	_	CD	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	lines	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	second	_	_	JJ	O	-1	none	_	_
3	E2F-I	_	_	NN	Protein	-1	none	_	_
4	binding	_	_	NN	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	most	_	_	RBS	O	-1	none	_	_
8	likely	_	_	JJ	O	-1	none	_	_
9	DP-I	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	apparently	_	_	RB	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	both	_	_	CC	O	-1	none	_	_
17	class	_	_	NN	O	-1	none	_	_
18	II	_	_	CD	O	-1	none	_	_
19	positive	_	_	JJ	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	-negative	_	_	JJ	O	-1	none	_	_
22	B-cell	_	_	NN	O	-1	none	_	_
23	lines	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	examined	_	_	VBD	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	IFN-gamma	_	_	NN	Protein	-1	none	_	_
6	induction	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	CIITA	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	RB	_	_	NN	Protein	-1	none	_	_
11	defective	_	_	JJ	O	-1	none	_	_
12	lines	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	CIITA	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	class	_	_	NN	O	-1	none	_	_
5	II	_	_	CD	O	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	transactivator	_	_	NN	O	-1	none	_	_
8	known	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	be	_	_	VB	O	-1	none	_	_
11	defective	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	one	_	_	CD	O	-1	none	_	_
14	form	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	BLS	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	required	_	_	VBN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	induction	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	MHC	_	_	NN	O	-1	none	_	_
26	class	_	_	NN	O	-1	none	_	_
27	II	_	_	CD	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	IFN-gamma	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	CIITA	_	_	NN	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	normally	_	_	RB	O	-1	none	_	_
5	inducible	_	_	JJ	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	IFN-gamma	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	class	_	_	NN	O	-1	none	_	_
10	II	_	_	CD	O	-1	none	_	_
11	non	_	_	JJ	O	-1	none	_	_
12	inducible	_	_	JJ	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	RB	_	_	NN	Protein	-1	none	_	_
15	defective	_	_	JJ	O	-1	none	_	_
16	lines	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	one	_	_	CD	O	-1	none	_	_
21	line	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	re-expression	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	RB	_	_	NN	Protein	-1	none	_	_
26	has	_	_	VBZ	O	-1	none	_	_
27	no	_	_	DT	O	-1	none	_	_
28	effect	_	_	NN	O	-1	none	_	_
29	on	_	_	IN	O	-1	none	_	_
30	CIITA	_	_	NN	Protein	-1	none	_	_
31	mRNA	_	_	NN	O	-1	none	_	_
32	induction	_	_	NN	O	-1	none	_	_
33	levels	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	block	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	MHC	_	_	NN	O	-1	none	_	_
7	class	_	_	NN	O	-1	none	_	_
8	II	_	_	CD	O	-1	none	_	_
9	inducibility	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	RB	_	_	NN	Protein	-1	none	_	_
12	defective	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	due	_	_	JJ	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	block	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	CIITA	_	_	NN	Protein	-1	none	_	_
22	inducibility	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	microtitre	_	_	NN	O	-1	none	_	_
3	assay	_	_	NN	O	-1	none	_	_
4	system	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	glucocorticoid	_	_	NN	Protein	7	multitoken	_	_
7	receptors	_	_	NNS	Protein	0	root	_	_
8	:	_	_	:	O	-1	none	_	_
9	decreased	_	_	VBN	O	-1	none	_	_
10	receptor	_	_	NN	O	-1	none	_	_
11	concentration	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	myocardial	_	_	JJ	O	-1	none	_	_
14	infarction	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	major	_	_	JJ	O	-1	none	_	_
3	difficulty	_	_	NN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	determination	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	glucocorticoid	_	_	NN	Protein	8	multitoken	_	_
8	receptor	_	_	NN	Protein	0	root	_	_
9	sites	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	very	_	_	RB	O	-1	none	_	_
13	complicated	_	_	JJ	O	-1	none	_	_
14	assay	_	_	NN	O	-1	none	_	_
15	procedure	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	describe	_	_	VBP	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	microtitre	_	_	NN	O	-1	none	_	_
7	assay	_	_	NN	O	-1	none	_	_
8	system	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	glucocorticoid	_	_	NN	Protein	11	multitoken	_	_
11	receptors	_	_	NNS	Protein	0	root	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	whole-cell	_	_	JJ	O	-1	none	_	_
16	competitive	_	_	JJ	O	-1	none	_	_
17	binding	_	_	NN	O	-1	none	_	_
18	radioassay	_	_	NN	O	-1	none	_	_
19	using	_	_	VBG	O	-1	none	_	_
20	[	_	_	CD	O	-1	none	_	_
21	3H	_	_	NN	O	-1	none	_	_
22	]-dexamethasone	_	_	NN	O	-1	none	_	_
23	as	_	_	IN	O	-1	none	_	_
24	radioligand	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	modification	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	previously	_	_	RB	O	-1	none	_	_
6	described	_	_	VBN	O	-1	none	_	_
7	protocol	_	_	NN	O	-1	none	_	_
8	simplifies	_	_	VBZ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	reduces	_	_	VBZ	O	-1	none	_	_
11	laboratory	_	_	NN	O	-1	none	_	_
12	work	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	allows	_	_	VBZ	O	-1	none	_	_
15	assay	_	_	NN	O	-1	none	_	_
16	reproducibility	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	controlled	_	_	VBN	O	-1	none	_	_
20	more	_	_	RBR	O	-1	none	_	_
21	reliably	_	_	RB	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	enabled	_	_	VBN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	perform	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	test	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	multiple	_	_	JJ	O	-1	none	_	_
9	blood	_	_	NN	O	-1	none	_	_
10	samples	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	parallel	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	we	_	_	PRP	O	-1	none	_	_
15	investigated	_	_	VBD	O	-1	none	_	_
16	cardiac	_	_	JJ	O	-1	none	_	_
17	infarction	_	_	NN	O	-1	none	_	_
18	patients	_	_	NNS	O	-1	none	_	_
19	over	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	12-day	_	_	JJ	O	-1	none	_	_
22	period	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	test	_	_	VB	O	-1	none	_	_
25	if	_	_	IN	O	-1	none	_	_
26	glucocorticoid	_	_	NN	Protein	27	multitoken	_	_
27	receptor	_	_	NN	Protein	0	root	_	_
28	binding	_	_	NN	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	altered	_	_	VBN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	this	_	_	DT	O	-1	none	_	_
33	'	_	_	''	O	-1	none	_	_
34	stressful	_	_	JJ	O	-1	none	_	_
35	'	_	_	''	O	-1	none	_	_
36	disease	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	first	_	_	JJ	O	-1	none	_	_
4	day	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	disease	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	glucocorticoid	_	_	NN	Protein	10	multitoken	_	_
10	receptor	_	_	NN	Protein	0	root	_	_
11	capacity	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	significantly	_	_	RB	O	-1	none	_	_
14	decreased	_	_	VBN	O	-1	none	_	_
15	without	_	_	IN	O	-1	none	_	_
16	alteration	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	receptor-ligand	_	_	JJ	O	-1	none	_	_
20	affinity	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	whereas	_	_	IN	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	days	_	_	NNS	O	-1	none	_	_
25	4	_	_	CD	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	12	_	_	CD	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	number	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	receptor	_	_	NN	O	-1	none	_	_
32	sites	_	_	NNS	O	-1	none	_	_
33	was	_	_	VBD	O	-1	none	_	_
34	normal	_	_	JJ	O	-1	none	_	_
35	again	_	_	RB	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	result	_	_	NN	O	-1	none	_	_
3	fits	_	_	VBZ	O	-1	none	_	_
4	well	_	_	RB	O	-1	none	_	_
5	into	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	general	_	_	JJ	O	-1	none	_	_
8	observation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	stress	_	_	NN	O	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	down-regulation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	immune	_	_	JJ	O	-1	none	_	_
15	responses	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Oncogenicity	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	papillomavirus-	_	_	NN	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	adenovirus	_	_	NN	O	-1	none	_	_
7	transformed	_	_	VBN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	correlates	_	_	VBZ	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	resistance	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	lysis	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	natural	_	_	JJ	O	-1	none	_	_
16	killer	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	reasons	_	_	NNS	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	dissimilar	_	_	JJ	O	-1	none	_	_
6	oncogenicities	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	adenoviruses	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	papillomaviruses	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	HPV	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	humans	_	_	NNS	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	unknown	_	_	JJ	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	may	_	_	MD	O	-1	none	_	_
22	relate	_	_	VB	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	differences	_	_	NNS	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	capacities	_	_	NNS	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	E1A	_	_	NN	Protein	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	E7	_	_	NN	Protein	-1	none	_	_
33	proteins	_	_	NNS	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	target	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	for	_	_	IN	O	-1	none	_	_
38	rejection	_	_	NN	O	-1	none	_	_
39	by	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	host	_	_	NN	O	-1	none	_	_
42	natural	_	_	JJ	O	-1	none	_	_
43	killer	_	_	NN	O	-1	none	_	_
44	(	_	_	-LRB-	O	-1	none	_	_
45	NK	_	_	NN	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	cell	_	_	NN	O	-1	none	_	_
48	response	_	_	NN	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Cells	_	_	NNS	O	-1	none	_	_
2	expressing	_	_	VBG	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	E1A	_	_	NN	Protein	-1	none	_	_
5	oncoprotein	_	_	NN	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	selectively	_	_	RB	O	-1	none	_	_
8	killed	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	unstimulated	_	_	JJ	O	-1	none	_	_
11	NK	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	while	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	same	_	_	JJ	O	-1	none	_	_
17	parental	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	expressing	_	_	VBG	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	HPV	_	_	NN	O	-1	none	_	_
23	type	_	_	NN	O	-1	none	_	_
24	16	_	_	CD	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	HPV-16	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	or	_	_	CC	O	-1	none	_	_
29	HPV-18	_	_	NN	O	-1	none	_	_
30	E7	_	_	NN	Protein	-1	none	_	_
31	oncoprotein	_	_	NN	O	-1	none	_	_
32	were	_	_	VBD	O	-1	none	_	_
33	resistant	_	_	JJ	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	NK	_	_	NN	O	-1	none	_	_
36	cell	_	_	NN	O	-1	none	_	_
37	lysis	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	ability	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IFN	_	_	NN	O	-1	none	_	_
5	activated	_	_	VBD	O	-1	none	_	_
6	NK	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	selectively	_	_	RB	O	-1	none	_	_
10	kill	_	_	VB	O	-1	none	_	_
11	virally	_	_	RB	O	-1	none	_	_
12	transformed	_	_	VBN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	depends	_	_	VBZ	O	-1	none	_	_
15	on	_	_	IN	O	-1	none	_	_
16	IFN	_	_	NN	O	-1	none	_	_
17	's	_	_	POS	O	-1	none	_	_
18	ability	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	induce	_	_	VB	O	-1	none	_	_
21	resistance	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	NK	_	_	NN	O	-1	none	_	_
24	cell	_	_	NN	O	-1	none	_	_
25	lysis	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	normal	_	_	JJ	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	i.e.	_	_	FW	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	non	_	_	JJ	O	-1	none	_	_
32	viral	_	_	JJ	O	-1	none	_	_
33	oncogene	_	_	NN	O	-1	none	_	_
34	expressing	_	_	VBG	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	but	_	_	CC	O	-1	none	_	_
37	not	_	_	RB	O	-1	none	_	_
38	virally	_	_	RB	O	-1	none	_	_
39	transformed	_	_	VBN	O	-1	none	_	_
40	cells	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	E1A	_	_	NN	Protein	-1	none	_	_
2	blocked	_	_	VBD	O	-1	none	_	_
3	IFN	_	_	NN	O	-1	none	_	_
4	's	_	_	POS	O	-1	none	_	_
5	induction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	cytolytic	_	_	JJ	O	-1	none	_	_
8	resistance	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	resulting	_	_	VBG	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	selective	_	_	JJ	O	-1	none	_	_
14	lysis	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	adenovirus	_	_	NN	O	-1	none	_	_
17	transformed	_	_	VBN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	IFN	_	_	NN	O	-1	none	_	_
21	activated	_	_	VBD	O	-1	none	_	_
22	NK	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	extent	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IFN	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	NK	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	killing	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	E1A	_	_	NN	Protein	-1	none	_	_
11	expressing	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	proportional	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	level	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	E1A	_	_	NN	Protein	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	correlated	_	_	VBD	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	ability	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	E1A	_	_	NN	Protein	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	block	_	_	VB	O	-1	none	_	_
30	IFN	_	_	NN	O	-1	none	_	_
31	stimulated	_	_	VBN	O	-1	none	_	_
32	gene	_	_	NN	O	-1	none	_	_
33	expression	_	_	NN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	target	_	_	NN	O	-1	none	_	_
36	cells	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	E7	_	_	NN	Protein	-1	none	_	_
5	blocked	_	_	VBD	O	-1	none	_	_
6	neither	_	_	CC	O	-1	none	_	_
7	IFN	_	_	NN	O	-1	none	_	_
8	stimulated	_	_	VBD	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	nor	_	_	CC	O	-1	none	_	_
12	IFN	_	_	NN	O	-1	none	_	_
13	's	_	_	POS	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cytolytic	_	_	JJ	O	-1	none	_	_
17	resistance	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	thereby	_	_	RB	O	-1	none	_	_
20	precluding	_	_	VBG	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	selective	_	_	JJ	O	-1	none	_	_
23	lysis	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	HPV	_	_	NN	O	-1	none	_	_
26	transformed	_	_	VBN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	IFN	_	_	NN	O	-1	none	_	_
30	activated	_	_	VBD	O	-1	none	_	_
31	NK	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	E1A	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	marks	_	_	VBZ	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	destruction	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	host	_	_	NN	O	-1	none	_	_
13	NK	_	_	NN	O	-1	none	_	_
14	cell	_	_	NN	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	whereas	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	E7	_	_	NN	Protein	-1	none	_	_
20	oncoprotein	_	_	NN	O	-1	none	_	_
21	lacks	_	_	VBZ	O	-1	none	_	_
22	this	_	_	DT	O	-1	none	_	_
23	activity	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Thyroid	_	_	NN	O	-1	none	_	_
2	hormone	_	_	NN	O	-1	none	_	_
3	receptors	_	_	NNS	O	-1	none	_	_
4	form	_	_	VBP	O	-1	none	_	_
5	distinct	_	_	JJ	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	dependent	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	independent	_	_	JJ	O	-1	none	_	_
11	complexes	_	_	NNS	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	thyroid	_	_	NN	O	-1	none	_	_
15	hormone	_	_	NN	O	-1	none	_	_
16	response	_	_	NN	O	-1	none	_	_
17	element	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	examined	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	proteins	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	recombinant	_	_	JJ	O	-1	none	_	_
11	thyroid	_	_	NN	O	-1	none	_	_
12	hormone	_	_	NN	O	-1	none	_	_
13	receptors	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	TRs	_	_	NNS	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	palindromic	_	_	JJ	O	-1	none	_	_
20	thyroid	_	_	NN	O	-1	none	_	_
21	hormone	_	_	NN	O	-1	none	_	_
22	responsive	_	_	JJ	O	-1	none	_	_
23	element	_	_	NN	O	-1	none	_	_
24	AGGTCATGACCT	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	TREp	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	using	_	_	VBG	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	gel	_	_	NN	O	-1	none	_	_
31	electrophoretic	_	_	JJ	O	-1	none	_	_
32	mobility	_	_	NN	O	-1	none	_	_
33	shift	_	_	NN	O	-1	none	_	_
34	assay	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Four	_	_	CD	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	protein-DNA	_	_	JJ	O	-1	none	_	_
4	complexes	_	_	NNS	O	-1	none	_	_
5	were	_	_	VBD	O	-1	none	_	_
6	detected	_	_	VBN	O	-1	none	_	_
7	after	_	_	IN	O	-1	none	_	_
8	incubation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	nuclear	_	_	JJ	O	-1	none	_	_
11	extracts	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	NE	_	_	NNS	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	T3	_	_	NN	O	-1	none	_	_
17	responsive	_	_	JJ	O	-1	none	_	_
18	pituitary	_	_	JJ	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	GH3	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	TREp	_	_	NN	O	-1	none	_	_
26	containing	_	_	VBG	O	-1	none	_	_
27	DNA	_	_	NN	O	-1	none	_	_
28	fragment	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	compared	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	TREp	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	reticulocyte	_	_	NN	O	-1	none	_	_
10	lysate	_	_	NN	O	-1	none	_	_
11	synthesized	_	_	VBN	O	-1	none	_	_
12	TRs	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	TR	_	_	NN	Protein	3	multitoken	_	_
2	alpha	_	_	NN	Protein	3	multitoken	_	_
3	1	_	_	CD	Protein	0	root	_	_
4	and	_	_	CC	O	-1	none	_	_
5	TR	_	_	NN	Protein	7	multitoken	_	_
6	beta	_	_	NN	Protein	7	multitoken	_	_
7	2	_	_	CD	Protein	0	root	_	_
8	each	_	_	DT	O	-1	none	_	_
9	formed	_	_	VBD	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	single	_	_	JJ	O	-1	none	_	_
12	major	_	_	JJ	O	-1	none	_	_
13	TR	_	_	NN	O	-1	none	_	_
14	:	_	_	:	O	-1	none	_	_
15	TREp	_	_	NN	O	-1	none	_	_
16	complex	_	_	NN	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	comigrated	_	_	VBD	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	least	_	_	JJS	O	-1	none	_	_
22	retarded	_	_	VBN	O	-1	none	_	_
23	complex	_	_	NN	O	-1	none	_	_
24	formed	_	_	VBN	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	GH3	_	_	NN	O	-1	none	_	_
27	NE	_	_	NNS	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	while	_	_	IN	O	-1	none	_	_
30	TR	_	_	NN	Protein	32	multitoken	_	_
31	beta	_	_	NN	Protein	32	multitoken	_	_
32	1	_	_	CD	Protein	0	root	_	_
33	formed	_	_	VBD	O	-1	none	_	_
34	multiple	_	_	JJ	O	-1	none	_	_
35	complexes	_	_	NNS	O	-1	none	_	_
36	suggesting	_	_	VBG	O	-1	none	_	_
37	that	_	_	IN	O	-1	none	_	_
38	it	_	_	PRP	O	-1	none	_	_
39	can	_	_	MD	O	-1	none	_	_
40	bind	_	_	VB	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	TREp	_	_	NN	O	-1	none	_	_
43	as	_	_	IN	O	-1	none	_	_
44	an	_	_	DT	O	-1	none	_	_
45	oligomer	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	coincubation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	35S-TR	_	_	NN	Protein	7	multitoken	_	_
6	alpha	_	_	NN	Protein	7	multitoken	_	_
7	1	_	_	CD	Protein	0	root	_	_
8	,	_	_	,	O	-1	none	_	_
9	GH3	_	_	NN	O	-1	none	_	_
10	NE	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	unlabeled	_	_	JJ	O	-1	none	_	_
14	TREp	_	_	NN	O	-1	none	_	_
15	resulted	_	_	VBD	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	only	_	_	RB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	35S-TR	_	_	NN	O	-1	none	_	_
21	:	_	_	:	O	-1	none	_	_
22	TREp	_	_	NN	O	-1	none	_	_
23	complex	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	but	_	_	CC	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	two	_	_	CD	O	-1	none	_	_
28	additional	_	_	JJ	O	-1	none	_	_
29	more	_	_	RBR	O	-1	none	_	_
30	greatly	_	_	RB	O	-1	none	_	_
31	retarded	_	_	VBN	O	-1	none	_	_
32	complexes	_	_	NNS	O	-1	none	_	_
33	containing	_	_	VBG	O	-1	none	_	_
34	35S-TR	_	_	NN	Protein	36	multitoken	_	_
35	alpha	_	_	NN	Protein	36	multitoken	_	_
36	1	_	_	CD	Protein	0	root	_	_
37	and	_	_	CC	O	-1	none	_	_
38	comigrating	_	_	VBG	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	those	_	_	DT	O	-1	none	_	_
41	formed	_	_	VBN	O	-1	none	_	_
42	by	_	_	IN	O	-1	none	_	_
43	GH3	_	_	NN	O	-1	none	_	_
44	extract	_	_	NN	O	-1	none	_	_
45	alone	_	_	RB	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	Incubation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	each	_	_	DT	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	TRs	_	_	NNS	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	NE	_	_	NNS	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	COS-7	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	which	_	_	WDT	O	-1	none	_	_
14	do	_	_	VBP	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	possess	_	_	VB	O	-1	none	_	_
17	sufficient	_	_	JJ	O	-1	none	_	_
18	endogenous	_	_	JJ	O	-1	none	_	_
19	TRs	_	_	NNS	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	mediate	_	_	VB	O	-1	none	_	_
22	T3-responses	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	resulted	_	_	VBD	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	formation	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	new	_	_	JJ	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	more	_	_	RBR	O	-1	none	_	_
32	greatly	_	_	RB	O	-1	none	_	_
33	shifted	_	_	VBN	O	-1	none	_	_
34	complex	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	similar	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	heat	_	_	NN	O	-1	none	_	_
5	labile	_	_	JJ	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	which	_	_	WDT	O	-1	none	_	_
8	altered	_	_	VBD	O	-1	none	_	_
9	mobility	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	TR	_	_	NN	O	-1	none	_	_
13	:	_	_	:	O	-1	none	_	_
14	TRE	_	_	NN	O	-1	none	_	_
15	complex	_	_	NN	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	also	_	_	RB	O	-1	none	_	_
18	present	_	_	JJ	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	NE	_	_	NNS	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	T3-unresponsive	_	_	JJ	O	-1	none	_	_
23	JEG-3	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	high	_	_	JJ	O	-1	none	_	_
3	concentration	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	NE	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	all	_	_	DT	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	TR	_	_	NN	O	-1	none	_	_
11	bound	_	_	VBD	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	TREp	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	more	_	_	RBR	O	-1	none	_	_
16	greatly	_	_	RB	O	-1	none	_	_
17	retarded	_	_	VBN	O	-1	none	_	_
18	than	_	_	IN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	absence	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	NE	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Truncation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	TR	_	_	NN	Protein	5	multitoken	_	_
4	alpha	_	_	NN	Protein	5	multitoken	_	_
5	1	_	_	CD	Protein	0	root	_	_
6	at	_	_	IN	O	-1	none	_	_
7	amino	_	_	NN	O	-1	none	_	_
8	acid	_	_	NN	O	-1	none	_	_
9	210	_	_	CD	O	-1	none	_	_
10	prevented	_	_	VBD	O	-1	none	_	_
11	additional	_	_	JJ	O	-1	none	_	_
12	complex	_	_	NN	O	-1	none	_	_
13	formation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	presence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	NE	_	_	NNS	O	-1	none	_	_
19	without	_	_	IN	O	-1	none	_	_
20	affecting	_	_	VBG	O	-1	none	_	_
21	DNA	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	suggesting	_	_	VBG	O	-1	none	_	_
25	that	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	carboxyl-terminus	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	TRs	_	_	NNS	O	-1	none	_	_
31	is	_	_	VBZ	O	-1	none	_	_
32	essential	_	_	JJ	O	-1	none	_	_
33	for	_	_	IN	O	-1	none	_	_
34	interaction	_	_	NN	O	-1	none	_	_
35	with	_	_	IN	O	-1	none	_	_
36	nuclear	_	_	JJ	O	-1	none	_	_
37	proteins	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ABSTRACT	_	_	NN	O	-1	none	_	_
3	TRUNCATED	_	_	VBD	O	-1	none	_	_
4	AT	_	_	IN	O	-1	none	_	_
5	250	_	_	CD	O	-1	none	_	_
6	WORDS	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_

1	Sp1	_	_	NN	Protein	-1	none	_	_
2	functions	_	_	NNS	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	chromatin	_	_	NN	O	-1	none	_	_
6	dependent	_	_	JJ	O	-1	none	_	_
7	manner	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	augment	_	_	VB	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	alpha-globin	_	_	NN	Protein	-1	none	_	_
12	promoter	_	_	NN	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	5	_	_	CD	O	-1	none	_	_
3	'	_	_	''	O	-1	none	_	_
4	flanking	_	_	JJ	O	-1	none	_	_
5	region	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	alpha-globin	_	_	NN	Protein	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	highly	_	_	RB	O	-1	none	_	_
13	G	_	_	NN	O	-1	none	_	_
14	+	_	_	CC	O	-1	none	_	_
15	C	_	_	NN	O	-1	none	_	_
16	rich	_	_	JJ	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	contains	_	_	VBZ	O	-1	none	_	_
19	multiple	_	_	JJ	O	-1	none	_	_
20	copies	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	consensus	_	_	NN	O	-1	none	_	_
24	sequence	_	_	NN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	Sp1	_	_	NN	Protein	-1	none	_	_
28	binding	_	_	NN	O	-1	none	_	_
29	site	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	role	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	this	_	_	DT	O	-1	none	_	_
7	G	_	_	NN	O	-1	none	_	_
8	+	_	_	CC	O	-1	none	_	_
9	C	_	_	NN	O	-1	none	_	_
10	rich	_	_	JJ	O	-1	none	_	_
11	region	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	augmenting	_	_	VBG	O	-1	none	_	_
14	alpha-globin	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	presence	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	far-upstream	_	_	JJ	O	-1	none	_	_
23	alpha-globin	_	_	NN	Protein	-1	none	_	_
24	enhancer	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	HS-40	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	transiently	_	_	RB	O	-1	none	_	_
6	transfected	_	_	VBN	O	-1	none	_	_
7	erythroid	_	_	JJ	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	deletion	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	alpha-globin	_	_	NN	Protein	-1	none	_	_
14	G	_	_	NN	O	-1	none	_	_
15	+	_	_	CC	O	-1	none	_	_
16	C	_	_	NN	O	-1	none	_	_
17	rich	_	_	JJ	O	-1	none	_	_
18	5	_	_	CD	O	-1	none	_	_
19	'	_	_	''	O	-1	none	_	_
20	flanking	_	_	JJ	O	-1	none	_	_
21	region	_	_	NN	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	no	_	_	DT	O	-1	none	_	_
24	effect	_	_	NN	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	alpha-globin	_	_	NN	Protein	-1	none	_	_
27	promoter	_	_	NN	O	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	upon	_	_	IN	O	-1	none	_	_
4	stable	_	_	JJ	O	-1	none	_	_
5	integration	_	_	NN	O	-1	none	_	_
6	into	_	_	IN	O	-1	none	_	_
7	chromatin	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	deletion	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	this	_	_	DT	O	-1	none	_	_
12	region	_	_	NN	O	-1	none	_	_
13	causes	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	nearly	_	_	RB	O	-1	none	_	_
16	90	_	_	CD	O	-1	none	_	_
17	%	_	_	NN	O	-1	none	_	_
18	decrease	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	activity	_	_	NN	O	-1	none	_	_
22	compared	_	_	VBN	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	expression	_	_	NN	O	-1	none	_	_
25	from	_	_	IN	O	-1	none	_	_
26	an	_	_	DT	O	-1	none	_	_
27	alpha-globin	_	_	NN	Protein	-1	none	_	_
28	promoter	_	_	NN	O	-1	none	_	_
29	retaining	_	_	VBG	O	-1	none	_	_
30	this	_	_	DT	O	-1	none	_	_
31	region	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	alpha-globin	_	_	NN	Protein	-1	none	_	_
7	G	_	_	NN	O	-1	none	_	_
8	+	_	_	CC	O	-1	none	_	_
9	C	_	_	NN	O	-1	none	_	_
10	rich	_	_	JJ	O	-1	none	_	_
11	5	_	_	CD	O	-1	none	_	_
12	'	_	_	''	O	-1	none	_	_
13	flanking	_	_	JJ	O	-1	none	_	_
14	region	_	_	NN	O	-1	none	_	_
15	augments	_	_	VBZ	O	-1	none	_	_
16	alpha-globin	_	_	NN	Protein	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	chromatin	_	_	NN	O	-1	none	_	_
22	dependent	_	_	JJ	O	-1	none	_	_
23	manner	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	further	_	_	RB	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	G	_	_	NN	O	-1	none	_	_
7	+	_	_	CC	O	-1	none	_	_
8	C	_	_	NN	O	-1	none	_	_
9	rich	_	_	JJ	O	-1	none	_	_
10	region	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	required	_	_	VBN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	alpha-globin	_	_	NN	Protein	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	during	_	_	IN	O	-1	none	_	_
21	erythroid	_	_	JJ	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	both	_	_	CC	O	-1	none	_	_
7	footprint	_	_	NN	O	-1	none	_	_
8	analysis	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	functional	_	_	JJ	O	-1	none	_	_
11	assays	_	_	NNS	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	ability	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	G	_	_	NN	O	-1	none	_	_
18	+	_	_	CC	O	-1	none	_	_
19	C	_	_	NN	O	-1	none	_	_
20	rich	_	_	JJ	O	-1	none	_	_
21	region	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	increase	_	_	VB	O	-1	none	_	_
24	alpha-globin	_	_	NN	Protein	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	activity	_	_	NN	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	stably	_	_	RB	O	-1	none	_	_
30	integrated	_	_	VBN	O	-1	none	_	_
31	alpha-globin	_	_	NN	Protein	-1	none	_	_
32	gene	_	_	NN	O	-1	none	_	_
33	is	_	_	VBZ	O	-1	none	_	_
34	mediated	_	_	VBN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	its	_	_	PRP$	O	-1	none	_	_
37	multiple	_	_	JJ	O	-1	none	_	_
38	binding	_	_	NN	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	for	_	_	IN	O	-1	none	_	_
41	the	_	_	DT	O	-1	none	_	_
42	transcription	_	_	NN	O	-1	none	_	_
43	factor	_	_	NN	O	-1	none	_	_
44	Sp1	_	_	NN	Protein	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	[	_	_	NN	O	-1	none	_	_
2	Glucocorticoid	_	_	NN	Protein	3	multitoken	_	_
3	receptors	_	_	NNS	Protein	0	root	_	_
4	in	_	_	IN	O	-1	none	_	_
5	peripheral	_	_	JJ	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	patients	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	bronchial	_	_	JJ	O	-1	none	_	_
12	asthma	_	_	NN	O	-1	none	_	_
13	]	_	_	NN	O	-1	none	_	_
14	Quantitation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	glucocorticoid	_	_	NN	Protein	17	multitoken	_	_
17	receptors	_	_	NNS	Protein	0	root	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	GCR	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	study	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	their	_	_	PRP$	O	-1	none	_	_
26	affinity	_	_	NN	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	glucocorticosteroids	_	_	NNS	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	GCS	_	_	NNS	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	were	_	_	VBD	O	-1	none	_	_
33	made	_	_	VBN	O	-1	none	_	_
34	in	_	_	IN	O	-1	none	_	_
35	peripheral	_	_	JJ	O	-1	none	_	_
36	blood	_	_	NN	O	-1	none	_	_
37	lymphocytes	_	_	NNS	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	bronchial	_	_	JJ	O	-1	none	_	_
40	asthma	_	_	NN	O	-1	none	_	_
41	(	_	_	-LRB-	O	-1	none	_	_
42	BA	_	_	NN	O	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	patients	_	_	NNS	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	consideration	_	_	NN	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	GCR	_	_	NN	Protein	-1	none	_	_
49	treatment	_	_	NN	O	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	serum	_	_	NN	O	-1	none	_	_
52	levels	_	_	NNS	O	-1	none	_	_
53	of	_	_	IN	O	-1	none	_	_
54	endogenous	_	_	JJ	O	-1	none	_	_
55	cortisol	_	_	NN	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	stated	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	GCR	_	_	NN	Protein	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	healthy	_	_	JJ	O	-1	none	_	_
8	controls	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	GCS	_	_	NNS	O	-1	none	_	_
11	untreated	_	_	JJ	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	outnumbered	_	_	VBD	O	-1	none	_	_
14	those	_	_	DT	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	cortisol	_	_	NN	O	-1	none	_	_
17	dependent	_	_	JJ	O	-1	none	_	_
18	BA	_	_	NN	O	-1	none	_	_
19	patients	_	_	NNS	O	-1	none	_	_
20	on	_	_	IN	O	-1	none	_	_
21	hormone	_	_	NN	O	-1	none	_	_
22	therapy	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Following	_	_	VBG	O	-1	none	_	_
2	discontinuation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	glucocorticoid	_	_	NN	O	-1	none	_	_
5	drugs	_	_	NNS	O	-1	none	_	_
6	GCR	_	_	NN	Protein	-1	none	_	_
7	count	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	cortisol	_	_	NN	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	BA	_	_	NN	O	-1	none	_	_
12	tends	_	_	VBZ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	rise	_	_	VB	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Endogenous	_	_	JJ	O	-1	none	_	_
2	cortisol	_	_	NN	O	-1	none	_	_
3	has	_	_	VBZ	O	-1	none	_	_
4	no	_	_	DT	O	-1	none	_	_
5	effect	_	_	NN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	GCR	_	_	NN	Protein	-1	none	_	_
8	level	_	_	NN	O	-1	none	_	_
9	estimated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	3H-triamcinolone	_	_	NN	O	-1	none	_	_
12	acetonide	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	I	_	_	CD	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	associates	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	negatively	_	_	RB	O	-1	none	_	_
13	regulated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	NF-kappa	_	_	NN	Protein	17	multitoken	_	_
17	B2	_	_	NN	Protein	0	root	_	_
18	p100	_	_	NN	Protein	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	product	_	_	NN	O	-1	none	_	_
21	:	_	_	:	O	-1	none	_	_
22	implications	_	_	NNS	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	viral	_	_	JJ	O	-1	none	_	_
25	latency	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T-cell	_	_	NN	O	-1	none	_	_
3	leukemia	_	_	NN	O	-1	none	_	_
4	virus	_	_	NN	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	I	_	_	CD	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	etiologic	_	_	JJ	O	-1	none	_	_
13	agent	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	adult	_	_	JJ	O	-1	none	_	_
17	T-cell	_	_	NN	O	-1	none	_	_
18	leukemia	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	an	_	_	DT	O	-1	none	_	_
21	aggressive	_	_	JJ	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	often	_	_	RB	O	-1	none	_	_
24	fatal	_	_	JJ	O	-1	none	_	_
25	malignancy	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	activated	_	_	VBN	O	-1	none	_	_
28	human	_	_	NN	O	-1	none	_	_
29	CD4	_	_	NN	Protein	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cells	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	HTLV-I	_	_	NNP	O	-1	none	_	_
2	encodes	_	_	VBZ	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	essential	_	_	JJ	O	-1	none	_	_
5	40-kDa	_	_	JJ	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	termed	_	_	VBN	O	-1	none	_	_
8	Tax	_	_	NN	Protein	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	only	_	_	RB	O	-1	none	_	_
12	transactivates	_	_	VBZ	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	long	_	_	JJ	O	-1	none	_	_
15	terminal	_	_	JJ	O	-1	none	_	_
16	repeat	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	this	_	_	DT	O	-1	none	_	_
19	retrovirus	_	_	NN	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	induces	_	_	VBZ	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	array	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	cellular	_	_	JJ	O	-1	none	_	_
27	genes	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Tax	_	_	NN	Protein	-1	none	_	_
2	mediated	_	_	VBD	O	-1	none	_	_
3	transformation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	likely	_	_	JJ	O	-1	none	_	_
8	involves	_	_	VBZ	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	deregulated	_	_	JJ	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	various	_	_	JJ	O	-1	none	_	_
14	cellular	_	_	JJ	O	-1	none	_	_
15	genes	_	_	NNS	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	normally	_	_	RB	O	-1	none	_	_
18	regulate	_	_	VBP	O	-1	none	_	_
19	lymphocyte	_	_	NN	O	-1	none	_	_
20	growth	_	_	NN	O	-1	none	_	_
21	produced	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	altered	_	_	JJ	O	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	various	_	_	JJ	O	-1	none	_	_
27	endogenous	_	_	JJ	O	-1	none	_	_
28	host	_	_	NN	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	factors	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	particular	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	Tax	_	_	NN	Protein	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	capable	_	_	JJ	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	modulating	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	various	_	_	JJ	O	-1	none	_	_
15	host	_	_	NN	O	-1	none	_	_
16	transcription	_	_	NN	O	-1	none	_	_
17	factors	_	_	NNS	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	including	_	_	VBG	O	-1	none	_	_
20	members	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	NF-kappa	_	_	NN	O	-1	none	_	_
24	B/Rel	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	CREB	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	ATF	_	_	NN	O	-1	none	_	_
29	families	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	as	_	_	RB	O	-1	none	_	_
32	well	_	_	RB	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	cellular	_	_	JJ	O	-1	none	_	_
36	factors	_	_	NNS	O	-1	none	_	_
37	HEB-1	_	_	NN	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	p67SRF	_	_	NN	Protein	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	additional	_	_	JJ	O	-1	none	_	_
3	distinguishing	_	_	JJ	O	-1	none	_	_
4	characteristic	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	HTLV-I	_	_	NN	O	-1	none	_	_
7	infection	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	profound	_	_	JJ	O	-1	none	_	_
11	state	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	viral	_	_	JJ	O	-1	none	_	_
14	latency	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	present	_	_	JJ	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	circulating	_	_	VBG	O	-1	none	_	_
20	primary	_	_	JJ	O	-1	none	_	_
21	leukemic	_	_	JJ	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	demonstrate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	HTLV-I	_	_	NN	O	-1	none	_	_
9	Tax	_	_	NN	Protein	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	physically	_	_	RB	O	-1	none	_	_
12	associate	_	_	VB	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	p100	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	product	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	Rel	_	_	NN	O	-1	none	_	_
21	related	_	_	JJ	O	-1	none	_	_
22	NF-kappa	_	_	NN	Protein	23	multitoken	_	_
23	B2	_	_	NN	Protein	0	root	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	both	_	_	CC	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	transfected	_	_	VBN	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	HTLV-I-infected	_	_	JJ	O	-1	none	_	_
33	leukemic	_	_	JJ	O	-1	none	_	_
34	T-cell	_	_	NN	O	-1	none	_	_
35	lines	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	physical	_	_	JJ	O	-1	none	_	_
5	interaction	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	p100	_	_	NN	Protein	-1	none	_	_
10	leads	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	inhibition	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	Tax	_	_	NN	Protein	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	HTLV-I	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	immunodeficiency	_	_	NN	O	-1	none	_	_
24	virus	_	_	NN	O	-1	none	_	_
25	type	_	_	NN	O	-1	none	_	_
26	1	_	_	CD	O	-1	none	_	_
27	long	_	_	JJ	O	-1	none	_	_
28	terminal	_	_	JJ	O	-1	none	_	_
29	repeats	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	reflecting	_	_	VBG	O	-1	none	_	_
32	p100	_	_	NN	Protein	-1	none	_	_
33	mediated	_	_	VBD	O	-1	none	_	_
34	cytoplasmic	_	_	JJ	O	-1	none	_	_
35	sequestration	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	normally	_	_	RB	O	-1	none	_	_
39	nuclearly	_	_	RB	O	-1	none	_	_
40	expressed	_	_	VBN	O	-1	none	_	_
41	Tax	_	_	NN	Protein	-1	none	_	_
42	protein	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	mutant	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	Tax	_	_	NN	Protein	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	selectively	_	_	RB	O	-1	none	_	_
10	fails	_	_	VBZ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	activate	_	_	VB	O	-1	none	_	_
13	nuclear	_	_	JJ	O	-1	none	_	_
14	NF-kappa	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	expression	_	_	NN	O	-1	none	_	_
17	does	_	_	VBZ	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	associate	_	_	JJ	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	p100	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ABSTRACT	_	_	NN	O	-1	none	_	_
3	TRUNCATED	_	_	VBD	O	-1	none	_	_
4	AT	_	_	IN	O	-1	none	_	_
5	250	_	_	CD	O	-1	none	_	_
6	WORDS	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	factor	_	_	NN	O	-1	none	_	_
5	kappa	_	_	NN	O	-1	none	_	_
6	B	_	_	NN	O	-1	none	_	_
7	subunit	_	_	NN	O	-1	none	_	_
8	p65	_	_	NN	Protein	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	accumulation	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	lipopolysaccharide	_	_	NN	O	-1	none	_	_
13	stimulated	_	_	VBN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	monocytic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	treated	_	_	VBN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	sodium	_	_	NN	O	-1	none	_	_
20	salicylate	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Lipopolysaccharide	_	_	NN	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	one	_	_	CD	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	most	_	_	RBS	O	-1	none	_	_
7	potent	_	_	JJ	O	-1	none	_	_
8	trigger	_	_	NN	O	-1	none	_	_
9	substances	_	_	NNS	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	monocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	macrophages	_	_	NNS	O	-1	none	_	_
14	causing	_	_	VBG	O	-1	none	_	_
15	secretion	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	inflammatory	_	_	JJ	O	-1	none	_	_
18	mediators	_	_	NNS	O	-1	none	_	_
19	such	_	_	JJ	O	-1	none	_	_
20	as	_	_	IN	O	-1	none	_	_
21	tumor	_	_	NN	O	-1	none	_	_
22	necrosis	_	_	NN	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	interleukin-1	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	nature	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	factors	_	_	NNS	O	-1	none	_	_
7	involved	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	regulation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	cytokine	_	_	NN	O	-1	none	_	_
13	genes	_	_	NNS	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	still	_	_	RB	O	-1	none	_	_
16	unknown	_	_	JJ	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	factor	_	_	NN	O	-1	none	_	_
3	kappa	_	_	NN	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	;	_	_	:	O	-1	none	_	_
9	heterodimer	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	p50	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	p65	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	have	_	_	VBP	O	-1	none	_	_
17	been	_	_	VBN	O	-1	none	_	_
18	suggested	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	play	_	_	VB	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	important	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	gene	_	_	NN	O	-1	none	_	_
26	transcription	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	inflammatory	_	_	JJ	O	-1	none	_	_
29	mediators	_	_	NNS	O	-1	none	_	_
30	when	_	_	WRB	O	-1	none	_	_
31	monocytes	_	_	NNS	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	stimulated	_	_	VBN	O	-1	none	_	_
34	with	_	_	IN	O	-1	none	_	_
35	lipopolysaccharide	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Nonsteroidal	_	_	JJ	O	-1	none	_	_
2	anti-inflammatory	_	_	JJ	O	-1	none	_	_
3	drugs	_	_	NNS	O	-1	none	_	_
4	such	_	_	JJ	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	salicylates	_	_	NNS	O	-1	none	_	_
7	have	_	_	VBP	O	-1	none	_	_
8	been	_	_	VBN	O	-1	none	_	_
9	used	_	_	VBN	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	treat	_	_	VB	O	-1	none	_	_
12	symptoms	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	inflammation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	new	_	_	JJ	O	-1	none	_	_
19	mechanism	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	drug	_	_	NN	O	-1	none	_	_
22	action	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	suggested	_	_	VBN	O	-1	none	_	_
25	recently	_	_	RB	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Salicylates	_	_	NNS	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	been	_	_	VBN	O	-1	none	_	_
4	shown	_	_	VBN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	inhibit	_	_	VB	O	-1	none	_	_
7	lipopolysaccharide	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBN	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	via	_	_	IN	O	-1	none	_	_
12	inhibition	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NF-kappa	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	preventing	_	_	VBG	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	degradation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	NF-kappa	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	inhibitor	_	_	NN	O	-1	none	_	_
25	"	_	_	''	O	-1	none	_	_
26	I	_	_	NN	Protein	28	multitoken	_	_
27	kappa	_	_	NN	Protein	28	multitoken	_	_
28	B	_	_	NN	Protein	0	root	_	_
29	"	_	_	''	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	blocking	_	_	VBG	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	translocation	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	NF-kappa	_	_	NN	O	-1	none	_	_
36	B	_	_	NN	O	-1	none	_	_
37	into	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	nuclear	_	_	JJ	O	-1	none	_	_
40	compartment	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	nature	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	subunit	_	_	NN	O	-1	none	_	_
8	involved	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	this	_	_	DT	O	-1	none	_	_
11	mechanism	_	_	NN	O	-1	none	_	_
12	has	_	_	VBZ	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	been	_	_	VBN	O	-1	none	_	_
15	defined	_	_	VBN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	examine	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	salicylates	_	_	NNS	O	-1	none	_	_
8	affect	_	_	VBP	O	-1	none	_	_
9	cytokine	_	_	NN	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	transcription	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	amount	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	active	_	_	JJ	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	inactive	_	_	JJ	O	-1	none	_	_
19	NF-kappa	_	_	NN	O	-1	none	_	_
20	B	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	NF-kappa	_	_	NN	O	-1	none	_	_
23	B	_	_	NN	O	-1	none	_	_
24	mRNA	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	Porphyromonas	_	_	NN	O	-1	none	_	_
28	gingivalis	_	_	NN	O	-1	none	_	_
29	lipopolysaccharide	_	_	NN	O	-1	none	_	_
30	stimulated	_	_	VBD	O	-1	none	_	_
31	human	_	_	NN	O	-1	none	_	_
32	monocytic	_	_	JJ	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	was	_	_	VBD	O	-1	none	_	_
35	assessed	_	_	VBN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	High	_	_	JJ	O	-1	none	_	_
2	doses	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	sodium	_	_	NN	O	-1	none	_	_
5	salicylate	_	_	NN	O	-1	none	_	_
6	suppressed	_	_	VBD	O	-1	none	_	_
7	NF-kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	p65	_	_	NN	Protein	-1	none	_	_
10	mRNA	_	_	NN	O	-1	none	_	_
11	accumulation	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	resulting	_	_	VBG	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	suppression	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	total	_	_	JJ	O	-1	none	_	_
18	NF-kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	p50	_	_	NN	Protein	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	tissue	_	_	NN	O	-1	none	_	_
24	oligonucleotide	_	_	NN	O	-1	none	_	_
25	had	_	_	VBD	O	-1	none	_	_
26	no	_	_	DT	O	-1	none	_	_
27	effects	_	_	NNS	O	-1	none	_	_
28	on	_	_	IN	O	-1	none	_	_
29	lipopolysaccharide	_	_	NN	O	-1	none	_	_
30	induced	_	_	VBD	O	-1	none	_	_
31	NF-kappa	_	_	NN	O	-1	none	_	_
32	B	_	_	NN	O	-1	none	_	_
33	activation	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	p65	_	_	NN	Protein	-1	none	_	_
7	subunit	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	NF-kappa	_	_	NN	O	-1	none	_	_
10	B	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	inhibited	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	salicylate	_	_	NN	O	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	highlight	_	_	VB	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	role	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	salicylate	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	control	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	gene	_	_	NN	O	-1	none	_	_
27	expression	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	inflammatory	_	_	JJ	O	-1	none	_	_
30	mediators	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	latency	_	_	NN	O	-1	none	_	_
5	BamHI-Q	_	_	NN	O	-1	none	_	_
6	promoter	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	positively	_	_	RB	O	-1	none	_	_
9	regulated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	STATs	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Zta	_	_	NN	Protein	-1	none	_	_
14	interference	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	JAK	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	STAT	_	_	NN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	leads	_	_	VBZ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	loss	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	BamHI-Q	_	_	NN	O	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	activity	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	)-associated	_	_	JJ	O	-1	none	_	_
7	tumors	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	nonimmunocompromised	_	_	JJ	O	-1	none	_	_
10	patients	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	EBV	_	_	NN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	is	_	_	VBZ	O	-1	none	_	_
16	highly	_	_	RB	O	-1	none	_	_
17	restricted	_	_	JJ	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	EBV	_	_	NN	Protein	8	multitoken	_	_
2	encoded	_	_	VBD	Protein	8	multitoken	_	_
3	nuclear	_	_	JJ	Protein	8	multitoken	_	_
4	antigen	_	_	NN	Protein	8	multitoken	_	_
5	(	_	_	-LRB-	Protein	8	multitoken	_	_
6	EBNA	_	_	NN	Protein	8	multitoken	_	_
7	)	_	_	-RRB-	Protein	8	multitoken	_	_
8	-1	_	_	CD	Protein	0	root	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	expressed	_	_	VBN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	whereas	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	immunogenic	_	_	JJ	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	proliferative	_	_	JJ	O	-1	none	_	_
17	EBNAs	_	_	NNS	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	pattern	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	EBNA	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	generated	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	usage	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	BamHI-Q	_	_	NN	O	-1	none	_	_
13	promoter	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	Qp	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	determined	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	JAK	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	STAT	_	_	NN	O	-1	none	_	_
9	pathway	_	_	NN	O	-1	none	_	_
10	positively	_	_	RB	O	-1	none	_	_
11	regulates	_	_	VBZ	O	-1	none	_	_
12	Qp	_	_	NN	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	transient-transfection	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	Qp-CAT	_	_	NN	O	-1	none	_	_
7	reporter	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	activated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	cotransfected	_	_	VBN	O	-1	none	_	_
12	JAK-1	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	cytokine	_	_	NN	O	-1	none	_	_
21	IL-6	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Consistent	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	role	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	STATs	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	Qp	_	_	NN	O	-1	none	_	_
9	function	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	Qp	_	_	NN	O	-1	none	_	_
12	using	_	_	VBG	O	-1	none	_	_
13	Burkitt	_	_	NN	O	-1	none	_	_
14	's	_	_	POS	O	-1	none	_	_
15	lymphoma	_	_	NN	O	-1	none	_	_
16	Rael	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	cultured	_	_	VBN	O	-1	none	_	_
20	nasopharyngeal	_	_	JJ	O	-1	none	_	_
21	carcinoma	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	NPC	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	contained	_	_	VBD	O	-1	none	_	_
27	nuclear	_	_	JJ	O	-1	none	_	_
28	STAT	_	_	NN	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	investigated	_	_	VBD	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	inability	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	maintain	_	_	VB	O	-1	none	_	_
8	EBV	_	_	NN	O	-1	none	_	_
9	positive	_	_	JJ	O	-1	none	_	_
10	NPC	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	lines	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	culture	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	related	_	_	VBN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	Qp	_	_	NN	O	-1	none	_	_
19	activity	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Passaging	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	NPC	_	_	NN	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	line	_	_	NN	O	-1	none	_	_
7	HK666	_	_	NN	O	-1	none	_	_
8	led	_	_	VBD	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	BZLF1	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	which	_	_	WDT	O	-1	none	_	_
17	encodes	_	_	VBZ	O	-1	none	_	_
18	Zta	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	loss	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	Qp	_	_	NN	O	-1	none	_	_
23	function	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	linked	_	_	VBD	O	-1	none	_	_
5	Zta	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	down-regulation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Qp	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Cotransfection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Zta	_	_	NN	Protein	-1	none	_	_
4	reduced	_	_	VBD	O	-1	none	_	_
5	Qp	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	reporter	_	_	NN	O	-1	none	_	_
9	assays	_	_	NNS	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	negative	_	_	JJ	O	-1	none	_	_
3	regulation	_	_	NN	O	-1	none	_	_
4	required	_	_	VBD	O	-1	none	_	_
5	Zta	_	_	NN	Protein	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	provide	_	_	VBP	O	-1	none	_	_
3	evidence	_	_	NN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Zta	_	_	NN	Protein	-1	none	_	_
6	up-regulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p53	_	_	NN	Protein	-1	none	_	_
9	leads	_	_	VBZ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	p53	_	_	NN	Protein	-1	none	_	_
12	mediated	_	_	VBD	O	-1	none	_	_
13	interference	_	_	NN	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	JAK	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	STAT	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	Qp	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	imply	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	JAK	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	STAT	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	has	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	EBV	_	_	NN	O	-1	none	_	_
14	associated	_	_	VBN	O	-1	none	_	_
15	malignancies	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Glucocorticoid	_	_	NN	O	-1	none	_	_
2	mediated	_	_	VBD	O	-1	none	_	_
3	inhibition	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	interleukin-2	_	_	NN	Protein	7	multitoken	_	_
6	receptor	_	_	NN	Protein	7	multitoken	_	_
7	alpha	_	_	NN	Protein	0	root	_	_
8	and	_	_	CC	O	-1	none	_	_
9	-beta	_	_	NN	Protein	-1	none	_	_
10	subunit	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	determine	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mechanism	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	glucocorticoid	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	GC	_	_	NN	O	-1	none	_	_
9	)-mediated	_	_	JJ	O	-1	none	_	_
10	inhibition	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	T	_	_	NN	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	functions	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	effect	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	dexamethasone	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	DM	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	proliferation	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	interleukin-2	_	_	NN	O	-1	none	_	_
29	receptor	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	IL-2R	_	_	NN	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	generation	_	_	NN	O	-1	none	_	_
34	were	_	_	VBD	O	-1	none	_	_
35	studied	_	_	VBN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	DM	_	_	NN	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IL-2R	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	Tac	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	p55	_	_	NN	Protein	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	CD25	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	beta	_	_	NN	Protein	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	p75	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	genes	_	_	NNS	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	activated	_	_	VBN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	was	_	_	VBD	O	-1	none	_	_
28	examined	_	_	VBN	O	-1	none	_	_
29	next	_	_	RB	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	stimulated	_	_	VBN	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	purified	_	_	VBN	O	-1	none	_	_
7	phytohemagglutinin	_	_	NN	Protein	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	PHA-p	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	4	_	_	CD	O	-1	none	_	_
13	beta-phorbol	_	_	NN	O	-1	none	_	_
14	12-myristate	_	_	NN	O	-1	none	_	_
15	13-acetate	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	PMA	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	addition	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	DM	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	cultures	_	_	NNS	O	-1	none	_	_
25	resulted	_	_	VBD	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	60	_	_	CD	O	-1	none	_	_
29	%	_	_	NN	O	-1	none	_	_
30	reduction	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	IL-2R	_	_	NN	Protein	33	multitoken	_	_
33	alpha	_	_	NN	Protein	0	root	_	_
34	and	_	_	CC	O	-1	none	_	_
35	a	_	_	DT	O	-1	none	_	_
36	30	_	_	CD	O	-1	none	_	_
37	%	_	_	NN	O	-1	none	_	_
38	reduction	_	_	NN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	IL-2R	_	_	NN	Protein	41	multitoken	_	_
41	beta	_	_	NN	Protein	0	root	_	_
42	membrane	_	_	NN	O	-1	none	_	_
43	expression	_	_	NN	O	-1	none	_	_
44	compared	_	_	VBN	O	-1	none	_	_
45	to	_	_	TO	O	-1	none	_	_
46	T	_	_	NN	O	-1	none	_	_
47	cells	_	_	NNS	O	-1	none	_	_
48	cultured	_	_	VBN	O	-1	none	_	_
49	in	_	_	IN	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	absence	_	_	NN	O	-1	none	_	_
52	of	_	_	IN	O	-1	none	_	_
53	DM	_	_	NN	O	-1	none	_	_
54	(	_	_	-LRB-	O	-1	none	_	_
55	p	_	_	NN	O	-1	none	_	_
56	<	_	_	JJR	O	-1	none	_	_
57	0.01	_	_	CD	O	-1	none	_	_
58	)	_	_	-RRB-	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	membrane	_	_	NN	O	-1	none	_	_
4	IL-2R	_	_	NN	Protein	5	multitoken	_	_
5	alpha	_	_	NN	Protein	0	root	_	_
6	and	_	_	CC	O	-1	none	_	_
7	IL-2R	_	_	NN	Protein	8	multitoken	_	_
8	beta	_	_	NN	Protein	0	root	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	10	_	_	CD	O	-1	none	_	_
12	(-6)	_	_	CD	O	-1	none	_	_
13	M	_	_	NN	O	-1	none	_	_
14	DM	_	_	NN	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	partially	_	_	RB	O	-1	none	_	_
17	reversible	_	_	JJ	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	recombinant	_	_	JJ	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	IL-2	_	_	NN	Protein	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	rhIL-2	_	_	NN	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	Northern	_	_	NN	O	-1	none	_	_
3	blot	_	_	NN	O	-1	none	_	_
4	analysis	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	DM	_	_	NN	O	-1	none	_	_
7	caused	_	_	VBD	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	comparable	_	_	JJ	O	-1	none	_	_
10	decrease	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	IL-2R	_	_	NN	Protein	13	multitoken	_	_
13	alpha	_	_	NN	Protein	0	root	_	_
14	and	_	_	CC	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	IL-2R	_	_	NN	Protein	17	multitoken	_	_
17	beta	_	_	NN	Protein	0	root	_	_
18	mRNA	_	_	NN	O	-1	none	_	_
19	levels	_	_	NNS	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	membrane	_	_	NN	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	expression	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	mitogen	_	_	NN	O	-1	none	_	_
26	stimulated	_	_	JJ	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	in	_	_	FW	O	-1	none	_	_
3	vitro	_	_	FW	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	assays	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	DM	_	_	NN	O	-1	none	_	_
8	regulated	_	_	VBD	O	-1	none	_	_
9	IL-2R	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	at	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	transcriptional	_	_	JJ	O	-1	none	_	_
16	level	_	_	NN	O	-1	none	_	_
17	while	_	_	IN	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	IL-2R	_	_	NN	Protein	21	multitoken	_	_
21	beta	_	_	NN	Protein	0	root	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	unaffected	_	_	JJ	O	-1	none	_	_
25	by	_	_	IN	O	-1	none	_	_
26	DM	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	action	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	DM	_	_	NN	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	IL-2R	_	_	NN	Protein	9	multitoken	_	_
9	alpha	_	_	NN	Protein	0	root	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	examined	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	determining	_	_	VBG	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	mRNA	_	_	NN	O	-1	none	_	_
17	levels	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	p50	_	_	NN	Protein	-1	none	_	_
21	subunit	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	nuclear	_	_	JJ	O	-1	none	_	_
24	factor	_	_	NN	O	-1	none	_	_
25	kappa	_	_	NN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	NF-kappa	_	_	NN	O	-1	none	_	_
29	B	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	transcription	_	_	NN	O	-1	none	_	_
34	factor	_	_	NN	O	-1	none	_	_
35	that	_	_	WDT	O	-1	none	_	_
36	stimulates	_	_	VBZ	O	-1	none	_	_
37	IL-2R	_	_	NN	Protein	38	multitoken	_	_
38	alpha	_	_	NN	Protein	0	root	_	_
39	gene	_	_	NN	O	-1	none	_	_
40	expression	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	10	_	_	CD	O	-1	none	_	_
6	(-6)	_	_	CD	O	-1	none	_	_
7	M	_	_	NN	O	-1	none	_	_
8	DM	_	_	NN	O	-1	none	_	_
9	increased	_	_	VBD	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	p50	_	_	NN	Protein	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	mRNA	_	_	NN	O	-1	none	_	_
16	levels	_	_	NNS	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	four-fold	_	_	JJ	O	-1	none	_	_
19	compared	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	levels	_	_	NNS	O	-1	none	_	_
23	obtained	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	absence	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	DM	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Further	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	level	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	proteins	_	_	NNS	O	-1	none	_	_
8	capable	_	_	JJ	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	binding	_	_	VBG	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	sites	_	_	NNS	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	activated	_	_	VBN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	increased	_	_	VBN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	response	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	DM	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	sum	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	DM	_	_	NN	O	-1	none	_	_
5	regulates	_	_	VBZ	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	membrane	_	_	NN	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	IL-2R	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	more	_	_	JJR	O	-1	none	_	_
14	than	_	_	IN	O	-1	none	_	_
15	one	_	_	CD	O	-1	none	_	_
16	molecular	_	_	JJ	O	-1	none	_	_
17	mechanism	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Protein-tyrosine	_	_	JJ	O	-1	none	_	_
2	kinase	_	_	NN	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	required	_	_	VBN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	lipopolysaccharide	_	_	NN	O	-1	none	_	_
8	induction	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	interleukin	_	_	NN	Protein	11	multitoken	_	_
11	1beta	_	_	NN	Protein	0	root	_	_
12	and	_	_	CC	O	-1	none	_	_
13	NFkappaB	_	_	NN	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	NFkappaB	_	_	NN	O	-1	none	_	_
19	nuclear	_	_	JJ	O	-1	none	_	_
20	translocation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	monocytes	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	interleukin	_	_	NN	Protein	6	multitoken	_	_
6	1beta	_	_	NN	Protein	0	root	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	production	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	steady	_	_	JJ	O	-1	none	_	_
11	state	_	_	NN	O	-1	none	_	_
12	mRNA	_	_	NN	O	-1	none	_	_
13	levels	_	_	NNS	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	increased	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	lipopolysaccharide	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	predominantly	_	_	RB	O	-1	none	_	_
22	as	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	result	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	increased	_	_	VBN	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	interleukin	_	_	NN	Protein	31	multitoken	_	_
31	1beta	_	_	NN	Protein	0	root	_	_
32	gene	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	interleukin	_	_	NN	Protein	4	multitoken	_	_
4	1beta	_	_	NN	Protein	0	root	_	_
5	and	_	_	CC	O	-1	none	_	_
6	other	_	_	JJ	O	-1	none	_	_
7	cytokines	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	such	_	_	JJ	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	interleukin	_	_	NN	Protein	12	multitoken	_	_
12	6	_	_	CD	Protein	0	root	_	_
13	and	_	_	CC	O	-1	none	_	_
14	tumor	_	_	NN	Protein	17	multitoken	_	_
15	necrosis	_	_	NN	Protein	17	multitoken	_	_
16	factor	_	_	NN	Protein	17	multitoken	_	_
17	alpha	_	_	NN	Protein	0	root	_	_
18	,	_	_	,	O	-1	none	_	_
19	has	_	_	VBZ	O	-1	none	_	_
20	been	_	_	VBN	O	-1	none	_	_
21	shown	_	_	VBN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	be	_	_	VB	O	-1	none	_	_
24	dependent	_	_	JJ	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	activation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	transcription	_	_	NN	O	-1	none	_	_
31	factor	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	NFkappaB	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	recent	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	lipopolysaccharide	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	tyrosine	_	_	NN	O	-1	none	_	_
10	kinase	_	_	NN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	required	_	_	VBN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	NFkappaB	_	_	NN	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	translocation	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	we	_	_	PRP	O	-1	none	_	_
21	sought	_	_	VBD	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	determine	_	_	VB	O	-1	none	_	_
24	whether	_	_	IN	O	-1	none	_	_
25	NFkappaB	_	_	NN	O	-1	none	_	_
26	translocated	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	absence	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	tyrosine	_	_	NN	O	-1	none	_	_
32	kinase	_	_	NN	O	-1	none	_	_
33	activity	_	_	NN	O	-1	none	_	_
34	was	_	_	VBD	O	-1	none	_	_
35	active	_	_	JJ	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	stimulating	_	_	VBG	O	-1	none	_	_
38	transcription	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	found	_	_	VBN	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	pro	_	_	JJ	O	-1	none	_	_
10	monocytic	_	_	JJ	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	line	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	THP-1	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	lipopolysaccharide	_	_	NN	O	-1	none	_	_
18	induced	_	_	VBN	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	interleukin	_	_	NN	Protein	22	multitoken	_	_
22	1beta	_	_	NN	Protein	0	root	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	dependent	_	_	JJ	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	tyrosine	_	_	NN	O	-1	none	_	_
27	kinase	_	_	NN	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Tyrosine	_	_	NN	O	-1	none	_	_
2	kinases	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	required	_	_	VBN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	lipopolysaccharide	_	_	NN	O	-1	none	_	_
8	mediated	_	_	VBN	O	-1	none	_	_
9	nuclear	_	_	JJ	O	-1	none	_	_
10	translocation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	NFkappaB	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	absence	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	tyrosine	_	_	NN	O	-1	none	_	_
8	kinase	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	ability	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NFkappaB	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	stimulate	_	_	VB	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	impaired	_	_	JJ	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	inhibition	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	transcription	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	specific	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	NFkappaB	_	_	NN	O	-1	none	_	_
9	;	_	_	:	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	absence	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	AP-1-dependent	_	_	JJ	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	is	_	_	VBZ	O	-1	none	_	_
21	enhanced	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	while	_	_	IN	O	-1	none	_	_
7	lipopolysaccharide	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBN	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	inflammatory	_	_	JJ	O	-1	none	_	_
12	mediators	_	_	NNS	O	-1	none	_	_
13	requires	_	_	VBZ	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	tyrosine	_	_	NN	O	-1	none	_	_
19	kinase	_	_	NN	O	-1	none	_	_
20	activity	_	_	NN	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	obligatory	_	_	JJ	O	-1	none	_	_
24	for	_	_	IN	O	-1	none	_	_
25	lipopolysaccharide	_	_	NN	O	-1	none	_	_
26	signal	_	_	NN	O	-1	none	_	_
27	transduction	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	TCF-1	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	encodes	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	DNA	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	uniquely	_	_	RB	O	-1	none	_	_
12	expressed	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	neoplastic	_	_	JJ	O	-1	none	_	_
17	T-lineage	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	TCF-1	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	encodes	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	putative	_	_	JJ	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	affinity	_	_	NN	O	-1	none	_	_
11	for	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	sequence	_	_	NN	O	-1	none	_	_
14	motif	_	_	NN	O	-1	none	_	_
15	occurring	_	_	VBG	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	number	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	T-cell	_	_	NN	O	-1	none	_	_
21	enhancers	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	TCF-1	_	_	NNP	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	originally	_	_	RB	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	specific	_	_	JJ	O	-1	none	_	_
14	fashion	_	_	NN	O	-1	none	_	_
15	within	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	set	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	human	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	mouse	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	lines	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	reportedly	_	_	RB	O	-1	none	_	_
6	occurs	_	_	VBZ	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	multiple	_	_	JJ	O	-1	none	_	_
9	nonlymphoid	_	_	JJ	O	-1	none	_	_
10	tissues	_	_	NNS	O	-1	none	_	_
11	during	_	_	IN	O	-1	none	_	_
12	murine	_	_	JJ	O	-1	none	_	_
13	embryogenesis	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	now	_	_	RB	O	-1	none	_	_
4	raised	_	_	VBN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	monoclonal	_	_	JJ	O	-1	none	_	_
7	antibody	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	document	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	biochemistry	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	TCF-1	_	_	NN	Protein	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	expected	_	_	VBN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	TCF-1	_	_	NN	Protein	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	detectable	_	_	JJ	O	-1	none	_	_
9	only	_	_	RB	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	lines	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	T	_	_	NN	O	-1	none	_	_
15	lineage	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Its	_	_	PRP$	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	always	_	_	RB	O	-1	none	_	_
5	restricted	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	nucleus	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Immunohistochemistry	_	_	NN	O	-1	none	_	_
2	on	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	panel	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	tissues	_	_	NNS	O	-1	none	_	_
8	revealed	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	TCF-1	_	_	NN	Protein	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	exclusively	_	_	RB	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	thymocytes	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	CD3+	_	_	JJ	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	peripheral	_	_	JJ	O	-1	none	_	_
25	lymphoid	_	_	JJ	O	-1	none	_	_
26	tissues	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blotting	_	_	NN	O	-1	none	_	_
3	yielded	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	set	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	bands	_	_	NNS	O	-1	none	_	_
8	ranging	_	_	VBG	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	25	_	_	CD	O	-1	none	_	_
11	kD	_	_	NN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	55	_	_	CD	O	-1	none	_	_
14	kD	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	resulting	_	_	VBG	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	extensive	_	_	JJ	O	-1	none	_	_
19	alternative	_	_	JJ	O	-1	none	_	_
20	splicing	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	TCF-1	_	_	NN	Protein	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	detectable	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	all	_	_	DT	O	-1	none	_	_
8	samples	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	set	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	22	_	_	CD	O	-1	none	_	_
14	T-cell	_	_	NN	O	-1	none	_	_
15	malignancies	_	_	NNS	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	various	_	_	JJ	O	-1	none	_	_
18	stages	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	maturation	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	but	_	_	CC	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	absent	_	_	JJ	O	-1	none	_	_
25	from	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	large	_	_	JJ	O	-1	none	_	_
28	number	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	other	_	_	JJ	O	-1	none	_	_
31	hematologic	_	_	JJ	O	-1	none	_	_
32	neoplasms	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	imply	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	T	_	_	NN	O	-1	none	_	_
6	cell	_	_	NN	O	-1	none	_	_
7	specific	_	_	JJ	O	-1	none	_	_
8	function	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	TCF-1	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	notion	_	_	NN	O	-1	none	_	_
14	corroborated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	recent	_	_	JJ	O	-1	none	_	_
17	observations	_	_	NNS	O	-1	none	_	_
18	on	_	_	IN	O	-1	none	_	_
19	Tcf-1	_	_	NN	Protein	-1	none	_	_
20	knock-out	_	_	JJ	O	-1	none	_	_
21	mice	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	indicate	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	nuclear	_	_	JJ	O	-1	none	_	_
9	TCF-1	_	_	NN	Protein	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	serve	_	_	VB	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	pan-T-lineage	_	_	JJ	O	-1	none	_	_
16	marker	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	diagnosis	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	lymphoid	_	_	JJ	O	-1	none	_	_
22	malignancies	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	T	_	_	NN	O	-1	none	_	_
2	helper	_	_	NN	O	-1	none	_	_
3	differentiation	_	_	NN	O	-1	none	_	_
4	proceeds	_	_	VBZ	O	-1	none	_	_
5	through	_	_	IN	O	-1	none	_	_
6	Stat1	_	_	NN	Protein	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	Stat4	_	_	NN	Protein	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Stat4	_	_	NN	Protein	-1	none	_	_
13	independent	_	_	JJ	O	-1	none	_	_
14	phases	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Much	_	_	JJ	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	our	_	_	PRP$	O	-1	none	_	_
4	focus	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	understanding	_	_	VBG	O	-1	none	_	_
7	Th1	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	Th2	_	_	NN	O	-1	none	_	_
10	development	_	_	NN	O	-1	none	_	_
11	has	_	_	VBZ	O	-1	none	_	_
12	been	_	_	VBN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	signals	_	_	NNS	O	-1	none	_	_
16	delivered	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	IL-12	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	IL-4	_	_	NN	Protein	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	final	_	_	JJ	O	-1	none	_	_
23	determinants	_	_	NNS	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	terminal	_	_	JJ	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	differentiation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	extinction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-12	_	_	NN	O	-1	none	_	_
5	signaling	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	early	_	_	JJ	O	-1	none	_	_
8	Th2	_	_	NN	O	-1	none	_	_
9	development	_	_	NN	O	-1	none	_	_
10	could	_	_	MD	O	-1	none	_	_
11	potentially	_	_	RB	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	important	_	_	JJ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	imprinting	_	_	VBG	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	more	_	_	RBR	O	-1	none	_	_
18	permanent	_	_	JJ	O	-1	none	_	_
19	Th2	_	_	NN	O	-1	none	_	_
20	phenotype	_	_	NN	O	-1	none	_	_
21	on	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	population	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	T	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	we	_	_	PRP	O	-1	none	_	_
29	have	_	_	VBP	O	-1	none	_	_
30	also	_	_	RB	O	-1	none	_	_
31	examined	_	_	VBN	O	-1	none	_	_
32	various	_	_	JJ	O	-1	none	_	_
33	parameters	_	_	NNS	O	-1	none	_	_
34	regulating	_	_	VBG	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	IL-12	_	_	NN	O	-1	none	_	_
37	signaling	_	_	NN	O	-1	none	_	_
38	pathway	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Whereas	_	_	IN	O	-1	none	_	_
2	IL-4	_	_	NN	Protein	-1	none	_	_
3	appears	_	_	VBZ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	repress	_	_	VB	O	-1	none	_	_
6	functional	_	_	JJ	O	-1	none	_	_
7	IL-12	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	through	_	_	IN	O	-1	none	_	_
10	inhibition	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	IL-12R	_	_	NN	Protein	14	multitoken	_	_
13	beta	_	_	NN	Protein	14	multitoken	_	_
14	2	_	_	CD	Protein	0	root	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	IFN-gamma	_	_	NN	Protein	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	mouse	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	IFN-alpha	_	_	NN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	appear	_	_	VBP	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	induce	_	_	VB	O	-1	none	_	_
30	IL-12R	_	_	NN	Protein	32	multitoken	_	_
31	beta	_	_	NN	Protein	32	multitoken	_	_
32	2	_	_	CD	Protein	0	root	_	_
33	expression	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	promote	_	_	VB	O	-1	none	_	_
36	IL-12	_	_	NN	O	-1	none	_	_
37	responsiveness	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	propose	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	Th1	_	_	NN	O	-1	none	_	_
5	development	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	considered	_	_	VBN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	two	_	_	CD	O	-1	none	_	_
11	stages	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	capacitance	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	development	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Capacitance	_	_	NN	O	-1	none	_	_
2	would	_	_	MD	O	-1	none	_	_
3	simply	_	_	RB	O	-1	none	_	_
4	involve	_	_	VB	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	IL-12R	_	_	NN	Protein	9	multitoken	_	_
8	beta	_	_	NN	Protein	9	multitoken	_	_
9	1	_	_	CD	Protein	0	root	_	_
10	and	_	_	CC	O	-1	none	_	_
11	beta	_	_	NN	Protein	12	multitoken	_	_
12	2	_	_	CD	Protein	0	root	_	_
13	subunits	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	regulated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	TCR	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	IL-4	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	IFNs	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	second	_	_	JJ	O	-1	none	_	_
3	stage	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	development	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	we	_	_	PRP	O	-1	none	_	_
8	propose	_	_	VBP	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	true	_	_	JJ	O	-1	none	_	_
12	IL-12	_	_	NN	O	-1	none	_	_
13	induced	_	_	VBD	O	-1	none	_	_
14	developmental	_	_	JJ	O	-1	none	_	_
15	stage	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	involving	_	_	VBG	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	Stat4	_	_	NN	Protein	-1	none	_	_
21	inducible	_	_	JJ	O	-1	none	_	_
22	proteins	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	human	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	may	_	_	MD	O	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	occur	_	_	VB	O	-1	none	_	_
9	via	_	_	IN	O	-1	none	_	_
10	IFN-alpha	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	able	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	activate	_	_	VB	O	-1	none	_	_
17	Stat4	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	perhaps	_	_	RB	O	-1	none	_	_
4	possible	_	_	JJ	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	all	_	_	DT	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	Stat4	_	_	NN	Protein	-1	none	_	_
9	actions	_	_	NNS	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	Th1	_	_	NN	O	-1	none	_	_
12	development	_	_	NN	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	exert	_	_	VBN	O	-1	none	_	_
16	directly	_	_	RB	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	Stat4	_	_	NN	Protein	-1	none	_	_
19	at	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	IFN-gamma	_	_	NN	Protein	-1	none	_	_
22	gene	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	however	_	_	RB	O	-1	none	_	_
25	we	_	_	PRP	O	-1	none	_	_
26	suggest	_	_	VBP	O	-1	none	_	_
27	that	_	_	IN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	more	_	_	RBR	O	-1	none	_	_
30	likely	_	_	JJ	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	Stat4	_	_	NN	Protein	-1	none	_	_
33	may	_	_	MD	O	-1	none	_	_
34	act	_	_	VB	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	induce	_	_	VB	O	-1	none	_	_
37	Th1	_	_	NN	O	-1	none	_	_
38	development	_	_	NN	O	-1	none	_	_
39	through	_	_	IN	O	-1	none	_	_
40	the	_	_	DT	O	-1	none	_	_
41	induction	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	other	_	_	JJ	O	-1	none	_	_
44	non	_	_	JJ	O	-1	none	_	_
45	cytokine	_	_	NN	O	-1	none	_	_
46	genes	_	_	NNS	O	-1	none	_	_
47	,	_	_	,	O	-1	none	_	_
48	whose	_	_	WP$	O	-1	none	_	_
49	stable	_	_	JJ	O	-1	none	_	_
50	expression	_	_	NN	O	-1	none	_	_
51	maintains	_	_	VBZ	O	-1	none	_	_
52	the	_	_	DT	O	-1	none	_	_
53	transcriptional	_	_	JJ	O	-1	none	_	_
54	state	_	_	NN	O	-1	none	_	_
55	of	_	_	IN	O	-1	none	_	_
56	a	_	_	DT	O	-1	none	_	_
57	Th1	_	_	NN	O	-1	none	_	_
58	cell	_	_	NN	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	56-59-kilodalton	_	_	JJ	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	identified	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	untransformed	_	_	JJ	O	-1	none	_	_
7	steroid	_	_	NN	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	complexes	_	_	NNS	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	unique	_	_	JJ	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	exists	_	_	VBZ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	cytosol	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	complex	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	both	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	70-	_	_	CD	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	90-kilodalton	_	_	JJ	Protein	29	multitoken	_	_
27	heat	_	_	NN	Protein	29	multitoken	_	_
28	shock	_	_	NN	Protein	29	multitoken	_	_
29	proteins	_	_	NNS	Protein	0	root	_	_
30	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	has	_	_	VBZ	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	been	_	_	VBN	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	9S	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	untransformed	_	_	JJ	O	-1	none	_	_
10	progestin	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	estrogen	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	androgen	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	glucocorticoid	_	_	NN	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	complexes	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	rabbit	_	_	NN	O	-1	none	_	_
22	uterine	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	liver	_	_	NN	O	-1	none	_	_
25	cytosols	_	_	NNS	O	-1	none	_	_
26	contain	_	_	VBP	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	59-kDa	_	_	JJ	O	-1	none	_	_
29	protein	_	_	NN	O	-1	none	_	_
30	[	_	_	CD	O	-1	none	_	_
31	Tai	_	_	NNP	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	P.K.	_	_	NNP	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	Maeda	_	_	NNP	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	Y.	_	_	NNP	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	Nakao	_	_	NNP	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	K.	_	_	NNP	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	Wakim	_	_	NNP	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	N.G.	_	_	NNP	O	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	Duhring	_	_	NNP	O	-1	none	_	_
48	,	_	_	,	O	-1	none	_	_
49	J.L.	_	_	NNP	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	&	_	_	CC	O	-1	none	_	_
52	Faber	_	_	NNP	O	-1	none	_	_
53	,	_	_	,	O	-1	none	_	_
54	L.E.	_	_	NNP	O	-1	none	_	_
55	(	_	_	-LRB-	O	-1	none	_	_
56	1986	_	_	CD	O	-1	none	_	_
57	)	_	_	-RRB-	O	-1	none	_	_
58	Biochemistry	_	_	NNP	O	-1	none	_	_
59	25	_	_	CD	O	-1	none	_	_
60	,	_	_	,	O	-1	none	_	_
61	5269-5275	_	_	CD	O	-1	none	_	_
62	]	_	_	NN	O	-1	none	_	_
63	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	work	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	monoclonal	_	_	JJ	O	-1	none	_	_
9	antibody	_	_	NN	O	-1	none	_	_
10	KN	_	_	NN	O	-1	none	_	_
11	382/EC1	_	_	NN	O	-1	none	_	_
12	raised	_	_	VBN	O	-1	none	_	_
13	against	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	rabbit	_	_	NN	O	-1	none	_	_
16	59-kDa	_	_	JJ	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	reacts	_	_	VBZ	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	9S	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	untransformed	_	_	JJ	O	-1	none	_	_
23	glucocorticoid	_	_	NN	O	-1	none	_	_
24	receptor	_	_	NN	O	-1	none	_	_
25	complexes	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	cytosol	_	_	NN	O	-1	none	_	_
28	prepared	_	_	VBN	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	human	_	_	NN	O	-1	none	_	_
31	IM-9	_	_	NN	O	-1	none	_	_
32	lymphocytes	_	_	NNS	O	-1	none	_	_
33	but	_	_	CC	O	-1	none	_	_
34	not	_	_	RB	O	-1	none	_	_
35	with	_	_	IN	O	-1	none	_	_
36	4S	_	_	NN	O	-1	none	_	_
37	salt	_	_	NN	O	-1	none	_	_
38	transformed	_	_	VBN	O	-1	none	_	_
39	receptors	_	_	NNS	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	protein	_	_	NN	O	-1	none	_	_
4	recognized	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	EC1	_	_	NN	O	-1	none	_	_
8	antibody	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	56-kDa	_	_	JJ	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	p56	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	moderate	_	_	JJ	O	-1	none	_	_
18	abundance	_	_	NN	O	-1	none	_	_
19	located	_	_	JJ	O	-1	none	_	_
20	predominantly	_	_	RB	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	cytoplasm	_	_	NN	O	-1	none	_	_
24	by	_	_	IN	O	-1	none	_	_
25	indirect	_	_	JJ	O	-1	none	_	_
26	immunofluorescence	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	at	_	_	IN	O	-1	none	_	_
4	least	_	_	JJS	O	-1	none	_	_
5	six	_	_	CD	O	-1	none	_	_
6	isomorphs	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	p56	_	_	NN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	two-dimensional	_	_	JJ	O	-1	none	_	_
11	gel	_	_	NN	O	-1	none	_	_
12	analysis	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	N-Terminal	_	_	NNP	O	-1	none	_	_
2	sequencing	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	20	_	_	CD	O	-1	none	_	_
5	amino	_	_	NN	O	-1	none	_	_
6	acids	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	shows	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	p56	_	_	NN	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	unique	_	_	JJ	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	When	_	_	WRB	O	-1	none	_	_
2	p56	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	immunoadsorbed	_	_	VBN	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	IM-9	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	cytosol	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	both	_	_	CC	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	70-	_	_	CD	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	90-kDa	_	_	JJ	Protein	17	multitoken	_	_
15	heat	_	_	NN	Protein	17	multitoken	_	_
16	shock	_	_	NN	Protein	17	multitoken	_	_
17	proteins	_	_	NNS	Protein	0	root	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	coadsorbed	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	an	_	_	DT	O	-1	none	_	_
22	immune	_	_	JJ	O	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	manner	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Neither	_	_	DT	O	-1	none	_	_
2	heat	_	_	NN	O	-1	none	_	_
3	shock	_	_	NN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	reacts	_	_	VBZ	O	-1	none	_	_
6	directly	_	_	RB	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	EC1	_	_	NN	O	-1	none	_	_
10	antibody	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	p56	_	_	NN	O	-1	none	_	_
5	exists	_	_	VBZ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	cytosol	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	higher	_	_	JJR	O	-1	none	_	_
11	order	_	_	NN	O	-1	none	_	_
12	complex	_	_	NN	O	-1	none	_	_
13	containing	_	_	VBG	O	-1	none	_	_
14	hsp70	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	hsp90	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	both	_	_	DT	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	which	_	_	WDT	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	turn	_	_	NN	O	-1	none	_	_
23	have	_	_	VBP	O	-1	none	_	_
24	been	_	_	VBN	O	-1	none	_	_
25	found	_	_	VBN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	be	_	_	VB	O	-1	none	_	_
28	associated	_	_	VBN	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	untransformed	_	_	JJ	O	-1	none	_	_
31	steroid	_	_	NN	O	-1	none	_	_
32	receptors	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Multiple	_	_	JJ	O	-1	none	_	_
2	NF-ATc	_	_	NN	Protein	-1	none	_	_
3	isoforms	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	individual	_	_	JJ	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	properties	_	_	NNS	O	-1	none	_	_
8	are	_	_	VBP	O	-1	none	_	_
9	synthesized	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transcription	_	_	NN	O	-1	none	_	_
3	factor	_	_	NN	O	-1	none	_	_
4	NF-ATc	_	_	NN	Protein	-1	none	_	_
5	that	_	_	WDT	O	-1	none	_	_
6	controls	_	_	VBZ	O	-1	none	_	_
7	gene	_	_	NN	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	lymphocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	embryonic	_	_	JJ	O	-1	none	_	_
14	cardiac	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	expressed	_	_	VBN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	three	_	_	CD	O	-1	none	_	_
20	prominent	_	_	JJ	O	-1	none	_	_
21	isoforms	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	due	_	_	JJ	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	alternative	_	_	JJ	O	-1	none	_	_
6	splice	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	polyadenylation	_	_	NN	O	-1	none	_	_
9	events	_	_	NNS	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	lead	_	_	VBP	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	predominant	_	_	JJ	O	-1	none	_	_
15	synthesis	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	two	_	_	CD	O	-1	none	_	_
18	long	_	_	JJ	O	-1	none	_	_
19	isoforms	_	_	NNS	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	naive	_	_	JJ	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	shorter	_	_	JJR	O	-1	none	_	_
27	NF-ATc	_	_	NN	Protein	-1	none	_	_
28	isoform	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	effector	_	_	NN	O	-1	none	_	_
31	T	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Various	_	_	JJ	O	-1	none	_	_
2	stimuli	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	induce	_	_	VBP	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TAD-A	_	_	NN	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	enhance	_	_	VBP	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	activity	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	TAD-B	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	unlike	_	_	IN	O	-1	none	_	_
22	TAD-A	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	TAD-B	_	_	NN	O	-1	none	_	_
25	remains	_	_	VBZ	O	-1	none	_	_
26	unphosphorylated	_	_	JJ	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	protein	_	_	NN	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	12-O-tetradecanoyl	_	_	NN	O	-1	none	_	_
31	12-phorbol	_	_	NN	O	-1	none	_	_
32	13-acetate-stimulated	_	_	JJ	O	-1	none	_	_
33	T	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	c-rel	_	_	NN	Protein	-1	none	_	_
3	protooncogene	_	_	NN	O	-1	none	_	_
4	product	_	_	NN	O	-1	none	_	_
5	represses	_	_	VBZ	O	-1	none	_	_
6	NF-kappa	_	_	NN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	p65	_	_	NN	Protein	-1	none	_	_
9	mediated	_	_	VBN	O	-1	none	_	_
10	transcriptional	_	_	JJ	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	long	_	_	JJ	O	-1	none	_	_
15	terminal	_	_	JJ	O	-1	none	_	_
16	repeat	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	type	_	_	NN	O	-1	none	_	_
19	1	_	_	CD	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	immunodeficiency	_	_	NN	O	-1	none	_	_
22	virus	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	long	_	_	JJ	O	-1	none	_	_
3	terminal	_	_	JJ	O	-1	none	_	_
4	repeat	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	LTR	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	type	_	_	NN	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	immunodeficiency	_	_	NN	O	-1	none	_	_
14	virus	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	HIV-1	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	5	_	_	CD	O	-1	none	_	_
21	'	_	_	''	O	-1	none	_	_
22	regulatory	_	_	JJ	O	-1	none	_	_
23	region	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	gene	_	_	NN	O	-1	none	_	_
27	encoding	_	_	VBG	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	interleukin	_	_	NN	Protein	33	multitoken	_	_
30	2	_	_	CD	Protein	33	multitoken	_	_
31	receptor	_	_	NN	Protein	33	multitoken	_	_
32	alpha	_	_	NN	Protein	33	multitoken	_	_
33	subunit	_	_	NN	Protein	0	root	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	IL-2R	_	_	NN	Protein	36	multitoken	_	_
36	alpha	_	_	NN	Protein	0	root	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	share	_	_	NN	O	-1	none	_	_
39	functional	_	_	JJ	O	-1	none	_	_
40	kappa	_	_	NN	O	-1	none	_	_
41	B	_	_	NN	O	-1	none	_	_
42	enhancer	_	_	NN	O	-1	none	_	_
43	elements	_	_	NNS	O	-1	none	_	_
44	involved	_	_	VBN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	the	_	_	DT	O	-1	none	_	_
47	regulation	_	_	NN	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	these	_	_	DT	O	-1	none	_	_
50	inducible	_	_	JJ	O	-1	none	_	_
51	transcription	_	_	NN	O	-1	none	_	_
52	units	_	_	NNS	O	-1	none	_	_
53	during	_	_	IN	O	-1	none	_	_
54	T-cell	_	_	NN	O	-1	none	_	_
55	activation	_	_	NN	O	-1	none	_	_
56	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	kappa	_	_	NN	O	-1	none	_	_
3	B	_	_	NN	O	-1	none	_	_
4	enhancer	_	_	NN	O	-1	none	_	_
5	elements	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	recognized	_	_	VBN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	structurally	_	_	RB	O	-1	none	_	_
11	related	_	_	JJ	O	-1	none	_	_
12	family	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	interactive	_	_	JJ	O	-1	none	_	_
15	proteins	_	_	NNS	O	-1	none	_	_
16	that	_	_	WDT	O	-1	none	_	_
17	includes	_	_	VBZ	O	-1	none	_	_
18	p50	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	p65	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	product	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	c-rel	_	_	NN	Protein	-1	none	_	_
28	protooncogene	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	c-Rel	_	_	NN	Protein	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Recent	_	_	JJ	O	-1	none	_	_
2	biochemical	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	shown	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	p65	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	p50	_	_	NN	Protein	-1	none	_	_
10	form	_	_	VBP	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	prototypical	_	_	JJ	O	-1	none	_	_
13	NF-kappa	_	_	NN	O	-1	none	_	_
14	B	_	_	NN	O	-1	none	_	_
15	complex	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	rapidly	_	_	RB	O	-1	none	_	_
20	translocated	_	_	VBN	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	cytoplasm	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	nucleus	_	_	NN	O	-1	none	_	_
27	during	_	_	IN	O	-1	none	_	_
28	T-cell	_	_	NN	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	intracellular	_	_	JJ	O	-1	none	_	_
3	signaling	_	_	NN	O	-1	none	_	_
4	complex	_	_	NN	O	-1	none	_	_
5	potently	_	_	RB	O	-1	none	_	_
6	stimulates	_	_	VBZ	O	-1	none	_	_
7	kappa	_	_	NN	O	-1	none	_	_
8	B	_	_	NN	O	-1	none	_	_
9	directed	_	_	VBD	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	either	_	_	CC	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	HIV-1	_	_	NN	O	-1	none	_	_
15	LTR	_	_	NN	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	IL-2R	_	_	NN	Protein	19	multitoken	_	_
19	alpha	_	_	NN	Protein	0	root	_	_
20	promoter	_	_	NN	O	-1	none	_	_
21	via	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	strong	_	_	JJ	O	-1	none	_	_
24	transactivation	_	_	NN	O	-1	none	_	_
25	domain	_	_	NN	O	-1	none	_	_
26	present	_	_	JJ	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	p65	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	nuclear	_	_	JJ	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	c-Rel	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	either	_	_	CC	O	-1	none	_	_
16	phorbol	_	_	NN	O	-1	none	_	_
17	ester	_	_	NN	O	-1	none	_	_
18	or	_	_	CC	O	-1	none	_	_
19	tumor	_	_	NN	Protein	22	multitoken	_	_
20	necrosis	_	_	NN	Protein	22	multitoken	_	_
21	factor	_	_	NN	Protein	22	multitoken	_	_
22	alpha	_	_	NN	Protein	0	root	_	_
23	with	_	_	IN	O	-1	none	_	_
24	delayed	_	_	VBN	O	-1	none	_	_
25	kinetics	_	_	NNS	O	-1	none	_	_
26	relative	_	_	JJ	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	p65	_	_	NN	Protein	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	markedly	_	_	RB	O	-1	none	_	_
31	represses	_	_	VBZ	O	-1	none	_	_
32	p65	_	_	NN	Protein	-1	none	_	_
33	mediated	_	_	JJ	O	-1	none	_	_
34	activation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	these	_	_	DT	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	units	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	effects	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	c-Rel	_	_	NN	Protein	-1	none	_	_
6	correlate	_	_	VBP	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	its	_	_	PRP$	O	-1	none	_	_
9	DNA	_	_	NN	O	-1	none	_	_
10	binding	_	_	NN	O	-1	none	_	_
11	activity	_	_	NN	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	its	_	_	PRP$	O	-1	none	_	_
16	ability	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	heterodimerize	_	_	VB	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	p50	_	_	NN	Protein	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	suggesting	_	_	VBG	O	-1	none	_	_
23	that	_	_	IN	O	-1	none	_	_
24	c-Rel	_	_	NN	Protein	-1	none	_	_
25	inhibition	_	_	NN	O	-1	none	_	_
26	involves	_	_	VBZ	O	-1	none	_	_
27	competition	_	_	NN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	p50	_	_	NN	Protein	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	p65	_	_	NN	Protein	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	occupancy	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	kappa	_	_	NN	O	-1	none	_	_
37	B	_	_	NN	O	-1	none	_	_
38	enhancer	_	_	NN	O	-1	none	_	_
39	element	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Together	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	suggest	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	one	_	_	CD	O	-1	none	_	_
8	function	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	c-Rel	_	_	NN	Protein	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	physiologic	_	_	JJ	O	-1	none	_	_
15	repressor	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	HIV-1	_	_	NN	O	-1	none	_	_
19	LTR	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	IL-2R	_	_	NN	Protein	22	multitoken	_	_
22	alpha	_	_	NN	Protein	0	root	_	_
23	promoters	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	serving	_	_	VBG	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	efficiently	_	_	RB	O	-1	none	_	_
28	counter	_	_	VB	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	strong	_	_	JJ	O	-1	none	_	_
31	transcriptional	_	_	JJ	O	-1	none	_	_
32	activating	_	_	NN	O	-1	none	_	_
33	effects	_	_	NNS	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	p65	_	_	NN	Protein	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Staphylococcal	_	_	JJ	O	-1	none	_	_
2	enterotoxins	_	_	NNS	O	-1	none	_	_
3	modulate	_	_	VBP	O	-1	none	_	_
4	interleukin	_	_	NN	O	-1	none	_	_
5	2	_	_	CD	O	-1	none	_	_
6	receptor	_	_	NN	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	ligand	_	_	NN	O	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	tyrosine	_	_	NN	O	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	Janus	_	_	NN	Protein	18	multitoken	_	_
16	protein-tyrosine	_	_	NN	Protein	18	multitoken	_	_
17	kinase	_	_	NN	Protein	18	multitoken	_	_
18	3	_	_	CD	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	Jak3	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	signal	_	_	NN	O	-1	none	_	_
24	transducers	_	_	NNS	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	activators	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	Stat	_	_	NN	O	-1	none	_	_
31	proteins	_	_	NNS	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Staphylococcal	_	_	JJ	O	-1	none	_	_
2	enterotoxins	_	_	NNS	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	SE	_	_	NN	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	stimulate	_	_	VBP	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	expressing	_	_	VBG	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	appropriate	_	_	JJ	O	-1	none	_	_
12	variable	_	_	JJ	O	-1	none	_	_
13	region	_	_	NN	O	-1	none	_	_
14	beta	_	_	NN	O	-1	none	_	_
15	chain	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	V	_	_	NN	O	-1	none	_	_
19	beta	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	T-cell	_	_	NN	O	-1	none	_	_
22	receptors	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	have	_	_	VBP	O	-1	none	_	_
25	been	_	_	VBN	O	-1	none	_	_
26	implicated	_	_	VBN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	pathogenesis	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	several	_	_	JJ	O	-1	none	_	_
32	autoimmune	_	_	JJ	O	-1	none	_	_
33	diseases	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Depending	_	_	VBG	O	-1	none	_	_
2	on	_	_	IN	O	-1	none	_	_
3	costimulatory	_	_	JJ	O	-1	none	_	_
4	signals	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	SE	_	_	NN	O	-1	none	_	_
7	induce	_	_	VBP	O	-1	none	_	_
8	either	_	_	CC	O	-1	none	_	_
9	proliferation	_	_	NN	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	anergy	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	SE	_	_	NN	O	-1	none	_	_
5	can	_	_	MD	O	-1	none	_	_
6	induce	_	_	VB	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	interleukin-2	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	IL-2	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	nonresponsive	_	_	JJ	O	-1	none	_	_
13	state	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	apoptosis	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	after	_	_	IN	O	-1	none	_	_
4	4	_	_	CD	O	-1	none	_	_
5	hr	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	exposure	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	SEA	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	SEB	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	IL-2R	_	_	NN	Protein	17	multitoken	_	_
17	beta	_	_	NN	Protein	0	root	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	down-regulated	_	_	VBN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	IL-2R	_	_	NN	Protein	22	multitoken	_	_
22	gamma	_	_	NN	Protein	0	root	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	slightly	_	_	RB	O	-1	none	_	_
25	up-regulated	_	_	VBN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	while	_	_	IN	O	-1	none	_	_
28	IL-2R	_	_	NN	Protein	29	multitoken	_	_
29	alpha	_	_	NN	Protein	0	root	_	_
30	remained	_	_	VBD	O	-1	none	_	_
31	largely	_	_	RB	O	-1	none	_	_
32	unaffected	_	_	JJ	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	After	_	_	IN	O	-1	none	_	_
2	16	_	_	CD	O	-1	none	_	_
3	hr	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	exposure	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	SE	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	IL-2R	_	_	NN	Protein	13	multitoken	_	_
13	beta	_	_	NN	Protein	0	root	_	_
14	remained	_	_	VBD	O	-1	none	_	_
15	low	_	_	JJ	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	while	_	_	IN	O	-1	none	_	_
18	that	_	_	DT	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	IL2R	_	_	NN	Protein	21	multitoken	_	_
21	alpha	_	_	NN	Protein	0	root	_	_
22	and	_	_	CC	O	-1	none	_	_
23	IL2R	_	_	NN	Protein	24	multitoken	_	_
24	gamma	_	_	NN	Protein	0	root	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	further	_	_	JJ	O	-1	none	_	_
27	up-regulated	_	_	VBN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	ligand	_	_	NN	O	-1	none	_	_
31	induced	_	_	VBD	O	-1	none	_	_
32	tyrosine	_	_	NN	O	-1	none	_	_
33	phosphorylation	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	Jak3	_	_	NN	Protein	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	Stat	_	_	NN	O	-1	none	_	_
38	proteins	_	_	NNS	O	-1	none	_	_
39	was	_	_	VBD	O	-1	none	_	_
40	partly	_	_	RB	O	-1	none	_	_
41	normalized	_	_	VBN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	[	_	_	NN	O	-1	none	_	_
2	Induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	apoptosis	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	glucocorticoids	_	_	NNS	O	-1	none	_	_
9	:	_	_	:	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	physiology	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	pharmacology	_	_	NN	O	-1	none	_	_
14	]	_	_	CD	O	-1	none	_	_
15	Glucocorticoids	_	_	NNS	O	-1	none	_	_
16	are	_	_	VBP	O	-1	none	_	_
17	physiological	_	_	JJ	O	-1	none	_	_
18	molecules	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	extensively	_	_	RB	O	-1	none	_	_
23	used	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	clinics	_	_	NNS	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	anti-inflammatory	_	_	JJ	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	immunosuppressive	_	_	JJ	O	-1	none	_	_
30	or	_	_	CC	O	-1	none	_	_
31	anti-tumoral	_	_	JJ	O	-1	none	_	_
32	agents	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Glucocorticoids	_	_	NNS	O	-1	none	_	_
2	can	_	_	MD	O	-1	none	_	_
3	induce	_	_	VB	O	-1	none	_	_
4	apoptosis	_	_	NN	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	normal	_	_	JJ	O	-1	none	_	_
7	lymphoid	_	_	JJ	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	play	_	_	VB	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	key	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	physiology	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	thymic	_	_	JJ	O	-1	none	_	_
19	selection	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	clinics	_	_	NNS	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	molecules	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	used	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	their	_	_	PRP$	O	-1	none	_	_
10	potencies	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	inducing	_	_	VBG	O	-1	none	_	_
13	apoptosis	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	malignant	_	_	JJ	O	-1	none	_	_
16	lymphoid	_	_	JJ	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Glucocorticoids	_	_	NNS	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	mediating	_	_	VBG	O	-1	none	_	_
4	their	_	_	PRP$	O	-1	none	_	_
5	effects	_	_	NNS	O	-1	none	_	_
6	after	_	_	IN	O	-1	none	_	_
7	binding	_	_	VBG	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	intracellular	_	_	JJ	O	-1	none	_	_
11	receptor	_	_	NN	O	-1	none	_	_
12	belonging	_	_	VBG	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	steroid	_	_	NN	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	superfamily	_	_	NN	O	-1	none	_	_
18	:	_	_	:	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	glucocorticoid	_	_	NN	Protein	21	multitoken	_	_
21	receptor	_	_	NN	Protein	0	root	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	GR	_	_	NN	Protein	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Once	_	_	RB	O	-1	none	_	_
2	activated	_	_	VBN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	GR	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	can	_	_	MD	O	-1	none	_	_
8	mediate	_	_	VB	O	-1	none	_	_
9	his	_	_	PRP$	O	-1	none	_	_
10	effects	_	_	NNS	O	-1	none	_	_
11	through	_	_	IN	O	-1	none	_	_
12	direct	_	_	JJ	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	via	_	_	IN	O	-1	none	_	_
19	protein/protein	_	_	NN	O	-1	none	_	_
20	interactions	_	_	NNS	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	transcription	_	_	NN	O	-1	none	_	_
23	factors	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Depending	_	_	VBG	O	-1	none	_	_
2	on	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	type	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	lymphocytes	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	mechanism	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	apoptosis	_	_	NN	O	-1	none	_	_
12	induced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	glucocorticoids	_	_	NNS	O	-1	none	_	_
15	fall	_	_	VBP	O	-1	none	_	_
16	roughly	_	_	RB	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	two	_	_	CD	O	-1	none	_	_
19	categories	_	_	NNS	O	-1	none	_	_
20	:	_	_	:	O	-1	none	_	_
21	induction	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	"	_	_	``	O	-1	none	_	_
24	death	_	_	NN	O	-1	none	_	_
25	genes	_	_	NNS	O	-1	none	_	_
26	"	_	_	''	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	activated	_	_	JJ	O	-1	none	_	_
30	GR	_	_	NN	Protein	-1	none	_	_
31	(	_	_	-LRB-	O	-1	none	_	_
32	I	_	_	NN	O	-1	none	_	_
33	kappa	_	_	NN	O	-1	none	_	_
34	B	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	c-jun	_	_	NN	Protein	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	or	_	_	CC	O	-1	none	_	_
39	repression	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	survival	_	_	NN	O	-1	none	_	_
42	factors	_	_	NNS	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	AP-1	_	_	NN	O	-1	none	_	_
45	,	_	_	,	O	-1	none	_	_
46	c-Myc	_	_	NN	Protein	-1	none	_	_
47	)	_	_	-RRB-	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	case	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	thymic	_	_	JJ	O	-1	none	_	_
6	selection	_	_	NN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	mechanism	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	more	_	_	RBR	O	-1	none	_	_
11	subtle	_	_	JJ	O	-1	none	_	_
12	depending	_	_	VBG	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	mutual	_	_	JJ	O	-1	none	_	_
16	repression	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	Nur77	_	_	NN	Protein	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	GR	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Mice	_	_	NNS	O	-1	none	_	_
2	deficient	_	_	JJ	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	55	_	_	CD	Protein	10	multitoken	_	_
6	kd	_	_	NN	Protein	10	multitoken	_	_
7	tumor	_	_	NN	Protein	10	multitoken	_	_
8	necrosis	_	_	NN	Protein	10	multitoken	_	_
9	factor	_	_	NN	Protein	10	multitoken	_	_
10	receptor	_	_	NN	Protein	0	root	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	resistant	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	endotoxic	_	_	JJ	O	-1	none	_	_
15	shock	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	yet	_	_	RB	O	-1	none	_	_
18	succumb	_	_	VBP	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	L.	_	_	FW	O	-1	none	_	_
21	monocytogenes	_	_	FW	O	-1	none	_	_
22	infection	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	multiple	_	_	JJ	O	-1	none	_	_
3	biological	_	_	JJ	O	-1	none	_	_
4	activities	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	tumor	_	_	NN	O	-1	none	_	_
7	necrosis	_	_	NN	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	TNF	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	are	_	_	VBP	O	-1	none	_	_
13	mediated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	two	_	_	CD	O	-1	none	_	_
16	distinct	_	_	JJ	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	surface	_	_	NN	O	-1	none	_	_
19	receptors	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	55	_	_	CD	O	-1	none	_	_
22	kd	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	TNFRp55	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	75	_	_	CD	O	-1	none	_	_
28	kd	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	TNFRp75	_	_	NN	Protein	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	gene	_	_	NN	O	-1	none	_	_
3	targeting	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	generated	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	TNFRp55	_	_	NN	Protein	-1	none	_	_
9	deficient	_	_	JJ	O	-1	none	_	_
10	mouse	_	_	NN	O	-1	none	_	_
11	strain	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Thymocyte	_	_	NN	O	-1	none	_	_
2	development	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	lymphocyte	_	_	NN	O	-1	none	_	_
5	populations	_	_	NNS	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	unaltered	_	_	JJ	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	clonal	_	_	JJ	O	-1	none	_	_
11	deletion	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	potentially	_	_	RB	O	-1	none	_	_
14	self-reactive	_	_	JJ	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	impaired	_	_	JJ	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	TNF	_	_	NN	O	-1	none	_	_
4	signaling	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	largely	_	_	RB	O	-1	none	_	_
7	abolished	_	_	VBN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	as	_	_	IN	O	-1	none	_	_
10	judged	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	failure	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	TNF	_	_	NN	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	induce	_	_	VB	O	-1	none	_	_
18	NF-kappa	_	_	NN	O	-1	none	_	_
19	B	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	lymphocytes	_	_	NNS	O	-1	none	_	_
23	from	_	_	IN	O	-1	none	_	_
24	TNFRp55	_	_	NN	Protein	-1	none	_	_
25	deficient	_	_	JJ	O	-1	none	_	_
26	mice	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	loss	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TNFRp55	_	_	NN	Protein	-1	none	_	_
5	function	_	_	NN	O	-1	none	_	_
6	renders	_	_	VBZ	O	-1	none	_	_
7	mice	_	_	NNS	O	-1	none	_	_
8	resistant	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	lethal	_	_	JJ	O	-1	none	_	_
11	dosages	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	either	_	_	CC	O	-1	none	_	_
14	lipopolysaccharides	_	_	NNS	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	S.	_	_	FW	O	-1	none	_	_
17	aureus	_	_	FW	O	-1	none	_	_
18	enterotoxin	_	_	NN	Protein	19	multitoken	_	_
19	B	_	_	NN	Protein	0	root	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	TNFRp55	_	_	NN	Protein	-1	none	_	_
5	deficient	_	_	JJ	O	-1	none	_	_
6	mice	_	_	NNS	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	severely	_	_	RB	O	-1	none	_	_
9	impaired	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	clear	_	_	JJ	O	-1	none	_	_
12	L.	_	_	FW	O	-1	none	_	_
13	monocytogenes	_	_	FW	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	readily	_	_	RB	O	-1	none	_	_
16	succumb	_	_	VBP	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	infection	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	55	_	_	CD	Protein	6	multitoken	_	_
5	kd	_	_	NN	Protein	6	multitoken	_	_
6	TNFR	_	_	NN	Protein	0	root	_	_
7	plays	_	_	VBZ	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	decisive	_	_	JJ	O	-1	none	_	_
10	role	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	host	_	_	NN	O	-1	none	_	_
14	's	_	_	POS	O	-1	none	_	_
15	defense	_	_	NN	O	-1	none	_	_
16	against	_	_	IN	O	-1	none	_	_
17	microorganisms	_	_	NNS	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	their	_	_	PRP$	O	-1	none	_	_
20	pathogenic	_	_	JJ	O	-1	none	_	_
21	factors	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Lineage	_	_	NN	O	-1	none	_	_
2	specific	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	STAT3	_	_	NN	Protein	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	interferon-gamma	_	_	NN	Protein	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	neutrophils	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Binding	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	interferon-gamma	_	_	NN	Protein	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	IFN-gamma	_	_	NN	Protein	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	its	_	_	PRP$	O	-1	none	_	_
9	heterodimeric	_	_	JJ	O	-1	none	_	_
10	receptor	_	_	NN	O	-1	none	_	_
11	induces	_	_	VBZ	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	kinases	_	_	NNS	O	-1	none	_	_
17	JAK1	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	JAK2	_	_	NN	Protein	-1	none	_	_
20	followed	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	tyrosine	_	_	NN	O	-1	none	_	_
23	phosphorylation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	STAT1alpha	_	_	NN	Protein	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Selective	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STAT1alpha	_	_	NN	Protein	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	IFN-gamma	_	_	NN	Protein	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	achieved	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	interaction	_	_	NN	O	-1	none	_	_
14	between	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	cytosolic	_	_	JJ	O	-1	none	_	_
17	tyrosine	_	_	NN	O	-1	none	_	_
18	motif	_	_	NN	O	-1	none	_	_
19	including	_	_	VBG	O	-1	none	_	_
20	Y440	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	IFN-gamma	_	_	NN	Protein	25	multitoken	_	_
24	receptor	_	_	NN	Protein	25	multitoken	_	_
25	alpha-chain	_	_	NN	Protein	0	root	_	_
26	and	_	_	CC	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	SH2	_	_	NN	O	-1	none	_	_
29	domain	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	STAT1alpha	_	_	NN	Protein	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	addition	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	STAT1alpha	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	STAT3	_	_	NN	Protein	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	activated	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	IFN-gamma	_	_	NN	Protein	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	neutrophils	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STAT3	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	found	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	eosinophils	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	monocytes	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	HL-60	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	although	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	STAT3	_	_	NN	Protein	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	expressed	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	single	_	_	JJ	O	-1	none	_	_
7	cytokine	_	_	NN	O	-1	none	_	_
8	receptor	_	_	NN	O	-1	none	_	_
9	can	_	_	MD	O	-1	none	_	_
10	activate	_	_	VB	O	-1	none	_	_
11	different	_	_	JJ	O	-1	none	_	_
12	STAT	_	_	NN	O	-1	none	_	_
13	family	_	_	NN	O	-1	none	_	_
14	members	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	cell	_	_	NN	O	-1	none	_	_
18	specific	_	_	JJ	O	-1	none	_	_
19	manner	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	might	_	_	MD	O	-1	none	_	_
23	result	_	_	VB	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	specific	_	_	JJ	O	-1	none	_	_
27	gene	_	_	NN	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Tumor	_	_	NN	Protein	4	multitoken	_	_
2	necrosis	_	_	NN	Protein	4	multitoken	_	_
3	factor	_	_	NN	Protein	4	multitoken	_	_
4	alpha	_	_	NN	Protein	0	root	_	_
5	decreases	_	_	VBZ	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	interleukin-10	_	_	NN	Protein	-1	none	_	_
9	increases	_	_	NNS	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	sensitivity	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	human	_	_	NN	O	-1	none	_	_
15	monocytes	_	_	NNS	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	dexamethasone	_	_	NN	O	-1	none	_	_
18	:	_	_	:	O	-1	none	_	_
19	potential	_	_	JJ	O	-1	none	_	_
20	regulation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	glucocorticoid	_	_	NN	Protein	24	multitoken	_	_
24	receptor	_	_	NN	Protein	0	root	_	_
25	.	_	_	.	O	-1	none	_	_

1	Resistance	_	_	NN	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	glucocorticoid	_	_	NN	O	-1	none	_	_
4	therapy	_	_	NN	O	-1	none	_	_
5	has	_	_	VBZ	O	-1	none	_	_
6	been	_	_	VBN	O	-1	none	_	_
7	observed	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	patients	_	_	NNS	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	autoimmune	_	_	JJ	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	inflammatory	_	_	JJ	O	-1	none	_	_
14	diseases	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	may	_	_	MD	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	related	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	inflammatory	_	_	JJ	O	-1	none	_	_
22	process	_	_	NN	O	-1	none	_	_
23	itself	_	_	PRP	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aim	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	examine	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	ability	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	tumor	_	_	NN	Protein	15	multitoken	_	_
13	necrosis	_	_	NN	Protein	15	multitoken	_	_
14	factor	_	_	NN	Protein	15	multitoken	_	_
15	alpha	_	_	NN	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	TNFalpha	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	proinflammatory	_	_	JJ	O	-1	none	_	_
21	cytokine	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	interleukin	_	_	NN	Protein	28	multitoken	_	_
25	(	_	_	-LRB-	Protein	28	multitoken	_	_
26	IL	_	_	NN	Protein	28	multitoken	_	_
27	)	_	_	-RRB-	Protein	28	multitoken	_	_
28	-10	_	_	CD	Protein	0	root	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	anti-inflammatory	_	_	JJ	O	-1	none	_	_
32	cytokine	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	to	_	_	TO	O	-1	none	_	_
35	differentially	_	_	RB	O	-1	none	_	_
36	regulate	_	_	VB	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	sensitivity	_	_	NN	O	-1	none	_	_
39	of	_	_	IN	O	-1	none	_	_
40	human	_	_	NN	O	-1	none	_	_
41	monocytes	_	_	NNS	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	macrophages	_	_	NNS	O	-1	none	_	_
44	to	_	_	TO	O	-1	none	_	_
45	glucocorticoids	_	_	NNS	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	accomplish	_	_	VB	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	first	_	_	RB	O	-1	none	_	_
7	analyzed	_	_	VBD	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	pattern	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	TNFalpha	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	IL-10	_	_	NN	Protein	-1	none	_	_
14	inhibition	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	dexamethasone	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	LPS	_	_	NN	O	-1	none	_	_
19	stimulated	_	_	VBD	O	-1	none	_	_
20	whole-blood	_	_	JJ	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	cultures	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Second	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	studied	_	_	VBD	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	modulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	sensitivity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	dexamethasone	_	_	NN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	preincubation	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	TNFalpha	_	_	NN	Protein	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	IL-10	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	measurement	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	LPS	_	_	NN	O	-1	none	_	_
25	stimulated	_	_	VBD	O	-1	none	_	_
26	IL-6	_	_	NN	Protein	-1	none	_	_
27	secretion	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	evaluated	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	dexamethasone	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	phorbolmyristate-acetate-stimulated	_	_	JJ	O	-1	none	_	_
12	IL-1	_	_	NN	Protein	14	multitoken	_	_
13	receptor	_	_	NN	Protein	14	multitoken	_	_
14	antagonist	_	_	NN	Protein	0	root	_	_
15	secretion	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	monocytic	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	line	_	_	NN	O	-1	none	_	_
22	U937	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Dexamethasone	_	_	NN	O	-1	none	_	_
2	had	_	_	VBD	O	-1	none	_	_
3	different	_	_	JJ	O	-1	none	_	_
4	effects	_	_	NNS	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	induced	_	_	VBD	O	-1	none	_	_
8	TNFalpha	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	IL-10	_	_	NN	Protein	-1	none	_	_
11	secretion	_	_	NN	O	-1	none	_	_
12	;	_	_	:	O	-1	none	_	_
13	whereas	_	_	IN	O	-1	none	_	_
14	it	_	_	PRP	O	-1	none	_	_
15	suppressed	_	_	VBD	O	-1	none	_	_
16	TNFalpha	_	_	NN	Protein	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	dose	_	_	NN	O	-1	none	_	_
20	dependent	_	_	JJ	O	-1	none	_	_
21	fashion	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	its	_	_	PRP$	O	-1	none	_	_
24	effect	_	_	NN	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	IL-10	_	_	NN	Protein	-1	none	_	_
27	secretion	_	_	NN	O	-1	none	_	_
28	was	_	_	VBD	O	-1	none	_	_
29	biphasic	_	_	JJ	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	producing	_	_	VBG	O	-1	none	_	_
32	stimulation	_	_	NN	O	-1	none	_	_
33	at	_	_	IN	O	-1	none	_	_
34	lower	_	_	JJR	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	inhibition	_	_	NN	O	-1	none	_	_
38	at	_	_	IN	O	-1	none	_	_
39	higher	_	_	JJR	O	-1	none	_	_
40	doses	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	concentration	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	LPS	_	_	NN	O	-1	none	_	_
5	employed	_	_	VBN	O	-1	none	_	_
6	influenced	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	effect	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	dexamethasone	_	_	NN	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	IL-10	_	_	NN	Protein	-1	none	_	_
13	secretion	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	P	_	_	NN	O	-1	none	_	_
16	<	_	_	JJR	O	-1	none	_	_
17	0.001	_	_	CD	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Pretreatment	_	_	NN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	TNFalpha	_	_	NN	Protein	-1	none	_	_
4	diminished	_	_	VBD	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	IL-10	_	_	NN	Protein	-1	none	_	_
9	improved	_	_	VBD	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	ability	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	dexamethasone	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	suppress	_	_	VB	O	-1	none	_	_
17	IL-6	_	_	NN	Protein	-1	none	_	_
18	secretion	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	whole-blood	_	_	JJ	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	cultures	_	_	NNS	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	P	_	_	NN	O	-1	none	_	_
25	<	_	_	JJR	O	-1	none	_	_
26	0.01	_	_	CD	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	both	_	_	CC	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	enhance	_	_	VB	O	-1	none	_	_
33	IL-1	_	_	NN	Protein	35	multitoken	_	_
34	receptor	_	_	NN	Protein	35	multitoken	_	_
35	antagonist	_	_	NN	Protein	0	root	_	_
36	secretion	_	_	NN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	U937	_	_	NN	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	(	_	_	-LRB-	O	-1	none	_	_
41	P	_	_	NN	O	-1	none	_	_
42	<	_	_	JJR	O	-1	none	_	_
43	0.05	_	_	CD	O	-1	none	_	_
44	for	_	_	IN	O	-1	none	_	_
45	both	_	_	CC	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	TNFalpha	_	_	NN	Protein	-1	none	_	_
2	decreased	_	_	VBD	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	P	_	_	NN	O	-1	none	_	_
5	<	_	_	JJR	O	-1	none	_	_
6	0.001	_	_	CD	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	while	_	_	IN	O	-1	none	_	_
10	IL-10	_	_	NN	Protein	-1	none	_	_
11	increased	_	_	VBD	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	P	_	_	NN	O	-1	none	_	_
14	<	_	_	JJR	O	-1	none	_	_
15	0.001	_	_	CD	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	concentration	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	dexamethasone	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	sites	_	_	NNS	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	no	_	_	DT	O	-1	none	_	_
30	discernible	_	_	JJ	O	-1	none	_	_
31	effect	_	_	NN	O	-1	none	_	_
32	on	_	_	IN	O	-1	none	_	_
33	their	_	_	PRP$	O	-1	none	_	_
34	binding	_	_	NN	O	-1	none	_	_
35	affinity	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	glucocorticoids	_	_	NNS	O	-1	none	_	_
5	differentially	_	_	RB	O	-1	none	_	_
6	modulate	_	_	VBP	O	-1	none	_	_
7	TNFalpha	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	IL-10	_	_	NN	Protein	-1	none	_	_
10	secretion	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	monocytes	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	dose	_	_	NN	O	-1	none	_	_
18	dependent	_	_	JJ	O	-1	none	_	_
19	fashion	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	sensitivity	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	these	_	_	DT	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	glucocorticoids	_	_	NNS	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	altered	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	TNFalpha	_	_	NN	Protein	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	IL-10	_	_	NN	Protein	-1	none	_	_
35	pretreatment	_	_	NN	O	-1	none	_	_
36	;	_	_	:	O	-1	none	_	_
37	TNFalpha	_	_	NN	Protein	-1	none	_	_
38	blocks	_	_	VBZ	O	-1	none	_	_
39	their	_	_	PRP$	O	-1	none	_	_
40	effects	_	_	NNS	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	whereas	_	_	IN	O	-1	none	_	_
43	IL-10	_	_	NN	Protein	-1	none	_	_
44	acts	_	_	VBZ	O	-1	none	_	_
45	synergistically	_	_	RB	O	-1	none	_	_
46	with	_	_	IN	O	-1	none	_	_
47	glucocorticoids	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	accompanied	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	opposite	_	_	JJ	O	-1	none	_	_
6	glucocorticoid	_	_	NN	Protein	7	multitoken	_	_
7	receptor	_	_	NN	Protein	0	root	_	_
8	changes	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	respectively	_	_	RB	O	-1	none	_	_
11	opposing	_	_	VBG	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	favoring	_	_	VBG	O	-1	none	_	_
14	glucocorticoid	_	_	NN	O	-1	none	_	_
15	actions	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	suggests	_	_	VBZ	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	pattern	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	pro	_	_	JJ	O	-1	none	_	_
9	/antiinflammatory	_	_	JJ	O	-1	none	_	_
10	cytokine	_	_	NN	O	-1	none	_	_
11	secretion	_	_	NN	O	-1	none	_	_
12	may	_	_	MD	O	-1	none	_	_
13	alter	_	_	VB	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	glucocorticoid	_	_	NN	O	-1	none	_	_
20	therapy	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Evidence	_	_	NN	O	-1	none	_	_
2	for	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	polyclonal	_	_	JJ	O	-1	none	_	_
5	etiology	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	palmar	_	_	JJ	O	-1	none	_	_
8	fibromatosis	_	_	NNS	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	X	_	_	NN	O	-1	none	_	_
2	chromosome	_	_	NN	O	-1	none	_	_
3	inactivation	_	_	NN	O	-1	none	_	_
4	patterns	_	_	NNS	O	-1	none	_	_
5	at	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	androgen	_	_	NN	Protein	8	multitoken	_	_
8	receptor	_	_	NN	Protein	0	root	_	_
9	locus	_	_	NN	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	evaluated	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	determine	_	_	VB	O	-1	none	_	_
14	clonality	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	microdissected	_	_	JJ	O	-1	none	_	_
17	lesional	_	_	JJ	O	-1	none	_	_
18	tissue	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	leukocytes	_	_	NNS	O	-1	none	_	_
22	from	_	_	IN	O	-1	none	_	_
23	2	_	_	CD	O	-1	none	_	_
24	women	_	_	NNS	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	Dupuytren	_	_	NN	O	-1	none	_	_
27	's	_	_	POS	O	-1	none	_	_
28	disease	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	tissue	_	_	NN	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	both	_	_	DT	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	generated	_	_	VBD	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	polyclonal	_	_	JJ	O	-1	none	_	_
9	pattern	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	X	_	_	NN	O	-1	none	_	_
12	chromosome	_	_	NN	O	-1	none	_	_
13	inactivation	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	androgen	_	_	NN	Protein	18	multitoken	_	_
18	receptor	_	_	NN	Protein	0	root	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	finding	_	_	NN	O	-1	none	_	_
3	supports	_	_	VBZ	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	polyclonal	_	_	JJ	O	-1	none	_	_
6	reactive	_	_	JJ	O	-1	none	_	_
7	process	_	_	NN	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	underlying	_	_	VBG	O	-1	none	_	_
11	etiology	_	_	NN	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	palmar	_	_	JJ	O	-1	none	_	_
14	fibromatosis	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Effects	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	intranasal	_	_	JJ	O	-1	none	_	_
4	glucocorticoids	_	_	NNS	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	endogenous	_	_	JJ	O	-1	none	_	_
7	glucocorticoid	_	_	NN	O	-1	none	_	_
8	peripheral	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	central	_	_	JJ	O	-1	none	_	_
11	function	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Glucocorticoids	_	_	NNS	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	among	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	most	_	_	RBS	O	-1	none	_	_
6	potent	_	_	JJ	O	-1	none	_	_
7	antiinflammatory	_	_	JJ	O	-1	none	_	_
8	agents	_	_	NNS	O	-1	none	_	_
9	that	_	_	WDT	O	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	be	_	_	VB	O	-1	none	_	_
12	used	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	rhinitis	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Their	_	_	PRP$	O	-1	none	_	_
2	mechanisms	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	action	_	_	NN	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	multiple	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	complex	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	number	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	reports	_	_	NNS	O	-1	none	_	_
14	describe	_	_	VBP	O	-1	none	_	_
15	significant	_	_	JJ	O	-1	none	_	_
16	systemic	_	_	JJ	O	-1	none	_	_
17	effects	_	_	NNS	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	locally	_	_	RB	O	-1	none	_	_
20	administered	_	_	VBN	O	-1	none	_	_
21	glucocorticoids	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	evaluate	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	short-term	_	_	JJ	O	-1	none	_	_
7	systemic	_	_	JJ	O	-1	none	_	_
8	effects	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	intranasally	_	_	RB	O	-1	none	_	_
11	administered	_	_	VBN	O	-1	none	_	_
12	glucocorticoids	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	14	_	_	CD	O	-1	none	_	_
15	normal	_	_	JJ	O	-1	none	_	_
16	healthy	_	_	JJ	O	-1	none	_	_
17	subjects	_	_	NNS	O	-1	none	_	_
18	were	_	_	VBD	O	-1	none	_	_
19	treated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	two	_	_	CD	O	-1	none	_	_
22	doses	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	either	_	_	CC	O	-1	none	_	_
25	budesonide	_	_	NN	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	BUD	_	_	NN	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	or	_	_	CC	O	-1	none	_	_
30	fluticasone	_	_	NN	O	-1	none	_	_
31	propionate	_	_	NN	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	FP	_	_	NN	O	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	2	_	_	CD	O	-1	none	_	_
37	weeks	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Before	_	_	IN	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	at	_	_	IN	O	-1	none	_	_
5	regular	_	_	JJ	O	-1	none	_	_
6	intervals	_	_	NNS	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	treatment	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	1	_	_	CD	O	-1	none	_	_
12	week	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	finally	_	_	RB	O	-1	none	_	_
15	6	_	_	CD	O	-1	none	_	_
16	weeks	_	_	NNS	O	-1	none	_	_
17	after	_	_	IN	O	-1	none	_	_
18	termination	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	treatment	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	effects	_	_	NNS	O	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	glucocorticoid	_	_	NN	Protein	26	multitoken	_	_
26	receptor	_	_	NN	Protein	0	root	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	GR	_	_	NN	Protein	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	methallothionein	_	_	NN	Protein	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	MTIIa	_	_	NN	Protein	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	mRNA	_	_	NN	O	-1	none	_	_
36	expression	_	_	NN	O	-1	none	_	_
37	levels	_	_	NNS	O	-1	none	_	_
38	were	_	_	VBD	O	-1	none	_	_
39	examined	_	_	VBN	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	peripheral	_	_	JJ	O	-1	none	_	_
42	lymphocytes	_	_	NNS	O	-1	none	_	_
43	using	_	_	VBG	O	-1	none	_	_
44	a	_	_	DT	O	-1	none	_	_
45	solution	_	_	NN	O	-1	none	_	_
46	hybridization	_	_	NN	O	-1	none	_	_
47	assay	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	Serum	_	_	NN	O	-1	none	_	_
2	cortisol	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	osteocalcin	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	urinary	_	_	JJ	O	-1	none	_	_
7	cortisol	_	_	NN	O	-1	none	_	_
8	levels	_	_	NNS	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	also	_	_	RB	O	-1	none	_	_
11	determined	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	insulin	_	_	NN	O	-1	none	_	_
3	tolerance	_	_	NN	O	-1	none	_	_
4	test	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	ITT	_	_	NNP	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	performed	_	_	VBN	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	end	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	second	_	_	JJ	O	-1	none	_	_
16	week	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	treatment	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	at	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	end	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	6-week	_	_	JJ	O	-1	none	_	_
26	washout	_	_	NN	O	-1	none	_	_
27	period	_	_	NN	O	-1	none	_	_
28	with	_	_	IN	O	-1	none	_	_
29	no	_	_	DT	O	-1	none	_	_
30	statistically	_	_	RB	O	-1	none	_	_
31	significant	_	_	JJ	O	-1	none	_	_
32	change	_	_	NN	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	cortisol	_	_	NN	O	-1	none	_	_
35	response	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	peripheral	_	_	JJ	O	-1	none	_	_
3	lymphocytes	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	GR	_	_	NN	Protein	-1	none	_	_
6	mRNA	_	_	NN	O	-1	none	_	_
7	levels	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	significantly	_	_	RB	O	-1	none	_	_
10	down-regulated	_	_	VBN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	MTIIa	_	_	NN	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	increased	_	_	VBD	O	-1	none	_	_
5	significantly	_	_	RB	O	-1	none	_	_
6	.	_	_	.	O	-1	none	_	_

1	Serum	_	_	NN	O	-1	none	_	_
2	osteocalcin	_	_	NN	Protein	-1	none	_	_
3	decreased	_	_	VBD	O	-1	none	_	_
4	significantly	_	_	RB	O	-1	none	_	_
5	during	_	_	IN	O	-1	none	_	_
6	treatment	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	both	_	_	CC	O	-1	none	_	_
9	BUD	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	FP	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Serum	_	_	NN	O	-1	none	_	_
2	cortisol	_	_	NN	O	-1	none	_	_
3	decreased	_	_	VBD	O	-1	none	_	_
4	after	_	_	IN	O	-1	none	_	_
5	1	_	_	CD	O	-1	none	_	_
6	week	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	treatment	_	_	NN	O	-1	none	_	_
9	whereas	_	_	IN	O	-1	none	_	_
10	urinary	_	_	JJ	O	-1	none	_	_
11	cortisol	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	affected	_	_	VBN	O	-1	none	_	_
15	until	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	second	_	_	JJ	O	-1	none	_	_
18	week	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	treatment	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	intranasal	_	_	JJ	O	-1	none	_	_
5	glucocorticoids	_	_	NNS	O	-1	none	_	_
6	at	_	_	IN	O	-1	none	_	_
7	clinically	_	_	RB	O	-1	none	_	_
8	recommended	_	_	VBN	O	-1	none	_	_
9	doses	_	_	NNS	O	-1	none	_	_
10	have	_	_	VBP	O	-1	none	_	_
11	not	_	_	RB	O	-1	none	_	_
12	only	_	_	RB	O	-1	none	_	_
13	significant	_	_	JJ	O	-1	none	_	_
14	systemic	_	_	JJ	O	-1	none	_	_
15	effects	_	_	NNS	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	adrenal	_	_	JJ	O	-1	none	_	_
18	function	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	also	_	_	RB	O	-1	none	_	_
22	have	_	_	VBP	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	effect	_	_	NN	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	specific	_	_	JJ	O	-1	none	_	_
27	gene	_	_	NN	O	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	peripheral	_	_	JJ	O	-1	none	_	_
31	lymphocytes	_	_	NNS	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	receptor	_	_	NN	O	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	reversible	_	_	JJ	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	according	_	_	VBG	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	serum	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	urinary	_	_	JJ	O	-1	none	_	_
15	cortisol	_	_	NN	O	-1	none	_	_
16	levels	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	ITT	_	_	NNP	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	leave	_	_	VBP	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	hypothalamic-pituitary-adrenal	_	_	JJ	O	-1	none	_	_
23	function	_	_	NN	O	-1	none	_	_
24	intact	_	_	JJ	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	short-term	_	_	JJ	O	-1	none	_	_
5	systemic	_	_	JJ	O	-1	none	_	_
6	effects	_	_	NNS	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	associated	_	_	VBN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	any	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	noticeable	_	_	JJ	O	-1	none	_	_
15	side-effects	_	_	NNS	O	-1	none	_	_
16	usually	_	_	RB	O	-1	none	_	_
17	observed	_	_	VBN	O	-1	none	_	_
18	during	_	_	IN	O	-1	none	_	_
19	long-term	_	_	JJ	O	-1	none	_	_
20	treatment	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	glucocorticoids	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transcriptionally	_	_	RB	O	-1	none	_	_
3	active	_	_	JJ	O	-1	none	_	_
4	factors	_	_	NNS	O	-1	none	_	_
5	mediating	_	_	VBG	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	effect	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	HTLV-I	_	_	NN	O	-1	none	_	_
11	Tax	_	_	NN	Protein	-1	none	_	_
12	transactivator	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	IL-2R	_	_	NN	Protein	16	multitoken	_	_
16	alpha	_	_	NN	Protein	0	root	_	_
17	kappa	_	_	NN	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	enhancer	_	_	NN	O	-1	none	_	_
20	include	_	_	VBP	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	product	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	c-rel	_	_	NN	Protein	-1	none	_	_
26	proto-oncogene	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	transactivator	_	_	NN	O	-1	none	_	_
3	HTLV-I	_	_	NN	O	-1	none	_	_
4	Tax	_	_	NN	Protein	-1	none	_	_
5	activates	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	coding	_	_	VBG	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	interleukin	_	_	NN	Protein	17	multitoken	_	_
15	2	_	_	CD	Protein	17	multitoken	_	_
16	alpha-chain	_	_	NN	Protein	17	multitoken	_	_
17	receptor	_	_	NN	Protein	0	root	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	IL-2R	_	_	NN	Protein	20	multitoken	_	_
20	alpha	_	_	NN	Protein	0	root	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	via	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	site	_	_	NN	O	-1	none	_	_
27	that	_	_	WDT	O	-1	none	_	_
28	can	_	_	MD	O	-1	none	_	_
29	bind	_	_	VB	O	-1	none	_	_
30	several	_	_	JJ	O	-1	none	_	_
31	protein	_	_	NN	O	-1	none	_	_
32	species	_	_	NNS	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	rel	_	_	NN	O	-1	none	_	_
36	family	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Tax1	_	_	NN	Protein	-1	none	_	_
2	strongly	_	_	RB	O	-1	none	_	_
3	activates	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	enhancer	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	this	_	_	DT	O	-1	none	_	_
9	motif	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	both	_	_	DT	O	-1	none	_	_
13	epithelial	_	_	JJ	O	-1	none	_	_
14	HeLa	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	lymphoid	_	_	JJ	O	-1	none	_	_
17	Jurkat	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	observed	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	undifferentiated	_	_	JJ	O	-1	none	_	_
8	embryocarcinoma	_	_	NN	O	-1	none	_	_
9	F9	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Overexpression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	p50	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	p65	_	_	NN	Protein	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	Rel	_	_	NN	O	-1	none	_	_
9	proteins	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	these	_	_	DT	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	showed	_	_	VBD	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	significant	_	_	JJ	O	-1	none	_	_
16	activation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	IL-2R	_	_	NN	Protein	20	multitoken	_	_
20	alpha	_	_	NN	Protein	0	root	_	_
21	kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	site	_	_	NN	O	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	observed	_	_	VBN	O	-1	none	_	_
26	only	_	_	RB	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	Rel	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	Rel	_	_	NN	O	-1	none	_	_
31	plus	_	_	CC	O	-1	none	_	_
32	p65	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	whereas	_	_	IN	O	-1	none	_	_
4	both	_	_	DT	O	-1	none	_	_
5	Tax	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	phorbol	_	_	NN	O	-1	none	_	_
8	12-myristate	_	_	NN	O	-1	none	_	_
9	13-acetate	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	PMA	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	able	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	efficiently	_	_	RB	O	-1	none	_	_
17	induce	_	_	VB	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	binding	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	NF-kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	IL-2R	_	_	NN	Protein	26	multitoken	_	_
26	alpha	_	_	NN	Protein	0	root	_	_
27	kappa	_	_	NN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	site	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	PMA	_	_	NN	O	-1	none	_	_
32	is	_	_	VBZ	O	-1	none	_	_
33	functionally	_	_	RB	O	-1	none	_	_
34	inactive	_	_	JJ	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	DNA	_	_	NN	O	-1	none	_	_
4	affinity	_	_	NN	O	-1	none	_	_
5	precipitation	_	_	NN	O	-1	none	_	_
6	assay	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	observed	_	_	VBD	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	Tax1	_	_	NN	Protein	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	able	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	efficiently	_	_	RB	O	-1	none	_	_
16	induce	_	_	VB	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	binding	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	Rel	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	whereas	_	_	IN	O	-1	none	_	_
23	PMA	_	_	NN	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	established	_	_	VBD	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	clear	_	_	JJ	O	-1	none	_	_
5	difference	_	_	NN	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	both	_	_	DT	O	-1	none	_	_
8	stimuli	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	indicating	_	_	VBG	O	-1	none	_	_
11	that	_	_	IN	O	-1	none	_	_
12	Rel	_	_	NN	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	functionally	_	_	RB	O	-1	none	_	_
16	active	_	_	JJ	O	-1	none	_	_
17	factor	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	functional	_	_	JJ	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	members	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	rel	_	_	NN	O	-1	none	_	_
15	family	_	_	NN	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	regulated	_	_	VBN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	their	_	_	PRP$	O	-1	none	_	_
20	interaction	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	DNA	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	Rel	_	_	NN	O	-1	none	_	_
26	can	_	_	MD	O	-1	none	_	_
27	be	_	_	VB	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	potent	_	_	JJ	O	-1	none	_	_
30	transcriptional	_	_	JJ	O	-1	none	_	_
31	activator	_	_	NN	O	-1	none	_	_
32	on	_	_	IN	O	-1	none	_	_
33	specific	_	_	JJ	O	-1	none	_	_
34	kappa	_	_	NN	O	-1	none	_	_
35	B	_	_	NN	O	-1	none	_	_
36	sites	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Phenotypic	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	functional	_	_	JJ	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	leukocytes	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	endometrium	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	endometriosis	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aetiology	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	endometriosis	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	common	_	_	JJ	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	disabling	_	_	VBG	O	-1	none	_	_
10	disorder	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	presently	_	_	RB	O	-1	none	_	_
14	unknown	_	_	JJ	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	although	_	_	IN	O	-1	none	_	_
17	immune	_	_	JJ	O	-1	none	_	_
18	dysfunction	_	_	NN	O	-1	none	_	_
19	could	_	_	MD	O	-1	none	_	_
20	allow	_	_	VB	O	-1	none	_	_
21	ectopic	_	_	JJ	O	-1	none	_	_
22	endometrial	_	_	JJ	O	-1	none	_	_
23	fragments	_	_	NNS	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	survive	_	_	VB	O	-1	none	_	_
26	outside	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	uterine	_	_	JJ	O	-1	none	_	_
29	cavity	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	investigate	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	relationship	_	_	NN	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	leukocyte	_	_	NN	O	-1	none	_	_
8	populations	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	steroid	_	_	NN	O	-1	none	_	_
11	hormone	_	_	NN	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	proliferative	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	bcl-2	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	apoptosis	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	eutopic	_	_	JJ	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	ectopic	_	_	JJ	O	-1	none	_	_
26	endometrium	_	_	NN	O	-1	none	_	_
27	from	_	_	IN	O	-1	none	_	_
28	women	_	_	NNS	O	-1	none	_	_
29	with	_	_	IN	O	-1	none	_	_
30	endometriosis	_	_	NN	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	adenomyosis	_	_	NN	O	-1	none	_	_
33	at	_	_	IN	O	-1	none	_	_
34	different	_	_	JJ	O	-1	none	_	_
35	phases	_	_	NNS	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	menstrual	_	_	JJ	O	-1	none	_	_
39	cycle	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Apoptotic	_	_	JJ	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	rarely	_	_	RB	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	control	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	subject	_	_	JJ	O	-1	none	_	_
10	endometria	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	endometriosis	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	adenomyotic	_	_	JJ	O	-1	none	_	_
7	lesions	_	_	NNS	O	-1	none	_	_
8	showed	_	_	VBD	O	-1	none	_	_
9	identical	_	_	JJ	O	-1	none	_	_
10	steroid	_	_	NN	O	-1	none	_	_
11	hormone	_	_	NN	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	proliferative	_	_	JJ	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	bcl-2	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	leukocyte	_	_	NN	O	-1	none	_	_
22	subpopulations	_	_	NNS	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	eutopic	_	_	JJ	O	-1	none	_	_
25	endometrium	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	indicating	_	_	VBG	O	-1	none	_	_
28	different	_	_	JJ	O	-1	none	_	_
29	aetiologies	_	_	NNS	O	-1	none	_	_
30	for	_	_	IN	O	-1	none	_	_
31	these	_	_	DT	O	-1	none	_	_
32	disorders	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	eGLs	_	_	NNS	O	-1	none	_	_
2	from	_	_	IN	O	-1	none	_	_
3	non	_	_	JJ	O	-1	none	_	_
4	pregnant	_	_	JJ	O	-1	none	_	_
5	endometrium	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	early	_	_	JJ	O	-1	none	_	_
8	pregnancy	_	_	NN	O	-1	none	_	_
9	showed	_	_	VBD	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	variable	_	_	JJ	O	-1	none	_	_
12	proliferative	_	_	JJ	O	-1	none	_	_
13	response	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	5	_	_	CD	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	100	_	_	CD	O	-1	none	_	_
18	U/ml	_	_	NN	O	-1	none	_	_
19	interleukin-2	_	_	NN	Protein	-1	none	_	_
20	over	_	_	IN	O	-1	none	_	_
21	48-h	_	_	JJ	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	120-h	_	_	JJ	O	-1	none	_	_
24	time	_	_	NN	O	-1	none	_	_
25	courses	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	eGLs	_	_	NNS	O	-1	none	_	_
2	are	_	_	VBP	O	-1	none	_	_
3	evidently	_	_	RB	O	-1	none	_	_
4	functionally	_	_	RB	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	eutopic	_	_	JJ	O	-1	none	_	_
9	endometrium	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Their	_	_	PRP$	O	-1	none	_	_
2	absence	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	endometriotic	_	_	JJ	O	-1	none	_	_
5	lesions	_	_	NNS	O	-1	none	_	_
6	together	_	_	RB	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	increased	_	_	VBN	O	-1	none	_	_
9	CD	_	_	NNP	O	-1	none	_	_
10	+8	_	_	CD	O	-1	none	_	_
11	T-cell	_	_	NN	O	-1	none	_	_
12	numbers	_	_	NNS	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	increased	_	_	VBD	O	-1	none	_	_
15	oestrogen	_	_	NN	O	-1	none	_	_
16	receptor	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	bcl-2	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	may	_	_	MD	O	-1	none	_	_
21	have	_	_	VB	O	-1	none	_	_
22	significant	_	_	JJ	O	-1	none	_	_
23	effects	_	_	NNS	O	-1	none	_	_
24	on	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	development	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	progression	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	endometriosis	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Altered	_	_	JJ	O	-1	none	_	_
2	memory	_	_	NN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	differentiation	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	patients	_	_	NNS	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	early	_	_	JJ	O	-1	none	_	_
10	rheumatoid	_	_	JJ	O	-1	none	_	_
11	arthritis	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	chronic	_	_	JJ	O	-1	none	_	_
3	immune	_	_	JJ	O	-1	none	_	_
4	response	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	rheumatoid	_	_	JJ	O	-1	none	_	_
7	arthritis	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	RA	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	might	_	_	MD	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	driven	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	activated	_	_	VBN	O	-1	none	_	_
16	Th1	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	without	_	_	IN	O	-1	none	_	_
19	sufficient	_	_	JJ	O	-1	none	_	_
20	Th2	_	_	NN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	differentiation	_	_	NN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	down-modulate	_	_	VB	O	-1	none	_	_
25	inflammation	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	test	_	_	VB	O	-1	none	_	_
3	whether	_	_	IN	O	-1	none	_	_
4	disordered	_	_	VBN	O	-1	none	_	_
5	memory	_	_	NN	O	-1	none	_	_
6	T	_	_	NN	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	differentiation	_	_	NN	O	-1	none	_	_
9	contributes	_	_	VBZ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	typical	_	_	JJ	O	-1	none	_	_
13	Th1	_	_	NN	O	-1	none	_	_
14	dominated	_	_	VBD	O	-1	none	_	_
15	chronic	_	_	JJ	O	-1	none	_	_
16	inflammation	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	RA	_	_	NN	O	-1	none	_	_
19	we	_	_	PRP	O	-1	none	_	_
20	investigated	_	_	VBD	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	resting	_	_	VBG	O	-1	none	_	_
24	CD4+	_	_	JJ	O	-1	none	_	_
25	memory	_	_	NN	O	-1	none	_	_
26	T	_	_	NN	O	-1	none	_	_
27	cells	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	patients	_	_	NNS	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	early	_	_	JJ	O	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	6	_	_	CD	O	-1	none	_	_
34	wk	_	_	NN	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	12	_	_	CD	O	-1	none	_	_
37	mo	_	_	NN	O	-1	none	_	_
38	)	_	_	-RRB-	O	-1	none	_	_
39	untreated	_	_	JJ	O	-1	none	_	_
40	RA	_	_	NN	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	in	_	_	IN	O	-1	none	_	_
43	age-	_	_	NN	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	sex	_	_	NN	O	-1	none	_	_
46	matched	_	_	VBD	O	-1	none	_	_
47	healthy	_	_	JJ	O	-1	none	_	_
48	controls	_	_	NNS	O	-1	none	_	_
49	in	_	_	FW	O	-1	none	_	_
50	vitro	_	_	FW	O	-1	none	_	_
51	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	difference	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	cytokine	_	_	NN	O	-1	none	_	_
5	secretion	_	_	NN	O	-1	none	_	_
6	profiles	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	freshly	_	_	RB	O	-1	none	_	_
9	isolated	_	_	VBN	O	-1	none	_	_
10	memory	_	_	NN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	detected	_	_	VBN	O	-1	none	_	_
15	between	_	_	IN	O	-1	none	_	_
16	patients	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	controls	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	culture	_	_	NN	O	-1	none	_	_
4	system	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	then	_	_	RB	O	-1	none	_	_
7	employed	_	_	VBN	O	-1	none	_	_
8	that	_	_	IN	O	-1	none	_	_
9	permitted	_	_	VBD	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Th	_	_	NN	O	-1	none	_	_
14	effectors	_	_	NNS	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	resting	_	_	VBG	O	-1	none	_	_
17	memory	_	_	NN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	short	_	_	JJ	O	-1	none	_	_
22	term	_	_	NN	O	-1	none	_	_
23	priming	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Marked	_	_	JJ	O	-1	none	_	_
2	differences	_	_	NNS	O	-1	none	_	_
3	were	_	_	VBD	O	-1	none	_	_
4	found	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	response	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	priming	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Th2	_	_	NN	O	-1	none	_	_
2	cells	_	_	NNS	O	-1	none	_	_
3	could	_	_	MD	O	-1	none	_	_
4	be	_	_	VB	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	all	_	_	DT	O	-1	none	_	_
8	healthy	_	_	JJ	O	-1	none	_	_
9	controls	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	priming	_	_	NN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	anti-CD28	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	absence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	TCR	_	_	NN	O	-1	none	_	_
19	ligation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	priming	_	_	NN	O	-1	none	_	_
5	under	_	_	IN	O	-1	none	_	_
6	those	_	_	DT	O	-1	none	_	_
7	conditions	_	_	NNS	O	-1	none	_	_
8	resulted	_	_	VBD	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	Th2	_	_	NN	O	-1	none	_	_
11	differentiation	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	only	_	_	RB	O	-1	none	_	_
14	9	_	_	CD	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	24	_	_	CD	O	-1	none	_	_
17	RA	_	_	NN	O	-1	none	_	_
18	patients	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Exogenous	_	_	JJ	O	-1	none	_	_
2	IL-4	_	_	NN	Protein	-1	none	_	_
3	could	_	_	MD	O	-1	none	_	_
4	overcome	_	_	VB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	apparent	_	_	JJ	O	-1	none	_	_
7	Th2	_	_	NN	O	-1	none	_	_
8	differentiation	_	_	NN	O	-1	none	_	_
9	defect	_	_	NN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	seven	_	_	CD	O	-1	none	_	_
12	patients	_	_	NNS	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	without	_	_	IN	O	-1	none	_	_
16	effect	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	remaining	_	_	VBG	O	-1	none	_	_
20	eight	_	_	CD	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Charybdotoxin	_	_	NN	O	-1	none	_	_
2	sensitive	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	Ca	_	_	JJ	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	2+	_	_	CD	O	-1	none	_	_
7	)-dependent	_	_	JJ	O	-1	none	_	_
8	membrane	_	_	NN	O	-1	none	_	_
9	potential	_	_	JJ	O	-1	none	_	_
10	changes	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	involved	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	or	_	_	CC	O	-1	none	_	_
18	B	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	proliferation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	involvement	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	ion	_	_	NN	O	-1	none	_	_
5	channels	_	_	NNS	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	B	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	lymphocyte	_	_	NN	O	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	supported	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	many	_	_	JJ	O	-1	none	_	_
16	reports	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	changes	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	ion	_	_	NN	O	-1	none	_	_
21	fluxes	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	membrane	_	_	NN	O	-1	none	_	_
24	potential	_	_	NN	O	-1	none	_	_
25	after	_	_	IN	O	-1	none	_	_
26	mitogen	_	_	NN	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Human	_	_	NN	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	B	_	_	NN	O	-1	none	_	_
5	lymphocytes	_	_	NNS	O	-1	none	_	_
6	demonstrate	_	_	VBP	O	-1	none	_	_
7	an	_	_	DT	O	-1	none	_	_
8	early	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	transient	_	_	JJ	O	-1	none	_	_
11	hyperpolarization	_	_	NN	O	-1	none	_	_
12	after	_	_	IN	O	-1	none	_	_
13	ligand	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Inasmuch	_	_	RB	O	-1	none	_	_
2	as	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	change	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	membrane	_	_	NN	O	-1	none	_	_
7	potential	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	dependent	_	_	JJ	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	elevation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	free	_	_	JJ	O	-1	none	_	_
14	cytosolic	_	_	JJ	O	-1	none	_	_
15	calcium	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	hyperpolarization	_	_	NN	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	presumably	_	_	RB	O	-1	none	_	_
21	through	_	_	IN	O	-1	none	_	_
22	opening	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	Ca	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	2+	_	_	CD	O	-1	none	_	_
27	)-stimulated	_	_	JJ	O	-1	none	_	_
28	K+	_	_	NN	O	-1	none	_	_
29	channels	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	used	_	_	VBN	O	-1	none	_	_
4	charybdotoxin	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	known	_	_	JJ	O	-1	none	_	_
8	inhibitor	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	Ca	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	2+	_	_	CD	O	-1	none	_	_
13	)-dependent	_	_	JJ	O	-1	none	_	_
14	K+	_	_	NN	O	-1	none	_	_
15	channels	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	study	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	role	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	these	_	_	DT	O	-1	none	_	_
23	channels	_	_	NNS	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	lymphocyte	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	mitogenesis	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	charybdotoxin	_	_	NN	O	-1	none	_	_
5	inhibits	_	_	VBZ	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	ligand	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	transient	_	_	JJ	O	-1	none	_	_
10	membrane	_	_	NN	O	-1	none	_	_
11	hyperpolarization	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	dose	_	_	NN	O	-1	none	_	_
20	dependent	_	_	JJ	O	-1	none	_	_
21	fashion	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	without	_	_	IN	O	-1	none	_	_
24	affecting	_	_	VBG	O	-1	none	_	_
25	changes	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	cytosolic	_	_	JJ	O	-1	none	_	_
28	Ca2+	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	blockade	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	Ca	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	2+	_	_	CD	O	-1	none	_	_
9	)-activated	_	_	JJ	O	-1	none	_	_
10	K+	_	_	NN	O	-1	none	_	_
11	channel	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	not	_	_	RB	O	-1	none	_	_
14	associated	_	_	VBN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	changes	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	cell-cycle	_	_	JJ	O	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	activation	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	IL-2	_	_	NN	Protein	-1	none	_	_
23	production	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	IL-2R	_	_	NN	O	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	or	_	_	CC	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	T	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	mitogenesis	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	imply	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	membrane	_	_	NN	O	-1	none	_	_
6	potential	_	_	JJ	O	-1	none	_	_
7	changes	_	_	NNS	O	-1	none	_	_
8	secondary	_	_	JJ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	ligand	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	opening	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	Ca	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	2+	_	_	CD	O	-1	none	_	_
18	)-activated	_	_	JJ	O	-1	none	_	_
19	K+	_	_	NN	O	-1	none	_	_
20	channels	_	_	NNS	O	-1	none	_	_
21	are	_	_	VBP	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	involved	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	T	_	_	NN	O	-1	none	_	_
28	lymphocyte	_	_	NN	O	-1	none	_	_
29	activation	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	mitogenesis	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Protein	_	_	NN	Protein	3	multitoken	_	_
2	kinase	_	_	NN	Protein	3	multitoken	_	_
3	B	_	_	NN	Protein	0	root	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	c-Akt	_	_	NN	Protein	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	phosphatidylinositol	_	_	NN	O	-1	none	_	_
9	3-kinase	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	STAT5	_	_	NN	Protein	-1	none	_	_
13	are	_	_	VBP	O	-1	none	_	_
14	activated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	erythropoietin	_	_	NN	Protein	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	EPO	_	_	NNP	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	HCD57	_	_	NN	O	-1	none	_	_
22	erythroid	_	_	JJ	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	but	_	_	CC	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	constitutively	_	_	RB	O	-1	none	_	_
27	active	_	_	JJ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	EPO	_	_	NN	Protein	-1	none	_	_
31	independent	_	_	JJ	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	apoptosis	_	_	NN	O	-1	none	_	_
34	resistant	_	_	JJ	O	-1	none	_	_
35	subclone	_	_	NN	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	HCD57-SREI	_	_	NN	O	-1	none	_	_
38	cells	_	_	NNS	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	found	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	erythropoietin	_	_	NN	Protein	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	EPO	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	stem	_	_	NN	Protein	11	multitoken	_	_
10	cell	_	_	NN	Protein	11	multitoken	_	_
11	factor	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	SCF	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	activated	_	_	VBN	O	-1	none	_	_
16	protein	_	_	NN	Protein	18	multitoken	_	_
17	kinase	_	_	NN	Protein	18	multitoken	_	_
18	B	_	_	NN	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	PKB	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	Akt	_	_	NN	Protein	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	EPO	_	_	NN	Protein	-1	none	_	_
26	dependent	_	_	JJ	O	-1	none	_	_
27	HCD57	_	_	NN	O	-1	none	_	_
28	erythroid	_	_	JJ	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	better	_	_	RBR	O	-1	none	_	_
3	understand	_	_	VB	O	-1	none	_	_
4	signals	_	_	NNS	O	-1	none	_	_
5	controlling	_	_	VBG	O	-1	none	_	_
6	proliferation	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	viability	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	erythroid	_	_	JJ	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	resist	_	_	VBP	O	-1	none	_	_
14	apoptosis	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	absence	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	EPO	_	_	NN	Protein	-1	none	_	_
20	were	_	_	VBD	O	-1	none	_	_
21	subcloned	_	_	VBN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	characterized	_	_	VBN	O	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	HCD57-SREI	_	_	NN	O	-1	none	_	_
26	cells	_	_	NNS	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	activations	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	PKB	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	Akt	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	STAT5a	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	STAT5b	_	_	NN	Protein	-1	none	_	_
12	were	_	_	VBD	O	-1	none	_	_
13	noted	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	these	_	_	DT	O	-1	none	_	_
16	EPO	_	_	NN	Protein	-1	none	_	_
17	independent	_	_	JJ	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	PI3-kinase	_	_	NN	O	-1	none	_	_
2	activity	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	upstream	_	_	JJ	O	-1	none	_	_
6	activator	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	PKB	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	Akt	_	_	NN	Protein	-1	none	_	_
11	because	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	PI3-kinase	_	_	NN	O	-1	none	_	_
14	inhibitor	_	_	NN	O	-1	none	_	_
15	LY294002	_	_	NN	O	-1	none	_	_
16	blocked	_	_	VBD	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	constitutive	_	_	JJ	O	-1	none	_	_
19	PKB	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	Akt	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	factor	_	_	NN	O	-1	none	_	_
24	dependent	_	_	JJ	O	-1	none	_	_
25	PKB	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	Akt	_	_	NN	Protein	-1	none	_	_
28	activity	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	LY294002	_	_	NN	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	proliferation	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	viability	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	both	_	_	CC	O	-1	none	_	_
11	HCD57-SREI	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	HCD57	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	correlated	_	_	VBD	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	PKB	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	Akt	_	_	NN	Protein	-1	none	_	_
23	;	_	_	:	O	-1	none	_	_
24	however	_	_	RB	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	PKB	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	Akt	_	_	NN	Protein	-1	none	_	_
29	activity	_	_	NN	O	-1	none	_	_
30	alone	_	_	RB	O	-1	none	_	_
31	did	_	_	VBD	O	-1	none	_	_
32	not	_	_	RB	O	-1	none	_	_
33	protect	_	_	VB	O	-1	none	_	_
34	these	_	_	DT	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	from	_	_	IN	O	-1	none	_	_
37	apoptosis	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HCD57	_	_	NN	O	-1	none	_	_
4	cells	_	_	NNS	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	SCF	_	_	NN	Protein	-1	none	_	_
7	also	_	_	RB	O	-1	none	_	_
8	activated	_	_	VBD	O	-1	none	_	_
9	PKB	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Akt	_	_	NN	Protein	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	did	_	_	VBD	O	-1	none	_	_
15	not	_	_	RB	O	-1	none	_	_
16	protect	_	_	VB	O	-1	none	_	_
17	from	_	_	IN	O	-1	none	_	_
18	apoptosis	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	result	_	_	NN	O	-1	none	_	_
3	suggested	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	PKB	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	PI3-kinase	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	necessary	_	_	JJ	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	sufficient	_	_	JJ	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	promote	_	_	VB	O	-1	none	_	_
16	viability	_	_	NN	O	-1	none	_	_
17	and/or	_	_	CC	O	-1	none	_	_
18	proliferation	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Modulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	E2F	_	_	NN	O	-1	none	_	_
4	complexes	_	_	NNS	O	-1	none	_	_
5	during	_	_	IN	O	-1	none	_	_
6	G0	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	S	_	_	NN	O	-1	none	_	_
9	phase	_	_	NN	O	-1	none	_	_
10	transition	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	primary	_	_	JJ	O	-1	none	_	_
14	B-lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	pocket	_	_	NN	O	-1	none	_	_
3	protein-E2F	_	_	JJ	O	-1	none	_	_
4	complexes	_	_	NNS	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	convergence	_	_	NN	O	-1	none	_	_
7	points	_	_	NNS	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	cycle	_	_	NN	O	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	report	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	identified	_	_	VBD	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	monitored	_	_	VBD	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	pocket	_	_	NN	O	-1	none	_	_
12	protein-E2F	_	_	JJ	O	-1	none	_	_
13	complexes	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	primary	_	_	JJ	O	-1	none	_	_
17	B-lymphocytes	_	_	NNS	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	phorbol	_	_	NN	O	-1	none	_	_
22	12-myristate	_	_	NN	O	-1	none	_	_
23	13-acetate	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Consistent	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	previous	_	_	JJ	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	from	_	_	IN	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	mouse	_	_	NN	O	-1	none	_	_
9	fibroblasts	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	T-lymphocytes	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	E2F4	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	DP1	_	_	NN	Protein	-1	none	_	_
16	form	_	_	VBP	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	predominant	_	_	JJ	O	-1	none	_	_
19	E2F	_	_	NN	O	-1	none	_	_
20	heterodimers	_	_	NNS	O	-1	none	_	_
21	both	_	_	CC	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	G0	_	_	NN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	G1	_	_	NN	O	-1	none	_	_
26	phases	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	human	_	_	NN	O	-1	none	_	_
30	B-lymphocyte	_	_	NN	O	-1	none	_	_
31	cell	_	_	NN	O	-1	none	_	_
32	cycle	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	whereas	_	_	IN	O	-1	none	_	_
35	E2F1	_	_	NN	Protein	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	-3	_	_	CD	Protein	-1	none	_	_
38	are	_	_	VBP	O	-1	none	_	_
39	first	_	_	JJ	O	-1	none	_	_
40	detected	_	_	VBN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	late	_	_	JJ	O	-1	none	_	_
43	G1	_	_	NN	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	their	_	_	PRP$	O	-1	none	_	_
47	expression	_	_	NN	O	-1	none	_	_
48	levels	_	_	NNS	O	-1	none	_	_
49	increase	_	_	VBP	O	-1	none	_	_
50	towards	_	_	IN	O	-1	none	_	_
51	S	_	_	NN	O	-1	none	_	_
52	phase	_	_	NN	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Intriguingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	major	_	_	JJ	O	-1	none	_	_
5	E2F	_	_	NN	O	-1	none	_	_
6	complex	_	_	NN	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	detected	_	_	VBD	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	quiescent	_	_	JJ	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	B-lymphocytes	_	_	NNS	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	consisted	_	_	VBN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	pRB	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	E2F4	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	DP1	_	_	NN	Protein	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Though	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	DP1	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	-2	_	_	CD	Protein	-1	none	_	_
8	increase	_	_	NN	O	-1	none	_	_
9	when	_	_	WRB	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	progress	_	_	VBP	O	-1	none	_	_
12	from	_	_	IN	O	-1	none	_	_
13	G0	_	_	NN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	S	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	proportion	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	DP1	_	_	NN	Protein	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	DP2	_	_	NN	Protein	-1	none	_	_
23	remains	_	_	VBZ	O	-1	none	_	_
24	relatively	_	_	RB	O	-1	none	_	_
25	constant	_	_	JJ	O	-1	none	_	_
26	during	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	cycle	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	observed	_	_	VBD	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	increase	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	electrophoretic	_	_	JJ	O	-1	none	_	_
8	mobility	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	predominant	_	_	JJ	O	-1	none	_	_
12	E2F	_	_	NN	O	-1	none	_	_
13	components	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	DP1	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	E2F4	_	_	NN	Protein	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	B-lymphocytes	_	_	NNS	O	-1	none	_	_
21	progressed	_	_	VBN	O	-1	none	_	_
22	from	_	_	IN	O	-1	none	_	_
23	G0	_	_	NN	O	-1	none	_	_
24	into	_	_	IN	O	-1	none	_	_
25	early	_	_	JJ	O	-1	none	_	_
26	G1	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	increase	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	mobility	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	attributable	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	dephosphorylation	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	as	_	_	IN	O	-1	none	_	_
11	lambda	_	_	NN	O	-1	none	_	_
12	phosphatase	_	_	NN	O	-1	none	_	_
13	treatment	_	_	NN	O	-1	none	_	_
14	could	_	_	MD	O	-1	none	_	_
15	convert	_	_	VB	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	slower	_	_	JJR	O	-1	none	_	_
18	migrating	_	_	JJ	O	-1	none	_	_
19	forms	_	_	NNS	O	-1	none	_	_
20	into	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	corresponding	_	_	JJ	O	-1	none	_	_
23	faster	_	_	JJR	O	-1	none	_	_
24	mobility	_	_	NN	O	-1	none	_	_
25	forms	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	further	_	_	RB	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	change	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	status	_	_	NN	O	-1	none	_	_
10	correlates	_	_	VBZ	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	decrease	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	DNA	_	_	NN	O	-1	none	_	_
16	binding	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	modulation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	mediated	_	_	VBN	O	-1	none	_	_
8	through	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	dephosphorylation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	DP1	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	E2F4	_	_	NN	Protein	-1	none	_	_
15	could	_	_	MD	O	-1	none	_	_
16	help	_	_	VB	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	explain	_	_	VB	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	lack	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	in	_	_	FW	O	-1	none	_	_
23	vivo	_	_	FW	O	-1	none	_	_
24	DNA	_	_	NN	O	-1	none	_	_
25	footprinting	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	late	_	_	JJ	O	-1	none	_	_
28	G1	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	S	_	_	NN	O	-1	none	_	_
31	phases	_	_	NNS	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	gene	_	_	NN	O	-1	none	_	_
34	promoters	_	_	NNS	O	-1	none	_	_
35	negatively	_	_	RB	O	-1	none	_	_
36	regulated	_	_	VBN	O	-1	none	_	_
37	through	_	_	IN	O	-1	none	_	_
38	E2F	_	_	NN	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	suggests	_	_	VBZ	O	-1	none	_	_
42	a	_	_	DT	O	-1	none	_	_
43	novel	_	_	JJ	O	-1	none	_	_
44	mechanism	_	_	NN	O	-1	none	_	_
45	for	_	_	IN	O	-1	none	_	_
46	controlling	_	_	VBG	O	-1	none	_	_
47	E2F	_	_	NN	O	-1	none	_	_
48	transcriptional	_	_	JJ	O	-1	none	_	_
49	activity	_	_	NN	O	-1	none	_	_
50	during	_	_	IN	O	-1	none	_	_
51	the	_	_	DT	O	-1	none	_	_
52	transition	_	_	NN	O	-1	none	_	_
53	from	_	_	IN	O	-1	none	_	_
54	quiescence	_	_	NN	O	-1	none	_	_
55	to	_	_	TO	O	-1	none	_	_
56	proliferation	_	_	NN	O	-1	none	_	_
57	.	_	_	.	O	-1	none	_	_

1	CD14	_	_	NN	Protein	-1	none	_	_
2	mediated	_	_	VBD	O	-1	none	_	_
3	signal	_	_	NN	O	-1	none	_	_
4	pathway	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Porphyromonas	_	_	NN	O	-1	none	_	_
7	gingivalis	_	_	NN	O	-1	none	_	_
8	lipopolysaccharide	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	gingival	_	_	JJ	O	-1	none	_	_
12	fibroblasts	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Lipopolysaccharide	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	LPS	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	induces	_	_	VBZ	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	inflammatory	_	_	JJ	O	-1	none	_	_
9	cytokines	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	monocytes	_	_	NNS	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	macrophages	_	_	NNS	O	-1	none	_	_
14	via	_	_	IN	O	-1	none	_	_
15	CD14	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	one	_	_	CD	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	LPS	_	_	NN	O	-1	none	_	_
21	receptors	_	_	NNS	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	expressed	_	_	VBN	O	-1	none	_	_
26	predominantly	_	_	RB	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	these	_	_	DT	O	-1	none	_	_
29	cells	_	_	NNS	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	has	_	_	VBZ	O	-1	none	_	_
3	been	_	_	VBN	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	Porphyromonas	_	_	NN	O	-1	none	_	_
7	gingivalis	_	_	NN	O	-1	none	_	_
8	LPS	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	P-LPS	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	able	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	induce	_	_	VB	O	-1	none	_	_
17	inflammatory	_	_	JJ	O	-1	none	_	_
18	cytokines	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	gingival	_	_	JJ	O	-1	none	_	_
22	fibroblasts	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	important	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	determine	_	_	VB	O	-1	none	_	_
8	whether	_	_	IN	O	-1	none	_	_
9	CD14	_	_	NN	Protein	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	expressed	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	gingival	_	_	JJ	O	-1	none	_	_
14	fibroblasts	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	define	_	_	VB	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	P-LPS-mediated	_	_	JJ	O	-1	none	_	_
20	signal	_	_	NN	O	-1	none	_	_
21	transducing	_	_	NN	O	-1	none	_	_
22	mechanism	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	cells	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	observed	_	_	VBD	O	-1	none	_	_
7	unexpectedly	_	_	RB	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	immunohistochemical	_	_	JJ	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	Western	_	_	NN	O	-1	none	_	_
12	blotting	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	immunoblotting	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	Northern	_	_	JJ	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	RNA	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	blotting	_	_	NN	O	-1	none	_	_
23	assays	_	_	NNS	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	CD14	_	_	NN	Protein	-1	none	_	_
26	is	_	_	VBZ	O	-1	none	_	_
27	expressed	_	_	VBN	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	high	_	_	JJ	O	-1	none	_	_
30	density	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	human	_	_	NN	O	-1	none	_	_
33	gingival	_	_	JJ	O	-1	none	_	_
34	fibroblasts	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	P-LPS-induced	_	_	NNP	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	monocyte	_	_	NN	Protein	8	multitoken	_	_
6	chemoattractant	_	_	NN	Protein	8	multitoken	_	_
7	protein	_	_	NN	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	MCP-1	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	inhibited	_	_	VBN	O	-1	none	_	_
18	markedly	_	_	RB	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	treatment	_	_	NN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	anti-human	_	_	JJ	O	-1	none	_	_
23	CD14	_	_	NN	Protein	-1	none	_	_
24	antibody	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	completely	_	_	RB	O	-1	none	_	_
28	inhibited	_	_	VBN	O	-1	none	_	_
29	by	_	_	IN	O	-1	none	_	_
30	herbimycin	_	_	NN	O	-1	none	_	_
31	A	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	a	_	_	DT	O	-1	none	_	_
34	potent	_	_	JJ	O	-1	none	_	_
35	inhibitor	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	tyrosine	_	_	NN	O	-1	none	_	_
38	kinase	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inhibitor	_	_	NN	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	dramatically	_	_	RB	O	-1	none	_	_
5	inhibited	_	_	VBD	O	-1	none	_	_
6	monocyte	_	_	NN	O	-1	none	_	_
7	chemotactic	_	_	JJ	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	MCP-1	_	_	NN	Protein	-1	none	_	_
12	production	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	P-LPS-induced	_	_	JJ	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	MCP-1	_	_	NN	Protein	-1	none	_	_
8	gene	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	also	_	_	RB	O	-1	none	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	blocked	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	inhibitors	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	two	_	_	CD	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factors	_	_	NNS	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	i.e.	_	_	FW	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	curcumin	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	an	_	_	DT	O	-1	none	_	_
27	inhibitor	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	AP-1	_	_	NN	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	pyrolidine	_	_	NN	O	-1	none	_	_
33	dithiocarbamate	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	an	_	_	DT	O	-1	none	_	_
36	inhibitor	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	NF-kappaB	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Both	_	_	DT	O	-1	none	_	_
2	inhibitors	_	_	NNS	O	-1	none	_	_
3	inhibited	_	_	VBD	O	-1	none	_	_
4	monocyte	_	_	NN	O	-1	none	_	_
5	chemotactic	_	_	JJ	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	culture	_	_	NN	O	-1	none	_	_
10	supernatant	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	P-LPS-treated	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Gel	_	_	NN	O	-1	none	_	_
2	shift	_	_	NN	O	-1	none	_	_
3	mobility	_	_	NN	O	-1	none	_	_
4	assay	_	_	NN	O	-1	none	_	_
5	showed	_	_	VBD	O	-1	none	_	_
6	stimulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	AP-1	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	NF-kappaB	_	_	NN	O	-1	none	_	_
12	contents	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	P-LPS-treated	_	_	JJ	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	study	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	first	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	demonstrate	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	expression	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	CD14	_	_	NN	Protein	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	gingival	_	_	JJ	O	-1	none	_	_
15	fibroblasts	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	show	_	_	VB	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	signal	_	_	NN	O	-1	none	_	_
22	transducing	_	_	NN	O	-1	none	_	_
23	pathway	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	P-LPS	_	_	NN	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	mediated	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	CD14	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Nonradioactive	_	_	JJ	O	-1	none	_	_
2	quantification	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	glucocorticoid	_	_	NN	Protein	5	multitoken	_	_
5	receptor	_	_	NN	Protein	0	root	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	differentiation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	monocytic	_	_	JJ	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	U937	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	describe	_	_	VBP	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	method	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	relative	_	_	JJ	O	-1	none	_	_
7	quantification	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	specific	_	_	JJ	O	-1	none	_	_
10	mRNA	_	_	NN	O	-1	none	_	_
11	using	_	_	VBG	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	nonradioactive	_	_	JJ	O	-1	none	_	_
14	assay	_	_	NN	O	-1	none	_	_
15	based	_	_	VBN	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	DNA	_	_	NN	O	-1	none	_	_
18	strand	_	_	NN	O	-1	none	_	_
19	competition	_	_	NN	O	-1	none	_	_
20	between	_	_	IN	O	-1	none	_	_
21	identical	_	_	JJ	O	-1	none	_	_
22	sequences	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	biotin-	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	fluorescein	_	_	NN	O	-1	none	_	_
27	labeled	_	_	VBN	O	-1	none	_	_
28	amplicon	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	probe	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	unlabeled	_	_	JJ	O	-1	none	_	_
34	amplicon	_	_	NN	O	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	target	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	during	_	_	IN	O	-1	none	_	_
39	hybridization	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	As	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	target	_	_	NN	O	-1	none	_	_
4	quantity	_	_	NN	O	-1	none	_	_
5	increased	_	_	VBD	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	that	_	_	DT	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	double	_	_	JJ	O	-1	none	_	_
11	labeled	_	_	JJ	O	-1	none	_	_
12	probe	_	_	NN	O	-1	none	_	_
13	decreased	_	_	VBD	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	accordance	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	mass	_	_	NN	O	-1	none	_	_
19	action	_	_	NN	O	-1	none	_	_
20	law	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	technique	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	successfully	_	_	RB	O	-1	none	_	_
5	applied	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	evaluate	_	_	VB	O	-1	none	_	_
8	differences	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	glucocorticoid	_	_	NN	Protein	11	multitoken	_	_
11	receptor	_	_	NN	Protein	0	root	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	U937	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	before	_	_	IN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	addition	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	potent	_	_	JJ	O	-1	none	_	_
23	differentiation	_	_	NN	O	-1	none	_	_
24	inducers	_	_	NNS	O	-1	none	_	_
25	:	_	_	:	O	-1	none	_	_
26	12-O-tetradecanoylphorbol	_	_	NN	O	-1	none	_	_
27	13-acetate	_	_	NN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	TPA	_	_	NN	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	combination	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	all-trans	_	_	JJ	O	-1	none	_	_
36	retinoic	_	_	JJ	O	-1	none	_	_
37	acid	_	_	NN	O	-1	none	_	_
38	(	_	_	-LRB-	O	-1	none	_	_
39	RA	_	_	NN	O	-1	none	_	_
40	)	_	_	-RRB-	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	1,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
43	D2	_	_	NN	O	-1	none	_	_
44	(	_	_	-LRB-	O	-1	none	_	_
45	VD	_	_	NN	O	-1	none	_	_
46	)	_	_	-RRB-	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	observed	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	TPA	_	_	NN	O	-1	none	_	_
5	treatment	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	associated	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	increase	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	[	_	_	CD	O	-1	none	_	_
16	3H	_	_	NN	O	-1	none	_	_
17	]	_	_	CD	O	-1	none	_	_
18	dexamethasone	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	up-regulation	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	GR	_	_	NN	Protein	-1	none	_	_
23	mRNA	_	_	NN	O	-1	none	_	_
24	while	_	_	IN	O	-1	none	_	_
25	no	_	_	DT	O	-1	none	_	_
26	enhanced	_	_	JJ	O	-1	none	_	_
27	GR	_	_	NN	Protein	-1	none	_	_
28	expression	_	_	NN	O	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	perceived	_	_	VBN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	RA/VD	_	_	NN	O	-1	none	_	_
33	treatment	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Detection	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	intracellular	_	_	JJ	O	-1	none	_	_
4	phosphorylated	_	_	VBN	O	-1	none	_	_
5	STAT-1	_	_	NN	Protein	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	flow	_	_	NN	O	-1	none	_	_
8	cytometry	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	applied	_	_	VBN	O	-1	none	_	_
4	flow	_	_	NN	O	-1	none	_	_
5	cytometry	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	investigation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	interferon-gamma	_	_	NN	Protein	-1	none	_	_
11	activation	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	monocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	approach	_	_	NN	O	-1	none	_	_
3	uses	_	_	VBZ	O	-1	none	_	_
4	monoclonal	_	_	JJ	O	-1	none	_	_
5	antibodies	_	_	NNS	O	-1	none	_	_
6	that	_	_	WDT	O	-1	none	_	_
7	distinguish	_	_	VBP	O	-1	none	_	_
8	between	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	native	_	_	JJ	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	phosphorylated	_	_	JJ	O	-1	none	_	_
13	forms	_	_	NNS	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	STAT-1	_	_	NN	Protein	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	enables	_	_	VBZ	O	-1	none	_	_
3	rapid	_	_	JJ	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	quantitative	_	_	JJ	O	-1	none	_	_
6	assessment	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	STAT-1	_	_	NN	Protein	-1	none	_	_
9	phosphorylation	_	_	NN	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	discrete	_	_	JJ	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	basis	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	is	_	_	VBZ	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	more	_	_	RBR	O	-1	none	_	_
19	sensitive	_	_	JJ	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	less	_	_	JJR	O	-1	none	_	_
22	time	_	_	NN	O	-1	none	_	_
23	consuming	_	_	NN	O	-1	none	_	_
24	than	_	_	IN	O	-1	none	_	_
25	immunoblotting	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	it	_	_	PRP	O	-1	none	_	_
4	allows	_	_	VBZ	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	discrimination	_	_	NN	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	mixture	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	differ	_	_	VBP	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	their	_	_	PRP$	O	-1	none	_	_
16	response	_	_	NN	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	interferon-gamma	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	approach	_	_	NN	O	-1	none	_	_
3	should	_	_	MD	O	-1	none	_	_
4	allow	_	_	VB	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	evaluation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	different	_	_	JJ	O	-1	none	_	_
10	intracellular	_	_	JJ	O	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	pathways	_	_	NNS	O	-1	none	_	_
13	using	_	_	VBG	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	combination	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	monoclonal	_	_	JJ	O	-1	none	_	_
18	reagents	_	_	NNS	O	-1	none	_	_
19	that	_	_	WDT	O	-1	none	_	_
20	are	_	_	VBP	O	-1	none	_	_
21	specific	_	_	JJ	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	native	_	_	JJ	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	activation	_	_	NN	O	-1	none	_	_
26	modified	_	_	VBN	O	-1	none	_	_
27	proteins	_	_	NNS	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Application	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	form	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	testing	_	_	NN	O	-1	none	_	_
7	should	_	_	MD	O	-1	none	_	_
8	prove	_	_	VB	O	-1	none	_	_
9	valuable	_	_	JJ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	screening	_	_	VBG	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	signaling	_	_	VBG	O	-1	none	_	_
14	defects	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	selected	_	_	VBN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	recurrent	_	_	JJ	O	-1	none	_	_
20	infections	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	technique	_	_	NN	O	-1	none	_	_
6	should	_	_	MD	O	-1	none	_	_
7	permit	_	_	VB	O	-1	none	_	_
8	dissection	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	full	_	_	JJ	O	-1	none	_	_
12	range	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cellular	_	_	JJ	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	pathways	_	_	NNS	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	protein	_	_	NN	O	-1	none	_	_
20	level	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	20-Epi	_	_	NNP	O	-1	none	_	_
2	analogues	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	1,25-dihydroxyvitamin	_	_	NN	O	-1	none	_	_
5	D3	_	_	NN	O	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	highly	_	_	RB	O	-1	none	_	_
8	potent	_	_	JJ	O	-1	none	_	_
9	inducers	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	DRIP	_	_	NN	O	-1	none	_	_
12	coactivator	_	_	NN	O	-1	none	_	_
13	complex	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	vitamin	_	_	NN	Protein	19	multitoken	_	_
18	D3	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	.	_	_	.	O	-1	none	_	_

1	1,25-Dihydroxyvitamin	_	_	NN	O	-1	none	_	_
2	D3	_	_	NN	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	1,25	_	_	CD	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	OH	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	2D3	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	plays	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	major	_	_	JJ	O	-1	none	_	_
13	role	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	stimulation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	bone	_	_	NN	O	-1	none	_	_
19	growth	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	mineralization	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	intestinal	_	_	JJ	O	-1	none	_	_
25	calcium	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	phosphate	_	_	NN	O	-1	none	_	_
28	absorption	_	_	NN	O	-1	none	_	_
29	;	_	_	:	O	-1	none	_	_
30	it	_	_	PRP	O	-1	none	_	_
31	also	_	_	RB	O	-1	none	_	_
32	acts	_	_	VBZ	O	-1	none	_	_
33	as	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	general	_	_	JJ	O	-1	none	_	_
36	inhibitor	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	cellular	_	_	JJ	O	-1	none	_	_
39	proliferation	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	new	_	_	JJ	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	clinically	_	_	RB	O	-1	none	_	_
5	relevant	_	_	JJ	O	-1	none	_	_
6	compounds	_	_	NNS	O	-1	none	_	_
7	dissociate	_	_	VBP	O	-1	none	_	_
8	antiproliferative	_	_	JJ	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	calcemic	_	_	JJ	O	-1	none	_	_
11	activities	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	1,25	_	_	CD	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	OH	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	2D3	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	but	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	molecular	_	_	JJ	O	-1	none	_	_
22	basis	_	_	NN	O	-1	none	_	_
23	for	_	_	IN	O	-1	none	_	_
24	this	_	_	DT	O	-1	none	_	_
25	has	_	_	VBZ	O	-1	none	_	_
26	not	_	_	RB	O	-1	none	_	_
27	been	_	_	VBN	O	-1	none	_	_
28	clearly	_	_	RB	O	-1	none	_	_
29	elucidated	_	_	VBN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	tested	_	_	VBD	O	-1	none	_	_
5	whether	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	potency	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	one	_	_	CD	O	-1	none	_	_
10	class	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	compounds	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	20-epi	_	_	NN	O	-1	none	_	_
15	analogues	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	to	_	_	TO	O	-1	none	_	_
18	induce	_	_	VB	O	-1	none	_	_
19	myeloid	_	_	JJ	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	differentiation	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	because	_	_	IN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	direct	_	_	JJ	O	-1	none	_	_
27	molecular	_	_	JJ	O	-1	none	_	_
28	effects	_	_	NNS	O	-1	none	_	_
29	on	_	_	IN	O	-1	none	_	_
30	vitamin	_	_	NN	Protein	32	multitoken	_	_
31	D	_	_	NN	Protein	32	multitoken	_	_
32	receptor	_	_	NN	Protein	0	root	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	VDR	_	_	NN	Protein	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	two	_	_	CD	O	-1	none	_	_
5	20-epi	_	_	NN	O	-1	none	_	_
6	analogues	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	MC1627	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	MC1288	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	p21	_	_	NN	Protein	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	Waf1	_	_	NN	Protein	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	Cip1	_	_	NN	Protein	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	a	_	_	DT	O	-1	none	_	_
25	key	_	_	JJ	O	-1	none	_	_
26	VDR	_	_	NN	Protein	-1	none	_	_
27	target	_	_	NN	O	-1	none	_	_
28	gene	_	_	NN	O	-1	none	_	_
29	involved	_	_	VBN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	growth	_	_	NN	O	-1	none	_	_
32	inhibition	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	at	_	_	IN	O	-1	none	_	_
35	a	_	_	DT	O	-1	none	_	_
36	concentration	_	_	NN	O	-1	none	_	_
37	100-fold	_	_	RB	O	-1	none	_	_
38	lower	_	_	JJR	O	-1	none	_	_
39	than	_	_	IN	O	-1	none	_	_
40	that	_	_	DT	O	-1	none	_	_
41	of	_	_	IN	O	-1	none	_	_
42	1,25	_	_	CD	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	OH	_	_	NN	O	-1	none	_	_
45	)	_	_	-RRB-	O	-1	none	_	_
46	2D3	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	compared	_	_	VBD	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	sensitivity	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	analogue	_	_	NN	O	-1	none	_	_
7	effects	_	_	NNS	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	VDR	_	_	NN	Protein	-1	none	_	_
10	interacting	_	_	NN	O	-1	none	_	_
11	proteins	_	_	NNS	O	-1	none	_	_
12	:	_	_	:	O	-1	none	_	_
13	RXR	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	GRIP-1	_	_	NN	Protein	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	DRIP205	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	subunit	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	DRIP	_	_	NN	O	-1	none	_	_
25	coactivator	_	_	NN	O	-1	none	_	_
26	complex	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Compared	_	_	VBN	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	interaction	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	VDR	_	_	NN	Protein	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	RXR	_	_	NN	O	-1	none	_	_
9	or	_	_	CC	O	-1	none	_	_
10	GRIP-1	_	_	NN	Protein	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	differentiation	_	_	NN	O	-1	none	_	_
14	dose	_	_	NN	O	-1	none	_	_
15	response	_	_	NN	O	-1	none	_	_
16	most	_	_	RBS	O	-1	none	_	_
17	closely	_	_	RB	O	-1	none	_	_
18	correlated	_	_	VBN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	ligand	_	_	NN	O	-1	none	_	_
22	dependent	_	_	JJ	O	-1	none	_	_
23	recruitment	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	DRIP	_	_	NN	O	-1	none	_	_
27	coactivator	_	_	NN	O	-1	none	_	_
28	complex	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	VDR	_	_	NN	Protein	-1	none	_	_
31	and	_	_	CC	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	ability	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	receptor	_	_	NN	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	activate	_	_	VB	O	-1	none	_	_
40	transcription	_	_	NN	O	-1	none	_	_
41	in	_	_	IN	O	-1	none	_	_
42	a	_	_	DT	O	-1	none	_	_
43	cell-free	_	_	JJ	O	-1	none	_	_
44	system	_	_	NN	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	provide	_	_	VBP	O	-1	none	_	_
4	compelling	_	_	JJ	O	-1	none	_	_
5	links	_	_	NNS	O	-1	none	_	_
6	between	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	efficiency	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	20-epi	_	_	NN	O	-1	none	_	_
12	analogue	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	inducing	_	_	VBG	O	-1	none	_	_
15	VDR	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	DRIP	_	_	NN	O	-1	none	_	_
18	interactions	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	transactivation	_	_	NN	O	-1	none	_	_
21	in	_	_	FW	O	-1	none	_	_
22	vitro	_	_	FW	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	its	_	_	PRP$	O	-1	none	_	_
26	enhanced	_	_	VBN	O	-1	none	_	_
27	ability	_	_	NN	O	-1	none	_	_
28	to	_	_	TO	O	-1	none	_	_
29	induce	_	_	VB	O	-1	none	_	_
30	cellular	_	_	JJ	O	-1	none	_	_
31	differentiation	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Cleavage	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	transcription	_	_	NN	O	-1	none	_	_
4	factor	_	_	NN	O	-1	none	_	_
5	SP1	_	_	NN	Protein	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	caspases	_	_	NNS	O	-1	none	_	_
8	during	_	_	IN	O	-1	none	_	_
9	anti-IgM-induced	_	_	JJ	O	-1	none	_	_
10	B-cell	_	_	NN	O	-1	none	_	_
11	apoptosis	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Apoptosis	_	_	NN	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	instrumental	_	_	JJ	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	processes	_	_	NNS	O	-1	none	_	_
7	generating	_	_	VBG	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	diversity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	B-cell	_	_	NN	O	-1	none	_	_
13	repertoire	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	Autoreactive	_	_	JJ	O	-1	none	_	_
2	B-cells	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	eliminated	_	_	VBN	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	anti-IgM	_	_	JJ	O	-1	none	_	_
7	crosslinking	_	_	NN	O	-1	none	_	_
8	after	_	_	IN	O	-1	none	_	_
9	encountering	_	_	VBG	O	-1	none	_	_
10	self-antigens	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	but	_	_	CC	O	-1	none	_	_
13	precise	_	_	JJ	O	-1	none	_	_
14	mechanisms	_	_	NNS	O	-1	none	_	_
15	leading	_	_	VBG	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	B-cell	_	_	NN	O	-1	none	_	_
18	apoptosis	_	_	NN	O	-1	none	_	_
19	are	_	_	VBP	O	-1	none	_	_
20	still	_	_	RB	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	well	_	_	RB	O	-1	none	_	_
23	understood	_	_	VBN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	cleavage	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	factor	_	_	NN	O	-1	none	_	_
10	SP1	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	human	_	_	NN	O	-1	none	_	_
14	Burkitt	_	_	NN	O	-1	none	_	_
15	lymphoma	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	line	_	_	NN	O	-1	none	_	_
18	BL60	_	_	NN	O	-1	none	_	_
19	during	_	_	IN	O	-1	none	_	_
20	anti-IgM-induced	_	_	JJ	O	-1	none	_	_
21	apoptosis	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Western	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	revealed	_	_	VBD	O	-1	none	_	_
5	two	_	_	CD	O	-1	none	_	_
6	cleavage	_	_	NN	O	-1	none	_	_
7	products	_	_	NNS	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	approximately	_	_	RB	O	-1	none	_	_
10	68	_	_	CD	O	-1	none	_	_
11	kDa	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	45	_	_	CD	O	-1	none	_	_
14	kDa	_	_	NN	O	-1	none	_	_
15	after	_	_	IN	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	apoptosis	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Cleavage	_	_	NN	O	-1	none	_	_
2	could	_	_	MD	O	-1	none	_	_
3	be	_	_	VB	O	-1	none	_	_
4	completely	_	_	RB	O	-1	none	_	_
5	inhibited	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	zDEVD-fmk	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	inhibitor	_	_	NN	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	caspase	_	_	NN	O	-1	none	_	_
14	3	_	_	CD	O	-1	none	_	_
15	like	_	_	IN	O	-1	none	_	_
16	proteases	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	In-vitro	_	_	FW	O	-1	none	_	_
2	cleavage	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	recombinant	_	_	JJ	O	-1	none	_	_
5	SP1	_	_	NN	Protein	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	recombinant	_	_	JJ	O	-1	none	_	_
8	caspase	_	_	NN	Protein	9	multitoken	_	_
9	3	_	_	CD	Protein	0	root	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	CPP32	_	_	NN	Protein	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	or	_	_	CC	O	-1	none	_	_
14	caspase	_	_	NN	Protein	15	multitoken	_	_
15	7	_	_	CD	Protein	0	root	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	Mch	_	_	NN	Protein	18	multitoken	_	_
18	3	_	_	CD	Protein	0	root	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	results	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	similar	_	_	JJ	O	-1	none	_	_
23	cleavage	_	_	NN	O	-1	none	_	_
24	products	_	_	NNS	O	-1	none	_	_
25	as	_	_	IN	O	-1	none	_	_
26	those	_	_	DT	O	-1	none	_	_
27	observed	_	_	VBN	O	-1	none	_	_
28	in	_	_	FW	O	-1	none	_	_
29	vivo	_	_	FW	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Recombinant	_	_	JJ	O	-1	none	_	_
2	caspase	_	_	NN	Protein	3	multitoken	_	_
3	6	_	_	CD	Protein	0	root	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	Mch	_	_	NN	Protein	6	multitoken	_	_
6	2	_	_	CD	Protein	0	root	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	primarily	_	_	RB	O	-1	none	_	_
9	generates	_	_	VBZ	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	68-kDa	_	_	JJ	O	-1	none	_	_
12	cleavage	_	_	NN	O	-1	none	_	_
13	product	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	as	_	_	IN	O	-1	none	_	_
16	observed	_	_	VBN	O	-1	none	_	_
17	after	_	_	IN	O	-1	none	_	_
18	calcium	_	_	NN	O	-1	none	_	_
19	ionophore	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	CaI	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	induced	_	_	VBD	O	-1	none	_	_
24	B-cell	_	_	NN	O	-1	none	_	_
25	apoptosis	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	caspase	_	_	NN	Protein	5	multitoken	_	_
5	1	_	_	CD	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	ICE	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	did	_	_	VBD	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	cleave	_	_	VB	O	-1	none	_	_
12	SP1	_	_	NN	Protein	-1	none	_	_
13	in	_	_	FW	O	-1	none	_	_
14	vitro	_	_	FW	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	time	_	_	NN	O	-1	none	_	_
3	course	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	SP1	_	_	NN	Protein	-1	none	_	_
6	cleavage	_	_	NN	O	-1	none	_	_
7	during	_	_	IN	O	-1	none	_	_
8	anti-IgM-induced	_	_	JJ	O	-1	none	_	_
9	apoptosis	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	paralleled	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	an	_	_	DT	O	-1	none	_	_
14	increase	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	caspase	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	measured	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	DEVD-p-nitroanilide	_	_	NN	O	-1	none	_	_
21	(	_	_	-LRB-	O	-1	none	_	_
22	DEVD-pNA	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	cleavage	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	DNA	_	_	NN	O	-1	none	_	_
2	band-shift	_	_	NN	O	-1	none	_	_
3	assays	_	_	NNS	O	-1	none	_	_
4	revealed	_	_	VBD	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	decrease	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	intensity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	full	_	_	JJ	O	-1	none	_	_
13	length	_	_	NN	O	-1	none	_	_
14	SP1	_	_	NN	Protein	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	DNA	_	_	NN	O	-1	none	_	_
17	complex	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	increase	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	intensity	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	a	_	_	DT	O	-1	none	_	_
26	smaller	_	_	JJR	O	-1	none	_	_
27	complex	_	_	NN	O	-1	none	_	_
28	due	_	_	JJ	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	binding	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	one	_	_	CD	O	-1	none	_	_
34	SP1	_	_	NN	Protein	-1	none	_	_
35	cleavage	_	_	NN	O	-1	none	_	_
36	product	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	Edman	_	_	NN	O	-1	none	_	_
3	sequencing	_	_	NN	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	could	_	_	MD	O	-1	none	_	_
6	identify	_	_	VB	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	caspase	_	_	NN	Protein	9	multitoken	_	_
9	3	_	_	CD	Protein	0	root	_	_
10	cleavage	_	_	NN	O	-1	none	_	_
11	site	_	_	NN	O	-1	none	_	_
12	after	_	_	IN	O	-1	none	_	_
13	Asp584	_	_	NN	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	D584AQPQAGR	_	_	NN	O	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	generating	_	_	VBG	O	-1	none	_	_
19	a	_	_	DT	O	-1	none	_	_
20	22-kDa	_	_	JJ	O	-1	none	_	_
21	C-terminal	_	_	JJ	O	-1	none	_	_
22	SP1	_	_	NN	Protein	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	fragment	_	_	NN	O	-1	none	_	_
25	which	_	_	WDT	O	-1	none	_	_
26	still	_	_	RB	O	-1	none	_	_
27	contains	_	_	VBZ	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	DNA	_	_	NN	O	-1	none	_	_
30	binding	_	_	NN	O	-1	none	_	_
31	site	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	cleavage	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factor	_	_	NN	O	-1	none	_	_
11	SP1	_	_	NN	Protein	-1	none	_	_
12	in	_	_	FW	O	-1	none	_	_
13	vivo	_	_	FW	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	in	_	_	FW	O	-1	none	_	_
16	vitro	_	_	FW	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	underlining	_	_	VBG	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	central	_	_	JJ	O	-1	none	_	_
21	role	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	caspase	_	_	NN	Protein	24	multitoken	_	_
24	3	_	_	CD	Protein	0	root	_	_
25	like	_	_	IN	O	-1	none	_	_
26	proteases	_	_	NNS	O	-1	none	_	_
27	during	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	process	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	anti-IgM-induced	_	_	JJ	O	-1	none	_	_
32	apoptosis	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	ICAM-1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	LFA-3	_	_	NN	Protein	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	Tax1	_	_	NN	Protein	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	human	_	_	NN	O	-1	none	_	_
10	T-cell	_	_	NN	O	-1	none	_	_
11	leukemia	_	_	NN	O	-1	none	_	_
12	virus	_	_	NN	O	-1	none	_	_
13	type	_	_	NN	O	-1	none	_	_
14	1	_	_	CD	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	mechanism	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	down-regulation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	ICAM-1	_	_	NN	Protein	-1	none	_	_
21	or	_	_	CC	O	-1	none	_	_
22	LFA-1	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	adult-T-cell-leukemia	_	_	JJ	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	lines	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	present	_	_	JJ	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	undertaken	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	determine	_	_	VB	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	role	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	HTLV-I	_	_	NN	O	-1	none	_	_
12	TaxI	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	up-regulation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	ICAM-I	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	LFA-3	_	_	NN	Protein	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	transformed	_	_	VBN	O	-1	none	_	_
25	with	_	_	IN	O	-1	none	_	_
26	HTLV-I	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	mechanism	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	down-regulation	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	ICAM-I	_	_	NN	Protein	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	LFA-I	_	_	NN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	ATL	_	_	NN	O	-1	none	_	_
38	derived	_	_	VBN	O	-1	none	_	_
39	cell	_	_	NN	O	-1	none	_	_
40	lines	_	_	NNS	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	TaxI	_	_	NN	Protein	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	T-cell	_	_	NN	O	-1	none	_	_
8	line	_	_	NN	O	-1	none	_	_
9	Jurkat	_	_	NN	O	-1	none	_	_
10	carrying	_	_	VBG	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	TaxI	_	_	NN	Protein	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	under	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	metallothionein	_	_	NN	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	led	_	_	VBD	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	increases	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	mRNA	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	surface	_	_	NN	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	ICAM-I	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	response	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	LFA-3	_	_	NN	Protein	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	TaxI	_	_	NN	Protein	-1	none	_	_
7	induction	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	on	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	other	_	_	JJ	O	-1	none	_	_
13	hand	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	relatively	_	_	RB	O	-1	none	_	_
16	slow	_	_	JJ	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	weak	_	_	JJ	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	might	_	_	MD	O	-1	none	_	_
22	be	_	_	VB	O	-1	none	_	_
23	indirect	_	_	JJ	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Transactivation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	ICAM-I	_	_	NN	Protein	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	TaxI	_	_	NN	Protein	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	further	_	_	JJ	O	-1	none	_	_
10	shown	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	co-transfection	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	CAT	_	_	NN	Protein	-1	none	_	_
16	reporter	_	_	NN	O	-1	none	_	_
17	construct	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	ICAM-I	_	_	NN	Protein	-1	none	_	_
21	promoter	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	plasmid	_	_	NN	O	-1	none	_	_
25	expressing	_	_	VBG	O	-1	none	_	_
26	TaxI	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mechanism	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	down-regulation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	ICAM-I	_	_	NN	Protein	-1	none	_	_
7	or	_	_	CC	O	-1	none	_	_
8	LFA-I	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	4	_	_	CD	O	-1	none	_	_
11	ATL	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	lines	_	_	NNS	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	next	_	_	JJ	O	-1	none	_	_
16	examined	_	_	VBN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	ICAM-I	_	_	NNP	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	quite	_	_	RB	O	-1	none	_	_
5	low	_	_	JJ	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	MT-I	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	no	_	_	DT	O	-1	none	_	_
11	genomic	_	_	JJ	O	-1	none	_	_
12	changes	_	_	NNS	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	CAT	_	_	NN	Protein	-1	none	_	_
3	reporter	_	_	NN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	ICAM-I	_	_	NN	Protein	-1	none	_	_
7	promoter	_	_	NN	O	-1	none	_	_
8	was	_	_	VBD	O	-1	none	_	_
9	inactive	_	_	JJ	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	MT-I	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	combined	_	_	JJ	O	-1	none	_	_
4	treatment	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	MT-I	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	5-azacytidine	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	IFN-gamma	_	_	NN	Protein	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	re-expression	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	ICAM-I	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Collectively	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	s	_	_	VBZ	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	necessary	_	_	JJ	O	-1	none	_	_
12	for	_	_	IN	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	ICAM-I	_	_	NN	Protein	-1	none	_	_
16	gene	_	_	NN	O	-1	none	_	_
17	may	_	_	MD	O	-1	none	_	_
18	be	_	_	VB	O	-1	none	_	_
19	repressed	_	_	VBN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	MT-I	_	_	NN	O	-1	none	_	_
22	through	_	_	IN	O	-1	none	_	_
23	DNA	_	_	NN	O	-1	none	_	_
24	methylation	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Three	_	_	CD	O	-1	none	_	_
2	other	_	_	JJ	O	-1	none	_	_
3	ATL	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	lines	_	_	NNS	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	TL-OmI	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	H582	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	HuT102	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	were	_	_	VBD	O	-1	none	_	_
14	found	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	have	_	_	VB	O	-1	none	_	_
17	little	_	_	JJ	O	-1	none	_	_
18	mRNA	_	_	NN	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	LFA-I	_	_	NN	Protein	23	multitoken	_	_
22	beta	_	_	NN	Protein	23	multitoken	_	_
23	chain	_	_	NN	Protein	0	root	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	CD18	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	H582	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	HuT102	_	_	NN	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	also	_	_	RB	O	-1	none	_	_
6	negative	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	LFA-I	_	_	NN	Protein	11	multitoken	_	_
10	alpha	_	_	NN	Protein	11	multitoken	_	_
11	chain	_	_	NN	Protein	0	root	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	CDIIa	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	mRNA	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	No	_	_	DT	O	-1	none	_	_
2	genomic	_	_	JJ	O	-1	none	_	_
3	changes	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	CAT	_	_	NN	Protein	-1	none	_	_
10	reporter	_	_	NN	O	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	CD18	_	_	NN	Protein	-1	none	_	_
15	promoter	_	_	NN	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	inactive	_	_	JJ	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	3	_	_	CD	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	them	_	_	PRP	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	again	_	_	RB	O	-1	none	_	_
25	suggesting	_	_	VBG	O	-1	none	_	_
26	lack	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	transcriptional	_	_	JJ	O	-1	none	_	_
32	factor	_	_	NN	O	-1	none	_	_
33	(	_	_	-LRB-	O	-1	none	_	_
34	s	_	_	VBZ	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	necessary	_	_	JJ	O	-1	none	_	_
37	for	_	_	IN	O	-1	none	_	_
38	CD18	_	_	NN	Protein	-1	none	_	_
39	expression	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Phorbol	_	_	NN	O	-1	none	_	_
2	ester	_	_	NN	O	-1	none	_	_
3	induced	_	_	VBD	O	-1	none	_	_
4	mononuclear	_	_	JJ	O	-1	none	_	_
5	cell	_	_	NN	O	-1	none	_	_
6	differentiation	_	_	NN	O	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	blocked	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mitogen	_	_	NN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	kinase	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	MEK	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	inhibitor	_	_	NN	O	-1	none	_	_
20	PD98059	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	purpose	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	evaluate	_	_	VB	O	-1	none	_	_
9	whether	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	mitogen	_	_	NN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	kinase	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	MAPK	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	signaling	_	_	NN	O	-1	none	_	_
19	pathway	_	_	NN	O	-1	none	_	_
20	contributes	_	_	VBZ	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	12-O-tetradecanoylphorbol-13-acetate	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	TPA	_	_	NN	O	-1	none	_	_
25	)-induced	_	_	JJ	O	-1	none	_	_
26	mononuclear	_	_	JJ	O	-1	none	_	_
27	differentiation	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	human	_	_	NN	O	-1	none	_	_
31	myeloblastic	_	_	JJ	O	-1	none	_	_
32	leukemia	_	_	NN	O	-1	none	_	_
33	ML-1	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	TPA	_	_	NN	O	-1	none	_	_
3	treatment	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	ERK1	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	ERK2	_	_	NN	Protein	-1	none	_	_
11	rapidly	_	_	RB	O	-1	none	_	_
12	increased	_	_	VBD	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	with	_	_	IN	O	-1	none	_	_
15	maximal	_	_	JJ	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	between	_	_	IN	O	-1	none	_	_
18	1	_	_	CD	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	3	_	_	CD	O	-1	none	_	_
21	h	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	while	_	_	IN	O	-1	none	_	_
24	ERK2	_	_	NN	Protein	-1	none	_	_
25	protein	_	_	NN	O	-1	none	_	_
26	levels	_	_	NNS	O	-1	none	_	_
27	remained	_	_	VBD	O	-1	none	_	_
28	constant	_	_	JJ	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	activity	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	JNK1	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	significantly	_	_	RB	O	-1	none	_	_
8	induced	_	_	VBN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	JNK1	_	_	NN	Protein	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	levels	_	_	NNS	O	-1	none	_	_
14	increasing	_	_	VBG	O	-1	none	_	_
15	moderately	_	_	RB	O	-1	none	_	_
16	during	_	_	IN	O	-1	none	_	_
17	exposure	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	TPA	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	PD98059	_	_	NN	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	specific	_	_	JJ	O	-1	none	_	_
9	inhibitor	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	mitogen	_	_	NN	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	protein	_	_	NN	O	-1	none	_	_
14	kinase	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	MEK	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	inhibited	_	_	VBD	O	-1	none	_	_
21	TPA	_	_	NN	O	-1	none	_	_
22	induced	_	_	JJ	O	-1	none	_	_
23	ERK2	_	_	NN	Protein	-1	none	_	_
24	activity	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	PD98059	_	_	NN	O	-1	none	_	_
4	completely	_	_	RB	O	-1	none	_	_
5	blocked	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	TPA	_	_	NN	O	-1	none	_	_
8	induced	_	_	VBD	O	-1	none	_	_
9	differentiation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	ML-1	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	as	_	_	IN	O	-1	none	_	_
15	assessed	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	number	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	features	_	_	NNS	O	-1	none	_	_
21	associated	_	_	VBN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	mononuclear	_	_	JJ	O	-1	none	_	_
24	differentiation	_	_	NN	O	-1	none	_	_
25	including	_	_	VBG	O	-1	none	_	_
26	changes	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	morphology	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	nonspecific	_	_	JJ	O	-1	none	_	_
31	esterase	_	_	NN	O	-1	none	_	_
32	activity	_	_	NN	O	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	phagocytic	_	_	JJ	O	-1	none	_	_
35	ability	_	_	NN	O	-1	none	_	_
36	,	_	_	,	O	-1	none	_	_
37	NADPH	_	_	NN	O	-1	none	_	_
38	oxidase	_	_	NN	O	-1	none	_	_
39	activity	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	mitochondrial	_	_	JJ	O	-1	none	_	_
42	respiration	_	_	NN	O	-1	none	_	_
43	,	_	_	,	O	-1	none	_	_
44	and	_	_	CC	O	-1	none	_	_
45	c-jun	_	_	NN	Protein	-1	none	_	_
46	mRNA	_	_	NN	O	-1	none	_	_
47	inducibility	_	_	NN	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	conclude	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	MEK	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	ERK	_	_	NN	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	pathway	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	necessary	_	_	JJ	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	TPA	_	_	NN	O	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	mononuclear	_	_	JJ	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	differentiation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Mutation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	Jak3	_	_	NN	Protein	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	patient	_	_	NN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	SCID	_	_	NN	O	-1	none	_	_
9	:	_	_	:	O	-1	none	_	_
10	essential	_	_	JJ	O	-1	none	_	_
11	role	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	Jak3	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	lymphoid	_	_	JJ	O	-1	none	_	_
16	development	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Males	_	_	NNS	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	X	_	_	NN	O	-1	none	_	_
4	linked	_	_	VBN	O	-1	none	_	_
5	severe	_	_	JJ	O	-1	none	_	_
6	combined	_	_	JJ	O	-1	none	_	_
7	immunodeficiency	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	XSCID	_	_	NN	O	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	have	_	_	VBP	O	-1	none	_	_
12	defects	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	common	_	_	JJ	O	-1	none	_	_
16	cytokine	_	_	NN	Protein	19	multitoken	_	_
17	receptor	_	_	NN	Protein	19	multitoken	_	_
18	gamma	_	_	NN	Protein	19	multitoken	_	_
19	chain	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	gamma	_	_	NN	Protein	22	multitoken	_	_
22	c	_	_	NN	Protein	0	root	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	that	_	_	WDT	O	-1	none	_	_
26	encodes	_	_	VBZ	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	shared	_	_	VBN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	essential	_	_	JJ	O	-1	none	_	_
31	component	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	receptors	_	_	NNS	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	interleukin-2	_	_	NN	Protein	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	IL-2	_	_	NN	Protein	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	IL-4	_	_	NN	Protein	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	IL-7	_	_	NN	Protein	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	IL-9	_	_	NN	Protein	-1	none	_	_
46	,	_	_	,	O	-1	none	_	_
47	and	_	_	CC	O	-1	none	_	_
48	IL-15	_	_	NN	Protein	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Janus	_	_	NN	O	-1	none	_	_
3	family	_	_	NN	O	-1	none	_	_
4	tyrosine	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	Jak3	_	_	NN	Protein	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	only	_	_	JJ	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	molecule	_	_	NN	O	-1	none	_	_
12	known	_	_	VBN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	associated	_	_	VBN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	gamma	_	_	NN	Protein	18	multitoken	_	_
18	c	_	_	NN	Protein	0	root	_	_
19	,	_	_	,	O	-1	none	_	_
20	so	_	_	IN	O	-1	none	_	_
21	it	_	_	PRP	O	-1	none	_	_
22	was	_	_	VBD	O	-1	none	_	_
23	hypothesized	_	_	VBN	O	-1	none	_	_
24	that	_	_	IN	O	-1	none	_	_
25	defects	_	_	NNS	O	-1	none	_	_
26	in	_	_	IN	O	-1	none	_	_
27	Jak3	_	_	NN	Protein	-1	none	_	_
28	might	_	_	MD	O	-1	none	_	_
29	cause	_	_	VB	O	-1	none	_	_
30	an	_	_	DT	O	-1	none	_	_
31	XSCID	_	_	NN	O	-1	none	_	_
32	like	_	_	IN	O	-1	none	_	_
33	phenotype	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	girl	_	_	NN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	immunological	_	_	JJ	O	-1	none	_	_
5	features	_	_	NNS	O	-1	none	_	_
6	indistinguishable	_	_	JJ	O	-1	none	_	_
7	from	_	_	IN	O	-1	none	_	_
8	those	_	_	DT	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	XSCID	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	therefore	_	_	RB	O	-1	none	_	_
13	selected	_	_	VBN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	analysis	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	An	_	_	DT	O	-1	none	_	_
2	Epstein-Barr	_	_	JJ	O	-1	none	_	_
3	virus	_	_	NN	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	)-transformed	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	line	_	_	NN	O	-1	none	_	_
9	derived	_	_	VBN	O	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	her	_	_	PRP$	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	had	_	_	VBD	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	gamma	_	_	NN	Protein	16	multitoken	_	_
16	c	_	_	NN	Protein	0	root	_	_
17	expression	_	_	NN	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	lacked	_	_	VBD	O	-1	none	_	_
20	Jak3	_	_	NN	Protein	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	had	_	_	VBD	O	-1	none	_	_
24	greatly	_	_	RB	O	-1	none	_	_
25	diminished	_	_	VBN	O	-1	none	_	_
26	Jak3	_	_	NN	Protein	-1	none	_	_
27	messenger	_	_	NN	O	-1	none	_	_
28	RNA	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Sequencing	_	_	NN	O	-1	none	_	_
2	revealed	_	_	VBD	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	different	_	_	JJ	O	-1	none	_	_
5	mutation	_	_	NN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	each	_	_	DT	O	-1	none	_	_
8	allele	_	_	NN	O	-1	none	_	_
9	:	_	_	:	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	single	_	_	JJ	O	-1	none	_	_
12	nucleotide	_	_	NN	O	-1	none	_	_
13	insertion	_	_	NN	O	-1	none	_	_
14	resulting	_	_	VBG	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	frame	_	_	NN	O	-1	none	_	_
18	shift	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	premature	_	_	JJ	O	-1	none	_	_
21	termination	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	Jak3	_	_	NN	Protein	-1	none	_	_
25	JH4	_	_	NN	O	-1	none	_	_
26	domain	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	nonsense	_	_	NN	O	-1	none	_	_
30	mutation	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	Jak3	_	_	NN	Protein	-1	none	_	_
34	JH2	_	_	NN	O	-1	none	_	_
35	domain	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	lack	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Jak3	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	correlated	_	_	VBD	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	impaired	_	_	JJ	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	signaling	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	demonstrated	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	inability	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	IL-4	_	_	NN	Protein	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	activate	_	_	VB	O	-1	none	_	_
22	Stat6	_	_	NN	Protein	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	EBV	_	_	NN	O	-1	none	_	_
26	transformed	_	_	VBN	O	-1	none	_	_
27	cell	_	_	NN	O	-1	none	_	_
28	line	_	_	NN	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	patient	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	observations	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	functions	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	gamma	_	_	NN	Protein	9	multitoken	_	_
9	c	_	_	NN	Protein	0	root	_	_
10	are	_	_	VBP	O	-1	none	_	_
11	dependent	_	_	JJ	O	-1	none	_	_
12	on	_	_	IN	O	-1	none	_	_
13	Jak3	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	Jak3	_	_	NN	Protein	-1	none	_	_
17	is	_	_	VBZ	O	-1	none	_	_
18	essential	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	lymphoid	_	_	JJ	O	-1	none	_	_
21	development	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	signaling	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Signal	_	_	NN	O	-1	none	_	_
2	transduction	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	DR3	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	death	_	_	NN	O	-1	none	_	_
8	domain	_	_	NN	O	-1	none	_	_
9	containing	_	_	VBG	O	-1	none	_	_
10	receptor	_	_	NN	O	-1	none	_	_
11	related	_	_	JJ	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	TNFR-1	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	CD95	_	_	NN	Protein	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Tumor	_	_	NN	Protein	4	multitoken	_	_
2	necrosis	_	_	NN	Protein	4	multitoken	_	_
3	factor	_	_	NN	Protein	4	multitoken	_	_
4	receptor-1	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	TNFR-1	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	CD95	_	_	NN	Protein	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	called	_	_	VBD	O	-1	none	_	_
13	Fas	_	_	NN	Protein	-1	none	_	_
14	or	_	_	CC	O	-1	none	_	_
15	APO-1	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	cytokine	_	_	NN	O	-1	none	_	_
19	receptors	_	_	NNS	O	-1	none	_	_
20	that	_	_	WDT	O	-1	none	_	_
21	engage	_	_	VBP	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	apoptosis	_	_	NN	O	-1	none	_	_
24	pathway	_	_	NN	O	-1	none	_	_
25	through	_	_	IN	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	region	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	intracellular	_	_	JJ	O	-1	none	_	_
30	homology	_	_	NN	O	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	designated	_	_	VBN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	"	_	_	``	O	-1	none	_	_
35	death	_	_	NN	O	-1	none	_	_
36	domain	_	_	NN	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_
38	"	_	_	''	O	-1	none	_	_

1	Another	_	_	DT	O	-1	none	_	_
2	death	_	_	NN	O	-1	none	_	_
3	domain	_	_	NN	O	-1	none	_	_
4	containing	_	_	VBG	O	-1	none	_	_
5	member	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	TNFR	_	_	NN	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	death	_	_	NN	Protein	13	multitoken	_	_
12	receptor	_	_	NN	Protein	13	multitoken	_	_
13	3	_	_	CD	Protein	0	root	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	DR3	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	identified	_	_	VBN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	was	_	_	VBD	O	-1	none	_	_
22	shown	_	_	VBN	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	induce	_	_	VB	O	-1	none	_	_
25	both	_	_	CC	O	-1	none	_	_
26	apoptosis	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	nuclear	_	_	JJ	O	-1	none	_	_
31	factor	_	_	NN	O	-1	none	_	_
32	kappaB	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Expression	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	DR3	_	_	NN	Protein	-1	none	_	_
4	appears	_	_	VBZ	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	restricted	_	_	JJ	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	tissues	_	_	NNS	O	-1	none	_	_
10	enriched	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	DR3	_	_	NN	Protein	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	transduction	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	mediated	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	complex	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	intracellular	_	_	JJ	O	-1	none	_	_
11	signaling	_	_	VBG	O	-1	none	_	_
12	molecules	_	_	NNS	O	-1	none	_	_
13	including	_	_	VBG	O	-1	none	_	_
14	TRADD	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	TRAF2	_	_	NN	Protein	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	FADD	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	FLICE	_	_	NNP	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	DR3	_	_	NN	Protein	-1	none	_	_
4	likely	_	_	JJ	O	-1	none	_	_
5	plays	_	_	VBZ	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	role	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	regulating	_	_	VBG	O	-1	none	_	_
10	lymphocyte	_	_	NN	O	-1	none	_	_
11	homeostasis	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Transient	_	_	JJ	O	-1	none	_	_
2	pseudo-hypoaldosteronism	_	_	NN	O	-1	none	_	_
3	following	_	_	VBG	O	-1	none	_	_
4	resection	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	ileum	_	_	NN	O	-1	none	_	_
8	:	_	_	:	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	level	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	lymphocytic	_	_	JJ	O	-1	none	_	_
13	aldosterone	_	_	NN	Protein	14	multitoken	_	_
14	receptors	_	_	NNS	Protein	0	root	_	_
15	outside	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	acute	_	_	JJ	O	-1	none	_	_
18	phase	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Pseudo-hypoaldosteronism	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	PHA	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	due	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	mineralocorticoid	_	_	NN	O	-1	none	_	_
9	resistance	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	manifests	_	_	VBZ	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	hyponatremia	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	hyperkalemia	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	increased	_	_	VBN	O	-1	none	_	_
18	plasma	_	_	NN	O	-1	none	_	_
19	aldosterone	_	_	NN	O	-1	none	_	_
20	levels	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	may	_	_	MD	O	-1	none	_	_
3	be	_	_	VB	O	-1	none	_	_
4	familial	_	_	JJ	O	-1	none	_	_
5	or	_	_	CC	O	-1	none	_	_
6	secondary	_	_	JJ	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	abnormal	_	_	JJ	O	-1	none	_	_
9	renal	_	_	JJ	O	-1	none	_	_
10	sodium	_	_	NN	O	-1	none	_	_
11	handling	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	case	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	54-year-old	_	_	JJ	O	-1	none	_	_
8	woman	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	multifocal	_	_	JJ	O	-1	none	_	_
11	cancer	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	colon	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	who	_	_	WP	O	-1	none	_	_
17	developed	_	_	VBD	O	-1	none	_	_
18	PHA	_	_	NN	O	-1	none	_	_
19	after	_	_	IN	O	-1	none	_	_
20	subtotal	_	_	JJ	O	-1	none	_	_
21	colectomy	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	ileal	_	_	JJ	O	-1	none	_	_
24	resection	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	jejunostomy	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	She	_	_	PRP	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	treated	_	_	VBN	O	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	6	_	_	CD	O	-1	none	_	_
6	g	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	salt	_	_	NN	O	-1	none	_	_
9	daily	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	prevent	_	_	VB	O	-1	none	_	_
12	dehydration	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	which	_	_	WDT	O	-1	none	_	_
15	she	_	_	PRP	O	-1	none	_	_
16	stopped	_	_	VBD	O	-1	none	_	_
17	herself	_	_	PRP	O	-1	none	_	_
18	because	_	_	IN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	reduced	_	_	VBN	O	-1	none	_	_
21	fecal	_	_	JJ	O	-1	none	_	_
22	losses	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	month	_	_	NN	O	-1	none	_	_
3	later	_	_	RB	O	-1	none	_	_
4	she	_	_	PRP	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	admitted	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	signs	_	_	NNS	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	acute	_	_	JJ	O	-1	none	_	_
11	adrenal	_	_	JJ	O	-1	none	_	_
12	failure	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	i.e.	_	_	FW	O	-1	none	_	_
15	fatigue	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	severe	_	_	JJ	O	-1	none	_	_
18	nausea	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	blood	_	_	NN	O	-1	none	_	_
21	pressure	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	80/60	_	_	CD	O	-1	none	_	_
24	mmHg	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	extracellular	_	_	JJ	O	-1	none	_	_
27	dehydration	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	hyponatremia	_	_	NN	O	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	118	_	_	CD	O	-1	none	_	_
32	mmol/l	_	_	NN	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	;	_	_	:	O	-1	none	_	_
35	hyperkalemia	_	_	NN	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	7.6	_	_	CD	O	-1	none	_	_
38	mmol/l	_	_	NN	O	-1	none	_	_
39	)	_	_	-RRB-	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	increased	_	_	VBN	O	-1	none	_	_
42	blood	_	_	NN	O	-1	none	_	_
43	urea	_	_	NN	O	-1	none	_	_
44	nitrogen	_	_	NN	O	-1	none	_	_
45	(	_	_	-LRB-	O	-1	none	_	_
46	BUN	_	_	NN	O	-1	none	_	_
47	)	_	_	-RRB-	O	-1	none	_	_
48	(	_	_	-LRB-	O	-1	none	_	_
49	200	_	_	CD	O	-1	none	_	_
50	mg/dl	_	_	NN	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	creatininemia	_	_	NN	O	-1	none	_	_
54	(	_	_	-LRB-	O	-1	none	_	_
55	2.5	_	_	CD	O	-1	none	_	_
56	mg/dl	_	_	NN	O	-1	none	_	_
57	)	_	_	-RRB-	O	-1	none	_	_
58	,	_	_	,	O	-1	none	_	_
59	and	_	_	CC	O	-1	none	_	_
60	decreased	_	_	VBD	O	-1	none	_	_
61	plasma	_	_	NN	O	-1	none	_	_
62	bicarbonates	_	_	NNS	O	-1	none	_	_
63	level	_	_	NN	O	-1	none	_	_
64	(	_	_	-LRB-	O	-1	none	_	_
65	HCO3-:	_	_	NN	O	-1	none	_	_
66	16	_	_	CD	O	-1	none	_	_
67	mmol/l	_	_	NN	O	-1	none	_	_
68	;	_	_	:	O	-1	none	_	_
69	N	_	_	NN	O	-1	none	_	_
70	:	_	_	:	O	-1	none	_	_
71	27-30	_	_	CD	O	-1	none	_	_
72	)	_	_	-RRB-	O	-1	none	_	_
73	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	plasma	_	_	NN	O	-1	none	_	_
5	cortisol	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	high	_	_	JJ	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	66	_	_	CD	O	-1	none	_	_
10	microg/100	_	_	NN	O	-1	none	_	_
11	ml	_	_	NN	O	-1	none	_	_
12	at	_	_	IN	O	-1	none	_	_
13	10:00	_	_	CD	O	-1	none	_	_
14	h	_	_	NN	O	-1	none	_	_
15	;	_	_	:	O	-1	none	_	_
16	N	_	_	NN	O	-1	none	_	_
17	:	_	_	:	O	-1	none	_	_
18	8-15	_	_	CD	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	ACTH	_	_	NN	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	normal	_	_	JJ	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	13	_	_	CD	O	-1	none	_	_
27	pg/ml	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	N	_	_	NN	O	-1	none	_	_
30	:	_	_	:	O	-1	none	_	_
31	10-60	_	_	CD	O	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	;	_	_	:	O	-1	none	_	_
34	there	_	_	EX	O	-1	none	_	_
35	was	_	_	VBD	O	-1	none	_	_
36	a	_	_	DT	O	-1	none	_	_
37	marked	_	_	JJ	O	-1	none	_	_
38	increase	_	_	NN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	plasma	_	_	NN	O	-1	none	_	_
41	renin	_	_	NN	Protein	-1	none	_	_
42	activity	_	_	NN	O	-1	none	_	_
43	(	_	_	-LRB-	O	-1	none	_	_
44	>	_	_	JJR	O	-1	none	_	_
45	37	_	_	CD	O	-1	none	_	_
46	ng/ml/h	_	_	NN	O	-1	none	_	_
47	;	_	_	:	O	-1	none	_	_
48	N	_	_	NN	O	-1	none	_	_
49	supine	_	_	NN	O	-1	none	_	_
50	<	_	_	JJR	O	-1	none	_	_
51	3	_	_	CD	O	-1	none	_	_
52	)	_	_	-RRB-	O	-1	none	_	_
53	,	_	_	,	O	-1	none	_	_
54	active	_	_	JJ	O	-1	none	_	_
55	renin	_	_	NN	Protein	-1	none	_	_
56	(	_	_	-LRB-	O	-1	none	_	_
57	869	_	_	CD	O	-1	none	_	_
58	pg/ml	_	_	NN	O	-1	none	_	_
59	;	_	_	:	O	-1	none	_	_
60	N	_	_	NN	O	-1	none	_	_
61	supine	_	_	NN	O	-1	none	_	_
62	:	_	_	:	O	-1	none	_	_
63	1.120	_	_	CD	O	-1	none	_	_
64	)	_	_	-RRB-	O	-1	none	_	_
65	,	_	_	,	O	-1	none	_	_
66	aldosterone	_	_	NN	O	-1	none	_	_
67	(	_	_	-LRB-	O	-1	none	_	_
68	>	_	_	JJR	O	-1	none	_	_
69	2000	_	_	CD	O	-1	none	_	_
70	pg/ml	_	_	NN	O	-1	none	_	_
71	;	_	_	:	O	-1	none	_	_
72	N	_	_	NN	O	-1	none	_	_
73	supine	_	_	NN	O	-1	none	_	_
74	<	_	_	JJR	O	-1	none	_	_
75	150	_	_	CD	O	-1	none	_	_
76	)	_	_	-RRB-	O	-1	none	_	_
77	and	_	_	CC	O	-1	none	_	_
78	plasma	_	_	NN	O	-1	none	_	_
79	AVP	_	_	NN	O	-1	none	_	_
80	(	_	_	-LRB-	O	-1	none	_	_
81	20	_	_	CD	O	-1	none	_	_
82	pmol/l	_	_	NN	O	-1	none	_	_
83	;	_	_	:	O	-1	none	_	_
84	N	_	_	NN	O	-1	none	_	_
85	:	_	_	:	O	-1	none	_	_
86	0.5-2	_	_	CD	O	-1	none	_	_
87	.5	_	_	CD	O	-1	none	_	_
88	)	_	_	-RRB-	O	-1	none	_	_
89	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	plasma	_	_	NN	O	-1	none	_	_
3	ANH	_	_	NN	O	-1	none	_	_
4	level	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	38	_	_	CD	O	-1	none	_	_
7	pmol/l	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	N	_	_	NN	O	-1	none	_	_
10	supine	_	_	NN	O	-1	none	_	_
11	:	_	_	:	O	-1	none	_	_
12	5-25	_	_	CD	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	urinary	_	_	JJ	O	-1	none	_	_
3	steroidogram	_	_	NN	O	-1	none	_	_
4	resulted	_	_	VBD	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	highly	_	_	RB	O	-1	none	_	_
7	elevated	_	_	JJ	O	-1	none	_	_
8	tetrahydrocortisol	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	THF	_	_	NN	O	-1	none	_	_
11	:	_	_	:	O	-1	none	_	_
12	13.3	_	_	CD	O	-1	none	_	_
13	mg/24h	_	_	NN	O	-1	none	_	_
14	;	_	_	:	O	-1	none	_	_
15	N	_	_	NN	O	-1	none	_	_
16	:	_	_	:	O	-1	none	_	_
17	1.4	_	_	CD	O	-1	none	_	_
18	+/-0.8	_	_	CD	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	no	_	_	DT	O	-1	none	_	_
22	increase	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	tetrahydrocortisone	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	THE	_	_	DT	O	-1	none	_	_
27	:	_	_	:	O	-1	none	_	_
28	3.16	_	_	CD	O	-1	none	_	_
29	mg/24h	_	_	NN	O	-1	none	_	_
30	;	_	_	:	O	-1	none	_	_
31	N	_	_	NN	O	-1	none	_	_
32	:	_	_	:	O	-1	none	_	_
33	2.7	_	_	CD	O	-1	none	_	_
34	+/-2.0	_	_	CD	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	excretion	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	with	_	_	IN	O	-1	none	_	_
40	low	_	_	JJ	O	-1	none	_	_
41	THE	_	_	DT	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	THF	_	_	NN	O	-1	none	_	_
44	(	_	_	-LRB-	O	-1	none	_	_
45	0.24	_	_	CD	O	-1	none	_	_
46	;	_	_	:	O	-1	none	_	_
47	N	_	_	NN	O	-1	none	_	_
48	:	_	_	:	O	-1	none	_	_
49	1.87	_	_	CD	O	-1	none	_	_
50	+/-0.36	_	_	CD	O	-1	none	_	_
51	)	_	_	-RRB-	O	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	alpha	_	_	NN	O	-1	none	_	_
54	THF	_	_	NN	O	-1	none	_	_
55	and	_	_	CC	O	-1	none	_	_
56	THF	_	_	NN	O	-1	none	_	_
57	(	_	_	-LRB-	O	-1	none	_	_
58	0.35	_	_	CD	O	-1	none	_	_
59	;	_	_	:	O	-1	none	_	_
60	N	_	_	NN	O	-1	none	_	_
61	:	_	_	:	O	-1	none	_	_
62	0.92	_	_	CD	O	-1	none	_	_
63	+/-0.42	_	_	CD	O	-1	none	_	_
64	)	_	_	-RRB-	O	-1	none	_	_
65	ratios	_	_	NNS	O	-1	none	_	_
66	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	number	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	mineralocorticoid	_	_	NN	Protein	5	multitoken	_	_
5	receptors	_	_	NNS	Protein	0	root	_	_
6	in	_	_	IN	O	-1	none	_	_
7	mononuclear	_	_	JJ	O	-1	none	_	_
8	leukocytes	_	_	NNS	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	lower	_	_	JJR	O	-1	none	_	_
13	normal	_	_	JJ	O	-1	none	_	_
14	range	_	_	NN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	age	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	while	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	number	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	glucocorticoid	_	_	NN	Protein	23	multitoken	_	_
23	receptors	_	_	NNS	Protein	0	root	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	reduced	_	_	VBN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Small-bowel	_	_	JJ	O	-1	none	_	_
2	resection	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	ileostomized	_	_	JJ	O	-1	none	_	_
5	patients	_	_	NNS	O	-1	none	_	_
6	causes	_	_	VBZ	O	-1	none	_	_
7	excessive	_	_	JJ	O	-1	none	_	_
8	fecal	_	_	JJ	O	-1	none	_	_
9	sodium	_	_	NN	O	-1	none	_	_
10	losses	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	results	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	chronic	_	_	JJ	O	-1	none	_	_
15	sodium	_	_	NN	O	-1	none	_	_
16	depletion	_	_	NN	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	contraction	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	plasma	_	_	NN	O	-1	none	_	_
22	volume	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	severe	_	_	JJ	O	-1	none	_	_
25	secondary	_	_	JJ	O	-1	none	_	_
26	hyperaldosteronism	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Nevertheless	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	hyperaldosteronism	_	_	NN	O	-1	none	_	_
5	may	_	_	MD	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	associated	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	hyponatremia	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	hyperkalemia	_	_	NN	O	-1	none	_	_
12	suggesting	_	_	VBG	O	-1	none	_	_
13	PHA	_	_	NN	O	-1	none	_	_
14	related	_	_	JJ	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	major	_	_	JJ	O	-1	none	_	_
18	importance	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	colon	_	_	NN	O	-1	none	_	_
22	for	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	absorption	_	_	NN	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	sodium	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	case	_	_	NN	O	-1	none	_	_
6	report	_	_	NN	O	-1	none	_	_
7	emphasizes	_	_	VBZ	O	-1	none	_	_
8	1	_	_	CD	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	possibility	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	syndrome	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	acquired	_	_	VBN	O	-1	none	_	_
17	PHA	_	_	NN	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	severe	_	_	JJ	O	-1	none	_	_
20	hyperkalemia	_	_	NN	O	-1	none	_	_
21	after	_	_	IN	O	-1	none	_	_
22	resection	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	ileum	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	colon	_	_	NN	O	-1	none	_	_
28	responding	_	_	VBG	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	oral	_	_	JJ	O	-1	none	_	_
31	salt	_	_	NN	O	-1	none	_	_
32	supplementation	_	_	NN	O	-1	none	_	_
33	;	_	_	:	O	-1	none	_	_
34	2	_	_	CD	O	-1	none	_	_
35	)	_	_	-RRB-	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	major	_	_	JJ	O	-1	none	_	_
38	increase	_	_	NN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	AVP	_	_	NN	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	the	_	_	DT	O	-1	none	_	_
43	small	_	_	JJ	O	-1	none	_	_
44	increase	_	_	NN	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	ANH	_	_	NN	O	-1	none	_	_
47	;	_	_	:	O	-1	none	_	_
48	3	_	_	CD	O	-1	none	_	_
49	)	_	_	-RRB-	O	-1	none	_	_
50	the	_	_	DT	O	-1	none	_	_
51	strong	_	_	JJ	O	-1	none	_	_
52	increase	_	_	NN	O	-1	none	_	_
53	in	_	_	IN	O	-1	none	_	_
54	urinary	_	_	JJ	O	-1	none	_	_
55	THF	_	_	NN	O	-1	none	_	_
56	with	_	_	IN	O	-1	none	_	_
57	low	_	_	JJ	O	-1	none	_	_
58	THE	_	_	DT	O	-1	none	_	_
59	and	_	_	CC	O	-1	none	_	_
60	THF	_	_	NN	O	-1	none	_	_
61	and	_	_	CC	O	-1	none	_	_
62	alpha	_	_	NN	O	-1	none	_	_
63	THF	_	_	NN	O	-1	none	_	_
64	and	_	_	CC	O	-1	none	_	_
65	THF	_	_	NN	O	-1	none	_	_
66	ratios	_	_	NNS	O	-1	none	_	_
67	;	_	_	:	O	-1	none	_	_
68	4	_	_	CD	O	-1	none	_	_
69	)	_	_	-RRB-	O	-1	none	_	_
70	the	_	_	DT	O	-1	none	_	_
71	normal	_	_	JJ	O	-1	none	_	_
72	number	_	_	NN	O	-1	none	_	_
73	of	_	_	IN	O	-1	none	_	_
74	lymphocytic	_	_	JJ	O	-1	none	_	_
75	mineralocorticoid	_	_	NN	Protein	76	multitoken	_	_
76	receptors	_	_	NNS	Protein	0	root	_	_
77	outside	_	_	IN	O	-1	none	_	_
78	the	_	_	DT	O	-1	none	_	_
79	acute	_	_	JJ	O	-1	none	_	_
80	episode	_	_	NN	O	-1	none	_	_
81	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	DNA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	steroid	_	_	NN	O	-1	none	_	_
5	binding	_	_	NN	O	-1	none	_	_
6	domains	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	glucocorticoid	_	_	NN	Protein	10	multitoken	_	_
10	receptor	_	_	NN	Protein	0	root	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	altered	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	mononuclear	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	treated	_	_	JJ	O	-1	none	_	_
19	CLL	_	_	NN	O	-1	none	_	_
20	patients	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	aim	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	this	_	_	DT	O	-1	none	_	_
5	study	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	investigate	_	_	VB	O	-1	none	_	_
9	whether	_	_	IN	O	-1	none	_	_
10	mutations	_	_	NNS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	glucocorticoid	_	_	NN	Protein	14	multitoken	_	_
14	receptor	_	_	NN	Protein	0	root	_	_
15	could	_	_	MD	O	-1	none	_	_
16	account	_	_	VB	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	increasing	_	_	VBG	O	-1	none	_	_
20	unresponsiveness	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	patients	_	_	NNS	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	chronic	_	_	JJ	O	-1	none	_	_
25	lymphatic	_	_	JJ	O	-1	none	_	_
26	leukemia	_	_	NN	O	-1	none	_	_
27	(	_	_	-LRB-	O	-1	none	_	_
28	CLL	_	_	NN	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	combination	_	_	NN	O	-1	none	_	_
32	chemotherapy	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	receptor	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	tested	_	_	VBN	O	-1	none	_	_
5	immunocytochemically	_	_	RB	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	steroid	_	_	NN	O	-1	none	_	_
9	binding	_	_	NN	O	-1	none	_	_
10	assays	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	mutation	_	_	NN	O	-1	none	_	_
16	screening	_	_	NN	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	denaturing	_	_	VBG	O	-1	none	_	_
19	gradient	_	_	NN	O	-1	none	_	_
20	gel	_	_	NN	O	-1	none	_	_
21	electrophoresis	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	receptor-cDNA	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	receptor	_	_	NN	O	-1	none	_	_
3	concentration	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	measured	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	staining	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	steroid	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	test	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	varied	_	_	VBD	O	-1	none	_	_
15	considerably	_	_	RB	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	showed	_	_	VBD	O	-1	none	_	_
18	no	_	_	DT	O	-1	none	_	_
19	clear	_	_	JJ	O	-1	none	_	_
20	correlation	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	clinical	_	_	JJ	O	-1	none	_	_
23	response	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	highly	_	_	RB	O	-1	none	_	_
4	sensitive	_	_	JJ	O	-1	none	_	_
5	mutation	_	_	NN	O	-1	none	_	_
6	screening	_	_	NN	O	-1	none	_	_
7	assay	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	DNA-	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	steroid	_	_	NN	O	-1	none	_	_
14	binding	_	_	NN	O	-1	none	_	_
15	region	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	none	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	treated	_	_	JJ	O	-1	none	_	_
21	patients	_	_	NNS	O	-1	none	_	_
22	revealed	_	_	VBD	O	-1	none	_	_
23	any	_	_	DT	O	-1	none	_	_
24	mutation	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	suggesting	_	_	VBG	O	-1	none	_	_
27	that	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	glucocorticoid	_	_	NN	Protein	30	multitoken	_	_
30	receptor	_	_	NN	Protein	0	root	_	_
31	in	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	CLL	_	_	NN	O	-1	none	_	_
34	patients	_	_	NNS	O	-1	none	_	_
35	tested	_	_	VBN	O	-1	none	_	_
36	is	_	_	VBZ	O	-1	none	_	_
37	not	_	_	RB	O	-1	none	_	_
38	altered	_	_	VBN	O	-1	none	_	_
39	in	_	_	IN	O	-1	none	_	_
40	these	_	_	DT	O	-1	none	_	_
41	domains	_	_	NNS	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	one	_	_	CD	O	-1	none	_	_
3	individual	_	_	NN	O	-1	none	_	_
4	who	_	_	WP	O	-1	none	_	_
5	had	_	_	VBD	O	-1	none	_	_
6	not	_	_	RB	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	treated	_	_	VBN	O	-1	none	_	_
9	before	_	_	IN	O	-1	none	_	_
10	analysis	_	_	NN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	silent	_	_	JJ	O	-1	none	_	_
13	mutation	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	found	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	one	_	_	CD	O	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	allele	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	mechanisms	_	_	NNS	O	-1	none	_	_
6	other	_	_	JJ	O	-1	none	_	_
7	than	_	_	IN	O	-1	none	_	_
8	altered	_	_	JJ	O	-1	none	_	_
9	ligand	_	_	NN	O	-1	none	_	_
10	or	_	_	CC	O	-1	none	_	_
11	DNA	_	_	NN	O	-1	none	_	_
12	binding	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	receptor	_	_	NN	O	-1	none	_	_
16	may	_	_	MD	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	responsible	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	lack	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	response	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	chemotherapy	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	conclusion	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	discussed	_	_	VBN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	relation	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	mechanism	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	corticoid	_	_	NN	O	-1	none	_	_
12	resistance	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	mouse	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	lymphoma	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	culture	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Clonality	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	isolated	_	_	VBN	O	-1	none	_	_
4	eosinophils	_	_	NNS	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	hypereosinophilic	_	_	JJ	O	-1	none	_	_
8	syndrome	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	idiopathic	_	_	JJ	O	-1	none	_	_
3	hypereosinophilic	_	_	JJ	O	-1	none	_	_
4	syndrome	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	IHES	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	rare	_	_	JJ	O	-1	none	_	_
11	disorder	_	_	NN	O	-1	none	_	_
12	characterized	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	unexplained	_	_	JJ	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	persistent	_	_	JJ	O	-1	none	_	_
17	eosinophilia	_	_	NN	O	-1	none	_	_
18	associated	_	_	VBN	O	-1	none	_	_
19	with	_	_	IN	O	-1	none	_	_
20	multiple	_	_	JJ	O	-1	none	_	_
21	organ	_	_	NN	O	-1	none	_	_
22	dysfunction	_	_	NN	O	-1	none	_	_
23	due	_	_	JJ	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	eosinophilic	_	_	JJ	O	-1	none	_	_
26	tissue	_	_	NN	O	-1	none	_	_
27	infiltration	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	absence	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	karyotypic	_	_	JJ	O	-1	none	_	_
6	abnormalities	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	there	_	_	EX	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	no	_	_	DT	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	test	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	detect	_	_	VB	O	-1	none	_	_
15	clonal	_	_	JJ	O	-1	none	_	_
16	eosinophilia	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	IHES	_	_	NN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Analysis	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	X-chromosome	_	_	NN	O	-1	none	_	_
4	inactivation	_	_	NN	O	-1	none	_	_
5	patterns	_	_	NNS	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	used	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	determine	_	_	VB	O	-1	none	_	_
11	whether	_	_	IN	O	-1	none	_	_
12	proliferative	_	_	JJ	O	-1	none	_	_
13	disorders	_	_	NNS	O	-1	none	_	_
14	are	_	_	VBP	O	-1	none	_	_
15	clonal	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	origin	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Methylation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	HpaII	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	Hha	_	_	NN	O	-1	none	_	_
6	I	_	_	PRP	O	-1	none	_	_
7	sites	_	_	NNS	O	-1	none	_	_
8	near	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	polymorphic	_	_	JJ	O	-1	none	_	_
11	trinucleotide	_	_	NN	O	-1	none	_	_
12	repeat	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	human	_	_	NN	Protein	17	multitoken	_	_
16	androgen	_	_	NN	Protein	17	multitoken	_	_
17	receptor	_	_	NN	Protein	0	root	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	HUMARA	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	has	_	_	VBZ	O	-1	none	_	_
23	been	_	_	VBN	O	-1	none	_	_
24	shown	_	_	VBN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	correlate	_	_	VB	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	X	_	_	NN	O	-1	none	_	_
29	inactivation	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	used	_	_	VBN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	polymerase	_	_	NN	O	-1	none	_	_
10	chain	_	_	NN	O	-1	none	_	_
11	reaction	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	PCR	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	nested	_	_	JJ	O	-1	none	_	_
17	primers	_	_	NNS	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	analyze	_	_	VB	O	-1	none	_	_
20	X	_	_	NN	O	-1	none	_	_
21	inactivation	_	_	NN	O	-1	none	_	_
22	patterns	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	HUMARA	_	_	NN	Protein	-1	none	_	_
26	loci	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	purified	_	_	VBN	O	-1	none	_	_
29	eosinophils	_	_	NNS	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	female	_	_	JJ	O	-1	none	_	_
32	patients	_	_	NNS	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	eosinophilia	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Peripheral	_	_	JJ	O	-1	none	_	_
2	blood	_	_	NN	O	-1	none	_	_
3	eosinophils	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	isolated	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	their	_	_	PRP$	O	-1	none	_	_
8	autofluoresence	_	_	NN	O	-1	none	_	_
9	using	_	_	VBG	O	-1	none	_	_
10	flow	_	_	NN	O	-1	none	_	_
11	cytometric	_	_	JJ	O	-1	none	_	_
12	sorting	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Eosinophils	_	_	NNS	O	-1	none	_	_
2	purified	_	_	VBN	O	-1	none	_	_
3	from	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	female	_	_	JJ	O	-1	none	_	_
6	patient	_	_	NN	O	-1	none	_	_
7	presenting	_	_	VBG	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	IHES	_	_	NN	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	found	_	_	VBN	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	show	_	_	VB	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	clonal	_	_	JJ	O	-1	none	_	_
16	pattern	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	X	_	_	NN	O	-1	none	_	_
19	inactivation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Eosinophil	_	_	NN	O	-1	none	_	_
2	depleted	_	_	VBD	O	-1	none	_	_
3	leukocytes	_	_	NNS	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	patient	_	_	NN	O	-1	none	_	_
7	were	_	_	VBD	O	-1	none	_	_
8	polyclonal	_	_	JJ	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	HUMARA	_	_	NN	Protein	-1	none	_	_
11	analysis	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	thus	_	_	RB	O	-1	none	_	_
14	excluding	_	_	VBG	O	-1	none	_	_
15	skewedness	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	random	_	_	JJ	O	-1	none	_	_
18	X	_	_	NN	O	-1	none	_	_
19	inactivation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	corticosteroid	_	_	NN	O	-1	none	_	_
3	suppression	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	her	_	_	PRP$	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	eosinophilia	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	clonal	_	_	JJ	O	-1	none	_	_
11	population	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	eosinophils	_	_	NNS	O	-1	none	_	_
14	could	_	_	MD	O	-1	none	_	_
15	no	_	_	RB	O	-1	none	_	_
16	longer	_	_	RB	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	detected	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	purified	_	_	VBN	O	-1	none	_	_
21	eosinophils	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	eosinophils	_	_	NNS	O	-1	none	_	_
5	purified	_	_	VBN	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	patient	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	Churg-Strauss	_	_	JJ	O	-1	none	_	_
11	syndrome	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	from	_	_	IN	O	-1	none	_	_
14	six	_	_	CD	O	-1	none	_	_
15	patients	_	_	NNS	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	reactive	_	_	JJ	O	-1	none	_	_
18	eosinophilias	_	_	NNS	O	-1	none	_	_
19	attributed	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	allergy	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	parasitic	_	_	JJ	O	-1	none	_	_
24	infection	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	or	_	_	CC	O	-1	none	_	_
27	drug	_	_	NN	O	-1	none	_	_
28	reaction	_	_	NN	O	-1	none	_	_
29	showed	_	_	VBD	O	-1	none	_	_
30	a	_	_	DT	O	-1	none	_	_
31	polyclonal	_	_	JJ	O	-1	none	_	_
32	pattern	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	X	_	_	NN	O	-1	none	_	_
35	inactivation	_	_	NN	O	-1	none	_	_
36	by	_	_	IN	O	-1	none	_	_
37	HUMARA	_	_	NN	Protein	-1	none	_	_
38	analysis	_	_	NN	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	finding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	clonal	_	_	JJ	O	-1	none	_	_
5	eosinophilia	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	patient	_	_	NN	O	-1	none	_	_
9	presenting	_	_	VBG	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	IHES	_	_	NN	O	-1	none	_	_
12	indicates	_	_	VBZ	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	such	_	_	JJ	O	-1	none	_	_
15	patients	_	_	NNS	O	-1	none	_	_
16	may	_	_	MD	O	-1	none	_	_
17	have	_	_	VB	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	reality	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	low-grade	_	_	JJ	O	-1	none	_	_
24	clonal	_	_	JJ	O	-1	none	_	_
25	disorder	_	_	NN	O	-1	none	_	_
26	that	_	_	WDT	O	-1	none	_	_
27	can	_	_	MD	O	-1	none	_	_
28	be	_	_	VB	O	-1	none	_	_
29	distinguished	_	_	VBN	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	reactive	_	_	JJ	O	-1	none	_	_
32	eosinophilias	_	_	NNS	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	HUMARA	_	_	NN	Protein	-1	none	_	_
35	analysis	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Further	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	method	_	_	NN	O	-1	none	_	_
5	described	_	_	VBN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	used	_	_	VBN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	monitor	_	_	VB	O	-1	none	_	_
11	disease	_	_	NN	O	-1	none	_	_
12	progression	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Cutting	_	_	JJ	O	-1	none	_	_
2	edge	_	_	NN	O	-1	none	_	_
3	:	_	_	:	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	NF	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	activated	_	_	VBN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	eosinophils	_	_	NNS	O	-1	none	_	_
14	:	_	_	:	O	-1	none	_	_
15	regulation	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	IL-4	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	IL-5	_	_	NN	Protein	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	report	_	_	VBP	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	NF-AT1	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	NF-AT4	_	_	NN	Protein	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	expressed	_	_	VBN	O	-1	none	_	_
9	cytoplasmically	_	_	RB	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	resting	_	_	VBG	O	-1	none	_	_
12	eosinophils	_	_	NNS	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	whereas	_	_	IN	O	-1	none	_	_
15	NF-AT2	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	NF-AT3	_	_	NN	Protein	-1	none	_	_
18	have	_	_	VBP	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	been	_	_	VBN	O	-1	none	_	_
21	seen	_	_	VBN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Likewise	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	NF-AT1	_	_	NN	Protein	-1	none	_	_
4	mRNA	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	NF-AT4	_	_	NN	Protein	-1	none	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	have	_	_	VBP	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	detected	_	_	VBN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	resting	_	_	VBG	O	-1	none	_	_
13	eosinophils	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	their	_	_	PRP$	O	-1	none	_	_
17	levels	_	_	NNS	O	-1	none	_	_
18	can	_	_	MD	O	-1	none	_	_
19	be	_	_	VB	O	-1	none	_	_
20	significantly	_	_	RB	O	-1	none	_	_
21	up-regulated	_	_	VBN	O	-1	none	_	_
22	by	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	Th2	_	_	NN	O	-1	none	_	_
25	associated	_	_	VBN	O	-1	none	_	_
26	cytokines	_	_	NNS	O	-1	none	_	_
27	IL-4	_	_	NN	Protein	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	IL-5	_	_	NN	Protein	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	no	_	_	DT	O	-1	none	_	_
4	detectable	_	_	JJ	O	-1	none	_	_
5	NF-AT	_	_	NN	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	nuclei	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	resting	_	_	VBG	O	-1	none	_	_
13	eosinophils	_	_	NNS	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	delineate	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	novel	_	_	JJ	O	-1	none	_	_
6	pathway	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	cytokine	_	_	NN	O	-1	none	_	_
10	network	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	which	_	_	WDT	O	-1	none	_	_
13	Th2	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	"	_	_	``	O	-1	none	_	_
16	control	_	_	NN	O	-1	none	_	_
17	"	_	_	''	O	-1	none	_	_
18	eosinophils	_	_	NNS	O	-1	none	_	_
19	via	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	release	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	IL-4	_	_	NN	Protein	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	IL-5	_	_	NN	Protein	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	NF-AT	_	_	NN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	eosinophils	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	also	_	_	RB	O	-1	none	_	_
4	suggest	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	later	_	_	JJ	O	-1	none	_	_
8	feedback	_	_	NN	O	-1	none	_	_
9	"	_	_	''	O	-1	none	_	_
10	talking	_	_	VBG	O	-1	none	_	_
11	"	_	_	``	O	-1	none	_	_
12	may	_	_	MD	O	-1	none	_	_
13	exist	_	_	VB	O	-1	none	_	_
14	between	_	_	IN	O	-1	none	_	_
15	eosinophils	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	Th2	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Epstein-Barr	_	_	NNP	Protein	5	multitoken	_	_
2	virus	_	_	NN	Protein	5	multitoken	_	_
3	nuclear	_	_	JJ	Protein	5	multitoken	_	_
4	antigen	_	_	NN	Protein	5	multitoken	_	_
5	2	_	_	CD	Protein	0	root	_	_
6	transactivates	_	_	VBZ	O	-1	none	_	_
7	latent	_	_	JJ	O	-1	none	_	_
8	membrane	_	_	NN	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	LMP1	_	_	NN	Protein	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	lines	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	evidence	_	_	NN	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	compatible	_	_	JJ	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	hypothesis	_	_	NN	O	-1	none	_	_
10	that	_	_	IN	O	-1	none	_	_
11	Epstein-Barr	_	_	JJ	Protein	18	multitoken	_	_
12	virus	_	_	NN	Protein	18	multitoken	_	_
13	(	_	_	-LRB-	Protein	18	multitoken	_	_
14	EBV	_	_	NN	Protein	18	multitoken	_	_
15	)	_	_	-RRB-	Protein	18	multitoken	_	_
16	nuclear	_	_	JJ	Protein	18	multitoken	_	_
17	antigen	_	_	NN	Protein	18	multitoken	_	_
18	2	_	_	CD	Protein	0	root	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	EBNA-2	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	or	_	_	CC	O	-1	none	_	_
23	leader	_	_	NN	O	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	EBNA-LP	_	_	NN	Protein	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	affects	_	_	VBZ	O	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	EBV	_	_	NN	O	-1	none	_	_
33	latent	_	_	JJ	O	-1	none	_	_
34	infection	_	_	NN	O	-1	none	_	_
35	membrane	_	_	NN	O	-1	none	_	_
36	protein	_	_	NN	O	-1	none	_	_
37	LMP1	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	now	_	_	RB	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	following	_	_	VBG	O	-1	none	_	_
6	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	i	_	_	FW	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	Acute	_	_	JJ	O	-1	none	_	_
5	transfection	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	EBNA-2	_	_	NN	Protein	-1	none	_	_
10	under	_	_	IN	O	-1	none	_	_
11	control	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	simian	_	_	JJ	O	-1	none	_	_
14	virus	_	_	NN	O	-1	none	_	_
15	40	_	_	CD	O	-1	none	_	_
16	or	_	_	CC	O	-1	none	_	_
17	Moloney	_	_	NN	O	-1	none	_	_
18	murine	_	_	JJ	O	-1	none	_	_
19	leukemia	_	_	NN	O	-1	none	_	_
20	virus	_	_	NN	O	-1	none	_	_
21	promoters	_	_	NNS	O	-1	none	_	_
22	resulted	_	_	VBD	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	increased	_	_	VBN	O	-1	none	_	_
25	LMP1	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	P3HR-1-infected	_	_	JJ	O	-1	none	_	_
29	Burkitt	_	_	NN	O	-1	none	_	_
30	's	_	_	POS	O	-1	none	_	_
31	lymphoma	_	_	NN	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	the	_	_	DT	O	-1	none	_	_
35	P3HR-1	_	_	NN	O	-1	none	_	_
36	or	_	_	CC	O	-1	none	_	_
37	Daudi	_	_	NN	O	-1	none	_	_
38	cell	_	_	NN	O	-1	none	_	_
39	line	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ii	_	_	LS	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	Transfection	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	EBNA-LP	_	_	NN	Protein	-1	none	_	_
9	alone	_	_	RB	O	-1	none	_	_
10	had	_	_	VBD	O	-1	none	_	_
11	no	_	_	DT	O	-1	none	_	_
12	effect	_	_	NN	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	LMP1	_	_	NN	Protein	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	did	_	_	VBD	O	-1	none	_	_
18	not	_	_	RB	O	-1	none	_	_
19	act	_	_	VB	O	-1	none	_	_
20	synergistically	_	_	RB	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	EBNA-2	_	_	NN	Protein	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	affect	_	_	VB	O	-1	none	_	_
25	LMP1	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	iii	_	_	LS	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	LMP1	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	Daudi	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	P3HR-1-infected	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	controlled	_	_	VBN	O	-1	none	_	_
13	at	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	mRNA	_	_	NN	O	-1	none	_	_
16	level	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	EBNA-2	_	_	NN	Protein	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	Daudi	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	increased	_	_	VBD	O	-1	none	_	_
25	LMP1	_	_	NN	Protein	-1	none	_	_
26	mRNA	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	iv	_	_	NN	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	No	_	_	DT	O	-1	none	_	_
5	other	_	_	JJ	O	-1	none	_	_
6	EBV	_	_	NN	O	-1	none	_	_
7	genes	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	required	_	_	VBN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	EBNA-2	_	_	NN	Protein	-1	none	_	_
12	transactivation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	LMP1	_	_	NN	Protein	-1	none	_	_
15	since	_	_	IN	O	-1	none	_	_
16	cotransfection	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	recombinant	_	_	JJ	O	-1	none	_	_
19	EBNA-2	_	_	NN	Protein	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	vectors	_	_	NNS	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	genomic	_	_	JJ	O	-1	none	_	_
24	LMP1	_	_	NN	Protein	-1	none	_	_
25	DNA	_	_	NN	O	-1	none	_	_
26	fragments	_	_	NNS	O	-1	none	_	_
27	enhanced	_	_	VBD	O	-1	none	_	_
28	LMP1	_	_	NN	Protein	-1	none	_	_
29	expression	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	EBV	_	_	NN	O	-1	none	_	_
33	negative	_	_	JJ	O	-1	none	_	_
34	B-lymphoma	_	_	NN	O	-1	none	_	_
35	cell	_	_	NN	O	-1	none	_	_
36	lines	_	_	NNS	O	-1	none	_	_
37	BJAB	_	_	NN	O	-1	none	_	_
38	,	_	_	,	O	-1	none	_	_
39	Louckes	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	and	_	_	CC	O	-1	none	_	_
42	BL30	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	vi	_	_	LS	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	The	_	_	DT	O	-1	none	_	_
5	EBV	_	_	NN	O	-1	none	_	_
6	type	_	_	NN	O	-1	none	_	_
7	2	_	_	CD	O	-1	none	_	_
8	EBNA-2	_	_	NN	Protein	-1	none	_	_
9	transactivated	_	_	VBD	O	-1	none	_	_
10	LMP1	_	_	NN	Protein	-1	none	_	_
11	as	_	_	RB	O	-1	none	_	_
12	well	_	_	RB	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	EBV	_	_	NN	O	-1	none	_	_
16	type	_	_	NN	O	-1	none	_	_
17	1	_	_	CD	O	-1	none	_	_
18	EBNA-2	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	vii	_	_	LS	O	-1	none	_	_
3	)	_	_	-RRB-	O	-1	none	_	_
4	Two	_	_	CD	O	-1	none	_	_
5	deletions	_	_	NNS	O	-1	none	_	_
6	within	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	EBNA-2	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	which	_	_	WDT	O	-1	none	_	_
11	rendered	_	_	VBD	O	-1	none	_	_
12	EBV	_	_	NN	O	-1	none	_	_
13	transformation	_	_	NN	O	-1	none	_	_
14	incompetent	_	_	JJ	O	-1	none	_	_
15	did	_	_	VBD	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	transactivate	_	_	VB	O	-1	none	_	_
18	LMP1	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	whereas	_	_	IN	O	-1	none	_	_
21	a	_	_	DT	O	-1	none	_	_
22	transformation-competent	_	_	JJ	O	-1	none	_	_
23	EBNA-2	_	_	NN	Protein	-1	none	_	_
24	deletion	_	_	NN	O	-1	none	_	_
25	mutant	_	_	NN	O	-1	none	_	_
26	did	_	_	VBD	O	-1	none	_	_
27	transactivate	_	_	VB	O	-1	none	_	_
28	LMP1	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	LMP1	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	potent	_	_	JJ	O	-1	none	_	_
5	effector	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	B-lymphocyte	_	_	NN	O	-1	none	_	_
8	activation	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	can	_	_	MD	O	-1	none	_	_
11	act	_	_	VB	O	-1	none	_	_
12	synergistically	_	_	RB	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	EBNA-2	_	_	NN	Protein	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	induce	_	_	VB	O	-1	none	_	_
17	cellular	_	_	JJ	O	-1	none	_	_
18	CD23	_	_	NN	Protein	-1	none	_	_
19	gene	_	_	NN	O	-1	none	_	_
20	expression	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	EBNA-2	_	_	NN	Protein	-1	none	_	_
4	transactivation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	LMP1	_	_	NN	Protein	-1	none	_	_
7	amplifies	_	_	VBZ	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	biological	_	_	JJ	O	-1	none	_	_
10	impact	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	EBNA-2	_	_	NN	Protein	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	underscores	_	_	VBZ	O	-1	none	_	_
15	its	_	_	PRP$	O	-1	none	_	_
16	central	_	_	JJ	O	-1	none	_	_
17	role	_	_	NN	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	EBV	_	_	NN	O	-1	none	_	_
20	induced	_	_	VBD	O	-1	none	_	_
21	growth	_	_	NN	O	-1	none	_	_
22	transformation	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	L-selectin	_	_	NN	Protein	-1	none	_	_
6	gene	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	fresh	_	_	JJ	O	-1	none	_	_
9	leukemic	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	adult	_	_	JJ	O	-1	none	_	_
13	T-cell	_	_	NN	O	-1	none	_	_
14	leukemia	_	_	NN	O	-1	none	_	_
15	that	_	_	WDT	O	-1	none	_	_
16	can	_	_	MD	O	-1	none	_	_
17	be	_	_	VB	O	-1	none	_	_
18	transactivated	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	T-cell	_	_	NN	O	-1	none	_	_
22	lymphotropic	_	_	JJ	O	-1	none	_	_
23	virus	_	_	NN	O	-1	none	_	_
24	type	_	_	NN	O	-1	none	_	_
25	1	_	_	CD	O	-1	none	_	_
26	Tax	_	_	NN	Protein	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	L-selectin	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	adhesion	_	_	NN	O	-1	none	_	_
5	molecule	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	selectin	_	_	NN	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	mediates	_	_	VBZ	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	initial	_	_	JJ	O	-1	none	_	_
14	step	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	leukocyte	_	_	NN	O	-1	none	_	_
17	adhesion	_	_	NN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	vascular	_	_	JJ	O	-1	none	_	_
20	endothelium	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Upon	_	_	IN	O	-1	none	_	_
2	cellular	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	L-selectin	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	downregulated	_	_	VBN	O	-1	none	_	_
12	at	_	_	IN	O	-1	none	_	_
13	both	_	_	CC	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	protein	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	mRNA	_	_	NN	O	-1	none	_	_
18	levels	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	understand	_	_	VB	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	mechanism	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	leukemic	_	_	JJ	O	-1	none	_	_
7	cell	_	_	NN	O	-1	none	_	_
8	infiltration	_	_	NN	O	-1	none	_	_
9	into	_	_	IN	O	-1	none	_	_
10	organs	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	we	_	_	PRP	O	-1	none	_	_
13	studied	_	_	VBD	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	expression	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	regulation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	L-selectin	_	_	NN	Protein	-1	none	_	_
20	mRNA	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	fresh	_	_	JJ	O	-1	none	_	_
23	leukemic	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	of	_	_	IN	O	-1	none	_	_
26	adult	_	_	JJ	O	-1	none	_	_
27	T-cell	_	_	NN	O	-1	none	_	_
28	leukemia	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	ATL	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	patients	_	_	NNS	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	investigated	_	_	VBD	O	-1	none	_	_
35	the	_	_	DT	O	-1	none	_	_
36	response	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	L-selectin	_	_	NN	Protein	-1	none	_	_
40	promoter	_	_	NN	O	-1	none	_	_
41	to	_	_	TO	O	-1	none	_	_
42	human	_	_	NN	O	-1	none	_	_
43	T-cell	_	_	NN	O	-1	none	_	_
44	lymphotropic	_	_	JJ	O	-1	none	_	_
45	virus	_	_	NN	O	-1	none	_	_
46	type	_	_	NN	O	-1	none	_	_
47	1	_	_	CD	O	-1	none	_	_
48	(	_	_	-LRB-	O	-1	none	_	_
49	HTLV-1	_	_	NN	O	-1	none	_	_
50	)	_	_	-RRB-	O	-1	none	_	_
51	Tax	_	_	NN	Protein	-1	none	_	_
52	,	_	_	,	O	-1	none	_	_
53	which	_	_	WDT	O	-1	none	_	_
54	is	_	_	VBZ	O	-1	none	_	_
55	a	_	_	DT	O	-1	none	_	_
56	viral	_	_	JJ	O	-1	none	_	_
57	transcriptional	_	_	JJ	O	-1	none	_	_
58	transactivator	_	_	NN	O	-1	none	_	_
59	.	_	_	.	O	-1	none	_	_

1	Flow	_	_	NN	O	-1	none	_	_
2	cytometry	_	_	NN	O	-1	none	_	_
3	showed	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	L-selectin	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	expressed	_	_	VBN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	fresh	_	_	JJ	O	-1	none	_	_
10	ATL	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	along	_	_	IN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	other	_	_	JJ	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	antigens	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	blot	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	ATL	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	overexpressed	_	_	VBD	O	-1	none	_	_
9	that	_	_	IN	O	-1	none	_	_
10	L-selectin	_	_	NN	Protein	-1	none	_	_
11	mRNA	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	that	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	level	_	_	NN	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	aberrantly	_	_	RB	O	-1	none	_	_
18	upregulated	_	_	VBN	O	-1	none	_	_
19	after	_	_	IN	O	-1	none	_	_
20	PMA	_	_	NN	O	-1	none	_	_
21	stimulation	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Studies	_	_	NNS	O	-1	none	_	_
2	using	_	_	VBG	O	-1	none	_	_
3	in	_	_	FW	O	-1	none	_	_
4	situ	_	_	FW	O	-1	none	_	_
5	hybridization	_	_	NN	O	-1	none	_	_
6	showed	_	_	VBD	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	L-selectin	_	_	NN	Protein	-1	none	_	_
11	mRNA	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	infiltrating	_	_	VBG	O	-1	none	_	_
15	leukemic	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	liver	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	two	_	_	CD	O	-1	none	_	_
22	ATL	_	_	NN	O	-1	none	_	_
23	patients	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Intravenous	_	_	JJ	O	-1	none	_	_
2	injection	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	rat	_	_	NN	O	-1	none	_	_
6	T-cell	_	_	NN	O	-1	none	_	_
7	line	_	_	NN	O	-1	none	_	_
8	that	_	_	WDT	O	-1	none	_	_
9	overexpresses	_	_	VBZ	O	-1	none	_	_
10	L-selectin	_	_	NN	Protein	-1	none	_	_
11	showed	_	_	VBD	O	-1	none	_	_
12	increased	_	_	VBN	O	-1	none	_	_
13	organ	_	_	NN	O	-1	none	_	_
14	infiltration	_	_	NN	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	Tax	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	JPX9	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	resulted	_	_	VBD	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	about	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	twofold	_	_	JJ	O	-1	none	_	_
14	increase	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	mRNA	_	_	NN	O	-1	none	_	_
18	expression	_	_	NN	O	-1	none	_	_
19	levels	_	_	NNS	O	-1	none	_	_
20	compared	_	_	VBN	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	basal	_	_	JJ	O	-1	none	_	_
24	level	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Chloramphenicol	_	_	NN	Protein	2	multitoken	_	_
2	acetyltransferase	_	_	NN	Protein	0	root	_	_
3	(	_	_	-LRB-	O	-1	none	_	_
4	CAT	_	_	NN	Protein	-1	none	_	_
5	)	_	_	-RRB-	O	-1	none	_	_
6	assay	_	_	NN	O	-1	none	_	_
7	after	_	_	IN	O	-1	none	_	_
8	transient	_	_	JJ	O	-1	none	_	_
9	cotransfection	_	_	NN	O	-1	none	_	_
10	showed	_	_	VBD	O	-1	none	_	_
11	about	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	fivefold	_	_	JJ	O	-1	none	_	_
14	transactivation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	L-selectin	_	_	NN	Protein	-1	none	_	_
18	promoter	_	_	NN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	Tax	_	_	NN	Protein	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	serum	_	_	NN	O	-1	none	_	_
3	level	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	shed	_	_	NN	O	-1	none	_	_
7	form	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	L-selectin	_	_	NN	Protein	-1	none	_	_
10	was	_	_	VBD	O	-1	none	_	_
11	significantly	_	_	RB	O	-1	none	_	_
12	increased	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	ATL	_	_	NN	O	-1	none	_	_
15	patients	_	_	NNS	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	mean	_	_	NN	O	-1	none	_	_
18	+/-	_	_	CC	O	-1	none	_	_
19	SD	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	4,215.4	_	_	CD	O	-1	none	_	_
22	+/-	_	_	CC	O	-1	none	_	_
23	4,111	_	_	CD	O	-1	none	_	_
24	ng/mL	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	compared	_	_	VBN	O	-1	none	_	_
27	with	_	_	IN	O	-1	none	_	_
28	those	_	_	DT	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	asymptomatic	_	_	JJ	O	-1	none	_	_
31	carriers	_	_	NNS	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	healthy	_	_	JJ	O	-1	none	_	_
34	blood	_	_	NN	O	-1	none	_	_
35	donors	_	_	NNS	O	-1	none	_	_
36	(	_	_	-LRB-	O	-1	none	_	_
37	mean	_	_	NN	O	-1	none	_	_
38	+/-	_	_	CC	O	-1	none	_	_
39	SD	_	_	NN	O	-1	none	_	_
40	,	_	_	,	O	-1	none	_	_
41	1,148.0	_	_	CD	O	-1	none	_	_
42	+/-	_	_	CC	O	-1	none	_	_
43	269.0	_	_	CD	O	-1	none	_	_
44	ng/mL	_	_	NN	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	991.9	_	_	CD	O	-1	none	_	_
47	+/-	_	_	CC	O	-1	none	_	_
48	224	_	_	CD	O	-1	none	_	_
49	ng/mL	_	_	NN	O	-1	none	_	_
50	,	_	_	,	O	-1	none	_	_
51	respectively	_	_	RB	O	-1	none	_	_
52	)	_	_	-RRB-	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	ATL	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	constitutively	_	_	RB	O	-1	none	_	_
8	overexpress	_	_	VBP	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	L-selectin	_	_	NN	Protein	-1	none	_	_
11	gene	_	_	NN	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	can	_	_	MD	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	transactivated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	HTLV-1	_	_	NN	O	-1	none	_	_
18	Tax	_	_	NN	Protein	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	L-selectin	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	as	_	_	RB	O	-1	none	_	_
7	well	_	_	RB	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	inflammatory	_	_	JJ	O	-1	none	_	_
11	cytokines	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	ATL	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	may	_	_	MD	O	-1	none	_	_
17	provide	_	_	VB	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	basis	_	_	NN	O	-1	none	_	_
20	for	_	_	IN	O	-1	none	_	_
21	ATL	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	attach	_	_	VB	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	vascular	_	_	JJ	O	-1	none	_	_
27	endothelium	_	_	NN	O	-1	none	_	_
28	,	_	_	,	O	-1	none	_	_
29	leading	_	_	VBG	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	transmigration	_	_	NN	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	organ	_	_	NN	O	-1	none	_	_
34	infitration	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	SOCS-3	_	_	NNP	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	tyrosine	_	_	NN	O	-1	none	_	_
4	phosphorylated	_	_	JJ	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	response	_	_	NN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	interleukin-2	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	suppresses	_	_	VBZ	O	-1	none	_	_
11	STAT5	_	_	NN	Protein	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	lymphocyte	_	_	NN	O	-1	none	_	_
15	proliferation	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Members	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	recently	_	_	RB	O	-1	none	_	_
5	discovered	_	_	VBN	O	-1	none	_	_
6	SOCS/CIS/SSI	_	_	NN	O	-1	none	_	_
7	family	_	_	NN	O	-1	none	_	_
8	have	_	_	VBP	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	proposed	_	_	VBN	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	regulators	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cytokine	_	_	NN	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	while	_	_	IN	O	-1	none	_	_
19	targets	_	_	NNS	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	mechanisms	_	_	NNS	O	-1	none	_	_
22	have	_	_	VBP	O	-1	none	_	_
23	been	_	_	VBN	O	-1	none	_	_
24	suggested	_	_	VBN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	some	_	_	DT	O	-1	none	_	_
27	family	_	_	NN	O	-1	none	_	_
28	members	_	_	NNS	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	precise	_	_	JJ	O	-1	none	_	_
32	role	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	these	_	_	DT	O	-1	none	_	_
35	proteins	_	_	NNS	O	-1	none	_	_
36	remains	_	_	VBZ	O	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	be	_	_	VB	O	-1	none	_	_
39	defined	_	_	VBN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	To	_	_	TO	O	-1	none	_	_
2	date	_	_	VB	O	-1	none	_	_
3	no	_	_	DT	O	-1	none	_	_
4	SOCS	_	_	NN	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	been	_	_	VBN	O	-1	none	_	_
8	specifically	_	_	RB	O	-1	none	_	_
9	implicated	_	_	VBN	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	interleukin-2	_	_	NN	Protein	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	SOCS-3	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	response	_	_	NN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	IL-2	_	_	NN	Protein	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	both	_	_	CC	O	-1	none	_	_
12	T-cell	_	_	NN	O	-1	none	_	_
13	lines	_	_	NNS	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	peripheral	_	_	JJ	O	-1	none	_	_
17	blood	_	_	NN	O	-1	none	_	_
18	lymphocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	SOCS-3	_	_	NNP	Protein	-1	none	_	_
2	protein	_	_	NN	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	detectable	_	_	JJ	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	early	_	_	JJ	O	-1	none	_	_
7	as	_	_	IN	O	-1	none	_	_
8	30	_	_	CD	O	-1	none	_	_
9	min	_	_	NN	O	-1	none	_	_
10	following	_	_	VBG	O	-1	none	_	_
11	IL-2	_	_	NN	Protein	-1	none	_	_
12	stimulation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	while	_	_	IN	O	-1	none	_	_
15	CIS	_	_	NN	Protein	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	seen	_	_	VBN	O	-1	none	_	_
18	only	_	_	RB	O	-1	none	_	_
19	at	_	_	IN	O	-1	none	_	_
20	low	_	_	JJ	O	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	after	_	_	IN	O	-1	none	_	_
23	2	_	_	CD	O	-1	none	_	_
24	h.	_	_	NN	O	-1	none	_	_
25	Unlike	_	_	IN	O	-1	none	_	_
26	CIS	_	_	NN	Protein	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	SOCS-3	_	_	NN	Protein	-1	none	_	_
29	was	_	_	VBD	O	-1	none	_	_
30	rapidly	_	_	RB	O	-1	none	_	_
31	tyrosine	_	_	NN	O	-1	none	_	_
32	phosphorylated	_	_	JJ	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	response	_	_	NN	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	IL-2	_	_	NN	Protein	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	Tyrosine	_	_	NN	O	-1	none	_	_
2	phosphorylation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	SOCS-3	_	_	NN	Protein	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	upon	_	_	IN	O	-1	none	_	_
8	coexpression	_	_	NN	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	Jak1	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	Jak2	_	_	NN	Protein	-1	none	_	_
13	but	_	_	CC	O	-1	none	_	_
14	only	_	_	RB	O	-1	none	_	_
15	weakly	_	_	RB	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	Jak3	_	_	NN	Protein	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	experiments	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	SOCS-3	_	_	NN	Protein	-1	none	_	_
6	associated	_	_	VBN	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	Jak1	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	inhibited	_	_	VBD	O	-1	none	_	_
11	Jak1	_	_	NN	Protein	-1	none	_	_
12	phosphorylation	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	this	_	_	DT	O	-1	none	_	_
16	inhibition	_	_	NN	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	markedly	_	_	RB	O	-1	none	_	_
19	enhanced	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	presence	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	IL-2	_	_	NN	Protein	27	multitoken	_	_
25	receptor	_	_	NN	Protein	27	multitoken	_	_
26	beta	_	_	NN	Protein	27	multitoken	_	_
27	chain	_	_	NN	Protein	0	root	_	_
28	(	_	_	-LRB-	O	-1	none	_	_
29	IL-2Rbeta	_	_	NN	Protein	-1	none	_	_
30	)	_	_	-RRB-	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Moreover	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	following	_	_	VBG	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	stimulation	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	T	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	SOCS-3	_	_	NN	Protein	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	able	_	_	JJ	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	interact	_	_	VB	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	IL-2	_	_	NN	Protein	-1	none	_	_
18	receptor	_	_	NN	O	-1	none	_	_
19	complex	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	particular	_	_	JJ	O	-1	none	_	_
24	tyrosine	_	_	NN	O	-1	none	_	_
25	phosphorylated	_	_	JJ	O	-1	none	_	_
26	Jak1	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	IL-2Rbeta	_	_	NN	Protein	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	when	_	_	WRB	O	-1	none	_	_
6	SOCS-3	_	_	NN	Protein	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	rapidly	_	_	RB	O	-1	none	_	_
9	induced	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	IL-2	_	_	NN	Protein	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	it	_	_	PRP	O	-1	none	_	_
17	acts	_	_	VBZ	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	inhibit	_	_	VB	O	-1	none	_	_
20	IL-2	_	_	NN	Protein	-1	none	_	_
21	responses	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	classical	_	_	JJ	O	-1	none	_	_
25	negative	_	_	JJ	O	-1	none	_	_
26	feedback	_	_	NN	O	-1	none	_	_
27	loop	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Signal	_	_	NN	O	-1	none	_	_
2	transduction	_	_	NN	O	-1	none	_	_
3	through	_	_	IN	O	-1	none	_	_
4	interferon-gamma	_	_	NN	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	eosinophils	_	_	NNS	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	BACKGROUND	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	We	_	_	PRP	O	-1	none	_	_
4	reported	_	_	VBD	O	-1	none	_	_
5	on	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	constitutive	_	_	JJ	O	-1	none	_	_
8	interferon-gamma	_	_	NN	O	-1	none	_	_
9	receptor	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	IFN-gammaR	_	_	NN	O	-1	none	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	on	_	_	IN	O	-1	none	_	_
15	eosinophils	_	_	NNS	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	But	_	_	CC	O	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	transduction	_	_	NN	O	-1	none	_	_
4	through	_	_	IN	O	-1	none	_	_
5	IFN-gammaR	_	_	NN	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	eosinophils	_	_	NNS	O	-1	none	_	_
8	remains	_	_	VBZ	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	be	_	_	VB	O	-1	none	_	_
11	elucidated	_	_	VBN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	examined	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	involvement	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	Jak	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	Stat	_	_	NN	O	-1	none	_	_
14	pathway	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	signaling	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	eosinophils	_	_	NNS	O	-1	none	_	_
20	after	_	_	IN	O	-1	none	_	_
21	IFN-gammaR	_	_	NN	O	-1	none	_	_
22	conjugation	_	_	NN	O	-1	none	_	_
23	by	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	ligand	_	_	NN	O	-1	none	_	_
26	binding	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	METHODS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	Purified	_	_	VBN	O	-1	none	_	_
4	peripheral	_	_	JJ	O	-1	none	_	_
5	eosinophils	_	_	NNS	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	stimulated	_	_	VBN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	IFN-gamma	_	_	NN	O	-1	none	_	_
10	at	_	_	IN	O	-1	none	_	_
11	37	_	_	CD	O	-1	none	_	_
12	degrees	_	_	NNS	O	-1	none	_	_
13	C	_	_	NN	O	-1	none	_	_
14	for	_	_	IN	O	-1	none	_	_
15	1-60	_	_	CD	O	-1	none	_	_
16	min	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Tyrosine	_	_	NN	O	-1	none	_	_
2	phosphorylation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IFN-gammaR	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	Jak1	_	_	NN	Protein	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	Jak2	_	_	NN	Protein	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	Stat1alpha	_	_	NN	Protein	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	examined	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	immunoblotting	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	RESULTS	_	_	NNS	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	We	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	binding	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	IFN-gamma	_	_	NN	O	-1	none	_	_
9	to	_	_	TO	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	eosinophils	_	_	NNS	O	-1	none	_	_
12	initiated	_	_	VBD	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	series	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	events	_	_	NNS	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	resulted	_	_	VBD	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	rapid	_	_	JJ	O	-1	none	_	_
22	tyrosine	_	_	NN	O	-1	none	_	_
23	phosphorylation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	not	_	_	RB	O	-1	none	_	_
26	only	_	_	RB	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	IFN-gammaRalpha	_	_	NN	Protein	29	multitoken	_	_
29	chain	_	_	NN	Protein	0	root	_	_
30	but	_	_	CC	O	-1	none	_	_
31	also	_	_	RB	O	-1	none	_	_
32	Jak1	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	Jak2	_	_	NN	Protein	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	and	_	_	CC	O	-1	none	_	_
37	Stat1alpha	_	_	NN	Protein	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IFN-gamma	_	_	NN	O	-1	none	_	_
5	enhanced	_	_	VBD	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	DNA	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	Stat1alpha	_	_	NN	Protein	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	CONCLUSION	_	_	NN	O	-1	none	_	_
2	:	_	_	:	O	-1	none	_	_
3	These	_	_	DT	O	-1	none	_	_
4	data	_	_	NNS	O	-1	none	_	_
5	indicate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	IFN-gamma	_	_	NN	O	-1	none	_	_
8	affects	_	_	VBZ	O	-1	none	_	_
9	eosinophils	_	_	NNS	O	-1	none	_	_
10	through	_	_	IN	O	-1	none	_	_
11	its	_	_	PRP$	O	-1	none	_	_
12	specific	_	_	JJ	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	utilizes	_	_	VBZ	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	Jak	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	Stat	_	_	NN	O	-1	none	_	_
20	pathway	_	_	NN	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	its	_	_	PRP$	O	-1	none	_	_
23	mode	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	signaling	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	p38	_	_	NN	O	-1	none	_	_
2	mitogen	_	_	NN	O	-1	none	_	_
3	activated	_	_	VBN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	kinase	_	_	NN	O	-1	none	_	_
6	mediates	_	_	VBZ	O	-1	none	_	_
7	signal	_	_	NN	O	-1	none	_	_
8	integration	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	TCR	_	_	NN	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	CD28	_	_	NN	Protein	-1	none	_	_
13	costimulation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	primary	_	_	JJ	O	-1	none	_	_
16	murine	_	_	JJ	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Optimal	_	_	JJ	O	-1	none	_	_
2	T	_	_	NN	O	-1	none	_	_
3	cell	_	_	NN	O	-1	none	_	_
4	activation	_	_	NN	O	-1	none	_	_
5	requires	_	_	VBZ	O	-1	none	_	_
6	two	_	_	CD	O	-1	none	_	_
7	signals	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	one	_	_	CD	O	-1	none	_	_
10	generated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	TCR	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	another	_	_	DT	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	CD28	_	_	NN	Protein	19	multitoken	_	_
18	costimulatory	_	_	JJ	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	investigated	_	_	VBD	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	regulation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	costimulation	_	_	NN	O	-1	none	_	_
11	induced	_	_	VBD	O	-1	none	_	_
12	mitogen	_	_	NN	O	-1	none	_	_
13	activated	_	_	JJ	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	MAPK	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	primary	_	_	JJ	O	-1	none	_	_
22	mouse	_	_	NN	O	-1	none	_	_
23	T	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	that	_	_	DT	O	-1	none	_	_
5	reported	_	_	VBN	O	-1	none	_	_
6	for	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	Jurkat	_	_	NN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	we	_	_	PRP	O	-1	none	_	_
13	found	_	_	VBD	O	-1	none	_	_
14	that	_	_	IN	O	-1	none	_	_
15	p38	_	_	NN	O	-1	none	_	_
16	MAPK	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	but	_	_	CC	O	-1	none	_	_
19	not	_	_	RB	O	-1	none	_	_
20	Jun	_	_	NN	O	-1	none	_	_
21	NH2-terminal	_	_	JJ	O	-1	none	_	_
22	kinase	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	JNK	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	weakly	_	_	RB	O	-1	none	_	_
29	activated	_	_	VBN	O	-1	none	_	_
30	upon	_	_	IN	O	-1	none	_	_
31	stimulation	_	_	NN	O	-1	none	_	_
32	with	_	_	IN	O	-1	none	_	_
33	either	_	_	CC	O	-1	none	_	_
34	anti-CD3	_	_	NN	O	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	anti-CD28	_	_	NN	Protein	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	murine	_	_	JJ	O	-1	none	_	_
39	thymocytes	_	_	NNS	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	splenic	_	_	JJ	O	-1	none	_	_
42	T	_	_	NN	O	-1	none	_	_
43	cells	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	p38	_	_	NN	O	-1	none	_	_
4	MAPK	_	_	NN	O	-1	none	_	_
5	correlates	_	_	VBZ	O	-1	none	_	_
6	closely	_	_	RB	O	-1	none	_	_
7	with	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	stimulation	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cell	_	_	NN	O	-1	none	_	_
13	proliferation	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	PMA	_	_	NN	O	-1	none	_	_
5	induced	_	_	VBD	O	-1	none	_	_
6	JNK	_	_	NN	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	inhibited	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	Ca2+	_	_	NN	O	-1	none	_	_
12	ionophore	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	T	_	_	NN	O	-1	none	_	_
2	cell	_	_	NN	O	-1	none	_	_
3	proliferation	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	production	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	IL-2	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	IL-4	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	IFN-gamma	_	_	NN	Protein	-1	none	_	_
13	induced	_	_	VBN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	both	_	_	CC	O	-1	none	_	_
16	CD3	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	CD3	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	CD28	_	_	NN	Protein	-1	none	_	_
21	ligation	_	_	NN	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	nuclear	_	_	JJ	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	c-Jun	_	_	NN	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	ATF-2	_	_	NN	Protein	-1	none	_	_
31	proteins	_	_	NNS	O	-1	none	_	_
32	are	_	_	VBP	O	-1	none	_	_
33	each	_	_	DT	O	-1	none	_	_
34	blocked	_	_	VBN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	p38	_	_	NN	O	-1	none	_	_
38	MAPK	_	_	NN	O	-1	none	_	_
39	inhibitor	_	_	NN	O	-1	none	_	_
40	SB203580	_	_	NN	O	-1	none	_	_
41	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	p38	_	_	NN	O	-1	none	_	_
6	MAPK	_	_	NN	O	-1	none	_	_
7	1	_	_	CD	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	plays	_	_	VBZ	O	-1	none	_	_
10	an	_	_	DT	O	-1	none	_	_
11	important	_	_	JJ	O	-1	none	_	_
12	role	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	integration	_	_	NN	O	-1	none	_	_
16	during	_	_	IN	O	-1	none	_	_
17	costimulation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	primary	_	_	JJ	O	-1	none	_	_
20	mouse	_	_	NN	O	-1	none	_	_
21	T	_	_	NN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	2	_	_	CD	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	may	_	_	MD	O	-1	none	_	_
27	be	_	_	VB	O	-1	none	_	_
28	involved	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	induction	_	_	NN	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	c-Jun	_	_	NN	Protein	-1	none	_	_
34	activation	_	_	NN	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	augmentation	_	_	NN	O	-1	none	_	_
37	of	_	_	IN	O	-1	none	_	_
38	AP-1	_	_	NN	O	-1	none	_	_
39	transcriptional	_	_	JJ	O	-1	none	_	_
40	activity	_	_	NN	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	3	_	_	CD	O	-1	none	_	_
44	)	_	_	-RRB-	O	-1	none	_	_
45	regulates	_	_	VBZ	O	-1	none	_	_
46	whether	_	_	IN	O	-1	none	_	_
47	T	_	_	NN	O	-1	none	_	_
48	cells	_	_	NNS	O	-1	none	_	_
49	enter	_	_	VBP	O	-1	none	_	_
50	a	_	_	DT	O	-1	none	_	_
51	state	_	_	NN	O	-1	none	_	_
52	of	_	_	IN	O	-1	none	_	_
53	functional	_	_	JJ	O	-1	none	_	_
54	unresponsiveness	_	_	NN	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	Dimerization	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	NF-KB2	_	_	NN	Protein	-1	none	_	_
4	with	_	_	IN	O	-1	none	_	_
5	RelA	_	_	NN	Protein	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	p65	_	_	NN	Protein	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	regulates	_	_	VBZ	O	-1	none	_	_
10	DNA	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	transcriptional	_	_	JJ	O	-1	none	_	_
14	activation	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	inhibition	_	_	NN	O	-1	none	_	_
18	by	_	_	IN	O	-1	none	_	_
19	an	_	_	DT	O	-1	none	_	_
20	I	_	_	NN	Protein	22	multitoken	_	_
21	kappa	_	_	NN	Protein	22	multitoken	_	_
22	B-alpha	_	_	NN	Protein	0	root	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	MAD-3	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Inducible	_	_	JJ	O	-1	none	_	_
2	expression	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	immunodeficiency	_	_	NN	O	-1	none	_	_
6	virus	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	HIV	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	regulated	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	cellular	_	_	JJ	O	-1	none	_	_
15	transcription	_	_	NN	O	-1	none	_	_
16	factor	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	kappa	_	_	NN	O	-1	none	_	_
21	B	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	NF-kappa	_	_	NN	O	-1	none	_	_
24	B	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	NF-kappa	_	_	NN	O	-1	none	_	_
2	B	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	composed	_	_	VBN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	distinct	_	_	JJ	O	-1	none	_	_
7	subunits	_	_	NNS	O	-1	none	_	_
8	;	_	_	:	O	-1	none	_	_
9	five	_	_	CD	O	-1	none	_	_
10	independent	_	_	JJ	O	-1	none	_	_
11	genes	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	NFKB1	_	_	NN	Protein	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	p105	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	NFKB2	_	_	NN	Protein	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	p100	_	_	NN	Protein	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	RelA	_	_	NN	Protein	-1	none	_	_
24	(	_	_	-LRB-	O	-1	none	_	_
25	p65	_	_	NN	Protein	-1	none	_	_
26	)	_	_	-RRB-	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	c-rel	_	_	NN	Protein	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	relB	_	_	NN	Protein	-1	none	_	_
31	,	_	_	,	O	-1	none	_	_
32	that	_	_	WDT	O	-1	none	_	_
33	encode	_	_	VBP	O	-1	none	_	_
34	related	_	_	JJ	O	-1	none	_	_
35	proteins	_	_	NNS	O	-1	none	_	_
36	that	_	_	WDT	O	-1	none	_	_
37	bind	_	_	VBP	O	-1	none	_	_
38	to	_	_	TO	O	-1	none	_	_
39	kappa	_	_	NN	O	-1	none	_	_
40	B	_	_	NN	O	-1	none	_	_
41	DNA	_	_	NN	O	-1	none	_	_
42	elements	_	_	NNS	O	-1	none	_	_
43	have	_	_	VBP	O	-1	none	_	_
44	been	_	_	VBN	O	-1	none	_	_
45	isolated	_	_	VBN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	previously	_	_	RB	O	-1	none	_	_
4	found	_	_	VBN	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	NFKB2	_	_	NN	Protein	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	p49	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	p52	_	_	NN	Protein	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	acts	_	_	VBZ	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	concert	_	_	NN	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	RelA	_	_	NN	Protein	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	p65	_	_	NN	Protein	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	stimulate	_	_	VB	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	HIV	_	_	NN	O	-1	none	_	_
24	enhancer	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	Jurkat	_	_	NN	O	-1	none	_	_
27	T-leukemia	_	_	NN	O	-1	none	_	_
28	cells	_	_	NNS	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	examine	_	_	VBP	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	biochemical	_	_	JJ	O	-1	none	_	_
6	basis	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	transcriptional	_	_	JJ	O	-1	none	_	_
10	regulation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	HIV	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	NFKB2	_	_	NN	Protein	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Using	_	_	VBG	O	-1	none	_	_
2	Scatchard	_	_	NN	O	-1	none	_	_
3	analysis	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	have	_	_	VBP	O	-1	none	_	_
7	determined	_	_	VBN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	dissociation	_	_	NN	O	-1	none	_	_
10	constants	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	homodimeric	_	_	JJ	O	-1	none	_	_
13	p49	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	heterodimeric	_	_	JJ	O	-1	none	_	_
16	p49	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	p65	_	_	NN	Protein	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	binding	_	_	VBG	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	HIV	_	_	NN	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	site	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	p49	_	_	NN	Protein	-1	none	_	_
2	has	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	approximately	_	_	RB	O	-1	none	_	_
5	18-fold-lower	_	_	JJ	O	-1	none	_	_
6	affinity	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	HIV	_	_	NN	O	-1	none	_	_
10	kappa	_	_	NN	O	-1	none	_	_
11	B	_	_	NN	O	-1	none	_	_
12	site	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	KD	_	_	NN	O	-1	none	_	_
15	=	_	_	JJ	O	-1	none	_	_
16	69.1	_	_	CD	O	-1	none	_	_
17	pM	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	than	_	_	IN	O	-1	none	_	_
20	does	_	_	VBZ	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	approximately	_	_	RB	O	-1	none	_	_
23	50-kDa	_	_	JJ	O	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	NFKB1	_	_	NN	Protein	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	p50	_	_	NN	Protein	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	derived	_	_	VBN	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	p105	_	_	NN	Protein	-1	none	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	KD	_	_	NN	O	-1	none	_	_
34	=	_	_	JJ	O	-1	none	_	_
35	3.9	_	_	CD	O	-1	none	_	_
36	pM	_	_	NN	O	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	affinity	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	heterodimeric	_	_	JJ	O	-1	none	_	_
8	NFKB2	_	_	NN	Protein	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	p49	_	_	NN	Protein	-1	none	_	_
11	)/RelA	_	_	NN	Protein	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	p65	_	_	NN	Protein	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	this	_	_	DT	O	-1	none	_	_
17	site	_	_	NN	O	-1	none	_	_
18	is	_	_	VBZ	O	-1	none	_	_
19	approximately	_	_	RB	O	-1	none	_	_
20	6-fold	_	_	RB	O	-1	none	_	_
21	higher	_	_	JJR	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	KD	_	_	NN	O	-1	none	_	_
24	=	_	_	JJ	O	-1	none	_	_
25	11.8	_	_	CD	O	-1	none	_	_
26	pM	_	_	NN	O	-1	none	_	_
27	)	_	_	-RRB-	O	-1	none	_	_
28	than	_	_	IN	O	-1	none	_	_
29	that	_	_	DT	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	p49	_	_	NN	Protein	-1	none	_	_
32	alone	_	_	RB	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Consistent	_	_	JJ	O	-1	none	_	_
2	with	_	_	IN	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	findings	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	in	_	_	FW	O	-1	none	_	_
7	vitro	_	_	FW	O	-1	none	_	_
8	transcription	_	_	NN	O	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	stimulated	_	_	VBN	O	-1	none	_	_
11	18-fold	_	_	RB	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	addition	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	preformed	_	_	JJ	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	heterodimeric	_	_	JJ	O	-1	none	_	_
19	NFKB2	_	_	NN	Protein	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	p49	_	_	NN	Protein	-1	none	_	_
22	)/RelA	_	_	NN	Protein	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	p65	_	_	NN	Protein	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	protein	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Transcriptional	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	HIV	_	_	NN	O	-1	none	_	_
6	enhancer	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	also	_	_	RB	O	-1	none	_	_
9	subject	_	_	JJ	O	-1	none	_	_
10	to	_	_	TO	O	-1	none	_	_
11	regulation	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	recently	_	_	RB	O	-1	none	_	_
14	cloned	_	_	VBN	O	-1	none	_	_
15	I	_	_	NN	Protein	17	multitoken	_	_
16	kappa	_	_	NN	Protein	17	multitoken	_	_
17	B-alpha	_	_	NN	Protein	0	root	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	MAD-3	_	_	NN	Protein	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	Recombinant	_	_	JJ	O	-1	none	_	_
2	I	_	_	NN	Protein	4	multitoken	_	_
3	kappa	_	_	NN	Protein	4	multitoken	_	_
4	B-alpha	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	MAD-3	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	inhibited	_	_	VBD	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	DNA	_	_	NN	O	-1	none	_	_
11	binding	_	_	NN	O	-1	none	_	_
12	activity	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	p65	_	_	NN	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	p49	_	_	NN	Protein	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	p65	_	_	NN	Protein	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	p50	_	_	NN	Protein	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	p65	_	_	NN	Protein	-1	none	_	_
24	but	_	_	CC	O	-1	none	_	_
25	stimulated	_	_	VBD	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	NFKB2	_	_	NN	Protein	-1	none	_	_
30	(	_	_	-LRB-	O	-1	none	_	_
31	p49	_	_	NN	Protein	-1	none	_	_
32	)	_	_	-RRB-	O	-1	none	_	_
33	or	_	_	CC	O	-1	none	_	_
34	NFKB1	_	_	NN	Protein	-1	none	_	_
35	(	_	_	-LRB-	O	-1	none	_	_
36	p50	_	_	NN	Protein	-1	none	_	_
37	)	_	_	-RRB-	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Functional	_	_	JJ	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	HIV	_	_	NN	O	-1	none	_	_
6	reporter	_	_	NN	O	-1	none	_	_
7	plasmid	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	p49	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	p65	_	_	NN	Protein	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	transiently	_	_	RB	O	-1	none	_	_
14	transfected	_	_	VBN	O	-1	none	_	_
15	Jurkat	_	_	NN	O	-1	none	_	_
16	T-leukemia	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	was	_	_	VBD	O	-1	none	_	_
19	also	_	_	RB	O	-1	none	_	_
20	inhibited	_	_	VBN	O	-1	none	_	_
21	by	_	_	IN	O	-1	none	_	_
22	coexpression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	MAD-3	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	(	_	_	-LRB-	O	-1	none	_	_
2	ABSTRACT	_	_	NN	O	-1	none	_	_
3	TRUNCATED	_	_	VBD	O	-1	none	_	_
4	AT	_	_	IN	O	-1	none	_	_
5	250	_	_	CD	O	-1	none	_	_
6	WORDS	_	_	NNS	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_

1	Cell	_	_	NN	O	-1	none	_	_
2	cycle	_	_	NN	O	-1	none	_	_
3	dependent	_	_	JJ	O	-1	none	_	_
4	initiation	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	lineage	_	_	NN	O	-1	none	_	_
7	dependent	_	_	JJ	O	-1	none	_	_
8	abrogation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	GATA-1	_	_	NN	Protein	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	pure	_	_	JJ	O	-1	none	_	_
14	differentiating	_	_	VBG	O	-1	none	_	_
15	hematopoietic	_	_	JJ	O	-1	none	_	_
16	progenitors	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	programmed	_	_	JJ	O	-1	none	_	_
3	activation	_	_	NN	O	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	repression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	transcription	_	_	NN	O	-1	none	_	_
8	factors	_	_	NNS	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	early	_	_	JJ	O	-1	none	_	_
11	hematopoietic	_	_	JJ	O	-1	none	_	_
12	differentiation	_	_	NN	O	-1	none	_	_
13	has	_	_	VBZ	O	-1	none	_	_
14	not	_	_	RB	O	-1	none	_	_
15	yet	_	_	RB	O	-1	none	_	_
16	been	_	_	VBN	O	-1	none	_	_
17	explored	_	_	VBN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	DNA	_	_	NN	O	-1	none	_	_
3	binding	_	_	NN	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	GATA-1	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	required	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	normal	_	_	JJ	O	-1	none	_	_
10	erythroid	_	_	JJ	O	-1	none	_	_
11	development	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	regulates	_	_	VBZ	O	-1	none	_	_
14	erythroid	_	_	JJ	O	-1	none	_	_
15	expressed	_	_	VBN	O	-1	none	_	_
16	genes	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	maturing	_	_	VBG	O	-1	none	_	_
19	erythroblasts	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	analyzed	_	_	VBD	O	-1	none	_	_
3	GATA-1	_	_	NN	Protein	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	early	_	_	JJ	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	adult	_	_	JJ	O	-1	none	_	_
9	hematopoiesis	_	_	NN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	using	_	_	VBG	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	in	_	_	FW	O	-1	none	_	_
14	vitro	_	_	FW	O	-1	none	_	_
15	system	_	_	NN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	which	_	_	WDT	O	-1	none	_	_
18	"	_	_	``	O	-1	none	_	_
19	pure	_	_	JJ	O	-1	none	_	_
20	"	_	_	''	O	-1	none	_	_
21	early	_	_	JJ	O	-1	none	_	_
22	hematopoietic	_	_	JJ	O	-1	none	_	_
23	progenitors	_	_	NNS	O	-1	none	_	_
24	are	_	_	VBP	O	-1	none	_	_
25	induced	_	_	VBN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	gradual	_	_	JJ	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	synchronized	_	_	VBD	O	-1	none	_	_
30	differentiation	_	_	NN	O	-1	none	_	_
31	selectively	_	_	RB	O	-1	none	_	_
32	along	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	erythroid	_	_	JJ	O	-1	none	_	_
35	or	_	_	CC	O	-1	none	_	_
36	granulocyte-macrophage	_	_	JJ	O	-1	none	_	_
37	pathway	_	_	NN	O	-1	none	_	_
38	by	_	_	IN	O	-1	none	_	_
39	differential	_	_	JJ	O	-1	none	_	_
40	treatment	_	_	NN	O	-1	none	_	_
41	with	_	_	IN	O	-1	none	_	_
42	hematopoietic	_	_	JJ	O	-1	none	_	_
43	growth	_	_	NN	O	-1	none	_	_
44	factors	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	GATA-1	_	_	NN	Protein	-1	none	_	_
3	gene	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	though	_	_	IN	O	-1	none	_	_
6	virtually	_	_	RB	O	-1	none	_	_
7	silent	_	_	JJ	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	quiescent	_	_	JJ	O	-1	none	_	_
10	progenitors	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	activated	_	_	VBN	O	-1	none	_	_
14	after	_	_	IN	O	-1	none	_	_
15	entrance	_	_	NN	O	-1	none	_	_
16	into	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	cycle	_	_	NN	O	-1	none	_	_
20	upon	_	_	IN	O	-1	none	_	_
21	stimulation	_	_	NN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	hematopoietic	_	_	JJ	O	-1	none	_	_
24	growth	_	_	NN	O	-1	none	_	_
25	factors	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Subsequently	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	increasing	_	_	VBG	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	along	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	erythroid	_	_	JJ	O	-1	none	_	_
8	pathway	_	_	NN	O	-1	none	_	_
9	contrasts	_	_	VBZ	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	abrupt	_	_	JJ	O	-1	none	_	_
13	downregulation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	granulocyte-macrophage	_	_	JJ	O	-1	none	_	_
17	lineage	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	suggest	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	microenvironment	_	_	NN	O	-1	none	_	_
6	directed	_	_	VBN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	two-step	_	_	JJ	O	-1	none	_	_
9	model	_	_	NN	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	GATA-1	_	_	NN	Protein	-1	none	_	_
12	expression	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	differentiating	_	_	VBG	O	-1	none	_	_
15	hematopoietic	_	_	JJ	O	-1	none	_	_
16	progenitors	_	_	NNS	O	-1	none	_	_
17	that	_	_	WDT	O	-1	none	_	_
18	involves	_	_	VBZ	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	i	_	_	FW	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	cycle	_	_	NN	O	-1	none	_	_
23	dependent	_	_	JJ	O	-1	none	_	_
24	initiation	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	ii	_	_	LS	O	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	lineage	_	_	NN	O	-1	none	_	_
30	dependent	_	_	JJ	O	-1	none	_	_
31	maintenance	_	_	NN	O	-1	none	_	_
32	or	_	_	CC	O	-1	none	_	_
33	suppression	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Hypothetically	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	on/off	_	_	JJ	O	-1	none	_	_
4	switches	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	lineage	_	_	NN	O	-1	none	_	_
7	restricted	_	_	JJ	O	-1	none	_	_
8	transactivators	_	_	NNS	O	-1	none	_	_
9	may	_	_	MD	O	-1	none	_	_
10	underlie	_	_	VB	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	binary	_	_	JJ	O	-1	none	_	_
13	fate	_	_	NN	O	-1	none	_	_
14	decisions	_	_	NNS	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	hematopoietic	_	_	JJ	O	-1	none	_	_
17	progenitors	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Inhibition	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	T	_	_	NN	O	-1	none	_	_
4	cell	_	_	NN	O	-1	none	_	_
5	activation	_	_	NN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	extracellular	_	_	JJ	O	-1	none	_	_
9	matrix	_	_	NN	O	-1	none	_	_
10	protein	_	_	NN	O	-1	none	_	_
11	tenascin	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Tenascin	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	TN	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	extracellular	_	_	JJ	O	-1	none	_	_
8	matrix	_	_	NN	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	that	_	_	WDT	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	expressed	_	_	VBN	O	-1	none	_	_
13	widely	_	_	RB	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	fetus	_	_	NN	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	sparingly	_	_	RB	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	adult	_	_	JJ	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	but	_	_	CC	O	-1	none	_	_
24	reappears	_	_	VBZ	O	-1	none	_	_
25	at	_	_	IN	O	-1	none	_	_
26	high	_	_	JJ	O	-1	none	_	_
27	levels	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	certain	_	_	JJ	O	-1	none	_	_
30	areas	_	_	NNS	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	tissue	_	_	NN	O	-1	none	_	_
33	insult	_	_	NN	O	-1	none	_	_
34	such	_	_	JJ	O	-1	none	_	_
35	as	_	_	IN	O	-1	none	_	_
36	tumor	_	_	NN	O	-1	none	_	_
37	matrices	_	_	NNS	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	sites	_	_	NNS	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	wound	_	_	NN	O	-1	none	_	_
42	healing	_	_	NN	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	soluble	_	_	JJ	O	-1	none	_	_
6	TN	_	_	NN	O	-1	none	_	_
7	inhibits	_	_	VBZ	O	-1	none	_	_
8	proliferation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	T	_	_	NN	O	-1	none	_	_
12	cells	_	_	NNS	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	response	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	alpha	_	_	NN	O	-1	none	_	_
17	CD3	_	_	NN	O	-1	none	_	_
18	Ab	_	_	NN	O	-1	none	_	_
19	co-immobilized	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	extracellular	_	_	JJ	O	-1	none	_	_
23	matrix	_	_	NN	O	-1	none	_	_
24	protein	_	_	NN	O	-1	none	_	_
25	fibronectin	_	_	NN	Protein	-1	none	_	_
26	(	_	_	-LRB-	O	-1	none	_	_
27	FN	_	_	NN	Protein	-1	none	_	_
28	)	_	_	-RRB-	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	The	_	_	DT	O	-1	none	_	_
2	presence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	TN	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	culture	_	_	NN	O	-1	none	_	_
7	medium	_	_	NN	O	-1	none	_	_
8	does	_	_	VBZ	O	-1	none	_	_
9	not	_	_	RB	O	-1	none	_	_
10	detectably	_	_	RB	O	-1	none	_	_
11	alter	_	_	VB	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	pattern	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	resulting	_	_	VBG	O	-1	none	_	_
18	from	_	_	IN	O	-1	none	_	_
19	T	_	_	NN	O	-1	none	_	_
20	cell	_	_	NN	O	-1	none	_	_
21	triggering	_	_	NN	O	-1	none	_	_
22	with	_	_	IN	O	-1	none	_	_
23	alpha	_	_	NN	O	-1	none	_	_
24	CD3	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	but	_	_	CC	O	-1	none	_	_
27	at	_	_	IN	O	-1	none	_	_
28	later	_	_	JJR	O	-1	none	_	_
29	time	_	_	NN	O	-1	none	_	_
30	points	_	_	NNS	O	-1	none	_	_
31	prevents	_	_	VBZ	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	appearance	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	functional	_	_	JJ	O	-1	none	_	_
36	NF-AT1	_	_	NN	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	factor	_	_	NN	O	-1	none	_	_
39	complexes	_	_	NNS	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	T	_	_	NN	O	-1	none	_	_
42	cell	_	_	NN	O	-1	none	_	_
43	nuclear	_	_	JJ	O	-1	none	_	_
44	extracts	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	findings	_	_	NNS	O	-1	none	_	_
3	are	_	_	VBP	O	-1	none	_	_
4	consistent	_	_	JJ	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	postulated	_	_	JJ	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	TN	_	_	NN	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	natural	_	_	JJ	O	-1	none	_	_
14	antagonist	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	FN	_	_	NN	Protein	-1	none	_	_
17	action	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	suggest	_	_	VBP	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	responses	_	_	NNS	O	-1	none	_	_
25	occurring	_	_	VBG	O	-1	none	_	_
26	at	_	_	IN	O	-1	none	_	_
27	tissue	_	_	NN	O	-1	none	_	_
28	sites	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	which	_	_	WDT	O	-1	none	_	_
31	TN	_	_	NN	O	-1	none	_	_
32	is	_	_	VBZ	O	-1	none	_	_
33	expressed	_	_	VBN	O	-1	none	_	_
34	could	_	_	MD	O	-1	none	_	_
35	be	_	_	VB	O	-1	none	_	_
36	influenced	_	_	VBN	O	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	its	_	_	PRP$	O	-1	none	_	_
39	presence	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	Circadian	_	_	JJ	O	-1	none	_	_
2	rhythm	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	glucocorticoid	_	_	NN	Protein	5	multitoken	_	_
5	receptors	_	_	NNS	Protein	0	root	_	_
6	in	_	_	IN	O	-1	none	_	_
7	human	_	_	NN	O	-1	none	_	_
8	peripheral	_	_	JJ	O	-1	none	_	_
9	leukocytes	_	_	NNS	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	their	_	_	PRP$	O	-1	none	_	_
12	reactivity	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	glucocorticoids	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	1	_	_	CD	O	-1	none	_	_
2	)	_	_	-RRB-	O	-1	none	_	_
3	There	_	_	EX	O	-1	none	_	_
4	exists	_	_	VBZ	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	CR	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	GR	_	_	NN	Protein	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	human	_	_	NN	O	-1	none	_	_
11	leukocytes	_	_	NNS	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	PMN	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	monocytes	_	_	NNS	O	-1	none	_	_
17	with	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	peak	_	_	NN	O	-1	none	_	_
20	values	_	_	NNS	O	-1	none	_	_
21	from	_	_	IN	O	-1	none	_	_
22	0400	_	_	CD	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	0800	_	_	CD	O	-1	none	_	_
25	hr	_	_	NN	O	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	trough	_	_	NN	O	-1	none	_	_
29	values	_	_	NNS	O	-1	none	_	_
30	between	_	_	IN	O	-1	none	_	_
31	2300	_	_	CD	O	-1	none	_	_
32	and	_	_	CC	O	-1	none	_	_
33	0000	_	_	CD	O	-1	none	_	_
34	hr	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	difference	_	_	NN	O	-1	none	_	_
3	between	_	_	IN	O	-1	none	_	_
4	them	_	_	PRP	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	significant	_	_	JJ	O	-1	none	_	_
7	statistically	_	_	RB	O	-1	none	_	_
8	.	_	_	.	O	-1	none	_	_

1	2	_	_	CD	O	-1	none	_	_
2	)	_	_	-RRB-	O	-1	none	_	_
3	The	_	_	DT	O	-1	none	_	_
4	FI	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	chemotactic	_	_	JJ	O	-1	none	_	_
8	migration	_	_	NN	O	-1	none	_	_
9	rate	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	PMN	_	_	NN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	cortisol	_	_	NN	O	-1	none	_	_
14	also	_	_	RB	O	-1	none	_	_
15	showed	_	_	VBD	O	-1	none	_	_
16	diurnal	_	_	JJ	O	-1	none	_	_
17	changes	_	_	NNS	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	synchronous	_	_	JJ	O	-1	none	_	_
21	with	_	_	IN	O	-1	none	_	_
22	that	_	_	DT	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	GR	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	indicates	_	_	VBZ	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	CR	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	GR	_	_	NN	Protein	-1	none	_	_
8	may	_	_	MD	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	functional	_	_	JJ	O	-1	none	_	_
12	significance	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	3	_	_	CD	O	-1	none	_	_
2	)	_	_	-RRB-	O	-1	none	_	_
3	In	_	_	IN	O	-1	none	_	_
4	Cushing	_	_	NN	O	-1	none	_	_
5	's	_	_	POS	O	-1	none	_	_
6	syndrome	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	CR	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	GR	_	_	NN	Protein	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	normal	_	_	JJ	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	spite	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	fact	_	_	NN	O	-1	none	_	_
19	that	_	_	IN	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	CR	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	plasma	_	_	NN	O	-1	none	_	_
24	cortisol	_	_	NN	O	-1	none	_	_
25	was	_	_	VBD	O	-1	none	_	_
26	disturbed	_	_	VBN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	indicates	_	_	VBZ	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	independency	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	CR	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	GR	_	_	NN	Protein	-1	none	_	_
10	from	_	_	IN	O	-1	none	_	_
11	that	_	_	DT	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	cortisol	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	4	_	_	CD	O	-1	none	_	_
2	)	_	_	-RRB-	O	-1	none	_	_
3	In	_	_	IN	O	-1	none	_	_
4	apoplexy	_	_	NN	O	-1	none	_	_
5	caused	_	_	VBN	O	-1	none	_	_
6	by	_	_	IN	O	-1	none	_	_
7	brain	_	_	NN	O	-1	none	_	_
8	ischemia	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	CR	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	GR	_	_	NN	Protein	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	abolished	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	patients	_	_	NNS	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	basal	_	_	JJ	O	-1	none	_	_
20	lesions	_	_	NNS	O	-1	none	_	_
21	but	_	_	CC	O	-1	none	_	_
22	preserved	_	_	VBN	O	-1	none	_	_
23	when	_	_	WRB	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	lesions	_	_	NNS	O	-1	none	_	_
26	were	_	_	VBD	O	-1	none	_	_
27	located	_	_	VBN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	cerebral	_	_	JJ	O	-1	none	_	_
31	cortex	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	strongly	_	_	RB	O	-1	none	_	_
4	suggest	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	main	_	_	JJ	O	-1	none	_	_
8	"	_	_	``	O	-1	none	_	_
9	circadian	_	_	JJ	O	-1	none	_	_
10	pacemaker	_	_	NN	O	-1	none	_	_
11	"	_	_	''	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	GR	_	_	NN	Protein	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	located	_	_	JJ	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	basal	_	_	JJ	O	-1	none	_	_
19	brain	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	most	_	_	JJS	O	-1	none	_	_
22	probably	_	_	RB	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	suprachiasmatic	_	_	JJ	O	-1	none	_	_
26	nuclei	_	_	NNS	O	-1	none	_	_
27	as	_	_	IN	O	-1	none	_	_
28	has	_	_	VBZ	O	-1	none	_	_
29	been	_	_	VBN	O	-1	none	_	_
30	suggested	_	_	VBN	O	-1	none	_	_
31	for	_	_	IN	O	-1	none	_	_
32	rodents	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Interferon-alpha	_	_	NN	O	-1	none	_	_
2	induction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	STATs1	_	_	NN	Protein	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	-3	_	_	CD	Protein	-1	none	_	_
7	DNA	_	_	NN	O	-1	none	_	_
8	binding	_	_	NN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	growth	_	_	NN	O	-1	none	_	_
11	arrest	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	independent	_	_	JJ	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	Lck	_	_	NN	Protein	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	active	_	_	JJ	O	-1	none	_	_
18	mitogen	_	_	NN	O	-1	none	_	_
19	activated	_	_	JJ	O	-1	none	_	_
20	kinase	_	_	NN	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	T	_	_	NN	O	-1	none	_	_
23	cells	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Type	_	_	NN	O	-1	none	_	_
2	I	_	_	CD	O	-1	none	_	_
3	interferons	_	_	NNS	O	-1	none	_	_
4	(	_	_	-LRB-	O	-1	none	_	_
5	IFNs	_	_	NNS	O	-1	none	_	_
6	)	_	_	-RRB-	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	family	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	cytokines	_	_	NNS	O	-1	none	_	_
12	that	_	_	WDT	O	-1	none	_	_
13	have	_	_	VBP	O	-1	none	_	_
14	antiviral	_	_	JJ	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	antiproliferative	_	_	JJ	O	-1	none	_	_
17	effects	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Data	_	_	NNS	O	-1	none	_	_
2	regarding	_	_	VBG	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	processes	_	_	NNS	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	which	_	_	WDT	O	-1	none	_	_
7	these	_	_	DT	O	-1	none	_	_
8	cytokines	_	_	NNS	O	-1	none	_	_
9	transduce	_	_	VBP	O	-1	none	_	_
10	signals	_	_	NNS	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	cell	_	_	NN	O	-1	none	_	_
14	membrane	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	nucleus	_	_	NN	O	-1	none	_	_
18	are	_	_	VBP	O	-1	none	_	_
19	becoming	_	_	VBG	O	-1	none	_	_
20	increasingly	_	_	RB	O	-1	none	_	_
21	complex	_	_	JJ	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	most	_	_	RBS	O	-1	none	_	_
3	characterized	_	_	VBN	O	-1	none	_	_
4	pathway	_	_	NN	O	-1	none	_	_
5	is	_	_	VBZ	O	-1	none	_	_
6	via	_	_	IN	O	-1	none	_	_
7	JAK-STAT	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	.	_	_	.	O	-1	none	_	_

1	Previous	_	_	JJ	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	established	_	_	VBD	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	potential	_	_	JJ	O	-1	none	_	_
6	role	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	Src	_	_	NN	O	-1	none	_	_
10	family	_	_	NN	O	-1	none	_	_
11	kinase	_	_	NN	O	-1	none	_	_
12	Lck	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	JAK-STAT	_	_	NN	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	was	_	_	VBD	O	-1	none	_	_
6	designed	_	_	VBN	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	analyze	_	_	VB	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	role	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	Lck	_	_	NN	Protein	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	IFN-alpha	_	_	NN	O	-1	none	_	_
15	signaling	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	using	_	_	VBG	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	Jurkat	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	JCam	_	_	NN	O	-1	none	_	_
22	(	_	_	-LRB-	O	-1	none	_	_
23	an	_	_	DT	O	-1	none	_	_
24	Lck	_	_	NN	Protein	-1	none	_	_
25	defective	_	_	JJ	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	line	_	_	NN	O	-1	none	_	_
28	derived	_	_	VBN	O	-1	none	_	_
29	from	_	_	IN	O	-1	none	_	_
30	Jurkat	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	and	_	_	CC	O	-1	none	_	_
34	JCam	_	_	NN	O	-1	none	_	_
35	and	_	_	CC	O	-1	none	_	_
36	Lck	_	_	NN	Protein	-1	none	_	_
37	(	_	_	-LRB-	O	-1	none	_	_
38	JCam	_	_	NN	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	with	_	_	IN	O	-1	none	_	_
41	Lck	_	_	NN	Protein	-1	none	_	_
42	restored	_	_	VBD	O	-1	none	_	_
43	)	_	_	-RRB-	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	IFN-alpha	_	_	NN	O	-1	none	_	_
6	can	_	_	MD	O	-1	none	_	_
7	induce	_	_	VB	O	-1	none	_	_
8	MAPK	_	_	NN	O	-1	none	_	_
9	activity	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	only	_	_	RB	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	containing	_	_	VBG	O	-1	none	_	_
16	Lck	_	_	NN	Protein	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Furthermore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	STATs1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	-3	_	_	CD	Protein	-1	none	_	_
6	are	_	_	VBP	O	-1	none	_	_
7	effectively	_	_	RB	O	-1	none	_	_
8	phosphorylated	_	_	VBN	O	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	activated	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	bind	_	_	VB	O	-1	none	_	_
13	DNA	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	absence	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	Lck	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	IFN-alpha-treated	_	_	JJ	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Finally	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	demonstrate	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	IFN-alpha	_	_	NN	O	-1	none	_	_
8	exerts	_	_	VBZ	O	-1	none	_	_
9	an	_	_	DT	O	-1	none	_	_
10	antiproliferative	_	_	JJ	O	-1	none	_	_
11	effect	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	all	_	_	DT	O	-1	none	_	_
14	three	_	_	CD	O	-1	none	_	_
15	cell	_	_	NN	O	-1	none	_	_
16	lines	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	Lck	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	active	_	_	JJ	O	-1	none	_	_
8	MAPK	_	_	NN	O	-1	none	_	_
9	do	_	_	VBP	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	affect	_	_	VB	O	-1	none	_	_
12	IFN-alpha-induced	_	_	JJ	O	-1	none	_	_
13	growth	_	_	NN	O	-1	none	_	_
14	arrest	_	_	NN	O	-1	none	_	_
15	or	_	_	CC	O	-1	none	_	_
16	induction	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	STAT1s1	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	-3	_	_	CD	O	-1	none	_	_
21	DNA	_	_	NN	O	-1	none	_	_
22	binding	_	_	NN	O	-1	none	_	_
23	ability	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Copyright	_	_	NN	O	-1	none	_	_
2	1999	_	_	CD	O	-1	none	_	_
3	Academic	_	_	NNP	O	-1	none	_	_
4	Press	_	_	NNP	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	Signal	_	_	NN	O	-1	none	_	_
2	transduction	_	_	NN	O	-1	none	_	_
3	pathways	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	normal	_	_	JJ	O	-1	none	_	_
6	human	_	_	NN	O	-1	none	_	_
7	monocytes	_	_	NNS	O	-1	none	_	_
8	stimulated	_	_	VBN	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	cytokines	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	mediators	_	_	NNS	O	-1	none	_	_
13	:	_	_	:	O	-1	none	_	_
14	comparative	_	_	JJ	O	-1	none	_	_
15	study	_	_	NN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	normal	_	_	JJ	O	-1	none	_	_
18	human	_	_	NN	O	-1	none	_	_
19	neutrophils	_	_	NNS	O	-1	none	_	_
20	or	_	_	CC	O	-1	none	_	_
21	transformed	_	_	VBN	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	putative	_	_	JJ	O	-1	none	_	_
26	roles	_	_	NNS	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	functionality	_	_	NN	O	-1	none	_	_
29	and	_	_	CC	O	-1	none	_	_
30	cell	_	_	NN	O	-1	none	_	_
31	biology	_	_	NN	O	-1	none	_	_
32	.	_	_	.	O	-1	none	_	_

1	Granulocyte-macrophage	_	_	JJ	Protein	4	multitoken	_	_
2	colony	_	_	NN	Protein	4	multitoken	_	_
3	stimulating	_	_	NN	Protein	4	multitoken	_	_
4	factor	_	_	NN	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	GM-CSF	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	interleukin	_	_	NN	Protein	13	multitoken	_	_
10	(	_	_	-LRB-	Protein	13	multitoken	_	_
11	IL	_	_	NN	Protein	13	multitoken	_	_
12	)	_	_	-RRB-	Protein	13	multitoken	_	_
13	-3	_	_	CD	Protein	0	root	_	_
14	induced	_	_	VBN	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	92-kDa	_	_	JJ	O	-1	none	_	_
19	protein	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	normal	_	_	JJ	O	-1	none	_	_
22	human	_	_	NN	O	-1	none	_	_
23	monocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	identified	_	_	VBD	O	-1	none	_	_
3	this	_	_	DT	O	-1	none	_	_
4	92-kDa	_	_	JJ	O	-1	none	_	_
5	protein	_	_	NN	O	-1	none	_	_
6	as	_	_	IN	O	-1	none	_	_
7	STAT5	_	_	NN	Protein	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	but	_	_	CC	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	as	_	_	IN	O	-1	none	_	_
12	STATs1	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	3	_	_	CD	Protein	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	6	_	_	CD	Protein	-1	none	_	_
18	nor	_	_	CC	O	-1	none	_	_
19	c-fes	_	_	NN	Protein	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	vav	_	_	NN	Protein	-1	none	_	_
22	protooncogene	_	_	NN	O	-1	none	_	_
23	products	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	demonstrated	_	_	VBD	O	-1	none	_	_
27	its	_	_	PRP$	O	-1	none	_	_
28	translocation	_	_	NN	O	-1	none	_	_
29	to	_	_	TO	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	nucleus	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	enhancement	_	_	NN	O	-1	none	_	_
34	of	_	_	IN	O	-1	none	_	_
35	specific	_	_	JJ	O	-1	none	_	_
36	DNA	_	_	NN	O	-1	none	_	_
37	binding	_	_	NN	O	-1	none	_	_
38	capacity	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	and	_	_	CC	O	-1	none	_	_
41	potentiation	_	_	NN	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	trancriptional	_	_	JJ	O	-1	none	_	_
44	activity	_	_	NN	O	-1	none	_	_
45	by	_	_	IN	O	-1	none	_	_
46	GM-CSF	_	_	NN	Protein	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	N-formyl-methionyl-leucyl-phenylalanine	_	_	NN	O	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	FMLP	_	_	NN	O	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	phorbol	_	_	NN	O	-1	none	_	_
7	myristate	_	_	NN	O	-1	none	_	_
8	acetate	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	PMA	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	induced	_	_	VBD	O	-1	none	_	_
13	tyrosine	_	_	NN	O	-1	none	_	_
14	phosphorylation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	42-	_	_	CD	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	44-kDa	_	_	JJ	O	-1	none	_	_
19	proteins	_	_	NNS	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	which	_	_	WDT	O	-1	none	_	_
22	were	_	_	VBD	O	-1	none	_	_
23	identified	_	_	VBN	O	-1	none	_	_
24	as	_	_	IN	O	-1	none	_	_
25	extracellular	_	_	JJ	O	-1	none	_	_
26	signal	_	_	NN	O	-1	none	_	_
27	regulated	_	_	VBN	O	-1	none	_	_
28	kinase	_	_	NN	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	ERK	_	_	NN	O	-1	none	_	_
31	)	_	_	-RRB-	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	in	_	_	IN	O	-1	none	_	_
34	human	_	_	NN	O	-1	none	_	_
35	monocytes	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	marked	_	_	JJ	O	-1	none	_	_
3	contrast	_	_	NN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	neutrophils	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	MO7e	_	_	NN	O	-1	none	_	_
8	cells	_	_	NNS	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	GM-CSF	_	_	NN	Protein	-1	none	_	_
11	did	_	_	VBD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	induce	_	_	VB	O	-1	none	_	_
14	tyrosine	_	_	NN	O	-1	none	_	_
15	phosphorylation	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	ERK	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	monocytes	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Among	_	_	IN	O	-1	none	_	_
2	upstream	_	_	JJ	O	-1	none	_	_
3	signaling	_	_	VBG	O	-1	none	_	_
4	molecules	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	ERK	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	Shc	_	_	NN	Protein	-1	none	_	_
9	was	_	_	VBD	O	-1	none	_	_
10	constitutively	_	_	RB	O	-1	none	_	_
11	associated	_	_	VBN	O	-1	none	_	_
12	with	_	_	IN	O	-1	none	_	_
13	Grb2	_	_	NN	Protein	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	was	_	_	VBD	O	-1	none	_	_
16	not	_	_	RB	O	-1	none	_	_
17	tyrosine	_	_	NN	O	-1	none	_	_
18	phosphorylated	_	_	VBN	O	-1	none	_	_
19	by	_	_	IN	O	-1	none	_	_
20	GM-CSF	_	_	NN	Protein	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	FMLP	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	Sos1	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	c-Raf-1	_	_	NN	Protein	-1	none	_	_
28	were	_	_	VBD	O	-1	none	_	_
29	not	_	_	RB	O	-1	none	_	_
30	phosphorylated	_	_	VBN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	GM-CSF	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	IL-3	_	_	NN	Protein	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	TNF	_	_	NN	Protein	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	and	_	_	CC	O	-1	none	_	_
39	FMLP	_	_	NN	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	monocytes	_	_	NNS	O	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	whereas	_	_	IN	O	-1	none	_	_
44	all	_	_	PDT	O	-1	none	_	_
45	these	_	_	DT	O	-1	none	_	_
46	signaling	_	_	VBG	O	-1	none	_	_
47	molecules	_	_	NNS	O	-1	none	_	_
48	were	_	_	VBD	O	-1	none	_	_
49	affected	_	_	VBN	O	-1	none	_	_
50	and/or	_	_	CC	O	-1	none	_	_
51	utilized	_	_	VBN	O	-1	none	_	_
52	by	_	_	IN	O	-1	none	_	_
53	GM-CSF	_	_	NN	Protein	-1	none	_	_
54	in	_	_	IN	O	-1	none	_	_
55	MO7e	_	_	NN	O	-1	none	_	_
56	cells	_	_	NNS	O	-1	none	_	_
57	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	neutrophils	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	p38	_	_	NN	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	constitutively	_	_	RB	O	-1	none	_	_
9	phosphorylated	_	_	VBN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	agonist	_	_	NN	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	phosphorylation	_	_	NN	O	-1	none	_	_
14	and	_	_	CC	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	was	_	_	VBD	O	-1	none	_	_
17	not	_	_	RB	O	-1	none	_	_
18	detected	_	_	VBN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	human	_	_	NN	O	-1	none	_	_
21	monocytes	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	Superoxide	_	_	NN	O	-1	none	_	_
2	release	_	_	NN	O	-1	none	_	_
3	stimulated	_	_	VBN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	FMLP	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	inhibited	_	_	VBN	O	-1	none	_	_
8	partially	_	_	RB	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	PD98059	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	SB203580	_	_	NN	O	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	inhibitor	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	ERK	_	_	NN	O	-1	none	_	_
19	or	_	_	CC	O	-1	none	_	_
20	p38	_	_	NN	O	-1	none	_	_
21	pathway	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	was	_	_	VBD	O	-1	none	_	_
25	almost	_	_	RB	O	-1	none	_	_
26	completely	_	_	RB	O	-1	none	_	_
27	inhibited	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	combination	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	both	_	_	DT	O	-1	none	_	_
33	inhibitors	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	whereas	_	_	IN	O	-1	none	_	_
36	PMA	_	_	NN	O	-1	none	_	_
37	induced	_	_	VBD	O	-1	none	_	_
38	superoxide	_	_	NN	O	-1	none	_	_
39	release	_	_	NN	O	-1	none	_	_
40	was	_	_	VBD	O	-1	none	_	_
41	resistant	_	_	JJ	O	-1	none	_	_
42	to	_	_	TO	O	-1	none	_	_
43	these	_	_	DT	O	-1	none	_	_
44	two	_	_	CD	O	-1	none	_	_
45	inhibitors	_	_	NNS	O	-1	none	_	_
46	in	_	_	IN	O	-1	none	_	_
47	monocytes	_	_	NNS	O	-1	none	_	_
48	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Present	_	_	JJ	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	trancriptional	_	_	JJ	O	-1	none	_	_
5	roles	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	STAT5	_	_	NN	Protein	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	functional	_	_	JJ	O	-1	none	_	_
10	roles	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	ERK	_	_	NN	O	-1	none	_	_
13	and/or	_	_	CC	O	-1	none	_	_
14	p38	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	normal	_	_	JJ	O	-1	none	_	_
17	human	_	_	NN	O	-1	none	_	_
18	monocytes	_	_	NNS	O	-1	none	_	_
19	stimulated	_	_	VBN	O	-1	none	_	_
20	by	_	_	IN	O	-1	none	_	_
21	physiological	_	_	JJ	O	-1	none	_	_
22	receptor	_	_	NN	O	-1	none	_	_
23	mediated	_	_	VBN	O	-1	none	_	_
24	agonists	_	_	NNS	O	-1	none	_	_
25	GM-CSF	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	FMLP	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Possible	_	_	JJ	O	-1	none	_	_
2	roles	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	ERK	_	_	NN	O	-1	none	_	_
5	in	_	_	IN	O	-1	none	_	_
6	proliferation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	transformed	_	_	VBN	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	suggested	_	_	VBN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	ICSAT	_	_	NN	Protein	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	not	_	_	RB	O	-1	none	_	_
5	sufficient	_	_	JJ	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	cause	_	_	VB	O	-1	none	_	_
8	adult	_	_	JJ	O	-1	none	_	_
9	T-cell	_	_	NN	O	-1	none	_	_
10	leukemia	_	_	NN	O	-1	none	_	_
11	or	_	_	CC	O	-1	none	_	_
12	multiple	_	_	JJ	O	-1	none	_	_
13	myeloma	_	_	NN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	ICSAT	_	_	NN	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	Interferon	_	_	NN	Protein	11	multitoken	_	_
4	Consensus	_	_	NN	Protein	11	multitoken	_	_
5	Sequence	_	_	NN	Protein	11	multitoken	_	_
6	binding	_	_	NN	Protein	11	multitoken	_	_
7	protein	_	_	NN	Protein	11	multitoken	_	_
8	for	_	_	IN	Protein	11	multitoken	_	_
9	Activated	_	_	VBN	Protein	11	multitoken	_	_
10	T	_	_	NN	Protein	11	multitoken	_	_
11	cells	_	_	NNS	Protein	0	root	_	_
12	)	_	_	-RRB-	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	lymphocyte	_	_	NN	O	-1	none	_	_
16	specific	_	_	JJ	O	-1	none	_	_
17	member	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	interferon	_	_	NN	O	-1	none	_	_
21	regulatory	_	_	JJ	O	-1	none	_	_
22	factor	_	_	NN	O	-1	none	_	_
23	(	_	_	-LRB-	O	-1	none	_	_
24	IRF	_	_	NN	O	-1	none	_	_
25	)	_	_	-RRB-	O	-1	none	_	_
26	family	_	_	NN	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	transcription	_	_	NN	O	-1	none	_	_
29	factors	_	_	NNS	O	-1	none	_	_
30	,	_	_	,	O	-1	none	_	_
31	originally	_	_	RB	O	-1	none	_	_
32	identified	_	_	VBN	O	-1	none	_	_
33	through	_	_	IN	O	-1	none	_	_
34	Southwestern	_	_	NN	O	-1	none	_	_
35	screening	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	ATL	_	_	NN	O	-1	none	_	_
39	(	_	_	-LRB-	O	-1	none	_	_
40	Adult	_	_	JJ	O	-1	none	_	_
41	T-cell	_	_	NN	O	-1	none	_	_
42	leukemia	_	_	NN	O	-1	none	_	_
43	)-16T	_	_	NN	O	-1	none	_	_
44	expression	_	_	NN	O	-1	none	_	_
45	library	_	_	NN	O	-1	none	_	_
46	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	study	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	created	_	_	VBD	O	-1	none	_	_
7	transgenic	_	_	JJ	O	-1	none	_	_
8	mice	_	_	NNS	O	-1	none	_	_
9	overexpressing	_	_	VBG	O	-1	none	_	_
10	ICSAT	_	_	NN	Protein	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	lymphocytes	_	_	NNS	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	spontaneous	_	_	JJ	O	-1	none	_	_
3	tumorigenesis	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	not	_	_	RB	O	-1	none	_	_
6	observed	_	_	VBN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	production	_	_	NN	O	-1	none	_	_
10	with	_	_	IN	O	-1	none	_	_
11	Concanavalin	_	_	NN	O	-1	none	_	_
12	A	_	_	NN	O	-1	none	_	_
13	stimulation	_	_	NN	O	-1	none	_	_
14	was	_	_	VBD	O	-1	none	_	_
15	significantly	_	_	RB	O	-1	none	_	_
16	increased	_	_	VBN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	transgenic	_	_	JJ	O	-1	none	_	_
19	mice	_	_	NNS	O	-1	none	_	_
20	overexpressing	_	_	VBG	O	-1	none	_	_
21	ICSAT	_	_	NN	Protein	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	ICSAT	_	_	NN	Protein	-1	none	_	_
2	overexpression	_	_	NN	O	-1	none	_	_
3	in	_	_	IN	O	-1	none	_	_
4	lymphocytes	_	_	NNS	O	-1	none	_	_
5	seems	_	_	VBZ	O	-1	none	_	_
6	insufficient	_	_	JJ	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	leukemogenesis	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	ATL	_	_	NN	O	-1	none	_	_
12	or	_	_	CC	O	-1	none	_	_
13	multiple	_	_	JJ	O	-1	none	_	_
14	myeloma	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	MM	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	however	_	_	RB	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	it	_	_	PRP	O	-1	none	_	_
22	may	_	_	MD	O	-1	none	_	_
23	regulate	_	_	VB	O	-1	none	_	_
24	T	_	_	NN	O	-1	none	_	_
25	cell	_	_	NN	O	-1	none	_	_
26	activation	_	_	NN	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	its	_	_	PRP$	O	-1	none	_	_
29	overexpression	_	_	NN	O	-1	none	_	_
30	may	_	_	MD	O	-1	none	_	_
31	lead	_	_	VB	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	leukemogenesis	_	_	NN	O	-1	none	_	_
34	via	_	_	IN	O	-1	none	_	_
35	controlling	_	_	VBG	O	-1	none	_	_
36	IL-2	_	_	NN	Protein	-1	none	_	_
37	production	_	_	NN	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Copyright	_	_	NN	O	-1	none	_	_
2	1999	_	_	CD	O	-1	none	_	_
3	Academic	_	_	NNP	O	-1	none	_	_
4	Press	_	_	NNP	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	Epstein-Barr	_	_	NNP	O	-1	none	_	_
2	virus	_	_	NN	O	-1	none	_	_
3	nuclear	_	_	JJ	Protein	5	multitoken	_	_
4	antigen	_	_	NN	Protein	5	multitoken	_	_
5	2	_	_	CD	Protein	0	root	_	_
6	and	_	_	CC	O	-1	none	_	_
7	latent	_	_	JJ	O	-1	none	_	_
8	membrane	_	_	NN	O	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	independently	_	_	RB	O	-1	none	_	_
11	transactivate	_	_	VBP	O	-1	none	_	_
12	p53	_	_	NN	Protein	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	induction	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	NF-kappaB	_	_	NN	O	-1	none	_	_
17	activity	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	B-cell	_	_	NN	O	-1	none	_	_
2	immortalization	_	_	NN	O	-1	none	_	_
3	by	_	_	IN	O	-1	none	_	_
4	Epstein-Barr	_	_	JJ	O	-1	none	_	_
5	virus	_	_	NN	O	-1	none	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	EBV	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	dependent	_	_	JJ	O	-1	none	_	_
11	on	_	_	IN	O	-1	none	_	_
12	permanent	_	_	JJ	O	-1	none	_	_
13	control	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	cellular	_	_	JJ	O	-1	none	_	_
17	processes	_	_	NNS	O	-1	none	_	_
18	which	_	_	WDT	O	-1	none	_	_
19	normally	_	_	RB	O	-1	none	_	_
20	regulate	_	_	VBP	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	division	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	apoptosis	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	functions	_	_	VBZ	O	-1	none	_	_
27	possessed	_	_	VBN	O	-1	none	_	_
28	by	_	_	IN	O	-1	none	_	_
29	p53	_	_	NN	Protein	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	a	_	_	DT	O	-1	none	_	_
32	number	_	_	NN	O	-1	none	_	_
33	of	_	_	IN	O	-1	none	_	_
34	normal	_	_	JJ	O	-1	none	_	_
35	cell	_	_	NN	O	-1	none	_	_
36	types	_	_	NNS	O	-1	none	_	_
37	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	initiated	_	_	VBN	O	-1	none	_	_
4	to	_	_	TO	O	-1	none	_	_
5	evaluate	_	_	VB	O	-1	none	_	_
6	relationships	_	_	NNS	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	EBV	_	_	NN	O	-1	none	_	_
9	latent	_	_	JJ	O	-1	none	_	_
10	genes	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	p53	_	_	NN	Protein	-1	none	_	_
13	,	_	_	,	O	-1	none	_	_
14	p53	_	_	NN	Protein	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	found	_	_	VBN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	increase	_	_	VB	O	-1	none	_	_
20	approximately	_	_	RB	O	-1	none	_	_
21	10-fold	_	_	RB	O	-1	none	_	_
22	4	_	_	CD	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	5	_	_	CD	O	-1	none	_	_
25	days	_	_	NNS	O	-1	none	_	_
26	after	_	_	IN	O	-1	none	_	_
27	EBV	_	_	NN	O	-1	none	_	_
28	infection	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	purified	_	_	VBN	O	-1	none	_	_
31	resting	_	_	VBG	O	-1	none	_	_
32	human	_	_	NN	O	-1	none	_	_
33	B	_	_	NN	O	-1	none	_	_
34	cells	_	_	NNS	O	-1	none	_	_
35	;	_	_	:	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	induced	_	_	JJ	O	-1	none	_	_
38	p53	_	_	NN	Protein	-1	none	_	_
39	was	_	_	VBD	O	-1	none	_	_
40	transcriptionally	_	_	RB	O	-1	none	_	_
41	active	_	_	JJ	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Latent	_	_	JJ	Protein	4	multitoken	_	_
2	membrane	_	_	NN	Protein	4	multitoken	_	_
3	protein	_	_	NN	Protein	4	multitoken	_	_
4	1	_	_	CD	Protein	0	root	_	_
5	and	_	_	CC	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	to	_	_	TO	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	lesser	_	_	JJR	O	-1	none	_	_
10	extent	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	EBV	_	_	NN	O	-1	none	_	_
13	nuclear	_	_	JJ	Protein	15	multitoken	_	_
14	antigen	_	_	NN	Protein	15	multitoken	_	_
15	2	_	_	CD	Protein	0	root	_	_
16	mediated	_	_	VBD	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	increase	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	p53	_	_	NN	Protein	-1	none	_	_
21	levels	_	_	NNS	O	-1	none	_	_
22	via	_	_	IN	O	-1	none	_	_
23	activation	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	NF-kappaB	_	_	NN	O	-1	none	_	_
27	transcription	_	_	NN	O	-1	none	_	_
28	factor	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	CBP	_	_	NN	Protein	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	p300	_	_	NN	Protein	-1	none	_	_
4	integrates	_	_	VBZ	O	-1	none	_	_
5	Raf	_	_	NN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	Rac	_	_	NN	O	-1	none	_	_
8	signaling	_	_	NN	O	-1	none	_	_
9	pathways	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	transcriptional	_	_	JJ	O	-1	none	_	_
13	induction	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	NF-ATc	_	_	NN	Protein	-1	none	_	_
16	during	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	activation	_	_	NN	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	NF-ATc	_	_	NNP	Protein	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	an	_	_	DT	O	-1	none	_	_
4	inducibly	_	_	RB	O	-1	none	_	_
5	expressed	_	_	VBN	O	-1	none	_	_
6	transcription	_	_	NN	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	controls	_	_	VBZ	O	-1	none	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	expression	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	cardiomyocytes	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	show	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	transcriptional	_	_	JJ	O	-1	none	_	_
7	co-activators	_	_	NNS	O	-1	none	_	_
8	CBP	_	_	NN	Protein	-1	none	_	_
9	and	_	_	CC	O	-1	none	_	_
10	p300	_	_	NN	Protein	-1	none	_	_
11	bind	_	_	VBP	O	-1	none	_	_
12	to	_	_	TO	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	control	_	_	VB	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	activity	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	inducible	_	_	JJ	O	-1	none	_	_
20	N-terminal	_	_	JJ	O	-1	none	_	_
21	transactivation	_	_	NN	O	-1	none	_	_
22	domain	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	NF-ATc	_	_	NN	Protein	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	TAD-A	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Similar	_	_	JJ	O	-1	none	_	_
2	to	_	_	TO	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	N	_	_	NN	O	-1	none	_	_
5	terminal	_	_	JJ	O	-1	none	_	_
6	transactivation	_	_	NN	O	-1	none	_	_
7	domain	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	c-Jun	_	_	NN	Protein	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	TAD-A	_	_	NN	O	-1	none	_	_
12	is	_	_	VBZ	O	-1	none	_	_
13	inducibly	_	_	RB	O	-1	none	_	_
14	phosphorylated	_	_	VBN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	but	_	_	CC	O	-1	none	_	_
17	this	_	_	DT	O	-1	none	_	_
18	phosphorylation	_	_	NN	O	-1	none	_	_
19	is	_	_	VBZ	O	-1	none	_	_
20	dispensable	_	_	JJ	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	interaction	_	_	NN	O	-1	none	_	_
24	with	_	_	IN	O	-1	none	_	_
25	CBP	_	_	NN	Protein	-1	none	_	_
26	and	_	_	CC	O	-1	none	_	_
27	p300	_	_	NN	Protein	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	Constitutive	_	_	JJ	O	-1	none	_	_
2	active	_	_	JJ	O	-1	none	_	_
3	versions	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	c-Raf	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	Rac	_	_	NN	O	-1	none	_	_
8	synergistically	_	_	RB	O	-1	none	_	_
9	enhance	_	_	VBP	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	CBP	_	_	NN	Protein	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	p300	_	_	NN	Protein	-1	none	_	_
14	mediated	_	_	JJ	O	-1	none	_	_
15	increase	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	TAD-A	_	_	NN	O	-1	none	_	_
18	activity	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	indicating	_	_	VBG	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	important	_	_	JJ	O	-1	none	_	_
23	role	_	_	NN	O	-1	none	_	_
24	CBP	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	p300	_	_	NN	Protein	-1	none	_	_
27	plays	_	_	VBZ	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	integration	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cell	_	_	NN	O	-1	none	_	_
34	activation	_	_	NN	O	-1	none	_	_
35	signals	_	_	NNS	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	mutation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	CBP	_	_	NN	Protein	-1	none	_	_
6	abolishing	_	_	VBG	O	-1	none	_	_
7	HAT	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	almost	_	_	RB	O	-1	none	_	_
11	as	_	_	RB	O	-1	none	_	_
12	active	_	_	JJ	O	-1	none	_	_
13	as	_	_	IN	O	-1	none	_	_
14	wild-type	_	_	JJ	O	-1	none	_	_
15	CBP	_	_	NN	Protein	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	functions	_	_	NNS	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	CBP	_	_	NN	Protein	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	p300	_	_	NN	Protein	-1	none	_	_
25	other	_	_	JJ	O	-1	none	_	_
26	than	_	_	IN	O	-1	none	_	_
27	histone	_	_	NN	O	-1	none	_	_
28	acetylation	_	_	NN	O	-1	none	_	_
29	appear	_	_	VBP	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	control	_	_	VB	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	NF-AT-dependent	_	_	JJ	O	-1	none	_	_
34	transcription	_	_	NN	O	-1	none	_	_
35	in	_	_	IN	O	-1	none	_	_
36	T	_	_	NN	O	-1	none	_	_
37	cells	_	_	NNS	O	-1	none	_	_
38	.	_	_	.	O	-1	none	_	_

1	Transcription	_	_	NN	O	-1	none	_	_
2	factors	_	_	NNS	O	-1	none	_	_
3	as	_	_	IN	O	-1	none	_	_
4	targets	_	_	NNS	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	oxidative	_	_	JJ	O	-1	none	_	_
7	signalling	_	_	NN	O	-1	none	_	_
8	during	_	_	IN	O	-1	none	_	_
9	lymphocyte	_	_	NN	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	previously	_	_	RB	O	-1	none	_	_
3	have	_	_	VBP	O	-1	none	_	_
4	demonstrated	_	_	VBN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	requirement	_	_	NN	O	-1	none	_	_
7	for	_	_	IN	O	-1	none	_	_
8	oxidative	_	_	JJ	O	-1	none	_	_
9	events	_	_	NNS	O	-1	none	_	_
10	during	_	_	IN	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	cycle	_	_	NN	O	-1	none	_	_
13	entry	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	T	_	_	NN	O	-1	none	_	_
16	lymphocytes	_	_	NNS	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	have	_	_	VBP	O	-1	none	_	_
19	hypothesised	_	_	VBN	O	-1	none	_	_
20	that	_	_	IN	O	-1	none	_	_
21	reactive	_	_	JJ	O	-1	none	_	_
22	oxygen	_	_	NN	O	-1	none	_	_
23	species	_	_	NNS	O	-1	none	_	_
24	may	_	_	MD	O	-1	none	_	_
25	act	_	_	VB	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	intracellular	_	_	JJ	O	-1	none	_	_
28	signalling	_	_	NN	O	-1	none	_	_
29	agents	_	_	NNS	O	-1	none	_	_
30	during	_	_	IN	O	-1	none	_	_
31	lymphocyte	_	_	NN	O	-1	none	_	_
32	activation	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	current	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	cysteamine	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	aminothiol	_	_	NN	O	-1	none	_	_
10	compound	_	_	NN	O	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	antioxidant	_	_	JJ	O	-1	none	_	_
13	activity	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	has	_	_	VBZ	O	-1	none	_	_
16	been	_	_	VBN	O	-1	none	_	_
17	used	_	_	VBN	O	-1	none	_	_
18	to	_	_	TO	O	-1	none	_	_
19	further	_	_	RB	O	-1	none	_	_
20	investigate	_	_	VB	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	role	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	oxidative	_	_	JJ	O	-1	none	_	_
25	signalling	_	_	NN	O	-1	none	_	_
26	during	_	_	IN	O	-1	none	_	_
27	lymphocyte	_	_	NN	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Treatment	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	normal	_	_	JJ	O	-1	none	_	_
4	human	_	_	NN	O	-1	none	_	_
5	peripheral	_	_	JJ	O	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	lymphocytes	_	_	NNS	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	cysteamine	_	_	NN	O	-1	none	_	_
10	in	_	_	FW	O	-1	none	_	_
11	vitro	_	_	FW	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	found	_	_	VBN	O	-1	none	_	_
14	to	_	_	TO	O	-1	none	_	_
15	inhibit	_	_	VB	O	-1	none	_	_
16	proliferation	_	_	NN	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	dose	_	_	NN	O	-1	none	_	_
20	dependent	_	_	JJ	O	-1	none	_	_
21	manner	_	_	NN	O	-1	none	_	_
22	,	_	_	,	O	-1	none	_	_
23	with	_	_	IN	O	-1	none	_	_
24	essentially	_	_	RB	O	-1	none	_	_
25	complete	_	_	JJ	O	-1	none	_	_
26	inhibition	_	_	NN	O	-1	none	_	_
27	occurring	_	_	VBG	O	-1	none	_	_
28	at	_	_	IN	O	-1	none	_	_
29	a	_	_	DT	O	-1	none	_	_
30	dose	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	400	_	_	CD	O	-1	none	_	_
33	microM	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	was	_	_	VBD	O	-1	none	_	_
5	limited	_	_	VBN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	first	_	_	JJ	O	-1	none	_	_
9	2	_	_	CD	O	-1	none	_	_
10	h	_	_	NN	O	-1	none	_	_
11	after	_	_	IN	O	-1	none	_	_
12	mitogenic	_	_	JJ	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	localizing	_	_	VBG	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	time-frame	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	action	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	cysteamine	_	_	NN	O	-1	none	_	_
22	to	_	_	TO	O	-1	none	_	_
23	within	_	_	IN	O	-1	none	_	_
24	the	_	_	DT	O	-1	none	_	_
25	commitment	_	_	NN	O	-1	none	_	_
26	period	_	_	NN	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	therefore	_	_	RB	O	-1	none	_	_
3	was	_	_	VBD	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	interest	_	_	NN	O	-1	none	_	_
6	to	_	_	TO	O	-1	none	_	_
7	establish	_	_	VB	O	-1	none	_	_
8	which	_	_	WDT	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	if	_	_	IN	O	-1	none	_	_
11	any	_	_	DT	O	-1	none	_	_
12	,	_	_	,	O	-1	none	_	_
13	commitment	_	_	NN	O	-1	none	_	_
14	events	_	_	NNS	O	-1	none	_	_
15	were	_	_	VBD	O	-1	none	_	_
16	affected	_	_	VBN	O	-1	none	_	_
17	by	_	_	IN	O	-1	none	_	_
18	oxidative	_	_	JJ	O	-1	none	_	_
19	signalling	_	_	NN	O	-1	none	_	_
20	during	_	_	IN	O	-1	none	_	_
21	cell	_	_	NN	O	-1	none	_	_
22	cycle	_	_	NN	O	-1	none	_	_
23	entry	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Taking	_	_	VBG	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	IL-2	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	as	_	_	IN	O	-1	none	_	_
6	a	_	_	DT	O	-1	none	_	_
7	candidate	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	we	_	_	PRP	O	-1	none	_	_
10	examined	_	_	VBD	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	effect	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	cysteamine	_	_	NN	O	-1	none	_	_
15	treatment	_	_	NN	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	early	_	_	JJ	O	-1	none	_	_
18	gene	_	_	NN	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	during	_	_	IN	O	-1	none	_	_
21	lymphocyte	_	_	NN	O	-1	none	_	_
22	activation	_	_	NN	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	on	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	activity	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	transcription	_	_	NN	O	-1	none	_	_
30	factors	_	_	NNS	O	-1	none	_	_
31	AP-1	_	_	NN	O	-1	none	_	_
32	,	_	_	,	O	-1	none	_	_
33	NF-kappa	_	_	NN	O	-1	none	_	_
34	B	_	_	NN	O	-1	none	_	_
35	,	_	_	,	O	-1	none	_	_
36	NF-AT	_	_	NN	O	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	Oct1	_	_	NN	Protein	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	whose	_	_	WP$	O	-1	none	_	_
41	functions	_	_	NNS	O	-1	none	_	_
42	are	_	_	VBP	O	-1	none	_	_
43	required	_	_	VBN	O	-1	none	_	_
44	for	_	_	IN	O	-1	none	_	_
45	expression	_	_	NN	O	-1	none	_	_
46	of	_	_	IN	O	-1	none	_	_
47	the	_	_	DT	O	-1	none	_	_
48	IL-2	_	_	NN	Protein	-1	none	_	_
49	mRNA	_	_	NN	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	Cysteamine	_	_	NN	O	-1	none	_	_
2	treatment	_	_	NN	O	-1	none	_	_
3	inhibited	_	_	VBD	O	-1	none	_	_
4	both	_	_	CC	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	IL-2	_	_	NN	Protein	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	secretion	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	into	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	culture	_	_	NN	O	-1	none	_	_
17	medium	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	inhibitory	_	_	JJ	O	-1	none	_	_
3	effect	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	cysteamine	_	_	NN	O	-1	none	_	_
6	may	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	mediated	_	_	VBN	O	-1	none	_	_
9	at	_	_	IN	O	-1	none	_	_
10	least	_	_	JJS	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	part	_	_	NN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	effect	_	_	NN	O	-1	none	_	_
16	on	_	_	IN	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	function	_	_	NN	O	-1	none	_	_
20	,	_	_	,	O	-1	none	_	_
21	as	_	_	IN	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	DNA	_	_	NN	O	-1	none	_	_
24	binding	_	_	NN	O	-1	none	_	_
25	activities	_	_	NNS	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	AP-1	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	NF-kappa	_	_	NN	O	-1	none	_	_
30	B	_	_	NN	O	-1	none	_	_
31	extracted	_	_	VBN	O	-1	none	_	_
32	from	_	_	IN	O	-1	none	_	_
33	mitogen	_	_	NN	O	-1	none	_	_
34	stimulated	_	_	JJ	O	-1	none	_	_
35	cells	_	_	NNS	O	-1	none	_	_
36	were	_	_	VBD	O	-1	none	_	_
37	significantly	_	_	RB	O	-1	none	_	_
38	inhibited	_	_	VBN	O	-1	none	_	_
39	by	_	_	IN	O	-1	none	_	_
40	cysteamine	_	_	NN	O	-1	none	_	_
41	treatment	_	_	NN	O	-1	none	_	_
42	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	Oct1	_	_	NN	Protein	-1	none	_	_
4	and	_	_	CC	O	-1	none	_	_
5	NF-AT	_	_	NN	O	-1	none	_	_
6	DNA	_	_	NN	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	activity	_	_	NN	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	affected	_	_	VBN	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	cysteamine	_	_	NN	O	-1	none	_	_
14	treatment	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	suggesting	_	_	VBG	O	-1	none	_	_
17	that	_	_	IN	O	-1	none	_	_
18	oxidative	_	_	JJ	O	-1	none	_	_
19	signalling	_	_	NN	O	-1	none	_	_
20	processes	_	_	NNS	O	-1	none	_	_
21	operate	_	_	VBP	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	a	_	_	DT	O	-1	none	_	_
24	selective	_	_	JJ	O	-1	none	_	_
25	manner	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	identification	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	regulatory	_	_	JJ	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	such	_	_	JJ	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	transcription	_	_	NN	O	-1	none	_	_
10	factors	_	_	NNS	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	as	_	_	IN	O	-1	none	_	_
13	molecular	_	_	JJ	O	-1	none	_	_
14	targets	_	_	NNS	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	oxidative	_	_	JJ	O	-1	none	_	_
17	signalling	_	_	NN	O	-1	none	_	_
18	provides	_	_	VBZ	O	-1	none	_	_
19	further	_	_	JJ	O	-1	none	_	_
20	evidence	_	_	NN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	implicate	_	_	VB	O	-1	none	_	_
23	oxidative	_	_	JJ	O	-1	none	_	_
24	signalling	_	_	NN	O	-1	none	_	_
25	as	_	_	IN	O	-1	none	_	_
26	being	_	_	VBG	O	-1	none	_	_
27	intimately	_	_	RB	O	-1	none	_	_
28	involved	_	_	VBN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	the	_	_	DT	O	-1	none	_	_
31	G0	_	_	NN	O	-1	none	_	_
32	to	_	_	TO	O	-1	none	_	_
33	G1	_	_	NN	O	-1	none	_	_
34	phase	_	_	NN	O	-1	none	_	_
35	transition	_	_	NN	O	-1	none	_	_
36	in	_	_	IN	O	-1	none	_	_
37	T	_	_	NN	O	-1	none	_	_
38	lymphocytes	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	Age	_	_	NNP	O	-1	none	_	_
2	related	_	_	JJ	O	-1	none	_	_
3	decreases	_	_	NNS	O	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	IL-2	_	_	NN	Protein	-1	none	_	_
6	production	_	_	NN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	human	_	_	NN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	associated	_	_	VBN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	impaired	_	_	JJ	O	-1	none	_	_
15	activation	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	nuclear	_	_	JJ	O	-1	none	_	_
18	transcriptional	_	_	JJ	O	-1	none	_	_
19	factors	_	_	NNS	O	-1	none	_	_
20	AP-1	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	NF-AT	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	transcriptional	_	_	JJ	O	-1	none	_	_
3	factors	_	_	NNS	O	-1	none	_	_
4	AP-1	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	nuclear	_	_	JJ	O	-1	none	_	_
7	factor	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	activated	_	_	VBN	O	-1	none	_	_
10	T	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	NF-AT	_	_	NN	O	-1	none	_	_
14	)	_	_	-RRB-	O	-1	none	_	_
15	are	_	_	VBP	O	-1	none	_	_
16	important	_	_	JJ	O	-1	none	_	_
17	for	_	_	IN	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	normal	_	_	JJ	O	-1	none	_	_
20	induction	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	IL-2	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	it	_	_	PRP	O	-1	none	_	_
25	is	_	_	VBZ	O	-1	none	_	_
26	unknown	_	_	JJ	O	-1	none	_	_
27	if	_	_	IN	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	age	_	_	NN	O	-1	none	_	_
30	related	_	_	JJ	O	-1	none	_	_
31	decline	_	_	NN	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	IL-2	_	_	NN	Protein	-1	none	_	_
34	production	_	_	NN	O	-1	none	_	_
35	by	_	_	IN	O	-1	none	_	_
36	activated	_	_	VBN	O	-1	none	_	_
37	human	_	_	NN	O	-1	none	_	_
38	T	_	_	NN	O	-1	none	_	_
39	cells	_	_	NNS	O	-1	none	_	_
40	may	_	_	MD	O	-1	none	_	_
41	be	_	_	VB	O	-1	none	_	_
42	associated	_	_	VBN	O	-1	none	_	_
43	with	_	_	IN	O	-1	none	_	_
44	aberrancies	_	_	NNS	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	transcriptional	_	_	JJ	O	-1	none	_	_
47	regulatory	_	_	JJ	O	-1	none	_	_
48	proteins	_	_	NNS	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	current	_	_	JJ	O	-1	none	_	_
4	studies	_	_	NNS	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	IL-2	_	_	NN	Protein	-1	none	_	_
7	production	_	_	NN	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	elderly	_	_	JJ	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	mean	_	_	NN	O	-1	none	_	_
15	78	_	_	CD	O	-1	none	_	_
16	years	_	_	NNS	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	young	_	_	JJ	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	mean	_	_	VB	O	-1	none	_	_
22	37	_	_	CD	O	-1	none	_	_
23	years	_	_	NNS	O	-1	none	_	_
24	)	_	_	-RRB-	O	-1	none	_	_
25	humans	_	_	NNS	O	-1	none	_	_
26	was	_	_	VBD	O	-1	none	_	_
27	measured	_	_	VBN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	cultures	_	_	NNS	O	-1	none	_	_
30	stimulated	_	_	VBN	O	-1	none	_	_
31	with	_	_	IN	O	-1	none	_	_
32	PHA	_	_	NN	Protein	-1	none	_	_
33	,	_	_	,	O	-1	none	_	_
34	PHA	_	_	NN	Protein	-1	none	_	_
35	plus	_	_	CC	O	-1	none	_	_
36	PMA	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	crosslinked	_	_	VBN	O	-1	none	_	_
39	anti-CD3	_	_	JJ	O	-1	none	_	_
40	mAB	_	_	NN	O	-1	none	_	_
41	OKT3	_	_	NN	O	-1	none	_	_
42	plus	_	_	CC	O	-1	none	_	_
43	PMA	_	_	NN	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	or	_	_	CC	O	-1	none	_	_
46	PMA	_	_	NN	O	-1	none	_	_
47	plus	_	_	CC	O	-1	none	_	_
48	ionomycin	_	_	NN	O	-1	none	_	_
49	.	_	_	.	O	-1	none	_	_

1	Substantial	_	_	JJ	O	-1	none	_	_
2	decreases	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	IL-2	_	_	NN	Protein	-1	none	_	_
5	production	_	_	NN	O	-1	none	_	_
6	were	_	_	VBD	O	-1	none	_	_
7	observed	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	cell	_	_	NN	O	-1	none	_	_
10	cultures	_	_	NNS	O	-1	none	_	_
11	from	_	_	IN	O	-1	none	_	_
12	7	_	_	CD	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	12	_	_	CD	O	-1	none	_	_
15	elderly	_	_	JJ	O	-1	none	_	_
16	individuals	_	_	NNS	O	-1	none	_	_
17	in	_	_	IN	O	-1	none	_	_
18	response	_	_	NN	O	-1	none	_	_
19	to	_	_	TO	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	different	_	_	JJ	O	-1	none	_	_
22	stimuli	_	_	NNS	O	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	whereas	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	levels	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	IL-2	_	_	NN	Protein	-1	none	_	_
29	produced	_	_	VBN	O	-1	none	_	_
30	by	_	_	IN	O	-1	none	_	_
31	stimulated	_	_	VBN	O	-1	none	_	_
32	T	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	from	_	_	IN	O	-1	none	_	_
35	other	_	_	JJ	O	-1	none	_	_
36	elderly	_	_	JJ	O	-1	none	_	_
37	individuals	_	_	NNS	O	-1	none	_	_
38	were	_	_	VBD	O	-1	none	_	_
39	equivalent	_	_	JJ	O	-1	none	_	_
40	to	_	_	TO	O	-1	none	_	_
41	those	_	_	DT	O	-1	none	_	_
42	observed	_	_	VBN	O	-1	none	_	_
43	for	_	_	IN	O	-1	none	_	_
44	stimulated	_	_	VBN	O	-1	none	_	_
45	T	_	_	NN	O	-1	none	_	_
46	cells	_	_	NNS	O	-1	none	_	_
47	of	_	_	IN	O	-1	none	_	_
48	young	_	_	JJ	O	-1	none	_	_
49	subjects	_	_	NNS	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	Analyses	_	_	NNS	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	nuclear	_	_	JJ	O	-1	none	_	_
4	extracts	_	_	NNS	O	-1	none	_	_
5	by	_	_	IN	O	-1	none	_	_
6	electrophoretic	_	_	JJ	O	-1	none	_	_
7	DNA	_	_	NN	O	-1	none	_	_
8	mobility	_	_	NN	O	-1	none	_	_
9	shift	_	_	NN	O	-1	none	_	_
10	assays	_	_	NNS	O	-1	none	_	_
11	showed	_	_	VBD	O	-1	none	_	_
12	that	_	_	IN	O	-1	none	_	_
13	decreased	_	_	VBN	O	-1	none	_	_
14	IL-2	_	_	NN	Protein	-1	none	_	_
15	production	_	_	NN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	stimulated	_	_	VBN	O	-1	none	_	_
18	T	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	elderly	_	_	JJ	O	-1	none	_	_
22	individuals	_	_	NNS	O	-1	none	_	_
23	was	_	_	VBD	O	-1	none	_	_
24	closely	_	_	RB	O	-1	none	_	_
25	associated	_	_	VBN	O	-1	none	_	_
26	with	_	_	IN	O	-1	none	_	_
27	impairments	_	_	NNS	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	the	_	_	DT	O	-1	none	_	_
30	activation	_	_	NN	O	-1	none	_	_
31	of	_	_	IN	O	-1	none	_	_
32	both	_	_	CC	O	-1	none	_	_
33	AP-1	_	_	NN	O	-1	none	_	_
34	and	_	_	CC	O	-1	none	_	_
35	NF-AT	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	By	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	T	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	from	_	_	IN	O	-1	none	_	_
7	elderly	_	_	JJ	O	-1	none	_	_
8	subjects	_	_	NNS	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	normal	_	_	JJ	O	-1	none	_	_
11	levels	_	_	NNS	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	IL-2	_	_	NN	Protein	-1	none	_	_
14	production	_	_	NN	O	-1	none	_	_
15	exhibited	_	_	VBD	O	-1	none	_	_
16	normal	_	_	JJ	O	-1	none	_	_
17	activation	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	AP-1	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	NF-AT	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	results	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	competition	_	_	NN	O	-1	none	_	_
8	experiments	_	_	NNS	O	-1	none	_	_
9	analyzing	_	_	VBG	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	normal	_	_	JJ	O	-1	none	_	_
12	components	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	NF-AT	_	_	NN	O	-1	none	_	_
15	showed	_	_	VBD	O	-1	none	_	_
16	that	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	age	_	_	NN	O	-1	none	_	_
19	related	_	_	JJ	O	-1	none	_	_
20	reductions	_	_	NNS	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	stimulus	_	_	NN	O	-1	none	_	_
23	dependent	_	_	JJ	O	-1	none	_	_
24	NF-AT	_	_	NN	O	-1	none	_	_
25	complexes	_	_	NNS	O	-1	none	_	_
26	corresponded	_	_	VBD	O	-1	none	_	_
27	to	_	_	TO	O	-1	none	_	_
28	the	_	_	DT	O	-1	none	_	_
29	slow	_	_	JJ	O	-1	none	_	_
30	migrating	_	_	VBG	O	-1	none	_	_
31	complexes	_	_	NNS	O	-1	none	_	_
32	that	_	_	WDT	O	-1	none	_	_
33	were	_	_	VBD	O	-1	none	_	_
34	composed	_	_	VBN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	c-Fos	_	_	NN	Protein	-1	none	_	_
37	and	_	_	CC	O	-1	none	_	_
38	c-Jun	_	_	NN	Protein	-1	none	_	_
39	AP-1	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	resting	_	_	VBG	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	stimulated	_	_	VBN	O	-1	none	_	_
5	levels	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	NF	_	_	NN	O	-1	none	_	_
8	kappa	_	_	NN	O	-1	none	_	_
9	B	_	_	NN	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	reduced	_	_	VBN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	T	_	_	NN	O	-1	none	_	_
14	cells	_	_	NNS	O	-1	none	_	_
15	from	_	_	IN	O	-1	none	_	_
16	certain	_	_	JJ	O	-1	none	_	_
17	elderly	_	_	JJ	O	-1	none	_	_
18	individuals	_	_	NNS	O	-1	none	_	_
19	;	_	_	:	O	-1	none	_	_
20	however	_	_	RB	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	alterations	_	_	NNS	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	NF	_	_	NN	O	-1	none	_	_
25	kappa	_	_	NN	O	-1	none	_	_
26	B	_	_	NN	O	-1	none	_	_
27	did	_	_	VBD	O	-1	none	_	_
28	not	_	_	RB	O	-1	none	_	_
29	correlate	_	_	VB	O	-1	none	_	_
30	with	_	_	IN	O	-1	none	_	_
31	changes	_	_	NNS	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	IL-2	_	_	NN	Protein	-1	none	_	_
34	expression	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Thus	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	these	_	_	DT	O	-1	none	_	_
4	results	_	_	NNS	O	-1	none	_	_
5	show	_	_	VBP	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	age	_	_	NN	O	-1	none	_	_
8	related	_	_	JJ	O	-1	none	_	_
9	impairments	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	activation	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	AP-1	_	_	NN	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	NF-AT	_	_	NN	O	-1	none	_	_
17	are	_	_	VBP	O	-1	none	_	_
18	closely	_	_	RB	O	-1	none	_	_
19	associated	_	_	VBN	O	-1	none	_	_
20	with	_	_	IN	O	-1	none	_	_
21	decreased	_	_	VBN	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	of	_	_	IN	O	-1	none	_	_
24	IL-2	_	_	NN	Protein	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	further	_	_	RB	O	-1	none	_	_
27	suggest	_	_	VBP	O	-1	none	_	_
28	that	_	_	IN	O	-1	none	_	_
29	aberrancies	_	_	NNS	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	signaling	_	_	NN	O	-1	none	_	_
33	pathways	_	_	NNS	O	-1	none	_	_
34	important	_	_	JJ	O	-1	none	_	_
35	for	_	_	IN	O	-1	none	_	_
36	the	_	_	DT	O	-1	none	_	_
37	induction	_	_	NN	O	-1	none	_	_
38	of	_	_	IN	O	-1	none	_	_
39	transcriptionally	_	_	RB	O	-1	none	_	_
40	active	_	_	JJ	O	-1	none	_	_
41	c-Fos	_	_	NN	Protein	-1	none	_	_
42	and	_	_	CC	O	-1	none	_	_
43	c-Jun	_	_	NN	Protein	-1	none	_	_
44	AP-1	_	_	NN	O	-1	none	_	_
45	may	_	_	MD	O	-1	none	_	_
46	contribute	_	_	VB	O	-1	none	_	_
47	to	_	_	TO	O	-1	none	_	_
48	the	_	_	DT	O	-1	none	_	_
49	impaired	_	_	JJ	O	-1	none	_	_
50	activation	_	_	NN	O	-1	none	_	_
51	of	_	_	IN	O	-1	none	_	_
52	NF-AT	_	_	NN	O	-1	none	_	_
53	.	_	_	.	O	-1	none	_	_

1	Cytomegalovirus	_	_	NN	O	-1	none	_	_
2	modulates	_	_	VBZ	O	-1	none	_	_
3	interleukin-6	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	.	_	_	.	O	-1	none	_	_

1	Complications	_	_	NNS	O	-1	none	_	_
2	after	_	_	IN	O	-1	none	_	_
3	lung	_	_	NN	O	-1	none	_	_
4	transplantation	_	_	NN	O	-1	none	_	_
5	include	_	_	VBP	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	development	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	rejection	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	an	_	_	DT	O	-1	none	_	_
12	increased	_	_	JJ	O	-1	none	_	_
13	incidence	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	infection	_	_	NN	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	particularly	_	_	RB	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	cytomegalovirus	_	_	NN	O	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	CMV	_	_	NN	O	-1	none	_	_
22	)	_	_	-RRB-	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	Several	_	_	JJ	O	-1	none	_	_
2	recent	_	_	JJ	O	-1	none	_	_
3	studies	_	_	NNS	O	-1	none	_	_
4	have	_	_	VBP	O	-1	none	_	_
5	suggested	_	_	VBN	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	interleukin	_	_	NN	Protein	11	multitoken	_	_
8	(	_	_	-LRB-	Protein	11	multitoken	_	_
9	IL	_	_	NN	Protein	11	multitoken	_	_
10	)	_	_	-RRB-	Protein	11	multitoken	_	_
11	-6	_	_	CD	Protein	0	root	_	_
12	may	_	_	MD	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	used	_	_	VBN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	detect	_	_	VB	O	-1	none	_	_
17	both	_	_	CC	O	-1	none	_	_
18	infection	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	rejection	_	_	NN	O	-1	none	_	_
21	after	_	_	IN	O	-1	none	_	_
22	lung	_	_	NN	O	-1	none	_	_
23	transplantation	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	addition	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	IL-6	_	_	NN	Protein	-1	none	_	_
5	may	_	_	MD	O	-1	none	_	_
6	play	_	_	VB	O	-1	none	_	_
7	a	_	_	DT	O	-1	none	_	_
8	role	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	development	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	bronchiolitis	_	_	NN	O	-1	none	_	_
14	obliterans	_	_	NNS	O	-1	none	_	_
15	after	_	_	IN	O	-1	none	_	_
16	transplantation	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	Because	_	_	IN	O	-1	none	_	_
2	CMV	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	also	_	_	RB	O	-1	none	_	_
5	associated	_	_	VBN	O	-1	none	_	_
6	with	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	development	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	bronchiolitis	_	_	NN	O	-1	none	_	_
11	obliterans	_	_	NNS	O	-1	none	_	_
12	after	_	_	IN	O	-1	none	_	_
13	transplantation	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	we	_	_	PRP	O	-1	none	_	_
16	determined	_	_	VBD	O	-1	none	_	_
17	whether	_	_	IN	O	-1	none	_	_
18	CMV	_	_	NN	O	-1	none	_	_
19	induces	_	_	VBZ	O	-1	none	_	_
20	IL-6	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	expression	_	_	NN	O	-1	none	_	_
23	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrated	_	_	VBD	O	-1	none	_	_
3	that	_	_	IN	O	-1	none	_	_
4	CMV	_	_	NN	O	-1	none	_	_
5	infection	_	_	NN	O	-1	none	_	_
6	increased	_	_	VBD	O	-1	none	_	_
7	both	_	_	CC	O	-1	none	_	_
8	IL-6	_	_	NN	Protein	-1	none	_	_
9	protein	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	mRNA	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	peripheral	_	_	JJ	O	-1	none	_	_
14	blood	_	_	NN	O	-1	none	_	_
15	mononuclear	_	_	JJ	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	also	_	_	RB	O	-1	none	_	_
3	demonstrated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	CMV	_	_	NN	O	-1	none	_	_
7	immediate	_	_	JJ	Protein	9	multitoken	_	_
8	early	_	_	JJ	Protein	9	multitoken	_	_
9	1	_	_	CD	Protein	0	root	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	product	_	_	NN	O	-1	none	_	_
12	increased	_	_	VBD	O	-1	none	_	_
13	expression	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	IL-6	_	_	NN	Protein	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	CMV	_	_	NN	O	-1	none	_	_
6	immediate	_	_	JJ	Protein	8	multitoken	_	_
7	early	_	_	JJ	Protein	8	multitoken	_	_
8	1	_	_	CD	Protein	0	root	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	product	_	_	NN	O	-1	none	_	_
11	was	_	_	VBD	O	-1	none	_	_
12	dependent	_	_	JJ	O	-1	none	_	_
13	upon	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	presence	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	specific	_	_	JJ	O	-1	none	_	_
18	transcription	_	_	NN	O	-1	none	_	_
19	factor	_	_	NN	O	-1	none	_	_
20	binding	_	_	VBG	O	-1	none	_	_
21	sites	_	_	NNS	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	IL-6	_	_	NN	Protein	-1	none	_	_
25	promoter	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	studies	_	_	NNS	O	-1	none	_	_
3	demonstrate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	CMV	_	_	NN	O	-1	none	_	_
6	may	_	_	MD	O	-1	none	_	_
7	be	_	_	VB	O	-1	none	_	_
8	an	_	_	DT	O	-1	none	_	_
9	important	_	_	JJ	O	-1	none	_	_
10	cofactor	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	development	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	rejection	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	infection	_	_	NN	O	-1	none	_	_
18	after	_	_	IN	O	-1	none	_	_
19	transplantation	_	_	NN	O	-1	none	_	_
20	through	_	_	IN	O	-1	none	_	_
21	its	_	_	PRP$	O	-1	none	_	_
22	effects	_	_	NNS	O	-1	none	_	_
23	on	_	_	IN	O	-1	none	_	_
24	IL-6	_	_	NN	Protein	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Regulation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	interferon-gamma	_	_	NN	Protein	-1	none	_	_
4	gene	_	_	NN	O	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	.	_	_	.	O	-1	none	_	_

1	Interferon-gamma	_	_	NN	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	IFN-gamma	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	also	_	_	RB	O	-1	none	_	_
7	known	_	_	VBN	O	-1	none	_	_
8	as	_	_	IN	O	-1	none	_	_
9	type	_	_	NN	Protein	11	multitoken	_	_
10	II	_	_	CD	Protein	11	multitoken	_	_
11	interferon	_	_	NN	Protein	0	root	_	_
12	,	_	_	,	O	-1	none	_	_
13	is	_	_	VBZ	O	-1	none	_	_
14	an	_	_	DT	O	-1	none	_	_
15	important	_	_	JJ	O	-1	none	_	_
16	immunoregulatory	_	_	JJ	O	-1	none	_	_
17	gene	_	_	NN	O	-1	none	_	_
18	that	_	_	WDT	O	-1	none	_	_
19	has	_	_	VBZ	O	-1	none	_	_
20	multiple	_	_	JJ	O	-1	none	_	_
21	effects	_	_	NNS	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	development	_	_	NN	O	-1	none	_	_
25	,	_	_	,	O	-1	none	_	_
26	maturation	_	_	NN	O	-1	none	_	_
27	,	_	_	,	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	function	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	immune	_	_	JJ	O	-1	none	_	_
33	system	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	IFN-gamma	_	_	NN	Protein	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	protein	_	_	NN	O	-1	none	_	_
5	are	_	_	VBP	O	-1	none	_	_
6	expressed	_	_	VBN	O	-1	none	_	_
7	predominantly	_	_	RB	O	-1	none	_	_
8	by	_	_	IN	O	-1	none	_	_
9	T	_	_	NN	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	large	_	_	JJ	O	-1	none	_	_
13	granular	_	_	JJ	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	IFN-gamma	_	_	NN	Protein	-1	none	_	_
3	mRNA	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	induced	_	_	VBN	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	inhibited	_	_	VBN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	these	_	_	DT	O	-1	none	_	_
10	cell	_	_	NN	O	-1	none	_	_
11	types	_	_	NNS	O	-1	none	_	_
12	by	_	_	IN	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	wide	_	_	JJ	O	-1	none	_	_
15	variety	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	extracellular	_	_	JJ	O	-1	none	_	_
18	signals	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	thus	_	_	RB	O	-1	none	_	_
21	implicating	_	_	VBG	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	number	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	diverse	_	_	JJ	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	yet	_	_	RB	O	-1	none	_	_
28	convergent	_	_	JJ	O	-1	none	_	_
29	signal	_	_	NN	O	-1	none	_	_
30	transduction	_	_	NN	O	-1	none	_	_
31	pathways	_	_	NNS	O	-1	none	_	_
32	in	_	_	IN	O	-1	none	_	_
33	its	_	_	PRP$	O	-1	none	_	_
34	transcriptional	_	_	JJ	O	-1	none	_	_
35	control	_	_	NN	O	-1	none	_	_
36	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	this	_	_	DT	O	-1	none	_	_
3	review	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	I	_	_	PRP	O	-1	none	_	_
6	describe	_	_	VBP	O	-1	none	_	_
7	how	_	_	WRB	O	-1	none	_	_
8	DNA	_	_	NN	O	-1	none	_	_
9	methylation	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	DNA	_	_	NN	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	regulate	_	_	VB	O	-1	none	_	_
17	transcription	_	_	NN	O	-1	none	_	_
18	of	_	_	IN	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	IFN-gamma	_	_	NN	Protein	-1	none	_	_
21	gene	_	_	NN	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	response	_	_	NN	O	-1	none	_	_
24	to	_	_	TO	O	-1	none	_	_
25	extracellular	_	_	JJ	O	-1	none	_	_
26	signals	_	_	NNS	O	-1	none	_	_
27	.	_	_	.	O	-1	none	_	_

1	Disruption	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	GATA	_	_	NN	O	-1	none	_	_
5	motif	_	_	NN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	Duffy	_	_	NN	Protein	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	promoter	_	_	NN	O	-1	none	_	_
11	abolishes	_	_	VBZ	O	-1	none	_	_
12	erythroid	_	_	JJ	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	Duffy	_	_	NN	Protein	-1	none	_	_
17	negative	_	_	JJ	O	-1	none	_	_
18	individuals	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	mRNA	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	Duffy	_	_	NN	Protein	-1	none	_	_
6	blood	_	_	NN	O	-1	none	_	_
7	group	_	_	NN	O	-1	none	_	_
8	antigen	_	_	NN	O	-1	none	_	_
9	,	_	_	,	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	erythrocyte	_	_	NN	O	-1	none	_	_
12	receptor	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	Plasmodium	_	_	NN	O	-1	none	_	_
16	vivax	_	_	NN	O	-1	none	_	_
17	malaria	_	_	NN	O	-1	none	_	_
18	parasite	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	has	_	_	VBZ	O	-1	none	_	_
21	recently	_	_	RB	O	-1	none	_	_
22	been	_	_	VBN	O	-1	none	_	_
23	cloned	_	_	VBN	O	-1	none	_	_
24	and	_	_	CC	O	-1	none	_	_
25	shown	_	_	VBN	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	encode	_	_	VB	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	widely	_	_	RB	O	-1	none	_	_
30	expressed	_	_	VBN	O	-1	none	_	_
31	chemokine	_	_	NN	O	-1	none	_	_
32	receptor	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	we	_	_	PRP	O	-1	none	_	_
4	show	_	_	VBP	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	Duffy	_	_	NN	Protein	9	multitoken	_	_
8	antigen/chemokine	_	_	NN	Protein	9	multitoken	_	_
9	receptor	_	_	NN	Protein	0	root	_	_
10	gene	_	_	NN	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	DARC	_	_	NN	Protein	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	composed	_	_	VBN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	single	_	_	JJ	O	-1	none	_	_
19	exon	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	that	_	_	IN	O	-1	none	_	_
22	most	_	_	JJS	O	-1	none	_	_
23	Duffy	_	_	NN	Protein	-1	none	_	_
24	negative	_	_	JJ	O	-1	none	_	_
25	blacks	_	_	NNS	O	-1	none	_	_
26	carry	_	_	VBP	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	silent	_	_	JJ	O	-1	none	_	_
29	FY	_	_	NN	Protein	31	multitoken	_	_
30	*	_	_	NN	Protein	31	multitoken	_	_
31	B	_	_	NN	Protein	0	root	_	_
32	allele	_	_	NN	O	-1	none	_	_
33	with	_	_	IN	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	single	_	_	JJ	O	-1	none	_	_
36	T	_	_	NN	O	-1	none	_	_
37	to	_	_	TO	O	-1	none	_	_
38	C	_	_	NN	O	-1	none	_	_
39	substitution	_	_	NN	O	-1	none	_	_
40	at	_	_	IN	O	-1	none	_	_
41	nucleotide	_	_	NN	O	-1	none	_	_
42	-46	_	_	CD	O	-1	none	_	_
43	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	mutation	_	_	NN	O	-1	none	_	_
3	impairs	_	_	VBZ	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	promoter	_	_	NN	O	-1	none	_	_
6	activity	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	erythroid	_	_	JJ	O	-1	none	_	_
9	cells	_	_	NNS	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	disrupting	_	_	VBG	O	-1	none	_	_
12	a	_	_	DT	O	-1	none	_	_
13	binding	_	_	NN	O	-1	none	_	_
14	site	_	_	NN	O	-1	none	_	_
15	for	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	GATA1	_	_	NN	Protein	-1	none	_	_
18	erythroid	_	_	JJ	O	-1	none	_	_
19	transcription	_	_	NN	O	-1	none	_	_
20	factor	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	With	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	recent	_	_	JJ	O	-1	none	_	_
4	characterization	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	FY	_	_	NN	Protein	9	multitoken	_	_
8	*	_	_	NN	Protein	9	multitoken	_	_
9	A	_	_	NN	Protein	0	root	_	_
10	and	_	_	CC	O	-1	none	_	_
11	FY	_	_	NN	Protein	13	multitoken	_	_
12	*	_	_	NN	Protein	13	multitoken	_	_
13	B	_	_	NN	Protein	0	root	_	_
14	alleles	_	_	NNS	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	these	_	_	DT	O	-1	none	_	_
17	findings	_	_	NNS	O	-1	none	_	_
18	provide	_	_	VBP	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	molecular	_	_	JJ	O	-1	none	_	_
21	basis	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	Duffy	_	_	NN	Protein	-1	none	_	_
25	blood	_	_	NN	O	-1	none	_	_
26	group	_	_	NN	O	-1	none	_	_
27	system	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	an	_	_	DT	O	-1	none	_	_
30	explanation	_	_	NN	O	-1	none	_	_
31	for	_	_	IN	O	-1	none	_	_
32	the	_	_	DT	O	-1	none	_	_
33	erythroid	_	_	JJ	O	-1	none	_	_
34	specific	_	_	JJ	O	-1	none	_	_
35	repression	_	_	NN	O	-1	none	_	_
36	of	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	DARC	_	_	NN	Protein	-1	none	_	_
39	gene	_	_	NN	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	Duffy	_	_	NN	Protein	-1	none	_	_
42	negative	_	_	JJ	O	-1	none	_	_
43	individuals	_	_	NNS	O	-1	none	_	_
44	.	_	_	.	O	-1	none	_	_

1	Cloning	_	_	NN	O	-1	none	_	_
2	a	_	_	DT	O	-1	none	_	_
3	cDNA	_	_	NN	O	-1	none	_	_
4	from	_	_	IN	O	-1	none	_	_
5	human	_	_	NN	O	-1	none	_	_
6	NK/T	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	which	_	_	WDT	O	-1	none	_	_
9	codes	_	_	VBZ	O	-1	none	_	_
10	for	_	_	IN	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	with	_	_	IN	O	-1	none	_	_
14	high	_	_	JJ	O	-1	none	_	_
15	proline	_	_	NN	O	-1	none	_	_
16	content	_	_	NN	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	cDNA	_	_	NN	O	-1	none	_	_
3	clone	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	B4-2	_	_	NN	Protein	-1	none	_	_
6	,	_	_	,	O	-1	none	_	_
7	was	_	_	VBD	O	-1	none	_	_
8	isolated	_	_	VBN	O	-1	none	_	_
9	from	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	natural	_	_	JJ	O	-1	none	_	_
12	killer	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	NK	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	minus	_	_	CC	O	-1	none	_	_
17	T	_	_	NN	O	-1	none	_	_
18	cell	_	_	NN	O	-1	none	_	_
19	subtractive	_	_	JJ	O	-1	none	_	_
20	library	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	B4-2	_	_	NN	Protein	-1	none	_	_
3	clone	_	_	NN	O	-1	none	_	_
4	coded	_	_	VBD	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	an	_	_	DT	O	-1	none	_	_
7	mRNA	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	2061	_	_	CD	O	-1	none	_	_
10	bp	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	length	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	It	_	_	PRP	O	-1	none	_	_
2	encodes	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	deduced	_	_	VBN	O	-1	none	_	_
5	327	_	_	CD	O	-1	none	_	_
6	aa	_	_	NN	O	-1	none	_	_
7	protein	_	_	NN	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	calculated	_	_	VBN	O	-1	none	_	_
11	molecular	_	_	JJ	O	-1	none	_	_
12	mass	_	_	NN	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	35.2	_	_	CD	O	-1	none	_	_
15	kDa	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Searching	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	B4-2	_	_	NN	Protein	-1	none	_	_
4	DNA	_	_	NN	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	protein	_	_	NN	O	-1	none	_	_
7	sequences	_	_	NNS	O	-1	none	_	_
8	against	_	_	IN	O	-1	none	_	_
9	various	_	_	JJ	O	-1	none	_	_
10	databases	_	_	NNS	O	-1	none	_	_
11	revealed	_	_	VBD	O	-1	none	_	_
12	no	_	_	DT	O	-1	none	_	_
13	high	_	_	JJ	O	-1	none	_	_
14	homology	_	_	NN	O	-1	none	_	_
15	to	_	_	TO	O	-1	none	_	_
16	other	_	_	JJ	O	-1	none	_	_
17	sequences	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	B4-2	_	_	NN	Protein	-1	none	_	_
4	has	_	_	VBZ	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	unusually	_	_	RB	O	-1	none	_	_
7	high	_	_	JJ	O	-1	none	_	_
8	proline	_	_	NN	O	-1	none	_	_
9	content	_	_	NN	O	-1	none	_	_
10	(	_	_	-LRB-	O	-1	none	_	_
11	13	_	_	CD	O	-1	none	_	_
12	%	_	_	NN	O	-1	none	_	_
13	)	_	_	-RRB-	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	contains	_	_	VBZ	O	-1	none	_	_
16	a	_	_	DT	O	-1	none	_	_
17	putative	_	_	JJ	O	-1	none	_	_
18	nuclear	_	_	JJ	O	-1	none	_	_
19	targeting	_	_	NN	O	-1	none	_	_
20	sequence	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	has	_	_	VBZ	O	-1	none	_	_
24	several	_	_	JJ	O	-1	none	_	_
25	SPXX	_	_	NN	O	-1	none	_	_
26	motifs	_	_	NNS	O	-1	none	_	_
27	which	_	_	WDT	O	-1	none	_	_
28	are	_	_	VBP	O	-1	none	_	_
29	frequently	_	_	RB	O	-1	none	_	_
30	found	_	_	VBN	O	-1	none	_	_
31	in	_	_	IN	O	-1	none	_	_
32	gene	_	_	NN	O	-1	none	_	_
33	regulatory	_	_	JJ	O	-1	none	_	_
34	proteins	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	One	_	_	CD	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	stretches	_	_	NNS	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	prolines	_	_	NNS	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	B4-2	_	_	NN	Protein	-1	none	_	_
9	closely	_	_	RB	O	-1	none	_	_
10	resembles	_	_	VBZ	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	ligand	_	_	NN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	with	_	_	IN	O	-1	none	_	_
16	SH3	_	_	NN	O	-1	none	_	_
17	domains	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Northern	_	_	NN	O	-1	none	_	_
2	hybridization	_	_	NN	O	-1	none	_	_
3	data	_	_	NNS	O	-1	none	_	_
4	showed	_	_	VBD	O	-1	none	_	_
5	that	_	_	IN	O	-1	none	_	_
6	B4-2	_	_	NN	Protein	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	not	_	_	RB	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	lymphoid	_	_	JJ	O	-1	none	_	_
11	specific	_	_	JJ	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	expressed	_	_	VBN	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	hepatoma	_	_	NN	O	-1	none	_	_
19	cell	_	_	NN	O	-1	none	_	_
20	line	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	also	_	_	RB	O	-1	none	_	_
23	weakly	_	_	RB	O	-1	none	_	_
24	transcribed	_	_	VBN	O	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	absent	_	_	JJ	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	variety	_	_	NN	O	-1	none	_	_
30	of	_	_	IN	O	-1	none	_	_
31	other	_	_	JJ	O	-1	none	_	_
32	cells	_	_	NNS	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	polyclonal	_	_	JJ	O	-1	none	_	_
3	antiserum	_	_	NN	O	-1	none	_	_
4	raised	_	_	VBN	O	-1	none	_	_
5	against	_	_	IN	O	-1	none	_	_
6	recombinant	_	_	JJ	O	-1	none	_	_
7	B4-2	_	_	NN	Protein	-1	none	_	_
8	recognizes	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	32-34	_	_	CD	O	-1	none	_	_
11	kDa	_	_	NN	O	-1	none	_	_
12	protein	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	lymphocytes	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Protein	_	_	NN	O	-1	none	_	_
2	kinase	_	_	NN	O	-1	none	_	_
3	inhibitor	_	_	NN	O	-1	none	_	_
4	H-7	_	_	NN	O	-1	none	_	_
5	blocks	_	_	VBZ	O	-1	none	_	_
6	accumulation	_	_	NN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	unspliced	_	_	JJ	O	-1	none	_	_
9	mRNA	_	_	NN	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	human	_	_	NN	O	-1	none	_	_
12	T-cell	_	_	NN	O	-1	none	_	_
13	leukemia	_	_	NN	O	-1	none	_	_
14	virus	_	_	NN	O	-1	none	_	_
15	type	_	_	NN	O	-1	none	_	_
16	I	_	_	CD	O	-1	none	_	_
17	(	_	_	-LRB-	O	-1	none	_	_
18	HTLV-I	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Rex	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	phosphoprotein	_	_	NN	O	-1	none	_	_
5	found	_	_	VBN	O	-1	none	_	_
6	in	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	cell	_	_	NN	O	-1	none	_	_
9	nucleolus	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	whose	_	_	WP$	O	-1	none	_	_
12	function	_	_	NN	O	-1	none	_	_
13	may	_	_	MD	O	-1	none	_	_
14	be	_	_	VB	O	-1	none	_	_
15	regulated	_	_	VBN	O	-1	none	_	_
16	by	_	_	IN	O	-1	none	_	_
17	its	_	_	PRP$	O	-1	none	_	_
18	localization	_	_	NN	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	phosphorylation	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	examined	_	_	VBN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	role	_	_	NN	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	phosphorylation	_	_	NN	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	Rex	_	_	NN	Protein	-1	none	_	_
10	function	_	_	NN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	using	_	_	VBG	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	kinase	_	_	NN	O	-1	none	_	_
16	inhibitor	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	H-7	_	_	NN	O	-1	none	_	_
19	[	_	_	CD	O	-1	none	_	_
20	1-(	_	_	CD	O	-1	none	_	_
21	5-isoquinolinyl-sulfonyl	_	_	JJ	O	-1	none	_	_
22	)-2-methylpiperazine	_	_	JJ	O	-1	none	_	_
23	]	_	_	NN	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	other	_	_	JJ	O	-1	none	_	_
5	viral	_	_	JJ	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	cellular	_	_	JJ	O	-1	none	_	_
8	products	_	_	NNS	O	-1	none	_	_
9	have	_	_	VBP	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	been	_	_	VBN	O	-1	none	_	_
12	influenced	_	_	VBN	O	-1	none	_	_
13	by	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	level	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	H-7	_	_	NN	O	-1	none	_	_
18	used	_	_	VBN	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	Therefore	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	phosphorylation	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Rex	_	_	NN	Protein	-1	none	_	_
7	is	_	_	VBZ	O	-1	none	_	_
8	required	_	_	VBN	O	-1	none	_	_
9	for	_	_	IN	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	viral	_	_	JJ	O	-1	none	_	_
12	RNA	_	_	NN	O	-1	none	_	_
13	partition	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	HTLV-I	_	_	NN	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	Latent	_	_	JJ	Protein	4	multitoken	_	_
2	membrane	_	_	NN	Protein	4	multitoken	_	_
3	protein	_	_	NN	Protein	4	multitoken	_	_
4	1	_	_	CD	Protein	0	root	_	_
5	of	_	_	IN	O	-1	none	_	_
6	Epstein-Barr	_	_	JJ	O	-1	none	_	_
7	virus	_	_	NN	O	-1	none	_	_
8	interacts	_	_	VBZ	O	-1	none	_	_
9	with	_	_	IN	O	-1	none	_	_
10	JAK3	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	activates	_	_	VBZ	O	-1	none	_	_
13	STAT	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	.	_	_	.	O	-1	none	_	_

1	Latent	_	_	JJ	Protein	4	multitoken	_	_
2	membrane	_	_	NN	Protein	4	multitoken	_	_
3	protein	_	_	NN	Protein	4	multitoken	_	_
4	1	_	_	CD	Protein	0	root	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	LMP1	_	_	NN	Protein	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	acts	_	_	VBZ	O	-1	none	_	_
9	like	_	_	IN	O	-1	none	_	_
10	a	_	_	DT	O	-1	none	_	_
11	permanently	_	_	RB	O	-1	none	_	_
12	activated	_	_	VBN	O	-1	none	_	_
13	receptor	_	_	NN	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	tumor	_	_	NN	O	-1	none	_	_
17	necrosis	_	_	NN	O	-1	none	_	_
18	factor	_	_	NN	O	-1	none	_	_
19	(	_	_	-LRB-	O	-1	none	_	_
20	TNF	_	_	NN	O	-1	none	_	_
21	)-receptor	_	_	NN	O	-1	none	_	_
22	superfamily	_	_	NN	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	is	_	_	VBZ	O	-1	none	_	_
25	absolutely	_	_	RB	O	-1	none	_	_
26	required	_	_	VBN	O	-1	none	_	_
27	for	_	_	IN	O	-1	none	_	_
28	B	_	_	NN	O	-1	none	_	_
29	cell	_	_	NN	O	-1	none	_	_
30	immortalization	_	_	NN	O	-1	none	_	_
31	by	_	_	IN	O	-1	none	_	_
32	Epstein-Barr	_	_	JJ	O	-1	none	_	_
33	virus	_	_	NN	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Molecular	_	_	JJ	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	biochemical	_	_	JJ	O	-1	none	_	_
4	approaches	_	_	NNS	O	-1	none	_	_
5	demonstrated	_	_	VBD	O	-1	none	_	_
6	that	_	_	IN	O	-1	none	_	_
7	LMP1	_	_	NN	Protein	-1	none	_	_
8	usurps	_	_	VBZ	O	-1	none	_	_
9	cellular	_	_	JJ	O	-1	none	_	_
10	signaling	_	_	NN	O	-1	none	_	_
11	pathways	_	_	NNS	O	-1	none	_	_
12	resulting	_	_	VBG	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	induction	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	NF-kappaB	_	_	NN	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	AP-1	_	_	NN	O	-1	none	_	_
20	via	_	_	IN	O	-1	none	_	_
21	two	_	_	CD	O	-1	none	_	_
22	C-terminal	_	_	JJ	O	-1	none	_	_
23	activating	_	_	VBG	O	-1	none	_	_
24	regions	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	demonstrate	_	_	VBP	O	-1	none	_	_
3	here	_	_	RB	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	third	_	_	JJ	O	-1	none	_	_
7	region	_	_	NN	O	-1	none	_	_
8	encompassing	_	_	VBG	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	proline	_	_	NN	O	-1	none	_	_
11	rich	_	_	JJ	O	-1	none	_	_
12	sequence	_	_	NN	O	-1	none	_	_
13	within	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	33	_	_	CD	O	-1	none	_	_
16	bp	_	_	NN	O	-1	none	_	_
17	repetitive	_	_	JJ	O	-1	none	_	_
18	stretch	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	LMP1	_	_	NN	Protein	-1	none	_	_
21	's	_	_	POS	O	-1	none	_	_
22	C-terminus	_	_	NN	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	required	_	_	VBN	O	-1	none	_	_
25	for	_	_	IN	O	-1	none	_	_
26	the	_	_	DT	O	-1	none	_	_
27	activation	_	_	NN	O	-1	none	_	_
28	of	_	_	IN	O	-1	none	_	_
29	Janus	_	_	NN	Protein	31	multitoken	_	_
30	kinase	_	_	NN	Protein	31	multitoken	_	_
31	3	_	_	CD	Protein	0	root	_	_
32	(	_	_	-LRB-	O	-1	none	_	_
33	JAK3	_	_	NN	Protein	-1	none	_	_
34	)	_	_	-RRB-	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	interaction	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	LMP1	_	_	NN	Protein	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	JAK3	_	_	NN	Protein	-1	none	_	_
7	leads	_	_	VBZ	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	enhanced	_	_	JJ	O	-1	none	_	_
11	tyrosine	_	_	NN	O	-1	none	_	_
12	auto	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	transphosphorylation	_	_	NN	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	JAK3	_	_	NN	Protein	-1	none	_	_
17	within	_	_	IN	O	-1	none	_	_
18	minutes	_	_	NNS	O	-1	none	_	_
19	after	_	_	IN	O	-1	none	_	_
20	crosslinking	_	_	NN	O	-1	none	_	_
21	of	_	_	IN	O	-1	none	_	_
22	a	_	_	DT	O	-1	none	_	_
23	conditional	_	_	JJ	O	-1	none	_	_
24	NGF-R	_	_	NN	Protein	-1	none	_	_
25	:	_	_	:	O	-1	none	_	_
26	LMP1	_	_	NN	Protein	-1	none	_	_
27	chimera	_	_	NN	O	-1	none	_	_
28	and	_	_	CC	O	-1	none	_	_
29	is	_	_	VBZ	O	-1	none	_	_
30	a	_	_	DT	O	-1	none	_	_
31	prerequisite	_	_	NN	O	-1	none	_	_
32	for	_	_	IN	O	-1	none	_	_
33	the	_	_	DT	O	-1	none	_	_
34	activation	_	_	NN	O	-1	none	_	_
35	of	_	_	IN	O	-1	none	_	_
36	STAT	_	_	NN	O	-1	none	_	_
37	transcription	_	_	NN	O	-1	none	_	_
38	factors	_	_	NNS	O	-1	none	_	_
39	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	reveal	_	_	VBP	O	-1	none	_	_
4	a	_	_	DT	O	-1	none	_	_
5	novel	_	_	JJ	O	-1	none	_	_
6	activating	_	_	VBG	O	-1	none	_	_
7	region	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	LMP1	_	_	NN	Protein	-1	none	_	_
11	C-terminus	_	_	NN	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	identify	_	_	VB	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	JAK	_	_	NN	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	STAT	_	_	NN	O	-1	none	_	_
18	pathway	_	_	NN	O	-1	none	_	_
19	as	_	_	IN	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	target	_	_	NN	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	this	_	_	DT	O	-1	none	_	_
24	viral	_	_	JJ	O	-1	none	_	_
25	integral	_	_	JJ	O	-1	none	_	_
26	membrane	_	_	NN	O	-1	none	_	_
27	protein	_	_	NN	O	-1	none	_	_
28	in	_	_	IN	O	-1	none	_	_
29	B	_	_	NN	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	A	_	_	DT	O	-1	none	_	_
2	chimeric	_	_	JJ	O	-1	none	_	_
3	type	_	_	NN	O	-1	none	_	_
4	II/type	_	_	NN	O	-1	none	_	_
5	I	_	_	PRP	O	-1	none	_	_
6	interleukin-1	_	_	NN	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	can	_	_	MD	O	-1	none	_	_
9	mediate	_	_	VB	O	-1	none	_	_
10	interleukin-1	_	_	NN	O	-1	none	_	_
11	induction	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	gene	_	_	NN	O	-1	none	_	_
14	expression	_	_	NN	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	T	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	type	_	_	NN	Protein	5	multitoken	_	_
3	I	_	_	CD	Protein	5	multitoken	_	_
4	interleukin-1	_	_	NN	Protein	5	multitoken	_	_
5	receptor	_	_	NN	Protein	0	root	_	_
6	(	_	_	-LRB-	O	-1	none	_	_
7	IL-1R	_	_	NN	O	-1	none	_	_
8	)	_	_	-RRB-	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	capable	_	_	JJ	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	transducing	_	_	VBG	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	signal	_	_	NN	O	-1	none	_	_
15	resulting	_	_	VBG	O	-1	none	_	_
16	in	_	_	IN	O	-1	none	_	_
17	promoter	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	in	_	_	IN	O	-1	none	_	_
20	T	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	signal	_	_	NN	O	-1	none	_	_
3	transduction	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	dependent	_	_	JJ	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	cytoplasmic	_	_	JJ	O	-1	none	_	_
9	domain	_	_	NN	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	which	_	_	WDT	O	-1	none	_	_
12	consists	_	_	VBZ	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	213	_	_	CD	O	-1	none	_	_
15	amino	_	_	NN	O	-1	none	_	_
16	acids	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	type	_	_	NN	O	-1	none	_	_
6	I	_	_	CD	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	type	_	_	NN	Protein	12	multitoken	_	_
11	II	_	_	CD	Protein	12	multitoken	_	_
12	IL-1R	_	_	NN	Protein	0	root	_	_
13	has	_	_	VBZ	O	-1	none	_	_
14	a	_	_	DT	O	-1	none	_	_
15	small	_	_	JJ	O	-1	none	_	_
16	cytoplasmic	_	_	JJ	O	-1	none	_	_
17	tail	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	it	_	_	PRP	O	-1	none	_	_
21	is	_	_	VBZ	O	-1	none	_	_
22	not	_	_	RB	O	-1	none	_	_
23	clear	_	_	JJ	O	-1	none	_	_
24	whether	_	_	IN	O	-1	none	_	_
25	this	_	_	DT	O	-1	none	_	_
26	receptor	_	_	NN	O	-1	none	_	_
27	is	_	_	VBZ	O	-1	none	_	_
28	a	_	_	DT	O	-1	none	_	_
29	signal	_	_	NN	O	-1	none	_	_
30	transducing	_	_	NN	O	-1	none	_	_
31	or	_	_	CC	O	-1	none	_	_
32	a	_	_	DT	O	-1	none	_	_
33	regulatory	_	_	JJ	O	-1	none	_	_
34	molecule	_	_	NN	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	type	_	_	NN	Protein	8	multitoken	_	_
7	II	_	_	CD	Protein	8	multitoken	_	_
8	IL-1R	_	_	NN	Protein	0	root	_	_
9	does	_	_	VBZ	O	-1	none	_	_
10	not	_	_	RB	O	-1	none	_	_
11	mediate	_	_	VB	O	-1	none	_	_
12	gene	_	_	NN	O	-1	none	_	_
13	activation	_	_	NN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	Jurkat	_	_	NN	O	-1	none	_	_
16	cells	_	_	NNS	O	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	hybrid	_	_	NN	O	-1	none	_	_
5	receptor	_	_	NN	O	-1	none	_	_
6	composed	_	_	VBN	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	the	_	_	DT	O	-1	none	_	_
9	extracellular	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	transmembrane	_	_	JJ	O	-1	none	_	_
12	regions	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	type	_	_	NN	Protein	18	multitoken	_	_
17	II	_	_	CD	Protein	18	multitoken	_	_
18	interleukin-1	_	_	NN	Protein	0	root	_	_
19	fused	_	_	VBN	O	-1	none	_	_
20	to	_	_	TO	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	cytoplasmic	_	_	JJ	O	-1	none	_	_
23	domain	_	_	NN	O	-1	none	_	_
24	of	_	_	IN	O	-1	none	_	_
25	the	_	_	DT	O	-1	none	_	_
26	human	_	_	NN	O	-1	none	_	_
27	type	_	_	NN	Protein	29	multitoken	_	_
28	I	_	_	CD	Protein	29	multitoken	_	_
29	IL-1R	_	_	NN	Protein	0	root	_	_
30	was	_	_	VBD	O	-1	none	_	_
31	capable	_	_	JJ	O	-1	none	_	_
32	of	_	_	IN	O	-1	none	_	_
33	transducing	_	_	VBG	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	signal	_	_	NN	O	-1	none	_	_
36	across	_	_	IN	O	-1	none	_	_
37	the	_	_	DT	O	-1	none	_	_
38	membrane	_	_	NN	O	-1	none	_	_
39	resulting	_	_	VBG	O	-1	none	_	_
40	in	_	_	IN	O	-1	none	_	_
41	a	_	_	DT	O	-1	none	_	_
42	pattern	_	_	NN	O	-1	none	_	_
43	of	_	_	IN	O	-1	none	_	_
44	gene	_	_	NN	O	-1	none	_	_
45	activation	_	_	NN	O	-1	none	_	_
46	identical	_	_	JJ	O	-1	none	_	_
47	to	_	_	TO	O	-1	none	_	_
48	that	_	_	DT	O	-1	none	_	_
49	mediated	_	_	VBN	O	-1	none	_	_
50	by	_	_	IN	O	-1	none	_	_
51	the	_	_	DT	O	-1	none	_	_
52	type	_	_	NN	O	-1	none	_	_
53	I	_	_	CD	O	-1	none	_	_
54	IL-1R	_	_	NN	O	-1	none	_	_
55	.	_	_	.	O	-1	none	_	_

1	Our	_	_	PRP$	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicated	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	extracellular	_	_	JJ	O	-1	none	_	_
7	domain	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	type	_	_	NN	Protein	12	multitoken	_	_
11	II	_	_	CD	Protein	12	multitoken	_	_
12	IL-1R	_	_	NN	Protein	0	root	_	_
13	was	_	_	VBD	O	-1	none	_	_
14	capable	_	_	JJ	O	-1	none	_	_
15	of	_	_	IN	O	-1	none	_	_
16	functionally	_	_	RB	O	-1	none	_	_
17	interacting	_	_	VBG	O	-1	none	_	_
18	with	_	_	IN	O	-1	none	_	_
19	interleukin-1	_	_	NN	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	transmitting	_	_	VBG	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	resulting	_	_	VBG	O	-1	none	_	_
24	signal	_	_	NN	O	-1	none	_	_
25	to	_	_	TO	O	-1	none	_	_
26	a	_	_	DT	O	-1	none	_	_
27	heterologous	_	_	JJ	O	-1	none	_	_
28	cytoplasmic	_	_	JJ	O	-1	none	_	_
29	domain	_	_	NN	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	Lipopolysaccharide	_	_	NN	O	-1	none	_	_
2	induces	_	_	VBZ	O	-1	none	_	_
3	phosphorylation	_	_	NN	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	MAD3	_	_	NN	Protein	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	activation	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	c-Rel	_	_	NN	Protein	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	related	_	_	JJ	O	-1	none	_	_
12	NF-kappa	_	_	NN	O	-1	none	_	_
13	B	_	_	NN	O	-1	none	_	_
14	proteins	_	_	NNS	O	-1	none	_	_
15	in	_	_	IN	O	-1	none	_	_
16	human	_	_	NN	O	-1	none	_	_
17	monocytic	_	_	JJ	O	-1	none	_	_
18	THP-1	_	_	NN	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Many	_	_	JJ	O	-1	none	_	_
2	effects	_	_	NNS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	lipopolysaccharide	_	_	NN	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	LPS	_	_	NN	O	-1	none	_	_
7	)	_	_	-RRB-	O	-1	none	_	_
8	on	_	_	IN	O	-1	none	_	_
9	gene	_	_	NN	O	-1	none	_	_
10	expression	_	_	NN	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	including	_	_	VBG	O	-1	none	_	_
13	that	_	_	DT	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	immunodeficiency	_	_	NN	O	-1	none	_	_
17	virus	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	HIV	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	in	_	_	IN	O	-1	none	_	_
23	monocytic	_	_	JJ	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	are	_	_	VBP	O	-1	none	_	_
26	mediated	_	_	VBN	O	-1	none	_	_
27	by	_	_	IN	O	-1	none	_	_
28	activation	_	_	NN	O	-1	none	_	_
29	of	_	_	IN	O	-1	none	_	_
30	kappa	_	_	NN	O	-1	none	_	_
31	B	_	_	NN	O	-1	none	_	_
32	DNA	_	_	NN	O	-1	none	_	_
33	binding	_	_	NN	O	-1	none	_	_
34	proteins	_	_	NNS	O	-1	none	_	_
35	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	specific	_	_	JJ	O	-1	none	_	_
5	members	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	NF-kappa	_	_	NN	O	-1	none	_	_
9	B/Rel	_	_	NN	O	-1	none	_	_
10	transcription	_	_	NN	O	-1	none	_	_
11	factor	_	_	NN	O	-1	none	_	_
12	family	_	_	NN	O	-1	none	_	_
13	involved	_	_	VBN	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	LPS	_	_	NN	O	-1	none	_	_
17	response	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	and	_	_	CC	O	-1	none	_	_
20	the	_	_	DT	O	-1	none	_	_
21	mechanisms	_	_	NNS	O	-1	none	_	_
22	through	_	_	IN	O	-1	none	_	_
23	which	_	_	WDT	O	-1	none	_	_
24	LPS	_	_	NN	O	-1	none	_	_
25	generated	_	_	VBD	O	-1	none	_	_
26	signals	_	_	NNS	O	-1	none	_	_
27	are	_	_	VBP	O	-1	none	_	_
28	transduced	_	_	VBN	O	-1	none	_	_
29	remain	_	_	VBP	O	-1	none	_	_
30	unclear	_	_	JJ	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	show	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	LPS	_	_	NN	O	-1	none	_	_
6	induces	_	_	VBZ	O	-1	none	_	_
7	nuclear	_	_	JJ	O	-1	none	_	_
8	expression	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	c-Rel	_	_	NN	Protein	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	p50	_	_	NN	Protein	-1	none	_	_
13	heterodimers	_	_	NNS	O	-1	none	_	_
14	as	_	_	RB	O	-1	none	_	_
15	well	_	_	RB	O	-1	none	_	_
16	as	_	_	IN	O	-1	none	_	_
17	p50	_	_	NN	Protein	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	p65	_	_	NN	Protein	-1	none	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	NF-kappa	_	_	NN	O	-1	none	_	_
22	B	_	_	NN	O	-1	none	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	kappa	_	_	NN	O	-1	none	_	_
25	B	_	_	NN	O	-1	none	_	_
26	DNA	_	_	NN	O	-1	none	_	_
27	binding	_	_	NN	O	-1	none	_	_
28	complexes	_	_	NNS	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	human	_	_	NN	O	-1	none	_	_
31	monocytic	_	_	JJ	O	-1	none	_	_
32	THP-1	_	_	NN	O	-1	none	_	_
33	cells	_	_	NNS	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	Nuclear	_	_	JJ	O	-1	none	_	_
2	localization	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	these	_	_	DT	O	-1	none	_	_
5	proteins	_	_	NNS	O	-1	none	_	_
6	occurred	_	_	VBD	O	-1	none	_	_
7	concomitantly	_	_	RB	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	rapid	_	_	JJ	O	-1	none	_	_
11	decrease	_	_	NN	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	their	_	_	PRP$	O	-1	none	_	_
14	cytosolic	_	_	JJ	O	-1	none	_	_
15	levels	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	was	_	_	VBD	O	-1	none	_	_
18	independent	_	_	JJ	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	phorbol	_	_	NN	O	-1	none	_	_
21	ester	_	_	NN	O	-1	none	_	_
22	sensitive	_	_	JJ	O	-1	none	_	_
23	protein	_	_	NN	O	-1	none	_	_
24	kinase	_	_	NN	O	-1	none	_	_
25	C.	_	_	NN	O	-1	none	_	_
26	Within	_	_	IN	O	-1	none	_	_
27	24	_	_	CD	O	-1	none	_	_
28	h	_	_	NN	O	-1	none	_	_
29	following	_	_	VBG	O	-1	none	_	_
30	LPS	_	_	NN	O	-1	none	_	_
31	stimulation	_	_	NN	O	-1	none	_	_
32	there	_	_	EX	O	-1	none	_	_
33	was	_	_	VBD	O	-1	none	_	_
34	a	_	_	DT	O	-1	none	_	_
35	striking	_	_	JJ	O	-1	none	_	_
36	increase	_	_	NN	O	-1	none	_	_
37	in	_	_	IN	O	-1	none	_	_
38	the	_	_	DT	O	-1	none	_	_
39	levels	_	_	NNS	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	c-Rel	_	_	NN	Protein	-1	none	_	_
42	,	_	_	,	O	-1	none	_	_
43	p105	_	_	NN	Protein	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	and	_	_	CC	O	-1	none	_	_
46	p50	_	_	NN	Protein	-1	none	_	_
47	in	_	_	IN	O	-1	none	_	_
48	the	_	_	DT	O	-1	none	_	_
49	cytosol	_	_	NN	O	-1	none	_	_
50	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	increased	_	_	JJ	O	-1	none	_	_
3	levels	_	_	NNS	O	-1	none	_	_
4	of	_	_	IN	O	-1	none	_	_
5	these	_	_	DT	O	-1	none	_	_
6	proteins	_	_	NNS	O	-1	none	_	_
7	correlated	_	_	VBD	O	-1	none	_	_
8	with	_	_	IN	O	-1	none	_	_
9	increases	_	_	NNS	O	-1	none	_	_
10	in	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	amounts	_	_	NNS	O	-1	none	_	_
13	of	_	_	IN	O	-1	none	_	_
14	their	_	_	PRP$	O	-1	none	_	_
15	mRNAs	_	_	NNS	O	-1	none	_	_
16	during	_	_	IN	O	-1	none	_	_
17	LPS	_	_	NN	O	-1	none	_	_
18	activation	_	_	NN	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	THP-1	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	LPS	_	_	NN	O	-1	none	_	_
2	activation	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	THP-1	_	_	NN	O	-1	none	_	_
5	cells	_	_	NNS	O	-1	none	_	_
6	resulted	_	_	VBD	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	phosphorylation	_	_	NN	O	-1	none	_	_
9	of	_	_	IN	O	-1	none	_	_
10	MAD3	_	_	NN	Protein	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	an	_	_	DT	O	-1	none	_	_
13	I	_	_	NN	O	-1	none	_	_
14	kappa	_	_	NN	O	-1	none	_	_
15	B	_	_	NN	O	-1	none	_	_
16	like	_	_	IN	O	-1	none	_	_
17	protein	_	_	NN	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	a	_	_	DT	O	-1	none	_	_
21	rapid	_	_	JJ	O	-1	none	_	_
22	increase	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	MAD3	_	_	NN	Protein	-1	none	_	_
25	mRNA	_	_	NN	O	-1	none	_	_
26	,	_	_	,	O	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	an	_	_	DT	O	-1	none	_	_
29	increase	_	_	NN	O	-1	none	_	_
30	in	_	_	IN	O	-1	none	_	_
31	MAD3	_	_	NN	Protein	-1	none	_	_
32	protein	_	_	NN	O	-1	none	_	_
33	by	_	_	IN	O	-1	none	_	_
34	2	_	_	CD	O	-1	none	_	_
35	h.	_	_	NN	O	-1	none	_	_
36	Thus	_	_	RB	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	LPS	_	_	NN	O	-1	none	_	_
39	activation	_	_	NN	O	-1	none	_	_
40	of	_	_	IN	O	-1	none	_	_
41	human	_	_	NN	O	-1	none	_	_
42	monocytic	_	_	JJ	O	-1	none	_	_
43	cells	_	_	NNS	O	-1	none	_	_
44	results	_	_	VBZ	O	-1	none	_	_
45	in	_	_	IN	O	-1	none	_	_
46	nuclear	_	_	JJ	O	-1	none	_	_
47	expression	_	_	NN	O	-1	none	_	_
48	of	_	_	IN	O	-1	none	_	_
49	c-Rel	_	_	NN	Protein	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	p50	_	_	NN	Protein	-1	none	_	_
52	and	_	_	CC	O	-1	none	_	_
53	p50	_	_	NN	Protein	-1	none	_	_
54	and	_	_	CC	O	-1	none	_	_
55	p65	_	_	NN	Protein	-1	none	_	_
56	(	_	_	-LRB-	O	-1	none	_	_
57	NF-kappa	_	_	NN	O	-1	none	_	_
58	B	_	_	NN	O	-1	none	_	_
59	)	_	_	-RRB-	O	-1	none	_	_
60	and	_	_	CC	O	-1	none	_	_
61	induces	_	_	VBZ	O	-1	none	_	_
62	phosphorylation	_	_	NN	O	-1	none	_	_
63	of	_	_	IN	O	-1	none	_	_
64	MAD3	_	_	NN	Protein	-1	none	_	_
65	.	_	_	.	O	-1	none	_	_

1	Daidzein	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	genistein	_	_	NN	O	-1	none	_	_
4	glucuronides	_	_	NNS	O	-1	none	_	_
5	in	_	_	FW	O	-1	none	_	_
6	vitro	_	_	FW	O	-1	none	_	_
7	are	_	_	VBP	O	-1	none	_	_
8	weakly	_	_	RB	O	-1	none	_	_
9	estrogenic	_	_	JJ	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	activate	_	_	VBP	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	natural	_	_	JJ	O	-1	none	_	_
14	killer	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	at	_	_	IN	O	-1	none	_	_
17	nutritionally	_	_	RB	O	-1	none	_	_
18	relevant	_	_	JJ	O	-1	none	_	_
19	concentrations	_	_	NNS	O	-1	none	_	_
20	.	_	_	.	O	-1	none	_	_

1	Daidzein	_	_	NN	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	genistein	_	_	NN	O	-1	none	_	_
4	glucuronides	_	_	NNS	O	-1	none	_	_
5	(	_	_	-LRB-	O	-1	none	_	_
6	DG	_	_	NNS	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	GG	_	_	NNS	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	,	_	_	,	O	-1	none	_	_
11	major	_	_	JJ	O	-1	none	_	_
12	isoflavone	_	_	NN	O	-1	none	_	_
13	metabolites	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	may	_	_	MD	O	-1	none	_	_
16	be	_	_	VB	O	-1	none	_	_
17	partly	_	_	RB	O	-1	none	_	_
18	responsible	_	_	JJ	O	-1	none	_	_
19	for	_	_	IN	O	-1	none	_	_
20	biological	_	_	JJ	O	-1	none	_	_
21	effects	_	_	NNS	O	-1	none	_	_
22	of	_	_	IN	O	-1	none	_	_
23	isoflavones	_	_	NNS	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	such	_	_	JJ	O	-1	none	_	_
26	as	_	_	IN	O	-1	none	_	_
27	estrogen	_	_	NN	Protein	28	multitoken	_	_
28	receptor	_	_	NN	Protein	0	root	_	_
29	binding	_	_	NN	O	-1	none	_	_
30	and	_	_	CC	O	-1	none	_	_
31	natural	_	_	JJ	O	-1	none	_	_
32	killer	_	_	NN	O	-1	none	_	_
33	cell	_	_	NN	O	-1	none	_	_
34	(	_	_	-LRB-	O	-1	none	_	_
35	NK	_	_	NN	O	-1	none	_	_
36	)	_	_	-RRB-	O	-1	none	_	_
37	activation	_	_	NN	O	-1	none	_	_
38	or	_	_	CC	O	-1	none	_	_
39	inhibition	_	_	NN	O	-1	none	_	_
40	.	_	_	.	O	-1	none	_	_

1	DG	_	_	NNS	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	GG	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	synthesized	_	_	VBN	O	-1	none	_	_
6	using	_	_	VBG	O	-1	none	_	_
7	3-methylcholanthrene-induced	_	_	JJ	O	-1	none	_	_
8	rat	_	_	NN	O	-1	none	_	_
9	liver	_	_	NN	O	-1	none	_	_
10	microsomes	_	_	NNS	O	-1	none	_	_
11	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	Km	_	_	NN	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	Vmax	_	_	NN	O	-1	none	_	_
5	for	_	_	IN	O	-1	none	_	_
6	daidzein	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	genistein	_	_	NN	O	-1	none	_	_
9	were	_	_	VBD	O	-1	none	_	_
10	9.0	_	_	CD	O	-1	none	_	_
11	and	_	_	CC	O	-1	none	_	_
12	7.7	_	_	CD	O	-1	none	_	_
13	micromol/L	_	_	NN	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	0.7	_	_	CD	O	-1	none	_	_
17	and	_	_	CC	O	-1	none	_	_
18	1.6	_	_	CD	O	-1	none	_	_
19	micromol/(	_	_	NN	O	-1	none	_	_
20	mg	_	_	NN	O	-1	none	_	_
21	protein	_	_	NN	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	min	_	_	NN	O	-1	none	_	_
2	)	_	_	-RRB-	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	respectively	_	_	RB	O	-1	none	_	_
5	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	absence	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	ultraviolet	_	_	JJ	O	-1	none	_	_
5	absorbance	_	_	NN	O	-1	none	_	_
6	maxima	_	_	NNS	O	-1	none	_	_
7	shifts	_	_	NNS	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	presence	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	sodium	_	_	NN	O	-1	none	_	_
13	acetate	_	_	NN	O	-1	none	_	_
14	confirmed	_	_	VBD	O	-1	none	_	_
15	that	_	_	IN	O	-1	none	_	_
16	the	_	_	DT	O	-1	none	_	_
17	synthesized	_	_	JJ	O	-1	none	_	_
18	products	_	_	NNS	O	-1	none	_	_
19	were	_	_	VBD	O	-1	none	_	_
20	7-O-glucuronides	_	_	NNS	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	DG	_	_	NNS	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	GG	_	_	NNS	O	-1	none	_	_
4	were	_	_	VBD	O	-1	none	_	_
5	further	_	_	JJ	O	-1	none	_	_
6	purified	_	_	VBN	O	-1	none	_	_
7	by	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	Sephadex	_	_	NN	O	-1	none	_	_
10	LH-20	_	_	NN	O	-1	none	_	_
11	column	_	_	NN	O	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	DG	_	_	NNS	O	-1	none	_	_
2	and	_	_	CC	O	-1	none	_	_
3	GG	_	_	NNS	O	-1	none	_	_
4	competed	_	_	VBD	O	-1	none	_	_
5	with	_	_	IN	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	binding	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	17beta-(	_	_	JJ	O	-1	none	_	_
10	3H	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	estradiol	_	_	NN	O	-1	none	_	_
13	to	_	_	TO	O	-1	none	_	_
14	estrogen	_	_	NN	Protein	15	multitoken	_	_
15	receptors	_	_	NNS	Protein	0	root	_	_
16	of	_	_	IN	O	-1	none	_	_
17	B6D2F1	_	_	NN	O	-1	none	_	_
18	mouse	_	_	NN	O	-1	none	_	_
19	uterine	_	_	NN	O	-1	none	_	_
20	cytosol	_	_	NN	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	concentrations	_	_	NNS	O	-1	none	_	_
3	required	_	_	VBN	O	-1	none	_	_
4	for	_	_	IN	O	-1	none	_	_
5	50	_	_	CD	O	-1	none	_	_
6	%	_	_	NN	O	-1	none	_	_
7	displacement	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	17beta-(	_	_	JJ	O	-1	none	_	_
10	3H	_	_	NN	O	-1	none	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	estradiol	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	CB50	_	_	NN	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	were	_	_	VBD	O	-1	none	_	_
17	:	_	_	:	O	-1	none	_	_
18	17beta-estradiol	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	1.34	_	_	CD	O	-1	none	_	_
21	nmol/L	_	_	NN	O	-1	none	_	_
22	;	_	_	:	O	-1	none	_	_
23	diethylstilbestrol	_	_	NN	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	1.46	_	_	CD	O	-1	none	_	_
26	nmol/L	_	_	NN	O	-1	none	_	_
27	;	_	_	:	O	-1	none	_	_
28	daidzein	_	_	NN	O	-1	none	_	_
29	,	_	_	,	O	-1	none	_	_
30	1.6	_	_	CD	O	-1	none	_	_
31	micromol/L	_	_	NN	O	-1	none	_	_
32	;	_	_	:	O	-1	none	_	_
33	DG	_	_	NNS	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	14.7	_	_	CD	O	-1	none	_	_
36	micromol/L	_	_	NN	O	-1	none	_	_
37	;	_	_	:	O	-1	none	_	_
38	genistein	_	_	NN	O	-1	none	_	_
39	,	_	_	,	O	-1	none	_	_
40	0.154	_	_	CD	O	-1	none	_	_
41	micromol/L	_	_	NN	O	-1	none	_	_
42	;	_	_	:	O	-1	none	_	_
43	GG	_	_	NNS	O	-1	none	_	_
44	,	_	_	,	O	-1	none	_	_
45	7.27	_	_	CD	O	-1	none	_	_
46	micromol/L	_	_	NN	O	-1	none	_	_
47	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	human	_	_	NN	O	-1	none	_	_
3	peripheral	_	_	JJ	O	-1	none	_	_
4	blood	_	_	NN	O	-1	none	_	_
5	NK	_	_	NN	O	-1	none	_	_
6	cells	_	_	NNS	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	genistein	_	_	NN	O	-1	none	_	_
9	at	_	_	IN	O	-1	none	_	_
10	<	_	_	JJR	O	-1	none	_	_
11	0.5	_	_	CD	O	-1	none	_	_
12	micromol/L	_	_	NN	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	DG	_	_	NNS	O	-1	none	_	_
15	and	_	_	CC	O	-1	none	_	_
16	GG	_	_	NNS	O	-1	none	_	_
17	at	_	_	IN	O	-1	none	_	_
18	0.1-10	_	_	CD	O	-1	none	_	_
19	micromol/L	_	_	NN	O	-1	none	_	_
20	enhanced	_	_	VBD	O	-1	none	_	_
21	NK	_	_	NN	O	-1	none	_	_
22	cell	_	_	NN	O	-1	none	_	_
23	mediated	_	_	JJ	O	-1	none	_	_
24	K562	_	_	NN	O	-1	none	_	_
25	cancer	_	_	NN	O	-1	none	_	_
26	cell	_	_	NN	O	-1	none	_	_
27	killing	_	_	NN	O	-1	none	_	_
28	significantly	_	_	RB	O	-1	none	_	_
29	(	_	_	-LRB-	O	-1	none	_	_
30	P	_	_	NN	O	-1	none	_	_
31	<	_	_	JJR	O	-1	none	_	_
32	0.05	_	_	CD	O	-1	none	_	_
33	)	_	_	-RRB-	O	-1	none	_	_
34	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	>	_	_	JJR	O	-1	none	_	_
3	0.5	_	_	CD	O	-1	none	_	_
4	micromol/L	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	genistein	_	_	NN	O	-1	none	_	_
7	inhibited	_	_	VBD	O	-1	none	_	_
8	NK	_	_	NN	O	-1	none	_	_
9	cytotoxicity	_	_	NN	O	-1	none	_	_
10	significantly	_	_	RB	O	-1	none	_	_
11	(	_	_	-LRB-	O	-1	none	_	_
12	P	_	_	NN	O	-1	none	_	_
13	<	_	_	JJR	O	-1	none	_	_
14	0.05	_	_	CD	O	-1	none	_	_
15	)	_	_	-RRB-	O	-1	none	_	_
16	.	_	_	.	O	-1	none	_	_

1	The	_	_	DT	O	-1	none	_	_
2	glucuronides	_	_	NNS	O	-1	none	_	_
3	only	_	_	RB	O	-1	none	_	_
4	inhibited	_	_	VBD	O	-1	none	_	_
5	NK	_	_	NN	O	-1	none	_	_
6	cytotoxicity	_	_	NN	O	-1	none	_	_
7	at	_	_	IN	O	-1	none	_	_
8	50	_	_	CD	O	-1	none	_	_
9	micromol/L	_	_	NN	O	-1	none	_	_
10	.	_	_	.	O	-1	none	_	_

1	Isoflavones	_	_	NNS	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	and	_	_	CC	O	-1	none	_	_
4	especially	_	_	RB	O	-1	none	_	_
5	the	_	_	DT	O	-1	none	_	_
6	isoflavone	_	_	NN	O	-1	none	_	_
7	glucuronides	_	_	NNS	O	-1	none	_	_
8	,	_	_	,	O	-1	none	_	_
9	enhanced	_	_	VBD	O	-1	none	_	_
10	activation	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	NK	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	interleukin-2	_	_	NN	Protein	-1	none	_	_
16	(	_	_	-LRB-	O	-1	none	_	_
17	IL-2	_	_	NN	Protein	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	additively	_	_	RB	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	At	_	_	IN	O	-1	none	_	_
2	physiological	_	_	JJ	O	-1	none	_	_
3	concentrations	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	DG	_	_	NNS	O	-1	none	_	_
6	and	_	_	CC	O	-1	none	_	_
7	GG	_	_	NNS	O	-1	none	_	_
8	were	_	_	VBD	O	-1	none	_	_
9	weakly	_	_	RB	O	-1	none	_	_
10	estrogenic	_	_	JJ	O	-1	none	_	_
11	,	_	_	,	O	-1	none	_	_
12	and	_	_	CC	O	-1	none	_	_
13	they	_	_	PRP	O	-1	none	_	_
14	activated	_	_	VBD	O	-1	none	_	_
15	human	_	_	NN	O	-1	none	_	_
16	NK	_	_	NN	O	-1	none	_	_
17	cells	_	_	NNS	O	-1	none	_	_
18	in	_	_	IN	O	-1	none	_	_
19	nutritionally	_	_	RB	O	-1	none	_	_
20	relevant	_	_	JJ	O	-1	none	_	_
21	concentrations	_	_	NNS	O	-1	none	_	_
22	in	_	_	FW	O	-1	none	_	_
23	vitro	_	_	FW	O	-1	none	_	_
24	,	_	_	,	O	-1	none	_	_
25	probably	_	_	RB	O	-1	none	_	_
26	at	_	_	IN	O	-1	none	_	_
27	a	_	_	DT	O	-1	none	_	_
28	site	_	_	NN	O	-1	none	_	_
29	different	_	_	JJ	O	-1	none	_	_
30	from	_	_	IN	O	-1	none	_	_
31	IL-2	_	_	NN	Protein	-1	none	_	_
32	action	_	_	NN	O	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	Retinoic	_	_	JJ	O	-1	none	_	_
2	acid	_	_	NN	O	-1	none	_	_
3	induced	_	_	VBN	O	-1	none	_	_
4	expression	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	CD38	_	_	NN	Protein	-1	none	_	_
7	antigen	_	_	NN	O	-1	none	_	_
8	in	_	_	IN	O	-1	none	_	_
9	myeloid	_	_	JJ	O	-1	none	_	_
10	cells	_	_	NNS	O	-1	none	_	_
11	is	_	_	VBZ	O	-1	none	_	_
12	mediated	_	_	VBN	O	-1	none	_	_
13	through	_	_	IN	O	-1	none	_	_
14	retinoic	_	_	JJ	Protein	16	multitoken	_	_
15	acid	_	_	NN	Protein	16	multitoken	_	_
16	receptor-alpha	_	_	NN	Protein	0	root	_	_
17	.	_	_	.	O	-1	none	_	_

1	CD38	_	_	NN	Protein	-1	none	_	_
2	is	_	_	VBZ	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	leukocyte	_	_	NN	O	-1	none	_	_
5	differentiation	_	_	NN	O	-1	none	_	_
6	antigen	_	_	NN	O	-1	none	_	_
7	that	_	_	WDT	O	-1	none	_	_
8	has	_	_	VBZ	O	-1	none	_	_
9	been	_	_	VBN	O	-1	none	_	_
10	thought	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	be	_	_	VB	O	-1	none	_	_
13	a	_	_	DT	O	-1	none	_	_
14	phenotypic	_	_	JJ	O	-1	none	_	_
15	marker	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	different	_	_	JJ	O	-1	none	_	_
18	subpopulations	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	T-	_	_	NN	O	-1	none	_	_
21	and	_	_	CC	O	-1	none	_	_
22	B-	_	_	NN	O	-1	none	_	_
23	lymphocytes	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	myeloid	_	_	JJ	O	-1	none	_	_
3	cells	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	CD38	_	_	NN	Protein	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	expressed	_	_	VBN	O	-1	none	_	_
8	during	_	_	IN	O	-1	none	_	_
9	early	_	_	JJ	O	-1	none	_	_
10	stages	_	_	NNS	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	differentiation	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Virtually	_	_	RB	O	-1	none	_	_
2	no	_	_	DT	O	-1	none	_	_
3	information	_	_	NN	O	-1	none	_	_
4	is	_	_	VBZ	O	-1	none	_	_
5	available	_	_	JJ	O	-1	none	_	_
6	on	_	_	IN	O	-1	none	_	_
7	regulation	_	_	NN	O	-1	none	_	_
8	and	_	_	CC	O	-1	none	_	_
9	functions	_	_	NNS	O	-1	none	_	_
10	of	_	_	IN	O	-1	none	_	_
11	CD38	_	_	NN	Protein	-1	none	_	_
12	.	_	_	.	O	-1	none	_	_

1	Recently	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	reported	_	_	VBD	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	all-trans-retinoic	_	_	JJ	O	-1	none	_	_
6	acid	_	_	NN	O	-1	none	_	_
7	(	_	_	-LRB-	O	-1	none	_	_
8	ATRA	_	_	NN	O	-1	none	_	_
9	)	_	_	-RRB-	O	-1	none	_	_
10	is	_	_	VBZ	O	-1	none	_	_
11	a	_	_	DT	O	-1	none	_	_
12	potent	_	_	JJ	O	-1	none	_	_
13	and	_	_	CC	O	-1	none	_	_
14	highly	_	_	RB	O	-1	none	_	_
15	specific	_	_	JJ	O	-1	none	_	_
16	inducer	_	_	NN	O	-1	none	_	_
17	of	_	_	IN	O	-1	none	_	_
18	CD38	_	_	NN	Protein	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	in	_	_	IN	O	-1	none	_	_
21	human	_	_	NN	O	-1	none	_	_
22	promyelocytic	_	_	JJ	O	-1	none	_	_
23	leukemia	_	_	NN	O	-1	none	_	_
24	cells	_	_	NNS	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Here	_	_	RB	O	-1	none	_	_
2	we	_	_	PRP	O	-1	none	_	_
3	report	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	ATRA	_	_	NN	O	-1	none	_	_
6	induced	_	_	VBN	O	-1	none	_	_
7	expression	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	CD38	_	_	NN	Protein	-1	none	_	_
10	antigen	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	myeloid	_	_	JJ	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	mediated	_	_	VBN	O	-1	none	_	_
16	through	_	_	IN	O	-1	none	_	_
17	retinoic	_	_	JJ	Protein	19	multitoken	_	_
18	acid-alpha	_	_	NN	Protein	19	multitoken	_	_
19	receptor	_	_	NN	Protein	0	root	_	_
20	(	_	_	-LRB-	O	-1	none	_	_
21	RAR	_	_	NN	Protein	22	multitoken	_	_
22	alpha	_	_	NN	Protein	0	root	_	_
23	)	_	_	-RRB-	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	ATRA	_	_	NN	O	-1	none	_	_
2	failed	_	_	VBD	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	induce	_	_	VB	O	-1	none	_	_
5	CD38	_	_	NN	Protein	-1	none	_	_
6	expression	_	_	NN	O	-1	none	_	_
7	in	_	_	IN	O	-1	none	_	_
8	a	_	_	DT	O	-1	none	_	_
9	mutant	_	_	NN	O	-1	none	_	_
10	subclone	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	the	_	_	DT	O	-1	none	_	_
13	HL-60	_	_	NN	O	-1	none	_	_
14	myeloid	_	_	JJ	O	-1	none	_	_
15	leukemia	_	_	NN	O	-1	none	_	_
16	cell	_	_	NN	O	-1	none	_	_
17	line	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	designated	_	_	VBN	O	-1	none	_	_
20	HL-60R	_	_	NN	O	-1	none	_	_
21	)	_	_	-RRB-	O	-1	none	_	_
22	that	_	_	WDT	O	-1	none	_	_
23	is	_	_	VBZ	O	-1	none	_	_
24	relatively	_	_	RB	O	-1	none	_	_
25	resistant	_	_	JJ	O	-1	none	_	_
26	to	_	_	TO	O	-1	none	_	_
27	ATRA	_	_	NN	O	-1	none	_	_
28	induced	_	_	VBD	O	-1	none	_	_
29	granulocytic	_	_	JJ	O	-1	none	_	_
30	differentiation	_	_	NN	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	Retroviral	_	_	JJ	O	-1	none	_	_
2	vector	_	_	NN	O	-1	none	_	_
3	mediated	_	_	VBN	O	-1	none	_	_
4	transduction	_	_	NN	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	RA	_	_	NN	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	RAR	_	_	NN	Protein	10	multitoken	_	_
10	alpha	_	_	NN	Protein	0	root	_	_
11	)	_	_	-RRB-	O	-1	none	_	_
12	into	_	_	IN	O	-1	none	_	_
13	this	_	_	DT	O	-1	none	_	_
14	HL-60R	_	_	NN	O	-1	none	_	_
15	subclone	_	_	NN	O	-1	none	_	_
16	completely	_	_	RB	O	-1	none	_	_
17	restored	_	_	VBD	O	-1	none	_	_
18	the	_	_	DT	O	-1	none	_	_
19	sensitivity	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	these	_	_	DT	O	-1	none	_	_
22	cells	_	_	NNS	O	-1	none	_	_
23	to	_	_	TO	O	-1	none	_	_
24	ATRA	_	_	NN	O	-1	none	_	_
25	in	_	_	IN	O	-1	none	_	_
26	terms	_	_	NNS	O	-1	none	_	_
27	of	_	_	IN	O	-1	none	_	_
28	their	_	_	PRP$	O	-1	none	_	_
29	ability	_	_	NN	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	express	_	_	VB	O	-1	none	_	_
32	CD38	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	contrast	_	_	NN	O	-1	none	_	_
3	,	_	_	,	O	-1	none	_	_
4	CD38	_	_	NN	Protein	-1	none	_	_
5	expression	_	_	NN	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	not	_	_	RB	O	-1	none	_	_
8	inducible	_	_	JJ	O	-1	none	_	_
9	by	_	_	IN	O	-1	none	_	_
10	ATRA	_	_	NN	O	-1	none	_	_
11	in	_	_	IN	O	-1	none	_	_
12	HL-60R	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	,	_	_	,	O	-1	none	_	_
15	transfected	_	_	VBN	O	-1	none	_	_
16	with	_	_	IN	O	-1	none	_	_
17	a	_	_	DT	O	-1	none	_	_
18	functional	_	_	JJ	O	-1	none	_	_
19	RAR	_	_	NN	Protein	20	multitoken	_	_
20	beta	_	_	NN	Protein	0	root	_	_
21	,	_	_	,	O	-1	none	_	_
22	RAR	_	_	NN	Protein	23	multitoken	_	_
23	gamma	_	_	NN	Protein	0	root	_	_
24	,	_	_	,	O	-1	none	_	_
25	or	_	_	CC	O	-1	none	_	_
26	RXR	_	_	NN	Protein	27	multitoken	_	_
27	alpha	_	_	NN	Protein	0	root	_	_
28	receptor	_	_	NN	O	-1	none	_	_
29	.	_	_	.	O	-1	none	_	_

1	Induction	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	CD38	_	_	NN	Protein	-1	none	_	_
4	in	_	_	IN	O	-1	none	_	_
5	acute	_	_	JJ	O	-1	none	_	_
6	promyelocytic	_	_	JJ	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	acute	_	_	JJ	O	-1	none	_	_
9	myeloblastic	_	_	JJ	O	-1	none	_	_
10	leukemia	_	_	NN	O	-1	none	_	_
11	cells	_	_	NNS	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	independent	_	_	JJ	O	-1	none	_	_
14	of	_	_	IN	O	-1	none	_	_
15	ATRA	_	_	NN	O	-1	none	_	_
16	induced	_	_	VBD	O	-1	none	_	_
17	cytodifferentiation	_	_	NN	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Following	_	_	VBG	O	-1	none	_	_
2	culture	_	_	NN	O	-1	none	_	_
3	with	_	_	IN	O	-1	none	_	_
4	ATRA	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	increased	_	_	VBD	O	-1	none	_	_
7	CD38	_	_	NN	Protein	-1	none	_	_
8	protein	_	_	NN	O	-1	none	_	_
9	levels	_	_	NNS	O	-1	none	_	_
10	were	_	_	VBD	O	-1	none	_	_
11	also	_	_	RB	O	-1	none	_	_
12	observed	_	_	VBN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	normal	_	_	JJ	O	-1	none	_	_
15	CD34+	_	_	JJ	O	-1	none	_	_
16	bone	_	_	NN	O	-1	none	_	_
17	marrow	_	_	NN	O	-1	none	_	_
18	cells	_	_	NNS	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	but	_	_	CC	O	-1	none	_	_
21	not	_	_	RB	O	-1	none	_	_
22	on	_	_	IN	O	-1	none	_	_
23	normal	_	_	JJ	O	-1	none	_	_
24	circulating	_	_	VBG	O	-1	none	_	_
25	granulocytes	_	_	NNS	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	From	_	_	IN	O	-1	none	_	_
2	these	_	_	DT	O	-1	none	_	_
3	results	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	we	_	_	PRP	O	-1	none	_	_
6	conclude	_	_	VBP	O	-1	none	_	_
7	that	_	_	IN	O	-1	none	_	_
8	CD38	_	_	NN	Protein	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	ATRA	_	_	NN	O	-1	none	_	_
11	inducible	_	_	JJ	O	-1	none	_	_
12	in	_	_	IN	O	-1	none	_	_
13	myeloid	_	_	JJ	O	-1	none	_	_
14	leukemia	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	and	_	_	CC	O	-1	none	_	_
17	normal	_	_	JJ	O	-1	none	_	_
18	CD34+	_	_	JJ	O	-1	none	_	_
19	bone	_	_	NN	O	-1	none	_	_
20	marrow	_	_	NN	O	-1	none	_	_
21	cells	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	This	_	_	DT	O	-1	none	_	_
2	effect	_	_	NN	O	-1	none	_	_
3	is	_	_	VBZ	O	-1	none	_	_
4	independent	_	_	JJ	O	-1	none	_	_
5	of	_	_	IN	O	-1	none	_	_
6	differentiation	_	_	NN	O	-1	none	_	_
7	and	_	_	CC	O	-1	none	_	_
8	is	_	_	VBZ	O	-1	none	_	_
9	mediated	_	_	VBN	O	-1	none	_	_
10	by	_	_	IN	O	-1	none	_	_
11	RAR	_	_	NN	Protein	12	multitoken	_	_
12	alpha	_	_	NN	Protein	0	root	_	_
13	in	_	_	IN	O	-1	none	_	_
14	HL-60	_	_	NN	O	-1	none	_	_
15	cells	_	_	NNS	O	-1	none	_	_
16	,	_	_	,	O	-1	none	_	_
17	suggesting	_	_	VBG	O	-1	none	_	_
18	a	_	_	DT	O	-1	none	_	_
19	similar	_	_	JJ	O	-1	none	_	_
20	role	_	_	NN	O	-1	none	_	_
21	for	_	_	IN	O	-1	none	_	_
22	RAR	_	_	NN	Protein	23	multitoken	_	_
23	alpha	_	_	NN	Protein	0	root	_	_
24	in	_	_	IN	O	-1	none	_	_
25	CD38	_	_	NN	Protein	-1	none	_	_
26	expression	_	_	NN	O	-1	none	_	_
27	in	_	_	IN	O	-1	none	_	_
28	other	_	_	JJ	O	-1	none	_	_
29	hematopoietic	_	_	JJ	O	-1	none	_	_
30	cells	_	_	NNS	O	-1	none	_	_
31	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Abnormal	_	_	JJ	O	-1	none	_	_
2	renal	_	_	JJ	O	-1	none	_	_
3	tubular	_	_	JJ	O	-1	none	_	_
4	phosphate	_	_	NN	O	-1	none	_	_
5	transport	_	_	NN	O	-1	none	_	_
6	is	_	_	VBZ	O	-1	none	_	_
7	considered	_	_	VBN	O	-1	none	_	_
8	to	_	_	TO	O	-1	none	_	_
9	be	_	_	VB	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	primary	_	_	JJ	O	-1	none	_	_
12	defect	_	_	NN	O	-1	none	_	_
13	in	_	_	IN	O	-1	none	_	_
14	X	_	_	NN	O	-1	none	_	_
15	linked	_	_	VBN	O	-1	none	_	_
16	hypophosphatemic	_	_	JJ	O	-1	none	_	_
17	rickets	_	_	NN	O	-1	none	_	_
18	(	_	_	-LRB-	O	-1	none	_	_
19	XLH	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	.	_	_	.	O	-1	none	_	_

1	However	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	the	_	_	DT	O	-1	none	_	_
4	resistance	_	_	NN	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	vitamin	_	_	NN	O	-1	none	_	_
7	D	_	_	NN	O	-1	none	_	_
8	treatment	_	_	NN	O	-1	none	_	_
9	in	_	_	IN	O	-1	none	_	_
10	XLH	_	_	NN	O	-1	none	_	_
11	can	_	_	MD	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	be	_	_	VB	O	-1	none	_	_
14	explained	_	_	VBN	O	-1	none	_	_
15	by	_	_	IN	O	-1	none	_	_
16	hypophosphatemia	_	_	NN	O	-1	none	_	_
17	alone	_	_	RB	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	Since	_	_	IN	O	-1	none	_	_
2	most	_	_	JJS	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	the	_	_	DT	O	-1	none	_	_
5	actions	_	_	NNS	O	-1	none	_	_
6	of	_	_	IN	O	-1	none	_	_
7	vitamin	_	_	NN	O	-1	none	_	_
8	D	_	_	NN	O	-1	none	_	_
9	are	_	_	VBP	O	-1	none	_	_
10	mediated	_	_	VBN	O	-1	none	_	_
11	by	_	_	IN	O	-1	none	_	_
12	its	_	_	PRP$	O	-1	none	_	_
13	receptors	_	_	NNS	O	-1	none	_	_
14	(	_	_	-LRB-	O	-1	none	_	_
15	VDR	_	_	NN	Protein	-1	none	_	_
16	)	_	_	-RRB-	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	abnormalities	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	VDR	_	_	NN	Protein	-1	none	_	_
21	have	_	_	VBP	O	-1	none	_	_
22	been	_	_	VBN	O	-1	none	_	_
23	postulated	_	_	VBN	O	-1	none	_	_
24	in	_	_	IN	O	-1	none	_	_
25	XLH	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	order	_	_	NN	O	-1	none	_	_
3	to	_	_	TO	O	-1	none	_	_
4	investigate	_	_	VB	O	-1	none	_	_
5	this	_	_	DT	O	-1	none	_	_
6	possibility	_	_	NN	O	-1	none	_	_
7	,	_	_	,	O	-1	none	_	_
8	we	_	_	PRP	O	-1	none	_	_
9	measured	_	_	VBD	O	-1	none	_	_
10	the	_	_	DT	O	-1	none	_	_
11	concentration	_	_	NN	O	-1	none	_	_
12	of	_	_	IN	O	-1	none	_	_
13	VDR	_	_	NN	Protein	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	PHA	_	_	NN	O	-1	none	_	_
16	activated	_	_	VBN	O	-1	none	_	_
17	peripheral	_	_	JJ	O	-1	none	_	_
18	mononuclear	_	_	JJ	O	-1	none	_	_
19	cells	_	_	NNS	O	-1	none	_	_
20	from	_	_	IN	O	-1	none	_	_
21	10	_	_	CD	O	-1	none	_	_
22	XLH	_	_	NN	O	-1	none	_	_
23	patients	_	_	NNS	O	-1	none	_	_
24	.	_	_	.	O	-1	none	_	_

1	Patients	_	_	NNS	O	-1	none	_	_
2	without	_	_	IN	O	-1	none	_	_
3	phosphate	_	_	NN	O	-1	none	_	_
4	supplementation	_	_	NN	O	-1	none	_	_
5	showed	_	_	VBD	O	-1	none	_	_
6	significantly	_	_	RB	O	-1	none	_	_
7	lower	_	_	JJR	O	-1	none	_	_
8	concentration	_	_	NN	O	-1	none	_	_
9	(	_	_	-LRB-	O	-1	none	_	_
10	21.7	_	_	CD	O	-1	none	_	_
11	+/-	_	_	CC	O	-1	none	_	_
12	5.1	_	_	CD	O	-1	none	_	_
13	fmol/mg	_	_	NN	O	-1	none	_	_
14	protein	_	_	NN	O	-1	none	_	_
15	,	_	_	,	O	-1	none	_	_
16	mean	_	_	NN	O	-1	none	_	_
17	+/-	_	_	CC	O	-1	none	_	_
18	SEM	_	_	NN	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	compared	_	_	VBN	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	the	_	_	DT	O	-1	none	_	_
23	normal	_	_	JJ	O	-1	none	_	_
24	controls	_	_	NNS	O	-1	none	_	_
25	(	_	_	-LRB-	O	-1	none	_	_
26	60.7	_	_	CD	O	-1	none	_	_
27	+/-	_	_	CC	O	-1	none	_	_
28	4.0	_	_	CD	O	-1	none	_	_
29	)	_	_	-RRB-	O	-1	none	_	_
30	.	_	_	.	O	-1	none	_	_

1	On	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	contrary	_	_	NN	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	there	_	_	EX	O	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	no	_	_	DT	O	-1	none	_	_
8	significant	_	_	JJ	O	-1	none	_	_
9	difference	_	_	NN	O	-1	none	_	_
10	between	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	phosphate	_	_	NN	O	-1	none	_	_
13	supplemented	_	_	VBN	O	-1	none	_	_
14	patients	_	_	NNS	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	58.3	_	_	CD	O	-1	none	_	_
17	+/-	_	_	CC	O	-1	none	_	_
18	2.7	_	_	CD	O	-1	none	_	_
19	)	_	_	-RRB-	O	-1	none	_	_
20	and	_	_	CC	O	-1	none	_	_
21	controls	_	_	NNS	O	-1	none	_	_
22	.	_	_	.	O	-1	none	_	_

1	There	_	_	EX	O	-1	none	_	_
2	was	_	_	VBD	O	-1	none	_	_
3	a	_	_	DT	O	-1	none	_	_
4	significant	_	_	JJ	O	-1	none	_	_
5	positive	_	_	JJ	O	-1	none	_	_
6	correlation	_	_	NN	O	-1	none	_	_
7	between	_	_	IN	O	-1	none	_	_
8	VDR	_	_	NN	Protein	-1	none	_	_
9	concentration	_	_	NN	O	-1	none	_	_
10	and	_	_	CC	O	-1	none	_	_
11	serum	_	_	NN	O	-1	none	_	_
12	phosphate	_	_	NN	O	-1	none	_	_
13	(	_	_	-LRB-	O	-1	none	_	_
14	P	_	_	NN	O	-1	none	_	_
15	less	_	_	JJR	O	-1	none	_	_
16	than	_	_	IN	O	-1	none	_	_
17	0.05	_	_	CD	O	-1	none	_	_
18	)	_	_	-RRB-	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	two	_	_	CD	O	-1	none	_	_
3	patients	_	_	NNS	O	-1	none	_	_
4	,	_	_	,	O	-1	none	_	_
5	VDR	_	_	NN	Protein	-1	none	_	_
6	was	_	_	VBD	O	-1	none	_	_
7	increased	_	_	VBN	O	-1	none	_	_
8	after	_	_	IN	O	-1	none	_	_
9	daily	_	_	JJ	O	-1	none	_	_
10	phosphate	_	_	NN	O	-1	none	_	_
11	supplementation	_	_	NN	O	-1	none	_	_
12	was	_	_	VBD	O	-1	none	_	_
13	started	_	_	VBN	O	-1	none	_	_
14	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	results	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	a	_	_	DT	O	-1	none	_	_
6	decreased	_	_	JJ	O	-1	none	_	_
7	concentration	_	_	NN	O	-1	none	_	_
8	of	_	_	IN	O	-1	none	_	_
9	VDR	_	_	NN	Protein	-1	none	_	_
10	secondary	_	_	JJ	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	persistent	_	_	JJ	O	-1	none	_	_
13	hypophosphatemia	_	_	NN	O	-1	none	_	_
14	is	_	_	VBZ	O	-1	none	_	_
15	one	_	_	CD	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	causes	_	_	NNS	O	-1	none	_	_
19	of	_	_	IN	O	-1	none	_	_
20	vitamin	_	_	NN	O	-1	none	_	_
21	D	_	_	NN	O	-1	none	_	_
22	resistance	_	_	NN	O	-1	none	_	_
23	in	_	_	IN	O	-1	none	_	_
24	XLH	_	_	NN	O	-1	none	_	_
25	.	_	_	.	O	-1	none	_	_

1	Activation	_	_	NN	O	-1	none	_	_
2	of	_	_	IN	O	-1	none	_	_
3	STAT5	_	_	NN	O	-1	none	_	_
4	by	_	_	IN	O	-1	none	_	_
5	IL-4	_	_	NN	Protein	-1	none	_	_
6	relies	_	_	VBZ	O	-1	none	_	_
7	on	_	_	IN	O	-1	none	_	_
8	Janus	_	_	NN	O	-1	none	_	_
9	kinase	_	_	NN	O	-1	none	_	_
10	function	_	_	NN	O	-1	none	_	_
11	but	_	_	CC	O	-1	none	_	_
12	not	_	_	RB	O	-1	none	_	_
13	on	_	_	IN	O	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	tyrosine	_	_	NN	O	-1	none	_	_
16	phosphorylation	_	_	NN	O	-1	none	_	_
17	,	_	_	,	O	-1	none	_	_
18	and	_	_	CC	O	-1	none	_	_
19	can	_	_	MD	O	-1	none	_	_
20	contribute	_	_	VB	O	-1	none	_	_
21	to	_	_	TO	O	-1	none	_	_
22	both	_	_	DT	O	-1	none	_	_
23	cell	_	_	NN	O	-1	none	_	_
24	proliferation	_	_	NN	O	-1	none	_	_
25	and	_	_	CC	O	-1	none	_	_
26	gene	_	_	NN	O	-1	none	_	_
27	regulation	_	_	NN	O	-1	none	_	_
28	.	_	_	.	O	-1	none	_	_

1	We	_	_	PRP	O	-1	none	_	_
2	have	_	_	VBP	O	-1	none	_	_
3	investigated	_	_	VBN	O	-1	none	_	_
4	mechanisms	_	_	NNS	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	consequences	_	_	NNS	O	-1	none	_	_
7	of	_	_	IN	O	-1	none	_	_
8	STAT5	_	_	NN	O	-1	none	_	_
9	activation	_	_	NN	O	-1	none	_	_
10	through	_	_	IN	O	-1	none	_	_
11	the	_	_	DT	O	-1	none	_	_
12	human	_	_	NN	O	-1	none	_	_
13	IL-4	_	_	NN	Protein	-1	none	_	_
14	receptor	_	_	NN	O	-1	none	_	_
15	(	_	_	-LRB-	O	-1	none	_	_
16	IL-4R	_	_	NN	O	-1	none	_	_
17	)	_	_	-RRB-	O	-1	none	_	_
18	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_

1	Genetic	_	_	JJ	O	-1	none	_	_
2	evidence	_	_	NN	O	-1	none	_	_
3	for	_	_	IN	O	-1	none	_	_
4	an	_	_	DT	O	-1	none	_	_
5	additional	_	_	JJ	O	-1	none	_	_
6	factor	_	_	NN	O	-1	none	_	_
7	required	_	_	VBN	O	-1	none	_	_
8	for	_	_	IN	O	-1	none	_	_
9	erythropoietin	_	_	NN	Protein	-1	none	_	_
10	induced	_	_	VBD	O	-1	none	_	_
11	signal	_	_	NN	O	-1	none	_	_
12	transduction	_	_	NN	O	-1	none	_	_
13	.	_	_	.	O	-1	none	_	_

1	Erythropoietin	_	_	NN	Protein	-1	none	_	_
2	(	_	_	-LRB-	O	-1	none	_	_
3	EPO	_	_	NN	Protein	-1	none	_	_
4	)	_	_	-RRB-	O	-1	none	_	_
5	and	_	_	CC	O	-1	none	_	_
6	its	_	_	PRP$	O	-1	none	_	_
7	receptor	_	_	NN	O	-1	none	_	_
8	(	_	_	-LRB-	O	-1	none	_	_
9	EPOR	_	_	NN	Protein	-1	none	_	_
10	)	_	_	-RRB-	O	-1	none	_	_
11	are	_	_	VBP	O	-1	none	_	_
12	required	_	_	VBN	O	-1	none	_	_
13	for	_	_	IN	O	-1	none	_	_
14	the	_	_	DT	O	-1	none	_	_
15	development	_	_	NN	O	-1	none	_	_
16	of	_	_	IN	O	-1	none	_	_
17	mature	_	_	JJ	O	-1	none	_	_
18	erythrocytes	_	_	NNS	O	-1	none	_	_
19	.	_	_	.	O	-1	none	_	_

1	After	_	_	IN	O	-1	none	_	_
2	binding	_	_	NN	O	-1	none	_	_
3	of	_	_	IN	O	-1	none	_	_
4	ligand	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	the	_	_	DT	O	-1	none	_	_
7	EPOR	_	_	NN	Protein	-1	none	_	_
8	activates	_	_	VBZ	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	variety	_	_	NN	O	-1	none	_	_
11	of	_	_	IN	O	-1	none	_	_
12	signaling	_	_	NN	O	-1	none	_	_
13	pathways	_	_	NNS	O	-1	none	_	_
14	that	_	_	WDT	O	-1	none	_	_
15	ultimately	_	_	RB	O	-1	none	_	_
16	control	_	_	VBP	O	-1	none	_	_
17	cellular	_	_	JJ	O	-1	none	_	_
18	proliferation	_	_	NN	O	-1	none	_	_
19	,	_	_	,	O	-1	none	_	_
20	survival	_	_	NN	O	-1	none	_	_
21	,	_	_	,	O	-1	none	_	_
22	and	_	_	CC	O	-1	none	_	_
23	specific	_	_	JJ	O	-1	none	_	_
24	gene	_	_	NN	O	-1	none	_	_
25	expression	_	_	NN	O	-1	none	_	_
26	.	_	_	.	O	-1	none	_	_

1	Although	_	_	IN	O	-1	none	_	_
2	erythroid	_	_	JJ	O	-1	none	_	_
3	progenitors	_	_	NNS	O	-1	none	_	_
4	appear	_	_	VBP	O	-1	none	_	_
5	to	_	_	TO	O	-1	none	_	_
6	be	_	_	VB	O	-1	none	_	_
7	the	_	_	DT	O	-1	none	_	_
8	principal	_	_	JJ	O	-1	none	_	_
9	EPO	_	_	NN	Protein	-1	none	_	_
10	responsive	_	_	JJ	O	-1	none	_	_
11	cell	_	_	NN	O	-1	none	_	_
12	type	_	_	NN	O	-1	none	_	_
13	in	_	_	FW	O	-1	none	_	_
14	vivo	_	_	FW	O	-1	none	_	_
15	due	_	_	JJ	O	-1	none	_	_
16	to	_	_	TO	O	-1	none	_	_
17	the	_	_	DT	O	-1	none	_	_
18	restricted	_	_	JJ	O	-1	none	_	_
19	expression	_	_	NN	O	-1	none	_	_
20	of	_	_	IN	O	-1	none	_	_
21	the	_	_	DT	O	-1	none	_	_
22	EPOR	_	_	NN	Protein	-1	none	_	_
23	,	_	_	,	O	-1	none	_	_
24	many	_	_	JJ	O	-1	none	_	_
25	growth	_	_	NN	O	-1	none	_	_
26	factor	_	_	NN	O	-1	none	_	_
27	dependent	_	_	JJ	O	-1	none	_	_
28	cell	_	_	NN	O	-1	none	_	_
29	lines	_	_	NNS	O	-1	none	_	_
30	expressing	_	_	VBG	O	-1	none	_	_
31	the	_	_	DT	O	-1	none	_	_
32	EPOR	_	_	NN	Protein	-1	none	_	_
33	can	_	_	MD	O	-1	none	_	_
34	respond	_	_	VB	O	-1	none	_	_
35	to	_	_	TO	O	-1	none	_	_
36	EPO	_	_	NN	Protein	-1	none	_	_
37	by	_	_	IN	O	-1	none	_	_
38	activating	_	_	VBG	O	-1	none	_	_
39	many	_	_	JJ	O	-1	none	_	_
40	or	_	_	CC	O	-1	none	_	_
41	all	_	_	DT	O	-1	none	_	_
42	of	_	_	IN	O	-1	none	_	_
43	these	_	_	DT	O	-1	none	_	_
44	pathways	_	_	NNS	O	-1	none	_	_
45	.	_	_	.	O	-1	none	_	_

1	In	_	_	IN	O	-1	none	_	_
2	the	_	_	DT	O	-1	none	_	_
3	present	_	_	JJ	O	-1	none	_	_
4	study	_	_	NN	O	-1	none	_	_
5	,	_	_	,	O	-1	none	_	_
6	we	_	_	PRP	O	-1	none	_	_
7	have	_	_	VBP	O	-1	none	_	_
8	identified	_	_	VBN	O	-1	none	_	_
9	a	_	_	DT	O	-1	none	_	_
10	cellular	_	_	JJ	O	-1	none	_	_
11	context	_	_	NN	O	-1	none	_	_
12	(	_	_	-LRB-	O	-1	none	_	_
13	the	_	_	DT	O	-1	none	_	_
14	interleukin-2	_	_	NN	Protein	-1	none	_	_
15	[	_	_	CD	O	-1	none	_	_
16	IL-2	_	_	NN	Protein	-1	none	_	_
17	]-dependent	_	_	JJ	O	-1	none	_	_
18	HT-2	_	_	NN	O	-1	none	_	_
19	line	_	_	NN	O	-1	none	_	_
20	)	_	_	-RRB-	O	-1	none	_	_
21	in	_	_	IN	O	-1	none	_	_
22	which	_	_	WDT	O	-1	none	_	_
23	the	_	_	DT	O	-1	none	_	_
24	EPO	_	_	NN	Protein	-1	none	_	_
25	stimulation	_	_	NN	O	-1	none	_	_
26	of	_	_	IN	O	-1	none	_	_
27	the	_	_	DT	O	-1	none	_	_
28	EPOR	_	_	NN	Protein	-1	none	_	_
29	fails	_	_	VBZ	O	-1	none	_	_
30	to	_	_	TO	O	-1	none	_	_
31	support	_	_	VB	O	-1	none	_	_
32	cellular	_	_	JJ	O	-1	none	_	_
33	proliferation	_	_	NN	O	-1	none	_	_
34	,	_	_	,	O	-1	none	_	_
35	STAT-5	_	_	NN	Protein	-1	none	_	_
36	induction	_	_	NN	O	-1	none	_	_
37	,	_	_	,	O	-1	none	_	_
38	or	_	_	CC	O	-1	none	_	_
39	MAPK	_	_	NN	O	-1	none	_	_
40	activation	_	_	NN	O	-1	none	_	_
41	,	_	_	,	O	-1	none	_	_
42	despite	_	_	IN	O	-1	none	_	_
43	efficient	_	_	JJ	O	-1	none	_	_
44	phosphorylation	_	_	NN	O	-1	none	_	_
45	of	_	_	IN	O	-1	none	_	_
46	the	_	_	DT	O	-1	none	_	_
47	EPOR	_	_	NN	Protein	-1	none	_	_
48	and	_	_	CC	O	-1	none	_	_
49	JAK2	_	_	NN	Protein	-1	none	_	_
50	and	_	_	CC	O	-1	none	_	_
51	inhibition	_	_	NN	O	-1	none	_	_
52	of	_	_	IN	O	-1	none	_	_
53	apoptosis	_	_	NN	O	-1	none	_	_
54	after	_	_	IN	O	-1	none	_	_
55	withdrawal	_	_	NN	O	-1	none	_	_
56	of	_	_	IN	O	-1	none	_	_
57	IL-2	_	_	NN	Protein	-1	none	_	_
58	.	_	_	.	O	-1	none	_	_

1	Interestingly	_	_	RB	O	-1	none	_	_
2	,	_	_	,	O	-1	none	_	_
3	when	_	_	WRB	O	-1	none	_	_
4	we	_	_	PRP	O	-1	none	_	_
5	fused	_	_	VBD	O	-1	none	_	_
6	HT-2	_	_	NN	O	-1	none	_	_
7	cells	_	_	NNS	O	-1	none	_	_
8	expressing	_	_	VBG	O	-1	none	_	_
9	the	_	_	DT	O	-1	none	_	_
10	EPOR	_	_	NN	Protein	-1	none	_	_
11	with	_	_	IN	O	-1	none	_	_
12	Ba/F3	_	_	NN	O	-1	none	_	_
13	cells	_	_	NNS	O	-1	none	_	_
14	in	_	_	IN	O	-1	none	_	_
15	a	_	_	DT	O	-1	none	_	_
16	complementation	_	_	NN	O	-1	none	_	_
17	assay	_	_	NN	O	-1	none	_	_
18	,	_	_	,	O	-1	none	_	_
19	the	_	_	DT	O	-1	none	_	_
20	resulting	_	_	VBG	O	-1	none	_	_
21	hybridomas	_	_	NNS	O	-1	none	_	_
22	proliferated	_	_	VBD	O	-1	none	_	_
23	and	_	_	CC	O	-1	none	_	_
24	potently	_	_	RB	O	-1	none	_	_
25	activated	_	_	VBN	O	-1	none	_	_
26	STAT-5	_	_	NN	Protein	-1	none	_	_
27	and	_	_	CC	O	-1	none	_	_
28	MAPK	_	_	NN	O	-1	none	_	_
29	in	_	_	IN	O	-1	none	_	_
30	response	_	_	NN	O	-1	none	_	_
31	to	_	_	TO	O	-1	none	_	_
32	EPO	_	_	NN	Protein	-1	none	_	_
33	.	_	_	.	O	-1	none	_	_

1	These	_	_	DT	O	-1	none	_	_
2	data	_	_	NNS	O	-1	none	_	_
3	indicate	_	_	VBP	O	-1	none	_	_
4	that	_	_	IN	O	-1	none	_	_
5	an	_	_	DT	O	-1	none	_	_
6	unidentified	_	_	JJ	O	-1	none	_	_
7	cellular	_	_	JJ	O	-1	none	_	_
8	factor	_	_	NN	O	-1	none	_	_
9	is	_	_	VBZ	O	-1	none	_	_
10	needed	_	_	VBN	O	-1	none	_	_
11	to	_	_	TO	O	-1	none	_	_
12	mediate	_	_	VB	O	-1	none	_	_
13	signaling	_	_	NN	O	-1	none	_	_
14	by	_	_	IN	O	-1	none	_	_
15	the	_	_	DT	O	-1	none	_	_
16	EPOR	_	_	NN	Protein	-1	none	_	_
17	.	_	_	.	O	-1	none	_	_

1	*skipped*	_	_	*skipped*	O	-1	skipped	_	_
